<SEC-DOCUMENT>0001140361-24-007260.txt : 20240213
<SEC-HEADER>0001140361-24-007260.hdr.sgml : 20240213
<ACCEPTANCE-DATETIME>20240213071556
ACCESSION NUMBER:		0001140361-24-007260
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240213
DATE AS OF CHANGE:		20240213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		24622585

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ef20015327_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:roiv="http://roivant.com/20231231" xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_b04ba911e6b545288f08ed06a343ecec" contextRef="c20230401to20231231" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_ebff28a4b74b4ce8a505b0132b81ef8b" contextRef="c20230401to20231231" format="ixt:date-month-day">03-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_5e0783854c1a48aa9316fd8bc24a4f3c" contextRef="c20230401to20231231">2023</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_2566ae06044d4426b5ae6761a06382ef" contextRef="c20230401to20231231">Q3</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_f11308edf91b41dba61215563c4ebaa4" contextRef="c20230401to20231231">0001635088</ix:nonNumeric><ix:nonNumeric name="roiv:NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" id="Fact_227cc2a973b342cdadc7924eb0824d99" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">P20D</ix:nonNumeric><ix:nonNumeric name="roiv:NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" id="Fact_2cef63e668c241b7bc426da933f7f568" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">P20D</ix:nonNumeric><ix:nonNumeric name="roiv:NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" id="Fact_d2125a9df960461aa915b45e9db9e81b" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">P30D</ix:nonNumeric><ix:nonNumeric name="roiv:NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" id="Fact_938065e85885426b93d64ce0a73dd639" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">P30D</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="Fact_5ffcc6c700034d4587790a5e791d733c" contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="Fact_1bcdc2e95f0b40ac8041dbfa7444510a" contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Fact_ca3f4592024941f287ede17a07ff606d" contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Fact_93006666e195494db2e26107da08a25a" contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="Fact_896fc6f03cbf47ba9500416e14491b89" contextRef="c20231231_StatementEquityComponentsAxis_EarnoutSharesMember">http://roivant.com/20231231#LiabilityInstrumentsMeasuredAtFairValue</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="Fact_8076c0698f4040ad9216b28dd1dd2471" contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember">http://roivant.com/20231231#LiabilityInstrumentsMeasuredAtFairValue</ix:nonNumeric><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_8ee3b8aa93764123a2f245e2aa34a8f5" contextRef="c20231231" unitRef="U002" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_402b29cf8c3f4fd7af7fd8ece657ecb2" contextRef="c20230331" unitRef="U002" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="roiv-20231231.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20230401to20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231201to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_TelavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220531_CounterpartyNameAxis_WelichemBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:WelichemBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220531_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220731_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220801to20220831_CounterpartyNameAxis_WelichemBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:WelichemBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_PfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:RocheTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-14</xbrli:startDate><xbrli:endDate>2023-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:RocheTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-14</xbrli:startDate><xbrli:endDate>2023-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:RocheTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221114to20221231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-14</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:NewlyFormedSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:NewlyFormedSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:NewlyFormedSubsidiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230731_RelatedPartyTransactionsByRelatedPartyAxis_SKIncMember_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SKIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:VantAIPreferredFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230801to20230831_BusinessAcquisitionAxis_ProteovantSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_SKBiopharmaceuticalsCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SKBiopharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:VantAIPreferredFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230731_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:VantAIPreferredFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180831_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-31</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-30</xbrli:startDate><xbrli:endDate>2028-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220530to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-30</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-31</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180831_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220501to20220531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220601to20220630_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220919_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:EquityOfferingsAtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:EquityOfferingsAtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230901to20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:RoivantParticipationOfImmunovantStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:RoivantParticipationOfImmunovantStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">roiv:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SamsungBiologicsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">roiv:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SamsungBiologicsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:PalantirTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:PalantirTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_TypeOfArrangementAxis_CashBonusProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_TypeOfArrangementAxis_CashBonusProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231001to20231231_TypeOfArrangementAxis_CashBonusProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240209to20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-09</xbrli:startDate><xbrli:endDate>2024-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TwentyPercentEarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TenPercentEarnOutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TwentyPercentEarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TenPercentEarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TwentyPercentEarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TenPercentEarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsAndPrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-31</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ClassOfWarrantOrRightAxis_PublicWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FinancialInstrumentAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:EarnOutSharesNonvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:OtherStockBasedAwardsAndInstrumentsIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:OtherStockBasedAwardsAndInstrumentsIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:EarnOutSharesNonvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>roiv:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>roiv:IncentivePlans</xbrli:measure></xbrli:unit><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_428210c60e944730a20f7b55694bf111" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_88d301b06f3b4647bd1a7bd6a42d22e1" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_4dfeb1fa823a44f986b1f8c8747e6e3b" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_1e7097176cf645f1845fbbe6eea85e94" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_7aa6e3e059604b539d74d42ac4d41f07" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_d60545cae465462f845da4052288e0b4" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f98ef47d156a48a3b5586b2e4b978334" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_9d3967aaf8b84bd59f44e1c76670b3b8" toRefs="Foot_284c7966a91e41ae90598fd7dee6f320" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_549a656b35d94b4d967ad2c826a11b60" toRefs="Foot_ce5839120cd543e7984048999d69cde8" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_4752edd86aed4ee592ba9116cf19a4e5" toRefs="Foot_ce5839120cd543e7984048999d69cde8" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship></ix:resources></ix:header></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">UNITED STATES<br/>
      </div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 15%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_d1342817f5fd478ea3b097c13cd06b0a" contextRef="c20230401to20231231">10-Q</ix:nonNumeric></div>

      <div>
        <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Mark One)</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
              <div><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_83eaf44af3864232b69230c1e42132dd" contextRef="c20230401to20231231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 96%; vertical-align: top;">
              <div style="font-weight: bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_77d4677249404987841d457e305723d9" contextRef="c20230401to20231231" format="ixt:date-monthname-day-year-en">December 31, 2023</ix:nonNumeric></div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">OR</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
              <div><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_75f253b62c2b402b8b74b8a9f66941c2" contextRef="c20230401to20231231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 96%; vertical-align: top;">
              <div style="font-weight: bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
<div>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_2a629753f68042b297a3a1e4c578891c" contextRef="c20230401to20231231">001-40782</ix:nonNumeric></div>

        <div><br/>
        </div>

      </div>

      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
      <div style="text-align: center; font-size: 24pt; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_752bb2bc265449e1b4cbd30a8060733b" contextRef="c20230401to20231231">ROIVANT SCIENCES LTD.</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of Registrant as specified in its Charter)</div>

      <div style="text-align: center; font-weight: bold;">
        <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; border: none; margin-left: auto; margin-right: auto;"/>
        <div> <br/>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_75c417da4c33437ab9450b3b22d22eda" contextRef="c20230401to20231231" format="ixt-sec:edgarprovcountryen">Bermuda</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: bottom;"><br/>
            </td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_3e2157c9efb843bfb3da490e8798459d" contextRef="c20230401to20231231">98-1173944</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation or organization)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom;"><br/>
            </td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(I.R.S. Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_0d88b6bb100f493e80d2e056a1012bfb" contextRef="c20230401to20231231">7th Floor</ix:nonNumeric><br/>
              </div>
              <div style="text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_159378a8b4984b58914a5903658ec618" contextRef="c20230401to20231231">50 Broadway</ix:nonNumeric></span><br/>
              </div>
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_d7c3ac5eaa6e49329c794117cbd5f3b2" contextRef="c20230401to20231231">London</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_624740da0a9f496dbfc64c1368f2f141" contextRef="c20230401to20231231">SW1H 0DB</ix:nonNumeric></div>
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_b726218524f74aacae742157aa2d3dbf" contextRef="c20230401to20231231" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: bottom;"><br/>
            </td>

    <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Not Applicable</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(Address of principal executive offices)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom;"><br/>
            </td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">+<ix:nonNumeric name="dei:CountryRegion" id="Fact_bcda329cae5648649295a7eb54b89a0a" contextRef="c20230401to20231231">44</ix:nonNumeric> <ix:nonNumeric name="dei:CityAreaCode" id="Fact_e16df5da524c4dda997faad239eac754" contextRef="c20230401to20231231">207</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_ff565a664deb47caab95dbb3e01a4877" contextRef="c20230401to20231231">400 3347</ix:nonNumeric></div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Registrant&#8217;s telephone number, including area code)</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Not Applicable</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Former Name, former address and former fiscal year, if changed since last report)</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; font-weight: bold;">
        <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;"><br/>
            </td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;"><br/>
            </td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: bottom; font-weight: bold; text-align: left;" rowspan="1"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c43c6edd5c7848d6b6ae30f60ee9d685" contextRef="c20230401to20231231">Common Shares, $0.0000000341740141 per share</ix:nonNumeric></td>

    <td rowspan="1" style="width: 2%; vertical-align: bottom;"> </td>

    <td rowspan="1" style="width: 32%; vertical-align: bottom; font-weight: bold; text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_b15a695da37f40d2905c830c848fc6b4" contextRef="c20230401to20231231">ROIV</ix:nonNumeric></td>

    <td rowspan="1" style="width: 2%; vertical-align: bottom;"> </td>

    <td rowspan="1" style="width: 32%; vertical-align: bottom; font-weight: bold; text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_93787d461eab432ab015b941f63bbd3c" contextRef="c20230401to20231231" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
        preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; &#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_01e58743aef44d6a903dd1c6f565d9c7" contextRef="c20230401to20231231">Yes</ix:nonNumeric>&#160; &#9746;&#160; &#160; No&#160; &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
        (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; &#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_74454031dc2a43afa76626665206821b" contextRef="c20230401to20231231">Yes</ix:nonNumeric>&#160;
        &#9746;&#160; &#160; No&#160; &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
        growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 17.32%; vertical-align: bottom;">
              <div>Large accelerated filer</div>
            </td>

    <td style="width: 59.14%; vertical-align: bottom;">
              <div>&#9744;</div>
            </td>

    <td style="width: 20.36%; vertical-align: bottom;">
              <div>Accelerated filer</div>
            </td>

    <td style="width: 1.04%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.01%; vertical-align: bottom;">
              <div>&#9744;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 17.32%; vertical-align: bottom;">
              <div><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_4b17c83cc4f14dbfab6b901defaa3964" contextRef="c20230401to20231231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 59.14%; vertical-align: bottom;">
              <div>&#9746;</div>
            </td>

    <td style="width: 20.36%; vertical-align: bottom;">
              <div>Smaller reporting company</div>
            </td>

    <td style="width: 1.04%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.01%; vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_b6c15324254a40ad8e9d9bfd63050ec3" contextRef="c20230401to20231231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 17.32%; vertical-align: bottom;"><br/>
            </td>

    <td style="width: 59.14%; vertical-align: bottom;"><br/>
            </td>

    <td style="width: 20.36%; vertical-align: bottom;">
              <div>Emerging growth company</div>
            </td>

    <td style="width: 1.04%; vertical-align: bottom;">&#160;</td>

    <td style="width: 2.01%; vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_437bdf416d774170ad1298670b6b698a" contextRef="c20230401to20231231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_79b60e0e803b45e48b14293f8911ef71" contextRef="c20230401to20231231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><br/>
        Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; &#160; Yes&#160; <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_10cbe75a83d94b3d897a99c723a85fba" contextRef="c20230401to20231231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160; &#160; No&#160; &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">As of February 9, 2024, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_fdb219b6bf0a4b09a63f5cc8096bcda4" contextRef="c20240209" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">805,846,006</ix:nonFraction>
        common shares, par value $0.0000000341740141 per share, outstanding (the &#8220;Common Shares&#8221;).</div>

      <div> <div><br/></div>

        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter">
          <div><br/>
          </div>

        </div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: center; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="TABLEOFCONTENTS"><!--Anchor--></a><span style="text-decoration: underline;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">TABLE OF CONTENTS</span></span></div>

      <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: center; font-weight: bold;">&#160;&#160;Page</div>
            </td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div style="text-align: justify; font-weight: bold;">PART I&#8212;FINANCIAL INFORMATION</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 1.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#FinancialStatementsUnaudi">Financial Statements (Unaudited)</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">7</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#BalanceSheets">Condensed Consolidated Balance Sheets as of December 31, 2023 and March 31, 2023</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">7</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify; text-indent: -9pt; margin-left: 9pt;"><a href="#StatementsofOperations">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended December 31, 2023 and 2022</a></div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;8</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify; text-indent: -9pt; margin-left: 9pt;"><a href="#ComprehensiveIncomeLoss">Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended December 31, 2023 and 2022</a></div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">9</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify; text-indent: -9pt; margin-left: 9pt;"><a href="#ShareholdersEquityandRede">Condensed Consolidated Statements of Shareholders&#8217; Equity and Redeemable Noncontrolling Interest for the Three and Nine Months Ended
                  December 31, 2023 and 2022</a></div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">10</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify; text-indent: -9pt; margin-left: 9pt;"><a href="#CashFlows">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2023 and 2022</a></div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">12</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#ConsolidatedFinancialStat">Notes to Condensed Consolidated Financial Statements</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">13</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 2.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#ManagementsDiscussionandA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">32<br/>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 3.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#QuantitativeandQualitativ">Quantitative and Qualitative Disclosures About Market Risk</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">47</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 4.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#ControlsandProcedures.">Controls and Procedures</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">48</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div style="text-align: justify; font-weight: bold;">PART II&#8212;OTHER INFORMATION</div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 1.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#LegalProceedings.">Legal Proceedings</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">49</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 1A.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#RiskFactors.">Risk Factors</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">49</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 2.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#UnregisteredSalesofEquity">Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities</a></div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">108</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 3.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#DefaultsUponSeniorSecurit">Defaults Upon Senior Securities</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">108</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 4.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#MineSafetyDisclosures.">Mine Safety Disclosures</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">108</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 5.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#OtherInformation.">Other Information</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">109</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%;">
              <div style="text-align: justify;">Item 6.</div>
            </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%;">
              <div style="text-align: justify;"><a href="#Exhibits.">Exhibits</a><br/>
              </div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">110</td>

  </tr>

  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: justify;">&#160;</td>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 82%; text-align: justify;">&#160;</td>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div style="text-align: justify;"><a href="#SIGNATURES">SIGNATURES</a></div>
            </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 9%; text-align: right;">111</td>

  </tr>


</table>
      <div><br/></div>

    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a></div>

      </div>

    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"><span style="font-weight: bold;">Where You Can Find More Information</span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
      <div style="text-align: justify; text-indent: 36pt; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Investors


        and others should note that we may announce material business and financial information to our investors using our investor relations website (https://investor.roivant.com), filings we make with the Securities and Exchange Commission (the &#8220;SEC&#8221;),
        our corporate twitter account (@Roivant), other social media platforms, webcasts, press releases and conference calls. Similarly, our subsidiary Immunovant, Inc. may announce material business and financial information to its investors and others
        using its investor relations website (https://immunovant.com/investors), filings it makes with the SEC, social media platforms, webcasts, press releases and conference calls. We and our public company subsidiaries use these mediums to communicate
        with our and our public company subsidiaries&#8217; shareholders and the public about our company, our subsidiaries, our product candidates and other matters. It is possible that the information that we make available in this manner may be deemed to be
        material information. We therefore encourage investors and others interested in our company and our public company subsidiaries to review this information.</div>

      <div style="text-align: justify; text-indent: 36pt; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
        above-referenced information is not incorporated by reference into this filing and the website addresses and Twitter account name are provided only as inactive textual references.</div>

      <div style="text-align: center; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Summary
        Risk Factors</div>

      <div style="text-align: justify; text-indent: 36pt; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">You
        should consider carefully the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1.A of this Quarterly Report on Form 10-Q. Unless the context otherwise requires, references in this section to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Roivant&#8221; and the &#8220;Company&#8221; refer
        to Roivant Sciences Ltd. and its consolidated subsidiaries, as the context requires. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following:</div>

      <div style="text-align: justify; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Risks
        Related to Our Business and Industry</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product development may make it difficult for us to execute on our business model and for you to assess our future viability. We have
                not generated significant revenue from our operations since inception, and there is no guarantee that we will do so in the future.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We may never achieve sustained profitability.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We have limited experience as a commercial company and the marketing and sale of VTAMA&#174; (tapinarof) or any future products may be unsuccessful or less successful than anticipated.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We may not be successful in our efforts to acquire or in-license new product candidates.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our drug discovery efforts may not be successful in identifying new product candidates.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We face risks associated with the allocation of capital and personnel across our businesses.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We face risks associated with the Vant structure.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We face risks associated with potential future payments related to our products and product candidates.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our business strategy and potential for future growth relies on a number of assumptions, some or all of which may not be realized.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our management has broad discretion in respect of use of our cash and cash equivalents, including the proceeds from the Roche Transaction. In the future, we may decide to return capital to shareholders, whether through share repurchases,
                cash dividends or otherwise, and the amount and timing of such capital returns is subject to the discretion of our board of directors and will vary from time to time.&#160; There is no guarantee that such proceeds will be used to increase our
                operating results or enhance the value of our Common Shares.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Clinical trials and preclinical studies are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or
                complete clinical trials or preclinical studies on the expected timelines, if at all.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Certain of our products and product candidates are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our
                business.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We may encounter difficulties enrolling and retaining patients in clinical trials, and clinical development activities could thereby be delayed or otherwise adversely affected.</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>The results of our preclinical studies and clinical trials may not support our proposed claims for our products or product candidates, or regulatory approvals on a timely basis or at all, and the results of earlier studies and trials may
                not be predictive of future trial results.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Interim, top-line or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in
                material changes in the final data.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or another regulator may delay, limit or deny approval. If we are unable to obtain regulatory approval in one or more
                jurisdictions for any products or product candidates, our business will be substantially harmed.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory
                approval and commercialization.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our products and product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the
                scope of any approved label or market acceptance.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We may require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to successfully market our products, acquire or in-license new products or product candidates, complete the
                development and commercialization of our products and product candidates and continue to pursue our drug discovery efforts.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We may not be able to complete certain strategic transactions if a proposed transaction may be subject to review or approval by regulatory authorities pursuant to certain U.S. laws or regulations.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We are exposed to risks and fluctuations related to our significant holdings of cash and cash equivalents</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We depend on the knowledge and skills of our senior leaders and may not be able to manage our business effectively if we are unable to attract and retain key personnel.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We will need to expand our organization and may experience difficulties in managing this growth, which could disrupt operations.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>If we are unable to obtain and maintain patent and other intellectual property protection for our technology, products and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we
                may not be able to compete effectively in our markets.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>If the patent applications we hold or have in-licensed with respect to our products or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our
                current and future products or product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize our products. Any such outcome could have a materially
                adverse effect on our business. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Patent terms and their scope may be inadequate to protect our competitive position on current and future products and product candidates for an adequate amount of time.</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Risks
        Related to Our Securities, Our Jurisdiction of Incorporation and Certain Tax Matters</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>If our performance does not meet market expectations, the price of our securities may decline.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>We have incurred and will continue to incur increased costs as a result of operating as a public company and our management has devoted and will continue to devote a substantial amount of time to new compliance initiatives.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our failure to timely and effectively implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act could have a material adverse effect on our business.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Anti-takeover provisions in our memorandum of association and bye-laws, as well as provisions of Bermuda law, could delay or prevent a change in control, limit the price investors may be willing to pay in the future for our Common Shares
                and could entrench management.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Our largest shareholders own a significant percentage of our Common Shares and are able to exert significant control over matters subject to shareholder approval.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>Future sales, or the perception of future sales, of our Common Shares by us or our existing shareholders could cause the market price for our Common Shares to decline and impact our ability to raise capital in the future.</div>
            </td>

  </tr>


</table>
      <div style="margin-top: 8pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: center; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Forward-Looking



















        Statements</div>

      <div style="text-align: justify; text-indent: 36pt; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">This
        Quarterly Report on Form 10-Q contains statements, including matters discussed under Part I, Item 2. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; Part II, Item 1. &#8220;Legal Proceedings,&#8221; Part II, Item 1A.
        &#8220;Risk Factors&#8221; and in other sections of this report, that are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to,
        statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts. In addition, any statements that refer to projections, forecasts or other
        characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221;
        &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.</div>

      <div style="text-align: justify; text-indent: 36pt; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
        forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations and beliefs concerning future developments and their potential effects on us taking into account information currently available to us.
        There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, they could cause our actual results to differ materially from the
        forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to risk associated with:</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our limited operating history and risks involved in biopharmaceutical product development;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our limited experience as a commercial-stage company and ability to successfully commercialize VTAMA&#174; (tapinarof);</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our ability to raise additional capital to fund our business on acceptable terms or at all;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the fact that we will likely incur significant operating losses for the foreseeable future;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our ability to acquire or in-license new product candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our ability to identify new product candidates through our discovery efforts;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our Vant structure and the potential that we may fail to capitalize on certain development opportunities;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our ability to consummate strategic transactions;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic) on our business (including our clinical trials and preclinical studies), operations and financial condition and results;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>clinical trials and preclinical studies, which are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the novelty, complexity and difficulty of manufacturing certain of our products and product candidates, including any manufacturing problems that result in delays in development or commercialization of our products and product
                candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>difficulties we may face in enrolling and retaining patients in clinical trials and/or clinical development activities;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the results of our clinical trials not supporting our proposed claims for a product candidate;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>interim, top-line and/or preliminary data from our clinical trials changing as more data becoming available or data being delayed due to audit and verification processes;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>changes in product manufacturing or formulation that could lead to the incurrence of costs or delays;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the failure of any third-party we contract with to conduct, supervise and monitor our clinical trials to perform in a satisfactory manner or to comply with applicable requirements;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the fact that obtaining approvals for new drugs is a lengthy, extensive, expensive and unpredictable process that may end with our inability to obtain regulatory approval by the FDA or other regulatory agencies in other jurisdictions;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the failure of our clinical trials to demonstrate substantial evidence of the safety and efficacy of our products and product candidates, including, but not limited to, scenarios in which our products and product candidates may cause
                adverse effects that could delay regulatory approval, discontinue clinical trials, limit the scope of approval or generally result in negative media coverage of us;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our inability to obtain regulatory approval for a product or product candidate in certain jurisdictions, even if we are able to obtain approval in certain other jurisdictions;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our ability to effectively manage growth and to attract and retain key personnel;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>any business, legal, regulatory, political, operational, financial and economic risks associated with conducting business globally;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>our ability to obtain and maintain patent and other intellectual property protection for our technology, products and product candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the inadequacy of patent terms and their scope to protect our competitive position;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the failure to issue (or the threatening of their breadth or strength of protection) or provide meaningful exclusivity for our current and future products and product candidates of our patent applications that we hold or have
                in-licensed;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the fact that we do not currently and may not in the future own or license any issued composition of matter patents covering certain of our products and product candidates and our inability to be certain that any of our other issued
                patents will provide adequate protection for such products and product candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the fact that our largest shareholders own a significant percentage of our stock and will be able to exert significant control over matters subject to shareholder approval;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>future sales of securities by us or our largest shareholders, or the perception of such sales, and the impact thereof on the price of our common shares;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the outcome of any pending or potential litigation, including but not limited to our expectations regarding the outcome of any such litigation and costs and expenses associated with such litigation;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>changes in applicable laws or regulations;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>the possibility that we may be adversely affected by other economic, business and/or competitive factors; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); margin-top: 8pt;" class="DSPFListTable">


  <tr>

    <td style="width: 38.25pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </td>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div>any other risks and uncertainties, including those described under Part II, Item 1A. &#8220;Risk Factors.&#8221;</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; text-indent: 36pt; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">These
        risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination
        of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
        statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our
        statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon
        these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</div>

      <div style="text-align: justify; text-indent: 36pt; margin-top: 8pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor-->PART I&#8212;FINANCIAL INFORMATION</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div>
        <!--Anchor-->
        <a id="FinancialStatementsUnaudi"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">
              <!--Anchor-->
    <td style="vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 1.</span> <br/>
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><!--Anchor--><span style="font-weight: bold;"><!--Anchor--><!--Anchor-->Financial Statements (Unaudited).</span></div>
              </td>

  </tr>


</table>
      </div>

      <div>
<div>&#160;<br/></div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">ROIVANT SCIENCES LTD.</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Condensed
          <!--Anchor--><!--Anchor-->Consolidated
          <!--Anchor--><!--Anchor-->Balance Sheets<a id="BalanceSheets"><!--Anchor--></a><!--Anchor--></div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited, in thousands, except share and per share amounts)</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td valign="bottom" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="font-weight: bold;">Assets</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div>Current assets:</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Cash and cash equivalents</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_0fec7d5337b949e981f6d5f599087f4b" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,670,810</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_677c9a30422046339d8446f23f7c7f74" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,676,813</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 9pt;">Other current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_6cf02db0d8204894961d623f10f1b475" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,923</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_7bda2315b1744dcea5a11e0052b7cd52" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,774</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 18pt;">Total current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_f40a3ed8727e48058e1092532bbdece6" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,806,733</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_9b08fc2146774e6e8686d64acee78f12" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,798,587</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Property and equipment, net</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_94bd5e8555e1409ea61b04ac85115f7f" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,857</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_72dc39d07f7746f2a5f6c7521fcd1e05" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,086</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Operating lease right-of-use assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_8260c01c307f44a29e3c3e01b9cfc0ca" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,898</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_3326d4d6e2a7410ba6489cacb10aeeea" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,251</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Investments measured at fair value</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_bcbedd68e86b4ab4a246a2e11f1a1a46" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">239,927</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_09f42b62729d496a86557c4d6f9f0049" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">304,317</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Intangible assets, net</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_bc25a7ce6b004ff98d67e4ecfb27e8d6" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">150,415</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_9ed2d71cceb54020ac97cac56f34e4bd" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">144,881</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div>Other assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_637a50bfa7b5467991c992be3f4719dc" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,849</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_4fda655ed0da46e0818834cce9aeca07" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,482</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="margin-left: 18pt;">Total assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_ac914f87d3f74b22a247e871950a4d0d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,312,679</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_d76b1db0cff243d5bde95b11886922f4" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,389,604</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="font-weight: bold; font-family: 'Times New Roman';">
                  <div style="text-align: left; font-size: 9pt; font-weight: bold;">Liabilities and Shareholders&#8217; Equity</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Current liabilities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="margin-left: 9pt;">Accounts payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_181e14b15c484728af27ddebeba7b880" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,226</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_8f9545e767fc456ea3aebfbc96ee9372" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,830</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Accrued expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_d1c4c8979aa344f98e415f8d40b81d75" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,148</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_32876a52fabf4b45b498aca7f950a1ec" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">167,129</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="margin-left: 9pt;">Operating lease liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_3195308842d14e2f9bcb38a9561ce43a" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,477</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_e265438a69534fdeaecf6d773ec8f0d6" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,693</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 18pt;">Current portion of long-term debt (includes $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" id="Fact_4f5292ddbb0a4f53abd0ae3aed8e01ee" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,950</ix:nonFraction></span> and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" id="Fact_8debdb7c757b4fd3a1be67cefd03cef8" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,940</ix:nonFraction></span> accounted for under the fair value option at December 31, 2023 and March 31, <span style="text-indent: 0pt;">2023</span>, respectively)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LongTermDebtCurrent" id="Fact_a72a79b5985f4c38a71d8ae275978d5d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,706</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LongTermDebtCurrent" id="Fact_3e6d4aabfa214d97ba9e3b723d20f80f" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,720</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 9pt;">Other current liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_f558cfbeeb7e4d159fd6ad8397e98342" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,342</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_155b6e9538704b6fbd1e5671a405c234" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,076</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 18pt;">Total current liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_dbcc5dbed3ae483e847e4029a70701b1" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">244,899</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_6b89b1f111ce4d6b99e310fde8f88371" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">272,448</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Liability instruments measured at fair value</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" id="Fact_031ee54bd63c4f2ab34ca440b831ac3d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,374</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" id="Fact_d4b87d4a81a74cd6854cc32bb987feba" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,546</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Operating lease liabilities, noncurrent</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_ceb15f21aa9a49dfa779e1e7a5f50f54" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,059</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_ad52c8fd76a045b3a889640afdd015b2" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,476</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Long-term debt, net of current portion (includes $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" id="Fact_6ecacae227d54822b14bff00c6cae596" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">194,560</ix:nonFraction></span> and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" id="Fact_786022393a8644ba984ae9949833cc43" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">180,700</ix:nonFraction></span> accounted for under the fair value option at <span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span> and March 31, <span style="text-indent: 0pt;">2023</span>, respectively)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">
                <div><ix:nonFraction name="us-gaap:LongTermDebt" id="Fact_aef9ce15b41948d8b278591595b0acff" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">403,337</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">
                <div><ix:nonFraction name="us-gaap:LongTermDebt" id="Fact_9bda62f22a56495f810f44c4ae349920" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">375,515</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Other liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_c8063c4188e54ec183906fd782ceb445" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,428</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_0c0b76bfcfc74a5ebe3576956c2404d9" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,032</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 18pt;">Total liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_87d891c3f1db4ab49fbf318d1c6fc3a4" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">728,097</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_3e4d49ee8c8f4f97a45654ed648c5b34" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">782,017</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Commitments and contingencies (Note 11)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Shareholders&#8217; equity:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><span style="-sec-ix-hidden:Fact_8ee3b8aa93764123a2f245e2aa34a8f5"> </span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><span style="-sec-ix-hidden:Fact_402b29cf8c3f4fd7af7fd8ece657ecb2"> </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 18pt;">Common shares, par value $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_c1ae166fc6a04af29076967af6fac8c4" contextRef="c20230331" unitRef="U003" decimals="16" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_3b2ad188219844fc93851d7aa67c8cb2" contextRef="c20231231" unitRef="U003" decimals="16" scale="0" format="ixt:num-dot-decimal">0.0000000341740141</ix:nonFraction></ix:nonFraction></span> per share, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_c6cebf60ceb54eda8abec04250d574b4" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_ac8832e210384c48b424daddb2860c26" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">7,000,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_a98bb495e1f84e09b8f3921f312075a7" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_94b85aa66db64c83aba1f0c940940594" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">804,890,910</ix:nonFraction></ix:nonFraction></span>
                  and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_93f11783b01b44c295f5c3342d23a6d2" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_70feae7cdd324059ac6e2923bc0c1425" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">760,143,393</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at <span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span> and March 31, <span style="text-indent: 0pt;">2023</span>, respectively</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_142a9fc04df1401892e8dc0cc3ddfce0" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_e7895281c9cd4ba78f4a789929e54aea" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 9pt;">Additional paid-in capital</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_6d8018da0ff14317ae8320b3a06c8a34" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,390,260</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_3e7aa5b3500e48798d87dc4cde45e5f5" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,933,137</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 18pt;">Retained earnings / (accumulated deficit)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_76a2261bc9ab4d3898f65166c35e693f" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">727,287</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_d0557b0bbb7e47ba809f5efcb3128521" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,772,754</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Accumulated other comprehensive loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" id="Fact_73698f5f0df0411cb48ff4a1953094f6" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,784</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" id="Fact_7f3e669f44df4337b939af3414673b89" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,617</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 18pt;">Shareholders&#8217; equity attributable to Roivant Sciences Ltd.</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c8fa236275504df8b531ceb3ff46b828" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,089,763</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2aecfa0b41ed4865922f00a0a32a8c50" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,157,766</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 18pt;">Noncontrolling interests</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:MinorityInterest" id="Fact_8044d8dab214492c8492af9503fe1a00" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">494,819</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:MinorityInterest" id="Fact_660057acf6694a89aa859141111d8a19" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">449,821</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="margin-left: 18pt;">Total shareholders&#8217; equity</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a2ef71e8f8e441078c3128412301e2ac" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,584,582</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_ca263c1857fd45989516bc614868c52c" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,607,587</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Total liabilities and shareholders&#8217; equity</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_6ddbeacac642464a89fbd7561202ce2a" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,312,679</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_ec7ffcfda6c8467c9651e42c4716fca7" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,389,604</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">ROIVANT SCIENCES LTD.</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Condensed
          <!--Anchor-->Consolidated
          <!--Anchor-->Statements of Operations<a id="StatementsofOperations"><!--Anchor--></a><!--Anchor--><!--Anchor--></div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited, in thousands, except share and per share amounts)</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;">Three Months Ended December 31,</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="6">
                <div><span style="font-weight: bold;"> Nine Months Ended December 31,</span><br/>
                </div>
              </td>

    <td valign="bottom" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">2023<br/>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">2022<br/>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div>Revenues:<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 9pt;">Product revenue, net<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2f7e881ea5e04b1b91d4f285d68ed405" contextRef="c20231001to20231231_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,666</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_826779f1f0f946edb9d43c4e074b04c5" contextRef="c20221001to20221231_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,244</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_797e51b866444af6ae8bef605a2bcc07" contextRef="c20230401to20231231_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,749</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_88ba8887d63c435b9a9c12c8d99c80cc" contextRef="c20220401to20221231_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,354</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;" rowspan="1">
                <div style="margin-left: 9pt;">License, milestone and other revenue<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e334de77043545428ebdafe4cc6e9a50" contextRef="c20231001to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,474</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7e565ce2b3994c98b04ac4d4b9904aa7" contextRef="c20221001to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,808</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_434d5df4aa2b405dbb3b70e2521d0d77" contextRef="c20230401to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,116</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b279eef936b04acf8d3b617c83e471a7" contextRef="c20220401to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,550</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Revenue, net<br/>
                  </div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a1bd0f2c4b664e1c8b889d5f6a2e9803" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,140</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d396da5a75a744369918e59b0cb42e91" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,052</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_deda963c97324f9197b528c1ea32fc95" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">95,865</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_dcf048549b80441797870b6a74878509" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,904</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
                <div>Operating expenses:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Cost of revenues</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:OperatingCosts" id="Fact_922aea593e234932b872acfb61c9bc33" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,668</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:OperatingCosts" id="Fact_a081c49aec46490683afe22b2dc5ebb2" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:OperatingCosts" id="Fact_0514b4c4ee6c493489d42869117a7f3a" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,148</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:OperatingCosts" id="Fact_1608733c82be4fa7b8f86d5a186920bb" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,953</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Research and development (includes $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_0d5b0f13fd7a47b1ac16671e8b44c736" contextRef="c20231001to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,475</ix:nonFraction></span> and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_1d087111d5344ca78c929c818a2a4f92" contextRef="c20221001to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,888</ix:nonFraction></span> of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_ac10694dfc604bc28f9e4af1d30567a0" contextRef="c20230401to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,305</ix:nonFraction></span> and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_2032e0cbad77462a8f98c7f04916426e" contextRef="c20220401to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,548</ix:nonFraction></span> for the nine months ended December
                  31, 2023 and 2022, respectively)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_0dd22cade78340678dd7e000d8dde300" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">123,717</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_1c858ccf7a44484f859d4a8eee73eb7b" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,533</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_222795562f35467c99886732c9536b96" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">380,834</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_f5573e2eb8e243aabc4c828ee52ef5b7" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">393,358</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Acquired in-process research and development</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" id="Fact_ff10bd2fb14b4fa9b220913fbc5b20c9" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" id="Fact_9298189c13034f8bac3a6dc137daaf33" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,749</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" id="Fact_81068bdf59a04272a43120660c72b302" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,450</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" id="Fact_6cb12d94c59d4b188c640531dc5eaeea" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,749</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Selling, general and administrative (includes $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8f5bec98a170467db18300e3ef8da786" contextRef="c20231001to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,944</ix:nonFraction></span> and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_2704bf6f348a4571849998f5d29708bd" contextRef="c20221001to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,741</ix:nonFraction></span> of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_3f96a76c63bd4fe4b69001419f689db8" contextRef="c20230401to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,445</ix:nonFraction></span> and $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_b14ddf35e0d3415e8e0678266bba1a23" contextRef="c20220401to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">165,771</ix:nonFraction></span> for the nine months ended December
                  31, 2023 and 2022, respectively)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_d1a927a6121e4fc5a68f9b054bb69265" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,282</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_99e5353f5a3c46eda236515f84b7b646" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,261</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_1b775a75551247eba2463bfabf24842a" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">517,827</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_b7f79319b86a4c64913ef7a1cd425485" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">474,996</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">
                <div style="margin-left: 18pt;">Total operating expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_78a6e9aa3a6646e68c47ff1941e260e2" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">324,667</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_6c0371194ddb424ea9c131e516f5836d" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">395,129</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_6fcb636d010c42b2914ce4fdcbbd9aa9" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">936,259</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_5317186370ef4cb0aabafdcb39b728dd" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">975,056</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Gain on sale of Telavant net assets <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_691d2d9298c9443f85a17f4d84b00794" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,348,410</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_f8f4b19c4c6a43978faf977e7c601fc2" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_36b22b58f2114a889716826c3f369479" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,348,410</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_a4159fbb16f643ffac9c34e78a024df7" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">Income (loss) from operations</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_acce8183655f4d97a9152320d0e2a418" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,060,883</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_20d4fe13caaa48b2ab1d5d22cd3eb476" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">378,077</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_341e5d0285af469791201088d9346d78" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,508,016</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_eaa29dabf3114a148804e4ec8c6332f7" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">941,152</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
                <div>Change in fair value of investments</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:GainLossOnInvestments" id="Fact_7b2ba8996d8b4405bb9eec6cd6419fc7" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,467</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:GainLossOnInvestments" id="Fact_9823f730ea6f481ca62b3ebef11c9c1b" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,948</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:GainLossOnInvestments" id="Fact_a52aeb2d0fb145b58b3421995662eb4e" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">63,880</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:GainLossOnInvestments" id="Fact_007a4fd161dd4a1e93ec4cd1fd5cf781" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53,277</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">
                <div>Change in fair value of debt and liability instruments</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" id="Fact_3c8c0da9f5ac4c38a71f31b3b396aff8" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,331</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" id="Fact_15aab40790ee439bacdc5e315be88cb5" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62,360</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" id="Fact_788b43e751e54d5d90bc18c4da198304" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,376</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" id="Fact_7c1a9df679904436a09c367e1461eaf7" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">90,032</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Gain on deconsolidation of subsidiaries</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" id="Fact_4f5f8e3091e54650966b27f507d52c6f" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" id="Fact_e3ebbf18875b4133ae632bba04e66fdd" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,514</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" id="Fact_a282fc4ecd9a41eebab0f5ca0eb0b1d4" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,354</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" id="Fact_4554baa862c24385a46f75b0a8300218" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,276</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;" rowspan="1">Interest income<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:InterestIncome" id="Fact_1d7840b4971842eda90d56627edfa047" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,953</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:InterestIncome" id="Fact_2d286a44cff148d0a4ee0e7fae99c2a7" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,249</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:InterestIncome" id="Fact_2805f5b9f3b94a809c8ea84bd78c199e" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,967</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:InterestIncome" id="Fact_4ae8d9e8e92e45e9b6dee9799fbf9fd9" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,900</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;" rowspan="1">Interest expense<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestExpense" id="Fact_18ff7bcee7ba40c389ad7ba4a2b76fe4" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,444</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestExpense" id="Fact_11ab5c28af944145b322e15b27adc17e" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,446</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestExpense" id="Fact_b3b88dd1ebbf4e51a02eb162d6d1903a" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,603</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestExpense" id="Fact_78cd7b871e42451fa812aab3f36a490d" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,393</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Other income, net</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_1020c325ab3d40d2b93e2cbeddbfd7ae" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,743</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_0d5314abfb0b48be918b4bd9e1e67b88" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,095</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_816358231a5b493abfe57ee0a1c9714a" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,405</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_4669b061834541a08e4d44a4c7e2a0c0" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,060</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
                <div style="margin-left: 9pt; text-indent: -9pt;">Net income (loss) before income taxes</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_fcb7578b825d400c896ac356cc30c231" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,098,337</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_573222d4c11a43d2a99ee4e340c9c077" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">382,077</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_48c05712046b411684d215fb4b688c52" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,444,883</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_9b4fb82dba37479d8e5db8794507e77f" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,045,618</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Income tax expense</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_3928023734ac4e13b210a33320b01ccb" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,672</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_03240dcd1b0e4fb5add3a1f4f0196dce" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,819</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_d311ca4470d44c6a9b5dc2e879650f64" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,181</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_7ebd1bf538414250912bac21bfd38cee" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,983</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">Net income (loss)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_34533d8890444bd58b2027870609e117" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,072,665</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_35c43e16743b4ae6869b2828e53a7b3c" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">384,896</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_c70b9d6a229445cb9f3aa5366531abac" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,413,702</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_e7b3b214e56a4ef0858f8115cd0b42d8" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,054,601</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Net loss attributable to noncontrolling interests</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" id="Fact_b78698a44be5464195df09b90cd8cd81" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,519</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" id="Fact_e064108b79e1453698cad9947d65d780" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,882</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" id="Fact_175899089ee84fd1a2e358d81caafab1" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">86,339</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" id="Fact_043f5613a5f84da3b049e61ebbf81d6e" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">79,188</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px;">
                <div style="margin-left: 9pt; text-indent: -9pt;">Net income (loss) attributable to Roivant Sciences Ltd.</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_688b7a7cae984c0cb0952f604392f4dd" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,096,184</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_acff1ff96afd40399ff496a09d7adb99" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,014</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8423b53e54b143c7bbfb46d6b0e0b666" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,500,041</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_91669f76f7bd4d25a559d97ea96e1fe6" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">975,413</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;" rowspan="1">Net income (loss) per common share: <br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt">Basic </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_beae55c050564805855f41e6a7c677bd" contextRef="c20231001to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.37</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_000c8fe481e44a4db6d24a1e0ee27553" contextRef="c20221001to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_d012f6bb764941f7af73a63934c67c0b" contextRef="c20230401to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.79</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_ebd7cf1f81474688a15a30920b82bd76" contextRef="c20220401to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">1.39</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Diluted</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_331598902e644b4e8929213a44548f5f" contextRef="c20231001to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.03</ix:nonFraction><br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_0e162eec5528444f89817f58b77e3ff1" contextRef="c20221001to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_76d68878a1464c23bf7ea9be5c693902" contextRef="c20230401to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.46</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_5f88740cfe5e4f88b6d5588f1b3077a6" contextRef="c20220401to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">1.39</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Weighted average shares outstanding:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 18pt; text-indent: -9pt;">Basic <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_239b5e5c33cd4a68866dbaf2a17ec886" contextRef="c20231001to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">800,587,716</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_7fbb1847974446c2b68dee23ec84e1e5" contextRef="c20221001to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">713,319,399</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_f2c2b094a278408297dac678753ab177" contextRef="c20230401to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">776,759,728</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_e03409693f014749aa556864a613ce24" contextRef="c20220401to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">703,054,773</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;" rowspan="1">
                <div style="margin-left: 18pt; text-indent: -9pt;">Diluted <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_016ff35f7f344711b58e28179c15d53c" contextRef="c20231001to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">844,461,685</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_97c29fad90fa422fb5d9f4c925369014" contextRef="c20221001to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">713,319,399</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_14dd5ebafab448c3b5d7594376cc2d12" contextRef="c20230401to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">824,310,013</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_f5dd486d418c48848dbe86d1ceafd56c" contextRef="c20220401to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">703,054,773</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">ROIVANT SCIENCES LTD.</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Condensed Consolidated
          <!--Anchor-->Statements
          <!--Anchor-->of
          <!--Anchor-->Comprehensive Income (Loss)<a id="ComprehensiveIncomeLoss"><!--Anchor--></a></div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited, in thousands)</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;">Three Months Ended December 31, </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="6">
                <div><span style="font-weight: bold;">Nine Months Ended December 31,</span></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2023 </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2022 </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">2023 </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2"><span style="font-weight: bold;">2022</span> </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">Net income (loss)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_5e98410819324493b36035938cefcf77" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,072,665</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_69e10c71b7284712950f81ab24987fb8" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">384,896</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_c55479e1541d4f359132bce3d36f0bc6" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,413,702</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_3c6f97a8354a49fda0a4fa3d7e8be1f2" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,054,601</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">Other comprehensive (loss) income:</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 18pt;">Foreign currency translation adjustment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_9f31ac1165f14d48849f30f5e7189b85" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,066</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_7f7de56f601444c28c8ff82263d361ad" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,972</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_2da1908d3cfc459cba075931c6844146" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,612</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_9c21ba8a52ae4aeab507601a2437ac6b" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">547</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Total other comprehensive (loss) income </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_d8f98fcbe90142faa6cf9656a1338ed5" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,066</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_bb90bfae56f24dc7b9d4f6ea0d765a4b" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,972</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_d6d8faa647444a2894554d82364d18b1" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,612</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_a8fba159e9c64bfc86a2d4fc5857b3a5" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">547</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">
                <div>Comprehensive income (loss)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" id="Fact_09c12f6bf1184c7d968a64117895a4c8" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,047,599</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" id="Fact_0d6d353294854d92bef7fb7b175f31d1" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">393,868</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" id="Fact_405f72b339604cd488d1eebf2fa3463f" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,388,090</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" id="Fact_f8cd028dc05f42a79c63c8b8c00a9206" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,054,054</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Comprehensive loss attributable to noncontrolling interests</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" id="Fact_88a9555ccbfb46adb229e81b53592819" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,873</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" id="Fact_7a1e56dd7b734763b9d7b794e45208c5" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,036</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" id="Fact_bf951d9043144e2f8e1a34b6c2a8e781" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">86,784</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" id="Fact_6dde2e70e3c040c39a5bb7aa3e3ef02b" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">78,858</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 9pt;">Comprehensive income (loss) attributable to Roivant Sciences Ltd.</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_597db978138a4eef9fb96176e272627f" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,071,472</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_3d617c64332e44c4a7f2ef489538cbb4" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">361,832</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_21c77e83ab684f80924b40c2cab701f6" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,474,874</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_c179b1bf8c744656b08f49fb62d230f4" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">975,196</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>


</table>
        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">ROIVANT SCIENCES LTD.</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Condensed Consolidated
          <!--Anchor-->Statements of
          <!--Anchor-->Shareholders&#8217; Equity and Redeemable
          <!--Anchor-->Noncontrolling Interest<a id="ShareholdersEquityandRede"><!--Anchor--></a></div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited, in thousands, except share data)</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="26">
                <div style="text-align: center; font-weight: bold;">Shareholders&#8217; Equity</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6"><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Additional</div>
                <div style="text-align: center; font-weight: bold;">Paid-in</div>
                <div style="text-align: center; font-weight: bold;">Capital</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Accumulated</div>
                <div style="text-align: center; font-weight: bold;">Other</div>
                <div style="text-align: center; font-weight: bold;">Comprehensive</div>
                <div style="text-align: center; font-weight: bold;">Loss<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">(Accumulated Deficit) / <br/>
                </div>
                <div style="text-align: center; font-weight: bold;">Retained Earnings</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Noncontrolling</div>
                <div style="text-align: center; font-weight: bold;">Interests</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Total</div>
                <div style="text-align: center; font-weight: bold;">Shareholders&#8217;</div>
                <div style="text-align: center; font-weight: bold;">Equity</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: middle; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="6">Common Stock</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Amount</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-weight: bold; text-indent: -18pt; margin-left: 18pt;">Balance at March 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e71abf25db4a471bb7e6ade5aad2e64a" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">760,143,393</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_915ca5fe05084bf395ee797c46c161a5" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_f7c6ab5560414fa8a351f64eb14465ac" contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,933,137</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a450b16a17424efda23f80884fd598c5" contextRef="c20230331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,617</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_91ef67b491a44903ad1d1091ea74ab37" contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,772,754</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_b6b9ea5581e5432f82c842f17c164bf6" contextRef="c20230331_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">449,821</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_82b5ab7bbdd14c3498477f356a3179e5" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,607,587</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of the Company&#8217;s common shares in connection with equity incentive plans and tax withholding payments</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_a5e115da991a4a47ae270d489c7bea81" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,994,468</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_c329eee209ee48f9aba6c473cc7107a3" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_7073fbecbdb7409a9aa5147d813a4be9" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,395</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_cf0986927542450e99b9b6813a1eeeb2" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_24f95ffd2bf34fb9a7429802a6d08ca2" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_62f0aba08ab242d5bc28e6969312f075" contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_27449a6882ad4ca498a0c4142876b8ad" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,395</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Subsidiary stock options exercised</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_2df0a42cefa14a23a1f49e3cfe53e7e0" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_4e2fe77eb27f4db4a1e28f89d59d853b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">503</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_9d7d650420d74358a4e64dab37e7b63b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_d050f842ee5b48b3b4aee18ba7c5f66e" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_76d0432fb01442be89e77ee52513fc54" contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">387</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_49b7d85c169048ada6735df548b21dfc" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">890</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Cash contributions to majority-owned subsidiaries<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_dc8c508d439543a2bcc028d0152b03ee" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_d0ffb6fbe0334b4db32310ad5953a8c2" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">623</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_3649d5504e824a50987f5ae07a4af3f4" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_e74ea07d55ee49aa926495e2aff5098f" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_8341224682d64a3399083e04228fb663" contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">623</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_4d550c2dccfc439d8fe9c71b656a5ccc" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Dividend declared by subsidiary<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:DividendDeclaredBySubsidiary" id="Fact_19070e6c76d74f4694fc6a05ddb1d83a" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:DividendDeclaredBySubsidiary" id="Fact_105e8f8529934601bdf988da19f9601a" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:DividendDeclaredBySubsidiary" id="Fact_3003ce1d8e714134adfde39a3167226a" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:DividendDeclaredBySubsidiary" id="Fact_621bedb07ae744b8a26a3260c93d6f3a" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:DividendDeclaredBySubsidiary" id="Fact_986e07e7dd2941beaf143d86a26fe97d" contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:DividendDeclaredBySubsidiary" id="Fact_fbfdaea85bcd4ce5abe8702d67fc9845" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;">
                <div style="text-indent: -18pt; margin-left: 18pt;">Share-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_1faf259633fd49efabb0d74a11d59356" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_fbd05ab176a649829ced8b72a1223cb7" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,498</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_333c0661dfd44b22a0916f8a851f31a9" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_7fec9bc2dd534431bb922a93b75b6d76" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_b224110ae9494a028cc8f91fa21bc4ef" contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,762</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_72b051c977c949a88c2d63bab5d8fb73" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,260</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Foreign currency translation adjustment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_2df20bf7a70c4612bb74aa92c560c3cc" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_f12e1a4f9357493c93b5e15f03fd1a2c" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_8b7730ebda8e4803a13f45f1b7a4a9de" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,993</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_01f7670f818948b0b89dee53bb073988" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_6920f5b498b9495583418ae7a0112512" contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">155</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_aa136fcaa54448729b7097a6ad6dc317" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,148</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 2px;">
                <div style="text-indent: -18pt; margin-left: 18pt;">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_cdcd8c249cee452e8a178dec237c60b8" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_bdbf8661ed9841a3b024c29b30a44f8d" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_3104a86c2d7741e9909de6bc85ea3ae9" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_c9ca7bed801749199cf4a0943eb428d5" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">291,816</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_5452c91014674d3dbaa21c2b8a41ad61" contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36,029</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_d73d55485eb94b2ab2e7bd051773a54a" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">327,845</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance at June 30, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f73230a3032648e78f1f4757ec44b26f" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">767,137,861</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_713ff488fcca43ac90afab0722ff70b4" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_82007bb8cc224382a8bba24a1924af34" contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,981,910</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_24d12dbb3401465f82d2b9653e1c1a03" contextRef="c20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,610</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_63e9281ba9c14d34901f0be7d7ec6f80" contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,064,570</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_94791098a27f476486e8251414cad023" contextRef="c20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">423,409</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_20ee4d5f0d5d4fc785698abe31b04bcf" contextRef="c20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,334,139</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 16%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares, net of issuance costs</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesNetIssuanceCosts" id="Fact_ed96ba7ea89241248106485a283a946d" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">19,600,685</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_41bb709882bf4aaa95c3cd9b6f8f8310" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_d3e0fdc2c9344e9b9545db5d8eca1496" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">199,822</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_1c7980f31e2c43a5a5768b34643475c2" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_e9f9e6008eb44d508fca1c7dc1793562" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_98590d3c1b8b4ddfbf84be853accc564" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_0550047e41b34a54a94c9f80562e06b5" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">199,822</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 16%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares related to settlement of warrants</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" id="Fact_13f38e1239cb44098d321e6e075a8782" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">7,554,549</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" id="Fact_5263a68a69834f1ab33586c3f357d4ab" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" id="Fact_eb2249824d17405abedc28fc3244a4f0" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,264</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" id="Fact_2926ca25b5ad4ee3a51ddd300b6f7553" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" id="Fact_7cad236cbc5145b48c361fd96d68be77" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" id="Fact_065ed85eb2a9492eb12ab2592b85b9ae" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" id="Fact_990b66a084c841ed80f26bc5bea2583c" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,264</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 16%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares under employee stock purchase plan</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" id="Fact_faf9892337424fc6a74962f6ea7e6272" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">96,385</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_7bd9e3abf06d453a9edf4e4948d8830b" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_73a3ed7b36d94bc1b1911320873fefe3" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">587</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_5478b944547644b28802902a3ad90f9e" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_d506ce34726a402fb7c4ed32a1e96719" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_dd16cec4419f44be9b98d76f94c52d0b" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_476a16ecb8a84c47a820b7e0089f1b7b" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">587</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 16%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="Fact_20526c6cebf5445bae8e69eb9728e7b2" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,402,885</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="Fact_77714735125a442195b1ccd5ac79ded5" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="Fact_8c20501690c24c0f9c3c44379d1907b2" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,873</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="Fact_ed483ffea4af41b09a38cb242ea0841d" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="Fact_76d85977d3d0455cb26c8ce288f992a4" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="Fact_896b621aa6194a29a2bfb09a705de137" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="Fact_0891d27528ca48afa0eb57f9af0122a4" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,873</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Deconsolidation of subsidiaries</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_1b58e5e3802d462391db4483cc0b4a52" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_ffcf68693c574cdf813acc868d29dda4" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_d2f20735cd314b9d81f7a0d12243a2d7" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_d539e16af3674962939f7677d385870b" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_5fdc2a45b8d64133a7aa5e958d982543" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,050</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_73930ce0fea14d068c8b939727fae57d" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,050</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Subsidiary stock options exercised <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_93d718f205634334bd81b760a895ca20" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_7b7779bd7bb743b085397e0f181be1a4" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">131</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_d97c5ebd765048f09832e27a8f7040b1" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_1eb6a415005249efac8cdce1f079a81f" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_47d2dbddc24c4042892470fe980c8b90" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">65</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_e972e4bee38b49ad947d2cdf80f2c04c" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">196</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Cash contributions to majority-owned subsidiaries<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_625a638e9afe4d7b9969df35f713ab10" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_f6631d8e7f7746378965da7efae67f4c" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">571</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_8da24ce8ea7c46d9bb929e7b249e2f8a" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_2e3e2574bd684d5aa6efa8b4078b809e" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_6c685dcfb3f240ab9d44fb1c9862767b" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">571</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" id="Fact_0120763eb319436b820355029b9568e2" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -18pt; margin-left: 18pt;">Share-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_6d74e8cd7e5848edb707fbe4b73aee1d" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_7e45590da0e4485ab87a84148b994a70" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,487</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_e041935a04424d20ba840a20e25f17bb" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_c4090aa8f93c40a0a87b1986545ee9f1" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_181cf0d7ff01414999ad4868945368dc" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,831</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_257d8fbde6e349bea7eca01920c268c9" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,318</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Foreign currency translation adjustment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_809627eb3a43491a8c6309e7a93ed9a5" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_12e604e50e85478b8760e3e9cf571250" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_bf8f548312c74de3a0dbb12149b2fe44" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,538</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_e55ecf03946345f5bc5c6b916341d55c" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_9cbd61f8ff7a4b048567eb46cd9b76c8" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_2a82bf9b4ae2487883c889306ddfea87" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,602</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -18pt; margin-left: 18pt;">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_ae50de21a50b45e393a447af451fc78b" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_9a0830162f1e4bf0b79d50d0c51ea743" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_8c80f7554ff4401d93e606ae57ce21a8" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_2cbfcec626cc4603b6cb857342113081" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">304,327</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_de10b092dac74df48c34e5147817487e" contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,791</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_51ea5cde89b14ffebee135e45ba7a727" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">331,118</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 2px;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt; font-weight: bold;">Balance at September 30, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_fc72818c37db41edaaa59fc97b56c0f4" contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">800,792,365</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_9c35f3e2758148f1961b663e0a815eaf" contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_af3bbdca0e414613966b0945ba7f8ddc" contextRef="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,320,503</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_312eaca7b2194a80bd99465da9e42f45" contextRef="c20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,072</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_81cf6f89c3fb446ba72043dff2cd5f81" contextRef="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,368,897</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_409624585c3944c6bee3806647016319" contextRef="c20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">377,099</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_34253fe81d51498e8e2f597da35a3188" contextRef="c20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,325,633</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Disposition of Telavant <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition" id="Fact_8743744bb8d240879b257b88aeba7142" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition" id="Fact_cdaedc04fb6545c685c819e99dc54963" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition" id="Fact_7be3705d420c44cb9fa399a10dd08d36" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition" id="Fact_3b1f7c3fa57844d88c67f1ea7685067f" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition" id="Fact_be32d028481b45078394d6e64cbb14cb" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,500</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition" id="Fact_5f413dc98ddf4bfaa2f0c968c6ad55da" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,500</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of the Company&#8217;s common shares in connection with equity incentive plans and tax withholding payments <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_52102239c47742459da93d65a5aebbee" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,098,545</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_c92e4c0408214454877e46ce6850d602" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_e6f0538723b045429db1134db459a586" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,456</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_2d8e1e62d92e40d49bab8f333b568e86" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_798eee2be1cd4dcdb49e798b5cba9027" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_428c956ffcac448fbf601f73ca3960bf" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_09c1c480d125440bbf2a47b59cbaa32d" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,456</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of subsidiary common shares, net of issuance costs <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" id="Fact_51ef72d619114159a0d602cdd9afe860" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_33bce87d81c6413488effeb6ffd589d1" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_b17930d067cd48ad97e74cc9692ee52f" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">129,763</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_cccc92f6586f48f0af549bd1fb146c8d" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_3ea408f71e9c41629b5bb2bee4bfd037" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_f7c967e08f73427e8254cd794bfa8e70" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">108,970</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_accfbc939d5e404894bcafaf8b9c7304" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">238,733</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Subsidiary stock options exercised <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_82e15b68bbf949739ed5f98f3f69d4e2" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_b56390b6f5964da1a4430c7bb9ff21c5" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,711</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_6a5e3223693744f0815ef2a09acb8c64" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_a29d233bc76b431cae8faa0d582e0573" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_3d40184dadab468d92a724798fa2eec1" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,400</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_a7e57fdc96c04e46b047424e5e0ac1b7" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,111</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of subsidiary common shares to the Company and cash contributions to the majority-owned subsidiaries <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_202ceffa99b249998357ab2f59106987" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_5087bbd9b980457bb006aa8fef50a669" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">104,172</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_38933e10c2c8496687770c2f84ae4208" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_a3887815f1c042b5830151130c128746" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_eda4ea13e615426ab2b62eb936aff4c5" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">104,172</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_ddf1bf2bb07e48dfb913817c28a05fd5" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Share-based compensation <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_ca7338cab8814096a09f6d83ce44cc82" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_5c831b8ec3e04eabb8a4bf20333e65f3" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,999</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_3404f21ee07d42d9935ad1224a949746" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_624d09d5ffa245a7be6e8b92f56d8d45" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_122069116b924059b3d192fa8c01d9e9" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,551</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_5908917e71734f8286389863420b117e" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,550</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Foreign currency translation adjustment <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_158fa34f7d164ca6866480deb5099f1d" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_21b9052add0a411493648daa1f32b174" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_2790c9ef2e0242ec8ea2a1913f7f4020" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24,712</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_d2483002dcd84e45b97979a0777094f5" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_73ab505ec0dc4a6698386bcc8b2f39cb" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">354</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_7652fd6364574ba3a657e1e64e578299" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,066</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 2px;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Net income (loss) <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_67a358642ac04a11975391410d0996fd" contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_afd638093e0a4b3789eb8bd48084e916" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_655e8e614fd34e6cab43c8a69c8616dd" contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_eb54de23617846bab63e64f16a46d71c" contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,096,184</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_096b829e29f341b4a8bdf15e5e837226" contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,519</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_b6607040dc8f4a0bb5e9bcaba9534533" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,072,665</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-weight: bold;">Balance at December 31, <span style="text-indent: 0pt;">2023</span></span> </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;<br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_1c6c6346e2ab4bd6925c0f4b381224ae" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">804,890,910</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_2ca88417ef1a41aeaa8cec9722800515" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_841a443c85fb4410a35fa32181412818" contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,390,260</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_fb1ceef67a494647aee461ca62516de7" contextRef="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,784</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_25737093a960490580b7fb8c84b01c80" contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">727,287</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_4e365a8fdbaf4e079beff6f1786fe6d5" contextRef="c20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">494,819</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a8ea4e6045c34b7f94b7674d6ec10403" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,584,582</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="26">
                <div style="text-align: center; font-weight: bold;">Shareholders&#8217; Equity<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"></sup></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Redeemable</div>
                <div style="text-align: center; font-weight: bold;">Noncontrolling</div>
                <div style="text-align: center; font-weight: bold;">Interest</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                <div style="text-align: center; font-weight: bold;"><br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Additional</div>
                <div style="text-align: center; font-weight: bold;">Paid-in</div>
                <div style="text-align: center; font-weight: bold;">Capital</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Accumulated</div>
                <div style="text-align: center; font-weight: bold;">Other</div>
                <div style="text-align: center; font-weight: bold;">Comprehensive</div>
                <div style="text-align: center; font-weight: bold;">Income (Loss)<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;"><br/>
                  <div style="text-align: center; font-weight: bold;">Accumulated Deficit</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Noncontrolling</div>
                <div style="text-align: center; font-weight: bold;">Interests</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="3" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="3" colspan="2">
                <div style="text-align: center; font-weight: bold;">Total</div>
                <div style="text-align: center; font-weight: bold;">Shareholders&#8217;</div>
                <div style="text-align: center; font-weight: bold;">Equity</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="3" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: middle; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="6">Common Stock</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Amount</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance at March 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" id="Fact_1c74cffc9c9845c1addc97d9866b262a" contextRef="c20220331_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,491</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f478373981c7438fa1cde1acf053ea1c" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">694,975,965</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_98d2f875edc54abbb57221e6a5251bf7" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_32810c6887d342ee8218e30ea2f378c3" contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,421,614</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a930b9836aad41be88191d54dde640b2" contextRef="c20220331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">946</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a4d9f82bbb90428186331c4b4d4029a6" contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,763,724</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_d620758959a147ee815b70ae8046daf0" contextRef="c20220331_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">381,999</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_53b88f6825ec444496efcda3383c71d5" contextRef="c20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,038,943</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of subsidiary common shares to the Company</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" id="Fact_b9bd3ff21c7a47af97bd145252d1c048" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_f331eafd9c544093922318e48f3d6d03" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_352ed7d511c642cea2467d99b490b176" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">251</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_ba21476aa6f7407f801124bf79f75de2" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_27c7de02e109434bbf73e2f8e5a8c1d5" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_4467ee7c20da4f399a499d3385220b9c" contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">251</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_02ce24610ddf4645b10267dd7fdd1a47" contextRef="c20220401to20220630" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares in connection with equity incentive plans and tax withholding payments</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_0b6e7331db55471bb54b96f3af4d12b8" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,739,781</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_be10ebf4be9b4ae08a97d8740e477d96" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_c91a9212eed148ccadfbeb9523c7ee43" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,329</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_fa1b8c92bbbc4d9995aff42a4301d1ad" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_402ce26b7911474d89a3ab74e83a865c" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_97d1ad90ebbf480e92b798d634a70cf6" contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_c0278ce2477d4c87bfe147832d99eb01" contextRef="c20220401to20220630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,329</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares related to settlement of transaction consideration<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" id="Fact_7abefcdf70e14e829fcc6ade022c3dbd" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,455,719</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" id="Fact_1173c8baa47b44ddb656dee063623ad7" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" id="Fact_07c9d6825e9f41ec8c06a22ef34fec1f" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" id="Fact_6383c3410b7c4be085b0005968d0e4fd" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" id="Fact_53c54ebf01754ad0b6fc9c6473960cdc" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" id="Fact_34eb68992f784daa974cef93d1077558" contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" id="Fact_0dd5b56628ca41f18a975f6a89fe1b79" contextRef="c20220401to20220630" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 9pt;">Share-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_38fcf214207e447fa4e71ca5806fbf28" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_57156ae30bb94c129aba396ae6526a19" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,590</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_176322fca0bf4f93a1169c6193c52fb8" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_d3cd1ef158184c65ab5cb836e69a7f4d" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_d971f341a2624e4ab3aeb91ad883888c" contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,204</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_ff387284b15a48ff94a896e31979fee3" contextRef="c20220401to20220630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,794</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Foreign currency translation adjustment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_2bac2e8408334aed82b7c1d4c8c3b2f1" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_80f6d268fe2d40a197bccb767d7e8ec4" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_53479ff907a14c4899742557c6f75eba" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,966</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_eaffc8d777574b85bfc936ddc7494f84" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_0c60d5899bf9460aa5ba5d4c4fbe16dc" contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">199</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_ca61ef40c0cc413992caa08af08b9246" contextRef="c20220401to20220630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,767</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 9pt;">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_53d6b43f8c524c339e56882794b3656d" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_55dab0bbc90540809f3566d9459f603b" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_28f970a45798430d987d11ab2a5d0e44" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_6e03c8e61e504064b9a87396167e8a7b" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">331,809</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_b90cd0b52d3f470495f74d1aaf445307" contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21,975</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_68273f772800450e888c818e5c1e4a07" contextRef="c20220401to20220630" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">353,784</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 2px;">
                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance at June 30, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" id="Fact_9e3e57fce12242db9c11dda6fb15cff0" contextRef="c20220630_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,491</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_d369b890db1344aa8d66aaadb00e3258" contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">701,171,465</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_bce04d09c1254863bd35bca3c7a72006" contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_42deea2348e347f3bda4b44bfd123aec" contextRef="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,474,624</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_1c07574f1a364186b080b8efaf9cb5b7" contextRef="c20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,020</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_21059a223c57411d9c0fb473204b8c0d" contextRef="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,095,533</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_478f9eeb786d4d7c858e8539933eb4bd" contextRef="c20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">371,280</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_4072e06180c043d3ad3381b9f0a3faed" contextRef="c20220630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,755,391</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares in connection with equity incentive plans<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" id="Fact_f1277ade95ee4fefba52b40c3ab8e666" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,185,639</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" id="Fact_5ec62dfcf9a5413183a63823bc61eb81" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" id="Fact_40778632202f4a71a469dd6695a71289" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" id="Fact_660a81e249f244e8b2c9e066cec0e38b" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" id="Fact_f0f15ac7d5ac4af19ad0be96e4f794af" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" id="Fact_adceb86951d045b68254f0d5f9f8637e" contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" id="Fact_7bfaf9f656a543b989ed806febf9a10f" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares and other consideration for an acquisition<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" id="Fact_e84b68e0c1f547008ecd9610dfcb81f6" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,029,877</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" id="Fact_c8c73b879986468ca3a0aa4b88d86103" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" id="Fact_cc63470c131747bb86c55bc66ab580d9" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,836</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" id="Fact_4973b10a802141968dfe3862416b78a3" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" id="Fact_90496b4574c842c7a50495a19bc816b8" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" id="Fact_e2c9b4fbee2544419714cf3f4760fa75" contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">112</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" id="Fact_b86e7296911048bcb600b890e2afe38a" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,948</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_fd26cccfb8c94ab69dbfe310244db0f0" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_995c501131cb4b9c962f2bc7d89a77a2" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,240</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_3195c165ebc7400bb7699c676a821647" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_a463e1c7a6e448de8043bc94417cd4e2" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_5a9d7fd5c5b64452ae19cb57e2db63b9" contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,240</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_876166bd8ef84df992030b1b69a865d4" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Deconsolidation of subsidiary<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" id="Fact_8b50cf32cb0549f1a3565254ed277bdd" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,491</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_82805b578708492da5a9dd73e33c41fd" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_f337f16542f44c379385565dbd26a869" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_58071e0ea001415483c83a1b131c458a" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_8acce353543c41cd87408e482b37d99d" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_418e253325804eb99743184e6c3ec575" contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_ade991a66634409db139d1f818a03e1f" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -18pt; margin-left: 18pt;">Share-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_20c3c2d3812e4e14b4c273fe7c580913" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_7598abbe07af46a18154f4e37aaf7f9a" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,415</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_0d0f54bdf6014fea82fa83ca38b742e9" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_278b296c3f1946e098a9ceb52f33c310" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_786cffd35a0f45948908543ef048655b" contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,564</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_dbc9e85af47c41caa2e319c2530ec86a" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,979</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Foreign currency translation adjustment<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_b77c582260c74b25b01ed03642e96864" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_06872ed2a63c4557b515d633c5ecef5e" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_483232ab705f4e14b2eff8bebc24d536" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,069</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_afd5619953474ccda4d09b231ac40870" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_070cdb5da1114eaba453f9cd55a3d55f" contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">317</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_5aa401cb11e04f0e8de7405f3358e51a" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,752</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -18pt; margin-left: 18pt;">Net loss<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_471cf4170d8a4ab6aae70c803e826268" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_3efc68f21e8840abac2fca931adfd5b7" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_4332f887aed74ce99d8e766656a03bc1" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_dab37501cdd04b44806b68b2c88cb076" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">291,590</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_44686c19c56b46ea87241282a057bcfc" contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24,331</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_527e598f16614bf58f716b595f9bbb8b" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">315,921</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 2px;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt; font-weight: bold;">Balance at September 30, <span style="text-indent: 0pt;">2022</span> </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" id="Fact_8d3b4fbd4ee44ffc828d81943c501600" contextRef="c20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_709006338d984097a5943441c841e82c" contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">704,386,981</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_8750e5488e4e447c8043cbe36b8afd8b" contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_438f3284ac014756819dfbbfc8a2b184" contextRef="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,538,635</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_ed5803f915fb4ca2b4891817c7fbc290" contextRef="c20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,089</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_9742e1f8415f4e35a48828036154e325" contextRef="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,387,123</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_1e8d986e44b043f8ae4bbf19ad915255" contextRef="c20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">353,548</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_26bc615472494be3af9b234cfbe1c78a" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,514,149</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of the Company&#8217;s common shares, net of issuance costs <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesNetIssuanceCosts" id="Fact_e4d50dd70f3a4a8592b766f7e320c55e" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_c43bbd4996ef439cac713f9096631b7a" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_3d4c39120b994577b2b271071c085c30" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">94,735</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_48e26c49f3ac44a88316dd0bc4cab11c" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_3ccc3b2f9e924d2a81faef8f65934d93" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_b729decce3ae4b50ab0c753648cd4963" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueNetIssuanceCosts" id="Fact_00c0d1ef33264938a7f71329cbc76f65" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">94,735</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of common shares in connection with equity incentive plans and tax withholding payments <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_22fdbbfac0d14bd9b16ec4f0febbf87c" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,417,850</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_f746f04910bc4bd1869341216f095b55" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_4c49caaaa6f44636ae7bb48ca82624be" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">982</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_edb84de6e1594e0dad551d04d410fbc4" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_d3344269bee6423f8ff3cd4931492aee" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_1a9ca2d95b5f40f8a46a399417c74327" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="Fact_200fc7f5eba5428fa355e1693f4d3f68" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">982</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of subsidiary common shares to the Company and cash contributions to majority- owned subsidiaries <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_02f77a4af86d4b0ea549c14e28d112cf" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_7bcfaffec2084b07bdfa5236d6a6e280" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,822</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_34956b25cd994b9089214c643edba62d" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_7e5b51b4d10f45d58e730c6c8f95dbd2" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_190ba1a228594ab8bc6695c241038168" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,822</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="Fact_a1529149898247eda13ebbc2ed8501ae" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of subsidiary common shares, net of issuance costs <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_6570954dad004db7ac0a5676647e9e24" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_a5f6c5f6e8524fadb43c2b34d41517b8" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,599</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_7c33b0d503e543ee9b5fb9ed6feece52" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_695123d21dfb4bc2a49e60000a499fe1" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_70927acae59c422f8bdc85d4a696e0ca" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,129</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="Fact_eda624b7c1fd42bea6b8ac80fa793781" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,728</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Subsidiary stock options exercised</div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_ceddec870d2b46fdbb27df0b667887f5" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_c1719e20e2204e6eac20741941fb5774" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">260</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_e8dbbc37fdc740669737de12ba5f3d4b" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_d252cf49ea2349e58c30ff21c2407085" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_0546f8ffa9fc4215a4cfab65e903eab4" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">177</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="Fact_6e42a80e7e97447abb6a5ab34a09dad8" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">437</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Deconsolidation of subsidiary <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_7099dcdf68ba4b00bd75dab8c1bca51d" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_0cc79e44afbd45f9a4038000dd5c9b3b" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_da4edd84f02c4f69b459f7517b78e858" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_6bed71de9ecf4120bdc489bb90c315fa" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_d67b855c784e4251909c4955a64ca112" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">292</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="Fact_31dcb1e27ca8406ca0f1c50fa6eec542" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">292</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Issuance of subsidiary preferred shares <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" id="Fact_7fd1882321db4724a8d2d8a92976a9a2" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" id="Fact_a464ae02857b4da6ab64a66d17623e3d" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" id="Fact_435d9076ea9246808f112c926a44c16e" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" id="Fact_53c84f438ef3488198f96ed5251bdcfc" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" id="Fact_4042f245b24548ffa1f0f0e44c88e8f7" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,500</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" id="Fact_150c6342409d4a768654132a5e5b8526" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,500</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Share-based compensation <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_e44e3a41926447a28c7a760d2a87962d" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_9924a2ca1f8442aa8b71aa1c8cb92126" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,961</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_25898d6dfe7c4af28d7beb9f70a26cba" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_c320420eb4464d2db4f8ddb4f5084192" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_a5800c2333f645bfac9757a623ac4cac" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,770</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="Fact_51085ffa298643e5a3d114666dc73a8f" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,731</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Foreign currency translation adjustment <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_8869d4b87a5c4845b1afa6aa6edc0edc" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_c46f4d211a754f238d7b3244909340c0" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_8a79243b9beb4c238a3ea598df29a123" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,818</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_990775eb23044a99b3d44b19d0df0b53" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_47895eda84fe47ab98b06ffb9d09736d" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">846</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_d75350cd776d4940970885e46c6f12f8" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,972</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 2px;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Net loss <br/>
                </div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_4ff4a5c379f44a75bc9a68e8ecd6f67b" contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_410cb8785d5147c7989bfa03069ffb6a" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_4538f2f70d83416e8528ee1911405715" contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_e70663bb9ffd4be292eca41141baf8e6" contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,014</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_2743168a685a4ad98e55578f42ac66a6" contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,882</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 7%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_b9f55dfb5afb4d8ca480bb4105b4eac0" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">384,896</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-weight: bold;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Balance at <span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" id="Fact_293db412ad4e4f81a1ae00e55f63240b" contextRef="c20221231_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f437e7861e584d89b2ef0781fddd2d5c" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">726,804,831</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_801a0b4831da40d5b2240160adb2bedb" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_d0e44e03c0a84466a5c87ebe3b13e477" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,695,386</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_39edc056ba3c49fa91a4d77db0389e37" contextRef="c20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">729</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_e23ba3f69f1747cf91b1a48023372dcf" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,739,137</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_693288f8ee6c4e37a0fce62adaaf4b3e" contextRef="c20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">471,618</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_bf60ba0db6074abb9313aa9becaba159" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,427,138</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

      </div>

      <div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">ROIVANT SCIENCES LTD.</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Condensed Consolidated
          <!--Anchor-->Statements of
          <!--Anchor--><!--Anchor--><a id="CashFlows"><!--Anchor--></a>Cash Flows<!--Anchor--></div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">(unaudited, in thousands)</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;">Nine Months Ended December 31,</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="font-weight: bold;">Cash flows from operating activities:</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">Net income (loss)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_2a4b699f00c94f8f928830d7b9ebf524" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,413,702</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_3e704ce9d8424f73b804401f02092687" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,054,601</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="margin-left: 9pt; text-indent: -9pt;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 18pt; text-indent: -9pt;">Non-cash acquired in-process research and development <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NonCashAcquiredInProcessResearchAndDevelopment" id="Fact_7805e281fcac40abbf5bb25462221e1e" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:NonCashAcquiredInProcessResearchAndDevelopment" id="Fact_f929b8a776dd4d8ebe46fa2c64be0395" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,749</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Share-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_cce46a527a0745fc8c070762b9a88eff" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,903</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_b04c6e88da5345ab8f29a90cbabcb9f7" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">192,504</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Change in fair value of investments</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:GainLossOnInvestments" id="Fact_88e948fe64ad4e2f8787933f4689b8d7" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">63,880</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:GainLossOnInvestments" id="Fact_332a720fb50d41fbb61340a483c55f40" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53,277</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Change in fair value of debt and liability instruments</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" id="Fact_936c06c958414209a474396ac935cef7" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,376</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" id="Fact_40fe75641c0a4e218a0098a4edec570b" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">90,032</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Gain on deconsolidation of subsidiaries<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" id="Fact_70570cca1d4545f2aa3d64e3dd2d80ae" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,354</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" id="Fact_a151b46132e742e4a152ff616f902fd0" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,276</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 18pt; text-indent: -9pt;">Gain on sale of Telavant net assets <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_b1b0204253c84956bbd321fea6aea5b5" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,348,410</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_93f1633809d04994a6d21494748eea52" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Depreciation and amortization</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_098816723bca4735a1b61234ec1a22b4" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,811</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_9c2e38073ea84edda34817d9195aba08" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,904</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Non-cash lease expense</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_9187303b4326483a869eb6e772476c8c" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,047</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_65350038fc814bc7827720699e7a102f" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,009</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Other</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" id="Fact_c1284585a1714bb69bb30b7117a3f648" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,846</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" id="Fact_1a092a43481147179354063d85e80788" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,066</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 9pt;">Changes in assets and liabilities, net of effects from acquisition and divestiture:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 9pt;">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Other current assets</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" id="Fact_e3f6c686498249ae867b7479ea7ce61a" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,767</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" id="Fact_17ab5aed4e0b49818eb3720287dc4e47" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,037</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="margin-left: 9pt;">Accounts payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" id="Fact_cf71c97a836042f798c68a5bc08e4663" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,797</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" id="Fact_dcfca5fd29ec43a7b7ab80adf8ef320e" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,970</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Accrued expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_3cb461b7fec246289ebaee71a4290d63" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,785</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_134e3b5397a443c397e5fdf96866c311" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,702</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="margin-left: 9pt;">Operating lease liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" id="Fact_91ef4c71ddcc4481b8335d96836cb569" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,151</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" id="Fact_7fcda848416e486c9a4df96896216482" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,814</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Other</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" id="Fact_9f24554f7b6245e98828262f7e56139f" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">41,986</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" id="Fact_fa3051800c6448209cbdcde7be83a6ea" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,342</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 18pt;">Net cash used in operating activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_44766c9ca5fb4d31b1b5060e898136e1" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">656,811</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_4d91d30999324b76a2a18f71005c9aae" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">664,305</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="font-weight: bold;">Cash flows from investing activities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 9pt;">Milestone payments<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:MilestonePayments" id="Fact_6598e24980fd40e19d3748bf78afbe32" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:MilestonePayments" id="Fact_83bda41e42ab4f1cab04c634a3a52035" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">140,136</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Purchase of property and equipment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_86cc706188a64936b495a4e5ec2167af" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,033</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_410440e9c83b40b7afa4f53eb1067e52" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,068</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 9pt;">Proceeds from sale of subsidiary interests<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" id="Fact_4ffcbfa025ff486bbaccb2f5abf64457" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,500</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" id="Fact_56352a7ad8244cbdb7305d6ad95e32dc" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Proceeds from sale of Telavant net assets, net <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:ProceedsFromSaleOfAssets" id="Fact_bcbfbc5c5ce7415eb83e31abac4e27f0" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,233,396</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:ProceedsFromSaleOfAssets" id="Fact_fbb87877cc4d44ae96315c34b8e8c7a4" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 9pt;">Cash decrease upon deconsolidation of subsidiaries<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:CashDivestedFromDeconsolidation" id="Fact_009cd5993216450eb9061a94b38a29b1" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,679</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:CashDivestedFromDeconsolidation" id="Fact_21561966525945d69f069ced2c798780" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,706</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 9pt;">Other <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" id="Fact_eee223ac8788413d9451c7a6bd6576af" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">511</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" id="Fact_b1b4d61cbaca484797034b57c519f5b2" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 18pt;">Net cash provided by (used in) investing activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_be3a39108dda48b7b4eb127fcf75f169" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,196,695</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_ca5ebf80e0c24888a43d694f1f088be0" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">157,822</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="font-weight: bold;">Cash flows from financing activities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Proceeds from issuance of the Company&#8217;s common shares, net of issuance costs paid<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_aa4c30ec86504f649bce26659c2e6e57" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">199,822</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_9e7c6c0b679b4531b760a6b6e5bd20e2" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">94,735</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Proceeds from issuance of subsidiary common shares, net of issuance costs paid <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" id="Fact_24d8e50c13054299b354c0e9d93f09e9" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">238,733</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" id="Fact_1a18e91c80f7497f937006c3befc897c" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,727</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Proceeds from subsidiary debt financings, net of financing costs paid</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" id="Fact_d56bbe659cbc4b5a9214496c1dbb3b07" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" id="Fact_e3c865fae2634744b9a30543fb49a0a7" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">159,899</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Payment of subsidiary dividend<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:PaymentsOfSubsidiaryDividends" id="Fact_fbd6aa0cc8e046449b90531e89a1c497" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:PaymentsOfSubsidiaryDividends" id="Fact_991cf6fa7ccb4754bcecc44abb0952e3" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Repayment of debt by subsidiary</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" id="Fact_55716f5515dd4e9bb04d7be031cd408b" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,815</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" id="Fact_1a51035b24154f5e8fdb5278b3a9ca6c" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,108</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 18pt;">Payment of offering costs and loan origination costs</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:PaymentForOfferingAndLoanCosts" id="Fact_2e931690534247ae8d1fb1234111cbe1" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:PaymentForOfferingAndLoanCosts" id="Fact_9ebe73bdcdd4426cafdb430e713e61e8" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,250</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Payments on principal portion of finance lease obligations<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_ab609be57db24ee8af4301a8bccdf7e7" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,225</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_3efd99e3b6d94a3eb7b211406658b19b" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Proceeds from exercise of the Company&#8217;s and subsidiary stock options<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_86ed49e266724d2482d22c00074eb221" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,023</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_2e63e065ab5f47dda017ae1faa8d4081" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">569</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-indent: -9pt; margin-left: 18pt;">Taxes paid related to net settlement of equity awards</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:PaymentsOfTaxesForTheRepurchaseOfEquity" id="Fact_185fbedcadfe46af95d59d084baa77bf" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,101</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="roiv:PaymentsOfTaxesForTheRepurchaseOfEquity" id="Fact_38201011e8d34bf18500e8e7351b3d56" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,442</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Proceeds from issuance of the Company&#8217;s common shares under employee stock purchase plan<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" id="Fact_aa054c1f1f0941d09d486bd989f83996" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">587</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" id="Fact_4822ac96138b4d0fae0648d840e1270f" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Proceeds from exercise of the Company&#8217;s warrants<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_f5210bc60077499f87b9869af2bdd729" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_268cc33e25fa4ae2a9253eb3bea6407d" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Payment for redemptions of the Company&#8217;s warrants<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="roiv:PaymentForWarrantRedemptions" id="Fact_1b948a3854ea433a92b88fde4128cf31" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">41</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:PaymentForWarrantRedemptions" id="Fact_4bda51415a9446f8924b946ba3ea2cfe" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: 0pt; margin-left: 18pt;">Net cash provided by financing activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_3819237778a2417fb2e6c0b7190af3df" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">451,988</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_9c05357c33794217a10b96fa22dd47c4" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">289,130</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_b9cc70bb369241f19adc0eba727cebef" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,471</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_ee405ec1b7e74e09839ea69f3604091d" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-indent: -18pt; margin-left: 27pt;">Net change in cash, cash equivalents and restricted cash</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_b774d9624e34446f8b5f5f96f7f2e2b5" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,993,343</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_666e21af754a46f6ba129d8a827ff1e3" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">532,997</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -9pt; margin-left: 27pt;">Cash, cash equivalents and restricted cash at beginning of period</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_c5748371322c49b4bbb5273d2ae308b8" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,692,115</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_44c5afb657f945759c8465b5d13ea8e4" contextRef="c20220331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,074,034</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <div style="text-indent: -9pt; margin-left: 27pt;">Cash, cash equivalents and restricted cash at end of period</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_8e6194be17634f5d897a9f7968fea706" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,685,458</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_f5c174f9acc1418ba265db8fcc659357" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,541,037</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="font-weight: bold;">Non-cash investing and financing activities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Cashless exercise of the Company&#8217;s warrants<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CashlessExerciseOfTheCompanyCommonStockWarrants" id="Fact_7d78d1daedc74d9ca9114b3ef34b16b5" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,258</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CashlessExerciseOfTheCompanyCommonStockWarrants" id="Fact_410017eb285f433bb72112b76541cee4" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Issuance of the Company&#8217;s common shares and other consideration for an acquisition<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" id="Fact_791ed4db9f174a14b850561d15db978c" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="roiv:CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" id="Fact_3dd6a82cbbf64bd8b0e617bf39785944" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,694</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="margin-left: 9pt;">Other</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:NoncashOther" id="Fact_157c127a466d4c4aa3ffa4c03baa8a3c" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">301</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="roiv:NoncashOther" id="Fact_e9020976598d437c92ab7489206b2b0c" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,063</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>

        <div style="text-align: center; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">ROIVANT SCIENCES LTD.</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor-->Notes to Condensed Consolidated Financial Statements<a id="ConsolidatedFinancialStat"><!--Anchor--></a></div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Unaudited)</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>


        <ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Text_1d704520f5cf4bf8a54773c0831f66c0" contextRef="c20230401to20231231" escape="true" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35851">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 1&#8212;Description of Business and Liquidity</div>
</ix:nonNumeric>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35851" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35852">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35852" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35853">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) Description of Business</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35853" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35854">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35854" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35855">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;RSL&#8221;) aims to improve health by rapidly delivering innovative
          medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization. In addition to
          biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April 7, 2014 as a Bermuda exempted limited company.</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35855" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35856">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35856" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35857">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">VTAMA&#174; (tapinarof) was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) in May 2022 for the treatment of plaque psoriasis in
          adult patients.</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35857" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35858">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35858" continuedAt="Text_6880aa2113f745d1a5da7de60e8a35859">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has determined that it has <ix:nonFraction name="us-gaap:NumberOfReportableSegments" id="Fact_34e78714195b4eadb74e957cc150c301" contextRef="c20230401to20231231" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_01bd28f6e54b488ea69ef765bc958c2d" contextRef="c20230401to20231231" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction>
          operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#8220;Equity
          Method Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities.</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a35859" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358510">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358510" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358511">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">On September 30, 2021, RSL completed its business combination (the &#8220;Business Combination&#8221;) with Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;), a
          special purpose acquisition company, and began trading on Nasdaq under the ticker symbol &#8220;ROIV.&#8221;</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358511" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358512">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358512" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358513">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(B) Liquidity</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358513" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358514">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358514" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358515">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">The













          <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">Company has incurred significant operating
            losses and negative cash flows from operations since its inception. In December 2023, the Company recognized a gain of approximately $<ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_fed5a283303747babcc8dc300be5887d" contextRef="c20231201to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_TelavantHoldingsIncMember" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal">5.3</ix:nonFraction>
            billion on the sale of Telavant net assets.&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company had cash and cash equivalents of approximately&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_661b387ce19541d89ec9153649a26d6e" contextRef="c20231231" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal">6.7</ix:nonFraction> billion</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and
            its retained earnings was&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_40e4bf7bb4914362884158e0a91220e8" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">727.3</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. For the&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine months ended</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">2022</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company incurred net income of approximately&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_83a837d60f644da380f29f85a952ad03" contextRef="c20230401to20231231" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal">4.4</ix:nonFraction>
            billion</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and a net loss of approximately&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_827028db14f34d38815a28d6d100e60b" contextRef="c20220401to20221231" unitRef="U002" decimals="-8" scale="9" sign="-" format="ixt:num-dot-decimal">1.1</ix:nonFraction> billion</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively. The Company has historically financed its operations primarily through the sale
            of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. Through its subsidiary, Dermavant Sciences Ltd., the Company has launched its first commercial product,
            VTAMA, following approval by the FDA in May 2022</span>.</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358515" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358516">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358516" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358517">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to
          commercialization of products, regulatory approvals to market its product candidates, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property
          rights. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may require additional capital to fully implement its business plan.</div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358517" continuedAt="Text_6880aa2113f745d1a5da7de60e8a358518">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_6880aa2113f745d1a5da7de60e8a358518">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure
          requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_1cfef57290ff45639577d3d3deac9bed" contextRef="c20230401to20231231" escape="true" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 2&#8212;Summary of Significant Accounting Policies</div>
</ix:nonNumeric>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a1" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a2" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a3">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) Basis of Presentation and Principles of Consolidation</div>
</ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a3" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a4">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a4" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a5"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_971156c9275b4805b34f2eafb7e7a4fe" contextRef="c20230401to20231231" escape="true" continuedAt="Text_482e9c53f6cc48a495ccd3c7d282019f1">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s fiscal year ends on March 31, and its fiscal quarters end on June 30, September 30, and December 31.</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a5" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a6"><ix:continuation id="Text_482e9c53f6cc48a495ccd3c7d282019f1" continuedAt="Text_482e9c53f6cc48a495ccd3c7d282019f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a6" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a7"><ix:continuation id="Text_482e9c53f6cc48a495ccd3c7d282019f2" continuedAt="Text_482e9c53f6cc48a495ccd3c7d282019f3">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
          accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and follow the requirements of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Accordingly, these unaudited condensed
          consolidated financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be
          condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a7" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a8"><ix:continuation id="Text_482e9c53f6cc48a495ccd3c7d282019f3" continuedAt="Text_482e9c53f6cc48a495ccd3c7d282019f4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a8" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a9"><ix:continuation id="Text_482e9c53f6cc48a495ccd3c7d282019f4" continuedAt="Text_482e9c53f6cc48a495ccd3c7d282019f5">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial
          statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the SEC. The unaudited condensed consolidated balance sheet at March 31, 2023 has been derived from the audited
          consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial
          position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the nine months ended December 31,
          2023 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2024, for any other interim period, or for any other future year.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a9" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a10"><ix:continuation id="Text_482e9c53f6cc48a495ccd3c7d282019f5" continuedAt="Text_482e9c53f6cc48a495ccd3c7d282019f6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a10" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a11"><ix:continuation id="Text_482e9c53f6cc48a495ccd3c7d282019f6">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting
          Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Updates (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in
          which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a11" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a12" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a13"><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" id="Text_941c61e16cb34594af99645f097cbe72" contextRef="c20230401to20231231" escape="true" continuedAt="Text_5dfadbf408014f689fafcc09055561c91">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to
          noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents
          noncontrolling interests as a component of shareholders&#8217; equity on its unaudited condensed consolidated balance sheets.</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a13" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a14"><ix:continuation id="Text_5dfadbf408014f689fafcc09055561c91" continuedAt="Text_5dfadbf408014f689fafcc09055561c92">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a14" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a15"><ix:continuation id="Text_5dfadbf408014f689fafcc09055561c92">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying
          amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest
          is adjusted is recognized within shareholders&#8217; equity attributable to RSL.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a15" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a16">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a16" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a17"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_88f5b331ff484d8185f4d396e889a6b3" contextRef="c20230401to20231231" escape="true" continuedAt="Text_b8d1b68866e74c61a96d9370d788fc311">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(B) Use of Estimates</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a17" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a18"><ix:continuation id="Text_b8d1b68866e74c61a96d9370d788fc311" continuedAt="Text_b8d1b68866e74c61a96d9370d788fc312">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a18" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a19"><ix:continuation id="Text_b8d1b68866e74c61a96d9370d788fc312">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts
          reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development
          costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
          values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a19" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a20">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a20" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a21"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="Text_659064c4fa2b47b29093588ea31292fa" contextRef="c20230401to20231231" escape="true" continuedAt="Text_d7528c742f0c4a40a3247bea05838a7f1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">(C) Concentrations</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a21" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a22"><ix:continuation id="Text_d7528c742f0c4a40a3247bea05838a7f1" continuedAt="Text_d7528c742f0c4a40a3247bea05838a7f2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a22" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a23"><ix:continuation id="Text_d7528c742f0c4a40a3247bea05838a7f2" continuedAt="Text_d7528c742f0c4a40a3247bea05838a7f3">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company
          maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and
          liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a23" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a24"><ix:continuation id="Text_d7528c742f0c4a40a3247bea05838a7f3" continuedAt="Text_d7528c742f0c4a40a3247bea05838a7f4">
<div><br/></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a24" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a25"><ix:continuation id="Text_d7528c742f0c4a40a3247bea05838a7f4">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has long-lived assets in different geographic locations. As of December 31, 2023 and March 31, 2023, a majority of the Company&#8217;s
          long-lived assets were located in the United States.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a25" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a26">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a26" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a27"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Text_db6a625a60eb427aa97f4a884e8f6f9d" contextRef="c20230401to20231231" escape="true" continuedAt="Text_a61dd2b4e9af430fb59654bf24810fbe1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">(D) Cash, Cash
          Equivalents, and Restricted Cash</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a27" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a28"><ix:continuation id="Text_a61dd2b4e9af430fb59654bf24810fbe1" continuedAt="Text_a61dd2b4e9af430fb59654bf24810fbe2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a28" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a29"><ix:continuation id="Text_a61dd2b4e9af430fb59654bf24810fbe2" continuedAt="Text_a61dd2b4e9af430fb59654bf24810fbe3">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company
          considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a29" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a30"><ix:continuation id="Text_a61dd2b4e9af430fb59654bf24810fbe3" continuedAt="Text_a61dd2b4e9af430fb59654bf24810fbe4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a30" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a31"><ix:continuation id="Text_a61dd2b4e9af430fb59654bf24810fbe4" continuedAt="Text_a61dd2b4e9af430fb59654bf24810fbe5"><ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Text_4eefbee7bfa44190aa164ffc19182145" contextRef="c20230401to20231231" escape="true" continuedAt="Text_77ea065b59a14b57a9b7b9f0ce43e8ed1">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted
          cash as presented on the accompanying condensed consolidated balance sheets as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation></ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a31" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a32"><ix:continuation id="Text_a61dd2b4e9af430fb59654bf24810fbe5" continuedAt="Text_a61dd2b4e9af430fb59654bf24810fbe6"><ix:continuation id="Text_77ea065b59a14b57a9b7b9f0ce43e8ed1" continuedAt="Text_77ea065b59a14b57a9b7b9f0ce43e8ed2">
<div><br/></div>
</ix:continuation></ix:continuation></ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a32" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a33"><ix:continuation id="Text_a61dd2b4e9af430fb59654bf24810fbe6"><ix:continuation id="Text_77ea065b59a14b57a9b7b9f0ce43e8ed2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_5f943e018ced4135b46c99ee18e00047" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,670,810</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_6ef1ef3ab96c4c31b60695c6b300be6c" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,676,813</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Restricted cash (included in &#8220;Other current assets&#8221;)<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RestrictedCashCurrent" id="Fact_66ae039e743646f6a4b3fe9ddd07b5cb" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,165</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RestrictedCashCurrent" id="Fact_6d0eb19c615341ca9cd4c08374c0569b" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,011</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);">
                <div style="margin-left: 9pt">Restricted cash (included in &#8220;Other assets&#8221;)<br/>
                </div>
              </td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" id="Fact_08a040975ba3433bbe90cde0074b96e8" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,483</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" id="Fact_3bd0759ad3044abc90d6dd815577cd31" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,291</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <div>Cash, cash equivalents and restricted cash</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_4611a28f316141a58ca576eb960d69a4" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,685,458</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_de1bc92c78a14a65af65267f54ac93f1" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,692,115</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a33" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a34">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a34" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a35"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="Text_48d508a27da244c39cbf3d11163ca26f" contextRef="c20230401to20231231" escape="true" continuedAt="Text_81d7562d816546bcae8037639c883a761">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(E) Contingencies</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a35" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a36"><ix:continuation id="Text_81d7562d816546bcae8037639c883a761" continuedAt="Text_81d7562d816546bcae8037639c883a762">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a36" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a37"><ix:continuation id="Text_81d7562d816546bcae8037639c883a762">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually
          assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at
          which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the
          Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a37" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a38">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a38" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a39"><ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" id="Text_d263b7e9970d4177810738840f5ce099" contextRef="c20230401to20231231" escape="true" continuedAt="Text_194200b62d86465da7e4b88e7cd489d71">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(F) Investments</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a39" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a40"><ix:continuation id="Text_194200b62d86465da7e4b88e7cd489d71" continuedAt="Text_194200b62d86465da7e4b88e7cd489d72">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a40" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a41"><ix:continuation id="Text_194200b62d86465da7e4b88e7cd489d72" continuedAt="Text_194200b62d86465da7e4b88e7cd489d73">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Investments in equity securities may be accounted for using (i) the fair value option, if elected, (ii) fair value through earnings if fair value
          is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the
          measurement alternative is made for each eligible investment.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a41" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a42"><ix:continuation id="Text_194200b62d86465da7e4b88e7cd489d73" continuedAt="Text_194200b62d86465da7e4b88e7cd489d74">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a42" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a43"><ix:continuation id="Text_194200b62d86465da7e4b88e7cd489d74">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company
          believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Equity Method Investments.&#8221;</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a43" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a44">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a44" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a45"><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Text_074d415c01634e328a6a0f65df6fd107" contextRef="c20230401to20231231" escape="true" continuedAt="Text_585769b125f349b9a48e69bb1880cdc81">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(G) Fair Value Measurements</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a45" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a46"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc81" continuedAt="Text_585769b125f349b9a48e69bb1880cdc82">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a46" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a47"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc82" continuedAt="Text_585769b125f349b9a48e69bb1880cdc83">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance
          establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are
          inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market
          participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received
          to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a
          three-tier fair value hierarchy that distinguishes among the following:</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a47" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a48"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc83" continuedAt="Text_585769b125f349b9a48e69bb1880cdc84">
<div><br/></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a48" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a49"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc84" continuedAt="Text_585769b125f349b9a48e69bb1880cdc85">
<div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                  <div style="text-align: left;">&#8226;</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">Level 1-Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</div>
                </td>

  </tr>


</table>
        </div>
</ix:continuation></ix:continuation>
      </div>

      <div style="text-align: justify;"><ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a49" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a50"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc85" continuedAt="Text_585769b125f349b9a48e69bb1880cdc86">
<div><br/></div>
</ix:continuation></ix:continuation>
        <div>
          <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a50" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a51"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc86" continuedAt="Text_585769b125f349b9a48e69bb1880cdc87">
<div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                    <div>&#8226;</div>
                  </td>

    <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">Level 2-Valuations are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models
                      for which all significant inputs are observable, either directly or indirectly.</div>
                  </td>

  </tr>


</table>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a51" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a52"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc87" continuedAt="Text_585769b125f349b9a48e69bb1880cdc88">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>
</ix:continuation></ix:continuation>
          <div>
            <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a52" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a53"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc88" continuedAt="Text_585769b125f349b9a48e69bb1880cdc89">
<div>
              <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                      <div>&#8226;</div>
                    </td>

    <td style="vertical-align: top; width: auto;">
                      <div style="text-align: justify;">Level 3-Valuations are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement.</div>
                    </td>

  </tr>


</table>
            </div>
</ix:continuation></ix:continuation>
          </div>

          <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a53" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a54"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc89" continuedAt="Text_585769b125f349b9a48e69bb1880cdc810">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>
</ix:continuation></ix:continuation>
        </div>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a54" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a55"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc810" continuedAt="Text_585769b125f349b9a48e69bb1880cdc811">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value
          requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the
          lowest level of any input that is significant to the fair value measurement.</div>
</ix:continuation></ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a55" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a56"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc811" continuedAt="Text_585769b125f349b9a48e69bb1880cdc812">
<div><br/></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin-top: 4px; margin-bottom: 4px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a56" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a57"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc812" continuedAt="Text_585769b125f349b9a48e69bb1880cdc813">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of common stock of
          Heracles Parent, L.L.C., the parent entity of Datavant, (as defined and discussed in Note 3, &#8220;Equity Method Investments&#8221;); liability instruments issued, including warrant and earn-out shares liabilities issued in connection with the Company&#8217;s
          business combination with MAAC (as discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private Placement Warrants&#8221;); its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and
          long-term debt.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a57" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a58"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc813" continuedAt="Text_585769b125f349b9a48e69bb1880cdc814">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a58" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a59"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc814" continuedAt="Text_585769b125f349b9a48e69bb1880cdc815">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a59" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a60"><ix:continuation id="Text_585769b125f349b9a48e69bb1880cdc815">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;">The shares of Arbutus common stock and
          investments in common stock with a readily determinable fair value are classified as Level 1, and their fair value is determined based upon quoted market prices in an active market. The shares of common stock of Heracles Parent, L.L.C., the
          parent entity of Datavant (as defined and discussed in Note 3, &#8220;Equity Method Investments&#8221;) and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private
          Placement Warrants&#8221;), are classified as Level 3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Prior to their settlement, the Public Warrants were publicly traded and
          therefore were classified as Level 1 as the Public Warrants had a readily determinable fair value. Cash and accounts payable are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature.
          Money market funds are included in Level 1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly
          owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level 2 of the fair value hierarchy. Long-term debt issued
          by Dermavant for which the fair value option has been elected is included in Level 3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a60" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a61">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
        <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a61" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a62">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a62" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a63"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_bbcb6500ac0442ceae9687f35c093fcb" contextRef="c20230401to20231231" escape="true" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a591">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(H) Significant Accounting Policies</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a63" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a64"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a591" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a592">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a64" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a65"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a592" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a593">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">There were no significant changes to the Company&#8217;s significant accounting policies from those disclosed in the Company&#8217;s Form 10-K for the year ended March 31, 2023.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a65" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a66"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a593" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a594">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a66" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a67"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a594" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a595">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(I) Recently Adopted Accounting Pronouncements</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a67" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a68"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a595" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a596">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a68" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a69"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a596" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a597">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">The Company did not adopt any material accounting pronouncements during the nine months ended December 31, 2023.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a69" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a70"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a597" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a598">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a70" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a71"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a598" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a599">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(J) Recently Issued Accounting Pronouncements Not Yet Adopted<br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a71" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a72"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a599" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a5910">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a72" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a73"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a5910" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a5911">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In
            November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&#8221; which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant
            segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU is applicable to the Company&#8217;s Annual Report on Form 10-K
            for the fiscal year ended March 31, 2025, and subsequent interim periods, with early adoption permitted. These amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently
            evaluating the impact of adopting this ASU on its consolidated financial statements</span>.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a73" continuedAt="Text_96e6cd729b744f0d99221a97d22f359a74"><ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a5911" continuedAt="Text_8f782113e73d49bea0b44c9bc0055a5912">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_8f782113e73d49bea0b44c9bc0055a5912"><ix:continuation id="Text_96e6cd729b744f0d99221a97d22f359a74">
<div style="display:none;"><br/></div>
<div style="text-indent: 18pt; text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In December 2023, the FASB issued ASU 2023-09, &#8220;Income
            Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; which includes updates to the income tax disclosures related to the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments are effective for fiscal
            years beginning after December 15, 2024 and is applicable to the Company&#8217;s fiscal year beginning April 1, 2025, with early adoption permitted. The amendments should be applied prospectively, however retrospective application is permitted. The
            Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span>  </div>
</ix:continuation></ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <div>
            <div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="Text_a96f05fdbfaf42e8bc6cc4c592fd6dec" contextRef="c20230401to20231231" escape="true" continuedAt="Text_0fd25a24d61b465eae4163c0313162881">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 3&#8212;Equity Method Investments</div>
</ix:nonNumeric>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162881" continuedAt="Text_0fd25a24d61b465eae4163c0313162882">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162882" continuedAt="Text_0fd25a24d61b465eae4163c0313162883">
<div style="display:none;"><br/></div>
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">The Company maintains equity method investments in certain entities. As of December 31, 2023 and March 31, 2023, the most significant of these were our
            investments in Arbutus and Datavant (as defined below), which are accounted for using the fair value option.</span> </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162883" continuedAt="Text_0fd25a24d61b465eae4163c0313162884">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162884" continuedAt="Text_0fd25a24d61b465eae4163c0313162885">
<div style="display:none;"><br/></div>
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">The </span><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company determined that it does not control these entities and as a result does not consolidate these entities. Due to the Company&#8217;s significant influence over operating and financial policies of
            these entities, the entities are considered related parties of the Company.</span><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162885" continuedAt="Text_0fd25a24d61b465eae4163c0313162886">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162886" continuedAt="Text_0fd25a24d61b465eae4163c0313162887">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Investment in Arbutus</div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162887" continuedAt="Text_0fd25a24d61b465eae4163c0313162888">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162888" continuedAt="Text_0fd25a24d61b465eae4163c0313162889">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company holds an investment in Arbutus in the form of <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6f887af8fb094e7bab646d5d39ff565b" contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">38,847,462</ix:nonFraction> common shares of Arbutus. As of December 31, 2023, RSL held approximately <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_0b3c21932a1649a3a70e11743b85c469" contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">23</ix:nonFraction>% of issued
          and outstanding shares of Arbutus.</div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c0313162889" continuedAt="Text_0fd25a24d61b465eae4163c03131628810">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628810" continuedAt="Text_0fd25a24d61b465eae4163c03131628811">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">At <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">March 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the aggregate fair value of the Company&#8217;s investment in Arbutus was&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_3ea8d968f9754879a7c6f485163e16f9" contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">97.1</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_8850f50047674960b55be504d25ed619" contextRef="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">117.7</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
              Company recognized an unrealized gain of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_0c3b7f0ae13c454185a8833eac8765b6" contextRef="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.3</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and an unrealized loss of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_d5acc1fa62b946a184075821189ef8e2" contextRef="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">20.6</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;on its investment in Arbutus, respectively, in the accompanying condensed consolidated statements of operations. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2022</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
              Company recognized an unrealized gain of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_28904081f4f2425c9f1484a7c1b6c338" contextRef="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.3</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and an unrealized loss of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_7c017ec4b9da4df5bbc0663fd8f15e39" contextRef="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">25.3</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;on its investment in Arbutus, respectively, in the accompanying condensed consolidated statements of operations. The fair value of the Company&#8217;s investment was
              determined using the closing price of Arbutus&#8217;s common stock on&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">March 31, 2023</span> of $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_49e1cc809d6a4c51bbb137c3de514e17" contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.50</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_5945c0e7ef4a454d8e29135beb970de2" contextRef="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.03</ix:nonFraction>, respectively. </span><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628811" continuedAt="Text_0fd25a24d61b465eae4163c03131628812">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628812" continuedAt="Text_0fd25a24d61b465eae4163c03131628813">
<div style="text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Investment
















            in Datavant </span> </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628813" continuedAt="Text_0fd25a24d61b465eae4163c03131628814">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628814" continuedAt="Text_0fd25a24d61b465eae4163c03131628815">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In June 2021, Datavant and Heracles Parent, L.L.C. (referred to herein as &#8220;Ciox Parent&#8221; and, after the closing of the Datavant Merger (as defined below), &#8220;Datavant&#8221;), primarily through its wholly owned subsidiary CIOX
            Health, LLC, entered into a definitive agreement to merge Datavant with and into a newly formed wholly owned subsidiary of Ciox Parent (the &#8220;Datavant Merger&#8221;). As of December 31, 2023, the Company&#8217;s minority equity interest represented
            approximately <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_c0085d30f2d944adba22fae20325e33c" contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">9</ix:nonFraction>% of the outstanding Class A units in Ciox Parent. Ciox Parent&#8217;s capital structure includes several classes of
            preferred units that, among other features, have liquidation preferences and conversion rights. Upon conversion of such preferred units into Class A units, the Company&#8217;s ownership interest would be diluted. </span><br/>
        </div>
</ix:continuation>
        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
          <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628815" continuedAt="Text_0fd25a24d61b465eae4163c03131628816">
<div style="text-align: left;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
            </span></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628816" continuedAt="Text_0fd25a24d61b465eae4163c03131628817">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">As
          <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">March 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
            fair value of the Company&#8217;s investment was&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_bfd6c544333b42a88b735a776edc22fd" contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">135.9</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_f430154892b54b6d9bd215752808a740" contextRef="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">178.6</ix:nonFraction>
            million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company recognized unrealized losses on its investment in Datavant of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_181fab6916e2457caa5448f407730fc3" contextRef="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">28.4</ix:nonFraction>
            million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_f394aa643a9349e3a932fe23df798e0e" contextRef="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">42.6</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively, in the accompanying condensed consolidated statements of operations. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2022</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
            Company recognized an unrealized gain on of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_4a3e4fb8c37b447089051e257e314c27" contextRef="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.5</ix:nonFraction> million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and an unrealized loss of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_054dd873ae5a4d2895b0e03831b8592b" contextRef="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">21.4</ix:nonFraction>
            million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;on its investment in Datavant, respectively, in the accompanying condensed consolidated statements of operations</span><span style="letter-spacing: normal; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628817" continuedAt="Text_0fd25a24d61b465eae4163c03131628818">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0fd25a24d61b465eae4163c03131628818">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The fair value of the Company&#8217;s investment was determined using valuation models that incorporate significant unobservable inputs and is
          classified as a Level 3 measurement within the fair value hierarchy. Refer to Note 13, &#8220;Fair Value Measurements&#8221; for more information.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="Text_8140b11ee8f444c1844eeb61076e2a2e" contextRef="c20230401to20231231" escape="true" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 4&#8212;Intangible Assets</div>
</ix:nonNumeric>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd1" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd2" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd3">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In July 2018, Dermavant acquired the worldwide rights (other than for China) with respect to certain intellectual property rights retained by
          Welichem Biotech Inc. (&#8220;Welichem&#8221;) to VTAMA and related compounds from Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Ltd. (collectively, &#8220;GSK&#8221;) pursuant to an asset purchase agreement. GSK previously acquired rights to
          a predecessor formulation from Welichem pursuant to an asset purchase agreement between GSK and Welichem entered into in May 2012. The Company evaluated the agreement and determined that the acquired assets did not meet the definition of a
          business and thus the transaction was accounted for as an asset acquisition.</div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd3" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd4">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd4" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd5">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Following the FDA approval of VTAMA in May 2022, the Company became obligated to pay a regulatory milestone to GSK of &#163;<ix:nonFraction name="roiv:MilestonePayable" id="Fact_cb0b319280de4cb5b6cb14d4134c5104" contextRef="c20220531_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" unitRef="U006" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction> million (approximately $<ix:nonFraction name="roiv:MilestonePayable" id="Fact_c08db14b5ff24c11831c2359969a87d9" contextRef="c20220531_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="roiv:MilestonePaid" id="Fact_67b347d83c69441f8e52c3c9f53870d9" contextRef="c20220701to20220731_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction></ix:nonFraction>
          million on the date of achievement) following the receipt of marketing approval of VTAMA in the United States. The milestone was paid in July 2022.</div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd5" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd6" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd7">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Additionally, the first sale of VTAMA in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$<ix:nonFraction name="roiv:MilestonePayable" id="Fact_b08bd6dcb1104600825881a39609848a" contextRef="c20220531_CounterpartyNameAxis_WelichemBiotechIncMember" unitRef="U007" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction> million (approximately $<ix:nonFraction name="roiv:MilestonePayable" id="Fact_3f2f250f38624bf1a9d5d704a2d67c00" contextRef="c20220531_CounterpartyNameAxis_WelichemBiotechIncMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="roiv:MilestonePaid" id="Fact_06bd60fbf8ba449bad7bbe102d9e79c8" contextRef="c20220801to20220831_CounterpartyNameAxis_WelichemBiotechIncMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></ix:nonFraction>
          million on the date of achievement). The milestone was paid in August 2022.</div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd7" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd8">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd8" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd9">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Both of the above milestones were capitalized as intangible assets upon achievement and are being amortized over their estimated useful lives. As
          of December 31, 2023, the remaining weighted average estimated useful lives of the intangible assets was <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact_e1fc62c547d14cc6a1f93fe216b672c1" contextRef="c20231231" format="ixt-sec:duryear">14.8</ix:nonNumeric> years.<br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd9" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd10">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>


        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd10" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd11"><ix:nonNumeric name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="Text_95a21f7a95a144749221d9ed517cd8b7" contextRef="c20230401to20231231" escape="true" continuedAt="Text_f4f98d84071443fa92929d29b5ba1fb61">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The following table summarizes the Company&#8217;s recognized intangible assets (in thousands):<br/>
        </div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd11" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd12"><ix:continuation id="Text_f4f98d84071443fa92929d29b5ba1fb61" continuedAt="Text_f4f98d84071443fa92929d29b5ba1fb62">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd12" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd13"><ix:continuation id="Text_f4f98d84071443fa92929d29b5ba1fb62">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;"/>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;"><span style="font-weight: bold;">December 31, 2023</span></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="font-weight: bold;">March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="text-align: center;">

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-align: left;">Gross amount</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_ac5c4a3a6f8f4f31835ef853d4462773" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">166,471</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_bc0caeaeb2ff44428e2b4865f3fe43a8" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,629</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div>Less: accumulated amortization</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_2e0c2221307b40f78fcdcb432b0238ae" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,056</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_4559d4250de9481f8bf2df6644570092" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,748</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">Net book value</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_bce1856282704dd4b3f2103c6812d777" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">150,415</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_4bc2c2394e2c4ba5b62ba7be0b155c8b" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">144,881</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd13" continuedAt="Text_732c0c951e2b4678aa5615f7f7eb94dd14">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_732c0c951e2b4678aa5615f7f7eb94dd14">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Amortization expense was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_e386be5a6e304d4e9e1284face211d24" contextRef="c20231001to20231231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction>
          million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_8217bb37e8d0471ca13b3ebfb00aeb8d" contextRef="c20221001to20221231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.2</ix:nonFraction> million for the three months ended December 31, 2023 and 2022, respectively, and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_63f74b7a56424620a5053a83e7c887a2" contextRef="c20230401to20231231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_bd78a92c7546466c8574ff7a5d48b7a7" contextRef="c20220401to20221231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.2</ix:nonFraction> million for the
          nine months ended December 31, 2023 and 2022, respectively. Amortization expense was recorded as part of &#8220;Cost of revenues&#8221; in the accompanying condensed consolidated statement of operations. Future amortization expense is approximately $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" id="Fact_f95ce84fa66a417699f595f280545ad0" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction> million for the remainder of the year ended March 31, 2024, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" id="Fact_97027214bc804037ac6c0f9516915b48" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" id="Fact_7208f85590754516a18bbea114a58063" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" id="Fact_2e774aaad2ff4b1e8c0ee4dfaf0d5aa3" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" id="Fact_03a555debc7f413c9b874d2e32b7affc" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million for each of the years ended from March 31, 2025 through March 31, 2028 and $<ix:nonFraction name="roiv:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" id="Fact_e383e66dac6144c0ad6ffab3a8861176" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">107.5</ix:nonFraction>
          million thereafter. The Company&#8217;s intangible assets are denominated in currencies other than U.S. dollar and therefore are subject to foreign currency movements.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0px;">
          <div><br/>
          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <ix:nonNumeric name="roiv:RecentTransactionsTextBlock" id="Text_3dbdcf9ffe6c43d384092a690a342e31" contextRef="c20230401to20231231" escape="true" continuedAt="Text_db9f1cf408f14944902e18d6e277a2681">
<div style="font-weight: bold; text-align: justify;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note
          5&#8212;Recent Transactions</span></div>
</ix:nonNumeric>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2681" continuedAt="Text_db9f1cf408f14944902e18d6e277a2682">
<div><br/></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2682" continuedAt="Text_db9f1cf408f14944902e18d6e277a2683">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(A) Telavant Disposition</div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2683" continuedAt="Text_db9f1cf408f14944902e18d6e277a2684">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>
</ix:continuation>
    </div>

    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2684" continuedAt="Text_db9f1cf408f14944902e18d6e277a2685">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">On December 14, 2023 (the &#8220;Transaction Date&#8221;), the Company completed the sale of its entire equity interest in its majority-owned subsidiary, Telavant
      Holdings, Inc. (&#8220;Telavant&#8221;), to Roche Holdings, Inc. (&#8220;Roche&#8221;) (the &#8220;Roche Transaction&#8221;). The Roche Transaction was made pursuant to a Stock Purchase Agreement dated October 22, 2023 among the Company, Telavant, Pfizer Inc. (&#8220;Pfizer&#8221;), and Roche (the
      &#8220;Stock Purchase Agreement&#8221;). Telavant was jointly formed by the Company and Pfizer in November 2022 to develop and commercialize RVT-3101, an anti-TL1A antibody in development for ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease, in the United States
      and Japan. Prior to the Roche Transaction, the Company held&#160;<ix:nonFraction name="roiv:OwnershipPercentage" id="Fact_c9296330fb5e472c802ee3f1d3cc5170" contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>% of the issued and outstanding shares of common stock and preferred stock of
      Telavant, and Pfizer owned the remaining&#160;<ix:nonFraction name="roiv:OwnershipPercentage" id="Fact_7a82589a7ea0454d814e11258a1ddd92" contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_PfizerMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>%, in each case on an as-converted basis.</div>
</ix:continuation>
    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2685" continuedAt="Text_db9f1cf408f14944902e18d6e277a2686">
<div><br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2686" continuedAt="Text_db9f1cf408f14944902e18d6e277a2687">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Pursuant to the Stock Purchase Agreement, Roche acquired all of the issued and outstanding shares of capital stock of Telavant in exchange for
      approximately $<ix:nonFraction name="roiv:UpfrontCashPaymentReceivedForSaleOfAssets" id="Fact_a813deec13a340bbad3c17c6aea86923" contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal">7.1</ix:nonFraction> billion in cash at the closing of the Roche Transaction and a one-time milestone payment of $<ix:nonFraction name="roiv:FutureMilestoneToBeReceivedFromSaleOfAssets" id="Fact_a099a80e0b5d4b69a9c781fcacf0780b" contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction> million in cash payable upon the initiation of a Phase 3 trial in UC. The $<ix:nonFraction name="roiv:UpfrontCashPaymentReceivedForSaleOfAssets" id="Fact_1e77298042f14d429af9b9aee29305dc" contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal">7.1</ix:nonFraction> billion in closing consideration was paid to all of Telavant&#8217;s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant
      prior to the closing of the Roche Transaction, and this same treatment will be applied to the one-time milestone payment. The Company received an upfront payment of approximately $<ix:nonFraction name="roiv:UpfrontCashPaymentReceivedForSaleOfAssets" id="Fact_09fe123a557c42aa809e4a7cf06e0be5" contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal">5.2</ix:nonFraction> billion in cash as its pro rata portion of the consideration upon closing of the Roche Transaction. Additionally, the Company is eligible to receive approximately $<ix:nonFraction name="roiv:FutureMilestoneToBeReceivedFromSaleOfAssets" id="Fact_6a701c647bdb4669bcfa2fe864faefd6" contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction> million for its pro rata portion of the one-time milestone payment if the milestone payment condition is satisfied.</div>
</ix:continuation>
    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2687" continuedAt="Text_db9f1cf408f14944902e18d6e277a2688">
<div>&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2688" continuedAt="Text_db9f1cf408f14944902e18d6e277a2689">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">At the closing of the Roche Transaction, Roche acquired the full rights to further develop and manufacture RVT-3101 and commercialize it in the United
      States and Japan pending clinical and regulatory success. Outside of the United States and Japan, Pfizer holds commercialization rights. In addition, following the closing of the Roche Transaction, Roche acquired Telavant&#8217;s option to enter into a
      global collaboration with Pfizer on a next generation p40/TL1A directed bispecific antibody, currently in Phase 1.</div>
</ix:continuation>
    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a2689" continuedAt="Text_db9f1cf408f14944902e18d6e277a26810">
<div>&#160;</div>
</ix:continuation>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageFooter" style="width: 100%;"></div>

      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
        </div>

      </div>

    </div>

    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26810" continuedAt="Text_db9f1cf408f14944902e18d6e277a26811">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Telavant entity that was sold did not meet the definition of a
        business, and therefore the Company concluded that the Roche Transaction was a sale of non-financial assets, with control transferred at closing.</span> The sale of Telavant did not meet the criteria for reporting discontinued operations as the
      sale does not represent a strategic shift in the Company<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8217;s</span> business. <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The
        Company recognized a gain on sale of Telavant net assets of approximately </span>$<ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_47d4feb4a57b4d3c81c6ac61af4d302f" contextRef="c20231001to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal"><ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_3be30fa4de31440d938082ef1d39bed6" contextRef="c20230401to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-8" scale="9" format="ixt:num-dot-decimal">5.3</ix:nonFraction></ix:nonFraction> billion<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> during the </span>three<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> and </span>nine<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> months ended December </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</span>2023<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> in the
        accompanying condensed consolidated statements of operations. The gain does not include the Company&#8217;s portion of the </span>one<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">-time milestone payment, which will
        be recognized in the period it is achieved. The gain on sale of Telavant net assets qualifies under the substantial shareholding exemption and consequently is not subject to the corporation income tax. </span><ix:nonNumeric name="roiv:ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" id="Text_1b920a8d1862484ab5e697548887f622" contextRef="c20230401to20231231" escape="true" continuedAt="Text_585a5436cde24bf688acf00d5605035e1"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">The table below summarizes
      the calculation of the gain.</span></ix:nonNumeric></div>
</ix:continuation>
    <ix:continuation id="Text_585a5436cde24bf688acf00d5605035e1" continuedAt="Text_585a5436cde24bf688acf00d5605035e2"><ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26811" continuedAt="Text_db9f1cf408f14944902e18d6e277a26812">
<div>&#160;</div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_585a5436cde24bf688acf00d5605035e2"><ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26812" continuedAt="Text_db9f1cf408f14944902e18d6e277a26813">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(in</span><span style="font-weight: bold;"> thousand</span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);"><span style="font-weight: bold;">s</span>)</span></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Consideration:</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Upfront cash payment</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">$</span></div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';"><ix:nonFraction name="roiv:UpfrontCashPaymentReceivedForSaleOfAssets" id="Fact_9bd28393144f4aa08d88e93b4edbf293" contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,234,373</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Carrying amount of noncontrolling interest derecognized</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="roiv:DisposalGroupNoncontrollingInterestDerecognizedValue" id="Fact_9b9f3d585b044731863d93167dabfbf3" contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,500</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="text-align: left; margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total consideration</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonFraction name="roiv:ConsiderationReceivedForSaleOfAssets" id="Fact_831e38fa92124ae9aadf8b2a86f8dd33" contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,321,873</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Assets sold</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="roiv:DisposalGroupAssets" id="Fact_b3ab04380a3f43b899d4399c1a2991e3" contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,253</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Liabilities transferred</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="roiv:DisposalGroupLiabilities" id="Fact_e57bb7ace94b487f9f72c675bdbc6e72" contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,790</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Net liabilities sold</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(<ix:nonFraction name="roiv:DisposalGroupNetAssetsLiabilities" id="Fact_ee0fac31c6e344e0b0875b8327e12f68" contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,537</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Gain on sale of Telavant net assets</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">$</span></div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonFraction name="roiv:GainLossOnSaleOfAssets" id="Fact_c98aa651119542069dae91cf52c95f17" contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,348,410</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26813" continuedAt="Text_db9f1cf408f14944902e18d6e277a26814">
<div>&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26814" continuedAt="Text_db9f1cf408f14944902e18d6e277a26815">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">The pretax loss generated by Telavant was $<ix:nonFraction name="roiv:IncomeLossFromDisposalGroupBeforeIncomeTax" id="Fact_6b09f20346dc492fbae538c91ca26f34" contextRef="c20231001to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">27.3</ix:nonFraction>
      million for the period from October 1, 2023 to the Transaction Date and $<ix:nonFraction name="roiv:IncomeLossFromDisposalGroupBeforeIncomeTax" id="Fact_995c502baa4d458a97659ad3f78b7305" contextRef="c20230401to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">71.1</ix:nonFraction> million for the period from April 1, 2023 to the Transaction
      Date. The pretax loss generated by Telavant for the period from inception on November 14, 2022 to December 31, 2022 was $<ix:nonFraction name="roiv:IncomeLossFromDisposalGroupBeforeIncomeTax" id="Fact_6447aed369b047429b112aa615a29b43" contextRef="c20221114to20221231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">89.4</ix:nonFraction> million. The
      entirety of the Telavant pretax losses was attributable to the Company.</div>
</ix:continuation>
    <div class="BRPFPageFooter" style="width: 100%;"></div>

    <div>
      <div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
        <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26815" continuedAt="Text_db9f1cf408f14944902e18d6e277a26816">
<div><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26816" continuedAt="Text_db9f1cf408f14944902e18d6e277a26817">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(B) Asset Acquisition</div>
</ix:continuation>
        <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26817" continuedAt="Text_db9f1cf408f14944902e18d6e277a26818">
<div>&#160;</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26818" continuedAt="Text_db9f1cf408f14944902e18d6e277a26819">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26819" continuedAt="Text_db9f1cf408f14944902e18d6e277a26820">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In July 2023, a
        newly-formed subsidiary in-licensed certain intellectual property rights in exchange for a $<ix:nonFraction name="roiv:UpfrontCashPayment" id="Fact_38a5a0e14cb845a387feb35eeeccc6ca" contextRef="c20230701to20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.0</ix:nonFraction> million upfront cash payment. The
        transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The acquired rights represent in-process research and development assets, which were determined to have no alternative future
        use. Accordingly, the Company recorded $<ix:nonFraction name="roiv:AssetAcquisitionResearchAndDevelopmentExpenseInProcess" id="Fact_a8cc612cc6794b289b37d5602949c7ba" contextRef="c20230401to20231231_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.0</ix:nonFraction> million as acquired in-process research and development expense in the accompanying
        condensed consolidated statements of operations for the nine months ended December 31, 2023.</div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26820" continuedAt="Text_db9f1cf408f14944902e18d6e277a26821">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26821" continuedAt="Text_db9f1cf408f14944902e18d6e277a26822">
<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26822" continuedAt="Text_db9f1cf408f14944902e18d6e277a26823">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26823" continuedAt="Text_db9f1cf408f14944902e18d6e277a26824">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Additionally,


          the newly-formed subsidiary agreed to pay up to $<ix:nonFraction name="roiv:MilestonePaymentPayable" id="Fact_5eee853b78dd4fd1b7c1d5d08b6af3a4" contextRef="c20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember_RangeAxis_MaximumMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">280</ix:nonFraction> million of future development, regulatory, and commercial milestone payments and
          tiered high-single digit sales-based royalties.</span></div>
</ix:continuation><ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26824" continuedAt="Text_db9f1cf408f14944902e18d6e277a26825">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
       <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26825" continuedAt="Text_db9f1cf408f14944902e18d6e277a26826">
<div>&#160;
        </div>
</ix:continuation><ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26826" continuedAt="Text_db9f1cf408f14944902e18d6e277a26827">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(C) Deconsolidation of Subsidiaries</div>
</ix:continuation>
        <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26827" continuedAt="Text_db9f1cf408f14944902e18d6e277a26828">
<div>&#160;</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26828" continuedAt="Text_db9f1cf408f14944902e18d6e277a26829">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26829" continuedAt="Text_db9f1cf408f14944902e18d6e277a26830">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In July 2023, VantAI
        Holdings, Inc. (&#8220;VantAI&#8221;), a wholly-owned subsidiary of the Company, completed a transaction pursuant to which SK, Inc. (&#8220;SK&#8221;) contributed $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" id="Fact_7aeb64811c51414eb9c06404d16b541d" contextRef="c20230701to20230731_RelatedPartyTransactionsByRelatedPartyAxis_SKIncMember_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction>
        million to VantAI in exchange for preferred shares in VantAI (the &#8220;VantAI Preferred Financing&#8221;). In August 2023, the Company and SK Biopharmaceuticals Co., Ltd. (&#8220;SK Bio&#8221;), a subsidiary of SK, completed a transaction pursuant to which SK Bio
        purchased all of the Company&#8217;s shares in Proteovant Sciences, Inc. (&#8220;Proteovant&#8221;) in exchange for $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" id="Fact_4ce48f2eadab4a9eb8be6741e89d8f6e" contextRef="c20230801to20230831_BusinessAcquisitionAxis_ProteovantSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_SKBiopharmaceuticalsCoLtdMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">47.5</ix:nonFraction> million (the &#8220;Proteovant Sale&#8221;).</div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26830" continuedAt="Text_db9f1cf408f14944902e18d6e277a26831">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26831" continuedAt="Text_db9f1cf408f14944902e18d6e277a26832">
<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26832" continuedAt="Text_db9f1cf408f14944902e18d6e277a26833">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26833" continuedAt="Text_db9f1cf408f14944902e18d6e277a26834">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">As a result of changes in
        governance and voting rights, the Company determined that it no longer held a controlling financial interest in VantAI. Accordingly, the Company deconsolidated VantAI as of July 2023. The Company recorded a $<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" id="Fact_7a6d59e056224384b5b2407bc124ff84" contextRef="c20230401to20231231_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.4</ix:nonFraction> million gain on deconsolidation of Proteovant and VantAI in the accompanying condensed consolidated statements of operations for the nine months ended December 31, 2023.</div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26834" continuedAt="Text_db9f1cf408f14944902e18d6e277a26835">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26835" continuedAt="Text_db9f1cf408f14944902e18d6e277a26836">
<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26836" continuedAt="Text_db9f1cf408f14944902e18d6e277a26837">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_db9f1cf408f14944902e18d6e277a26837">
<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">Upon deconsolidation, the
        Company recorded its $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_e70c74c4cccb4fbaa11a1c17fa83837b" contextRef="c20230731_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.0</ix:nonFraction> million retained investment in VantAI based upon the fair value of the preferred shares held by the Company.
        Due to the Company&#8217;s significant influence over the operating and financial policies of VantAI, the Company will account for its retained interest under the equity method of accounting.</div>
</ix:continuation>

      <div style="text-align: left; font-family: 'Times New Roman';"> <br/>
      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Text_39abf10154f04c1c8fd7f088a3540706" contextRef="c20230401to20231231" escape="true" continuedAt="Text_bdae60d218b74b50a6c984b34bda11531">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 6&#8212;<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Certain Balance Sheet Components</span></div>
</ix:nonNumeric>
        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11531" continuedAt="Text_bdae60d218b74b50a6c984b34bda11532">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11532" continuedAt="Text_bdae60d218b74b50a6c984b34bda11533">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">(A) Other Current Assets</div>
</ix:continuation>
          <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11533" continuedAt="Text_bdae60d218b74b50a6c984b34bda11534">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"><br/>
          </div>
</ix:continuation>

          <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11534" continuedAt="Text_bdae60d218b74b50a6c984b34bda11535"><ix:nonNumeric name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="Text_e287129444c645e5ade6bed20cfc10db" contextRef="c20230401to20231231" escape="true" continuedAt="Text_b697d5bf40ca4fb9ae654638633116811">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;">Other current assets at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11535" continuedAt="Text_bdae60d218b74b50a6c984b34bda11536"><ix:continuation id="Text_b697d5bf40ca4fb9ae654638633116811" continuedAt="Text_b697d5bf40ca4fb9ae654638633116812">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 24.5pt;"> <br/>
          </div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

          <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11536" continuedAt="Text_bdae60d218b74b50a6c984b34bda11537"><ix:continuation id="Text_b697d5bf40ca4fb9ae654638633116812">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';">December 31, 2023</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';">March 31, 2023</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Prepaid expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" id="Fact_4f9a814638414ba493dceb084b956f78" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,642</ix:nonFraction></span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" id="Fact_509b5d2ffa5e496b81598ef6c0f2aa5d" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,827</ix:nonFraction></span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Trade receivables, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" id="Fact_68429926a55f4539bca9f9090f2ca269" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,078</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" id="Fact_21c327a55f754fb19d816dd9a9632dcd" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,379</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-weight: normal;">Restricted cash</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" id="Fact_e2a9d5b31a074b9d869416ffad474526" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,165</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" id="Fact_4a3e57681b4748888cbf016ebbfbc4cb" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,011</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; font-weight: normal;">Inventory <br/>
                </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_4d6f54b3547c482785d5c3550d537711" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,240</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_c80286014d5442329c3ffdce619ff051" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,761</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Income tax receivable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" id="Fact_2ab3a9b8b13648d9b88f41420020a885" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,209</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" id="Fact_4cca12502ed946589e9dbba2fb51e9d9" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,356</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">Interest receivable</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" rowspan="1"><ix:nonFraction name="us-gaap:InterestReceivable" id="Fact_3a67a14aebab48bca407e108f5e82b5b" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,901</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" rowspan="1"><ix:nonFraction name="us-gaap:InterestReceivable" id="Fact_d5582e989ced4f0d967828a411c86f40" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,909</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Other</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"><ix:nonFraction name="roiv:OtherOfOtherAssetsCurrent" id="Fact_669b00b7af7a42d0b41e18eb0da06944" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,688</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"><ix:nonFraction name="roiv:OtherOfOtherAssetsCurrent" id="Fact_006d041a1ffd4a669ee7d7f5999be57c" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,531</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; text-align: justify;">Total other current assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_7cf2cde8d97448198a1b186e8b43be60" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,923</ix:nonFraction></span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_43406c3f863c4e3fa9d962b1cc1316f1" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,774</ix:nonFraction></span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11537" continuedAt="Text_bdae60d218b74b50a6c984b34bda11538">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"><br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11538" continuedAt="Text_bdae60d218b74b50a6c984b34bda11539">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">(B) Accrued Expenses</div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda11539" continuedAt="Text_bdae60d218b74b50a6c984b34bda115310">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115310" continuedAt="Text_bdae60d218b74b50a6c984b34bda115311"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_e9959af064d4496bb773b88542f23b29" contextRef="c20230401to20231231" escape="true" continuedAt="Text_0ca7b068ca184d7ca2e0e2e34f7b49a81">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Accrued expenses at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115311" continuedAt="Text_bdae60d218b74b50a6c984b34bda115312"><ix:continuation id="Text_0ca7b068ca184d7ca2e0e2e34f7b49a81" continuedAt="Text_0ca7b068ca184d7ca2e0e2e34f7b49a82">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115312" continuedAt="Text_bdae60d218b74b50a6c984b34bda115313"><ix:continuation id="Text_0ca7b068ca184d7ca2e0e2e34f7b49a82">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Research and development expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="roiv:AccruedResearchAndDevelopmentExpensesCurrent" id="Fact_3c78d6ea7207422ab165a0bc5134b1c8" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,627</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="roiv:AccruedResearchAndDevelopmentExpensesCurrent" id="Fact_fed1200bb4dc49779f53a0d3d282e5f6" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,278</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Compensation-related expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_58a418e6dc4a48ed93aa325edbc7920e" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,406</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_7f8bed6bdf734aa58863d2c2c02952e1" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,186</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">Sales allowances</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="roiv:AccruedSalesAllowancesCurrent" id="Fact_f409af36e4e84392b884e7576fe3a21b" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,808</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="roiv:AccruedSalesAllowancesCurrent" id="Fact_3b683fd06a3f49a188f01d431f853558" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,569</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div>Other expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_2f9d6dfc9c91462aad4cfe7173afdd0d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,307</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_83c12dc939964d11b25da0f045082646" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,096</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div style="margin-left: 9pt;">Total accrued expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_cdfa4c6726594cef8d163ea06b71ed6c" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,148</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_18338a317a0349939bb32253fdd7d54b" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">167,129</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115313" continuedAt="Text_bdae60d218b74b50a6c984b34bda115314">
<div><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115314" continuedAt="Text_bdae60d218b74b50a6c984b34bda115315">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">(C) Other Current
          Liabilities</div>
</ix:continuation>
        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115315" continuedAt="Text_bdae60d218b74b50a6c984b34bda115316">
<div> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115316" continuedAt="Text_bdae60d218b74b50a6c984b34bda115317"><ix:nonNumeric name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="Text_96e9b8dc67874415a14406b68482ee05" contextRef="c20230401to20231231" escape="true" continuedAt="Text_6c90048bcd2b4f349edcd5b4b4faa2f21">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Other current liabilities at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</span></div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115317" continuedAt="Text_bdae60d218b74b50a6c984b34bda115318"><ix:continuation id="Text_6c90048bcd2b4f349edcd5b4b4faa2f21" continuedAt="Text_6c90048bcd2b4f349edcd5b4b4faa2f22">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_bdae60d218b74b50a6c984b34bda115318"><ix:continuation id="Text_6c90048bcd2b4f349edcd5b4b4faa2f22">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">December 31, 2023<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">March 31, 2023<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Deferred revenue</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" id="Fact_944a682cc23d44ceb6b0049876708959" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,695</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" id="Fact_b5dd3bcd459a48cf86094466fe326abc" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,444</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Income tax payable</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:TaxesPayableCurrent" id="Fact_77d00156dd1d4037a49361bd0da361f5" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,223</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;">
                  <div><ix:nonFraction name="us-gaap:TaxesPayableCurrent" id="Fact_3e639588823c4ce68e9bf91508f9daa7" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">542</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Other</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" id="Fact_4deadd14aaaa4302bb438050de65e094" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,424</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" id="Fact_e4d363633b0e4d07b44fdb1c9543afaa" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,090</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 4px;">
                  <div style="text-align: left; text-indent: 0pt; margin-left: 9pt;">Total other current liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_17c506f47db44ccbbca636691c0d9804" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,342</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_101d134ac1d74b508df94e0fb25cf6d7" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,076</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
            </div>
</ix:continuation></ix:continuation>
        <div><br/></div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" id="Text_efd1d9f6b7544733a3f9031e39538923" contextRef="c20230401to20231231" escape="true" continuedAt="Text_19d638c097eb408189514817b70775aa1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 7&#8212;Long-Term Debt</div>
</ix:nonNumeric>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa1" continuedAt="Text_19d638c097eb408189514817b70775aa2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa2" continuedAt="Text_19d638c097eb408189514817b70775aa3">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Dermavant</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa3" continuedAt="Text_19d638c097eb408189514817b70775aa4">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa4" continuedAt="Text_19d638c097eb408189514817b70775aa5">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Funding Agreement with NovaQuest</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa5" continuedAt="Text_19d638c097eb408189514817b70775aa6">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa6" continuedAt="Text_19d638c097eb408189514817b70775aa7">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In connection with Dermavant&#8217;s acquisition of tapinarof from GSK pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;), Dermavant and
          NovaQuest Co-Investment Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_228fb8e309284427bdbbc0e0bece6724" contextRef="c20180831_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction> million in August 2018 and $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_dd99840eccc040c0adb12c83a5cba070" contextRef="c20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.5</ix:nonFraction> million in October 2018.
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa7" continuedAt="Text_19d638c097eb408189514817b70775aa8">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa8" continuedAt="Text_19d638c097eb408189514817b70775aa9">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In exchange for the $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" id="Fact_ff8a2f792be04dc6bc7eef445da9da69" contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">117.5</ix:nonFraction> million
          in total funding from NovaQuest, Dermavant agreed to make fixed payments to NovaQuest under the NovaQuest Agreement upon regulatory approval of tapinarof. For each of the atopic dermatitis and psoriasis indications, Dermavant is required to make
          <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="Fact_a17e22b0110d496f906580472908b569" contextRef="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">quarterly</ix:nonNumeric> payments to NovaQuest totaling $<ix:nonFraction name="roiv:TotalRequiredDebtInstrumentQuarterlyPaymentsMade" id="Fact_40b027499b3545d6a4ecfe528149c6c5" contextRef="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">176.3</ix:nonFraction>
          million per indication over a <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_2ab8d4c259ef4cd484361bd60b352b29" contextRef="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" format="ixt-sec:durwordsen">six-year</ix:nonNumeric> period following regulatory approval of tapinarof for the applicable indication in the United
          States. In the event that Dermavant receives regulatory approval for one indication, and Dermavant terminates the development of the other indication for any reason other than a Technical Failure (as defined below), then Dermavant will be
          required to make the above-referenced quarterly payments to NovaQuest up to $<ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" id="Fact_2babb88cdd34484aa555e6d01becb33b" contextRef="c20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">440.6</ix:nonFraction> million over a <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_9cc950d7cb604278a421c52d6d5a96fc" contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" format="ixt-sec:duryear">15</ix:nonNumeric>-year period for the approved indication, which are referred to as <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_00eb707dc39d489b86a4789a29d03af4" contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" format="ixt-sec:duryear">15</ix:nonNumeric>-year Payments. A Technical Failure is deemed to occur for an indication if the development program for such indication is terminated due to (1) significant safety concerns, (2) material adverse developments or
          (3) the receipt by Dermavant of a complete response letter or a final non-approval letter from the FDA is expected to result in significant delay in or cost to reach commercialization for the applicable indication. In addition, Dermavant is
          required to make up to $<ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" id="Fact_34c7bce721f5410fbe494cb76fec6982" contextRef="c20180831_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">141.0</ix:nonFraction> million in payments to NovaQuest upon achievement of certain commercial milestones. In the event that
          Dermavant is required to start making <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_16fc28babf8642cbac1792039e12b182" contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" format="ixt-sec:duryear">15</ix:nonNumeric>-year Payments, then Dermavant has the right to offset such amounts by up to $<ix:nonFraction name="roiv:MaximumMilestonePaymentOffsetAmount" id="Fact_91f7b24a9cca4174b6ffb945d60db973" contextRef="c20180831_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">88.1</ix:nonFraction> million of the commercial milestone payments, with such offset being applied to the quarterly payments in reverse chronological order (such that
          the final quarterly payments owed will be used first to offset the commercial milestone payments). The NovaQuest Agreement does not contain any royalty payment requirements on commercialization of tapinarof. Upon receiving FDA approval for the
          psoriasis indication, Dermavant made its first quarterly payment of $<ix:nonFraction name="roiv:DebtInstrumentQuarterlyPaymentsMade" id="Fact_cebd521ed64b4793ac927dab4b47ff0f" contextRef="c20220501to20220531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.3</ix:nonFraction> million under the NovaQuest Agreement in May 2022 and has made
          cumulative <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="Fact_c26389a4e37a48cc85dd1d0ea9c07174" contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">quarterly</ix:nonNumeric> payments totaling $<ix:nonFraction name="roiv:TotalRequiredDebtInstrumentQuarterlyPaymentsMade" id="Fact_6ea09ddae92f42b3be5c141715993ea9" contextRef="c20220530to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">51.4</ix:nonFraction>
          million as of December 31, 2023.&#160; </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa9" continuedAt="Text_19d638c097eb408189514817b70775aa10">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_19d638c097eb408189514817b70775aa10" continuedAt="Text_19d638c097eb408189514817b70775aa11">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In
          lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the statements of operations at the end of each reporting period.
          Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of December 31, 2023 and March 31, 2023, the fair value of the debt was $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_8921e67f9af24c60a6f021960de9958d" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">221.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_07208de8798c4672ba5534061d0a383c" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">207.6</ix:nonFraction> million, respectively. Refer to Note
          13, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement.</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa11" continuedAt="Text_19d638c097eb408189514817b70775aa12">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_19d638c097eb408189514817b70775aa12" continuedAt="Text_19d638c097eb408189514817b70775aa13"><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Text_807bdf51ddbe4ec99802a5d557edece0" contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" escape="true" continuedAt="Text_cc1ef6e0f5bb408c8220b4efb1e5ff861">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The carrying balance of the debt issued to NovaQuest was as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa13" continuedAt="Text_19d638c097eb408189514817b70775aa14"><ix:continuation id="Text_cc1ef6e0f5bb408c8220b4efb1e5ff861" continuedAt="Text_cc1ef6e0f5bb408c8220b4efb1e5ff862">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa14" continuedAt="Text_19d638c097eb408189514817b70775aa15"><ix:continuation id="Text_cc1ef6e0f5bb408c8220b4efb1e5ff862">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Fair value of long-term debt</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_8e286b017e944299acd5374166999208" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">221,510</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_e08bb2e6c18145e8bb40bf70888ee2e3" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,640</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div>Less: current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShorttermDebtFairValue" id="Fact_64a986ff98164782acc8f8e9b5ca42db" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,950</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShorttermDebtFairValue" id="Fact_05cdda6a203d4ddfaf75beba97fe59da" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,940</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Total long-term debt, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebtFairValue" id="Fact_d77de7340ebc466d9cc17e163ed41135" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">194,560</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebtFairValue" id="Fact_49b663fa59954da1b77b7a309f5887d2" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">180,700</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_19d638c097eb408189514817b70775aa15" continuedAt="Text_19d638c097eb408189514817b70775aa16">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa16" continuedAt="Text_19d638c097eb408189514817b70775aa17">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Credit Facility with XYQ Luxco</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa17" continuedAt="Text_19d638c097eb408189514817b70775aa18">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa18" continuedAt="Text_19d638c097eb408189514817b70775aa19">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In May 2021, Dermavant and certain of its subsidiaries entered into a $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" id="Fact_22ec21367178494fbb65e6aaf751905e" contextRef="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction> million senior secured credit facility (the &#8220;Credit Facility&#8221;) with XYQ Luxco S.A.R.L (&#8220;XYQ Luxco&#8221;), as lender, and U.S. Bank National Association, as collateral agent. The Credit
          Facility has a <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_6756826a10874a899920d484910228ba" contextRef="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> maturity and bears an interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_a36a13c29d184e308843f44415f38488" contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">10.0</ix:nonFraction>% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the
          maturity date. Dermavant is also obligated to pay an exit fee of $<ix:nonFraction name="roiv:DebtInstrumentExitFeeAndEndOfTermCharge" id="Fact_99536e04b41143e390b29b902ad44381" contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million. The exit fee can be reduced to $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" id="Fact_c94d65800e0b4144b5b21c0a22585fe8" contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction> million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of December 31, 2023. In connection
          with the funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Fact_9cdd609898c2493fad6853a714b6acd7" contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,199,072</ix:nonFraction> common shares of Dermavant at
          an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_12ed9daf0f7d478db7347b1a5a33a2aa" contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per common share.</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa19" continuedAt="Text_19d638c097eb408189514817b70775aa20">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_19d638c097eb408189514817b70775aa20" continuedAt="Text_19d638c097eb408189514817b70775aa21"><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Text_3517a87cfe534e17a41b8d61acac6125" contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" escape="true" continuedAt="Text_8908c903a60f4a519d2c7713d460da511">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Outstanding debt obligations to XYQ Luxco were as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa21" continuedAt="Text_19d638c097eb408189514817b70775aa22"><ix:continuation id="Text_8908c903a60f4a519d2c7713d460da511" continuedAt="Text_8908c903a60f4a519d2c7713d460da512">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa22" continuedAt="Text_19d638c097eb408189514817b70775aa23"><ix:continuation id="Text_8908c903a60f4a519d2c7713d460da512">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div>Principal amount</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_5e41185baeab4b3c9fd0e170736c9440" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_9f13b0db65db48afb00075e351e74358" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Exit fee</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="roiv:DebtInstrumentExitFee" id="Fact_59d63c3ffee348d2a8bdfc22a0dcf83a" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="roiv:DebtInstrumentExitFee" id="Fact_19d5ba7969394bb4b7818d0227be0c4a" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Less: unamortized discount and debt issuance costs</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" id="Fact_0afabb3b4e39410c926809a72a8e2d87" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,221</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" id="Fact_79519d6e74bf4fe18032430cb87cd2a8" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,170</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div>Total debt, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebt" id="Fact_38291391b5034db9ae462d63ff0c5660" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,779</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebt" id="Fact_d72b1bd7828947db98faf71b1b330ee9" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,830</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Less: current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebtCurrent" id="Fact_47319ae2c82245178df0528d7621fd00" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebtCurrent" id="Fact_5bfcb9611ad949dfa0b67c9325a5aaf7" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <div>Total long-term debt, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" id="Fact_9c67093600ef4e799b180e3b0b76773a" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,779</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" id="Fact_8c783dc704324933a9e4f101d0993395" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,830</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_19d638c097eb408189514817b70775aa23" continuedAt="Text_19d638c097eb408189514817b70775aa24">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa24" continuedAt="Text_19d638c097eb408189514817b70775aa25">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Revenue Interest Purchase and Sale Agreement</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa25" continuedAt="Text_19d638c097eb408189514817b70775aa26">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa26" continuedAt="Text_19d638c097eb408189514817b70775aa27">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In
          May 2021, Dermavant, as seller, entered into a $<ix:nonFraction name="roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" id="Fact_25a09944d63240c8a7ae520d2a5562cf" contextRef="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">160.0</ix:nonFraction> million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its
          investigational product tapinarof with XYQ Luxco, NovaQuest Co-Investment Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P., together with U.S. Bank
          National Association, as collateral agent. Under the terms of the RIPSA, Dermavant is obligated to pay royalties based on a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States, up
          to a cap of $<ix:nonFraction name="roiv:CommittedFundingUnderRIPSA" id="Fact_a40a2bdf332c44c7b48757e4cb470b17" contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">344.0</ix:nonFraction> million, in exchange for the $<ix:nonFraction name="roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" id="Fact_7ef0d5afb4174a5b8b3deaa82cc25887" contextRef="c20220601to20220630_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">160.0</ix:nonFraction> million in committed funding, which was paid to Dermavant in June 2022 following the approval of tapinarof by the FDA.</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa27" continuedAt="Text_19d638c097eb408189514817b70775aa28">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_19d638c097eb408189514817b70775aa28" continuedAt="Text_19d638c097eb408189514817b70775aa29">
<div><br/></div>
</ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_19d638c097eb408189514817b70775aa29" continuedAt="Text_19d638c097eb408189514817b70775aa30">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa30" continuedAt="Text_19d638c097eb408189514817b70775aa31">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">The













          transaction is accounted for as debt. Over the term of the arrangement, the effective interest rate will be updated prospectively each reporting period based on the carrying amount of the note, payments made to date, and the estimated remaining
          cash flows related to the note.</div>
</ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa31" continuedAt="Text_19d638c097eb408189514817b70775aa32">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0px;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_19d638c097eb408189514817b70775aa32" continuedAt="Text_19d638c097eb408189514817b70775aa33"><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Text_b467bc448c164d02821574edb5c659e0" contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" escape="true" continuedAt="Text_9007b3add44749508af8aa798bf533451">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The RIPSA carrying balance was as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_19d638c097eb408189514817b70775aa33"><ix:continuation id="Text_9007b3add44749508af8aa798bf533451">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div>
                    <div>Carrying balance</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_57bf40fb04544b1baefcb24fd07c8eb8" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">195,297</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_782262380cd3468db1e6a4f58150ae03" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">178,571</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div>Less: unamortized issuance costs</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div>(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" id="Fact_fb8140cdb4494c8791468489cffc9d29" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,543</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div>(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" id="Fact_4118daa2db36418388344490bed3a35c" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,806</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                  <div>
                    <div>Total debt, net</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:LongTermDebt" id="Fact_458547d7e82345da9ca272192a1d1e32" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">190,754</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div><br/>
                    </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:LongTermDebt" id="Fact_864b861836aa4b9da856dbf73709fbe2" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">173,765</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div><br/>
                    </div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div>
                    <div>Less: current portion</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div>(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" id="Fact_e8e5c2ad655141aca9f015b83a7d18b3" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,756</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div>)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div>(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" id="Fact_05830475145942d7b63ca5cbea8f3492" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,780</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div>Total long-term debt, net</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" id="Fact_34163b4ecc7d4379b340014df898ab96" contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">171,998</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div>$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" id="Fact_1a64e48f95d34454892823615c1c6af0" contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">159,985</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        </div>
</ix:continuation></ix:continuation>
      </div>


      <div><br/>
      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_f49d16b5daf44b9786b3e73378a630ba" contextRef="c20230401to20231231" escape="true" continuedAt="Text_29e671c361254ebdba1cf902a1ab79581">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 8&#8212;Shareholders&#8217; Equity</div>
</ix:nonNumeric>
        <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79581" continuedAt="Text_29e671c361254ebdba1cf902a1ab79582">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79582" continuedAt="Text_29e671c361254ebdba1cf902a1ab79583">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(A) At-the-Market Equity Offering Program</span></div>
</ix:continuation>
        <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79583" continuedAt="Text_29e671c361254ebdba1cf902a1ab79584">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79584" continuedAt="Text_29e671c361254ebdba1cf902a1ab79585">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79585" continuedAt="Text_29e671c361254ebdba1cf902a1ab79586">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79586" continuedAt="Text_29e671c361254ebdba1cf902a1ab79587">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;">On September 19, 2022, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC
            (&#8220;Cowen&#8221;) to sell its common shares having an aggregate offering price of up to $<ix:nonFraction name="roiv:CommonSharesOfferingPriceAuthorized" id="Fact_c8f0aecc97ab40ba80cfb52f1d4d80c0" contextRef="c20220919_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">400.0</ix:nonFraction> million from time to time through an
            &#8220;at-the-market&#8221; equity offering program under which Cowen acts as the Company&#8217;s agent (the &#8220;ATM Facility&#8221;).</div>
</ix:continuation>
          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79587" continuedAt="Text_29e671c361254ebdba1cf902a1ab79588">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79588" continuedAt="Text_29e671c361254ebdba1cf902a1ab79589">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab79589" continuedAt="Text_29e671c361254ebdba1cf902a1ab795810">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795810" continuedAt="Text_29e671c361254ebdba1cf902a1ab795811">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;">As of December 31, 2023, the Company had $<ix:nonFraction name="roiv:CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" id="Fact_af03b8506b99407996106acbfdb5afd2" contextRef="c20231231_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">400.0</ix:nonFraction> million of remaining capacity available under the ATM Facility.</div>
</ix:continuation>
          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795811" continuedAt="Text_29e671c361254ebdba1cf902a1ab795812">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795812" continuedAt="Text_29e671c361254ebdba1cf902a1ab795813">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795813" continuedAt="Text_29e671c361254ebdba1cf902a1ab795814">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">(B) Common Share
              Purchase and Share Agreements</div>
</ix:continuation>
            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795814" continuedAt="Text_29e671c361254ebdba1cf902a1ab795815">
<div style="text-align: left; font-weight: normal; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795815" continuedAt="Text_29e671c361254ebdba1cf902a1ab795816">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

          <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795816" continuedAt="Text_29e671c361254ebdba1cf902a1ab795817">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="font-weight: normal; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795817" continuedAt="Text_29e671c361254ebdba1cf902a1ab795818">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795818" continuedAt="Text_29e671c361254ebdba1cf902a1ab795819">
<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In September 2023, the Company entered into common share purchase and sale agreements with certain institutional investors, pursuant to which the Company sold an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_3f17fd2deeae4f8ebc29cacbedc7d47d" contextRef="c20230901to20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">19,600,685</ix:nonFraction> of its common shares at a purchase price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" id="Fact_1bc1797759554f94aa7b56b84bd73dd0" contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.21</ix:nonFraction>
              per share. Net proceeds to the Company were approximately $<ix:nonFraction name="roiv:NetProceedsFromIssuanceOfCommonStock" id="Fact_8c887ca5ae1f4867b9b63b5e8646e328" contextRef="c20230901to20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">199.8</ix:nonFraction> million after deducting offering expenses.</div>
</ix:continuation>
            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795819" continuedAt="Text_29e671c361254ebdba1cf902a1ab795820">
<div style="text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795820" continuedAt="Text_29e671c361254ebdba1cf902a1ab795821">
<div style="text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(C) Consolidated Vant Equity Transaction</span></div>
</ix:continuation>
            <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">
              <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795821" continuedAt="Text_29e671c361254ebdba1cf902a1ab795822">
<div style="text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                  </span></span></div>
</ix:continuation>
              <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795822" continuedAt="Text_29e671c361254ebdba1cf902a1ab795823">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Immunovant</span></span></div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795823" continuedAt="Text_29e671c361254ebdba1cf902a1ab795824">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_29e671c361254ebdba1cf902a1ab795824">
<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">October 2023, the Company&#8217;s subsidiary, Immunovant, Inc. (&#8220;Immunovant&#8221;), completed an underwritten public offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_907c5fd676e543ad8d1cd9c53a8fecce" contextRef="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">8,475,500</ix:nonFraction>
                shares of its common stock (including <ix:nonFraction name="roiv:StockPurchasedDuringPeriodByEntityShares" id="Fact_0e9f366846b941959378e29400fc5641" contextRef="c20231001to20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,526,316</ix:nonFraction> shares of common stock purchased by the Company on the same terms as other
                investors in the offering and the full exercise of the underwriters&#8217; option to purchase <ix:nonFraction name="roiv:OptionToPurchaseAdditionalSharesOfCommonStock" id="Fact_07173017e3d541a088fb9ef7d8f1e4d3" contextRef="c20231001to20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,105,500</ix:nonFraction> additional shares of common
                stock) at a price to the public of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" id="Fact_92060141bfd54cd682a38df68edd6d65" contextRef="c20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">38.00</ix:nonFraction> per share. Concurrent with the public offering, the Company purchased <ix:nonFraction name="roiv:StockPurchasedDuringPeriodByEntityShares" id="Fact_f414ff1c2c554485800189802ae33791" contextRef="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,473,684</ix:nonFraction> shares of Immunovant&#8217;s common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as
                amended, at the same price per share as investors in the public offering of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" id="Fact_159f83456c544acb9b79fb39417fc41c" contextRef="c20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">38.00</ix:nonFraction> per share. The net proceeds to Immunovant were
                approximately $<ix:nonFraction name="roiv:EstimatedNetProceedsFromIssuanceOfCommonStock" id="Fact_8b5b8cf605114374b8369137354b46fc" contextRef="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">466.7</ix:nonFraction> million after deducting underwriting discounts and commissions, placement agent fees and offering expenses.
                The Company&#8217;s equity ownership interest in Immunovant is approximately <ix:nonFraction name="roiv:OwnershipPercentage" id="Fact_3a42b1dad4c94b94b6170b43bcf2b387" contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>% as of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, and the Company continues to consolidate
                Immunovant</span>. </div>
</ix:continuation>
          </div>

           </div>

        <div><br/></div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_a8fc0f7c950c462d8aa62c99675ec623" contextRef="c20230401to20231231" escape="true" continuedAt="Text_0b76250c126948209be3c173ad5b961e1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 9&#8212;Share-Based Compensation</div>
</ix:nonNumeric>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e1" continuedAt="Text_0b76250c126948209be3c173ad5b961e2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e2" continuedAt="Text_0b76250c126948209be3c173ad5b961e3">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) RSL Equity Incentive Plans</div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e3" continuedAt="Text_0b76250c126948209be3c173ad5b961e4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e4" continuedAt="Text_0b76250c126948209be3c173ad5b961e5">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">RSL has <ix:nonFraction name="roiv:NumberOfEquityIncentivePlans" id="Fact_dcbe0e60d37f47eaac04f3ce45ff08b1" contextRef="c20230401to20231231" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> equity incentive
          plans: the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#8220;RSL 2021 EIP&#8221;), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan
          (collectively, the &#8220;RSL Equity Plans&#8221;). The RSL 2021 EIP was approved and adopted in connection with the Business Combination and became effective immediately prior to closing. At December 31, 2023, a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_60c323f540d742afb5a479213f030da3" contextRef="c20231231_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">41,986,389</ix:nonFraction> common shares were available for future grants under the RSL 2021 EIP.</div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e5" continuedAt="Text_0b76250c126948209be3c173ad5b961e6">
<div><br/></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e6" continuedAt="Text_0b76250c126948209be3c173ad5b961e7">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Stock Options and Performance Stock Options</div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e7" continuedAt="Text_0b76250c126948209be3c173ad5b961e8">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e8" continuedAt="Text_0b76250c126948209be3c173ad5b961e9"><ix:nonNumeric name="roiv:ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" id="Text_a7b8373926fa49849cba2681e5056d5e" contextRef="c20230401to20231231" escape="true" continuedAt="Text_71a33480201640908fc3033bc5972ddc1">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for stock options and performance stock options under the RSL Equity Plans for the nine months ended December 31, 2023 was as follows:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e9" continuedAt="Text_0b76250c126948209be3c173ad5b961e10"><ix:continuation id="Text_71a33480201640908fc3033bc5972ddc1" continuedAt="Text_71a33480201640908fc3033bc5972ddc2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e10" continuedAt="Text_0b76250c126948209be3c173ad5b961e11"><ix:continuation id="Text_71a33480201640908fc3033bc5972ddc2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Number of Options</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div>Options outstanding at&#160;March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_c499337aabfb46c0b5235e76900ffc91" contextRef="c20230331_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">154,271,791</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div>Granted</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_d7715f3365274d41acc2219f97f82320" contextRef="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,497,911</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: 0pt; margin-left: 9pt; width: 88%; background-color: #CCEEFF;">Exercised<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_780e17436fc54854b7c79aab5de98771" contextRef="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,796,348</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                <div>Forfeited/Canceled</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" id="Fact_d7a83367d3a345d985c4a189553a9ec8" contextRef="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">604,245</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Options outstanding at December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_5d610324609444248d305205c228af49" contextRef="c20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">147,369,109</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px;">
                <div>Options exercisable at&#160;December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_bc12984bf0fb4f2cbd953b287ec791da" contextRef="c20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">91,671,364</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e11" continuedAt="Text_0b76250c126948209be3c173ad5b961e12">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e12" continuedAt="Text_0b76250c126948209be3c173ad5b961e13">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Restricted Stock Units and Performance Stock Units</div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e13" continuedAt="Text_0b76250c126948209be3c173ad5b961e14">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e14" continuedAt="Text_0b76250c126948209be3c173ad5b961e15"><ix:nonNumeric name="roiv:ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" id="Text_f98932c4daf1400d829ed43c084cb8dd" contextRef="c20230401to20231231" escape="true" continuedAt="Text_526421d82d50411197d75c43622d7aa11">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for restricted stock units and performance stock units under the RSL Equity Plans for the nine months ended December 31, 2023 was as
          follows:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e15" continuedAt="Text_0b76250c126948209be3c173ad5b961e16"><ix:continuation id="Text_526421d82d50411197d75c43622d7aa11" continuedAt="Text_526421d82d50411197d75c43622d7aa12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e16" continuedAt="Text_0b76250c126948209be3c173ad5b961e17"><ix:continuation id="Text_526421d82d50411197d75c43622d7aa12">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Number of Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div>Non-vested balance at&#160;March 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_08bfd43d05d747cab4f7820cd7bc7d9b" contextRef="c20230331_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,700,788</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div>Granted</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_bfe8b585c1ef4fb590f77fe78b572676" contextRef="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,199,120</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div>Vested</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_be7b6ef5e7f3410788311ecb33d677fe" contextRef="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,498,323</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                <div>Forfeited</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_333185303f354cd4a4fbe781e311a5cb" contextRef="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,175,450</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Non-vested balance at&#160;December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_2aeb4dda7f92432e855bab2e3f9a8bbc" contextRef="c20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">18,226,135</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e17" continuedAt="Text_0b76250c126948209be3c173ad5b961e18">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e18" continuedAt="Text_0b76250c126948209be3c173ad5b961e19">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Capped Value Appreciation Rights</div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e19" continuedAt="Text_0b76250c126948209be3c173ad5b961e20">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e20" continuedAt="Text_0b76250c126948209be3c173ad5b961e21">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">March 2020 CVAR Grants</span></div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e21" continuedAt="Text_0b76250c126948209be3c173ad5b961e22">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e22" continuedAt="Text_0b76250c126948209be3c173ad5b961e23">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">As <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of&#160;</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, <ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" id="Fact_a353319b562f4a1ca61c060638d7aec6" contextRef="c20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">27,531,825</ix:nonFraction> CVARs remain outstanding and subject to
              the applicable hurdle price and knock-in condition. All outstanding capped value appreciation rights</span> (&#8220;CVARs&#8221;) <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">relating to the March 2020 grants had met the service vesting condition as of December 31, 2023. During the&#160;</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">nine months ended December 31, 2023</span>,
            <ix:nonFraction name="roiv:EquityInstrumentsVestedAndSettledShares" id="Fact_6f48c64fbbbd41449f09c8043d910156" contextRef="c20230401to20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,499,113</ix:nonFraction> service-vested CVARs satisfied their applicable hurdle price and the knock-in condition, if relevant, on the applicable
            measurement date, and as a result, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" id="Fact_c8b192d947ba43e0aa9fcff299b5e972" contextRef="c20230401to20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,445,420</ix:nonFraction> common shares were issued upon their settlement</span>.<br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e23" continuedAt="Text_0b76250c126948209be3c173ad5b961e24">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e24" continuedAt="Text_0b76250c126948209be3c173ad5b961e25">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">November 2021 CVAR Grants</span></div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e25" continuedAt="Text_0b76250c126948209be3c173ad5b961e26">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"> <br/>
          </span></div>
</ix:continuation>

        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e26" continuedAt="Text_0b76250c126948209be3c173ad5b961e27"><ix:nonNumeric name="roiv:ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" id="Text_8034fc63aa64495daa3caa31e527c9ca" contextRef="c20230401to20231231" escape="true" continuedAt="Text_f80258c17e374b1a85632f050552b8a01">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for CVARs under the RSL 2021 EIP for the nine months ended December 31, 2023 was as follows:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e27" continuedAt="Text_0b76250c126948209be3c173ad5b961e28"><ix:continuation id="Text_f80258c17e374b1a85632f050552b8a01" continuedAt="Text_f80258c17e374b1a85632f050552b8a02">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e28" continuedAt="Text_0b76250c126948209be3c173ad5b961e29"><ix:continuation id="Text_f80258c17e374b1a85632f050552b8a02">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Number of CVARs</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div>Non-vested balance at&#160;March 31, 2023</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_b431c5e31b454c81bc31134780167c93" contextRef="c20230331_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,222,645</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div>Vested</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_61b771720c324147b56672f3e3462d59" contextRef="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">955,782</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Forfeited</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_8d7345ff79ef44fea09d8405c7b48e68" contextRef="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">128,377</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px;">
                <div>Non-vested balance at&#160;December 31, 2023</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_193bc10ead90464f9b491b1d1dd1251d" contextRef="c20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,138,486</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e29" continuedAt="Text_0b76250c126948209be3c173ad5b961e30">
<div> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e30" continuedAt="Text_0b76250c126948209be3c173ad5b961e31">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">During the nine months ended December 31, 2023, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" id="Fact_7a66c7268b2b4a6f86209f6c67daaf96" contextRef="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">955,782</ix:nonFraction> common shares were issued upon their settlement.</span><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e31" continuedAt="Text_0b76250c126948209be3c173ad5b961e32">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e32" continuedAt="Text_0b76250c126948209be3c173ad5b961e33">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: bold;"> </span> </span></div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e33" continuedAt="Text_0b76250c126948209be3c173ad5b961e34">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="font-weight: bold;">(B) Subsidiary Equity Incentive Plans</span></div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e34" continuedAt="Text_0b76250c126948209be3c173ad5b961e35">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e35" continuedAt="Text_0b76250c126948209be3c173ad5b961e36">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: bold;"> <span style="font-weight: normal;"><br/>
            </span></span></div>
</ix:continuation>
        <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e36" continuedAt="Text_0b76250c126948209be3c173ad5b961e37">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_0b76250c126948209be3c173ad5b961e37">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain subsidiaries of
              RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive non-qualified and incentive
              stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. The Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_738d3832ea0e4818b0cb170b0db2afc7" contextRef="c20231001to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_dcd2971e3fa74a5cbd04bbd13bc8a0e4" contextRef="c20230401to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">53.1</ix:nonFraction> million for
              the three and nine months ended December 31, 2023, respectively, and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_7df950b8081b4716820b354cb6bdb636" contextRef="c20221001to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_731f6f2264bc4b8794268fdad98ab58a" contextRef="c20220401to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">37.8</ix:nonFraction> million for the three and nine months ended December 31, 2022, respectively, related to subsidiary EIPs.</span><br/>
          </div>
</ix:continuation>
        </div>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
        <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

        <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/></div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_d61be8a3a8804cc3b9ac36ad0f0557e2" contextRef="c20230401to20231231" escape="true" continuedAt="Text_62b013f36c0346a495cb191e56396fe61">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 10&#8212;Income Taxes</div>
</ix:nonNumeric>
        <ix:continuation id="Text_62b013f36c0346a495cb191e56396fe61" continuedAt="Text_62b013f36c0346a495cb191e56396fe62">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_62b013f36c0346a495cb191e56396fe62" continuedAt="Text_62b013f36c0346a495cb191e56396fe63">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s effective tax rate for the three and nine <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">months













            ended <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">December 31</span>, 2023 was </span><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_08435601b3fd4ea284b63fd926a3870d" contextRef="c20231001to20231231" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.5</ix:nonFraction>%
          and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_2880661df03e4759b520a1f3050105fa" contextRef="c20230401to20231231" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.7</ix:nonFraction>%, respectively, and the effective tax rate for the three and nine months ended December 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> was (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_b443e01173584957af974187cc8fa8bb" contextRef="c20221001to20221231" unitRef="U005" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.7</ix:nonFraction>)% and (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_4c8f5973c56b41d9ab267ad50868dea4" contextRef="c20220401to20221231" unitRef="U005" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.9</ix:nonFraction>)%, </span>respectively. The effective tax rates for three and nine months ended December 31, 2023 are driven by the Company&#8217;s gain on sale of Telavant net assets,
          which qualifies for the substantial shareholding exemption and consequently is not subject to the corporation income tax, as well as the jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net
          deferred tax assets. The effective tax rates for three and nine months ended December 31, 2022 are driven by the jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets.</div>
</ix:continuation>
        <ix:continuation id="Text_62b013f36c0346a495cb191e56396fe63" continuedAt="Text_62b013f36c0346a495cb191e56396fe64">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_62b013f36c0346a495cb191e56396fe64">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company assesses the realizability of its deferred tax assets at each balance sheet date based on available positive and negative evidence in
          order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary.</div>
</ix:continuation>

        <div><br/>
        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_9425667ffed7404dba9616741b06600e" contextRef="c20230401to20231231" escape="true" continuedAt="Text_02145b22e187454a8dca0bcad79ddf181">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 11&#8212;Commitments and Contingencies</div>
</ix:nonNumeric>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf181" continuedAt="Text_02145b22e187454a8dca0bcad79ddf182">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf182" continuedAt="Text_02145b22e187454a8dca0bcad79ddf183">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) Commitments</div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf183" continuedAt="Text_02145b22e187454a8dca0bcad79ddf184">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf184" continuedAt="Text_02145b22e187454a8dca0bcad79ddf185">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has entered into commitments under various asset acquisition and license agreements. Additionally, the Company enters into agreements with contract service providers to assist in the performance of its
            research and development activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods
            and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and
            supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources.</span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf185" continuedAt="Text_02145b22e187454a8dca0bcad79ddf186">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </span></div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf186" continuedAt="Text_02145b22e187454a8dca0bcad79ddf187">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company also has commitments relating to its long-term debt and leases. Refer to Note 7, &#8220;Long-Term Debt&#8221; for further information. There have been no material changes to the commitments relating to the Company&#8217;s
              leases during the nine months ended December 31, 2023 outside the ordinary course of business. For further information regarding the Company&#8217;s lease commitments, refer to Note 15, &#8220;Leases&#8221; in the Company&#8217;s Annual Report on Form 10-K for the
              year ended March 31, 2023. </span></span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf187" continuedAt="Text_02145b22e187454a8dca0bcad79ddf188">
<div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf188" continuedAt="Text_02145b22e187454a8dca0bcad79ddf189">
<div style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
        </span></div>
</ix:continuation>
      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf189" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1810">
<div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1810" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1811">
<div style="text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Purchase Commitments</span><br/>
            </span></span> </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1811" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1812">
<div style="display:none;"><br/></div>
<div style="text-indent: 18pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
            </span></span></div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1812" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1813">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-variant: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-transform: none;">In conjunction with Dermavant&#8217;s entry into the GSK
            Agreement in 2018, Dermavant entered into a clinical supply agreement pursuant to which GSK would provide a supply of tapinarof and clinical product at an agreed upon price during the Company&#8217;s clinical trials. In April 2019, Dermavant entered
            into a commercial supply agreement with GSK to continue to provide certain quantities of tapinarof and commercial product at agreed upon minimum quantities and price. The commercial supply agreement commenced in April 2022 upon completion of
            certain quality and regulatory conditions. In July 2022, Dermavant and GSK amended the terms of the clinical supply and commercial supply agreements which released GSK of certain commitments to supply tapinarof and released Dermavant of certain
            commitments to purchase tapinarof in exchange for a supplementary fee. Other supply and purchase commitments under the agreements remain in effect. In addition, Dermavant and Thermo Fisher Scientific (&#8220;TFS&#8221;) entered into a Commercial
            Manufacturing and Supply Agreement for which TFS agreed to provide a supply of tapinarof to Dermavant at an agreed upon price. The agreements discussed above require Dermavant to purchase certain quantities of inventory over a period</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> of <ix:nonNumeric name="us-gaap:LongtermPurchaseCommitmentPeriod" id="Fact_8c1f86a48a5f4c72a9baeb3e50c75600" contextRef="c20230401to20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. As of December 31, 2023, the remaining minimum purchase commitment related to these agreements was estimated to be approximately $<ix:nonFraction name="roiv:RemainingMinimumPurchaseCommitmentRelatedToAgreement" id="Fact_c86d1e4841304033b093b0697c9062d1" contextRef="c20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">43.1</ix:nonFraction> million. </span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1813" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1814">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1814" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1815">
<div> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1815" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1816">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1816" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1817">
<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">In
        November 2021, the Company&#8217;s subsidiary, Immunovant, entered into a Product Service Agreement (&#8220;PSA&#8221;) with Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) by which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial
        sale and perform other manufacturing-related services with respect to batoclimab. As of December 31, 2023, the remaining minimum purchase commitment related to this agreement was estimated to be approximately $<ix:nonFraction name="roiv:RemainingMinimumPurchaseCommitmentRelatedToAgreement" id="Fact_55ff4e6dca274f98937128a1f1d9305f" contextRef="c20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.3</ix:nonFraction> million. Immunovant had the right to terminate the PSA with <ix:nonNumeric name="roiv:PeriodOfRightToTerminateTheProductServiceAgreement" id="Fact_73035ad7c8db4ea7853fa736b78f327f" contextRef="c20230401to20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; written notice to Samsung, exercisable no later than January 2024, in the event Immunovant decided to stop all development of, and all attempts to obtain regulatory approval for,
        batoclimab; subject to payment to Samsung of non-cancellable service fees and costs incurred by Samsung for all batches of batoclimab scheduled to be manufactured during the two-year period following such termination. Because efforts to develop and
        obtain regulatory approval for batoclimab remain ongoing, Immunovant did not exercise that early termination right and it has lapsed. As a result, Immunovant has an additional minimum obligation to Samsung of approximately $<ix:nonFraction name="us-gaap:PurchaseObligation" id="Fact_953c70f562304d1e9e8dedacd2b4b592" contextRef="c20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction> million to purchase additional batches of batoclimab in the <ix:nonNumeric name="roiv:PeriodToPurchaseAdditionalBatchesOfBatoclimab" id="Fact_5b775fe3b94143919b67668c13c424f0" contextRef="c20230401to20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period of 2026 through 2029.</div>
</ix:continuation>
      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1817" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1818">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div><ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1818" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1819">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1819" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1820">
<div><br/></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1820" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1821">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1821" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1822">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In May 2021, the Company entered into a master subscription agreement with Palantir Technologies Inc. (&#8220;Palantir&#8221;) for access to Palantir&#8217;s proprietary software for a <ix:nonNumeric name="roiv:ProprietarySoftwareSubscriptionPeriod" id="Fact_39ad6db789924cc482fa498c1f27cdeb" contextRef="c20230401to20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> period. As of December 31, 2023, the remaining minimum payments for this software subscription were $<ix:nonFraction name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" id="Fact_34aea1cc127d4c75823e27a2ce0bca4c" contextRef="c20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.1</ix:nonFraction> million.</span><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1822" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1823">
<div> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1823" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1824">
<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1824" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1825">
<div style="text-align: justify;"> <span style="font-weight: bold; font-style: italic; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash
          Bonus Program</span><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1825" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1826">
<div> <br/>
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1826" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1827">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023, the Company approved a special one-time cash retention bonus award to its employees in the aggregate amount of $<ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_9fd2986ee45e4c4fa76c7844d9ec32fc" contextRef="c20231231_TypeOfArrangementAxis_CashBonusProgramMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">76.9</ix:nonFraction> million (the &#8220;<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash Bonus Program&#8221;)</span>. During the three and nine months ended December 31, 2023, the Company recognized selling, general and administrative expense and research and development expense of $<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_f2a2941f5ee6417fb62d2c4c8f7f67db" contextRef="c20230401to20231231_TypeOfArrangementAxis_CashBonusProgramMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_3ccc5cbdb575400082719783bed9968b" contextRef="c20231001to20231231_TypeOfArrangementAxis_CashBonusProgramMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.2</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_52eeef07e81347c6b500329d19034079" contextRef="c20231001to20231231_TypeOfArrangementAxis_CashBonusProgramMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_167857d8e84c42e584943dd9c6adaf20" contextRef="c20230401to20231231_TypeOfArrangementAxis_CashBonusProgramMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.1</ix:nonFraction></ix:nonFraction>
            million, respectively, representing the portion of the bonus award that was vested and payable immediately. The remaining portion will be recognized over the applicable service period of the award. In February 2024, the Company expanded this
            Cash Bonus Program to include an award to its Chief Financial Officer on similar terms as the other awards previously made to other employees. The Chief Financial Officer did not receive a payment from the Cash Bonus Program approved in
            December. This award to the Chief Financial Officer was in the aggregate amount of $<ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_13c9f8e6565d4e35b411c419add91a93" contextRef="c20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction> million. <ix:nonFraction name="roiv:PercentageOfBonusPayableInNext30DaysOfGrantDate" id="Fact_6c4ea09009e64aa2a0d50d5cfb0d666f" contextRef="c20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember" unitRef="U005" decimals="2" scale="-2" format="ixt-sec:numwordsen">Fifty </ix:nonFraction>percent of the bonus will be payable within <ix:nonNumeric name="roiv:FiftyPercentBonusPayablePeriodFromGrantDate" id="Fact_d1209397e349416281d7f4bd6c4557d7" contextRef="c20240209to20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember" format="ixt-sec:durwordsen">30 days</ix:nonNumeric> of the grant date, with the balance subject to vesting tied to the employee&#8217;s continued service to the Company, as described in more detail in Part II, Item 5 of this Quarterly Report.</span><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1827" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1828">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1828" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1829">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">(B) Loss Contingencies</div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1829" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1830">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1830" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1831">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable
            that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim,
            including an estimable range, if possible. </span></div>
</ix:continuation>
      </div>

      <div> <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1831" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1832">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1832" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1833">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;">Immunovant Securities
          Litigation</div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1833" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1834">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1834" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1835">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In February 2021, a putative securities class action complaint was filed against Immunovant and certain of its current and former officers in the U.S. District Court for the Eastern District of New
              York on behalf of a class consisting of those who acquired Immunovant&#8217;s securities from October 2, 2019 and February 1, 2021. The complaint alleged that Immunovant and certain of its officers violated Sections 10(b) and 20(a) of the
              Securities Exchange Act of 1934, as amended, by making false and misleading statements regarding the safety of batoclimab and sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including
              reasonable attorneys&#8217; fees. In December 2021, the U.S. District Court appointed a lead plaintiff. In March 2022, the lead plaintiff filed an amended complaint adding both (i) the Company and (ii) Immunovant&#8217;s directors and underwriters as
              defendants, and asserting additional claims under Section 11, 12(a)(2), and 15 of the Securities Act of 1933, as amended, on behalf of a putative class consisting of those who purchased or otherwise acquired Immunovant&#8217;s securities pursuant
              and/or traceable to Immunovant&#8217;s follow-on public offering on or about September 2, 2020. In February 2023, after further briefing on the amended complaint the U.S. District Court issued an order permitting the lead plaintiff to file a second
              amended complaint. That second amended complaint was filed in March 2023. The defendants&#8217; served motions to dismiss the second amended complaint on April 28, 2023. The fully briefed motions to dismiss, including defendants&#8217; opening briefs,
              lead plaintiff&#8217;s opposition and defendants&#8217; replies, were filed with the court on June 30, 2023. No hearing date has yet been set. The Company intends to continue to vigorously defend the case and has not recorded a liability related to this
              lawsuit because, at this time, the Company is unable to reasonably estimate possible losses or determine whether an unfavorable outcome is either probable or remote.</span> </span> <span style="font-size: 10pt;"> </span> </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1835" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1836">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"> </span><br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1836" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1837">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;">Acuitas Declaratory
          Judgment Action</div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1837" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1838">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1838" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1839">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In March 2022,
              Acuitas Therapeutics Inc. (&#8220;Acuitas&#8221;) filed a lawsuit in the U.S. District Court for the Southern District of New York (&#8220;SDNY&#8221;) against two of the Company&#8217;s affiliates, Genevant and Arbutus, seeking a declaratory judgment that certain patents
              held by Arbutus and licensed by Genevant are not infringed by the manufacture, use, offer for sale, sale or importation into the United States of COMIRNATY, Pfizer&#8217;s and BioNTech&#8217;s vaccine for COVID-19 and are otherwise invalid. On September
              6, 2022, Acuitas filed a First Amended Complaint. In response, on October 4, 2022, Genevant and Arbutus filed a motion to dismiss the first amended complaint for lack of a controversy and supporting brief. Briefing on this motion was
              completed in mid-November. On August 4, 2023, Acuitas voluntarily dismissed the action in the SDNY and re-filed a complaint in the U.S. District Court for the District of New Jersey. On October 13, 2023, Genevant and Arbutus filed a motion to
              dismiss the re-filed complaint. No hearing date has been set. Each of Genevant and Arbutus intends to continue to vigorously defend the case.</span> </span> </div>
</ix:continuation>
        <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1839" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1840">
<div><br/></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1840" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1841">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">(C) Indemnification
          Agreements</div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1841" continuedAt="Text_02145b22e187454a8dca0bcad79ddf1842">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_02145b22e187454a8dca0bcad79ddf1842">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the
            occurrence of certain events. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company also indemnifies each of its directors and officers for certain events or occurrences,
            subject to certain limits. The maximum amount of potential future indemnification is unlimited; however, the Company currently maintains director and officer liability insurance, which may cover certain liabilities arising from the Company&#8217;s
            obligation to indemnify its directors and officers. To date, the Company has not incurred any material costs related to these indemnification obligations and has not accrued any liabilities related to such obligations in the condensed
            consolidated financial statements as of December 31, 2023 and March 31, 2023. </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
</ix:continuation>
        <div><br/>
        </div>

        <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
 </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <ix:nonNumeric name="roiv:EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" id="Text_77803b80dce94600a52d0df74389fef6" contextRef="c20230401to20231231" escape="true" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb21">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 12&#8212;Earn-Out Shares, Public Warrants and Private Placement Warrants</div>
</ix:nonNumeric>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb21" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb22">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb22" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb23">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Earn-Out Shares</div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb23" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb24">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb24" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb25">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">In connection with the Business Combination, the Company issued the following: </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb25" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb26">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb26" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb27">
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="c2d6ce1f9431483b81d4e2da22271795" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="width: 27pt;"/>

    <td style="vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(a)<br/>
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_b4e47c70c53d439088ed657f3acc9cf9" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,033,591</ix:nonFraction> common shares to Patient Square Capital LLC (the &#8220;MAAC Sponsor&#8221;) and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_4dc7700346be4d1eaa7b0c136c43c870" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> common shares issued to each of MAAC&#8217;s independent directors (collectively, the &#8220;<ix:nonFraction name="roiv:PercentageOfEarnOutShares" id="Fact_b1d8fe6c67af4103a7311048952a75bd" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% Earn-Out Shares&#8221;), which will vest if the closing price of the Company&#8217;s common shares is greater than or equal to $<ix:nonFraction name="roiv:EarnOutSharePrice" id="Fact_55260793c3e64bcba7718f459ae02fd2" contextRef="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction> over any <span style="-sec-ix-hidden:Fact_2cef63e668c241b7bc426da933f7f568">twenty</span> out of <span style="-sec-ix-hidden:Fact_d2125a9df960461aa915b45e9db9e81b">thirty</span> trading day period during the Vesting Period (defined below).</div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb27" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb28">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb28" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb29">
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="c759375f6a474886b6c60be6cd797d32" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="width: 27pt;"/>

    <td style="vertical-align: top; width: 36pt;">(b)<br/>
              </td>

    <td style="vertical-align: top; width: auto; text-align: justify;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_25bfe8002f554f1182877ac92938b64d" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,016,796</ix:nonFraction> common shares issued to the MAAC Sponsor and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_7ceba1aff1c74b53b9cf10dd9197f0ba" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction> common shares issued to each of MAAC&#8217;s independent directors (collectively, the &#8220;<ix:nonFraction name="roiv:PercentageOfEarnOutShares" id="Fact_fb58c7089d4846319f6413554d862216" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% Earn-Out Shares&#8221; and, together with the <ix:nonFraction name="roiv:PercentageOfEarnOutShares" id="Fact_aa7f3dbae3e84f7fa927e659196e92e0" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember" unitRef="U005" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% Earn-Out Shares, the
                &#8220;Earn-Out Shares&#8221;), each in respect of its MAAC Class B Shares, will vest if the closing price of the Company&#8217;s common shares is greater than or equal to $<ix:nonFraction name="roiv:EarnOutSharePrice" id="Fact_d85d00a5e2bd46cb91beb2359bf48576" contextRef="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">20.00</ix:nonFraction> over any <span style="-sec-ix-hidden:Fact_227cc2a973b342cdadc7924eb0824d99">twenty</span> out of <span style="-sec-ix-hidden:Fact_938065e85885426b93d64ce0a73dd639">thirty</span> trading day period during the Vesting Period (as defined below).</td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb29" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb210">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <!--PROfilePageNumberReset%Num%27%%%-->
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb210" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb211">
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="ad9db901fae345a298e6d370b7b21acf" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="width: 27pt;"/>

    <td style="vertical-align: top; width: 36pt;">(c)<br/>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify;">The remaining number of common shares issued to the MAAC Sponsor and each of MAAC&#8217;s independent director are not subject to the vesting conditions described above (the &#8220;Retained Shares&#8221;).</div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb211" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb212">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb212" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb213">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Vesting Period commenced on November 9, 2021 and ends no later than September 30, 2026 (the &#8220;Vesting Period&#8221;). The Vesting Period will, if a definitive purchase agreement with respect to a Sale (as defined in the
            Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs
            during such Vesting Period, then all of the Earn-Out Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any Earn-Out Shares have not vested on or prior to the end of such Vesting
            Period, then such Earn-Out Shares will be forfeited. </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb213" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb214">
<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb214" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb215">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb215" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb216">
<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb216" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb217">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">
          The Earn-Out Shares require liability classification and are classified as &#8220;Liability instruments measured at fair value&#8221; on the condensed consolidated balance sheets. The Earn-Out Shares liability is subject to remeasurement at each balance
          sheet date with changes in fair value recognized in the Company&#8217;s statements of operations. As of December 31, 2023, <ix:nonFraction name="roiv:NumberOfEarnOutSharesVested" id="Fact_36109f42fa4b42f0a09c9919616ad43b" contextRef="c20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> Earn-Out
          Shares have vested. </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb217" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb218">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt;"><br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb218" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb219">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb219" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb220">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Public Warrants and Private Placement Warrants</div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb220" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb221">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb221" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb222">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Immediately following the Business Combination, the Company had <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_4a7f651986b74bdca2c712a7ca11e3c8" contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,214,365</ix:nonFraction> outstanding warrants for the
            purchase of one of the Company&#8217;s common shares, which were held by the MAAC Sponsor at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_f17c4d512b7b4e2ab518aedf176b01f9" contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> (the &#8220;Private
            Placement Warrants&#8221;), and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_2e3a57be45cc439ab67a334957547ff7" contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,535,896</ix:nonFraction> outstanding warrants for the purchase of one of the Company&#8217;s common shares, which were held by
            MAAC&#8217;s shareholders at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_711d2bf6d9f44fb6b5fc4ed22dc687d7" contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;(the &#8220;Public Warrants&#8221; and, together with the Private Placement
              Warrants, the &#8220;Warrants&#8221;). Pursuant to the Warrant Agreement, dated October 6, 2020, by and between the Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;) and Continental Stock Transfer &amp; Trust Company, as predecessor warrant agent, as modified
              by the Warrant Assumption Agreement, dated September 30, 2021, by and among MAAC, the Company and American Stock Transfer &amp; Trust Company, LLC as successor warrant agent (as modified, the &#8220;Warrant Agreement&#8221;), the Warrants </span>became
            exercisable <ix:nonNumeric name="roiv:PeriodToExerciseWarrantsAfterBusinessCombination" id="Fact_2410d7f112464efa80b9093fe43c57f4" contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember" format="ixt-sec:durday">30</ix:nonNumeric> days following the completion of the Business Combination and would expire <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_d117ec0937c749cfa3f71eea205f1e29" contextRef="c20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> after the completion of the Business Combination, or earlier upon redemption or liquidation. </span></div>
</ix:continuation><ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb222" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb223">
<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span>
         <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="text-align: left;">
          <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb223" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb224">
<div>&#160;</div>
</ix:continuation>
          <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb224" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb225">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Prior to their settlement, the Warrants required liability classification and were classified as &#8220;Liability instruments measured at fair value&#8221; on the condensed consolidated balance sheets. The Private Placement
              Warrants liability and Public Warrants liability were subject to remeasurement with changes in fair value recognized in the Company&#8217;s statements of operations. The Warrants were remeasured immediately prior to settlement. These remeasurements
              were recognized in &#8220;Change in fair value of debt and liability instruments&#8221; in the accompanying condensed consolidated statements of operations. </span></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb225" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb226">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb226" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb227">
<div style="display:none;"><br/></div>
<div style="text-indent: 18pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb227" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb228">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb228" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb229">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Under the terms of the Warrant Agreement, the Company was entitled to redeem the Public Warrants at a redemption price of $<ix:nonFraction name="roiv:ClassOfWarrantOrRightRedemptionPrice" id="Fact_67871a5fd45d43c2a2b55c03d17c1db2" contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction>
            per Public Warrant because the last reported sales price (the &#8220;Reference Value&#8221;) of the Company&#8217;s common shares was at least $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" id="Fact_635c4914319046deb43dccd9bc10a209" contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
            per share for any twenty (<ix:nonNumeric name="roiv:NumberOfTradingDays" id="Fact_00644c9cb41a4255a34668345f61e4e4" contextRef="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember" format="ixt-sec:durday">20</ix:nonNumeric>) trading days within the thirty (<ix:nonNumeric name="roiv:NumberOfTradingDays" id="Fact_7b6e7425895e434e8cb9b76a8103962f" contextRef="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MaximumMember" format="ixt-sec:durday">30</ix:nonNumeric>) trading-day period ending on the third trading day prior to the date on which RSL gave a Notice of Redemption. In addition, because the Reference Value was less than $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_da41eed7c32941ffac71b167c1d38a71" contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RangeAxis_MinimumMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share, the outstanding Private Placement Warrants were also required to be concurrently called for redemption on the same terms as the
            outstanding Public Warrants. This share price performance requirement was satisfied as of July 28, 2023. On August 2, 2023, the Company announced that it would redeem all Warrants that remain outstanding on September 1, 2023 (the &#8220;Redemption
            Date&#8221;).</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb229" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb230">
<div><br/></div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb230" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb231">
<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">Prior
















          to the Redemption Date, Warrant holders were permitted to exercise the Warrants (i) for cash, at an exercise price of $<ix:nonFraction name="roiv:CashExercisePrice" id="Fact_d3e0df4a3e8844c5a2f1a00909e2750e" contextRef="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per common
          share, or (ii) on a &#8220;cashless basis&#8221; whereby, in lieu of paying the Company the $<ix:nonFraction name="roiv:ExercisePrice" id="Fact_a667d5006b414e3e87267cca7ad98fe5" contextRef="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> exercise price per common share, the
          surrendering holder would receive approximately <ix:nonFraction name="roiv:StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" id="Fact_18df1efe4a774195b1830380f76f4ce6" contextRef="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="4" scale="0" format="ixt:num-dot-decimal">0.2495</ix:nonFraction> common shares per Warrant as determined in accordance with the terms of the
          Warrant Agreement.</div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb231" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb232">
<div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb232" continuedAt="Text_b06d226eed8743bca71fe410eaf80bb233">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Of the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_0a8c805f3043418187e732ea92da968a" contextRef="c20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,475,875</ix:nonFraction> Public Warrants that were outstanding as of June 30, 2023, <ix:nonFraction name="roiv:PublicWarrantCashExercised" id="Fact_8ae8188f9a58405dbf8fbe8fa6903d36" contextRef="c20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">397</ix:nonFraction> Public Warrants were exercised for cash at an exercise price of $<ix:nonFraction name="roiv:CashExercisePrice" id="Fact_bde6401d312f453a889b4ac8865c65cb" contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per common share in exchange for an aggregate of <ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesCashWarrantExercises" id="Fact_4c410ed2ddcf49e8b037afb8ec4e86ee" contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">397</ix:nonFraction> common shares and <ix:nonFraction name="roiv:CashlessPublicWarrantExercised" id="Fact_8ec28dd873864e49913938a6bdff8f5c" contextRef="c20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,061,507</ix:nonFraction> were exercised on a cashless basis in exchange for an aggregate of <ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesCashlessWarrantExercises" id="Fact_0ae8f5cfda1441ceba715717b152a013" contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,005,531</ix:nonFraction> common shares. The remaining <ix:nonFraction name="roiv:ClassOfWarrantOrRightUnexercisedPriceOfWarrants" id="Fact_c07f665660cd4ea4b5711343bfdf66e1" contextRef="c20230401to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">413,971</ix:nonFraction> unexercised Public Warrants
            were redeemed at the $<ix:nonFraction name="roiv:ClassOfWarrantOrRightRedemptionPrice" id="Fact_60fce00170e1483db8439851031fa82d" contextRef="c20230630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction> redemption price. In addition, all of the Private Placement Warrants were exercised on a cashless basis in
            exchange for an aggregate of <ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesCashlessWarrantExercises" id="Fact_ba667f92d61046c18dd2e35474725642" contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,548,621</ix:nonFraction> common shares.</span> </div>
</ix:continuation>
        <ix:continuation id="Text_b06d226eed8743bca71fe410eaf80bb233">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="text-indent: 18pt; text-align: justify;"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

      </div>

    </div>


  </div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
  <div>
    <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_a70d3ff60cd5420dbfa2f5b9e89b8d1f" contextRef="c20230401to20231231" escape="true" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 13&#8212;Fair Value Measurements</div>
</ix:nonNumeric>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c1" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c2" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c3">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Recurring Fair Value Measurements</div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c3" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c4">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
  </div>


  <div>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c4" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c5"><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Text_cc3aa55eefd14e91a020c9b1d4e02595" contextRef="c20230401to20231231" escape="true" continuedAt="Text_a17cce8ee05a4c8285447f4562cdc1271">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The
      following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and March 31, 2023, by level, within the fair value hierarchy (in thousands): </div>
</ix:nonNumeric></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c5" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c6"><ix:continuation id="Text_a17cce8ee05a4c8285447f4562cdc1271" continuedAt="Text_a17cce8ee05a4c8285447f4562cdc1272">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 9pt;"> <br/>
    </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c6" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c7"><ix:continuation id="Text_a17cce8ee05a4c8285447f4562cdc1272" continuedAt="Text_a17cce8ee05a4c8285447f4562cdc1273">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="14">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="14">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Level 1</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Level 2</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Level 3</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Balance as of</div>
            <div style="text-align: center; font-weight: bold;">December 31,</div>
            <div style="text-align: center; font-weight: bold;">2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Level 1</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Level 2</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Level 3</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Balance as <br/>
            </div>
            <div style="text-align: center; font-weight: bold;">of March 31,</div>
            <div style="text-align: center; font-weight: bold;">2023 </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
            <div style="text-indent: -9pt; margin-left: 9pt;">Assets:</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Money market funds</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_0c13619bab054cebb09033253ee50412" contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,513,936</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_f61b2c5432fe4d04be1da85057d76cf9" contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_fbaf16a57f2444f2a8b29177f806ac68" contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_37b1738bd94f4af8af5c03e1a4f6da10" contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,513,936</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_cd0771b0e00549898dc302274ae36af9" contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,496,726</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_4d938c76aba64f49bbd6ceeb923036bd" contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_e57dfcee0edb4fdcabea8eaadb6605d3" contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_3d0fb8e33b714b84b571fc9acea21e3a" contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,496,726</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;">
            <div style="text-indent: -9pt; margin-left: 9pt;">Investment in Datavant Class A units</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_929c262008874a0282712825b0971146" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_98b053480d3648a387feea4714f5277c" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_81f8cced0ab64658be4271403eaa4573" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,934</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_5702140e237d4b04b62f159ffd88316f" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,934</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_4079b9dfb62443bcac5c97f066768557" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_db2ded18af3f4a35b5fad1bb43133ec4" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_c641f9a9b6934327b038b5d279847c30" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">178,579</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_d02e720e566c46fb813bcc188b1eb121" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">178,579</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Investment in Arbutus common shares</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_ecb6305054734f009328e7b02477e6f4" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,119</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_70365858095f455a92a6432699c1ba3a" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_1f39157fcd3c4e48aa8c8449a91deeb3" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_ab70119a614d4ea48fe7ef17f01cbfb2" contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,119</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_f975256cfcb94a2daa52c0e332238a7e" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,708</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_f30b7b5514574a24bf7d81fbf29b3866" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_c6c2812738f94c99bec8188c5afc651c" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_f3e6d53a678b4ce7a749b07535a22604" contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,708</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 2px;">
            <div style="text-indent: -9pt; margin-left: 9pt;">Other investments</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_33b1612ad67046628e28557f2e95568e" contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,874</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_37ae4088ec844009b5ae1d7b848fd71a" contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_20c751e2831d4cf3a5a4f97a2216adf1" contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_7d9cbd56dd604f1db1a4bdab9e8ebdff" contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,874</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_419c9faf0d7a416cb3feaa085205d7e6" contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,030</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1"> </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_c82c3622937547758706ee5915407ab7" contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_9c14ce8d99004ffbb1678c4549fa2616" contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_143570076be145f694cb6526cf5aa286" contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,030</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Total assets at fair value</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_6f4e59226abf47708f951de49bcfbd98" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,617,929</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_bba5e9ad94334c1797476501927d28eb" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_86f52576cbae4fba891e4ce67cb50868" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,934</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_8f331db804c7441aa6e3f962a8fcedee" contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,753,863</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_5dd594fe01424e8b9502cc45003ee321" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,622,464</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"> </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_28d9948e5ed143f09b04d8fc6c921134" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_27c5a8f943884552b63795b62e55f731" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">178,579</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_e053960a65fe4059854f67ce9f908fdc" contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,801,043</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%;">
            <div style="text-indent: -9pt; margin-left: 9pt;">Liabilities:</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Debt issued by Dermavant to NovaQuest</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_62581ebf79ee4f7eb2210b14ccb3fee9" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_47be66c539db46049fade43f0923da91" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_b744e489af96491db325b1809ba0d1bc" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">221,510</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_d6eb51a7e5984c8c8d219ba401c07b7b" contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">221,510</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_905801e5ee82488f9f4781246bcbdca0" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_4cde8c79bb6d4ae18864e3f9d44eddbf" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_e80f0a3b7cfe4516a706fc842e3c1ea1" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,640</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" id="Fact_f770fed778514296ba1903c5cbd68d9f" contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,640</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 2px;">
            <div style="text-indent: -9pt; margin-left: 9pt;">Liability instruments measured at fair value<sup>(1)</sup></div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_88d301b06f3b4647bd1a7bd6a42d22e1" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_4dfeb1fa823a44f986b1f8c8747e6e3b" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_7aa6e3e059604b539d74d42ac4d41f07" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,374</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_9d3967aaf8b84bd59f44e1c76670b3b8" contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,374</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_d60545cae465462f845da4052288e0b4" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,895</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_f98ef47d156a48a3b5586b2e4b978334" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_428210c60e944730a20f7b55694bf111" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,651</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" id="Fact_1e7097176cf645f1845fbbe6eea85e94" contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,546</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Total liabilities at fair value</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_79ba7f9ae638489ab7fe02fbd5e62884" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_81e7e6ee12b244859d7d94a079b514bc" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_0ff59a98cd8c406aacee90f7851b3a39" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">249,884</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_f0cd7542fd6b45b3a87b1cbc10bde76e" contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">249,884</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_eccfb9007b754fe8aabddc5c0362a2f1" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,895</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_e6b9545d0f7348598e3b5b5d0bbe7bc9" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_ad9102e481a84d15a67379c57212298d" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">241,291</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="Fact_9f6b7639ca524e44a4ed07fa2a539c15" contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">271,186</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c7" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c8"><ix:continuation id="Text_a17cce8ee05a4c8285447f4562cdc1273" continuedAt="Text_a17cce8ee05a4c8285447f4562cdc1274">
<div><br/>
    </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c8" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c9"><ix:continuation id="Text_a17cce8ee05a4c8285447f4562cdc1274">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
            <div style="font-style: normal;"><sup>(1)</sup></div>
          </td>

    <td style="width: 96%; vertical-align: top;">
            <div style="text-align: justify;"><ix:footnote id="Foot_284c7966a91e41ae90598fd7dee6f320" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_e74ff6ff61574036a863f096d8a7bde3" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.9</ix:nonFraction> million and other liability instruments issued of $<ix:nonFraction name="roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" id="Fact_a5c0a52c0f9d46d3810cd832b3ed7af7" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_183021528e7944e2a052039e0781e614" contextRef="c20230331_ClassOfWarrantOrRightAxis_PublicWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">29.9</ix:nonFraction>
              million, and Level 3 includes the fair value of the Earn-Out Shares of $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_bb6efee56a8a4984989a53845b736851" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.2</ix:nonFraction> million, Private Placement Warrants of $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_d66c42e9db1d4596bf30e9058ef4b34b" contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_WarrantMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.2</ix:nonFraction> million, and other liability instruments issued of $<ix:nonFraction name="roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" id="Fact_9951d6dda98a413887f7f124e7f01458" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.3</ix:nonFraction> million.</ix:footnote></div>
          </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c9" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c10">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c10" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c11">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c11" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c12">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy that occurred during the nine months ended December 31, 2023. </span> </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c12" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c13">
<div><br/></div>
</ix:continuation>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
        </div>

      </div>

    </div>

    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c13" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c14">
<div style="font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Level 3 Disclosures</div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c14" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c15">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c15" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c16">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company measures its Level 3 assets and liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. The
        valuation of the Level 3 assets and liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as
        additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c16" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c17">
<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c17" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c18">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span> </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c18" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c19">
<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c19" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c20">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"> The
      fair value of Level 3 assets and liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information,
      considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value
      amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c20" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c21">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c21" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c22">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      <br/>
    </div>
</ix:continuation>
  </div>
<ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_c7575c269a9142e6b8f4279ef7bd0f5b" contextRef="c20230401to20231231" escape="true" continuedAt="Text_212cd2b466af47568ad053e50a887dcb1"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c22" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c23">
<div><span style="font-size: 10pt;"> </span>
  <span style="font-size: 10pt;"> </span></div>
</ix:continuation></ix:nonNumeric>
  <div><ix:continuation id="Text_212cd2b466af47568ad053e50a887dcb1" continuedAt="Text_212cd2b466af47568ad053e50a887dcb2"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c23" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c24">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_212cd2b466af47568ad053e50a887dcb2" continuedAt="Text_212cd2b466af47568ad053e50a887dcb3"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c24" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c25">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The changes in fair value of the Level 3
      assets during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_212cd2b466af47568ad053e50a887dcb3" continuedAt="Text_212cd2b466af47568ad053e50a887dcb4"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c25" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c26">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_212cd2b466af47568ad053e50a887dcb4"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c26" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c27">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" id="Fact_7f617ceaf53a4ca6a75aa9343239cb54" contextRef="c20220331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">193,963</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_5ffcc6c700034d4587790a5e791d733c">Changes in fair value of investment in Datavant, included in net loss</span></span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" id="Fact_e2ae86f1f1064e81843007057664ebca" contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21,452</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" id="Fact_1b68a8ad84d9470e970eadf8d4a59e99" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">172,511</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%;">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div>$</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
            <div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" id="Fact_c156f2d70ed444db9f457857bba57741" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">178,579</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_1bcdc2e95f0b40ac8041dbfa7444510a">Changes in fair value of investment in Datavant, included in net loss</span></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
            <div>(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" id="Fact_0d7f35e1f4ec42f9a729785ef8f72867" contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">42,645</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div>$</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" id="Fact_d5d56083200b4acf976187d714174988" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,934</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c27" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c28">
<div><br/>
    </div>
</ix:continuation>
  </div>


  <div>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c28" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c29"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_0a78f89e05f54726be734be8422fea1a" contextRef="c20230401to20231231" escape="true" continuedAt="Text_ecb323364eb7477fa571793f82ff7fdf1">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The
      changes in fair value of the Level 3 liabilities during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): </div>
</ix:nonNumeric></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c29" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c30"><ix:continuation id="Text_ecb323364eb7477fa571793f82ff7fdf1" continuedAt="Text_ecb323364eb7477fa571793f82ff7fdf2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c30" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c31"><ix:continuation id="Text_ecb323364eb7477fa571793f82ff7fdf2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Balance at <span style="text-indent: 0pt;">March 31</span>, </span><span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div>$</div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
            <div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_2a2ca2aa014344e89df8bbcbc8d8d839" contextRef="c20220331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">204,293</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%;">
            <div style="margin-left: 9pt; text-indent: -9pt;">Fair value of liability instrument issued <br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" id="Fact_0eefc3b7db6047a9b7ba32bf751c6015" contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">248</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Payments related to long-term
                debt</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" id="Fact_37758ae4f2be41259976356a209afb3f" contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,031</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_93006666e195494db2e26107da08a25a">Changes in fair value of debt and liability instruments, included in net loss</span></span> </span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
            <div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" id="Fact_73ac526a841f446b8642c38614b8f520" contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,328</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div>$</div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_0ab33bd5d99049f59ca84f14515985c6" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">250,838</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%;">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div>$</div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
            <div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_d361d907b9b245bea7c2d26aa230c47e" contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">241,291</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%;">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Payments related to long-term
                debt</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" id="Fact_ef05d771eee040c0b08d822f7e425150" contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,031</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Exercise of Private Placement Warrants</div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="roiv:ExerciseOfPrivatePlacementWarrantsValue" id="Fact_6cece2a67adb4867803cbf3abaf1a3c4" contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,090</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_ca3f4592024941f287ede17a07ff606d">Changes in fair value of debt and liability instruments, included in net loss</span></span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" id="Fact_32ce11d7b99a4fc480960f438231f0f4" contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,714</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_79ebedd4b10c4d0c87de6e70144d5871" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">249,884</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c31" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c32">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c32" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c33">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Investment in Datavant</div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c33" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c34">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c34" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c35">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method
        (&#8220;OPM&#8221;). The OPM allows for the allocation of a company&#8217;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#8217; liquidation preferences, participation rights, dividend
        policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. </span><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_9778c6fa0e6d4bc38c7055b20005db6d" contextRef="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" escape="true" continuedAt="Text_c21993ef62334d78a5b019be2c26cee71"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The fair value was calculated using significant unobservable inputs including the following: </span></span></ix:nonNumeric></div>
</ix:continuation>
    <ix:continuation id="Text_c21993ef62334d78a5b019be2c26cee71" continuedAt="Text_c21993ef62334d78a5b019be2c26cee72"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c35" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c36">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_c21993ef62334d78a5b019be2c26cee72"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c36" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c37">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold; font-style: normal;">Input</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
            <div>Volatility</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" id="Fact_7fe28950f75b41a1a44bc7114b3dadf2" contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">95.0</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" id="Fact_51f43aabc8bc40329616b03f4fa96c77" contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">100.0</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div>Risk-free rate</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" id="Fact_e7d859a751c5467082af8860e8d3de4a" contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.46</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" id="Fact_0d1c406981254fe8a35dda576a162def" contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.02</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c37" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c38">
<div><br/></div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

    </div>

    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c38" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c39">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Debt issued by Dermavant to NovaQuest</div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c39" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c40">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt;"><br/>
      </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c40" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c41">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c41" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c42">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The fair value of the debt instrument as of December 31, 2023 and March 31, 2023 represents the fair value of amounts payable to NovaQuest calculated using the Monte Carlo simulation method under the income approach
        determined by using probability assessments of the expected future payments through 2032. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The
        estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c42" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c43">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c43" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c44">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Earn-Out Shares</div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c44" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c45">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c45" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c46">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The fair value of the Earn-Out Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the lock-up periods to
        which the Earn-Out Shares are subject. Refer to Note 12, &#8220;Earn-Out Shares, Public Warrants and Private Placement Warrants&#8221; for additional details. </span><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_1d87f29774f242f094d0bdea5fa559ad" contextRef="c20230401to20231231_StatementEquityComponentsAxis_EarnoutSharesMember" escape="true" continuedAt="Text_42d10e91a40e429eb452f9d7c5d3e70c1"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Significant unobservable inputs used to calculate the fair value of the Earn-Out Shares included the following: </span></span></ix:nonNumeric></div>
</ix:continuation>
    <div>
      <ix:continuation id="Text_42d10e91a40e429eb452f9d7c5d3e70c1" continuedAt="Text_42d10e91a40e429eb452f9d7c5d3e70c2"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c46" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c47">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
    </div>

    <ix:continuation id="Text_42d10e91a40e429eb452f9d7c5d3e70c2"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c47" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c48">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
            <div style="font-weight: bold;">Input</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
            <div>Volatility</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueEarnoutSharesMeasurementInput" id="Fact_0212e2d774924f7e89101bb0dea01248" contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">61.9</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueEarnoutSharesMeasurementInput" id="Fact_176924d4f5174393a9ee15cf6d1e5115" contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">79.9</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div>Risk-free rate</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueEarnoutSharesMeasurementInput" id="Fact_e5c856279ff945bf9a1231d7497bce7b" contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.07</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="roiv:FairValueEarnoutSharesMeasurementInput" id="Fact_4a1f5aced78e4379b0d3ee19ebc53365" contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.76</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c48" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c49">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c49" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c50">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2023 and March 31, 2023, the fair value of the Earn-Out Shares was $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_4849e76e09ae4160859cffcd3dbc48b6" contextRef="c20231231_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_a42461a63c8943828eb9052cd41a6a1b" contextRef="c20230331_StatementEquityComponentsAxis_EarnoutSharesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.2</ix:nonFraction> million, respectively. Earn-Out Shares were included in &#8220;<span style="-sec-ix-hidden:Fact_896fc6f03cbf47ba9500416e14491b89">Liability instruments measured at fair value</span>&#8221; in the accompanying condensed consolidated balance sheets. </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c50" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c51">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c51" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c52">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0px;"><span style="font-size: 10pt;"> </span><br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c52" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c53">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Private Placement Warrants</div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c53" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c54">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>
</ix:continuation>
    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c54" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c55">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Prior to their settlement, the fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured
        to incorporate the redemption features as discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private Placement Warrants&#8221; and the added restriction by which the Company could not redeem the Private Placement Warrants if the Reference Value
        was greater than $18.00. </span><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Text_92e07351b6f04b73aa3f712e05b6e69d" contextRef="c20230401to20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember" escape="true" continuedAt="Text_ff06d1080131418eb4e438392e79df2b1"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Significant unobservable
        inputs used to calculate the fair value of the Private Placement Warrants included the following: </span></span></ix:nonNumeric></div>
</ix:continuation>
    <div>
      <ix:continuation id="Text_ff06d1080131418eb4e438392e79df2b1" continuedAt="Text_ff06d1080131418eb4e438392e79df2b2"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c55" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c56">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
    </div>

    <ix:continuation id="Text_ff06d1080131418eb4e438392e79df2b2"><ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c56" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c57">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
            <div style="font-weight: bold;">Input</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);">
            <div>Volatility</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_59fa66ffd0494e578387725375417f38" contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U005" decimals="3" scale="-2" format="ixt:num-dot-decimal">50.5</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.43%;">
            <div>Risk-free rate</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.19%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.36%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10.54%;" colspan="1">
            <div style="text-align: center;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_aa533eeefd914da998f50d9fd4fd175f" contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U005" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.76</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.19%; white-space: nowrap;" colspan="1">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);">
            <div>Term (in years)</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="text-align: center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_09b357257e7d4d8bbd6884656f082400" contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">3.50</ix:nonNumeric></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c57" continuedAt="Text_40e8d05ca7774f48b757b54738b12e6c58">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>
</ix:continuation>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
        </div>

      </div>

    </div>

    <ix:continuation id="Text_40e8d05ca7774f48b757b54738b12e6c58">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In August 2023, the Company announced that it would redeem all Warrants that remain outstanding on September 1, 2023. All of the Private Placement Warrants were exercised. As of March 31, 2023, the fair value of the Private Placement
        Warrants was $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_586ca63baa4048c4a98640d374fc19d5" contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.2</ix:nonFraction> million, which was included in &#8220;<span style="-sec-ix-hidden:Fact_8076c0698f4040ad9216b28dd1dd2471">Liability instruments measured at fair value</span>&#8221; in the accompanying condensed consolidated balance sheets. </span>  </div>
</ix:continuation>
    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

  </div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" id="Text_d45c814617b643bf963a44208d1bc69e" contextRef="c20230401to20231231" escape="true" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d1">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 14&#8212;Net Income (Loss) per Common Share</div>
</ix:nonNumeric>
      <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d1" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d2">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d2" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d3">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Basic net income (loss) per common share is computed by dividing net income (loss) attributable to Roivant Sciences Ltd. by the
          weighted-average number of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common
          stock outstanding during the period.</span> <span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d3" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d4">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d4" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d5">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"><br/>
        </span> </div>
</ix:continuation>
    </div>


    <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d5" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d6"><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Text_448a3ee29d52400aac4c0a55f155b478" contextRef="c20230401to20231231" escape="true" continuedAt="Text_6d4579f8d20f48d9a8a267174199d2301">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The computations for basic and diluted net income (loss) per common share were as follows (in thousands, except share and per share amounts):</span></div>
</ix:nonNumeric></ix:continuation>
    <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d6" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d7"><ix:continuation id="Text_6d4579f8d20f48d9a8a267174199d2301" continuedAt="Text_6d4579f8d20f48d9a8a267174199d2302">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d7" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d8"><ix:continuation id="Text_6d4579f8d20f48d9a8a267174199d2302">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Three Months Ended December 31,</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Nine Months Ended December 31,</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2023</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2023</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2022</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
            <div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Numerator:</div>
          </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Net income (loss) attributable to Roivant Sciences Ltd.<br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_790ce43355fc49369e7889670dc73025" contextRef="c20231001to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,096,184</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_27ce233d64314e1d9e0ba1ac3b7074b1" contextRef="c20221001to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,014</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ea85a02895d54969943f775618137bfc" contextRef="c20230401to20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,500,041</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cb17ea3f52c947d69b7081aaa87344b1" contextRef="c20220401to20221231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">975,413</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 52%;">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Denominator:</div>
          </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Weighted average shares outstanding, basic</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_135ab34e86634d95b0953c848e6f81f0" contextRef="c20231001to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">800,587,716</ix:nonFraction><br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_aca5323244634d12a277dd9ad311fb01" contextRef="c20221001to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">713,319,399</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_51d72cbcd7194b4089ec3fed5436f98d" contextRef="c20230401to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">776,759,728</ix:nonFraction><br/>
          </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_0cb5d389a2934b8b8357a1d7648f7b2f" contextRef="c20220401to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">703,054,773</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Effect of dilutive common stock equivalents</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_0209ccd9e7794fa1a8686f1a18a6ed56" contextRef="c20231001to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">43,873,969</ix:nonFraction><br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_0a9efb5db85f443a80138830caf015c7" contextRef="c20221001to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_4e394db7e1b649d7bfaee53ee38404e8" contextRef="c20230401to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">47,550,285</ix:nonFraction><br/>
          </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_37ce6492ddde4b44875f5a234af56ca6" contextRef="c20220401to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Weighted average shares outstanding, diluted</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_224f85bb916f4e2a9ce4f39436085168" contextRef="c20231001to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">844,461,685</ix:nonFraction><br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_ffa449edb6904a6ba9be9a0ee3a7906c" contextRef="c20221001to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">713,319,399</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_8790d4b7328e41e29178875738d427fe" contextRef="c20230401to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">824,310,013</ix:nonFraction><br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_7aeee14d5b76432ba1c3dc0a99707ba4" contextRef="c20220401to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">703,054,773</ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 52%; background-color: #CCEEFF;">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net income (loss) per common share, basic</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_f6be068f89dd4fdd92d9337a3871e42f" contextRef="c20231001to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.37</ix:nonFraction><br/>
              </span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_5d389ca30c6f4356a1466137a5be4872" contextRef="c20221001to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">$<br/>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_7694bbfcc888444db3c38d7637e42bd1" contextRef="c20230401to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.79</ix:nonFraction><br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_beb10629910744a3abaa86bd18aedbf0" contextRef="c20220401to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">1.39</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net income (loss) per common share, diluted</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_a515f715ea3844849d590ba11801ce8c" contextRef="c20231001to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.03</ix:nonFraction><br/>
              </span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_9d80d3a706934f958fc0c35f3ae22c6f" contextRef="c20221001to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$<br/>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_1db15951b05c4b1b9fde3d583b8d9a93" contextRef="c20230401to20231231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.46</ix:nonFraction><br/>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_d1efbe20efc74564b4c139e311d0b287" contextRef="c20220401to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">1.39</ix:nonFraction></span></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
    </div>

  <div><ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d8" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d9">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
    </span></div>
</ix:continuation>
    <div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%31%%%-->
      <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d9" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d10">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. For the three and nine months ended
          December 31, 2022, all outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss. </span> </div>
</ix:continuation>
      <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d10" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d11">
<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt;"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d11" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d12">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation></div>
<ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_19b3c06a3d8747de81cf9dd64123d536" contextRef="c20230401to20231231" escape="true" continuedAt="Text_3f1dbe4222434505b8df207dffdea7e11"><ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d12" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d13">
<div><span style="font-size: 10pt;"> </span>
    <span style="font-size: 10pt;"> </span></div>
</ix:continuation></ix:nonNumeric>
    <div>
      <ix:continuation id="Text_3f1dbe4222434505b8df207dffdea7e11" continuedAt="Text_3f1dbe4222434505b8df207dffdea7e12"><ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d13" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d14">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As
        of December 31, 2023 and 2022, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net income (loss) per common share because including them would have been anti-dilutive: </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_3f1dbe4222434505b8df207dffdea7e12" continuedAt="Text_3f1dbe4222434505b8df207dffdea7e13"><ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d14" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d15">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_3f1dbe4222434505b8df207dffdea7e13" continuedAt="Text_3f1dbe4222434505b8df207dffdea7e14"><ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d15" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d16">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">December 31, 2022</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -9pt; margin-left: 9pt;">Stock options and performance stock options</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_c25f3b23b89846619cb18562522270ee" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">65,518,394</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_25aa8798ba534da5b2c66a21db205b5c" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">154,631,025</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Restricted stock units and performance stock units (non-vested)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8cabd30cb28c413ebd00564eccc6fa03" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,422,465</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8d6e227ab54247bcbd4956f26442d2d8" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">22,153,774</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -9pt; margin-left: 9pt;">March 2020 CVARs<sup>(1)</sup></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_549a656b35d94b4d967ad2c826a11b60" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">17,548,368</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4752edd86aed4ee592ba9116cf19a4e5" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">32,011,996</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">November 2021 CVARs (non-vested)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_5d1032caa3cf421db1845e0499d13cb5" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">359,730</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b83a4a95ad354bc9a33e3a49d1b71ee3" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,609,021</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -9pt; margin-left: 9pt;">Restricted common stock (non-vested)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4fbc4213675648c4a420716b208e4f85" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">238,059</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b51f66a20cf245bc836e696d19001c4d" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">730,522</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Earn-Out Shares (non-vested)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_d64632882dac49ce9bb0e40cc87964be" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,080,387</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ec6dc9eaffec45a5ab60183d0748f1f7" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,080,387</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -9pt; margin-left: 9pt;">Private Placement Warrants</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8569cbd6baa242daa128e9ffdc6737e2" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_6baae4fa580e438abecd8737eb7d236c" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,214,365</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Public Warrants</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2c88c79311de46fb8e689a21c56ec94f" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8f7f5b2fbef0422a854c4946c9315d24" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">20,475,875</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="margin-left: 9pt; text-indent: -9pt;">Other stock based awards and instruments issued</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_de762d50491243d4aecfdc02459a480f" contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,147,404</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_32b7f496b4984b7d84d20eb458da5e8a" contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,178,990</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_3f1dbe4222434505b8df207dffdea7e14" continuedAt="Text_3f1dbe4222434505b8df207dffdea7e15"><ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d16" continuedAt="Text_5c78ad52b73545b6960b8a29f9c24f1d17">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_3f1dbe4222434505b8df207dffdea7e15"><ix:continuation id="Text_5c78ad52b73545b6960b8a29f9c24f1d17">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
              <div><sup>(1)</sup></div>
            </td>

    <td style="width: 96%; vertical-align: top;">
              <div style="text-align: justify;"><ix:footnote id="Foot_ce5839120cd543e7984048999d69cde8" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Refer to Note 9, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs.</ix:footnote></div>
            </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">31</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

    </div>

  </div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <a id="ManagementsDiscussionandA"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 46.95pt;">
                <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Item 2.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</div>
              </td>

  </tr>


</table>
      </div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; font-style: italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our (1) unaudited condensed consolidated financial
        statements and notes to those statements included in this Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) and (2) audited consolidated financial statements and notes to those statements and management&#8217;s discussion and analysis of financial
        condition and results of operations for the fiscal year ended March 31, 2023, included in our Annual Report on Form 10-K, filed with the SEC on June 28, 2023 (the &#8220;Form 10-K&#8221;). Certain information contained in the discussion and analysis set forth
        below includes forward-looking statements that involve risks and uncertainties. Roivant&#8217;s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. Please see &#8220;Cautionary Statement
        Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; in this Quarterly Report. Our fiscal year ends on March 31 and our fiscal quarters end on June 30, September 30 and December 31.</div>

      <div>&#160;</div>

      <div style="font-weight: bold;">Overview</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Today, Roivant&#8217;s
        pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (&#8220;FcRn&#8221;) in
        development across several immunoglobulin G (&#8220;IgG&#8221;) mediated autoimmune indications; brepocitinib, a novel TYK2/JAK1 inhibitor in late stage development for dermatomyositis and other autoimmune conditions, in addition to other clinical stage
        molecules. We advance our pipeline by creating nimble subsidiaries or &#8220;Vants&#8221; to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups
        complementary to its biopharmaceutical business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The following table summarizes selected commercial and development-stage pipeline products and product candidates.</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 22.01%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Product/Product <br/>
                Candidate</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 30%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Indication</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 11%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Vant</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 13%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Modality</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 16%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Phase</div>
            </td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>VTAMA (tapinarof)<br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Psoriasis</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Dermavant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Topical</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Commercial</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>VTAMA (tapinarof)<br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Atopic Dermatitis</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Dermavant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Topical</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>Phase 3 Completed*</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Batoclimab<br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Myasthenia Gravis</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Biologic</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 3*</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Batoclimab<br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Thyroid Eye Disease</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Biologic</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 3*</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Batoclimab<br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Chronic Inflammatory Demyelinating Polyneuropathy</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Biologic</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 2*</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Batoclimab&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Graves&#8217; Disease</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Biologic</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 2</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>IMVT-1402&#160; <br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Numerous Indications</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Biologic</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 1</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Brepocitinib<br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Dermatomyositis</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Priovant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Small Molecule</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 3*</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Brepocitinib<br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Other Indications</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Priovant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Small Molecule</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 2</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 22.01%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 13%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 16%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 22.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Namilumab <br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Sarcoidosis</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Kinevant</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 13%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Biologic</div>
            </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 16%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Phase 2*</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic;">Note: All clinical stage drugs in our current pipeline are investigational and subject to health authority approval. Pipeline reflects both ongoing clinical trials and expected upcoming trials.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic;">* Indicates registrational or potentially registrational trials.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">The following table summarizes our ownership of certain of our subsidiary companies and affiliates as of December 31, 2023.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="text-align: justify;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                <div style="text-align: center; font-weight: bold;">Roivant Ownership</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="font-weight: bold;">Vant</div>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="font-weight: bold;">Basic<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="font-weight: bold;">Fully Diluted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Dermavant<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>100</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>85</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                <div>Immunovant<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">55</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">%<sup style="line-height: 1; font-size: smaller;">3</sup></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">49</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">%<sup style="line-height: 1; font-size: smaller;">3</sup></td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Priovant <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>75</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>68</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Genevant<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>83</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>65</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Kinevant<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>96</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>90</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Covant<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>100</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>86</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Psivant<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>100</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>88</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Arbutus<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>23</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%<sup style="line-height: 1; font-size: smaller;">3</sup></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>20</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%<sup style="line-height: 1; font-size: smaller;">3</sup></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Lokavant<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>57</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>50</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>VantAI<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>60</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>49</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Datavant <br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>*</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>*</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      </div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div>
        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 36pt;">
                  <div style="font-style: italic; text-align: left;">1.</div>
                </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                  <div style="font-style: italic; text-align: justify;">Basic ownership refers to Roivant&#8217;s percentage ownership of the issued and outstanding common and preferred shares (if applicable) of the entity.</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-style: italic;">2.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-style: italic;">Fully diluted ownership refers to Roivant&#8217;s percentage ownership of all outstanding equity interests of the entity, including unvested RSUs as well as options and warrants, in each case whether vested or
                unvested.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-style: italic;">3.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-style: italic;">Denotes entities that are publicly traded.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top;">*</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-style: italic;">As of December 31, 2023, the Company&#8217;s minority equity interest in Datavant represented approximately 9% of the outstanding Class A units. Datavant&#8217;s capital structure includes several classes of preferred
                units that, among other features, have liquidation preferences and conversion features. Upon conversion of such preferred units into Class A units, the Company&#8217;s ownership interest would be diluted. For more information on Roivant&#8217;s
                ownership interest in Datavant, please refer to Note 3 to Roivant&#8217;s unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In the upcoming year, we have a robust set of expected near-term catalysts, including the items set forth below. In addition, we plan to in-license multiple potentially category-leading drugs per
        year.</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 17.39%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Program</div>
            </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 10.3%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Vant</div>
            </td>

    <td style="width: 0.76%; vertical-align: bottom;">&#160;</td>

    <td style="width: 59%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Catalyst</div>
            </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 9.88%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Expected </div>
              <div style="font-weight: bold;">Timing</div>
            </td>

    <td style="width: 0.68%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>VTAMA (tapinarof) cream</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Dermavant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Updates on commercial launch of VTAMA in psoriasis</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">Ongoing</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Roivant pipeline growth</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Roivant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>New mid/late-stage in-licensing announcements</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">Ongoing</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>LNP platform<br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Genevant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Updates to LNP patent litigation</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">Ongoing</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Brepocitinib<br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Priovant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Topline data from proof-of-concept trial in noninfectious uveitis</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">1Q 2024</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>VTAMA (tapinarof) cream</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Dermavant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Expected sNDA filing for VTAMA in atopic dermatitis</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">1Q 2024</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Batoclimab<br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Initial data from period 1 of Phase 2B trial in chronic inflammatory demyelinating polyneuropathy</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">2Q/3Q 2024</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Namilumab<br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Kinevant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Topline data from Phase 2 trial in sarcoidosis</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">2H 2024</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Batoclimab<br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Topline data from Phase 3 trial in myasthenia gravis</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">2H 2024</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Batoclimab<br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Immunovant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Topline data from Phase 3 trials in thyroid eye disease</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">1H 2025</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 17.39%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 10.3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 59%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 9.88%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 17.39%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Brepocitinib<br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Priovant</div>
            </td>

    <td style="width: 0.76%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 59%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Topline data from Phase 3 trial in dermatomyositis</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">2025</div>
            </td>

    <td style="width: 0.68%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic;">Note: References are to calendar years. All catalyst timings are based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-weight: bold;">Recent Developments</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;"><span style="font-weight: bold;">Roivant: </span>In December 2023, Roivant announced the completion of the sale of Telavant to Roche for an upfront payment of approximately $7.1 billion with an additional
                $150 million in cash payable upon the completion of a near-term milestone. Under the terms of the agreement, Roche gained the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory
                bowel disease and potentially other diseases. Prior to the closing of the transaction, Roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of Telavant and Pfizer owned the remaining 25%, in each case
                on an as-converted basis.&#160; Roivant&#8217;s net cash proceeds from the transaction are approximately $5.2 billion. Approximately $110 million of the additional milestone payment will be payable to Roivant.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="margin-left: 36pt; color: rgb(0, 0, 0); text-align: justify;">Roivant reported its consolidated cash, cash equivalents and restricted cash of $6.7 billion at December 31, 2023. </div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Immunovant:</span><span style="font-size: 10pt;"> In
                    November 2023, Immunovant reported IMVT-1402, a second-generation antibody targeting the neonatal fragment crystallizable receptor (FcRn), continued to show potentially best-in-class profile in a Phase 1 clinical trial in healthy
                    adults. Initial data from the 600 mg MAD cohort showed that four subcutaneously administered doses of 600 mg IMVT-1402 reduced total immunoglobulin G (IgG) levels by a mean of 74%, very similar to the 76% IgG reduction after four weekly
                    injections of 680 mg batoclimab, but with no or minimal changes in serum albumin and LDL cholesterol, consistent with observations in placebo.</span></div>
                <div style="font-size: 10pt;">&#160;</div>
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In December 2023, Immunovant reported in an open-label Phase 2 proof-of-concept clinical trial of batoclimab in Graves&#8217; disease, response rates
                  from an initial cohort of patients who were hyperthyroid despite treatment with an anti-thyroid medication for more than 12 weeks were meaningfully higher than 50 percent, after receiving once-weekly subcutaneous injections of 680 mg
                  batoclimab for 12 weeks. This trial is ongoing.</div>
              </div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;"><span style="font-weight: bold;">Dermavant</span><span style="font-weight: bold; color: rgb(0, 0, 0);">:</span><span style="color: rgb(0, 0, 0);"> For the third quarter ended December 31, 2023, Roivant
                  reported VTAMA net product revenue of $20.7M, representing a 28.5% gross-to-net yield for the quarter. As of February 2024, over 300,000 VTAMA prescriptions have been written by approximately 14,000 unique prescribers for psoriasis, based
                  on IQVIA data. </span>VTAMA is covered for<span style="color: rgb(0, 0, 0);"> 137 million US commercial lives, including coverage by all three of the top pharmacy benefit managers.</span></div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="margin-left: 36pt; color: rgb(0, 0, 0); text-align: justify;">In January 2024, Dermavant announced new positive efficacy and safety data from analyses of ADORING 3, an ongoing open-label, long-term extension Phase 3 trial being conducted
        to evaluate the safety and efficacy of VTAMA cream, 1% in patients with AD for up to 48 weeks of total treatment. The integrated analysis across the ADORING development program showed that efficacy continued to improve beyond the 8-week double
        blind treatment period in ADORING 1 and ADORING 2 across multiple endpoints including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">o</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">vIGA-AD score of 0 (clear) or 1 (almost clear) with at least a 2-grade improvement from baseline was observed in 73% (519/711) of patients included </div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">o</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">80.7% (574/711) of patients achieved at least a 75% improvement in the Eczema Area and Severity Index (EASI75)</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">o</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">77.9% (218/280) of patients &#8805;12 years old with a baseline Peak Pruritus Numeric Rating Scale (PP-NRS) score &#8805;4 achieved a &#8805;4-point reduction in PP-NRS</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">o</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">92.3% (656/711) of patients achieved at least a 1-grade improvement in vIGA-AD score</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="margin-left: 36pt; color: #000000;">The interim analysis of the ADORING 3 open-label, long-term extension Phase 3 trial demonstrated that 51.2% (373/728) of patients achieved complete disease clearance (vIGA-AD score of 0). No new safety
        signals were observed with up to 56 weeks of treatment. Data from these analyses will be included in sNDA submission expected this quarter.</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;"><span style="font-weight: bold; color: rgb(0, 0, 0);">Hemavant:</span><span style="color: rgb(0, 0, 0);"> We have discontinued the development of RVT-2001 after</span> an<span style="color: rgb(0, 0, 0);">
                  interim data analysis from the Phase 1/2 study.</span></div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="font-weight: bold;">Components of Results of Operations</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Product revenue, net</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">With the FDA approval of VTAMA for the treatment of plaque psoriasis in adult patients and our initial product launch in May 2022, we began to recognize product revenues. We record product revenue
        net of estimated chargebacks, discounts, rebates, returns, and other allowances associated with the respective sales.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">License, milestone and other revenue</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">License, milestone and other revenue includes the recognition of upfront payments received in connection with license agreements as well as<span style="color: #000000;"> revenue generated by
          subscription and service-based fees.</span></div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Cost of revenues</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We began to recognize cost of product revenues after the initial launch of VTAMA in May 2022. Cost of product revenues includes the cost of producing and distributing inventories related to product
        revenue during the respective period, including manufacturing, freight, and indirect overhead costs. Additionally, milestone payments made in connection with regulatory approvals and sales-based milestones are capitalized and amortized to cost of
        revenue over the remaining useful life of the asset. Our cost of revenues also relates to subscription and service-based revenue recognized for the use of technology developed and consists primarily of employee, hosting, and third-party data costs.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">34</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Research and development expenses</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Research and development expenses consist mainly of costs incurred in connection with the discovery and development of our product candidates. Research and development expenses primarily include
        the following:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">Program-specific costs, including direct third-party costs, which include expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;),
                manufacturing costs in connection with producing materials for use in conducting nonclinical and clinical studies, the cost of consultants who assist with the development of our product candidates on a program-specific basis, investigator
                grants, sponsored research, and any other third-party expenses directly attributable to the development of our product candidates.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">Unallocated internal costs, including:</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">o</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">employee-related expenses, such as salaries, share-based compensation, and benefits, for research and development personnel; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">o</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">other expenses that are not allocated to a specific program.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Research and development activities will continue to be central to our business model. We anticipate that our research and development expenses will increase for the foreseeable future as we
        advance our product candidates and our recently in-licensed assets through preclinical studies and clinical trials, as well as acquire or discover new product candidates. We expect higher employee-related expenses, including share-based
        compensation expenses, as well as higher consulting costs as we hire additional resources to support increasing development activity.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The duration, costs and timing of preclinical studies and clinical trials of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">the scope, rate of progress, expense and results of our preclinical development activities, any future clinical trials of our product candidates, and other research and development activities that we may
                conduct;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">the number and scope of preclinical and clinical programs we decide to pursue;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">the uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">the number of doses that patients receive;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">the countries in which the trials are conducted;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">our ability to secure and leverage adequate CRO support for the conduct of clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">our ability to establish an appropriate safety and efficacy profile for our product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the timing, receipt and terms of any approvals from applicable regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">the potential additional safety monitoring or other studies requested by regulatory agencies;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the significant and changing government regulation and regulatory guidance;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">our ability to establish clinical and commercial manufacturing capabilities, or make arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make
                product successfully;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">the impact of any business interruptions to our operations due to the COVID-19 pandemic or other epidemics; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">our ability to maintain a continued acceptable safety profile of our product candidates following approval of our product candidates.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The successful development of our product candidates is highly uncertain, and we cannot reasonably estimate the costs that will be necessary to complete the remainder of the development of our
        product candidates. In addition, the probability of success for our product candidates will depend on numerous factors, including competition, manufacturing capability and commercial viability.</div>

      <div><br/></div>

      <div style="font-style: italic; font-weight: bold;">Acquired in-process research and development expenses</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses include consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements as well as payments made in
        connection with asset acquisitions and license agreements upon the achievement of development milestones.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements includes cash upfront payments, shares and other liability instruments issued, and fair value of future
        contingent consideration payments.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">35</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Selling, general and administrative expenses</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of employee-related expenses, such as salaries, share-based compensation, sales incentive compensation and benefits, for
        employees engaged in SG&amp;A activities. SG&amp;A employees include those responsible for the identification and acquisition or in-license of new drug candidates as well as for managing Vant operations and facilitating the use of our platform and
        technologies at the Vants. SG&amp;A expenses also consist of marketing programs, advertising, legal and accounting fees, consulting services, and other operating costs relating to corporate matters and daily operations. Additionally, SG&amp;A
        expenses include costs incurred relating to the identification, acquisition or in-license and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We expect SG&amp;A expenses to increase in future periods as we continue to expand our sales and marketing infrastructure and general administrative functions. These increases will likely include
        salaries, sales incentive compensation, share-based compensation and travel expenses associated with our sales force, which began promoting VTAMA in the United States following approval by the FDA in May 2022, as well as expected costs associated
        with the further build out of our commercial operations functions. We anticipate these expenses to further increase if any of our other current or future product candidates receives regulatory approval in the United States or another jurisdiction.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Gain on sale of Telavant net assets</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Gain on sale of Telavant net assets represents the gain resulting from the sale of our entire equity interest in our majority-owned subsidiary, Telavant Holdings, Inc. (&#8220;Telavant&#8221;), to Roche
        Holdings, Inc. (&#8220;Roche&#8221;) in December 2023 (the &#8220;Roche Transaction&#8221;). Prior to the Roche Transaction, we held 75% of the issued and outstanding shares of common stock and preferred stock of Telavant, and Pfizer Inc. (together with Roivant, the
        &#8220;Sellers&#8221;) owned the remaining 25%, in each case on an as-converted basis. At closing, we received approximately $5.2 billion in cash. We additionally are eligible to receive approximately $110 million for our portion of a one-time milestone
        payment if the milestone payment condition is satisfied. Refer to Note 5, &#8220;Recent Transactions&#8221; of our financial statements for further information regarding the Roche Transaction.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Change in fair value of investments</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Change in fair value of investments primarily includes the unrealized loss (gain) on equity investments in publicly-traded companies, including Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;), as well as
        our equity investment in Heracles Parent, L.L.C., the parent entity of the Datavant business (&#8220;Datavant&#8221;). We have elected the fair value option to account for these investments.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Change in fair value of debt and liability instruments</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Change in fair value of debt and liability instruments primarily includes the loss relating to the measurement and recognition of fair value on a recurring basis of certain liabilities, including
        debt issued by a wholly-owned subsidiary of Dermavant Sciences Ltd. to NovaQuest Co-Investment Fund VIII, L.P. (the &#8220;NovaQuest Facility&#8221;), and other liability instruments, including warrant and earn-out share liabilities issued in connection with
        our business combination (the &#8220;Business Combination&#8221;) with Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;), a special purpose acquisition company.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Gain on deconsolidation of subsidiaries</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Gain on deconsolidation of subsidiaries resulted from the determination that we no longer had a controlling financial interest in certain subsidiaries.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Interest income</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Interest income consists of interest earned on our cash equivalents.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Interest expense</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Interest expense results from interest accrued on long-term debt and the amortization of debt discount and issuance costs.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">36</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Income tax expense</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Income tax expense is recorded for the jurisdictions in which we do business. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
        the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those
        temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded
        when, after consideration of all positive and negative evidence, it is not more likely than not that our deferred tax assets will be realizable. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that
        the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and
        circumstances.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Net loss attributable to noncontrolling interests</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Net loss attributable to noncontrolling interests consists of the portion of net loss of those consolidated entities that is not allocated to us. Changes in the amount of net loss attributable to
        noncontrolling interests are directly impacted by the net loss of our consolidated entities and changes in ownership percentages.</div>

      <div>&#160;</div>

      <div style="font-weight: bold;">Results of Operations</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Comparison of the three and nine months ended <span style="color: #000000;">December 31, 2023</span> and <span style="color: #000000;">2022</span></div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The following table sets forth our results of operations for the three months ended <span style="color: #000000;">December 31, 2023</span> and <span style="color: #000000;">2022</span>:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Revenues:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Product revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">20,666</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">9,244</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">11,422</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">License, milestone and other revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">16,474</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">7,808</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">8,666</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt; color: rgb(0, 0, 0);">Revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: #000000;">37,140</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: #000000;">17,052</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: #000000;">20,088</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Operating expenses:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Cost of revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">3,668</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">3,586</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">82</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">123,717</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">125,533</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(1,816</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Acquired in-process research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">&#8212;</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">97,749</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">(97,749</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Selling, general and administrative</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">197,282</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">168,261</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">29,021</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt; color: rgb(0, 0, 0);">Total operating expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">324,667</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">395,129</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: #000000;">(70,462</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gain on sale of Telavant net assets</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">5,348,410</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">&#8212;</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">5,348,410</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income (loss) from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: #000000;">5,060,883</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: #000000;">(378,077</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: #000000;">5,438,960</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Change in fair value of investments</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">10,467</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(25,948</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">36,415</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Change in fair value of debt and liability instruments</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">9,331</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">62,360</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(53,029</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gain on deconsolidation of subsidiaries</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">&#8212;</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(12,514</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">12,514</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest income</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(31,953</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(10,249</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(21,704</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">9,444</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">8,446</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">998</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other income, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(34,743</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(18,095</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(16,648</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss) before income taxes</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">5,098,337</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(382,077</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">5,480,414</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income tax expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">25,672</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">2,819</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">22,853</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">5,072,665</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(384,896</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">5,457,561</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss attributable to noncontrolling interests</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(23,519</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(32,882</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">9,363</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss) attributable to Roivant Sciences Ltd.</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">5,096,184</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">(352,014</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">5,448,198</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">37</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">The following table sets forth our results of operations for the nine months ended <span style="color: rgb(0, 0, 0);">December 31, 2023</span> and <span style="color: rgb(0, 0, 0);">2022</span>:<br/>
        <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Revenues:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Product revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">55,749</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">14,354</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">41,395</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">License, milestone and other revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">40,116</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">19,550</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">20,566</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt; color: rgb(0, 0, 0);">Revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">95,865</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">33,904</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">61,961</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Operating expenses:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Cost of revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">11,148</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">8,953</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">2,195</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">380,834</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">393,358</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(12,524</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Acquired in-process research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">26,450</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">97,749</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(71,299</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Selling, general and administrative</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">517,827</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">474,996</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">42,831</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 25.2pt; color: rgb(0, 0, 0);">Total operating expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">936,259</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">975,056</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(38,797</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gain on sale of Telavant net assets</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">5,348,410</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">&#8212;</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">5,348,410</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income (loss) from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">4,508,016</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(941,152</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">5,449,168</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Change in fair value of investments</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">63,880</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">53,277</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">10,603</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Change in fair value of debt and liability instruments</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">85,376</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">90,032</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(4,656</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gain on deconsolidation of subsidiaries</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(17,354</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(29,276</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">11,922</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest income</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(62,967</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(17,900</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(45,067</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">27,603</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">19,393</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">8,210</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other income, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(33,405</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(11,060</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(22,345</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss) before income taxes</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">4,444,883</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(1,045,618</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">5,490,501</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income tax expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">31,181</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">8,983</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">22,198</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">4,413,702</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(1,054,601</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">5,468,303</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss attributable to noncontrolling interests</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(86,339</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(79,188</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(7,151</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss) attributable to Roivant Sciences Ltd.</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">4,500,041</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">(975,413</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">5,475,454</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Variance analysis for three and nine months ended December 31, 2023 and 2022</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Revenue, net</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For the three months ended <span style="color: #000000;">December 31, 2023</span> and <span style="color: #000000;">2022</span>, our revenue consisted of the following:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Product revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">20,666</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">9,244</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">11,422</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">License, milestone and other revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">16,474</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">7,808</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">8,666</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">37,140</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">17,052</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">20,088</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Product revenue, net increased by $11.4 million to $20.7 million for the three months ended December 31, 2023, compared to $9.2 million for the three months ended December 31, 2022, primarily due
        to higher units sold. Product revenue, net consists of net product revenues from VTAMA sales, following the approval of VTAMA for the treatment of plaque psoriasis in adult patients by the FDA in May 2022. License, milestone and other revenue
        increased by $8.7 million to $16.5 million for the three months ended December 31, 2023, compared to $7.8 million for the three months ended December 31, 2022. The increase was largely related to an increase in revenues generated from licensing
        arrangements, primarily at Genevant Sciences Ltd., during the three months ended December 31, 2023.<br/>
        <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">38</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">For the nine months ended December 31, 2023 and 2022, our revenue consisted of the following:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Product revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">55,749</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">14,354</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">41,395</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">License, milestone and other revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">40,116</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">19,550</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">20,566</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Revenue, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">95,865</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">33,904</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">61,961</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Product revenue, net increased by $41.4 million to $55.7 million for the nine months ended December 31, 2023, compared to $14.4 million for the nine months ended December 31, 2022, primarily due to
        higher units sold. Product revenue, net consists of net product revenues from VTAMA sales, following the approval of VTAMA for the treatment of plaque psoriasis in adult patients by the FDA in May 2022. License, milestone and other revenue
        increased by $20.6 million to $40.1 million for the nine months ended December 31, 2023, compared to $19.6 million for the nine months ended December 31, 2022. The increase was primarily driven by $15.0 million of revenue relating to milestone
        income at Dermavant pursuant to a collaboration and license agreement with Japan Tobacco Inc. during the nine months ended December 31, 2023.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Cost of revenues</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For the three months ended <span style="color: #000000;">December 31, 2023</span> and <span style="color: #000000;">2022</span><span style="font-weight: bold;">,</span> our cost of revenues
        consisted of the following:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cost of product and other revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">1,226</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">1,358</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(132</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Amortization of intangible assets</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">2,442</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">2,228</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">214</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Cost of revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">3,668</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">3,586</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">82</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Cost of revenues increased by $0.1 million to $3.7 million for the three months ended December 31, 2023, compared to $3.6 million for the three months ended December 31, 2022. During the three
        months ended December 31, 2023 and 2022, cost of revenues included $0.8 million and $0.4 million, respectively, of costs relating to VTAMA sales as well as amortization expense recognized in connection with milestones capitalized following the FDA
        approval of VTAMA in May 2022.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For the nine months ended December 31, 2023 and 2022, our cost of revenues consisted of the following:<br/>
        <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cost of product and other revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">3,937</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">3,783</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">154</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Amortization of intangible assets</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">7,211</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">5,170</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: #000000;">2,041</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Cost of revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">11,148</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">8,953</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div><span style="color: #000000;">2,195</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Cost of revenues increased by $2.2 million to $11.1 million for the nine months ended December 31, 2023 compared to $9.0 million for the nine months ended December 31, 2022. During the nine months
        ended December 31, 2023 and 2022, cost of revenues included $2.1 million and $1.0 million, respectively, of costs relating to VTAMA sales as well as amortization expense recognized in connection with milestones capitalized following the FDA
        approval of VTAMA in May 2022.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">39</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Research and development expenses</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For the three months ended <span style="color: #000000;">December 31, 2023</span> and <span style="color: #000000;">2022</span><span style="font-weight: bold;">,</span> our research and
        development expenses consisted of the following:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-style: italic;">Program-specific costs:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Batoclimab<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">19,688</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">22,748</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">(3,060</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Brepocitinib</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">10,409</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">11,113</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(704</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Tapinarof</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">8,781</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">9,787</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(1,006</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">IMVT-1402<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">5,768</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">2,317</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">3,451</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">RVT-3101</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">5,651</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">1,659</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">3,992</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Namilumab</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">3,280</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">3,315</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(35</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">RVT-2001</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">1,897</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">4,964</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(3,067</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other development and discovery programs</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">12,287</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">21,810</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">(9,523</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Total program-specific costs</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">67,761</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">77,713</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(9,952</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-style: italic;">Unallocated internal costs:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Share-based compensation</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">7,475</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">6,888</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">587</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Personnel-related expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">37,636</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">31,171</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">6,465</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">10,845</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">9,761</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">1,084</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-weight: bold;">Total research and development expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">123,717</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">125,533</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">(1,816</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1) </sup>Certain prior period amounts have been reclassified to conform to current period presentation.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Research and development expenses decreased by $1.8 million to $123.7 million for the three months ended December 31, 2023, compared to $125.5 million for the three months ended December 31, 2022.
        Changes in the components of research and development expenses included a decrease in program-specific costs of $10.0 million offset by increases in personnel-related expenses of $6.5 million and other expenses of $1.1 million.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Within program-specific costs, the decrease of $10.0 million was primarily driven by a decrease of $9.5 million related to other development and discovery programs due to the deconsolidation of
        Proteovant Sciences, Inc. (&#8220;Proteovant&#8221;) in August 2023, along with the reprioritization of certain programs and drug discovery efforts, and decreases of $3.1 million each related to RVT-2001 and batoclimab. These decreases were partially offset by
        an increase in expense of $4.0 million related to RVT-3101, which was acquired in November 2022, and an increase of $3.5 million related to IMVT-1402. The rights to further develop and manufacture RVT-3101 were sold to Roche in December 2023.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The increase of $6.5 million in personnel-related expenses was primarily driven by a special one-time cash retention bonus award granted to employees during the three months ended December 31,
        2023.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">40</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">For the nine months ended December 31, 2023 and 2022, our research and development expenses consisted of the following:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-style: italic;">Program-specific costs:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Batoclimab<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">50,814</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">48,164</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div><span style="color: #000000;">2,650</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">RVT-3101</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">35,129</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">1,659</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">33,470</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">IMVT-1402<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">29,599</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">7,037</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">22,562</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Tapinarof</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">27,675</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">32,770</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">(5,095</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Brepocitinib</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">26,927</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">32,007</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(5,080</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Namilumab</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">9,913</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">9,424</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">489</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">RVT-2001</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">9,458</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">11,733</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(2,275</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other development and discovery programs</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">33,480</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">96,779</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">(63,299</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Total program-specific costs</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">222,995</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">239,573</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(16,578</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-style: italic;">Unallocated internal costs:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Share-based compensation</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">24,305</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">26,548</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">(2,243</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Personnel-related expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">101,079</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">100,886</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: #000000;">193</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">32,455</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">26,351</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">6,104</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-weight: bold;">Total research and development expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">380,834</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">393,358</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div><span style="color: #000000;">(12,524</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>


</table>
      <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1) </sup>Certain prior period amounts have been reclassified to conform to current period presentation.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Research and development expenses decreased by $12.5 million to $380.8 million for the nine months ended December 31, 2023, compared to $393.4 million for the nine months ended December 31, 2022,
        primarily due to decreases in program-specific costs of $16.6 million and share-based compensation of $2.2 million, partially offset by an increase in other expenses of $6.1 million.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The decrease of $16.6 million in program-specific costs was primarily driven by a decrease of $63.3 million in other development and discovery program expense, which in part resulted from the
        deconsolidation of Proteovant in August 2023 along with the reprioritization of certain programs and drug discovery efforts. This decrease was partially offset by increases of $33.5 million relating to RVT-3101, which was acquired in November 2022,
        and $22.6 million relating to IMVT-1402. The rights to further develop and manufacture RVT-3101 were sold to Roche in December 2023.</div>

      <div>&#160;</div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Acquired in-process research and development expenses</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Acquired in-process research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">&#8212;</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">97,749</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(97,749</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">26,450</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">97,749</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(71,299</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Acquired in-process research and development expenses were $97.7 million for the three months ended December 31, 2022, primarily due to consideration for the purchase of IPR&amp;D of $87.7 million
        relating to the acquisition of RVT-3101 in November 2022 and the achievement of a development milestone relating to batoclimab, which resulted in a one-time milestone expense of $10.0 million.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Acquired in-process research and development expenses decreased by $71.3 million to $26.5 million for the nine months ended December 31, 2023, compared to $97.7 million for the nine months ended
        December 31, 2022. The decrease was primarily due to higher consideration for the purchase of IPR&amp;D during the nine months ended December 31, 2022 as a result of consideration for the purchase of IPR&amp;D of $87.7 million relating to the
        acquisition of RVT-3101 in November 2022 and the achievement of a development milestone relating to batoclimab, which resulted in a one-time milestone expense of $10.0 million. Acquired in-process research and development expenses for the nine
        months ended December 31, 2023 was driven by $14.0 million of consideration for the purchase of IPR&amp;D relating to an asset acquisition completed by a newly-formed subsidiary and $12.5 million relating to the achievement of development and
        regulatory milestones for batoclimab.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">41</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Selling, general and administrative expenses</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Selling, general and administrative</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">197,282</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">168,261</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">29,021</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">517,827</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">474,996</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">42,831</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Selling, general and administrative expenses increased by $29.0 million to $197.3 million for the three months ended December 31, 2023, compared to $168.3 million for the three months ended
        December 31, 2022, primarily due to an increase in personnel-related expenses of $27.0 million as a result of a special one-time cash retention bonus award granted to employees.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Selling, general and administrative expenses increased by $42.8 million to $517.8 million for the nine months ended December 31, 2023, compared to $475.0 million for the nine months ended December
        31, 2022, primarily due to an increase in selling, general and administrative expenses of $47.2 million at Dermavant as a result of the progression of the commercial launch of VTAMA and an increase in personnel-related expenses of $22.1 million
        primarily as a result of a special one-time cash retention bonus award granted to employees. These increases were partially offset by a decrease of $37.3 million in share-based compensation expense.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Gain on sale of Telavant net assets</div>

      <div style="font-style: italic; font-weight: bold;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gain on sale of Telavant net assets</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">5,348,410</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">&#8212;</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">5,348,410</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">5,348,410</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">&#8212;</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">5,348,410</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Gain on sale of Telavant net assets was approximately $5.3 billion for the three and nine months ended December 31, 2023 and resulted from the sale of our entire equity interest in Telavant to
        Roche in December 2023. At closing, we received approximately $5.2 billion in cash for our pro rata portion of the consideration. Additionally, we derecognized the carrying amount of noncontrolling interest in Telavant of $87.5 million and
        transferred net liabilities of $26.5 million. This resulted in a gain of approximately $5.3 billion. Refer to Note 5, &#8220;Recent Transactions&#8221; of our financial statements for further information regarding the Roche Transaction.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Change in fair value of investments</div>

      <div style="font-style: italic; font-weight: bold;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -16.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Change in fair value of investments</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">10,467</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(25,948</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">36,415</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">63,880</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">53,277</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">10,603</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Change in fair value of investments were an unrealized loss of $10.5 million and a gain of $25.9 million for the three months ended December 31, 2023 and 2022, respectively. The change of $36.4
        million was primarily driven by changes in the public share prices of our equity investments, including Arbutus, as well as the change in fair value of our investment in Datavant.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Change in fair value of investments were unrealized losses of $63.9 million and $53.3 million for the nine months ended December 31, 2023 and 2022, respectively. The change of $10.6 million was
        primarily driven by changes in the public share prices of our equity investments, including Arbutus, as well as the change in fair value of our investment in Datavant.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Change in fair value of debt and liability instruments</div>

      <div style="color: #000000; font-style: italic; font-weight: bold;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Change in fair value of debt and liability instruments</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">9,331</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">62,360</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(53,029</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">85,376</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">90,032</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(4,656</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Change in fair value of debt and liability instruments were losses of $9.3 million and $62.4 million for the three months ended December 31, 2023 and 2022, respectively. Change in fair value of
        debt and liability instruments for the three months ended December 31, 2023 primarily consisted of a loss of $11.8 million relating to the NovaQuest Facility, which was largely due to the passage of time, partially offset by a gain of $2.8 million
        relating to the earn-out share liabilities issued as part of the Business Combination. Change in fair value of debt and liability instruments for the three months ended December 31, 2022 primarily consisted of a loss of $60.2 million relating to
        the warrant and earn-out share liabilities issued as part of the Business Combination.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">42</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Change in fair value of debt and liability instruments were losses of $85.4 million and $90.0 million for the nine months ended December 31, 2023 and 2022, respectively. Change in fair value of
        debt and liability instruments for the nine months ended December 31, 2023 primarily consisted of a loss of $48.9 million relating to the warrant and earn-out share liabilities issued as part of the Business Combination and a loss of $35.9 million
        relating to the NovaQuest Facility, which was largely due to the passage of time. The change in fair value of debt and liability instruments for the nine months ended December 31, 2022 primarily consisted of a loss of $55.2 million relating to the
        NovaQuest facility, which was primarily due to the impact of VTAMA approval in psoriasis, and a loss of $40.7 million relating to the warrant and earn-out share liabilities issued as part of the Business Combination.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Gain on deconsolidation of subsidiaries</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gain on deconsolidation of subsidiaries</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">&#8212;</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(12,514</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">12,514</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(17,354</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(29,276</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">11,922</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Gain on deconsolidation of subsidiaries was $17.4 million for the nine months ended December 31, 2023 and resulted from the deconsolidation of VantAI Holdings, Inc. (&#8220;VantAI&#8221;) in July 2023 and
        Proteovant in August 2023.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Gain on deconsolidation of subsidiaries was $12.5 million and $29.3 million for the three and nine months ended December 31, 2022, respectively, and resulted from the deconsolidation of certain
        subsidiaries in November 2022 and July 2022.</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Interest income</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest income</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(31,953</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(10,249</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(21,704</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(62,967</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(17,900</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(45,067</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Interest income increased by $21.7 million to $32.0 million for the three months ended December 31, 2023, compared to $10.2 million for the three months ended December 31, 2022. The increase is
        primarily due to higher cash balances in our interest-bearing cash accounts as well as higher interest rates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Interest income increased by $45.1 million to $63.0 million for the nine months ended December 31, 2023, compared to $17.9 million for the nine months ended December 31, 2022. The increase is
        primarily due to higher cash balances in our interest-bearing cash accounts as well as higher interest rates.</div>

      <div>&#160;</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Interest expense</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">9,444</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">8,446</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">998</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">27,603</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">19,393</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">8,210</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Interest expense increased by $1.0 million to $9.4 million for the three months ended December 31, 2023, compared to $8.4 million for the three months ended December 31, 2022.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Interest expense increased by $8.2 million to $27.6 million for the nine months ended December 31, 2023, compared to $19.4 million for the nine months ended December 31, 2022. The increase
        primarily resulted from Dermavant&#8217;s revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;), pursuant to which funding of $160.0 million was received in June 2022 following the approval of VTAMA by the FDA in May 2022.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">43</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="font-weight: bold;">Liquidity and Capital Resources</div>

      <div style="text-align: justify; text-indent: 36pt;">
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">For the nine months ended December 31, 2023 and 2022, we incurred net income of approximately $4.4 billion and a net loss of approximately $1.1
          billion, respectively. As of December&#160;31, 2023, we had cash and cash equivalents of approximately $6.7 billion and our retained earnings was $727.3 million. Through our subsidiary Dermavant, we launched our first commercial product, VTAMA,
          following approval by the FDA in May 2022. We began generating product revenue, net from sales of VTAMA in the United States in May 2022. We also have generated revenue through license agreements as well as from subscription and service-based
          fees. Our operations to date have been financed primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements.</div>

      </div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In September 2023, we entered into common share purchase and sale agreements with certain institutional investors, pursuant to which we sold an aggregate of 19,600,685 of our common shares at a
        purchase price of $10.21 per share. Net proceeds to us were approximately $199.8 million after deducting offering expenses.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In October 2023, Immunovant completed an underwritten public offering of 8,475,500 shares of its common stock (including 1,526,316 shares of common stock purchased by us on the same terms as other
        investors in the offering and the full exercise of the underwriters&#8217; option to purchase 1,105,500 additional shares of common stock) at a price to the public of $38.00 per share. Concurrent with the public offering, we purchased 4,473,684 shares of
        Immunovant&#8217;s common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at the same price per share as investors in the public offering of $38.00 per share. The net proceeds to
        Immunovant were approximately $466.7 million after deducting underwriting discounts and commissions, placement agent fees and offering expenses.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">On December 14, 2023, we completed the sale of our entire equity interest in our majority-owned subsidiary, Telavant, to Roche. The Roche Transaction was made pursuant to a Stock Purchase Agreement
        dated October 22, 2023 among us, Telavant, Pfizer Inc. (&#8220;Pfizer&#8221;), and Roche. Telavant was jointly formed by us and Pfizer in November 2022 to develop and commercialize RVT-3101, an anti-TL1A antibody in development for ulcerative colitis (&#8220;UC&#8221;)
        and Crohn&#8217;s disease, in the United States and Japan. Prior to the Roche Transaction, we held 75% of the issued and outstanding shares of common stock and preferred stock of Telavant, and Pfizer owned the remaining 25%, in each case on an
        as-converted basis.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Pursuant to the Stock Purchase Agreement, Roche acquired all of the issued and outstanding shares of capital stock of Telavant in exchange for approximately $7.1 billion in cash at the closing of
        the Roche Transaction and a one-time milestone payment of $150 million in cash payable upon the initiation of a Phase 3 trial in UC. The $7.1 billion in closing consideration was paid to all of Telavant&#8217;s equity holders, including holders of
        restricted stock units, on a pro rata basis relative to their ownership of Telavant prior to the closing of the Roche Transaction, and this same treatment will be applied to the one-time milestone payment. We received an upfront payment of
        approximately $5.2 billion in cash as our pro rata portion of the consideration upon closing of the Roche Transaction. Additionally, we are eligible to receive approximately $110 million for our pro rata portion of the one-time milestone payment if
        the milestone payment condition is satisfied.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our short-term and long-term liquidity requirements as of December 31, 2023 included:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">contractual payments related to our long-term debt (see Note 7, &#8220;Long-Term Debt&#8221; of our condensed consolidated financial statements);</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">obligations under our leases;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">certain commitments to Palantir Technologies Inc. (&#8220;Palantir&#8221;) totaling $19.1 million related to a master subscription agreement entered in May 2021 for access to Palantir&#8217;s proprietary software for a
                five-year period;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">certain commitments to Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) pursuant to a Product Service Agreement entered between Immunovant and Samsung by which Samsung will manufacture and supply Immunovant with
                batoclimab drug substance for commercial sale and perform other manufacturing-related services with respect to batoclimab. The minimum purchase commitment related to this agreement was estimated to be approximately $18.3 million as of
                December 31, 2023. Immunovant had the right to terminate the PSA with 30 days&#8217; written notice to Samsung, exercisable no later than January 2024, in the event Immunovant decided to stop all development of, and all attempts to obtain
                regulatory approval for, batoclimab; subject to payment to Samsung of non-cancellable service fees and costs incurred by Samsung for all batches of batoclimab scheduled to be manufactured during the two-year period following such
                termination. Because efforts to develop and obtain regulatory approval for batoclimab remain ongoing, Immunovant did not exercise that early termination right and it has lapsed. As a result, Immunovant has an additional minimum obligation
                to Samsung of approximately $28.0 million to purchase additional batches of batoclimab in the four-year period of 2026 through 2029.; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">44</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">certain commitments to GSK pursuant to a commercial supply agreement entered between Dermavant and GSK. In conjunction with Dermavant&#8217;s entry into the GSK Agreement in 2018, Dermavant entered into a clinical
                supply agreement pursuant to which GSK would provide a supply of tapinarof and clinical product at an agreed upon price during our clinical trials. In April 2019, Dermavant entered into a commercial supply agreement with GSK to continue to
                provide certain quantities of tapinarof and commercial product at agreed upon minimum quantities and price. The commercial supply agreement commenced in April 2022 upon completion of certain quality and regulatory conditions. In July 2022,
                Dermavant and GSK amended the terms of the clinical supply and commercial supply agreements which released GSK of certain commitments to supply tapinarof and released Dermavant of certain commitments to purchase tapinarof in exchange for a
                supplementary fee. Other supply and purchase commitments under the agreements remain in effect. In addition, Dermavant and Thermo Fisher Scientific (&#8220;TFS&#8221;) entered into a Commercial Manufacturing and Supply Agreement for which TFS agreed to
                provide a supply of tapinarof to Dermavant at an agreed upon price. The agreements discussed above require Dermavant to purchase certain quantities of inventory over a period of five years. The minimum purchase commitment related to these
                agreements was estimated to be approximately $43.1 million.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The above purchase commitments do not represent all of our anticipated purchases, but instead represents only the contractually obligated minimum purchases or firm commitments of non-cancelable
        minimum amounts. There have been no material changes to the commitments relating to our leases during the three months ended December 31, 2023 outside the ordinary course of business. For further information regarding our lease commitments, refer
        to Note 15, &#8220;Leases&#8221; in our Form 10-K.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Additionally, we have certain payment obligations under various asset acquisition and license agreements. Under these agreements we are required to make milestone payments upon successful
        completion and achievement of certain development, regulatory and commercial milestones. The payment obligations under the asset acquisition and license agreements are contingent upon future events such as our achievement of specified development,
        regulatory and commercial milestones, and we will be required to make milestone payments and royalty payments in connection with the sale of products developed under these agreements.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Funding Requirements</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we advance the discovery efforts, preclinical activities, clinical trials and potential
        commercialization of our product candidates. Additionally, we expect to incur significant commercialization expenses with respect to VTAMA. Our operating results, including our net losses, may fluctuate significantly from quarter-to-quarter and
        year-to-year, depending on the timing of our planned clinical trials, our expenditures on other research and development activities and our commercialization efforts. We anticipate that our expenses will increase substantially as we:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">fund preclinical studies and clinical trials for our product candidates, which we are pursuing or may choose to pursue in the future;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">fund the manufacturing of drug substance and drug product of our product candidates in development;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">seek to identify, acquire, develop and commercialize additional product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">invest in activities related to the discovery of novel drugs and advancement of our internal programs;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">integrate acquired technologies into a comprehensive regulatory and product development strategy;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">maintain, expand and protect our intellectual property portfolio;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">hire scientific, clinical, quality control and administrative personnel;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">add operational, financial and management information systems and personnel, including personnel to support our drug development efforts;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">achieve milestones under our agreements with third parties that will require us to make substantial payments to those parties;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">build out our sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize VTAMA and any drug candidates for which we may obtain regulatory approval; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">operate as a public company.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In the future, we may require significant additional capital to continue our operations, pursue business opportunities or strategic transactions, or respond to challenges, competition or unforeseen
        circumstances. Until such time, if ever, that we can generate substantial revenues, we may finance future cash needs through a combination of equity offerings, debt financings, strategic alliances and license and development agreements or other
        collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that
        adversely affect your rights as a common shareholder. Any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional
        debt, making capital expenditures or declaring dividends. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial
        markets in the United States and worldwide. If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our product
        and product candidates, future revenue streams, research programs or technologies or grant licenses on terms that may not be favorable to us.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">45</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">If adequate funds are not available to us, we may be required to forego potential in-licensing or acquisition opportunities, delay, limit or terminate one or more development or discovery programs,
        scale back marketing efforts for our current and future products or be unable to expand operations or otherwise capitalize on business opportunities.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Finally, as part of our ongoing business strategy we regularly evaluate new acquisition and in-licensing opportunities as well as our capital structure. We may from time to time use our existing
        cash to fund such opportunities or to retire outstanding debt obligations or to return capital to shareholders though share repurchases or the issuance of cash dividends on our common shares to optimize our capital structure. See &#8220;Risk
        Factors&#8212;Risks Related to Our Business and Industry&#8212;We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management&#8221; and &#8220;Risk Factors&#8212;Risks Related to Our
        Business and Industry&#8212;Our management has broad discretion in respect of use of our cash and cash equivalents, including the proceeds from the Roche Transaction. In the future, we may decide to return capital to shareholders, whether through share
        repurchases, cash dividends or otherwise, and the amount and timing of such capital returns is subject to the discretion of our board of directors and will vary from time to time. There is no guarantee that such proceeds will be used to increase
        our operating results or enhance the value of our Common Shares.&#8221; for more information.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Cash Flows</div>

      <div><br/></div>

      <div style="text-align: justify; text-indent: 36pt;">The following table sets forth a summary of our cash flows for the <span style="color: #000000;">nine months ended December 31, 2023</span> and <span style="color: #000000;">2022</span>:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Nine Months Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash used in operating activities</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(656,811</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">(664,305</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash provided by (used in) investing activities</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div><span style="color: #000000;">5,196,695</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div><span style="color: #000000;">(157,822</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div><span style="color: #000000;">)</span></div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash provided by financing activities</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">451,988</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">$</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div><span style="color: #000000;">289,130</span></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Operating Activities</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash flow from operating
        activities is derived from adjusting our net loss for non-cash items and changes in working capital.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For the nine months ended December 31, 2023, cash used in operating activities decreased by $7.5 million to $656.8 million compared to the nine months ended December 31, 2022.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Investing Activities</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Cash flow from investing activities includes proceeds from sale of Telavant net assets, milestone payments, cash decreases upon deconsolidation of subsidiaries, proceeds from sale of subsidiary
        interests, and purchase of property and equipment.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For the nine months ended December 31, 2023 and 2022, cash flow from investing activities changed by $5.4 billion. For the nine months ended December 31, 2023, net cash provided by investing
        activities was $5.2 billion, compared to net cash used in investing activities of $157.8 million for the nine months ended December 31, 2022. This change in cash flow is primarily due to proceeds received upon closing of the Roche Transaction
        during the nine months ended December 31, 2023, partially offset by the milestone payments relating to VTAMA made during the nine months ended December 31, 2022.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Financing Activities</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For the nine months ended December 31, 2023, cash provided by financing activities increased by $162.9 million to $452.0 million compared to the nine months ended December 31, 2022. During the nine
        months ended December 31, 2023, net proceeds were primarily generated by the issuance of common shares of our majority-owned subsidiary Immunovant as well as the issuance of our common shares pursuant to purchase and sale agreements entered with
        certain institutional investors. During the nine months ended December 31, 2022, proceeds were generated by funding pursuant to the terms of the RIPSA following the approval of VTAMA by the FDA in May 2022 as well as net proceeds from the issuance
        of our common shares and the common shares of our majority-owned subsidiary Immunovant.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">46</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="font-weight: bold;">Critical Accounting Policies and Significant Judgments and Estimates</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in
        accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of
        assets and liabilities, and disclosures of contingencies as of the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. In accordance with U.S. GAAP, we
        evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
        about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and
        estimates in light of changes in circumstances, facts, or experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We define our critical accounting policies as those under U.S. GAAP that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material
        impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">There have been no significant changes to our critical accounting policies and use of estimates from those disclosed under Management&#8217;s Discussion and Analysis of Financial Condition and Results of
        Operations for the year ended March 31, 2023 in our Form 10-K.</div>

      <div>&#160;</div>

      <div style="font-weight: bold;">JOBS Act</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an
        extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have
        elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</div>

      <div>&#160;</div>

      <div>
        <a id="QuantitativeandQualitativ"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 46.95pt;">
                <div style="text-align: left; font-weight: bold;">Item 3.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="font-weight: bold;">Quantitative and Qualitative Disclosures About Market Risk.</div>
              </td>

  </tr>


</table>
      </div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Under SEC rules and regulations, because we are considered to be a &#8220;smaller reporting company,&#8221; we are not required to provide the information required by this item in this report.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">47</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div>
        <a id="ControlsandProcedures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 46.95pt;">
                <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Item 4.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Controls and Procedures.</div>
              </td>

  </tr>


</table>
      </div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Evaluation of Disclosure Controls and Procedures.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We maintain &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 as amended, (the &#8220;Exchange Act&#8221;)), that are designed to
        provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and
        forms.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by us in the reports that
        we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December
        31, 2023, the end of the period covered by this Quarterly Report. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2023
        at the reasonable assurance level.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Changes in Internal Control Over Financial Reporting.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended <span style="color: #000000;">December 31, 2023</span> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Inherent Limitation on the Effectiveness of Internal Control.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our management, including our Principal Executive Officer and Principal Financial Officer, does not expect that our disclosure controls and procedures, or our internal controls, will prevent all
        error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact
        that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control
        issues and instances of fraud, if any, within our Company have been detected.<br/>
        <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">48</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: center; font-weight: bold;">PART II&#8212;OTHER INFORMATION</div>

      <div>&#160;</div>

      <a id="LegalProceedings."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.95pt; vertical-align: top; font-weight: bold;">Item 1.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Legal Proceedings.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">From time to time, we may become involved in legal or regulatory proceedings arising in the ordinary course of our business. We do not currently, however, expect such legal proceedings to have a
        material adverse effect on our business, operating results or financial condition. However, depending on the nature and timing of a given dispute, an unfavorable resolution could materially affect our current or future results of operations or cash
        flows.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For a description of our legal proceedings, refer to &#8220;Note 10&#8212;Commitments and Contingencies&#8221; in our unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report.</div>

      <div>&#160;</div>

      <a id="RiskFactors."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.95pt; vertical-align: top; font-weight: bold;">Item 1A.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Risk Factors.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Our business involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this Quarterly Report,
        including our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report, as well as the risks, uncertainties and other information set forth in the reports and other materials filed or
        furnished by us and our majority-controlled subsidiary, Immunovant, Inc. (&#8220;Immunovant&#8221;), with the SEC. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse
        impact on our business, prospects, results of operations, financial condition and cash flows. If any such events were to happen, the trading shares of our Common Shares could decline, and you could lose all or part of your investment.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Unless the context otherwise requires, references in this section to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Roivant&#8221; and the &#8220;Company&#8221; refer to Roivant Sciences Ltd. and its subsidiaries and
        affiliates, as the context requires.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-weight: bold;">Risks Related to Our Business and Industry</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Risks Related to Our Financial Position and Strategy</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product development may make it difficult for us to execute on our business
        model and for you to assess our future viability. We have not generated significant revenue from our operations since inception, and there is no guarantee that we will do so in the future.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are a commercial-stage biopharmaceutical and healthcare technology company with a limited operating history upon which you can evaluate our business and prospects. We were formed in April 2014,
        and our operations to date have primarily been limited to acquiring or in-licensing product candidates, pursuing the clinical development and commercialization of those product candidates, efforts to discover new product candidates, financing
        activities and the creation or acquisition of healthcare technology companies and products, as well as the oversight and management of our subsidiaries developing and commercializing medicines, which we refer to as &#8220;Vants.&#8221;</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Last year, following the approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in May 2022 of VTAMA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        (tapinarof) for the treatment of adults with plaque psoriasis, we commenced our transition from a clinical-stage to a company with commercial-stage assets. VTAMA is not currently approved in any other jurisdictions and we do not have any other
        product candidates that have received regulatory approvals in the U.S. or in any other jurisdiction.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our ability to execute on our business model and generate revenues depends on a number of factors, including our ability to:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>successfully continue to commercialize VTAMA;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>identify new acquisition or in-licensing opportunities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>successfully complete ongoing preclinical studies and clinical trials and obtain regulatory approvals for our current and future products and product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>successfully identify new product candidates through our discovery efforts and advance those product candidates into preclinical studies and clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>successfully grow our healthcare technology Vants and market the products and services offered by those Vants;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>raise additional funds when needed and on terms acceptable to us;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>attract and retain experienced management and advisory teams;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>add operational, financial and management information systems and personnel, including personnel to support clinical, preclinical manufacturing and commercialization efforts and operations;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">49</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>launch commercial sales of future product candidates, whether alone or in collaboration with others, including establishing sales, marketing and distribution systems;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of products and product candidates manufactured at acceptable cost and quality levels and in compliance with FDA and other
                regulatory requirements;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>set acceptable prices for products and product candidates and obtain coverage and adequate reimbursement from third-party payors;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>achieve market acceptance of products and product candidates in the medical community and with third-party payors and consumers; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>maintain, expand and protect our intellectual property portfolio.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If we cannot successfully execute on these objectives, our business may not succeed and the price of our Common Shares may be negatively impacted.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to predict when and if our products and product candidates
        will achieve various milestones in their clinical development, including marketing approval from the FDA or other regulatory authorities, the timing or amount of increased expenses related to these activities or when we will be able to generate
        meaningful revenues or maintain profitability, if ever. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory authorities to perform studies or clinical trials in addition to those that are currently
        anticipated or to otherwise provide data beyond that which we currently believe is necessary to support an application for marketing approval or to continue clinical development in the U.S. or another jurisdiction, or if there are any delays in any
        of our or our future collaborators&#8217; clinical trials or the development of our product candidates that we may identify. We anticipate incurring significant costs associated with commercializing VTAMA and any future product candidates, if approved,
        and advancing our ongoing clinical trials and discovery efforts until our revenue from product sales of VTAMA and any other approved products exceeds such expenses, which may never occur.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may never achieve sustained profitability.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain
        regulatory approval or become commercially viable. While we have received regulatory approval for one product candidate, VTAMA for the treatment of adults with plaque psoriasis in the U.S., we have yet to receive marketing approval for any of our
        other product candidates anywhere in the world and we have not generated significant product revenues from the commercial sale of our biopharmaceutical products. We cannot estimate with precision the extent of our future losses. Since inception, we
        have incurred significant losses and negative cash flows from operations. As of December 31, 2023, we had cash and cash equivalents of approximately <span style="color: #000000;">$6.7 billion</span> and retained earnings of <span style="color: #000000;">$727.3 million</span>.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We may never be able to develop new marketable drugs, successfully commercialize new marketable drugs or achieve sustained profitability. To achieve sustained profitability, we must succeed in
        developing and commercializing products that generate significant revenue. Revenue from the sale of any products or product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the
        territories for which we have or may gain regulatory approval, the accepted price for the product, the ability to obtain reimbursement at any price, the strength and term of patent exclusivity for the product, the competitive landscape of the
        product market, and whether we own the commercial rights for that territory. For example, even though VTAMA for the treatment of adults with plaque psoriasis has received regulatory approval in the U.S., we can provide no assurances that we will be
        able to achieve profitability based on sales in that indication alone or that we will be able to receive approval of and commercialize VTAMA for other indications or in other jurisdictions. Even if we achieve profitability from product revenues in
        the future, we may not be able to sustain profitability in subsequent periods. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, expand our
        pipeline, market our products and, if approved, product candidates, and continue our operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We may never generate meaningful product revenue from the commercial sales of our products or, if approved, product candidates or achieve or maintain profitability. It is possible that we will
        incur substantial operating losses for the foreseeable future. Our ability to generate meaningful product revenue and achieve sustained profitability is dependent on our ability to complete the development of our products and product candidates,
        obtain necessary regulatory approvals for our current and future products and product candidates and manufacture and successfully market our current and future products and product candidates alone or in collaboration with others.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">50</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic;"><span style="font-weight: bold;">We have limited experience as a commercial company and the marketing and sale of VTAMA or any future products may be</span>&#160;<span style="font-weight: bold;">unsuccessful


















          or less successful than anticipated.</span></div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In May 2022, the FDA approved VTAMA for the treatment of adults with plaque psoriasis in the U.S. While we have launched VTAMA in the U.S., we have limited experience as a commercial company and
        therefore face significant risks and uncertainties relating to the commercialization of VTAMA and any future products that receive marketing approval in the U.S. or another jurisdiction, including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to recruit and retain effective sales, marketing and customer service personnel;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to obtain and retain access to physicians or persuade adequate numbers of physicians to prescribe VTAMA and any future products;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the inability to manufacture and to price VTAMA and any future products at a price point sufficient to ensure an adequate and attractive level of profitability;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the extent to which coverage and adequate reimbursement for VTAMA and any future products will be available from government health administration authorities, private health insurers and other organizations;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the risks associated with potential co-promotion or partnership agreements, including the failure to realize the expected benefits of such arrangements; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>other unforeseen costs, expenses and risks associated with the commercialization of biopharmaceutical products, including compliance costs.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, in connection with our continued commercialization of VTAMA, we expect to continue to increase the amount of cash we spend in order to expand our commercial infrastructure. To the
        extent that we are able to gain regulatory approval for VTAMA in any other jurisdiction besides the U.S. or to gain regulatory approval for any of our other product candidates in any jurisdiction, we would expect to incur additional increased cash
        costs.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our limited experience as a commercial-stage company means that there is limited information about our ability to overcome many of the risks and uncertainties encountered by companies
        commercializing products in the biopharmaceutical industry, including those outlined herein. Further, given our limited experience of commercializing products, we do not have a track record of successfully executing on the commercialization of an
        approved product. As we continue to develop and seek regulatory approval of additional products and product candidates, as well as additional indications for VTAMA, and to pursue regulatory approvals for VTAMA and other products and product
        candidates outside the U.S., it could be difficult for us to obtain and devote the resources necessary to successfully manage our commercialization efforts. If we are unable to manage the risks and uncertainties associated with the
        commercialization of VTAMA and any future products or product candidates that receive marketing approval, we may be unable to generate significant revenues from the sales of these products and product candidates to achieve profitability, which will
        materially affect our business, prospects, financial condition and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our inability to successfully commercialize VTAMA or the failure of any of our product candidates in ongoing or future clinical trials or preclinical studies, in addition to having a direct adverse
        impact on our business and prospects, could also have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential
        counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our business is dependent to a significant extent on the successful commercialization of VTAMA and the development, regulatory approval, and commercialization of our current
        product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We currently have one product approved by the FDA &#8211; VTAMA, which was approved for the treatment of plaque psoriasis in adults in the U.S. The success of our business, including our ability to
        finance our company and generate any revenue in the future, will depend to a significant extent on the successful commercialization of VTAMA and the successful development, regulatory approval, and commercialization of other product candidates. The
        commercial success of VTAMA and the clinical and commercial success of other product candidates will depend on a number of factors, including the following:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to successfully implement and execute on a marketing strategy for VTAMA and to commercialize any of our product candidates in the United States and internationally, if approved, whether alone or in collaboration with others;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>acceptance by physicians, payers, and patients of the benefits, safety, and efficacy of VTAMA or any product candidates, if approved, including relative to alternative and competing treatments;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>timely completion of our nonclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">51</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>whether we are required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any
                future product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>acceptance of our proposed indications and primary and secondary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the prevalence, duration, and severity of potential side effects or other safety issues experienced with VTAMA or our product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>achieving, maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to VTAMA or any of our product
                candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the willingness of physicians and patients to utilize or adopt VTAMA and our product candidates, if approved;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the ability of third parties upon which we rely to manufacture clinical trial and commercial supplies of VTAMA or any of our product candidates to remain in good standing with relevant regulatory authorities and to develop, validate, and
                maintain commercially viable manufacturing processes that are compliant with Current Good Manufacturing Practice (&#8220;cGMP&#8221;);</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the availability of coverage and adequate reimbursement from private third-party payers and governmental healthcare programs, such as Medicare and Medicaid;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>patient demand for any approved products;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to establish and enforce intellectual property rights in and to any current and future products and product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to avoid third-party patent interference, intellectual property challenges, or intellectual property infringement claims; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the ability to raise any additional required capital on acceptable terms, or at all.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Further, competitors who are developing products in the dermatology field or that target the same indications as us with products that have a similar mechanism of action may experience problems
        with their products that could indicate or result in class-wide problems or additional requirements that would potentially harm our business. Due to these risks and uncertainties, we cannot provide assurances that we will be able to generate
        sufficient revenue through the sale of VTAMA or our product candidates or any future product candidates to continue our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may not be successful in our efforts to acquire or in-license new product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The success of our business depends in large part on our ability to successfully identify new product candidates, whether through acquisitions or in-licensing transactions or through our internal
        discovery capabilities. Our acquisition and in-licensing efforts focus on identifying assets in development by third parties across a diverse range of therapeutic areas that, in our view, are underserved or undervalued. Our strategy often entails
        designing low-cost studies that result in quick &#8220;go/no-go&#8221; decisions when deciding whether or how to proceed with future development for a given asset, once acquired. We may decide to proceed with the development of a product candidate on this
        basis and later determine that the more costly and time intensive trials do not support the initial value the product candidate was thought to hold. Even if a product candidate does prove to be valuable, its value may be less than anticipated at
        the time of investment. We may also face competition for attractive investment opportunities. A number of entities compete with us for such opportunities, many of which have considerably greater financial and technical resources. If we are unable
        to identify a sufficient number of such product candidates, or if the product candidates that we identify do not prove to be as valuable as anticipated, we will not be able to generate returns and implement our investment strategy and our business
        and results of operations may suffer materially. Any such failure to in-license or acquire new product candidates from third parties would have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">52</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our drug discovery efforts may not be successful in identifying new product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our drug discovery efforts are centered on our discovery Vants, including Psivant, Covant and VantAI, which employ a variety of approaches to the drug discovery process, including quantitative
        proteomics, induced proximity and covalency. As a company, we have relatively limited experience in drug discovery generally and with certain of the computational tools that are employed in those efforts. Our future success depends, in part, on our
        ability to successfully use these approaches and technologies to identify promising new product candidates and eventually advance those product candidates through preclinical studies and clinical trials. We have not yet succeeded and may not
        succeed in advancing any product candidates developed through these discovery efforts into clinical trials, demonstrating the efficacy and safety of such product candidates or obtaining regulatory approval thereafter. As a result, it is difficult
        to predict the time and cost of product candidate development from our discovery Vants and we cannot predict whether the application of these approaches will result in the development and regulatory approval of any products. In addition, many of
        the active drug discovery efforts at our discovery Vants are being conducted pursuant to collaboration agreements with third parties, in which the third parties are either owed milestone and royalty payments tied to the successful development and
        commercialization of successfully identified drug candidates, or have been granted exclusive or shared development and commercialization rights with respect to successfully identified drug candidates in exchange for upfront payments, shared
        expenses, and certain milestone and royalty payments owed to the discovery Vants. Any problems that we or our third party partners experience in the future related to this platform or any of our related development programs may cause significant
        delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any internally
        discovered product candidates we may develop on a timely or profitable basis, if at all. Even if successful, as a result of our collaboration agreements, our rights to commercialize any successfully discovered product candidates may be limited.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We face risks associated with the allocation of capital and personnel across our businesses.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Because we have limited financial and management resources, we have to make challenging decisions regarding the allocation of capital and personnel across our businesses. We face certain risks
        associated with these decisions and may fail to capitalize on viable commercial product candidates or profitable market opportunities. For example, we may decide not to pursue a particular in-licensing or acquisition opportunity, or a potential
        target indication for a product candidate, that later proves to have greater commercial potential than our current and planned development programs and product candidates. Similarly, our management&#8217;s attention to one product or product candidate
        may divert their attention from another opportunity that ultimately might have proven more successful. Our spending on current and future research and development programs and other future product candidates may not yield any commercially viable
        future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty
        arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidate.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Additionally, we may pursue additional in-licenses or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product
        candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or in-license of a successful product candidate, potentially resulting in a diversion of our management&#8217;s
        time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating,
        acquiring and developing products that ultimately do not provide a return on our investment.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We face risks associated with the Vant structure.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our products and product candidates are developed at our Vants, which operate similarly to independent biopharmaceutical companies. While we believe that there are significant competitive
        advantages to this structure, as compared to traditional pharmaceutical companies or smaller biopharma companies, the Vant structure also poses certain risks for our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Operating the Vants independently, rather than under a centralized, consolidated management team, may result in increased costs at the Vants, as certain functions or processes, including sales and
        marketing, clinical and nonclinical personnel, business development, finance, accounting, human resources and legal functions, are replicated across the Vants. There may also be certain start-up costs, associated with the establishment of a new
        Vant or integration of a newly acquired business into a Vant, which are greater under the Vant model than they would be under a centralized model. The use of the Vant model may also entail increased costs for us, including the time and expenses
        associated with hiring Vant CEOs and management teams, overseeing Vant equity incentive arrangements and managing compliance-related risks, including the internal controls, reporting systems and procedures necessary for us to operate as a public
        company. We may also be exposed to increased &#8220;key employee&#8221; risks, in the event a Vant CEO were to depart, including the loss of other senior Vant personnel, potentially resulting in adverse impacts to commercialization or development work at the
        Vant. These increased expenses, complexities and other challenges may make using and scaling the Vant model more challenging and costly than it would be for a traditional pharmaceutical company to both operate and expand the number of product
        candidates under development, which could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects. This decentralized model could also make compliance with applicable laws and regulations
        more challenging to monitor and may expose us to increased costs that could, in turn, harm our business, financial condition, results of operations or prospects.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">53</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, a single or limited number of the Vants may, now or in the future, comprise a large proportion of our value. Similarly, a large proportion of our consolidated revenues may be derived
        from one or a small number of Vants. For example, our only approved product, VTAMA, was developed and is being commercialized by Dermavant, one of our Vants. Any adverse development at Dermavant or any other Vant, including the loss of key members
        of management, the termination of a key license agreement or other loss of the intellectual property underlying a product or product candidate or the failure of a clinical trial for a product candidate under development at the Vant, could have a
        material adverse effect on our consolidated business, financial condition, results of operations or prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We do not wholly own many of our Vants, and certain of our Vants have issued debt or equity securities senior to our ownership interests, which dilutes our economic interest in the Vants. Future
        capital needs at individual Vants may also be financed through senior debt or equity securities, or common equity, all of which may further dilute our economic interest in a Vant.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We manage the Vants in part through our designees who serve on the Vant boards of directors. In their capacities as directors, those individuals may owe fiduciary duties to the Vants and their
        shareholders under applicable law, which may at times require them to take actions that are not directly in our interest. To the extent any such actions have an adverse effect on the value of our ownership interest in the Vant, it could further
        adversely impact our consolidated business, financial condition, results of operations or prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We face risks associated with potential future payments related to our products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our asset in-licensing transactions typically involve zero or low upfront payments combined with milestone and royalty payments. These arrangements generally involve a payment or payments upon the
        achievement of certain development or regulatory milestones, including regulatory approval, and then royalty payments upon the achievement of specified levels of sales, which can extend for up to the life of a product. Some of these payments may
        become due before a product is generating revenues, in which case we may not have sufficient funds available to meet our obligations. If this were to occur, we would default on our payment obligations and could face penalties, delays in
        commercialization or development activities or reputational damage. Even for a product that is commercialized and generating revenue, payments could become due that are so large that the investment is not profitable or is less profitable than
        anticipated. For example, this could occur if at the time of the initial investment, we overestimated the value of the product and agreed to a payment schedule using these inflated estimates. If we are unable to make milestone and royalty payments
        related to our product candidates when due, our business and prospects could suffer and our ability to in-license future product candidates could be impaired.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our business strategy and potential for future growth relies on a number of assumptions, some or all of which may not be realized.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our business strategy and plans for future growth rely on a number of assumptions, including, in the case of our products and product candidates, assumptions related to adoption of a particular
        therapy, incidence and prevalence of an indication, use of a product or product candidate versus competitor therapies and size of the addressable patient populations. Some or all of these assumptions may be incorrect. We cannot accurately predict
        whether our products or product candidates will achieve significant market acceptance in line with these assumptions or whether there will be a market for our products or product candidates that reaches the anticipated size. If any of these
        assumptions are incorrect or overstated, our results and future prospects will be materially and adversely affected.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic;"><span style="font-weight: bold;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions</span>&#160;<span style="font-weight: bold;">to our management.</span></div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">From time to time, we may consider strategic transactions, including acquisitions or divestitures of companies, asset purchases or sales and out-licensing or in-licensing of intellectual property,
        products or technologies. For example, in December 2023, we completed a transaction to sell Telavant, which was owned by us and Pfizer, to Roche for aggregate upfront consideration of $7.1 billion and a near-term, one-time milestone payment of $150
        million (the &#8220;Roche Transaction&#8221;). Additional potential transactions that we may consider in the future include a variety of business arrangements, including spinoffs, strategic partnerships, joint ventures, collaborations, restructurings,
        divestitures, business combinations and investments. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our or our Vants&#8217; equity securities, including our Common Shares, or the
        incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, and could expose us to the risk of litigation, any of which could affect our financial condition, liquidity and results of
        operations. Future acquisitions, which may or may not include using all or a portion of the cash proceeds from the Roche Transaction as consideration, may also require us to obtain additional financing, which may not be available on favorable terms
        or at all. These transactions may never be successful and may require significant time and attention of our management, as well as significant costs, whether or not successfully consummated. In addition, the integration of any business that we may
        acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. For any alliances or joint ventures that we enter into in the
        biopharmaceutical industry, we may encounter numerous difficulties in discovering, developing, manufacturing and marketing any new products or product candidates related to such businesses, which may delay or prevent us from realizing the expected
        benefits or enhancing our business. Divestiture transactions such as the Roche Transaction may adversely impact the price of our common shares, to the extent investors believe the value of the consideration received in the transaction is not
        equivalent to the value of the asset or program divested. Accordingly, there can be no assurance that transactions of the nature described above will be undertaken or successfully completed, and that any transaction we do complete will not have a
        material adverse effect on our business, results of operations, financial condition and prospects.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">54</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our management has broad discretion in respect of use of our cash and cash equivalents, including the proceeds from the Roche Transaction.&#160; In the future, we may decide to
        return capital to shareholders, whether through share repurchases, cash dividends or otherwise, and the amount and timing of such capital returns is subject to the discretion of our board of directors and will vary from time to time.&#160; There is no
        guarantee that such proceeds will be used to improve our operating results or enhance the value of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-indent: 36pt; text-align: justify;">As of December 31, 2023, we had cash and cash equivalents of approximately $6.7 billion, which includes the cash proceeds from the Roche Transaction. Our management has broad discretion in respect
        of use of our cash and cash equivalents, including the proceeds from the Roche Transaction&#160; We may use all or a portion of such proceeds in respect of one or more strategic transactions, including acquisitions or divestitures of companies, asset
        purchases or sales and out-licensing or in-licensing of intellectual property, products or technologies, as described above. We may not be able to find a suitable strategic transaction that we deem sufficiently attractive to pursue, and may not be
        able to complete a strategic transaction in the future. Our ability to complete a strategic transaction may be negatively impacted by general market conditions, volatility in the capital markets and the other risks described herein.</div>

      <div>&#160;</div>

      <div style="text-indent: 36pt; text-align: justify;">In the future, we may also decide to return capital to shareholders though one or a combination of public or private share repurchases, or the issuance of cash dividends on our Common Shares. The
        amount and timing of these returns of capital to shareholders may vary from time to time, and the decision whether to return capital to shareholders remain subject to the discretion of our board of directors that any such activity would be in the
        best interests of our shareholders and in compliance with all applicable laws and our contractual obligations. In the event that we decide to pursue share repurchases, we may be limited in our ability to repurchase our Common Shares by various
        governmental laws, rules and regulations which prevent us from purchasing our Common Shares during periods when we are in possession of material non-public information. In addition, our ability to pay dividends may be limited by covenants of any
        existing and future outstanding indebtedness we or our subsidiaries incur.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The amount of cash available to return to shareholders, if any, can vary significantly from period to period for a number of reasons, including, among other things, our results of operations,
        financial condition, cash requirements, contractual restrictions, applicable law and other factors that our board of directors may deem relevant. The returns of capital to shareholders may change in form, amount, value and frequency from time to
        time, and we cannot guarantee that any such returns of capital will continue. The trading price of our Common Shares may deteriorate if we are unable to meet investor expectations with respect to the timing and amount of capital returns to
        shareholders, and such deterioration may be material. There is no guarantee that our significant balance of cash and cash equivalents, including the proceeds from the Roche Transaction, will be used to increase our operating results, return capital
        to shareholders, or enhance the value of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to successfully market our products, acquire or
        in-license new products or product candidates, complete the development and commercialization of our products and product candidates and continue to pursue our drug discovery efforts.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Acquiring or in-licensing, discovering, developing, commercializing and marketing biopharmaceutical products and product candidates is expensive and time consuming, and, in the future, we may
        require additional capital to pursue these activities. We are also responsible for payments to third parties under our license and acquisition agreements, including milestone and royalty payments. Because of the inherent uncertainties in these
        activities &#8211; including the outcome of preclinical and clinical trials and the regulatory approval process &#8211; we cannot reasonably estimate the actual amounts necessary to successfully complete the development, regulatory approval process and
        commercialization of our current and future products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the time and costs necessary to complete our ongoing, planned and future clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the time and costs necessary to pursue regulatory approvals for our current and future product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the costs associated with future acquisitions or in-licensing transactions;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the approval, progress, timing, scope and costs of our preclinical studies, clinical trials and other related activities, including the ability to enroll patients in a timely manner for our ongoing and planned clinical trials and
                potential future clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the costs associated with our ongoing, planned and future preclinical studies and other drug discovery activities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to successfully identify and negotiate acceptable terms for third-party supply and contract manufacturing agreements with contract manufacturing organizations (&#8220;CMOs&#8221;);</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the costs of obtaining adequate clinical and commercial supplies of raw materials and drug products for our products and product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to successfully commercialize VTAMA, including:</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">55</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">o</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the manufacturing, selling and marketing costs associated with VTAMA, including the cost and timing of expanding sales and marketing capabilities or entering into strategic collaborations with third parties; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">o</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the amount and timing of sales and other revenues from VTAMA, including the sales price and the availability of adequate third-party reimbursement;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights, including current and future patent infringement actions brought against third parties;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the cost of pursuing and defending potential intellectual property disputes, including patent infringement actions with third parties relating to our current or future products or product candidates; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to hire, attract and retain qualified personnel.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In the event that we require additional financing, we cannot be certain that additional capital will be available to us or the Vants on acceptable terms, or at all. If we or the Vants are unable to
        raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue our in-licensing and acquisition, discovery, development, commercialization and marketing activities. In
        addition, attempting to secure additional capital may divert the time and attention of our management from day-to-day activities and harm our business. Because of the numerous risks and uncertainties associated with our business, we are unable to
        estimate the amounts of increased capital outlays, operating expenditures and capital requirements associated with our current and future product development programs and discovery efforts. Moreover, risks associated with broader market conditions,
        including high levels of inflation, heightened interest rates and increasing market and banking sector instability and volatility, all of which have been observed in recent periods, may further adversely impact our ability to obtain financing on
        acceptable terms or at all.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In the future, we may require significant additional capital to continue our operations, pursue business opportunities or strategic transactions, or respond to challenges, competition or unforeseen
        circumstances. Until such time, if ever, that we can generate substantial revenues, we may finance future cash needs through a combination of equity offerings, debt financings, strategic alliances and license and development agreements or other
        collaborations at Roivant and the Vants. To the extent that we raise additional capital by issuing equity securities at Roivant or the Vants, our existing shareholders&#8217; ownership, or our ownership in the Vants, may experience substantial dilution,
        and the terms of these securities may include liquidation or other preferences that could harm the rights of our shareholders. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting
        or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or
        licensing arrangements with third parties, we may have to relinquish valuable rights to our products and product candidates, future revenue streams, research programs or technologies or grant licenses on terms that may not be favorable to us. The
        foregoing restrictions associated with potential sources of additional capital may make it more difficult for us to raise additional capital or to pursue business opportunities, including potential acquisitions.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If adequate funds are not available to us, we may be required to forego potential in-licensing or acquisition opportunities, delay, limit or terminate one or more development or discovery programs,
        scale back marketing efforts for our current and future products or be unable to expand operations or otherwise capitalize on business opportunities, which could materially affect our business, prospects, financial condition and results of
        operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may not be able to complete certain strategic transactions if a proposed transaction may be subject to review or approval by regulatory authorities pursuant to certain U.S.
        laws or regulations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Certain potential acquisitions, divestitures or other business combinations that we may pursue could be subject to review or approval by regulatory authorities pursuant to certain U.S. laws or
        regulations. In the United States, certain mergers that potentially could affect competition may require certain filings and review by the Department of Justice and the Federal Trade Commission. In recent years, there has been enhanced regulatory
        scrutiny over such transactions. In the event that we were to make an investment, acquisition or disposition that was determined to be subject to regulatory review, and such regulatory approval or clearance is not obtained, or the review process is
        extended beyond the period of time that would permit such strategic transactions to be consummated, we may not be able to consummate such strategic transactions or counterparties may be deterred from pursuing potential strategic transactions with
        us. This may impair our ability to raise capital when needed and to pursue accretive transactions, which is an important part of our business model, and have an adverse effect on our business, financial condition and prospects.</div>

      <div>
        <div><br/>
        </div>

        <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">We are exposed to risks and fluctuations related to our significant holdings of cash and cash equivalents.</div>

        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our significant holdings of cash and cash equivalents can be negatively affected by changes in liquidity, financial results, market and economic conditions, political risk,
          currency risk, credit risk, sovereign risk, interest rate fluctuations or other factors. As a result, the value and liquidity of our cash and cash equivalents may fluctuate substantially. Additionally, we may from time to time have balances in
          bank accounts that are in excess of insured deposit limits, and could be subject to risks of bank failures. Therefore, although we have not realized any significant losses on our cash and cash equivalents, future fluctuations in their value could
          result in significant losses and could have a material adverse impact on our results of operations and financial condition.<br/>
          <br/>
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">56</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Risks Related to the Development of Our Products and Product Candidates</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Clinical trials and preclinical studies are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays
        in clinical trials, or may not be able to conduct or complete clinical trials or preclinical studies on the expected timelines, if at all.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our biopharmaceutical product candidates that are in clinical development or preclinical studies will require, as applicable, extensive clinical testing before a New Drug Application (&#8220;NDA&#8221;) or
        other similar application for regulatory approval, such as a Biologics License Application (&#8220;BLA&#8221;) or an application for marketing authorization in the European Union (&#8220;EU&#8221;) or United Kingdom (&#8220;UK&#8221;), may be submitted, or extensive preclinical
        testing before an Investigational New Drug application (&#8220;IND&#8221;) or an application for authorization to conduct a clinical trial in the EU or UK may be submitted, a Clinical Trial Application (&#8220;CTA&#8221;). We cannot provide any assurance that we will
        submit an IND, NDA, CTA or other similar application for regulatory approval for our product candidates within projected timeframes or whether any such application will be accepted for review or ultimately approved by the relevant regulatory
        authorities.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Clinical trials and preclinical studies are very expensive, time-consuming and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance,
        the FDA, an institutional review board (&#8220;IRB&#8221;), an Ethics Committee (&#8220;EC&#8221;) or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates, and during any such review,
        may identify unexpected efficacy or safety concerns, which may delay the effective date of an IND or approval of an NDA, BLA or similar application. The FDA, the European Medicines Agency (&#8220;EMA&#8221;), the European Commission, the Medicines and
        Healthcare product Regulatory Agency (&#8220;MHRA&#8221;) or other relevant regulatory authority may also find that the benefits of any product candidate in any applicable indication do not outweigh its risks in a manner sufficient to grant regulatory
        approval.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The FDA or other regulatory authorities may also not agree with the scope of our proposed investigational plan. For example, they may find that our proposed development program is not sufficient to
        support a marketing authorization application, or that the proposed indication is considered to be too broad. Moreover, the FDA or other regulatory authorities may also refuse or impose certain restrictions on our reliance on data supporting our
        clinical trial application or marketing authorization application should such data originate from studies outside of the relevant jurisdiction or be affected by regulatory non-compliance, including issues of data integrity. In the EU, data derived
        from clinical trials that were conducted outside the EU cannot be used to support a CTA unless the clinical trial was registered on a relevant database. In each case, this could delay the clinical development and authorization timeline for a given
        product candidate.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Failures can occur at any stage of development, including clinical trials or preclinical studies, and we could encounter problems that cause us to abandon or repeat clinical trials or preclinical
        studies. In addition, results from clinical trials or preclinical studies may require further evaluation, delaying the next stage of development or submission of an IND or an NDA or similar application in the U.S. or another jurisdiction. Further,
        product candidates in later stages of clinical trials may fail to show the desired safety and efficacy results despite having successfully progressed through preclinical and earlier stage clinical trials. Such product candidates may exhibit safety
        signals in later stage clinical trials that they did not exhibit in earlier studies or trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in, or the discontinuation of, advanced clinical trials with a
        product candidate due to lack of efficacy or adverse safety findings, despite having promising results in earlier trials or studies. Likewise, the results of early clinical trials or preclinical studies of our product candidates may not be
        predictive of the results of current or future development programs. There can also be no assurance that the results of studies conducted by collaborators or other third parties with similar product candidates in similar indications will be viewed
        favorably or indicative of our own future trial results.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The commencement and completion of preclinical studies and clinical trials may be delayed by several factors, including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>failure to obtain regulatory authorization to commence a clinical trial or reaching consensus with regulatory authorities regarding the design or implementation of our studies;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>other regulatory issues, including the receipt of any inspectional observations on FDA&#8217;s Form-483, Warning or Untitled Letters, clinical holds, or complete response letters or similar communications/objections by other regulatory
                authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>unforeseen safety issues, or subjects experiencing severe or unexpected adverse events;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>lack of effectiveness during clinical trials;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">57</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>resolving any dosing issues, including those raised by the FDA or other regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>slower than expected rates of patient recruitment or failure to recruit suitable patients to participate in a trial;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>failure to add a sufficient number of clinical trial sites;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>unanticipated impact from changes in or modifications to protocols or clinical trial design, including those that may be required by the FDA or other regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>inability or unwillingness of clinical investigators or study participants to follow our clinical and other applicable protocols or applicable regulatory requirements;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>an IRB or EC refusing to approve, suspending, or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>premature discontinuation of study participants from clinical trials or missing data;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>failure to manufacture or release sufficient quantities of our product candidates or failure to obtain sufficient quantities of active comparator medications for our clinical trials, if applicable, that in each case meet our quality
                standards, for use in clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>inability to monitor patients adequately during or after treatment; or</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>inappropriate unblinding of trial results.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, disruptions caused by any ongoing effects of the COVID-19 pandemic or future pandemics may increase the likelihood that we encounter such difficulties or delays in initiating,
        enrolling, conducting or completing our planned and ongoing clinical trials. Further, we, the FDA or other regulatory authorities may suspend our clinical trials in an entire country at any time, or an IRB/EC may suspend our clinical trial sites
        within any country, if it appears that we or our collaborators, or the principal investigator, are failing to conduct a trial in accordance with the protocol, applicable regulatory requirements, including Good Clinical Practice (&#8220;GCP&#8221;) regulations,
        that we are exposing participants to unacceptable health risks, or if the FDA or other regulatory authority finds deficiencies in our IND or equivalent applications for other countries or in the manner in which clinical trials are conducted.
        Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could
        be harmed, and our ability to generate product revenue from any of our product candidates, if approved, may be delayed. In addition, any delays in our clinical trials could increase our costs, cause a decline in our share price, slow down the
        approval process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause or lead to a
        termination or suspension of, or delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We may make formulation or manufacturing changes to our product
        candidates, in which case we may need to conduct additional preclinical or clinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during
        which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring product candidates to market before we do, and the commercial viability of our product candidates could be significantly reduced.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under
        certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator
        has created a conflict of interest or otherwise affected the integrity of the study. The FDA or other regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the
        clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing and authorization applications by the FDA or other regulatory authorities, as the case may be, and may ultimately lead to the denial
        of marketing approval of any of our product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, for our products or product candidates that are in clinical development, prior to our acquisition of the rights to those products or product candidates we had no involvement with or
        control over the preclinical or clinical development of those products or product candidates. We are therefore dependent on our licensing and other transaction partners having conducted such research and development in accordance with the
        applicable protocols and legal, regulatory and scientific standards, having used appropriately regulated and compliant equipment and devices during the preclinical or clinical development, having accurately reported the results of all clinical
        trials and other research they conducted prior to our acquisition of the rights to those products or product candidates, having correctly collected and interpreted the data from these trials and other research and having supplied us with complete
        information, data sets and reports required to adequately demonstrate the results reported through the date of our acquisition of these products or product candidates. Problems associated with the pre-acquisition development of our products or
        product candidates could result in increased costs and delays in the commercialization of our products or development of our product candidates, which could harm our ability to generate any future revenue from sales of products or, if approved,
        product candidates.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">58</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Certain of our products and product candidates are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our
        development or commercialization programs or otherwise harm our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The manufacturing processes our CMOs use to produce our products and product candidates are complex, novel and, in the case of our product candidates, have not necessarily been validated for
        commercial use. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions
        in the operations of our suppliers.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our biologic product candidates may require processing steps that are more complex than those required for most small molecule drugs. Moreover, unlike small molecules, the physical and chemical
        properties of biologics generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product is consistent from lot-to-lot or will perform in the intended manner. Accordingly, our
        CMOs must employ multiple steps to control the manufacturing process to assure that the process is reproducible and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process,
        even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory to conduct clinical trials or supply
        commercial markets. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet the FDA, the EU, the UK or other applicable standards or specifications with consistent and acceptable production yields
        and costs.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, the FDA, the EMA, the MHRA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of
        applicable tests at any time. Under some circumstances, the FDA, the EMA, the MHRA or other comparable regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing
        process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or
        clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our CMOs also may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our manufacturing processes,
        which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our CMOs&#8217; manufacturing processes or facilities could result in delays in planned clinical trials and
        increased costs, and could make us a less attractive collaborator for potential partners, including larger biopharmaceutical companies and academic research institutions, which could limit access to additional attractive development programs.
        Problems in any of our manufacturing processes could restrict our ability to meet potential future market demand for our products or to conduct clinical trials with our product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may encounter difficulties enrolling and retaining patients in clinical trials, and clinical development activities could thereby be delayed or otherwise adversely affected.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We may encounter delays or difficulties in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials for our products or product candidates on
        current timelines, or at all, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our clinical trials for these products or product candidates. Enrollment in our clinical trials may also be slower
        than we anticipate, or be stopped, leading to delays in the development timelines for our products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Patient enrollment and retention in clinical trials depends on many factors, including EC approval of patient participation as proposed, the size of the patient population, the nature of the trial
        protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, delays in enrollment due to travel or quarantine policies, or other factors, including those related to any ongoing effects of COVID-19
        pandemic or future pandemics, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of
        patients to clinical sites, the eligibility criteria for the trial and the proportion of patients screened that meets those criteria, our ability to obtain and maintain patient consents and our ability to successfully complete prerequisite studies
        before enrolling certain patient populations. For certain of our products and product candidates, including batoclimab, which targets certain rare autoimmune indications, there are limited patient pools from which to draw in order to complete our
        clinical trials in a timely and cost-effective manner. In addition, for certain of our early-stage development programs, there may be a limited number of sites where it is feasible to run clinical trials, making such programs particularly
        susceptible to delays caused by issues at those sites.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">59</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Furthermore, any negative results or new safety signals we may report in clinical trials of our products or product candidates may make it difficult or impossible to recruit and retain patients in
        other clinical trials we are conducting or to resume enrolling patients once a paused clinical trial has been resumed. For example, in February 2021, our subsidiary, Immunovant, voluntarily paused dosing in its clinical trials for batoclimab
        globally due to elevated total cholesterol and low-density lipoprotein (&#8220;LDL&#8221;) levels observed in some patients treated with batoclimab, resulting in a delay in Immunovant&#8217;s development of batoclimab. In current and future trials of batoclimab, it
        may be more difficult for Immunovant to recruit and retain patients for such clinical trials. Similarly, negative results reported by our competitors about their drug candidates may negatively affect patient recruitment in our clinical trials.
        Also, marketing authorization of competitors in this same class of drugs may impair our ability to enroll patients into our clinical trials, delaying or potentially preventing us from completing recruitment of one or more of our trials.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our products and
        product candidates, or could render further development impracticable. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials, and, while we intend to enter into agreements
        governing their services, we will be limited in our ability to compel their actual performance. Any such delays in our current or future clinical trials could have a material adverse impact on our operations and financial condition and results.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">The results of our preclinical studies and clinical trials may not support our proposed claims for our products or product candidates, or regulatory approvals on a timely basis
        or at all, and the results of earlier studies and trials may not be predictive of future trial results.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will
        replicate the results of prior preclinical studies and earlier clinical trials. For example, we cannot assure you that the reductions in IgG antibodies and favorable analyte profile observed in our Phase 1 trial of IMVT-1402 will be observed in
        future clinical trials, including pivotal trials necessary for regulatory approvals. Likewise, promising interim results or other preliminary analyses do not ensure that the clinical trial as a whole will be successful and may lack statistical
        significance, which would further limit the reliability of such interim or preliminary data. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in, or the discontinuation of,
        clinical trials, even after promising results were seen with their product candidates in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were
        underway and safety or efficacy observations made in clinical trials, including previously unobserved adverse events.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The results of preclinical studies and early clinical trials of our products and product candidates may not be predictive of the results of later-stage clinical trials. Products and product
        candidates in later stage clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and initial clinical trials. A future failure of a clinical trial to meet its pre-specified endpoints
        may cause us to abandon development of the product candidate in question. Any delay in, or termination of, our clinical trials will prevent or delay the submission of an NDA or other similar applications to the FDA or other relevant comparable
        non-U.S. regulatory authorities and, ultimately, our ability to commercialize our products or, if approved, our product candidates, and generate product revenues. Even if our clinical trials are completed as planned, we cannot be certain that their
        results will support our claims for differentiation or the effectiveness or safety of our products and product candidates. The FDA and other regulatory authorities, including the EMA and the MHRA, have substantial discretion in the review and
        approval process and may disagree that our data support the differentiated claims we propose. In addition, only a small percentage of product candidates under development result in the submission of an NDA or other similar application to the FDA
        and other comparable non-U.S. regulatory authorities and even fewer are approved for commercialization.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Interim, top-line or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to
        audit and verification procedures that could result in material changes in the final data.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">From time to time, and in some countries, in line with the applicable requirements set out in legislation and guidance, we may publicly disclose preliminary or top-line data from our clinical
        trials, which is based on a preliminary analysis of then-available top-line data. For example, we previously disclosed top-line data from our pivotal atopic dermatitis Phase 3 ADORING 1 and ADORING 2 trials of VTAMA, positive results from the
        initial cohort of patients in our Phase 2 trial of batoclimab in Graves&#8217; disease, and initial human data from our Phase 1 trial of IMVT-1402. These results and related findings and conclusions are subject to change following a full analysis of all
        data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result,
        the preliminary and top-line results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data
        also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line data we previously reported. As a result, preliminary and top-line data should be viewed with caution until the
        final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change
        as patient enrollment continues and more patient data become available. Adverse differences between preliminary, top-line or interim data and final data could significantly harm our business prospects. Further, disclosure of preliminary or interim
        data by us or by our competitors could result in increased volatility in the price of our shares.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">60</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Further, other parties, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of
        data differently, which could impact the value of the particular program, the approvability or commercialization of a particular product or product candidate and our business in general. In addition, the information we choose or are required to
        publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our
        disclosure. Any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the
        top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our products and product candidates, our business,
        operating results, prospects or financial condition may be harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Changes in methods of product manufacturing or formulation may result in additional costs or delay.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">As our products and product candidates proceed through the development process, it is common that various aspects of the development program, such as manufacturing methods and formulation, are
        altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause products or product candidates to perform differently and
        affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval, or another regulatory authority&#8217;s notification
        or approval, as applicable, since similar requirements apply in other jurisdictions. This could delay the completion, or result in the abandonment, of clinical trials, require the conduct of bridging clinical trials, the repetition of one or more
        clinical trials, increase clinical trial costs, delay approval of our products and product candidates and jeopardize our ability to commence sales and generate revenues.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner or fail to comply with applicable
        requirements, it may harm our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance. In addition, we rely
        upon CROs to monitor and manage data for our clinical programs, as well as the execution of future nonclinical studies. We expect to control only certain aspects of our CROs&#8217; activities. Nevertheless, we will be responsible for ensuring that each
        of our studies is conducted in accordance with the applicable contract, protocol, legal, regulatory and scientific standards and that clinical trial sites meet applicable protocol and regulatory requirements. Our reliance on CROs does not relieve
        us of our regulatory or specified contractual responsibilities.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We and our CROs are required to comply with Good Laboratory Practices (&#8220;GLPs&#8221;) and GCPs, which are regulations and guidelines enforced by the FDA and other comparable non-U.S. regulatory
        authorities, which also require compliance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines for any of our products and product candidates that are in preclinical and
        clinical development. The regulatory authorities enforce GCP regulations through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we may rely on CROs to conduct our GLP-compliant nonclinical studies
        and GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP nonclinical studies and GCP clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. Our
        expected reliance on the CROs does not relieve us of our regulatory or contractual responsibilities. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or non-U.S.
        regulatory authorities may reject our marketing authorization applications and require us to perform additional clinical trials to generate additional data before approving our marketing applications. Accordingly, if our CROs fail to comply with
        these regulations or other applicable laws, regulations or standards, or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process. Failure by any future CROs to
        properly execute study protocols in accordance with applicable law could also create product liability and healthcare regulatory risks for us as sponsors of those studies.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our CROs are independent, third-party organizations and we do not control whether they devote sufficient time, attention and resources to our clinical and nonclinical programs. These CROs may also
        have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. We face the risk of potential
        unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our
        proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
        to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product or
        product candidate that we develop. As a result, our financial results and the commercial prospects for any product or product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenues could be
        delayed.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">61</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">If our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms or in a timely manner. Switching or
        adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can adversely impact our ability to meet our
        desired clinical development timelines. Though we intend to carefully manage our relationships with the CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have
        an adverse impact on our business, financial condition and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of our products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We do not own or operate, and do not expect to own or operate, facilities for product manufacturing, storage and distribution or testing. Accordingly, we rely on third parties to produce commercial
        and clinical supplies of our products and product candidates. For example, Dermavant, ThermoFisher and GSK have entered into agreements pursuant to which ThermoFisher and GSK are providing commercial drug product and drug substance for VTAMA as
        well as drug product and drug substance for Dermavant&#8217;s completed pivotal atopic dermatitis Phase 3 ADORING 1 and ADORING 2 trials of VTAMA as well as its ongoing open label long-term extension study of VTAMA in atopic dermatitis. If these
        counterparties do not fulfill their obligations under these agreements, Dermavant&#8217;s ability to sell VTAMA commercially and conduct its ongoing and future clinical trials with VTAMA may be adversely impacted.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Third-party vendors may be difficult to identify for our product process and formulation development and manufacturing due to special capabilities required, and they may not be able to meet our
        quality standards. In addition, certain of our third-party manufacturers and suppliers may encounter delays in providing their services as a result of supply chain constraints. If any third-party manufacturers or third parties in the supply chain
        for materials used in the production of our products or product candidates are adversely impacted by supply chain constraints, our supply chain may be disrupted, limiting our ability to manufacture our products for commercialization and products or
        product candidates for our preclinical studies, clinical trials and research and development activities. Any significant delay in the supply of a product or product candidate, or the raw material components thereof, or of equipment and devices as
        necessary, for either commercialization or an ongoing clinical trial, due to the need to replace a third-party manufacturer or otherwise, could considerably delay marketing efforts for the product in question or the completion of clinical trials,
        product testing and potential regulatory approval of the product candidate in question. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our products or product candidates, the
        commercial launch of our products or product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenue from the sale of our products or product candidates and may require notification to
        the FDA or other regulatory authorities. Moreover, as a result of projected supply constraints for certain materials used in the production of our products or product candidates, we have in the past and may in the future reserve manufacturing
        capacity in advance of receiving required efficacy or safety results from our clinical trials, which may involve committing substantial financial resources to current or future products or product candidates that may never be approved or achieve
        commercialization at scale or at all. In addition, legislative, executive and regulatory proposals were recently enacted or are pending to, among other things, prevent drug shortages, improve pandemic preparedness and reduce the dependency of the
        United States on foreign supply chains and manufacturing. While we are still assessing these developments, they could impact our selection and utilization of CMOs, vendors and other suppliers and could have a material adverse impact on our
        business, financial condition and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The facilities used by our contract manufacturers to manufacture our products and product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an
        NDA or other similar application to the FDA. Such facilities must also register with the FDA. Similar requirements apply in other jurisdictions. We do not control the manufacturing process of, and are completely dependent on, our contract
        manufacturing partners for compliance with cGMP requirements for the manufacture of products and product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict
        regulatory requirements of the FDA or comparable non-U.S. regulatory authorities, we will not be able to secure or maintain regulatory approval for our products or product candidates. In addition, we have limited control over the ability of our
        contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable non-U.S. regulatory authorities do not approve these facilities for the manufacture of our products or product
        candidates or if they withdraw any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to market our products and develop, obtain regulatory approval for or market our
        product candidates, if approved.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our products and product candidates ourselves, including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>inability to meet our product specifications and quality requirements consistently;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>delay or inability to procure or expand sufficient manufacturing capacity;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>manufacturing and product quality issues related to scale-up of manufacturing;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>costs and validation of new equipment and facilities required for scale-up;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">62</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>failure to comply with applicable laws, regulations and standards, including cGMP and similar standards;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>deficient or improper record-keeping;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our
                products or product candidates in a timely fashion, in sufficient quantities or under acceptable terms;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier or other regulatory sanctions related to the
                manufacturer of another company&#8217;s product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>carrier disruptions or increased costs that are beyond our control; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>failure to deliver our products or product candidates under specified storage conditions and in a timely manner.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Any of these events could lead to clinical trial delays, cost overruns, delay or failure to obtain regulatory approval or impact our ability to successfully commercialize our products and product
        candidates as well as potential product liability litigation, product recalls or product withdrawals. Some of these events could be the basis for FDA or other regulatory authority action, including injunction, recall, seizure, total or partial
        suspension of production, or suspension or revocation of manufacturing/import authorizations and GMP certificates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If the contract manufacturing facilities on which we rely do not continue to meet regulatory requirements or are unable to meet our requirements, including providing an adequate
        supply, our business will be harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">All entities involved in the preparation of products and product candidates for clinical trials or commercial sale, including our existing CMOs for all of our products and product candidates, are
        subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP, or similar regulatory requirements outside the United
        States. These regulations govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale.
        Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our products and product candidates. Our failure, or the failure of third-party manufacturers, to comply
        with applicable regulations could result in the issuance of inspectional observations on FDA&#8217;s Form-483, Warning or Untitled Letters, similar communications or objections by other authorities, public safety alerts identifying our company or
        products and sanctions being imposed on us, including clinical holds, import alerts, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production, seizures or recalls of products
        or product candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect clinical or commercial supplies of our products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We and/or our CMOs must supply all necessary documentation in support of an NDA or similar regulatory application on a timely basis, and must adhere to regulations enforced by the FDA and other
        regulatory agencies through their facilities inspection program. Some of our CMOs have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The
        facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our products and product candidates. In
        addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our products and product candidates or the associated quality systems for compliance with the regulations applicable
        to the activities being conducted. Although we oversee the CMOs, we cannot control the manufacturing process of, and are completely dependent on, our CMO partners for compliance with the regulatory requirements. If these facilities do not pass a
        pre-approval plant inspection, regulatory approval of the products and product candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The regulatory authorities also may, at any time following approval of a product for sale, inspect the manufacturing facilities of our third-party contractors. If any such inspection or audit
        identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial
        measures that may be costly and/or time consuming for us or a third-party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such
        remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">63</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through a supplemental NDA or similar regulatory filing, which could
        result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. In some cases, the technical skills required to manufacture our products and product candidates may
        be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all.
        In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify,
        such as through a manufacturing comparability study, that any new manufacturing process will produce our product or product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays
        associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often involve changes in
        manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability
        of clinical supplies, which could require the conduct of additional clinical trials. Accordingly, switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our products and
        product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we
        could lose potential revenue.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Risks Related to Regulatory Approval and Commercialization of Our Products and Product Candidates</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or another regulator may delay, limit or deny approval. If we
        are unable to obtain regulatory approval in one or more jurisdictions for any products or product candidates, our business will be substantially harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Approval by the FDA and comparable non-U.S. regulatory authorities
        is lengthy and unpredictable, and depends upon numerous factors, including substantial discretion of the regulatory authorities. Approval policies, regulations, or the type and amount of nonclinical or clinical data necessary to gain approval may
        change during the course of a product candidate&#8217;s development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. While we have obtained regulatory approval in the U.S. for one of
        our product candidates, VTAMA, for the treatment plaque psoriasis in adults, it is possible that VTAMA will not obtain regulatory approval in the U.S. for other indications or in other jurisdictions, and that other current and future product
        candidates will not be successful in obtaining regulatory approval in the U.S. and other jurisdictions. In addition, we cannot be certain that any products or product candidates that receive regulatory approval will be successfully commercialized.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Obtaining marketing approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process and the FDA or other non-U.S. regulatory authorities may delay, limit or deny
        approval of a product candidate for many reasons, including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may not be able to demonstrate that a product candidate is safe and effective as a treatment for the targeted indications, and in the case of our product candidates regulated as biological products, that the product candidate is safe,
                pure and potent for use in its targeted indication, to the satisfaction of the FDA or other relevant regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may require additional pre-approval studies or clinical trials, which would increase costs and prolong development timelines;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA or other relevant regulatory authorities for marketing approval;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may disagree with the number, design, size, conduct or implementation of clinical trials, including the design of proposed preclinical and early clinical trials of any future product
                candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the CROs that we retain to conduct clinical trials may take actions outside of our control, or otherwise commit errors or breaches of protocols, that adversely impact the clinical trials and ability to obtain marketing approvals;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may not find the data from nonclinical, preclinical studies or clinical trials sufficient to demonstrate that the clinical and other benefits of a product candidate outweigh its safety
                risks;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">64</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may disagree with an interpretation of data or significance of results from nonclinical, preclinical studies or clinical trials or may require additional studies;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may not accept data generated at clinical trial sites, including in situations where the authorities deem that the data was not generated in compliance with GCP, ethical standards or
                applicable data protection laws;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>if an NDA, BLA or a similar application is referred for review by an advisory committee, the FDA or other relevant regulatory authority, as the case may be, may have difficulties scheduling an advisory committee meeting in a timely
                manner or the advisory committee may recommend against approval of our application or may recommend that the FDA or other relevant regulatory authorities, as the case may be, require, as a condition of approval, additional nonclinical,
                preclinical studies or clinical trials, limitations on approved labelling or distribution and use restrictions;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may require development of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) drug safety program or its equivalent, as a condition of approval;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may require additional post-marketing studies and/or patient registries for product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may find the chemistry, manufacturing and controls data insufficient to support the quality of our product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers; or</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the FDA or other relevant regulatory authorities may change their approval policies or adopt new regulations.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s
        concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical
        industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In
        support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval. The FDA also continues to develop and finalize guidance documents and implement initiatives
        regarding the development and clinical research of oncology product candidates. Indeed, the FDA issued Draft Guidance for Industry, Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases
        (January 2023), to assist sponsors in identifying the optimal dosages for these products during clinical development and prior to submitting an application for approval for a new indication and usage.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our future success depends significantly on our ability to successfully complete clinical trials for our product candidates, obtain regulatory approval and then successfully commercialize those
        product candidates. Any inability to successfully initiate, conduct or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our
        product candidates, we may be required to or we may elect to conduct additional nonclinical studies or clinical trials to bridge data obtained from our modified product candidates to data obtained from nonclinical and clinical research conducted
        using earlier versions of these product candidates. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our
        ability to successfully commercialize product candidates and may harm our business and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Delays in the initiation, conduct or completion of any clinical trial of our product candidates will increase our costs, slow down the product candidate development and approval process and delay
        or potentially jeopardize our ability to receive regulatory approvals, commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also
        ultimately lead to the denial of regulatory approval of our product candidates. Any of these events could have a material adverse effect on our business, prospects, financial condition and results of operations and have a negative impact on the
        price of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which
        would prevent, delay or limit the scope of regulatory approval and commercialization.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical studies, preclinical studies
        and clinical trials that the applicable product candidate is both safe and effective for use in each target indication, and in the case of our product candidates regulated as biological products, that the product candidate is safe, pure, and potent
        for use in its targeted indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">65</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product
        candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support additional
        marketing approvals.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our
        targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition,
        even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable non-U.S. regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates
        for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are
        not satisfactory to the FDA or comparable non-U.S. regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of
        potential approval of our product candidates. Even when regulatory approval is secured for a product or product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial
        potential.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our products and product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue
        clinical trials, abandon further development or limit the scope of any approved label or market acceptance.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Adverse events caused by or associated with our products and product candidates have caused us and could, in the future, cause us, other reviewing entities, clinical trial sites or regulatory
        authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events or new safety signals are reported in our clinical trials for our product
        candidates or any future product candidates, our ability to obtain regulatory approval for such product candidates may be negatively impacted. Treatment-related side effects arising from, or those perceived to arise from, our product candidates or
        those from other companies targeting similar diseases, could also affect patient recruitment or the ability of enrolled patients to complete their participation in our clinical trials or result in potential product liability claims. In addition,
        these side effects may not be appropriately recognized or managed by the treating medical staff. For example, as previously disclosed, in early 2021, our subsidiary Immunovant voluntarily paused dosing in early phase clinical studies for batoclimab
        to evaluate treatment-induced elevations in total cholesterol and LDL levels observed in some trial subjects. After evaluation of the available safety data and following discussions with multiple regulatory agencies, Immunovant is continuing its
        clinical development of batoclimab. While Immunovant does not expect that increases in LDL over a short-term treatment duration would pose a safety concern for patients, the risk-benefit profile of long-term administration of batoclimab will need
        to incorporate any unfavorable effects on lipid profiles. These occurrences have harmed, and any reoccurrence may continue to harm our business, financial condition and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Furthermore, if any of our products, or any future product candidates that are approved, cause serious or unexpected side effects, a number of potentially significant negative consequences could
        result, including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>regulatory authorities may withdraw, suspend, vary, or limit their approval of the product or require a REMS (or equivalent outside the United States) to impose restrictions on its distribution or other risk management measures;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>regulatory authorities may request or require that we recall a product;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>additional restrictions being imposed on the distribution, marketing or manufacturing processes of the products or any components thereof, including a &#8220;black box&#8221; warning or contraindication on product labels or communications containing
                warnings or other safety information about the product;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>regulatory authorities may require the addition of labelling statements, such as warnings or contraindications, require other labelling changes of a product or require field alerts or other communications to physicians, pharmacies or the
                public;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may be required to change the way a product is administered or distributed, conduct additional clinical trials, change the labelling of a product or conduct additional post-marketing studies or surveillance;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may be required to repeat preclinical studies or clinical trials or terminate programs for a product candidate, even if other studies or trials related to the program are ongoing or have been successfully completed;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may be sued and held liable for harm caused to patients, or may be subject to fines, restitution or disgorgement of profits or revenues;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>physicians may stop prescribing a product;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>reimbursement may not be available for a product;</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">66</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may elect to discontinue the sale of our products;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our products may become less competitive; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our reputation may suffer.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected products or product candidates, substantially increase the costs of commercializing our products
        or product candidates in the future and have a negative impact on the price of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">The regulatory approval processes of the FDA and comparable non-U.S. regulatory authorities are lengthy, time consuming and inherently unpredictable, and gaining approval for a
        product candidate in one country or jurisdiction does not guarantee that we will be able to obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Prior to obtaining approval to commercialize a product candidate in any jurisdiction, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to
        the satisfaction of the FDA or comparable non-U.S. regulatory authorities, that such product candidate is safe and effective and, as applicable, pure and potent for its intended use. Results from nonclinical studies and clinical trials can be
        interpreted in different ways. Even if we believe the nonclinical or clinical data for a product candidate are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. In order to market any
        products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval of a product candidate by the FDA does not ensure approval
        by regulatory authorities in any other country or jurisdiction outside the United States. In addition, clinical trials conducted in one country, and the data generated therefrom, may not be accepted by regulatory authorities in other countries, and
        regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation, as well as additional administrative review periods.
        Seeking regulatory approval could result in difficulties and costs for us and require additional nonclinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and
        could delay or prevent the introduction of our products in those countries. We have one product, VTAMA, which has been approved by the FDA for the treatment of plaque psoriasis in adults in the U.S., but do not have any other products approved for
        sale in the U.S. or any other jurisdiction, including in international markets, and we do not have significant experience in obtaining regulatory approval in other markets. If we fail to comply with regulatory requirements in international markets
        or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">FDA approval for a product candidate in the United States does not guarantee that we will be able to or that we will make efforts to obtain approval for or commercialize our
        product candidates in any other jurisdiction, which would limit our ability to realize the drug candidate&#8217;s full market potential.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We have one product, VTAMA, approved by the FDA for the treatment of plaque psoriasis in adults in the U.S. In order to market VTAMA or any of our other products or product candidates outside of
        the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other
        countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or
        different administrative review periods from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other
        jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be sold in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to
        approval.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Seeking regulatory approval outside of the United States could result in difficulties and costs and require additional nonclinical studies or clinical trials which could be costly and
        time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The regulatory approval process outside of the United States may include all
        of the risks associated with obtaining FDA approval. Other than VTAMA, we do not have any products or product candidates approved for sale in any jurisdiction, including international markets, and we do not have significant experience in obtaining
        regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market
        will be reduced and our ability to realize the full market potential of our products will be harmed.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">67</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Following regulatory approvals for our products and product candidates, we will continue to face extensive ongoing quality and regulatory obligations and continued regulatory
        review, which may result in significant additional expense, and our products may face future development and quality or regulatory compliance difficulties.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We have one product, VTAMA, approved by the FDA for the treatment of plaque psoriasis in adults in the U.S. Any product or product candidate for which we obtain marketing approval will be subject
        to extensive and ongoing regulatory requirements, including for manufacturing processes, post-approval clinical data, labelling, packaging, distribution, adverse event reporting, storage, recordkeeping, traceability, conduct of potential
        post-marketing studies and post-marketing submission requirements, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other
        regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment of registration and drug listing requirements, continued compliance with cGMP or equivalent requirements
        relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of drug product samples to physicians, prior notification/review and/or approval of
        advertising and promotional materials by the competent authorities, record-keeping and GCP requirements for any clinical trials that we conduct post-approval. Even when marketing approval of a product or product candidate is granted, the approval
        may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including any requirement to implement a REMS. When a product or product candidate receives marketing approval, the
        accompanying label may limit the approved use of the drug or the FDA or other regulatory authorities may require that contraindications, warnings or precautions, including in some cases, a boxed warning, be included in the product labelling or
        accompanying documentation, which could limit sales of the product.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The FDA and other relevant regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product.
        Failure to complete such post-marketing requirements in accordance with the timelines and conditions set forth by the FDA and other relevant regulatory authorities could significantly increase costs, result in regulatory enforcement, or delay,
        limit or ultimately restrict the commercialization of such product. The FDA and other relevant regulatory authorities closely regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications
        and in accordance with the provisions of the approved labelling and that promotional and advertising materials and communications are truthful and non-misleading. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice
        of drug treatment made in the physician&#8217;s independent medical judgment, regulatory authorities impose stringent restrictions on manufacturers&#8217; communications and if we do not market our products or product candidates for their approved indications
        or in a manner which regulators believe to be truthful and non-misleading, we may be subject to enforcement action. Moreover, in the EU and the UK we will be prohibited from promoting prescription-only medicinal products to individuals who are not
        healthcare professionals. Violations of the FDCA in the United States and other comparable laws and regulations in other jurisdictions relating to the promotion of prescription drugs may lead to enforcement actions and investigations by the FDA,
        Department of Justice, State Attorneys General and other comparable non-U.S. regulatory agencies alleging violations of United States federal and state health care fraud and abuse laws, as well as state consumer protection laws and comparable laws
        in other jurisdictions.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, later discovery of previously unknown adverse events or other problems with our products or product candidates, manufacturers or manufacturing processes, or failure to comply with
        regulatory requirements, may negatively impact our business and the price of our Common Shares and may yield various results, including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>restrictions on the manufacture of such products or product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>restrictions on the labelling or marketing of such products or product candidates, including a &#8220;black box&#8221; warning or contraindication on the product label or communications containing warnings or other safety information about the
                product;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>restrictions on product distribution or use;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>requirements to conduct post-marketing studies or clinical trials, or any regulatory holds on our clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>requirement of a REMS (or equivalent outside the United States);</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Warning or Untitled Letters or similar communications from other relevant regulatory authorities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>withdrawal of the product or product candidates from the market;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>refusal to approve pending applications or supplements to approved applications that we submit;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>recall of products or product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>fines, restitution or disgorgement of profits or revenues;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>suspension, variation, revocation or withdrawal of marketing approvals;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">68</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>refusal to permit the import or export of our products or product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>seizure of our products or product candidates; or</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>lawsuits, injunctions or the imposition of civil or criminal penalties.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Non-compliance by us or any current or future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance can also result in significant financial penalties.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our failure to maintain or continuously improve our quality management program could have an adverse effect upon our business, subject us to regulatory actions and cause
        patients to lose confidence in us or our products, among other negative consequences.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Quality management plays an essential role in the manufacturing of drugs or drug products, conducting clinical trials, preventing defects, improving our product candidates and services and assuring
        the safety and efficacy of our products and product candidates. We seek to maintain a robust quality management program which includes the following broad pillars of quality:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>monitoring and assuring regulatory compliance for clinical trials, manufacturing and testing of good applicable practice (&#8220;GxP&#8221;) (e.g., GCP, GLP and GMP regulated) products;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>monitoring and providing oversight of all GxP suppliers (e.g., contract development manufacturing organizations and CROs);</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>establishing and maintaining an integrated, robust quality management system for clinical, manufacturing, supply chain and distribution operations; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>cultivating a proactive, preventative quality culture and employee and supplier training to ensure quality.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in adverse inspection reports, warning letters,
        monetary sanctions, injunctions to halt manufacture and distribution of drugs or drug products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal,
        suspension or variation of existing approvals and licenses. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, or a loss of patient confidence in us or our products or product
        candidates, which may result in difficulty in successfully launching products and the loss of potential future sales, which could have an adverse effect on our business, financial condition, and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Breakthrough Therapy Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or Orphan Drug Designation by the FDA or other relevant regulatory
        authorities, even if granted for any product candidate, may not lead to a faster development, regulatory review or approval process, and does not necessarily increase the likelihood that any product candidate will receive marketing approval in the
        United States or other jurisdictions.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We have sought, or may in the future seek, Breakthrough Therapy Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or Orphan Drug Designation for certain of our
        product candidates. For example, in July 2021, Immunovant was granted orphan drug designation in the U.S. by the FDA for batoclimab for the treatment of MG and, in August 2022, it received orphan drug designation from the European Commission for
        batoclimab for the treatment of MG. Immunovant plans to seek orphan drug designation from the FDA for batoclimab and/or IMVT-1402 where there is a medically plausible basis for batoclimab and/or IMVT-1402&#8217;s use. Immunovant may also seek orphan drug
        designation for batoclimab and/or IMVT-1402 for the treatment of other indications in the E.U. We may also do so for other of our products and product candidates in the future where there is a basis for doing so.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and
        preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
        For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of
        patients placed on potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the
        discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a
        Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the
        FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that such product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will
        not be shortened.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">69</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Recently, there has been heightened scrutiny of the accelerated approval pathway, with some stakeholders advocating for reform. The HHS Office of Inspector General has initiated, and partly
        completed, an assessment of how the FDA implements the accelerated approval pathway. In addition, Section 3210 of the Consolidated Appropriations Act, 2023, revised the accelerated approval pathway. Although this legislation did not change the
        standard for accelerated approval, it, among other things, requires the FDA to specify the conditions for required post-marketing trials, permits the FDA to require such trials to be underway prior to, or within a specific period after, approval,
        requires sponsors to provide reports on post-marketing trial progress no later than 180 days after approval and every 180 days thereafter until such trials are completed, makes the failure to conduct required post-marketing trials with due
        diligence and the failure to submit the required reports prohibited acts, and details procedures the FDA must follow to withdraw an accelerated approval on an expedited basis. We understand that FDA approval letters to products granted accelerated
        approval subsequent to passage of this legislation are including language that informs the sponsor that they are required to submit status reports of the progress of each requirement no later than 180 days post-approval and every 180 days
        thereafter. At this time, it is not clear what impact, if any, these developments may have on our business, financial condition results of operations, or prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the therapy
        sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would
        decide to grant it. Even if we do receive Fast Track Designation, we may not necessarily experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes
        that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Regulatory authorities in some jurisdictions, including the United States and the European Economic Area (the &#8220;EEA&#8221;), may designate drugs and biologics for relatively small patient populations as
        orphan drugs. In the United States, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals annually
        in the United States or for which there is no reasonable expectation that costs of research and development of the drug for the disease or condition can be recovered by sales of the drug in the United States. Generally, if a product with an orphan
        drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing
        application for the same drug or biologic for the same orphan indication for that time period. In the United States, in order for a product to receive orphan drug exclusivity, FDA must not have previously approved a drug considered the same drug
        for the same orphan indication, or the subsequent drug must be shown to be clinically superior to such a previously approved same drug. The applicable period of marketing exclusivity is seven years in the United States. A similar market exclusivity
        scheme exists in the EEA. The European Commission, on the basis of a scientific opinion by the EMA&#8217;s Committee for Orphan Medicinal Products grants Orphan Drug Designation to promote the development of products that are intended for the diagnosis,
        prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of
        a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological
        product. In any event, Orphan Drug Designation is granted only if there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.
        Orphan designation in the EU entitles a party to certain benefits, such as scientific assistance (protocol assistance), financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological
        product approval. This orphan market exclusivity period prevents the European Commission, EMA and the competent authorities of the EU Member States from accepting an application or granting marketing authorization for any similar medicinal product
        intended for the same orphan indication. The orphan market exclusivity applies in parallel to the &#8220;normal&#8221; data and market exclusivity in the EEA, whereby no company can make reference to (rely on) the innovator drug company&#8217;s preclinical and
        clinical data in order to obtain a marketing authorization for eight years from the date of the first approval of the innovator drug in the EEA and no generic or biosimilar drug can be marketed for ten years from the first approval of the innovator
        drug in the EEA; the innovator drug may qualify for an extra year&#8217;s protection. This additional one year of marketing exclusivity may be obtained where the innovator company is granted, during the first eight years of the ten years market
        exclusivity, a marketing authorization for a significant new indication for the relevant medicinal product. In such a situation, the generic or biosimilar company can only market their product after 11 years from the first grant of the innovator
        company&#8217;s marketing authorization for the product in the EEA.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug
        or biologic to meet the needs of patients with the rare disease or condition. In the EEA, orphan drug designation, and the related benefits, may be lost if it is established before the market authorization is granted that the designation criteria
        are no longer met.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Moreover, the ten year orphan market exclusivity in the EEA may be reduced to six years if the orphan drug designation criteria are no longer met at the end of the fifth year since grant of the
        approval, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">70</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">On April 26, 2023, as part of the EU Pharmaceutical Strategy, the European Commission published a proposal for a comprehensive revision of the EU pharmaceutical legislation (which will not apply in
        the UK). If adopted by the European Parliament and the Council, the new legislation is likely to significantly change the regulatory regime applicable to both the &#8220;normal&#8221; data and market exclusivity and the orphan exclusivities and reduce/modulate
        the exclusivities and rewards that could be granted to medicinal products. In addition, the proposal envisages changes to the concept of unmet medical need and considers introducing novel rewards for orphan medicinal products addressing a high
        unmet medical need. The adoption of the new legislation is not expected before the end of 2024 and it will start to apply 18 months after the entry in force.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even
        after an orphan drug is approved, the FDA or the European Commission can subsequently approve the same drug for a different condition or the same condition if the FDA or the EMA concludes that the later drug is clinically superior in that it is
        shown to be safer, more effective or makes a major contribution to patient care. In the EEA, a marketing authorization may also be granted, for the same therapeutic indication, to a competitor with a similar medicinal product during the exclusivity
        period if we are unable to supply sufficient quantities of the medicinal product for which we received marketing authorization. Moreover, our orphan exclusivity may be reduced if we are unable to comply with any new obligation that may be imposed
        by the upcoming reform of the EU pharmaceutical legislation, as discussed above.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Moreover, a September 2021 Eleventh Circuit decision in Catalyst Pharmaceuticals, Inc. vs. Becerra regarding interpretation of the Orphan Drug Act exclusivity provisions as applied to drugs
        approved for orphan indications narrower than the drug&#8217;s orphan designation could significantly broaden the scope of orphan drug exclusivity for such products. In January 2023, the FDA, however, issued a Federal Register notice clarifying its
        approach to orphan drug exclusivity following the Catalyst decision. Consistent with the court&#8217;s decision, the FDA set aside its approval of the drug at issue in the case, but announced that, while complying with the court&#8217;s order in Catalyst, the
        FDA intended to continue to apply its regulations tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved to matters beyond the scope of that order. Legislation has also been introduced that may reverse
        the Catalyst decision.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Receipt of marketing approval for our products and product candidates does not guarantee that they will achieve market acceptance by physicians, patients, third-party payors or
        others in the medical community necessary for commercial success.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The commercial success of our products and product candidates will depend upon their degree of market acceptance by physicians, patients, third-party payors and others in the medical community.
        Receipt of marketing approval for our products and product candidates does not guarantee that they will gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market
        acceptance for any product or product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the efficacy and safety of such products and product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the potential and perceived advantages compared to alternative treatments, including any similar generic treatments;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the ability to offer these products for sale at competitive prices;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the ability to offer appropriate patient financial assistance programs, such as commercial insurance co-pay assistance;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>convenience and ease of dosing and administration compared to alternative treatments;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the clinical indications for which the product or product candidate is approved by FDA or comparable non-U.S. regulatory agencies;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>product labelling or product insert requirements of the FDA or other comparable non-U.S. regulatory authorities, including any limitations, contraindications or warnings contained in a product&#8217;s approved labelling;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>restrictions on how the product is dispensed or distributed;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the timing of market introduction of competitive products;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>publicity concerning these products or competing products and treatments;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the strength of marketing and distribution support;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>favorable third-party coverage and sufficient reimbursement; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the prevalence and severity of any side effects or adverse events.</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">71</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe,
        therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other
        physicians to prescribe such products.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If approved, our product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;Affordable Care Act&#8221; or &#8220;ACA&#8221;), includes a subtitle called the Biologics
        Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;), which created an abbreviated approval pathway under section 351(k) of the PHSA for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological
        product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the
        approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a
        competing version of the reference product if the FDA approves a full BLA for the competing product submitted under section 351(a) of the PHSA containing the competing sponsor&#8217;s own preclinical data and data from adequate and well-controlled
        clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA and the FDA only approved the first interchangeable biosimilar in July 2021.
        As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent
        Samples legislation, purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing
        generic drug, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biological product samples. Its provisions do have the potential to facilitate the development and future approval of biosimilar versions of our products,
        introducing biosimilar competition that could have a material adverse impact on our business, financial condition and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Whether approval of a biological product qualifies for reference product exclusivity turns on whether the FDA consider the approval a &#8220;first licensure.&#8221; Not every licensure of a biological product
        is considered a &#8220;first licensure&#8221; that gives rise to its own exclusivity period. We believe that our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that
        this exclusivity could be shortened due to congressional action or otherwise. The extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution
        for non-biological products is variable, and will depend on a number of marketplace and regulatory factors. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to
        competition from such biosimilars, with the attendant competitive pressure and consequences.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If we are unable to continue to expand our sales, marketing and distribution capabilities or enter into agreements with third parties to sell, market and distribute our products
        and product candidates, we may not be successful in commercializing those products and, if approved, product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are currently in the process of further building out our commercial sales organization for the sales, marketing and distribution of VTAMA, which was approved by the FDA in May 2022 for the
        treatment of plaque psoriasis in adults in the U.S. The costs of establishing and maintaining this infrastructure may exceed the cost-effectiveness of doing so. In order to effectively market our products and, if approved, product candidates, we
        must continue to expand our sales, distribution, marketing, compliance, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. To achieve commercial success for our products and, if
        approved, product candidates, we will need an effective sales and marketing organization or to outsource these functions to third parties. To the extent we seek to do so, there is no guarantee that we will be able to enter into collaborations or
        strategic partnerships with third parties to engage in commercialization activities with respect to our products or product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a
        sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product or, if approved, product candidate for which we recruit a sales force and establish marketing and
        other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or
        reposition commercialization personnel.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Factors that may inhibit our efforts to commercialize a product or, if approved, product candidate on our own include:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">72</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the inability to price products at a sufficient price point to ensure an adequate and attractive level of profitability;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>unforeseen costs and expenses associated with creating an independent commercialization organization.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of a product or, if approved, product candidate, we may be forced to delay
        commercialization or reduce the scope of our sales or marketing activities. If we elect to increase our expenditures to fund commercialization activities ourselves, we may need to obtain additional capital, which may not be available to us on
        acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring a product or, if approved, product candidate to market or generate product revenue. We could enter into arrangements with collaborative partners at an
        earlier stage than otherwise would be ideal and we may be required to relinquish certain rights to our products or product candidate or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating
        results and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenue or the profitability of product revenue may be lower
        than if we were to market and sell any products we may develop internally. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are
        favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively or may expose us to legal and regulatory risk by not adhering
        to regulatory requirements and restrictions governing the sale and promotion of prescription drug products, including those restricting off-label promotion. If we do not establish commercialization capabilities successfully, either on our own or in
        collaboration with third parties, we will not be successful in commercializing our products or, if approved, product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our current and future relationships with investigators, health care professionals, consultants, third-party payors, patient support, charitable organizations, customers, and
        others are subject to applicable healthcare regulatory laws, which could expose us to penalties and other risks.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our business operations and current and potential future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient support, charitable organizations,
        customers, and others, expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws regulate the business or financial arrangements and relationships through which we conduct our operations, including how we
        research, market, sell and distribute our products and, if approved, product candidates. Such laws include, without limitation:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the federal Anti-Kickback Statute, which is a criminal law that prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash
                or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under
                a federal healthcare program (such as Medicare and Medicaid). The term &#8220;remuneration&#8221; has been broadly interpreted by the federal government to include anything of value. Although there are a number of statutory exceptions and regulatory
                safe harbors protecting certain activities from prosecution, the exceptions and safe harbors are drawn narrowly, and arrangements may be subject to scrutiny or penalty if they do not fully satisfy all elements of an available exception or
                safe harbor. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person or entity
                does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a
                violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $100,000 for each
                violation. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines and imprisonment of up to 10 years. Similarly, violations can
                result in exclusion from participation in government healthcare programs, including Medicare and Medicaid;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">73</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the federal false claims laws, including the False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented,
                to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim; or knowingly making or causing to be
                made, a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and
                penalties currently ranging from $13,508 to $27,018 for each false claim or statement for penalties assessed after January 30, 2023, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal
                healthcare programs;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the federal health care fraud statute (established by Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;)), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or
                attempting to execute, a scheme to defraud any healthcare benefit program or making false or fraudulent statements relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual
                knowledge of the statute or specific intent to violate it to have committed a violation;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Administrative Simplification provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, which impose obligations, including mandatory
                contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information on health plans, health care clearing houses and most healthcare providers (collectively, &#8220;covered
                entities&#8221;), and such covered entities&#8217; &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on
                behalf of the covered entity;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>various privacy, cybersecurity and data protection laws, rules and regulations at the international, federal, state and local level, which impose obligations with respect to safeguarding the privacy, security, and cross-border
                transmission of personally identifiable data, including personal health information;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1) knowingly presenting, or causing to be presented,
                a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal health care programs to provide
                items or services reimbursable by a federal health care program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with
                certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians, certain other healthcare providers, and teaching hospitals, and requires applicable manufacturers and
                group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician
                owners (covered manufacturers are required to submit reports to the government by the 90th day of each calendar year); and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>analogous state and EU and foreign national laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing
                arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or otherwise restrict payments that may be made to healthcare providers and other potential
                referral sources; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and state laws that
                require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and several recently passed state laws that require disclosures
                related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes, some of which contain ambiguous requirements that government officials have
                not yet clarified; and EU and foreign national laws prohibiting promotion of prescription-only medicinal products to individuals other than healthcare professionals, governing strictly all aspects of interactions with healthcare
                professionals and healthcare organizations, including prior notification, review and/or approval of agreements with healthcare professionals, and requiring public disclosure of transfers of value made to a broad range of stakeholders,
                including healthcare professionals, healthcare organizations, medical students, physicians associations, patient organizations and editors of specialized press.</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">74</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible
        that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of
        any of these or any other applicable health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines,
        disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting
        requirements and oversight if we become subject to a corporate integrity agreement or similar agreement and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of
        operations. Even the mere issuance of a subpoena, civil investigative demand or the fact of an investigation alone, regardless of the merit, may result in negative publicity, a drop in our share price and other harm to our business, financial
        condition and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that
        may be brought against us, our business may be impaired.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Healthcare legislative and regulatory measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The United States and many other jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could restrict or regulate post-approval activities
        for our products and affect our ability to profitably sell our products, and prevent or delay marketing approval of our current and any future product candidates. Changes in regulations, statutes or the interpretation of existing regulations could
        impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labelling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping
        requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs, including costs for pharmaceuticals. For example, in March 2010, the ACA
        was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential
        competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the
        minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain
        branded prescription drugs, and created a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their
        coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. However, effective January 1, 2025, this program will be replaced as a part of the Part D benefit redesign enacted under the Inflation
        Reduction Act of 2022 (&#8220;IRA&#8221;).</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and
        amendments to the ACA in the future, with unpredictable and uncertain results. During previous Congressional sessions, Congress had introduced several pieces of legislation aimed at significantly revising or repealing the ACA and may in the future
        consider legislation to replace, modify or augment elements of the ACA.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created
        measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals,
        thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent legislative
        amendments, will remain in effect through the first six months of 2032 unless additional Congressional action is taken. However, the Medicare sequester reductions under the Budget Control Act were suspended from May 1, 2020 through March 31, 2022
        due to the COVID-19 pandemic. There was a 1% reduction through the end of June 2022, after which the cuts returned to 2%. Absent further Congressional action, there is a possibility that an up to 4% Medicare sequester could be triggered in January
        2025, pursuant to the Statutory Pay-As-You-Go Act of 2010 (&#8220;PAYGO&#8221;). Under PAYGO, if the five- or ten-year PAYGO scorecard shows a net cost at the end of a Congressional session, then the Office of Management and Budget is required to issue a
        sequestration order. The American Rescue Plan Act of 2021 was expected to trigger a PAYGO sequestration order at the end of the 2021 Congressional session. However, subsequent legislation has delayed a Statutory PAYGO sequestration order until
        after 2024.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">75</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries
        and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and reform government program reimbursement methodologies for drugs. In July
        2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take
        actions to lower drug prices and promote generic competition. Moreover, in August 2022, Congress enacted the IRA, a law with sweeping changes to the payment of drugs under the Medicare program. Among other provisions, the IRA contains (i) a drug
        price negotiation program for certain high spend Medicare drugs that have been on the market for a certain length of time and lack generic or biosimilar competition under which Medicare prices for such drugs are capped by a &#8220;maximum fair price&#8221;;
        (ii) new manufacturer rebate obligations on certain drugs paid under Medicare Part B or D whose prices increase faster than inflation relative to a benchmark period; and (iii) a redesign of the Part D benefit, including capping patients&#8217; annual
        out-of-pocket costs on Part D drugs, lowering the beneficiary out-of-pocket threshold, streamlining the Part D benefit to eliminate the &#8220;coverage gap&#8221; phase, and replacing the manufacturer coverage gap discount program with a new manufacturer
        discount program that provides discounts throughout the post-deductible benefit phases. There are several ongoing legal challenges to the IRA&#8217;s drug price negotiation program, and we cannot predict the outcome of these cases or the impact they
        could have on implementation of the law. Further, CMS has begun to implement aspects of the IRA, including issuing final guidance describing drug negotiation, inflationary rebates, and Part D redesign, and selecting Part D drug products for the
        initial rounds of negation, which ultimately will result in the establishment of maximum fair prices effective in 2026. Over time, the IRA could increase our government discount and rebate liabilities, reduce the revenues we are able to collect
        from sales of our products as well as present challenges for payor negotiations and formulary access; however, the degree of impact that the IRA will ultimately have upon our business remains unclear.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">It is possible that Congress or the Administration may take further actions to control drug prices. In October 14, 2022, President Biden issued an executive order calling on the Secretary to
        consider whether to select for testing by the CMS innovation center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid
        programs, including models that may lead to lower cost-sharing for commonly used drugs and support value-based payment that promotes high-quality care. In response, the CMS innovation center released a report in February 2023, identifying three
        selected models: Medicare High-Value Drug Model, the Cell &amp; Gene Therapy Access Model, and the Accelerating Clinical Evidence Model. We cannot predict how these new provisions would be implemented or their impact on Roivant. Moreover, several
        states have passed, or are considering, legislation related to drug price transparency or controlling drug costs. For example, some state legislatures have established Prescription Drug Affordability Boards (&#8220;PDABs&#8221;), which under certain
        circumstances may conduct affordability reviews and establish upper payment limits for drugs purchased in the state. On August 4, 2023, the Colorado PDAB commenced an affordability review of five prescription drugs, including three products that
        are indicated to treat plaque psoriasis (ENBREL<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, COSENTYX<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, STELARA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>). We cannot predict the outcome of this affordability review, whether the Colorado PDAB will establish upper payment limits for one or more of these drugs, or the
        impact of any such upper payment limit on utilization of VTAMA. We may continue to see additional state action related to prescription drug pricing.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Additionally, U.S. regulators continue to pursue policies designed to lower drug costs for federal programs and patients. In May 2019, the CMS, issued a final rule to allow Medicare Advantage Plans
        the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020. Additionally, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
        manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. This rulemaking also created a new safe harbor for price reductions reflected at the point-of-sale, as
        well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. However, Congress has adopted various delays on the implementation or enforcement of the rule, including a postponement until January 2032
        under the IRA. On December 31, 2020, CMS enacted a final rule that, among other things, expanded the scope of drug products that may be considered &#8220;line extensions&#8221; subject to inflationary rebates under the Medicaid Drug Rebate Program. On May 23,
        2023, CMS issued a Medicaid Drug Rebate Program proposed rule, which if finalized, would, among other things, require drug manufacturers to aggregate certain price concessions when calculating Best Price, establish a price verification survey, and
        amend the definitions of a &#8220;covered outpatient drug&#8221; and a &#8220;manufacturer.&#8221; These changes, if finalized, could deepen rebates owed on Medicaid utilization, expand the scope of products subject to Medicaid rebates, and subject manufacturer drug
        pricing practices to further scrutiny.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Moreover, upcoming legislative and policy changes in the EU and the UK, some of which may materialize in the near term, are aimed at increasing accessibility and affordability of medicinal
        products, as well as at increased cooperation between the EU Member States. Such initiatives may further impact the price and reimbursement status of our products in the future.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the national and state levels in jurisdictions around the world directed at containing or lowering the cost
        of healthcare, including prescription drugs. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability through product revenue, or commercialize our products
        and, if approved, our product candidates. Such reforms could have an adverse effect on anticipated revenue from our products and, if approved, product candidates and may affect our overall financial condition and ability to develop future product
        candidates and obtain marketing approval for those product candidates. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors
        of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the demand for our products and, if approved, product candidates;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to receive or set a price that we believe is fair for our products;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our ability to generate revenue and achieve sustained profitability;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">76</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the amount of taxes that we are required to pay; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the availability of capital.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We expect that healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower
        reimbursement and new payment methodologies. This could lower the price that we receive for our products and, if approved, product candidates. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs
        may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain sustained profitability or successfully commercialize our products and, if approved, product
        candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Coverage and adequate reimbursement may not be available for our products and, if approved, product candidates, which could make it difficult for us to profitably sell our
        products and, if approved, product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Market acceptance and sales of our products and, if approved, product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and product
        candidates and related treatments will be available from third-party payors, including government health administration authorities and private health insurers. The pricing and reimbursement of our products and, if approved, product candidates,
        must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our products and, if approved, product candidates, will be adversely affected. The
        manner and level at which reimbursement is provided for services related to our products and product candidates (e.g., for administration of our products to patients) is also important. Inadequate reimbursement for such services may lead to
        physician resistance and adversely affect our ability to market or sell our products and, if approved, product candidates. There is no assurance that our products or, if approved, product candidates, would achieve adequate coverage and
        reimbursement levels.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In the United States, no uniform policy of coverage and reimbursement exists among third-party payors. Third-party payors decide which drugs they will pay for and establish reimbursement levels.
        Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any
        product or, if approved, product candidate will be made on a plan-by-plan basis. For example, while we have previously disclosed successes in achieving payor coverage for VTAMA, one payor&#8217;s determination to provide coverage for a product does not
        assure that other payors will also provide coverage, and adequate reimbursement, for the product. Discussions with payors, including PBMs, related to VTAMA are ongoing and whether such payors will provide coverage for VTAMA, and if so to what
        extent, is uncertain at this time. Additionally, a third-party payor&#8217;s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Each plan determines whether or not it will provide coverage for a
        drug, what amount it will pay the manufacturer for the drug, on what tier of its formulary the drug will be placed and whether to require step therapy. The position of a drug on a formulary generally determines the co-payment that a patient will
        need to make to obtain the drug and can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors
        to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our product or, if approved, product candidates, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of the
        product or product candidate. Further, from time to time, typically on an annual basis, payment rates are updated and revised by third-party payors. Such updates could impact the demand for our products or, if approved, product candidates, to the
        extent that patients who are prescribed our products or, if approved, product candidates, are not separately reimbursed for the cost of the product.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement
        rate that such a payor will pay for the product. Even if we obtain adequate levels of reimbursement, third-party payors, such as government or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge
        the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list
        prices and are challenging the prices for products. We may also be required to conduct expensive pharmacoeconomic studies to justify the coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and
        reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any product or, if
        approved, product candidate. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any product or, if approved, product candidate that we develop.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Additionally, there have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some other jurisdictions that could affect our ability to
        profitably sell any product or, if approved, product candidate. These legislative and regulatory changes may negatively impact the reimbursement for any product or, if approved, product candidate. There can be no assurance that our products or, if
        approved, product candidates, will be considered medically reasonable and necessary, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available, or that reimbursement
        policies and practices in the United States and in other countries where our products and, if approved, product candidates, are sold will not harm our ability to profitably sell our products and, if approved, product candidates.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">77</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our products or, if approved, product candidates. In addition to continuing
        pressure on prices and cost containment measures, legislative developments in the EU or the EU Member States may harm our ability to profitably sell our products and, if approved, product candidates. The delivery of healthcare in the EU, including
        the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national EU Member States law. National governments and health service providers have different priorities and
        approaches to the delivery of health care and the pricing and reimbursement of products in that context. The healthcare budgetary constraints in most countries have resulted in restrictions on the pricing and reimbursement of medicines, and a
        similar approach is taken in the UK where a key consideration is the affordability of drugs for treatment of patients under the National Health Service. In the UK there is also a budget cap on branded health service medicines, and a new voluntary
        pricing scheme has been introduced that increases the level of rebate payment that a company is required to make to the National Health Service to take account of any spend on branded products that is above the agreed cap, and also imposes
        different payment rates for newer or older medicines. A consultation on the parallel statutory scheme, which applies to companies that are not members of the voluntary scheme, is ongoing, but is also likely to lead to higher rebates than
        previously. In markets outside of the United States, EU and UK, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. All of this could
        affect our ability to commercialize our products and, if approved, product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Recent federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign
        countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We may face competition in the United States for our products and, if approved, product candidates, from therapies sourced from foreign countries that have placed price controls on pharmaceutical
        products. In the United States, the Medicare Modernization Act (&#8220;MMA&#8221;) contains provisions that may change U.S. importation laws and expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products
        from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety
        and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the Secretary of HHS made such certification to Congress, and on October 1, 2020, the FDA published a final rule that allows for the importation
        of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the
        issuance of the final rule, on November 23, 2020, several industry groups filed federal lawsuits in the U.S. District Court for the District of Columbia, requesting injunctive relief to prevent implementation of the rule. The court dismissed the
        case in February 2023. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal
        rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will
        not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code (&#8220;NDC&#8221;), for an FDA-approved drug that
        was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. In addition, the July 2021 executive order pertaining to drug pricing directs the FDA to support and work with States and Indian
        Tribes to develop importation plans to import prescription drugs from Canada under the MMA and final rule. Several states have enacted laws intended to support importation processes and have submitted importation program proposals to FDA. On
        January 5, 2024, FDA authorized Florida&#8217;s importation program for the importation of certain prescription drugs from Canada into Florida; however, the state must file Pre-Import Requests for specific drug products that FDA must grant before any
        importation may take place.&#160; In response, Health Canada issued a statement on January 8, 2024 making clear that it is ready to take immediate action to help safeguard the Canadian drug supply if necessary.&#160; If implemented in Florida or elsewhere,
        importation of drugs from Canada may materially and adversely affect the price we receive for our products and, if approved, product candidates. The regulatory and market implications of the final rule and guidance are unknown at this time.
        Proponents of drug reimportation may attempt to pass other legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we
        receive for our products and, if approved, product candidates and adversely affect our future revenues and prospects for profitability.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">78</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Other Risks Related to Our Business and Industry</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We depend on the knowledge and skills of our senior leaders and may not be able to manage our business effectively if we are unable to attract and retain key personnel.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We have benefited substantially from the leadership, performance and vision of our senior leaders, including our Principal Executive Officer, Matthew Gline, as well as other senior executives at
        Roivant and the Vants. We rely greatly on the investment experience and medical and scientific expertise of our senior leadership team to identify product candidates and guide future investments and opportunities, as well as the drug development
        expertise of our and the Vants&#8217; senior leadership to guide the preclinical and clinical development of our product candidates. Our success will depend on our ability to retain our current management team. In addition, while we expect to engage in
        an orderly transition process as we integrate newly appointed officers and managers, we face a variety of risks and uncertainties related to management transition, including diversion of management attention from business concerns, failure to
        retain other key personnel or loss of institutional knowledge. Competition for senior leadership in the healthcare investment industry is intense, and we cannot guarantee that we will be able to retain our key personnel or that of our Vants.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our senior leaders and key employees may terminate their positions with us at any time. Due to the small number of employees at some of the Vants, the loss of a key employee may have a larger
        impact on our business. In particular, we rely on a limited number of employees in certain key jurisdictions, including the United Kingdom (the &#8220;U.K.&#8221;) and Switzerland. If we lose one or more members of our or the Vants&#8217; senior leadership teams or
        other key employees, our ability to successfully implement our business strategies could be adversely impacted. Replacing these individuals may be difficult, cause disruption and may take an extended period of time due to the limited number of
        individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable
        to hire, train, retain or motivate additional key personnel. We do not maintain &#8220;key person&#8221; insurance for any members of our senior leadership team or other employees.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided certain equity awards that vest over time. The value to employees of equity
        awards that vest over time may be significantly affected by movements in our share price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain
        invaluable employees, members of our management, scientific and development teams may terminate their employment with us at any time. Although we have employment agreements with our key employees, certain of these employment agreements provide for
        at-will employment, which means that any of our employees could leave our employment at any time. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as
        junior, mid-level and senior scientific and medical personnel.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We will need to expand our organization and may experience difficulties in managing this growth, which could disrupt operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In connection with our continued growth, we expect to hire, either directly or through our current or future affiliates, additional employees for our managerial, finance and accounting, clinical,
        scientific and engineering, regulatory, operational, manufacturing, sales and marketing teams. We may have difficulties in connection with identifying, hiring, integrating and retaining new personnel. Future growth would impose significant
        additional responsibilities on management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, management may need to divert a disproportionate amount of its attention
        away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of operations across our entities, which may result in weaknesses in
        infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our future growth could require significant capital expenditures and may divert financial
        resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced,
        and we may not be able to implement our business strategy. Our future financial performance and ability to commercialize product candidates and new technologies and compete effectively will partly depend on our ability to effectively manage any
        future growth.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Many of the other pharmaceutical and healthcare technology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk
        profiles and a longer operating history in the industry than us. They also may provide more diverse opportunities and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates and
        consultants than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop our products and product candidates will be harmed, which
        could negatively impact our financial condition, results of operations and cash flows.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our international operations may expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business globally.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Part of our business strategy involves potential expansion internationally with third-party collaborators to seek regulatory approval for our products and product candidates globally. Doing
        business internationally involves a number of risks, including but not limited to:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>multiple conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and
                licenses;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>failure by us or our collaborators to obtain appropriate licenses or regulatory approvals for the sale or use of our products or, if approved, product candidates, in various countries;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">79</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>difficulties in managing operations in different jurisdictions;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>complexities associated with managing multiple payor-reimbursement regimes or self-pay systems;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to currency exchange rate fluctuations;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>varying protection for intellectual property rights;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>failure to comply with the United States Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), including its books and records provisions and its anti-bribery provisions, the United Kingdom Bribery Act 2010 (the &#8220;U.K. Bribery Act&#8221;), and similar
                anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#8217; activities.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our financial condition, results of operations
        and cash flows.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Unfavorable global and regional economic, political and health conditions could adversely affect our business, financial condition or results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our business could be adversely affected by global or regional economic, political and health conditions. For example, various macroeconomic factors could adversely affect our business, financial
        condition and results of operations, including changes in inflation, interest rates and overall economic conditions and uncertainties, including those resulting from political instability (including workforce uncertainty), international hostilities
        (including the current military conflicts&#160; between Russia and Ukraine and in the Middle East), trade disputes between nations and the current and future conditions in the global financial markets. For example, if sustained high rates of inflation
        or other factors were to significantly increase our business costs, we may be unable to manage such increased expenses or pass through price increases. A global financial crisis or global or regional political and economic instability, wars,
        terrorism, civil unrest, outbreaks of disease (for example, COVID-19), and other unexpected events, such as supply chain constraints or disruptions, could cause extreme volatility in the capital and credit markets and disrupt our business. Business
        disruptions could include, among others, disruptions to our commercial activities, including due to supply chain or distribution constraints or challenges, clinical enrollment, clinical site availability, patient accessibility, and conduct of our
        clinical trials, as well as temporary closures of the facilities of suppliers or contract manufacturers in the biotechnology supply chain. In addition, during certain crises and events, patients may prioritize other items over certain or all of
        their treatments and/or medications, which could have a negative impact on our commercial sales. A severe or prolonged economic downturn, political disruption or adverse health conditions could result in a variety of risks to our business,
        including our ability to raise capital when needed on acceptable terms, if at all. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions
        could adversely impact our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve certain regulatory
        approvals before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize our products and, if approved, product candidates and ultimately
        harm our financial condition.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The development and commercialization of new drug products is highly competitive. Now and in the future we may face competition from major pharmaceutical companies, specialty pharmaceutical
        companies and biotechnology companies worldwide with respect to our products and product candidates. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct
        research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development and commercialization of products and product candidates for the treatment of the
        indications that we are also pursuing. Examples of such competing products include, but are not limited to:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>ZORYVE (roflumilast), a topical PDE4 inhibitor, a potential competitor to VTAMA;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>OPZELURA (ruxolitinib), a topical Janus kinase inhibitor, a potential competitor to VTAMA;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), neonatal Fc receptor blockers, potential competitors to batoclimab and IMVT-1402;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Nipocalimab and RYSTIGGO (rozanolixizumab-noli), anti-FcRn antibodies, potential competitors to batoclimab and IMVT-1402;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>TEPEZZA (teprotumumab-trbw), an insulin-like growth factor-1 receptor inhibitor, a potential competitor to batoclimab; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>SOTYKTU (deucravacitinib), a TYK2 inhibitor, a potential competitor to brepocitinib.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing,
        preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">80</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete
        with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our
        programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than our
        products and product candidates. Furthermore, currently approved products could be discovered to have application for treatment of our targeted disease indications or similar indications, which could give such products significant regulatory and
        market timing advantages over our products and product candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from
        the FDA for indications that we are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our
        products or product candidates uneconomical or obsolete and we may not be successful in marketing our products or, if approved, any product candidates we may develop against competitors.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our
        competitors may allege that our products or product candidates infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for
        our products and, if approved, any product candidates we may develop.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">The markets in which our healthcare technology Vants participate are competitive, and if we do not compete effectively, our business and operating results could be adversely
        affected.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The overall market for healthcare technologies and software is global, rapidly evolving, competitive and subject to changing technology and shifting customer focus. Our healthcare technology Vants,
        including Lokavant, a clinical trial technology company, and VantAI, which uses machine learning to build computational models to generate new molecular entities for targets of interest, face competition from well-established providers of similar
        solutions, certain of which may have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. We also face competition from solutions that biopharmaceutical companies develop
        internally and from smaller companies that offer products and services directed at more specific markets than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, as well as a
        large number of companies that have been founded with the goal of applying machine learning technologies to drug discovery.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Many of our competitors are able to devote greater resources to the development, promotion, and sale of their software solutions and services. Third parties with greater available resources and the
        ability to initiate or withstand substantial price competition could acquire our current or potential competitors. Our competitors may also establish cooperative relationships among themselves or with third parties that may further enhance their
        product offerings or resources. If our competitors&#8217; products, services or technologies become more accepted than our solutions, if our competitors are successful in bringing their products or services to market earlier than ours, if our competitors
        are able to respond more quickly and effectively to new or changing opportunities, technologies, or customer requirements, or if their products or services are more technologically capable than ours, then the business and prospects of these Vants
        could be adversely affected.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, we are facing increasing competition from other companies that are utilizing artificial intelligence (&#8220;AI&#8221;) and other computational approaches for drug discovery. Some of these
        competitors are involved in drug discovery themselves and/or with partners, and others develop software or other tools utilizing AI which can be used, directly or indirectly, in drug discovery. To the extent these other AI approaches to drug
        discovery prove to be more successful than our approaches, we may not be successful in identifying potential targets or attracting collaborators to work with us.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We and our subsidiaries are subject to litigation and investigation risks which could adversely affect our business, results of operations and financial condition and could
        cause the market value of our Common Shares to decline. Insurance coverage may not be available for, or adequate to cover, all potential exposure for litigation and other business risks.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We and our subsidiaries are from time to time subject to various litigation matters and claims, including regulatory proceedings, administrative proceedings, securities litigation and other
        lawsuits, and governmental investigations. In addition, we and our subsidiaries may receive requests for information from governmental agencies in connection with their regulatory or investigatory authority or from private third parties pursuant to
        subpoena. These proceedings may be complex and prolonged, and may occupy the resources of our and our subsidiaries&#8217; management and employees. These proceedings are also costly to prosecute and defend and may involve substantial awards or damages
        payable by us or our subsidiaries if not favorably resolved. We and our subsidiaries may be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings. We also face risks relating to
        litigation arising from judgments made by us and the Vants as to the materiality of any developments in our businesses, including with respect to preclinical and clinical data, and the resulting disclosure (or lack thereof) may give rise to
        securities litigation.<br/>
        <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">81</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">We maintain insurance policies for certain litigation and various business risks, but such policies may not be adequate to compensate us for any or all potential losses. In addition, such insurance
        may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance, if available, may not cover all claims made against us and defending a suit, regardless of its merit, could be costly and divert
        management&#8217;s attention. Because of the uncertain nature of litigation, investigations and insurance coverage decisions, it is not possible to predict the outcome of these matters as they arise from time to time, and they could have a material
        adverse effect on our and our subsidiaries&#8217; business, results of operations, and financial condition, could impact our ability to consummate a transaction that is challenged or otherwise subject to such litigation and could cause the market value
        of our Common Shares to decline.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may not hold a controlling stake in certain of our Vant affiliates and thus may not be able to direct our business or the development of our product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In certain of our Vants, we may hold less than a majority ownership interest or otherwise be limited in our ability to direct or control the business and the development of the product candidates
        or technologies at the Vant. In addition, for certain other Vants, including Immunovant, we may in the future come to hold less than a majority ownership interest in the Vant. Furthermore, even if we own a majority ownership interest in a Vant, we
        may not necessarily be able to control the outcome of certain corporate actions. If the business or development of a product candidate at one of these Vants were to face challenges, we would be adversely affected as a result and would be limited in
        our ability to cause or influence the Vant in question to take appropriate remediative actions.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cyber-security protections.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our computer systems, as well as those of various third parties on which we presently rely, or may rely on in the future, including our CROs and other contractors, consultants, and law and
        accounting firms, may sustain damage from or otherwise be subject to computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and
        telecommunication and electrical failures. Such information technology systems are additionally vulnerable to security breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business
        partners, and/or other third parties. Any of the foregoing may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants, or lead to data leakage. The risks of a security breach or disruption,
        particularly through cyber-attacks or cyber intrusion, including by traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation-state and nation-state-supported actors, sovereign governments and
        cyber terrorists, have generally increased over time, including for geopolitical reasons and in conjunction with military conflicts and defense activities, along with the number, intensity and sophistication of attempted attacks and intrusions from
        around the world. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations,
        supply chain and ability to produce, sell and distribute our products and product candidates. Currently and in the coming years, there may be an increased risk of cybersecurity attacks due to the Russian invasion of Ukraine, including cybersecurity
        attacks perpetrated by Russia or others at its direction in response to economic sanctions and other actions taken against Russia as a result of the invasion. Any increase in such attacks on us or our third-party vendors or other systems could
        adversely affect our network systems or other operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We generally require our third-party providers to implement effective security measures and to identify and correct for any information technology security failures, deficiencies or breaches.
        Although we seek to supervise such third parties&#8217; security measures, our ability to do so is limited. If the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security
        breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such incidents and to develop and implement protections to prevent future events of this nature from
        occurring.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We cannot anticipate all possible types of security threats and we cannot guarantee that our data protection efforts and our investments in information technology will prevent significant
        breakdowns, data leakages, security breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or
        financial condition. If a significant cybersecurity compromise were to occur, it could result in a material disruption of our commercialization efforts, drug development programs, and other business operations. For example, the loss of nonclinical
        or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we rely on third parties to supply
        components for and to manufacture our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security
        breach were to result in a loss of or damage to our data or applications, or in an unauthorized disclosure of personal, confidential or proprietary information, we could incur liability and reputational damage and the commercialization efforts for
        our products and further development of any product candidate could be delayed. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">82</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We are subject to stringent privacy, data protection and information security laws, regulations, policies and contractual obligations related to data privacy and security and
        changes in such laws, regulations, policies and contractual obligations could adversely affect our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things,
        impose requirements relating to the privacy, security, transmission and disposal of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide. Failure to comply
        with applicable privacy and data security laws and regulations could result in enforcement actions against us, including possible fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our
        reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">There are numerous U.S. federal and state laws and regulations related to the privacy, data protection and security of personal information. At the federal level, regulations promulgated pursuant
        to HIPAA establish privacy and security standards for &#8220;covered entities&#8221; (group health plans and most healthcare providers) that limit the use and disclosure of individually identifiable health information those entities and their service providers
        receive or create (&#8220;protected health information&#8221;), and require the implementation of administrative, physical and technological safeguards to protect the security, confidentiality, integrity and availability of electronic protected health
        information. While we generally are not subject to the HIPAA privacy or security regulations, we do business with various entities (including clinical trial investigators) that are subject those regulations, and we have to expend resources to
        understand their obligations, adjust contractual terms in light of those obligations, or otherwise modify our business practices. Congress is actively considering adopting legislation to regulate the collection, use, and disclosure of personal
        health information more broadly than the HIPAA privacy and security regulations. Such legislation might require us to make substantial expenditures and would likely create additional liability risks.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The Federal Trade Commission (&#8220;FTC&#8221;) Act, while not focused on data privacy or security, has proven to be a significant federal enforcement tool with respect to protection of personal information,
        and recently, personal health information in particular. The FTC has used its authority under Section 5 of the FTC Act, which prohibits unfair and deceptive practices affecting consumers, to bring numerous cases against companies for failing to
        protect the privacy or security of personal information in a manner that is reasonable and fully consistent with stated privacy policies, notices, or other representations. Particularly because the FTC has taken these actions based on theories that
        are not codified in regulations, the optimal means to mitigate the risk of such an action are uncertain.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, many U.S. states in which we operate have laws that protect the privacy and security of personal information. Certain state laws may be more stringent or broader in scope, or offer
        greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, which complicates compliance efforts. For example, the California Confidentiality of Medical
        Information Act (the &#8220;CMIA&#8221;), a statute that expressly applies to pharmaceutical companies (as well as companies that provide certain technologies for processing personal health information), imposes stringent data privacy and security requirements
        and obligations with respect to the personal health information of California residents. Among other things, the CMIA, with limited exceptions, requires that a pharmaceutical company obtain a signed, written authorization from a patient or company
        employee in order to disclose his or her personal health information and requires pharmaceutical companies to maintain reasonable security measures to protect such information. The CMIA authorizes administrative fines and civil penalties of up to
        $25,000 for willful violations and up to $250,000 if the violation is for purposes of financial gain, as well as criminal fines. In addition, another more broadly applicable California law, the California Consumer Privacy Act of 2018, as amended by
        the California Privacy Rights Act of 2020 (the &#8220;CPRA&#8221;, and collectively, the &#8220;CCPA&#8221;) generally requires us to provide notice to California residents (including business and vendor contacts residing in California) regarding our collection, use, and
        sharing of their personal information.&#160; The CCPA also gives California residents the right to opt-out of the sale or sharing for targeted advertising of their personal information, as well as the right to limit more generally our use and disclosure
        of their &#8220;sensitive&#8221; (including health) personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data security breaches that result in the compromise of highly sensitive personal
        information, which may increase the likelihood of, and risks associated with, data breach litigation. Both the California Attorney General and the California Privacy Protection Agency, have authority to implement and enforce the CCPA. California&#8217;s
        aggressive steps to protect consumer privacy have been followed by similar actions in the legislatures of other states, including Colorado, Connecticut, Delaware, Indiana, Iowa, Montana, New Jersey, Oregon, Tennessee, Texas, Utah, and Virginia, all
        of which have passed CCPA/CPRA-like legislation to provide their respective residents with similar rights. Recently, both Nevada and Washington State enacted laws to protect the privacy of personal health information specifically, both of which
        generally require consent for the collection, use, or sharing of any such information. Violations of the Washington State law can result in civil penalties of up to $7,500 per violation, up to $25,000 in treble damages at the sole discretion of the
        court, and injunctive relief. Consumers also may bring their own actions to recover (i) actual damages, (ii) treble damages; and (iii) attorney&#8217;s fees. Violations of the Nevada law can result in up to $10,000 civil penalties per violation and
        injunctive relief.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">New legislation anticipated to be enacted in various other states will continue to shape the data privacy environment nationally. The effects on our business of this growing body of privacy and
        data protection laws are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">83</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Outside of the United States, laws, regulations and standards in many jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal
        information. For example, in EEA, the collection and use of personal data is governed by the provisions of the General Data Protection Regulation (the &#8220;GDPR&#8221;). The GDPR came into effect in May 2018, superseding the European Union Data Protection
        Directive, and imposing more stringent data privacy and security requirements on companies in relation to the processing of personal data. The GDPR, together with national legislation, regulations and guidelines of the EU member states governing
        the processing of personal data, impose strict obligations on controllers, including <span style="font-style: italic;">inter alia</span>: (i) accountability and transparency requirements, and enhanced requirements for obtaining valid consent; (ii)
        obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (iii) obligations to comply with data protection rights of data subjects; and (iv) reporting of certain
        personal data breaches to the supervisory authority without undue delay (and no later than 72 hours where feasible). The GDPR also prohibits the transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed
        to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. The EU-US Privacy Shield was such a transfer mechanism put in place by the EU and the United States, but the Privacy Shield was
        invalidated for international transfers of personal data in July 2020 by the Court of Justice of the European Union (&#8220;CJEU&#8221;). A replacement of the Privacy Shield &#8211; the EU-U.S. Data Privacy Framework (&#8220;DPF&#8221;) was since developed. In July 2023, the
        U.S. and EU implemented the DPF. Companies can now use this new mechanism to transfer personal data from the EU to the U.S. and potentially from Switzerland to the U.S., subject to national implementation in Switzerland. The UK Extension to the
        EU-U.S. Data Privacy Framework (&#8220;Data Bridge&#8221;) entered into force on October 12, allowing certifying entities to transfer personal data from the UK to the U.S. At the moment, it is unclear whether the anticipated legal challenges against the DPF,
        which may similar to the challenge that led to the invalidation of the Privacy Shield, would be successful.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The CJEU upheld the validity of standard contractual clauses (&#8220;SCCs&#8221;) as a legal mechanism to transfer personal data but companies relying on SCCs will, subject to additional guidance from
        regulators in the EEA and the U.K., need to evaluate and implement supplementary measures that provide privacy protections additional to those provided under SCCs. Due to potential legal challenges, it remains to be seen whether SCCs will remain a
        valid legal mechanism and whether additional means for lawful data transfers will become available. In June 2021, the European Commission adopted new SCCs that are designed to be a mechanism by which entities can transfer personal information out
        of the EEA to jurisdictions that the European Commission has not found to provide an adequate level of protection. Currently, the SCCs are a valid mechanism to transfer personal information outside of the EEA. The SCCs, however, require parties
        that rely upon that legal mechanism to comply with additional obligations, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the transferred personal information. The new SCCs
        may increase the legal risks and liabilities under European privacy, data protection, and information security laws. Given that, at present, there are few, if any, viable alternatives to the SCCs and the DPF, any transfers by us or our vendors of
        personal information from Europe may not comply with European data protection laws, which may increase our exposure to the GDPR&#8217;s heightened sanctions for violations of its cross-border data transfer restrictions and may prohibit our transfer of
        E.U. personal information outside of the E.U. (including clinical trial data), and may adversely impact our operations, product development and ability to provide our products. Moreover, the competent authorities and courts in a number of EU Member
        States increasingly scrutinize and question the GDPR compliance of processing of personal data by US-based entities or entities with links to US-based entities, independently of whether personal data is actually transferred outside the EEA. The
        GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, whichever is greater. Such fines are in addition to any civil litigation claims by customers and data subjects. European data protection authorities
        may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA. In June 2021, the CJEU issued a ruling that expanded the scope of the &#8220;one
        stop shop&#8221; under the GDPR. According to the ruling, the competent authorities of EU Member States may, under certain strict conditions, bring claims to their national courts against a company for breaches of the GDPR, including unlawful
        cross-border processing activities, even such company does not have an establishment in the EU member state in question and the competent authority bringing the claim is not the lead supervisory authority.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Further, as of January 1, 2021, and the expiry of transitional arrangements agreed to between the United Kingdom and the EU (<span style="font-style: italic;">i.e</span>., following the United
        Kingdom&#8217;s exit from the EU&#8212;otherwise known as Brexit), data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of
        which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. With respect to transfers of personal data from the EEA to the United Kingdom, on June 28, 2021 the European Commission issued an
        adequacy decision in respect of the United Kingdom&#8217;s data protection framework, enabling data transfers from EU member states to the United Kingdom to continue without requiring organizations to put in place contractual or other measures in order
        to lawfully transfer personal data between the territories. While it is intended to last for at least four years, this adequacy decisions will automatically expire in June 2025 unless the European Commission renews or extends it and may be modified
        or unilaterally revoked in the interim at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. Moreover, other countries have also passed or are considering passing laws requiring local data
        residency or restricting the international transfer of data.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">84</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">If we or our third-party service providers are unable to properly protect the privacy and security of personal information, or other confidential&#160; data we process in our business, we could be found
        to have breached our contracts. Further, if we fail to comply with applicable privacy laws, we could face civil and criminal penalties. Enforcement activity from state Attorneys General and agencies such as the California Privacy Protection Agency,
        the FTC, EU Data Protection Authorities, and other regulatory authorities in relation to privacy and cybersecurity matters can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant
        internal resources. In the United States, the threat of class action lawsuits based on data security breaches or alleged unfair practices adds a further layer of risk. We cannot be sure how these privacy laws and regulations will be interpreted,
        enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be
        costly and require ongoing modifications to our policies, procedures and systems.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Data privacy remains an evolving landscape at both the domestic and international level, with new laws and regulations frequently being adopted and coming into effect. It is possible that these
        laws may be interpreted and applied in a manner that is inconsistent with our current practices. Significant resources are needed to understand and comply with this changing landscape. Failure to comply with federal, state and international laws
        regarding privacy and security of personal information could expose us to penalties, including government-imposed fines or orders requiring that we change our practices or unwind certain lines of business, claims for damages or other liabilities,
        regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even absent any findings that we have violated these laws, government investigations into these
        issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our or our affiliates&#8217; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other vendors or potential
        collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are exposed to the risk that our or our affiliates&#8217; employees and contractors, including principal investigators, CROs, CMOs, consultants, commercial collaborators, service providers and other
        vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar
        regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing and the FDA&#8217;s GCP, GLP and GMP standards; federal, state and foreign healthcare fraud and abuse
        laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws
        intended to prevent fraud, kickbacks, self-dealing, bribery, corruption, antitrust violations and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including research, manufacturing, distribution,
        pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course
        of clinical trials, creating fraudulent data in our nonclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to
        identify and deter employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
        other actions or lawsuits stemming from a failure to comply with such laws or regulations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Additionally, we are subject to the risk that a person, including any person who may have engaged in any fraud or misconduct, or government agency could allege such fraud or other misconduct, even
        if none occurred. Furthermore, we rely on our CROs and clinical trial sites to adequately report data from our ongoing clinical trials. Moreover, in some instances, our licensing partners conduct clinical trials with respect to product candidates
        in different territories and we rely on any such partners to share data from their ongoing clinical trials as required under our agreements with such partners. For example, any failure by such parties to adequately report safety signals to us in a
        timely manner from any such trials may also affect the approvability of our product candidates or cause delays and disruptions for the approval of our product candidates, if at all. If our or our affiliates&#8217; employees, independent contractors,
        principal investigators, consultants, commercial collaborators, service providers or other vendors are alleged or found to be in violation of any such regulatory standards or requirements, or become subject to a corporate integrity agreement or
        similar agreement and curtailment of our operations, it could have a significant impact on our business and financial results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, suspension
        or delay in our clinical trials, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, FDA debarment, contractual damages, reputational harm, diminished profits and future earnings, and additional
        reporting requirements and oversight, any of which could harm our ability to operate our business and our results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of our products and, if approved, product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The sale of our products, including VTAMA, which was approved by the FDA in May 2022 for the treatment of plaque psoriasis in adults in the U.S. and the use of our existing product candidates in
        clinical trials expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, other pharmaceutical companies or others taking or otherwise coming into contact with our
        products or product candidates. On occasion, large judgments have been awarded in class action lawsuits where drugs have had unanticipated harmful effects. If we cannot successfully defend ourselves against product liability claims, we could incur
        substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">85</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>delays in or an inability to commercialize VTAMA, and any future products for which we obtain marketing approval;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>impairment of our business reputation and significant negative media attention;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>delay or termination of clinical trials, or withdrawal of participants from our clinical trials;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>significant costs to defend the related litigation;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>distraction of management&#8217;s attention from our primary business;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>substantial monetary awards to patients or other claimants;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>product recalls, withdrawals or labelling, marketing or promotional restrictions;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>decreased demand for our VTAMA, and current or future product candidates, if approved; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>loss of revenue.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or
        losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.
        We have acquired insurance coverage which extends to liabilities arising from the sale of our products; however, there is no assurance that we will be able to maintain this insurance coverage on commercially reasonable terms or in adequate amounts
        or that this coverage will be sufficient to cover any losses arising from any claims related to our products or, if approved, product candidates. A successful product liability claim or series of claims brought against us could adversely affect our
        results of operations and business, including preventing or limiting the commercialization of our products and, if approved, product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous
        materials and wastes. Certain of our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. We generally contract with third parties for the
        disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting
        damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance
        may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or
        radioactive materials.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair
        our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes, outbreak of disease or other natural disasters and our business continuity and disaster
        recovery plans may not adequately protect us from a serious disaster.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a
        natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our offices, that damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs, or that otherwise
        disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely
        to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our
        limited earthquake and flood insurance coverage, could have a material adverse effect on our business.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">86</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">The increasing use of social media platforms presents new risks and challenges.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Social media is increasingly being used to communicate about our research, products, product candidates, investigational medicines and the diseases our products, product candidates and
        investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of
        noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an
        alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face
        of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or
        negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums
        could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with
        applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business. The use of social media also creates additional risks in the EEA and the UK where promotion of prescription-only medicines to patients
        and the general public is strictly prohibited. Social media content that is generated, shared or liked by our company or our directors, employees, staff or other representatives may potentially be perceived or construed as constituting prohibited
        promotion of prescription-only medicinal products and trigger enforcement and penalties. This is an area of increased scrutiny in both the EEA and the UK.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Risks Related to Our Intellectual Property</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology, products and product candidates, or if the scope of the
        intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other
        third parties to protect the intellectual property related to our brand, current and future drug development programs, products and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the
        United States and other countries with respect to our current and future products and product candidates. We seek to protect our proprietary position by in-licensing or acquiring intellectual property and filing patent applications in the United
        States and abroad related to our current and future development programs, products and product candidates, defending our intellectual property rights against third-party challenges and enforcing our intellectual property rights to prevent
        third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, there is
        always a risk that our licensed or owned issued patents and any pending and future patent applications may not protect our products or product candidates, in whole or in part, and may not effectively prevent others from commercializing competitive
        products or product candidates, or that an alteration to our products or product candidates or processes may provide sufficient basis for a competitor to avoid infringing our patent claims. The risks associated with patent rights generally apply to
        patent rights that we in-license now or in the future, as well as patent rights that we may own now or in the future.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure
        and confidentiality agreements with parties who have access to confidential or patentable aspects of their research and development output, such as employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,
        consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to obtain patent protection. In addition, while we have
        pre-publication review procedures in effect, premature or inadvertent publication of potentially patentable subject matter could preclude our ability to obtain patent protection. We may choose not to seek patent protection for certain innovations,
        products or product candidates and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any
        event, any patent protection we obtain may be limited. As a result, our products and, if approved, product candidates may not be protected by patents in all jurisdictions. We generally apply for patents in those countries where we intend to make,
        have made, use, offer for sale, or sell products and product candidates and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell
        products and, if approved, product candidates and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country or major market, we may be
        precluded from doing so at a later date. The patent applications that we own or in-license may fail to result in issued patents with claims that cover products or product candidates in the United States or in other countries. We may also
        inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated
        or held unenforceable in enforcement and other adversarial proceedings.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">87</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current and future products or product candidates in the United States or in other
        countries. Our pending patent applications at the Patent Cooperation Treaty (the &#8220;PCT&#8221;) are not eligible to become issued patents until, among other things, we file a national stage patent application within 30 months in the countries in which we
        seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent applications and any patent protection on the inventions disclosed in such PCT patent
        applications. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. For example, any issued patents might not cover the pharmaceutical composition of the product or product
        candidate that is ultimately commercialized. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent
        application or be used to invalidate an issued patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may ultimately obtain. Even if patents do successfully issue and even if such
        patents cover our current and future products and product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowly construed, invalidated, or held unenforceable, any of which
        could limit our ability to prevent competitors and other third parties from developing and marketing similar products or product candidates or limit the length of terms of patent protection we may have for our products, product candidates and
        technologies. Other companies may also design around technologies we have patented, licensed or developed. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents
        that could prevent us from marketing products or product candidates, or practicing our own patented technology, or impose a substantial royalty burden to do so. Any successful opposition to these patents or any other patents owned by or licensed to
        us could deprive us of rights necessary for the successful commercialization of any products or, if approved, product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product or
        product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our products or, if approved, product
        candidates, and if we do not own or have exclusive rights to other enforceable patents protecting our products, product candidates or other technologies, competitors and other third parties could market products or product candidates and use
        processes that are substantially similar to, or superior to, ours and our business would suffer.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If the patent applications we hold or have in-licensed with respect to our products or product candidates fail to issue, if their breadth or strength of protection is
        threatened, or if they fail to provide meaningful exclusivity for our current and future products or product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize
        our products. Any such outcome could have a materially adverse effect on our business. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues
        from such applications.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much
        litigation. The standards that the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) and its counterparts in other countries use to grant patents are not always applied predictably or uniformly. In addition, the laws of countries other than the United
        States may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in such jurisdictions. For example, European patent law
        restricts the patentability of methods of treatment of the human body more than United States law does.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Other parties have developed technologies that may be related or competitive to our own technologies and such parties may have filed or may file patent applications, or may have received or may
        receive patents, claiming inventions that may overlap or conflict with those claimed in our own or licensed patent applications or issued patents. Furthermore, publications of discoveries in scientific literature often lag behind the actual
        discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the
        first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity,
        enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology, products or product candidates, in whole or in part, or
        which effectively prevent others from commercializing competitive technologies, products and product candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value
        of our patents or narrow the scope of our patent protection.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act (&#8220;the Leahy-Smith Act&#8221;), could increase those uncertainties and costs surrounding the prosecution of
        our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September 16, 2011 and includes a number of significant changes to U.S. patent law. These include provisions that affect the
        way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during
        patent prosecution and additional procedures to challenge the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <span style="font-style: italic;">inter partes</span> review, and derivation proceedings.
        After March 15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to
        the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent
        applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">88</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the
        United States and abroad. We are currently and may in the future be subject to third-party pre-issuance submissions of prior art to the USPTO or its equivalents and we or our licensors have in the past, and may in the future, become involved in
        opposition, derivation, reexamination, <span style="font-style: italic;">inter partes</span> review, post-grant review or interference proceedings in the U.S. or in other jurisdictions challenging our patent rights or the patent rights of others.
        A third-party may also claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. For example, three U.S. patents (U.S. Patent Nos. 8,058,069, 9,364,435 and 9,404,127) relating to lipid nanoparticle molar ratios
        and the aggregation of lipid nanoparticles that Genevant Sciences GmbH, as assignee of Genevant Sciences Ltd. (&#8220;Genevant&#8221;), exclusively licensed from Arbutus Biopharma Corp. (&#8220;Arbutus&#8221;) have been the subject of <span style="font-style: italic;">inter


          partes </span>review proceedings brought by Moderna Therapeutics, Inc. (&#8220;Moderna&#8221;) before the Patent Trial and Appeal Board of the USPTO (&#8220;PTAB&#8221;), whose decisions were subsequently reviewed by the United States Court of Appeals for the Federal
        Circuit (the &#8220;Federal Circuit&#8221;). The Federal Circuit ultimately (i) affirmed the PTAB&#8217;s decision that upheld all claims of U.S. Patent No. 8,058,069; (ii) affirmed the PTAB&#8217;s decision invalidating certain claims of U.S. Patent No. 9,364,435 but
        dismissed Moderna&#8217;s appeal with respect to those claims that the PTAB upheld for lack of standing and (iii) affirmed the PTAB&#8217;s decision invalidating all claims of U.S. Patent No. 9,404,127. Additionally, one European patent (EU Patent No.
        EP2279254) relating to lipid nanoparticle molar ratios that Genevant exclusively licensed from Arbutus is the subject of an opposition proceeding brought by Merck Sharp &amp; Dohme Corporation and Moderna at the European Patent Office Opposition
        Division. Genevant may commence litigation at any time to enforce its patent rights against infringers.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or
        invalidate, our patent rights, allow third parties to commercialize our technology, products or product candidates and compete directly with us, without payment to us, result in our inability to manufacture or commercialize products and, if
        approved, product candidates without infringing third-party patent rights or result in our breach of agreements pursuant to which we license such rights to our collaborators or licensees. In addition, if the breadth or strength of protection
        provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products or product candidates. Such challenges may result in loss of
        exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology, products and
        product candidates, or limit the duration of the patent protection of our technology, products and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the
        eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Even if they are unchallenged, our owned and licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing
        around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, a third-party may develop a competitive product that provides benefits
        similar to one or more of our products or product candidates but that falls outside the scope of our patent protection. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after
        it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, are limited. Without patent protection for our current or future products and product candidates, it may be open to competition from
        generic versions of such products or product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
        candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to our own and, which could have a material
        adverse effect on our business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Patent terms and their scope may be inadequate to protect our competitive position on current and future products and product candidates for an adequate amount of time.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional
        filing date. In certain instances, the patent term may be adjusted to add additional days to compensate for delays incurred by the USPTO in issuing the patent. Also, the patent term may be extended for a period of time to compensate for at least a
        portion of the time a product or product candidate was undergoing FDA regulatory review. However, the life of a patent, and the protection it affords, are limited. Even if patents covering products or product candidates are obtained, once the
        patent life has expired, we may be open to competition from other products or product candidates, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new products and product
        candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For example, the patent covering the use of VTAMA as an active ingredient to treat psoriasis and atopic dermatitis, but not
        limited to any formulation, expired in December 2020. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to our products and
        product candidates.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">89</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We do not currently and may not in the future own or license any issued composition of matter patents covering certain of our products or product candidates, including VTAMA,
        and we cannot be certain that any of our other issued patents will provide adequate protection for such products or product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Composition-of-matter patents on the active pharmaceutical ingredient (&#8220;API&#8221;) in prescription drug products are generally considered to be the strongest form of intellectual property protection for
        drug products because those types of patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. While we generally seek composition of matter patents for our products and product
        candidates, such patents may not be available for all of our products and product candidates. For example, we do not own or have a license to any issued composition of matter patents in the United States or any other jurisdiction with respect to
        VTAMA. Instead, we rely on four issued U.S. patents claiming topical formulations of VTAMA, including the commercial formulation which was studied in Phase 3 trials and approved by the FDA, and two issued U.S. patents covering methods of using the
        patented topical formulations to treat inflammatory diseases, including psoriasis and atopic dermatitis. The formulation and method-of-use patents have natural expiration dates in 2036. We additionally rely on three drug substance (&#8220;DS&#8221;) patents
        covering the high purity commercial crystal form of the DS, the commercial DS synthesis and several novel intermediates that are formed in the synthesis, which has a natural expiration date in 2038.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Method-of-use patents protect the use of a product for the specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other
        third-party from developing or marketing an identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with
        respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products
        off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common, and this type of infringement is difficult to prevent or prosecute.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our owned and licensed patents and pending patent applications, if issued, may not adequately protect our intellectual property or prevent competitors or others from designing around our patent
        claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. If the breadth or strength of protection provided by the patents and patent applications we own or
        license with respect to our products and product candidates is not sufficient to impede such competition or is otherwise threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our
        products and, if approved, product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term, our business may be harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States and other countries with respect to our proprietary
        technology, products, product candidates and our target indications. Given the amount of time required for the development, testing and regulatory review of products and product candidates, patents protecting our products and product candidates
        might expire before or shortly after such candidate begins to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, one or more of our U.S. patents may be eligible for a limited patent term extension (&#8220;PTE&#8221;) under
        the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as
        compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This
        extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing
        the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may
        refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of
        relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may
        still expire before or shortly after we receive FDA marketing approval for a given product or product candidate.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development
        and clinical trials by referencing our clinical and preclinical data to obtain approval of competing product candidates following our patent expiration and launch their product earlier than might otherwise be the case.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">90</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
        patent agencies, and our patent protection could be reduced or eliminated as a result of non-compliance with these requirements.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other patent agencies in other jurisdictions in several stages over the lifetime of the patent. The USPTO and
        various national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing
        partners to pay these fees due to U.S. and non-U.S. patent agencies and to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can in many cases be cured by
        payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent
        rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international
        patent applications, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications
        covering our current and future products and product candidates, our competitors might be able to enter the market earlier than anticipated, which would have an adverse effect on our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We rely on certain in-licensed patents and other intellectual property rights in connection with our development of certain products and product candidates and, if we fail to
        comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our ability to commercialize products and develop and eventually, if approved, commercialize product candidates is dependent on licenses to patent rights and other intellectual property granted to
        it by third parties. Further, development and commercialization of our current and future products and product candidates may require us to enter into additional license or collaboration agreements.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our current license agreements impose, and future agreements may impose, various development, diligence, commercialization and other obligations on us and require us to meet development timelines,
        or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. If we fail to comply with our obligations under these licenses, our licensors may have the right to terminate these
        license agreements, in which event we may not be able to market our products and product candidates. Termination of any of our license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or
        reinstated licenses with less favorable terms. Additionally, certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could
        affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and
        prospects. For example, disputes may arise with respect to our current or future licensing agreement include disputes relating to:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the scope of rights granted under the license agreement and other interpretation-related issues;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our financial or other obligations under the license agreement;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the extent to which our technology, products or product candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the sublicensing of patent and other rights;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our diligence obligations under the license agreements and what activities satisfy those diligence obligations;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the priority of invention of patented technology.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully
        develop and commercialize our products and product candidates. If our licenses are terminated, we may lose our rights to develop and market our technology, products and product candidates, lose patent protection for our products, product candidates
        and technology, experience significant delays in the development and commercialization of our products and product candidates, or incur liability for damages. In addition, we may need to obtain additional licenses from our licensors and, in
        connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive
        licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our products and product candidates.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">91</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory
        approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our products and product candidates. Moreover, if disputes over intellectual property that we
        license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected products or product candidates. In addition, certain of these
        license agreements, may not be assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions. Any of the foregoing could have a material adverse effect on our
        business, financial condition, results of operations and prospects. In addition, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents,
        covering technology that it licenses from third parties. Therefore, we cannot be certain that these or other patents will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. Additionally, we may
        not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain,
        maintain, defend and enforce the licensed patents. If our current or future licensors or collaboration partners fail to obtain, maintain, defend, protect or enforce any patents or patent applications licensed to us, our rights to such patents and
        patent applications may be reduced or eliminated and our right to develop and commercialize products and product candidates that are the subject of such licensed rights could be adversely affected.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Furthermore, certain of our current and future licenses may not provide us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with rights to use
        such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology, products and product candidates in the future. The intellectual property portfolio
        licensed to us by our licensors at least in some respects, may therefore be used by such licensors or licensed to third parties, and such third parties may have certain enforcement rights with respect to such intellectual property. For example,
        Immunovant does not have rights to develop, manufacture, use or commercialize batoclimab or file or enforce patents relating to these assets in territories other than the United States, Canada, Mexico, the EU, the U.K., Switzerland, the Middle
        East, North Africa and Latin America, as such rights in other jurisdictions have been retained by HanAll Biopharma Co., Ltd. (&#8220;HanAll&#8221;) or licensed by HanAll to third parties. Additionally, Dermavant does not have the right to develop, manufacture,
        use or commercialize VTAMA in China, including Hong Kong, Macau or Taiwan, as such rights were retained by Welichem Biotech Inc. or licensed to third parties. Patents licensed to us could be put at risk of being invalidated or interpreted narrowly
        in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to
        prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Third-party claims or litigation alleging infringement, misappropriation or other violations of third-party patents or other proprietary rights or seeking to invalidate our
        patents or other proprietary rights, may delay or prevent the development and commercialization of our current and future products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our commercial success depends in part on our avoidance of infringement, misappropriation and other violations of the patents and proprietary rights of third parties. However, our research,
        development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Our competitors or other third parties
        may assert infringement claims against us, alleging that our products or product candidates are covered by their patents. We cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the
        future. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits,
        interferences, derivation and administrative law proceedings,<span style="font-style: italic;"> inter partes</span> review, and post-grant review before the USPTO, as well as oppositions and similar processes in other jurisdictions. Numerous U.S.
        and non-U.S. issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and
        more patents are issued, and as we gain greater visibility, the risk increases that our products, product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties.
        Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or
        methods for treatment related to the use or manufacture of our products or product candidates. We could also be required to pay damages, which could be significant, including treble damages and attorneys&#8217; fees if we are found to have willfully
        infringed such patents.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Additionally, because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our products or product
        candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover any of our
        products or product candidates, the holders of any such patents may be able to block our ability to commercialize such products or, if approved, product candidates, unless we obtained a license under the applicable patents, or until such patents
        expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able
        to block our ability to develop and commercialize the applicable product or, if approved, product candidate, unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable
        terms or at all. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. In addition, we may be subject to claims that we are infringing other
        intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others
        in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions, which could be time-consuming and divert the attention of senior management.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">92</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or, if
        approved, product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement
        or other intellectual property claim against it, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected
        products or product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms.
        Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our products or, if approved, product candidates, and we have done so from time to time. We may
        fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our products or, if approved, product candidates, which could harm
        our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our
        sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because the competitors have substantially greater financial and
        other resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays or prohibit us from manufacturing, marketing or otherwise
        commercializing our products or, if approved, product candidates. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business,
        results of operation, financial condition or cash flows.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
        compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop
        and market our products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant
        patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of
        products or product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being
        commonly referred to as the priority date. In addition, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until
        patents issue. Therefore, patent applications covering our products and product candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain
        limitations, be later amended in a manner that could cover our current and future products and product candidates, or the use thereof, provided such pending patent applications result in issued patents. Our ability to develop and market our current
        and future products and product candidate can be adversely affected in jurisdictions where such patents are issued.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope
        of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products or, if approved, product candidates. We may incorrectly determine that our products or product candidates are not covered by a
        third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may
        be incorrect and we may incorrectly conclude that a third-party patent is invalid or unenforceable. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our current and future
        products and, if approved, product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such
        infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our products or, if approved, product candidates, that are held to be
        infringing. We might, if possible, also be forced to redesign products or product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to
        divert substantial financial and management resources that we would otherwise be able to devote to our business.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">93</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time
        consuming and unsuccessful.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we
        may be required to file and prosecute legal claims against one or more third parties, which can be expensive and time-consuming, even if ultimately successful. For example, in February 2022, Roivant&#8217;s subsidiary, Genevant Sciences GmbH (&#8220;Genevant
        GmbH&#8221;), and Arbutus filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378
        in the manufacture and sale of MRNA-1273, Moderna&#8217;s vaccine for COVID-19 (the &#8220;Moderna Action&#8221;). In November 2022, the District Court denied Moderna&#8217;s partial motion to dismiss pursuant to 28 U.S.C. &#167; 1498(a) (&#8220;&#167; 1498&#8221;). In March 2023, following
        the submission of a Statement of Interest in the case by the United States Government, the court reaffirmed its prior decision and again ruled that the complaint should not be partially dismissed on the basis of &#167; 1498. On February 8, 2024, the
        court held a Claim Construction hearing on disputed terms within the claims of the asserted patents. The court&#8217;s ruling is expected in April 2024. In March 2022, Acuitas Therapeutics Inc. (&#8220;Acuitas&#8221;) filed a lawsuit in the U.S. District Court for
        the Southern District of New York (&#8220;SDNY&#8221;) against two of the Company&#8217;s affiliates, Genevant and Arbutus, seeking a declaratory judgment that certain patents held by Arbutus and licensed by Genevant are not infringed by the manufacture, use, offer
        for sale, sale or importation into the United States of COMIRNATY, Pfizer&#8217;s and BioNTech&#8217;s vaccine for COVID-19 and are otherwise invalid. On September 6, 2022, Acuitas filed a First Amended Complaint. In response, on October 4, 2022, Genevant and
        Arbutus filed a motion to dismiss the first amended complaint for lack of a controversy and supporting brief. Briefing on this motion was completed in mid-November. On August 4, 2023, Acuitas voluntarily dismissed the action in the SDNY and
        re-filed a complaint in the U.S. District Court for the District of New Jersey (the &#8220;Acuitas Action&#8221;). On October 13, 2023, Genevant and Arbutus filed a motion to dismiss the re-filed complaint. On April 4, 2023, Genevant GmbH and Arbutus filed a
        lawsuit in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech seeking damages for infringement of U.S. Patent Nos. 9,504,651, 8,492,359, 11,141,378, 11,298,320 and 11,318,098 in the manufacture and sale of COMIRNATY
        (the &#8220;Pfizer Action&#8221;). On July 10, 2023, Pfizer and BioNTech filed an answer. The Pfizer Action is proceeding and in the early stages of discovery.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue
        on the grounds that our patents do not cover the technology in question. The standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, we
        cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court and if any such suits, including the Moderna Action and the Acuitas Action, will ultimately be
        resolved successfully. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an
        adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or
        interpreted narrowly in a manner insufficient to achieve our business objectives, or could put our patent applications at risk of not issuing. The initiation of a claim against a third-party may also cause the third-party to bring counter claims
        against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be
        an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of written description or non-statutory subject matter. Grounds for an unenforceability assertion could be an
        allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the
        USPTO in post-grant proceedings such as ex parte reexaminations, <span style="font-style: italic;">inter partes</span> review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or
        even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware
        during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third-party. If a defendant were to prevail on a legal
        assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future products or product candidates. Such a loss of patent protection could harm our business.
        Additionally, any adverse outcome could allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent
        rights.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Even if we establish infringement, we may not seek, or the court may decide not to grant, an injunction against further infringing activity and instead award only monetary damages, which may or may
        not be an adequate remedy. We may not be able to detect or prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United
        States. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.<br/>
        <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">94</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
        compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be
        negative, it could have an adverse effect on the price of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We may not have sufficient financial or other resources to adequately conduct the Moderna Action, the Acuitas Action or any other such litigation or proceedings. Some of our competitors or other
        third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Because of the expense and uncertainty of litigation, we may conclude that even if a
        third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may
        be too high or not in the best interest of our company or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Because many of the patents we own or have licensed are owned or licensed by our subsidiaries, and in certain cases by subsidiaries that are not or will not be directly
        commercializing products, we may not be in a position to obtain a permanent injunction against a third-party that is found to infringe our patents.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Many patents that we own or have licensed are assigned to or licensed by our direct or indirect subsidiaries. For example, any patents that Immunovant has licensed are assigned to its wholly-owned
        subsidiary Immunovant Sciences GmbH and any patents that Dermavant owns or has licensed are assigned to its wholly-owned subsidiary Dermavant Sciences GmbH. If a third-party is found to be infringing such patents, we and our direct subsidiaries may
        not be able to permanently enjoin the third-party from making, using, offering for sale or selling the infringing product or activity for the remaining life of such patent in the United States or other jurisdictions when the patent is assigned to a
        subsidiary, which is not the entity that is or would be commercializing a potentially competitive product or service. In such a circumstance, such third-party may be able to compete with us or our subsidiaries, which could have a material adverse
        effect on our competitive position, business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our
        products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property. Obtaining and enforcing patents in the biopharmaceutical industry involves both
        technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or USPTO rules and regulations could increase the
        uncertainties and costs.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The United States has recently enacted and implemented wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional
        uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent
        protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
        uncertainty with respect to the value of patents, once obtained. For example, in June 2022, the World Trade Organization members agreed to waive certain patent rights with respect to COVID-19 vaccines. Any waiver of our patent or other intellectual
        property protection by the U.S. and other foreign governments, including with respect to Genevant&#8217;s licensed lipid nanoparticle (&#8220;LNP&#8221;) delivery technology as used in connection with messenger RNA vaccine delivery, could have a material adverse
        effect on our competitive position, business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
        new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes
        in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. We cannot predict future changes in the
        interpretation of patent laws or changes to patent laws that might be enacted into law by United States and non-U.S. legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional
        patent protection in the future.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">95</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a
        &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor
        or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; For example, the research resulting in certain of our acquired or in-licensed patent rights and
        technology for certain products or product candidates was funded in part by the U.S. federal government. As a result, the federal government may have certain rights to such patent rights and technology, which include march-in rights. If the federal
        government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The federal government&#8217;s rights may also permit it to disclose our confidential information to third parties and to exercise
        march-in rights to use or allow third parties to use our licensed technology. The federal government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the
        government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. Further, the recipient of U.S. government funding is required to
        comply with certain other requirements, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. The U.S. government has the right to take title to such
        intellectual property rights if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated
        under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, our rights in such inventions may be subject to
        certain requirements to manufacture products or product candidates embodying such inventions in the United States. We cannot be certain that our current or future licensors will comply with the disclosure or reporting requirements of the Bayh-Dole
        Act at all times or be able to rectify any lapse in compliance with these requirements. Any exercise by the government of any of the foregoing rights or by any third-party of its reserved rights could have a material adverse effect on our
        competitive position, business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our products or product candidates, or patents that cover our biologic product
        candidates, can be challenged by third parties.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If a third-party files an application under Section 505(b)(2) or an abbreviated new drug application (&#8220;ANDA&#8221;) under Section 505(j) with respect to any of our products or, if approved, product
        candidates, for a generic product containing any of our products or product candidates, including VTAMA, and relies in whole or in part on studies conducted by or for us, the third-party will be required to certify to the FDA that either: (1) there
        is no patent information listed in the Orange Book with respect to our NDA for the applicable product or, if approved, product candidate; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will
        expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third-party&#8217;s generic product. A certification under 21 CFR &#167;
        314.94(a)(12)(i)(A)(4) that the new product will not infringe the Orange Book-listed patents for the applicable product or, if approved, product candidate, or that such patents are invalid, is called a paragraph IV certification. If the third-party
        submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third-party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in
        the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third-party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the
        lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third-party. If we do not file a patent infringement lawsuit within the required 45-day period, the third-party&#8217;s ANDA will not be subject to the
        30-month stay of FDA approval.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Moreover, a third-party may challenge the current patents, or patents that may issue in the future, within our portfolio, which could result in the invalidation of some or all of the patents that
        might otherwise be eligible for listing in the Orange Book for one of our products. If a third-party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products before an ANDA
        or 505(b)(2) NDA is filed we will be unable to obtain a 30-month stay of FDA approval of a 505(b)(2) or ANDA.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For example, our issued U.S. patents covering VTAMA may not provide adequate protection from competitive products developed by 505(b)(1) NDA, 505(b)(2) NDA or 505(j) ANDA applicants containing
        paragraph IV certifications if such applicants are able to design around the patents. One or more competitors may circumvent these patents by filing a marketing application with the FDA under Sections 505(b)(2) or 505(j) of the Federal Food, Drug
        and Cosmetic Act containing a paragraph IV certification for a competitive product containing the active moiety in VTAMA and successfully challenging the validity of the patents or successfully designing around the patents. Any successful challenge
        against the patents and/or designing around one or more of the patents could result in a generic version of VTAMA being commercialized before the expiration of the patents. If the patents are successfully challenged or designed around, our
        business, results of operations, financial condition and prospects would be harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">For biologics, the BPCIA provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell a biosimilar or interchangeable versions of brand name biological product
        candidates. Due to the large size and complexity of biological product candidates, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA
        does not require reference product sponsors to list patents in the FDA&#8217;s Orange Book and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal pre-litigation
        process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of
        this information, we may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims, it could result in the invalidation of, or render
        unenforceable, some or all of the relevant patent claims or result in a finding of non-infringement.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">96</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">If we are unsuccessful in enforcing our patents against generics or biosimilars, our products could face competition prior to the expiration of the patents which cover such products, which could
        have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, any such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may
        be very expensive and time-consuming, may divert management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our products and product candidates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may not be able to protect our intellectual property rights throughout the world.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Filing, prosecuting and defending patents on products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some
        countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be
        inconsistent. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws of the United States.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing product candidates made using our
        inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and product candidates and may also export infringing
        products and product candidates to territories where we have patent protection, but enforcement is not as strong as that in the United States. These product candidates may compete with our products or product candidates and our patents or other
        intellectual property rights may not be effective or sufficient to prevent them from competing.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We do not have patent rights in all countries in which a market may exist. Moreover, in jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial
        costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could
        provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from
        marketing and selling in other countries products and product candidates and services that are the same as or similar to our products and product candidates, and our competitive position would be harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in other jurisdictions. The legal systems of certain countries, particularly certain
        developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products and product candidates, which could make it difficult for us to stop the
        infringement of our patents or marketing of competing products or product candidates in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in
        substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties
        to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the
        world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant
        licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies, which could materially diminish the value of those
        patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that
        we develop or license.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If we are unable to protect the confidentiality of any trade secrets, our business and competitive position would be harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition to seeking patents for our products and product candidates, we may rely on trade secrets, including unpatented software, know-how, technology and other proprietary information, to
        maintain our competitive position. We seek to protect this software and information, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators,
        outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">97</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Because we rely and expect to continue to rely on third parties to manufacture our current and future products and product candidates, and we collaborate and expect to continue to collaborate with
        third parties on the development of current and future products and product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the
        terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or
        other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose
        our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
        become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third
        parties with whom we share facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade
        secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in the market. Further, adequate remedies may not exist in the event of unauthorized use or
        disclosure. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an
        adverse effect on our business and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although
        our agreements may contain certain limited publication rights. Policing unauthorized use of our or our licensors&#8217; intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized
        use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less
        willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors and other third parties may discover our trade secrets, including our proprietary software, either through breach of our agreements
        with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s or other third-party&#8217;s discovery of our trade secrets, including our proprietary software, would impair our
        competitive position and have an adverse impact on our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We cannot guarantee that we have entered into non-disclosure, confidentiality agreements, material transfer agreements or consulting agreements with each party that may have or have had access to
        our trade secrets or proprietary software, technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and proprietary software, and we may
        not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be
        effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is
        unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets, including our proprietary software, were to be lawfully obtained or independently
        developed by a competitor or other third-party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, including our proprietary
        software, were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Certain software utilized in our computational drug discovery efforts may include third-party open source software. Any failure to comply with the terms of one or more open
        source software licenses could adversely affect our business, subject us to litigation, or create potential liability.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Certain software utilized in our computational drug discovery efforts may include third-party open source software and we expect to continue to incorporate open source software in the future. The
        use of open source software involves a number of risks, many of which cannot be eliminated and could negatively affect our business. For example, we cannot ensure that we have effectively monitored our use of open source software or that we are in
        compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software asserting that the use of such open source software infringes the
        claimants&#8217; intellectual property rights. As a result, we could be subject to suits by third parties claiming infringement on such third parties&#8217; intellectual property rights. Litigation could be costly for us to defend, have a negative effect on
        our business, financial condition and results of operations, or require us to devote additional research and development resources to modify our computational drug discovery platform.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Use of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties, controls on the origin of the
        software or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open source licenses require that source code for software programs that
        interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same terms as the open source software license. The
        terms of various open source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to
        market our solutions. By the terms of certain open source licenses, if portions of our proprietary software are determined to be subject to an open source license or if we combine our proprietary software with open source software in a certain
        manner, we could be required to release the source code of our proprietary software and to make our proprietary software available under open source licenses, each of which could reduce or eliminate the effectiveness of our computational discovery
        efforts. We may also face claims alleging noncompliance with open source license terms or misappropriation or other violation of open source technology. Any of these events could create liability for us and damage our reputation, which could have a
        material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">98</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or
        other third parties.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We employ individuals who were previously employed at universities or other software, biotechnology or pharmaceutical companies, including our licensors, competitors or potential competitors.
        Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to not use the
        confidential information of their former employer, we may be subject to claims that we or our employees, consultants, independent contractors or other third parties have inadvertently or otherwise used or disclosed confidential information of our
        employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our owned or licensed patents or patent applications. Litigation may be necessary to
        defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive
        ownership of, or right to use, valuable intellectual property, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, could limit the duration of the patent protection
        covering our technology, products and product candidates and could result in our inability to develop, manufacture or commercialize our products and product candidates without infringing third-party patent rights. Such intellectual property rights
        could be awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize our current or future products and product candidates. Such a license may not be available on commercially reasonable terms or at
        all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability to form strategic
        alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We rely on a combination of internally developed and in-licensed intellectual property rights and we or our licensors may be subject to claims that former employees, collaborators or other third
        parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of
        employees, consultants or other third parties who are involved in developing our products and product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of
        our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive
        ownership of, or right to use, intellectual property that is important to our products or product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
        management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, while it is our policy to require our employees, contractors and other third parties who may be involved in the development of intellectual property to execute agreements assigning
        such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our invention assignment agreements may not be self-executing or may be
        breached, and we may not have adequate remedies for any such breach. Additionally, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual
        property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third-party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions
        developed by that individual.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the
        success of our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, including the Moderna Action, the Pfizer Action and the Acuitas Action, may cause us
        to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
        developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our Common Shares. Such litigation or proceedings could substantially increase our operating losses and reduce the
        resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be
        able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">99</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with
        litigation could compromise our ability to raise the funds necessary to pursue our commercialization efforts, continue our clinical trials and internal research programs or in-license needed technology or other future product candidates.
        Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to pursue our
        commercialization efforts, continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our products or, if approved,
        product candidates. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may not be successful in obtaining necessary intellectual property rights to future product candidates through acquisitions and in-licenses.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">A third-party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. Accordingly, we may seek to acquire or
        in-license patented or proprietary technologies to develop such product candidates or to grow our product offerings and technology portfolio. However, we may be unable to acquire or in-license intellectual property rights relating to, or necessary
        for, any such product candidate or technology from third parties on commercially reasonable terms or at all. Even if we are able to in-license any such necessary intellectual property, it could be on non-exclusive terms, thereby giving our
        competitors and other third parties access to the same intellectual property licensed to us, and it could require us to make substantial licensing and royalty payments. In that event, we may be unable to develop or commercialize such product
        candidates or technology. We may also be unable to identify product candidates or technology that we believe are an appropriate strategic fit for our company and protect intellectual property relating to, or necessary for, such product candidate
        and technology.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The in-licensing and acquisition of third-party intellectual property rights for any future product candidate is a competitive area, and a number of more established companies are also pursuing
        strategies to in-license or acquire third-party intellectual property rights for product candidates that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources
        and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain rights to additional
        technologies or product candidates, our business, financial condition, results of operations and prospects for growth could suffer.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for any future product candidate and technologies that are attractive to us
        may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates or
        technology on terms that would allow us to make an appropriate return on our investment.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We rely on trademarks as one means to distinguish our products from the products and product candidates of our competitors. Our current and future trademark applications in the United States and in
        other jurisdictions may not be allowed or may subsequently be opposed, challenged, infringed, circumvented, declared generic or determined to be infringing other marks. Additionally, once we select new trademarks and apply to register them, our
        trademark applications may not be approved. Third parties have in the past opposed, are currently opposing and may in the future oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks.
        In the event that our trademarks are successfully challenged, we could be forced to rebrand products or product candidates, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new
        brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have
        asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times,
        competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims
        brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and
        trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual
        property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">100</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Once granted, patents may remain open to invalidity challenges including opposition, interference, re-examination, post-grant review, <span style="font-style: italic;">inter partes</span> review,
        nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings,
        which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our
        business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Moreover, if a third-party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights.
        The following examples are illustrative:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>others may be able to make formulations or compositions that are the same as or similar to our products or product candidates, but that are not covered by the claims of the patents that we own;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>others may be able to make product candidates that are similar to our products or product candidates that we intend to commercialize that are not covered by the patents that we exclusively licensed and have the right to enforce;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we, our licensor or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we or our licensor or any collaborators might not have been the first to file patent applications covering certain of our inventions;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>it is possible that our pending patent applications will not lead to issued patents;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in
                countries where we do not have patent rights, and then use the information learned from such activities to develop competitive product candidates for sale in our major commercial markets; and we may not develop additional proprietary
                technologies that are patentable;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>third parties performing manufacturing or testing for us using our products, product candidates or technologies could use the intellectual property of others without obtaining a proper license;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may not develop or in-license additional proprietary technologies that are patentable;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the patents of others may harm our business; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent application covering such intellectual property.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Should any of these events occur, they could significantly harm our business and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-weight: bold;">Risks Related to Our Securities, Our Jurisdiction of Incorporation and Certain Tax Matters</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If our performance does not meet market expectations, the price of our securities may decline.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">If our performance does not meet market expectations, the price of our Common Shares may decline. In addition, the trading price of our Common Shares could be volatile and subject to wide
        fluctuations in response to various factors, some of which are beyond our control. Any of the factors listed below could have a material adverse effect on the price of our Common Shares.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">101</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Factors affecting the trading price of our Common Shares may include:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>actual or anticipated fluctuations in our quarterly and annual financial results or the quarterly and annual financial results of companies perceived to be similar to it;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>changes in the market&#8217;s expectations about operating results;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>our operating results failing to meet market expectations in a particular period;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>a Vant&#8217;s operating results failing to meet market expectations in a particular period, which could impact the market prices of shares of a public Vant or the valuation of a private Vant, and in turn adversely impact the trading price of
                our Common Shares;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>receipt of marketing approval for a product or product candidate in one or more jurisdictions, or the failure to receive such marketing approval;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the results of clinical trials or preclinical studies conducted by us and the Vants;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>changes in financial estimates and recommendations by securities analysts concerning us, the Vants or the biopharmaceutical industry and market in general;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>operating and stock price performance of other companies that investors deem comparable to us;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>changes in laws and regulations affecting our and the Vants&#8217; businesses;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the outcome of litigation or other claims or proceedings, including governmental and regulatory proceedings, against us or the Vants;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>changes in our capital structure, such as future issuances of securities or the incurrence of debt;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the volume of our Common Shares available for public sale and the relatively limited free float of our Common Shares;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>any significant change in our board of directors or management;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>sales of substantial amounts of our Common Shares by directors, executive officers or significant shareholders or the perception that such sales could occur; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Broad market and industry factors may depress the market price of our Common Shares irrespective of our or the Vants&#8217; operating performance. The stock market in general has experienced price and
        volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of
        investor confidence in the market for companies engaging in digital payments or the stocks of other companies which investors perceive to be similar to us could depress our stock price regardless of our business, prospects, financial conditions or
        results of operations. A decline in the market price of our Common Shares also could adversely affect our ability to issue additional securities and our ability to obtain additional financing in the future.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We have incurred and will continue to incur increased costs as a result of operating as a public company and our management has devoted and will continue to devote a substantial
        amount of time to new compliance initiatives.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses are expected to
        increase from March 31, 2024, after which we will no longer qualify as an emerging growth company, as defined in Section 2(a) of the Securities Act. As a public company, we are subject to the reporting requirements of the Exchange Act, the
        Sarbanes-Oxley Act and the Dodd-Frank Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance
        initiatives. Moreover, these rules and regulations have substantially increased our legal and financial compliance costs and made some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult
        and more expensive for us to obtain blended director and officer liability insurance and forced us to forego securities and corporate protection coverage. We cannot predict or estimate the amount or timing of additional costs we have incurred and
        will continue to incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive
        officers.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">102</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our failure to timely and effectively implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act could have a material adverse effect on our
        business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">As a public company, we are required to provide management&#8217;s attestation on internal controls as required under Section 404(a) of the Sarbanes-Oxley Act. The standards required for a public company
        under Section 404(a) of the Sarbanes-Oxley Act are significantly more stringent than those required of us as a privately-held company. If we are not successful in implementing the additional requirements of Section 404(a) in a timely manner or with
        adequate compliance, we may not be able to assess whether our internal controls over financial reporting are effective, which may subject us to adverse regulatory consequences and could harm investor confidence and the market price of our
        securities.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Currently, due to our status as an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company,&#8221; we are able to take advantage of exemptions from various reporting and other requirements that are
        applicable to other public companies that are not &#8220;emerging growth companies,&#8221; such as not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. However, because the market value of our
        Common Shares held by non-affiliates exceeded $700 million as of September 30, 2023 and we satisfy the other requirements of being a &#8220;large accelerated filer&#8221; pursuant to Rule 12b-2 under the Exchange Act, we will be deemed a &#8220;large accelerated
        filer&#8221; and will lose our current status as an &#8220;emerging growth company&#8221; as of March 31, 2024. As a result, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial
        reporting beginning with our annual report for the fiscal year ending on March 31, 2024. We expect to incur significant compliance costs and expend substantial management efforts in order to comply with the additional compliance and reporting
        requirements. This could result in continuing uncertainty regarding compliance matters and higher costs associated with ongoing revisions to disclosure and governance practices. It is possible that compliance initiatives may not be sufficient to
        satisfy our obligations as a public company on a timely basis. In addition, failure to properly implement internal controls on a timely basis may lead to the identification of one or more material weaknesses or control deficiencies in the future,
        which may prevent us from being able to report our financial results accurately on a timely basis or help prevent fraud, and could cause our reported financial results to be materially misstated and result in the loss of investor confidence or
        delisting and cause the market price of our Common Shares to decline. If we have material weaknesses in the future, it could affect the financial results that we report or create a perception that those financial results do not fairly state our
        financial position or results of operations. Either of those events could have an adverse effect on the value of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Further, even if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial
        statements for external purposes in accordance with U.S. GAAP, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls,
        or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We will no longer qualify as an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as of March 31, 2024 and, as a result, we will no longer be able to avail ourselves
        of certain reduced reporting requirements applicable to emerging growth companies or smaller reporting companies.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are currently an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we have taken advantage of certain exemptions from various requirements that are applicable to other public companies
        that are not &#8220;emerging growth companies,&#8221; including the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the
        requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, under the JOBS Act, emerging growth companies can delay adopting new or
        revised accounting standards until such time as those standards apply to private companies, and we have elected to take advantage of the benefits of such extended transition period. As a result, our historical consolidated financial statements may
        not be comparable to those of companies that comply with such new or revised accounting standards.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Because the market value of our Common Shares held by non-affiliates exceeded $700 million as of September 30, 2023 and we satisfy the other requirements of being a &#8220;large accelerated filer&#8221;
        pursuant to Rule 12b-2 under the Exchange Act, we will be deemed a &#8220;large accelerated filer&#8221; and will lose our current status as an &#8220;emerging growth company&#8221; as of March 31, 2024. As a result of our loss of &#8220;emerging growth company&#8221; status, it is
        possible that investors will find our Common Shares less attractive in light of the fact that we have relied on certain of these exemptions. If some investors find our Common Shares less attractive as a result, there may be a less active trading
        market for our Common Shares and our share price may be more volatile. In addition, any failure to comply with these additional requirements in a timely manner, or at all, could have an adverse effect on our business and results of operations and
        could cause a decline in the price of our Common Shares.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">103</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are subject to laws and regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements. Compliance
        with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material
        adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Anti-takeover provisions in our memorandum of association and bye-laws, as well as provisions of Bermuda law could delay or prevent a change in control, limit the price
        investors may be willing to pay in the future for our Common Shares and could entrench management</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our memorandum of association and bye-laws contain provisions that could make it more difficult for a third-party to acquire us without the consent of our board of directors. These provisions
        provide for:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>a classified board of directors with staggered three-year terms;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the ability of our board of directors to determine the powers, preferences and rights of preference shares and to cause us to issue the preference shares without shareholder approval; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>requiring advance notice for shareholder proposals and nominations and placing limitations on convening shareholder meetings.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">These provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our
        securities. These provisions could also discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us to take corporate actions other than those you desire, any of which could
        harm our share price.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our largest shareholders own a significant percentage of our Common Shares and are able to exert significant control over matters subject to shareholder approval.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our largest shareholders continue to hold a significant percentage of our Common Shares. As a result, these holders have the ability to substantially influence us and exert significant control
        through this ownership position and, in the case of certain holders, service on our board of directors. For example, these holders may be able to control elections of directors, issuance of equity, including to our employees under equity incentive
        plans, amendments of our organizational documents, or approval of any merger, amalgamation, sale of assets or other major corporate transaction. These holders&#8217; interests may not always coincide with our corporate interests or the interests of other
        shareholders, and they may exercise their voting and other rights in a manner with which you may not agree or that may not be in the best interests of our other shareholders. Furthermore, our largest shareholders may from time to time have
        interests that differ from ours or from one another, and from time to time there may be disputes with or between such shareholders, which could be costly, time-consuming and divert management resources. So long as these holders continue to own a
        significant amount of our equity, they will continue to be able to strongly influence our decisions.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Future sales and issuances of our or the Vants&#8217; equity securities or rights to purchase equity securities, including pursuant to our or the Vants&#8217; equity incentive and other
        compensatory plans, will result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We and the Vants may need additional capital in the future to continue our operations. To the extent we raise additional capital by issuing equity securities, including in our subsidiaries, our
        shareholders may experience substantial dilution. We or the Vants may sell securities, including convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell
        Common Shares, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. In addition, new investors could gain rights superior to our existing shareholders.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Pursuant to our 2021 Equity Incentive Plan (the &#8220;2021 EIP&#8221;), we are authorized to grant options, restricted stock units and other share-based awards to our employees, directors and consultants. The
        aggregate number of shares initially reserved for issuance under the 2021 EIP increases annually on the first day of each fiscal year during the term of the plan in an amount equal to the lesser of (i) 5% of the number of our Common Shares
        outstanding as of the day of the immediately preceding fiscal year and (ii) such number of our Common Shares as determined by our board of directors in its discretion. As a result of this annual increase, or if our board of directors elects in the
        future to make any additional increase in the number of shares available for future grant under the 2021 EIP, and if our shareholders approve of any such additional increase, our shareholders may experience additional dilution, and our share price
        may fall.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">104</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Issuance of options, restricted stock units and other share-based awards pursuant to equity incentive plans at the Vants may indirectly have a similar effect of diluting your ownership in us since
        a portion of the value of our Common Shares is tied to the value of the Vants, which would be diluted in the event of a grant of options or other similar equity grants to the employees of the Vants.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Future sales, or the perception of future sales, of our Common Shares by us or our existing shareholders could cause the market price for our Common Shares to decline and impact
        our ability to raise capital in the future.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Sales of a substantial number of our Common Shares by us or certain of our existing large shareholders, or the perception that these sales could occur, could substantially decrease the market price
        of our Common Shares. Shares held by certain of our large shareholders have been registered for re-sale pursuant to a registration statement on Form S-3 and may also be sold pursuant to Rule 144 under the Securities Act, subject to certain
        restrictions (including restrictions applicable to affiliates in the case of shares held by persons deemed to be our affiliates). While certain of our significant shareholders are subject to contractual lock-up agreements as described under the
        heading &#8220;Lock-Up Agreements&#8221; in the description of our share capital attached as exhibit 4.5 to our annual report on Form 10-K filed with the SEC on June 28, 2023, these lock-up agreements are subject to significant limitations and expire by their
        terms on February 29, 2024. The market price of our Common Shares could drop significantly if the holders of these shares sell them or are perceived by the market as intending to sell them. This, in turn, could also make it more difficult for us to
        raise additional funds through future offerings of our Common Shares or other securities at prices that are attractive to us, or at all.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">If securities analysts publish negative evaluations of our shares, the price of our Common Shares could decline.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, market or competitors. If any of the
        analysts who may cover us change their recommendation regarding our Common Shares adversely, or provide more favorable relative recommendations about its competitors, the price of our Common Shares would likely decline. If any analyst who may cover
        us were to cease coverage or fail to regularly publish reports, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Because there are no approved plans to pay cash dividends on our Common Shares for the foreseeable future, you may not receive any return on investment unless you sell our
        Common Shares for a price greater than that which you paid for it.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current approved plans to pay any cash dividends for the foreseeable future. Any decision to
        declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual
        restrictions, applicable law and other factors that our board of directors may deem relevant.&#160; As a result, you may not receive any return on an investment in our Common Shares unless you sell your shares of for a price greater than that which you
        paid for them.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We are an exempted company limited by shares incorporated under the laws of Bermuda and it may be difficult for you to enforce judgments against us or our directors and
        executive officers.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are an exempted company limited by shares incorporated under the laws of Bermuda. As a result, the rights of our shareholders are governed by Bermuda law and our memorandum of association and
        bye-laws. The rights of shareholders under Bermuda law may differ from the rights of shareholders of companies incorporated in another jurisdiction. It may be difficult for investors to enforce in the U.S. judgments obtained in U.S. courts against
        us based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce judgments obtained in other jurisdictions, including the U.S., against us or our directors or officers under the
        securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the securities laws of other jurisdictions.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Bermuda law differs from the laws in effect in the U.S. and may afford less protection to our shareholders.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are incorporated under the laws of Bermuda. As a result, our corporate affairs are governed by the Bermuda Companies Act 1981, as amended (the &#8220;Companies Act&#8221;), which differs in some material
        respects from laws typically applicable to U.S. corporations and shareholders, including the provisions relating to interested directors, amalgamations, mergers and acquisitions, takeovers, shareholder lawsuits and indemnification of directors.
        Generally, the duties of directors and officers of a Bermuda company are owed to the company only. Shareholders of Bermuda companies typically do not have rights to take action against directors or officers of the company and may only do so in
        limited circumstances. Shareholder class actions are not available under Bermuda law. The circumstances in which shareholder derivative actions may be available under Bermuda law are substantially more proscribed and less clear than they would be
        to shareholders of U.S. corporations. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be
        beyond the corporate power of the company or illegal or would result in the violation of the company&#8217;s memorandum of association or bye-laws. Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a
        fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#8217;s shareholders than those who actually approved it.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">105</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests of some shareholders, one or more shareholders may apply to the Supreme Court of
        Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company&#8217;s affairs in the future or ordering the purchase of the shares of any shareholders by other shareholders or by the company. Additionally,
        under our bye-laws and as permitted by Bermuda law, each shareholder will waive any claim or right of action against our directors or officers for any action taken by directors or officers in the performance of their duties, except for actions
        involving fraud or dishonesty. In addition, the rights of our shareholders and the fiduciary responsibilities of our directors under Bermuda law are not as clearly established as under statutes or judicial precedent in existence in jurisdictions in
        the U.S., particularly the State of Delaware. Therefore, our shareholders may have more difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction within the U.S.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">There are regulatory limitations on the ownership and transfer of our Common Shares.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Common shares may be offered or sold in Bermuda only in compliance with the provisions of the Companies Act and the Bermuda Investment Business Act 2003, which regulates the sale of securities in
        Bermuda. In addition, the Bermuda Monetary Authority must approve all issues and transfers of shares of a Bermuda exempted company. However, the Bermuda Monetary Authority has, pursuant to its statement of June 1, 2005, given its general permission
        under the Exchange Control Act 1972 and related regulations for the issue and free transfer of our Common Shares to and among persons who are non-residents of Bermuda for exchange control purposes as long as the shares are listed on an appointed
        stock exchange, which includes Nasdaq. Additionally, we have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of our Common Shares up to the amount of our authorized capital from time to
        time, and options, warrants, depository receipts, rights, loan notes, debt instruments and our other securities to persons resident and non-resident for exchange control purposes with the need for prior approval of such issue or transfer. The
        general permission or the specific permission would cease to apply if we were to cease to be listed on the Nasdaq or another appointed stock exchange.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">We may become subject to unanticipated tax liabilities and higher effective tax rates.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are incorporated under the laws of Bermuda. We are centrally managed and controlled in the U.K., and under current U.K. tax law, a company which is centrally managed and controlled in the U.K.
        is regarded as resident in the U.K. for taxation purposes. Accordingly, we expect to be subject to U.K. taxation on our income and gains, and subject to U.K.&#8217;s controlled foreign company rules, except where an exemption applies. We may be treated
        as a dual resident company for U.K. tax purposes. As a result, our right to claim certain reliefs from U.K. tax may be restricted, and changes in law or practice in the U.K. could result in the imposition of further restrictions on our right to
        claim U.K. tax reliefs. We may also become subject to income, withholding or other taxes in certain jurisdictions by reason of our activities and operations, and it is also possible that taxing authorities in any such jurisdictions could assert
        that we are subject to greater taxation than we currently anticipate, including as a result of the denial of treaty benefits that we may claim. Any such additional tax liability could materially adversely affect our results of operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">The intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various jurisdictions and on how we operate our
        business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We are incorporated under the laws of Bermuda and are centrally managed and controlled in the UK. We currently have subsidiaries in the U.S., U.K., Switzerland and certain other jurisdictions. If
        we succeed in growing our business, we expect to conduct increased operations through our subsidiaries in various countries and tax jurisdictions, in part through intercompany service agreements between our subsidiaries and us. In that case, our
        corporate structure and intercompany transactions, including the manner in which we develop and use our intellectual property, will be organized so that we can achieve our business objectives in a tax-efficient manner and in compliance with
        applicable transfer pricing rules and regulations. If two or more affiliated companies are located in different countries or tax jurisdictions, the tax laws and regulations of each country generally will require that transfer prices be the same as
        those between unrelated companies dealing at arm&#8217;s length and that appropriate documentation be maintained to support the transfer prices. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue
        to do so, our transfer pricing procedures are not binding on applicable taxing authorities. If taxing authorities in any of these countries were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions between two
        or more affiliated companies, they could require such affiliated companies to adjust their transfer prices and thereby reallocate the income between such affiliated companies to reflect these revised transfer prices, which could result in a higher
        tax liability to us. In addition, if the country from which the income is reallocated does not agree with the reallocation, both countries could tax the same income, resulting in double taxation. If taxing authorities were to allocate income to a
        higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase its consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">106</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations
        for which the ultimate tax determination is uncertain. For example, our effective tax rates could be adversely affected by changes in foreign currency exchange rates or by changes in the relevant tax, accounting, and other laws (including tax
        treaties), regulations, principles, and interpretations. As we intend to operate in numerous countries and taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of
        these jurisdictions. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm&#8217;s length standard is applied for transfer pricing
        purposes, or with respect to the valuation of intellectual property.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">In addition, tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. We continue to assess the impact of such changes in tax laws
        and interpretations on our business and may determine that changes to our structure, practice, tax positions or the manner in which we conduct our business are necessary in light of such changes and developments in the tax laws of other
        jurisdictions in which we operate. Such changes may nevertheless be ineffective in avoiding an increase in our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Changes in our effective tax rate may reduce our net income in future periods.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax authorities in
        Europe (including the U.K. and Switzerland), the U.S., Bermuda and other jurisdictions, as well as being affected by certain changes currently proposed by the Organization for Economic Co-operation and Development and their action plan on Base
        Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends continue. If such a situation were to arise, it could adversely impact our
        tax position and our effective tax rate. Failure to manage the risks associated with such changes, or misinterpretation of the laws providing such changes, could result in costly audits, interest, penalties, and reputational damage, which could
        adversely affect our business, results of our operations, and our financial condition.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates, including: (1) the jurisdictions in
        which profits are determined to be earned and taxed; (2) the resolution of issues arising from any future tax audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities; (4) increases in expenses
        not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions; (5) changes in the taxation of stock-based compensation; (6) changes in tax laws (including tax treaties) or the
        interpretation of such tax laws (including tax treaties) and changes in U.S. generally accepted accounting principles; (7) challenges to the transfer pricing policies related to our structure; (8) potential taxation under the OECD BEPS 2.0; and (9)
        potential limitation on tax attributes due to ownership changes (i.e. Internal Revenue Code 382 and 383) or expiration.</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">U.S. holders that own 10% or more of the combined voting power or value of our Common Shares may suffer adverse tax consequences because we and our non-U.S. subsidiaries may be
        characterized as &#8220;controlled foreign corporations&#8221; (&#8220;CFCs&#8221;) under Section 957(a) of the Code.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">A non-U.S. corporation is considered a CFC if more than 50% of (1) the total combined voting power of all classes of stock of such corporation entitled to vote, or (2) the total value of the stock
        of such corporation, is owned, or is considered as owned by applying certain constructive ownership rules, by U.S. shareholders (U.S. persons who own stock representing 10% or more of the combined voting power or value of all outstanding stock of
        such non-U.S. corporation) on any day during the taxable year of such non-U.S. corporation. Certain U.S. shareholders of a CFC generally are required to include currently in gross income such shareholders&#8217; share of the CFC&#8217;s &#8220;Subpart F income,&#8221; a
        portion of the CFC&#8217;s earnings to the extent the CFC holds certain U.S. property, and a portion of the CFC&#8217;s &#8220;global intangible low-taxed income&#8221; (as defined under Section 951A of the Code). Such U.S. shareholders are subject to current U.S. federal
        income tax with respect to such items, even if the CFC has not made an actual distribution to such shareholders. &#8220;Subpart F income&#8221; includes, among other things, certain passive income (such as income from dividends, interests, royalties, rents and
        annuities or gain from the sale of property that produces such types of income) and certain sales and services income arising in connection with transactions between the CFC and a person related to the CFC. &#8220;Global intangible low-taxed income&#8221; may
        include most of the remainder of a CFC&#8217;s income over a deemed return on its tangible assets.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">We believe that we will not be classified as a CFC for the taxable year ended March 31, 2023. However, our non-U.S. subsidiaries will be classified as CFCs for the taxable year ended March 31,
        2023. For U.S. holders who hold 10% or more of the combined voting power or value of our Common Shares, this may result in adverse U.S. federal income tax consequences, such as current U.S. taxation of Subpart F income (regardless of whether we
        make any distributions), taxation of amounts treated as global intangible low-taxed income under Section 951A of the Code with respect to such shareholder, and being subject to certain reporting requirements with the IRS. Any such U.S. holder who
        is an individual generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation. If you are a U.S. holder who holds 10% or more of the combined voting power or value of our Common Shares,
        you should consult your own tax advisors regarding the U.S. tax consequences of acquiring, owning, or disposing of our Common Shares.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">107</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">U.S. holders of our Common Shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the average quarterly value of our assets is attributable to assets that produce passive
        income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company (a &#8220;PFIC&#8221;) for U.S. federal income tax purposes. For purposes of these tests, passive income generally
        includes dividends, interest, gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business.
        Additionally, if we own (directly or indirectly) at least 25% (by value) of the stock of another corporation, for purposes of determining whether we are a PFIC, generally we would be treated as if we held our proportionate share of the assets of
        such other corporation and received directly our proportionate share of the income of such other corporation and generally we would retain the character of such assets and income as if they were held directly by us rather than by such other
        corporation. If we are characterized as a PFIC, U.S. holders of our Common Shares may suffer adverse tax consequences, including having gains realized on the sale of our Common Shares treated as ordinary income rather than capital gain, the loss of
        the preferential tax rate applicable to dividends received on our Common Shares by individuals who are U.S. holders, and having interest charges apply to certain distributions by us and the proceeds of sales or other dispositions of our Common
        Shares that result in a gain to the U.S. holder. In addition, special information reporting may be required.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets from time to time. The 50% passive asset test described above is
        generally based on the fair market value of each asset. If we are a CFC (determined by disregarding certain downward attribution rules) and not publicly traded for the relevant taxable year, however, the test shall be applied based on the adjusted
        basis of our assets. Because our Common Shares should be considered to be &#8220;publicly traded&#8221; for the taxable years ending on March 31, 2022 and March 31, 2023, we would apply the 50% passive asset test using the fair market value of our assets. In
        addition, our status may also depend, in part, on how quickly we utilize our cash on-hand and cash from future financings in our business.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Treasury regulations adopted in 2021 (the &#8220;2021 Regulations&#8221;) modify certain of the rules described above. The 2021 Regulations generally apply to taxable years of shareholders beginning on or
        after January 14, 2021. A shareholder, however, may choose to apply such rules for any open taxable year beginning before January 14, 2021, provided that, with respect to a non-U.S. corporation being tested for PFIC status, the shareholder
        consistently applies certain of the provisions of the 2021 Regulations and certain other Treasury regulations for such year and all subsequent years. Investors who are U.S. holders should consult their own tax advisors regarding the impact and
        applicability of the 2021 Regulations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Based on the foregoing, with respect to the taxable year that ended on March 31, 2023, we believe that we were not a PFIC based in part on our belief that we were not classified as a CFC in the
        taxable year that ended on March 31, 2023 and based upon the fair market value of our assets, including any goodwill and intangible property, and the nature and composition of our income and assets.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Our status as a PFIC is a fact-intensive determination made on an annual basis, which is subject to uncertainties, including but not limited to the fact that the value of our assets for purposes of
        the PFIC determination may be affected by the trading value of our Common Shares, which could fluctuate significantly. The total value of our assets for purposes of the PFIC asset test frequently (though not invariably) may be inferred using the
        market price of our ordinary shares, which may fluctuate considerably and thereby affect the determination of our PFIC status for future taxable years. Our U.S. counsel expresses no opinion with respect to our PFIC status for the current or future
        taxable years. We will endeavor to determine our PFIC status for each taxable year and make such determination available to U.S. holders.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <a id="UnregisteredSalesofEquity"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.95pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div><span style="font-weight: bold;">Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.</span></div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0); text-align: justify;">On January 22, 2024, we issued 313,023 Common Shares to certain current and former equityholders of a healthcare technology subsidiary of ours as deferred consideration to the
        sellers in connection with the acquisition of a controlling interest in such subsidiary that closed in July 2022. We did not receive any proceeds from the issuance.</div>

      <div>&#160;</div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0); text-align: justify;">We issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section 5 of the Securities Act of 1933, as amended, in
        reliance on the exemption afforded by Section 4(a)(2) thereof.</div>

      <div><span style="font-size: 8pt;"> </span><br/>
      </div>

      <a id="DefaultsUponSeniorSecurit"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.95pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
              <div><span style="font-weight: bold;">Defaults Upon Senior Securities.</span></div>
            </td>

  </tr>


</table>
      <div style="text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 8pt;"> </span><br/>
      </div>

      <div style="text-indent: -36pt; margin-left: 36pt;">None.</div>

      <div style="text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 8pt;"> </span><br/>
      </div>

      <a id="MineSafetyDisclosures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.95pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
              <div><span style="font-weight: bold;">Mine Safety Disclosures.</span></div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>Not applicable.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">108</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <a id="OtherInformation."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.95pt; vertical-align: top; font-weight: bold;">Item 5.</td>

    <td style="width: auto; vertical-align: top;">
              <div><span style="font-weight: bold;">Other Information.</span></div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: 36pt; text-align: justify;"><span style="color: rgb(0, 0, 0);">On February 9, 2024. the Company&#8217;s Board of Directors approved a special one-time cash retention bonus award to Richard Pulik, the Company&#8217;s Chief Financial
          Officer, in the aggregate amount of $</span>2.8 million<span style="color: rgb(0, 0, 0);">. Mr. Pulik&#8217;s retention bonus will vest and become payable as follows: 50% of the retention bonus will be vested and payable within thirty days of the grant
          date, (ii) 25% of the retention bonus will vest and become payable on or about September 20, 2024 and the remaining 25% of the retention bonus will vest and become payable on or about September 19, 2025, in each case subject to Mr. Pulik&#8217;s
          continued employment through the applicable vesting date. In the event Mr. Pulik&#8217;s employment is terminated without Cause (as defined in the Company&#8217;s 2021 Equity Incentive Plan) prior to the final vesting date, Mr. Pulik will be entitled to
          receive any unvested portion of his retention bonus within sixty days of his termination date, subject to his execution and non-revocation of a release of claims. The above-described terms of Mr. Pulik&#8217;s cash retention bonus award are similar to
          awards previously made to other employees out of the $76.9 million employee Cash Bonus </span>Program<span style="color: rgb(0, 0, 0);"> approved by the Company&#8217;s Board of Directors in December 2023.</span></div>

      <div>&#160;</div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">109</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div>
        <a id="Exhibits."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 46.95pt;">
                <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Item 6.</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-indent: -36pt; margin-left: 36pt; font-weight: bold;">Exhibits.</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10.26%; vertical-align: bottom;">&#160;</td>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Incorporated by Reference</div>
            </td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-weight: bold;">Number</div>
            </td>

    <td style="width: 50%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Description</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Form</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">File No.</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Filing Date</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.28%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.34%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;"><a href="ef20015327_ex31-1.htm">31.1</a></div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.28%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.34%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;"><a href="ef20015327_ex31-2.htm">31.2</a></div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.28%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.34%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;"><a href="ef20015327_ex32-1.htm">32.1</a></div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.28%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.34%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;"><a href="ef20015327_ex32-2.htm">32.2</a></div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.28%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.34%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>101.INS</div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Inline XBRL Instance Document</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.28%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.34%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>101.SCH</div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Inline XBRL Taxonomy Extension Schema Document</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.28%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.34%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>101.CAL</div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Inline XBRL Taxonomy Extension Calculation Linkbase Document</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.28%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.34%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>101.DEF</div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Inline XBRL Taxonomy Extension Definition Linkbase Document</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.28%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.34%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>101.LAB</div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Inline XBRL Taxonomy Extension Label Linkbase Document</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.28%; vertical-align: middle;">&#160;</td>

    <td style="width: 10.34%; vertical-align: middle;">&#160;</td>

    <td style="width: 10%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>101.PRE</div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Inline XBRL Taxonomy Extension Presentation Linkbase Document</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.28%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10.34%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10.26%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>104</div>
            </td>

    <td style="width: 50%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101)</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.28%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10.34%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: center;">&#8212;</div>
            </td>

    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div>Filed herewith</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div>
        <div>
          <div>
            <div>
              <div>
                <div>
                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                          <div style="text-align: left;">*</div>
                        </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                          <div>Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules upon request by the SEC;
                            provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits or schedules so furnished.</div>
                        </td>

  </tr>


</table>
                </div>

              </div>

            </div>

          </div>

        </div>

      </div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top;">#</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Portions of this exhibit have been omitted because they are both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <div style="text-align: justify; margin-left: 27pt;">Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are
        deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purpose of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or
        the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</div>

      <div style="text-align: justify; margin-left: 27pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">110</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#TABLEOFCONTENTS"><span style="font-weight: normal; font-style: italic; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: center; font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td colspan="2" style="width: 50%; vertical-align: bottom;">
              <div style="font-weight: bold;">ROIVANT SCIENCES LTD.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>

    <td style="width: 47%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Matthew Gline</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Name: Matthew Gline</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Title: Principal Executive Officer</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>

    <td style="width: 47%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Richard Pulik</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Name: Richard Pulik</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Title: Principal Financial Officer</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>

    <td style="width: 47%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Matt Maisak</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Name: Matt Maisak</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Title: Authorized Signatory</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 50%; vertical-align: top;">
              <div>February 13, 2024</div>
            </td>

    <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div> <br/>
      </div>

      <div style="text-align: center;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">111</span></div>

      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>


  </div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ef20015327_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 31.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>CERTIFICATION</u></div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">I, Matthew Gline, certify that:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z84a0a3d0287e4e519109e7a535ff67f6">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">I have reviewed this Quarterly Report on Form 10-Q of Roivant Sciences Ltd.;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8385d99eaf2b41129959f9081e5369be">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
                  the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z82274b03474f46aabcb43692a1e2d538">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results
                  of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3835d4ca1e4249c3865cde1acafd4675">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
                  and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb7bf9e0f34d44d1cb7e2f93b07743c02">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                    <div>
                      <div>
                        <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
                          consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3757974ae1c6444f90494bd274caa5a1">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font> <br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
                    designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
                    principles;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z01883d7913bc4be685fb9b6b6fd4ee1e">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our
                    conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd580ef2a26c94f9fb31e469c0effe301">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font> <br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the
                    registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over
                    financial reporting; and</td>
                </tr>

            </table>
          </div>
        </div>
        <div><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7d85b9a8d0c445f18046907c233fd64b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

              <tr style="vertical-align: top;">
                <td style="text-align: right; vertical-align: top; width: 18pt;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">5.</div>
                </td>
                <td style="text-align: left; vertical-align: top; width: auto;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
                    registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zaae17c96d17b4d7aa169013b7558713f">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font></td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
                    which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z393e06cdb2e945e9b3330617ff15fc9a">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font></td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the
                    registrant&#8217;s internal control over financial reporting.</td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Date: February 13, 2024</div>
      <div style="text-align: left;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z498c44d284ac44a1bb732a3a6e493a96" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Matthew Gline</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Matthew Gline</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Principal Executive Officer</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ef20015327_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 31.2</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>CERTIFICATION</u></div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">I, Richard Pulik, certify that:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z61cb580c0b374ef0aada30d2463d0a05" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">I have reviewed this Quarterly Report on Form 10-Q of Roivant Sciences Ltd.;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" id="zf98557303cd3467aad0d7197aa32c532" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
                  the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" id="zb1ce59af4c5049aa970b08087567635e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results
                  of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" id="z92291b3c06ad404797d40019881f263e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
                  and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" id="z5557fff7be4041cf83f99987f94441cf" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font> <br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
                    supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
                    prepared;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" id="zfc809f94414b4b62b772e52dfc26ddb3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
                    designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
                    principles;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" id="zd6095d484b1f45e9a43cb715ac652588" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our
                    conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" id="zeb286e4997174489bf7475989e0667fd" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font> <br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the
                    registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over
                    financial reporting; and</td>
                </tr>

            </table>
          </div>
        </div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" id="z72288f6b48574f9692997bf46709d6ee" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and
                  the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" id="zc6ca325d9c0c49f3b37970f6af5eaf2a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font> <br>
                  </td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
                    which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <div style="text-align: left;">
          <div>
            <table cellspacing="0" cellpadding="0" id="z16e726f44f7c4c92bd0ef18f940a5cc2" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt; vertical-align: top;"><br>
                  </td>
                  <td style="width: 24.1pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font></td>
                  <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the
                    registrant&#8217;s internal control over financial reporting.</td>
                </tr>

            </table>
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Date: February 13, 2024</div>
      <div style="text-align: left;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8266eb21428c442d8d31ac816a34b722">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Richard Pulik</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Richard Pulik</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Principal Financial Officer</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ef20015327_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 32.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CERTIFICATION</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title
        18 of the United States Code (18 U.S.C. &#167;1350), Matthew Gline, Principal Executive Officer of Roivant Sciences Ltd. (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge:</div>
      <br>
      <table cellspacing="0" cellpadding="0" id="z53da98ef216b4c9197b4e93bee512493" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies
                with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</div>
            </td>
          </tr>

      </table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z46da3250562c4bd68c3071e038e32df0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dated: February 13, 2024</div>
      <div style="text-align: left;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z33bc47ef84384c43b41a574aee0736c9">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Matthew Gline</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Matthew Gline</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Principal Executive Officer</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">A signed original of this written statement required by Section 906 of 18 U.S.C. &#167; 1350 has been provided to the Company, and will be retained by the Company and
        furnished to the Securities and Exchange Commission or its staff upon request.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by
        reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ef20015327_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 32.2</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CERTIFICATION</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title
        18 of the United States Code (18 U.S.C. &#167;1350), Richard Pulik, Principal Financial Officer of Roivant Sciences Ltd. (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5bbf806e50374427a153abe2ecf7f877">

            <tr>
              <td style="width: 17.3pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended December 31, 2023, to which this Certification is attached as Exhibit 32.2 (the &#8220;Periodic Report&#8221;), fully
                  complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbafed362a84d4424a54af943d9c169ed">

            <tr>
              <td style="width: 17.3pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: left;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dated: February 13, 2024</div>
      <div style="text-align: left;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z5d53cb026ac64d34b7dec7059310b86a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Richard Pulik</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Richard Pulik</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Principal Financial Officer</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">A signed original of this written statement required by Section 906 of 18 U.S.C. &#167; 1350 has been provided to the Company, and will be retained by the Company and
        furnished to the Securities and Exchange Commission or its staff upon request.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by
        reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>roiv-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<xs:schema targetNamespace="http://roivant.com/20231231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:roiv="http://roivant.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://roivant.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: Condensed Consolidated Balance Sheets-->
        <link:definition>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="CondensedConsolidatedStatementsOfOperationsParenthetical">
        <!--Parent Role: Condensed Consolidated Statements of Operations-->
        <link:definition>020100 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" id="CondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>030000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" id="CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
        <link:definition>040000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>050000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" id="DescriptionOfBusinessAndLiquidity">
        <link:definition>060100 - Disclosure - Description of Business and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/EquityMethodInvestments" id="EquityMethodInvestments">
        <link:definition>060300 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>060400 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/RecentTransactions" id="RecentTransactions">
        <link:definition>060500 - Disclosure - Recent Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CertainBalanceSheetComponents" id="CertainBalanceSheetComponents">
        <link:definition>060600 - Disclosure - Certain Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/LongtermDebt" id="LongtermDebt">
        <link:definition>060700 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/ShareholdersEquity" id="ShareholdersEquity">
        <link:definition>060800 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SharebasedCompensation" id="SharebasedCompensation">
        <link:definition>060900 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061000 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants" id="EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants">
        <link:definition>061200 - Disclosure - Earn-Out Shares, Public Warrants and Private Placement Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>061300 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/NetIncomeLossPerCommonShare" id="NetIncomeLossPerCommonShare">
        <link:definition>061400 - Disclosure - Net Income (Loss) per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <!--Parent Role: Intangible Assets-->
        <link:definition>080400 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/RecentTransactionsTables" id="RecentTransactionsTables">
        <!--Parent Role: Recent Transactions-->
        <link:definition>080500 - Disclosure - Recent Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CertainBalanceSheetComponentsTables" id="CertainBalanceSheetComponentsTables">
        <!--Parent Role: Certain Balance Sheet Components-->
        <link:definition>080600 - Disclosure - Certain Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/LongtermDebtTables" id="LongtermDebtTables">
        <!--Parent Role: Long-Term Debt-->
        <link:definition>080700 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SharebasedCompensationTables" id="SharebasedCompensationTables">
        <!--Parent Role: Share-Based Compensation-->
        <link:definition>080900 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <!--Parent Role: Fair Value Measurements-->
        <link:definition>081300 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/NetIncomeLossPerCommonShareTables" id="NetIncomeLossPerCommonShareTables">
        <!--Parent Role: Net Income (Loss) per Common Share-->
        <link:definition>081400 - Disclosure - Net Income (Loss) per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails" id="DescriptionOfBusinessAndLiquidityDetails">
        <!--Parent Role: Description of Business and Liquidity-->
        <link:definition>090100 - Disclosure - Description of Business and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails" id="EquityMethodInvestmentsInvestmentInArbutusDetails">
        <!--Parent Role: Equity Method Investments-->
        <link:definition>090300 - Disclosure - Equity Method Investments, Investment in Arbutus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails" id="EquityMethodInvestmentsInvestmentInDatavantDetails">
        <!--Parent Role: Equity Method Investments-->
        <link:definition>090302 - Disclosure - Equity Method Investments, Investment in Datavant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
        <!--Parent Role: Intangible Assets-->
        <link:definition>090400 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/RecentTransactionsTelavantDispositionDetails" id="RecentTransactionsTelavantDispositionDetails">
        <!--Parent Role: Recent Transactions-->
        <link:definition>090500 - Disclosure - Recent Transactions, Telavant Disposition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails" id="RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails">
        <!--Parent Role: Recent Transactions-->
        <link:definition>090502 - Disclosure - Recent Transactions, Asset Acquisition and Deconsolidation of Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails" id="CertainBalanceSheetComponentsOtherCurrentAssetsDetails">
        <!--Parent Role: Certain Balance Sheet Components-->
        <link:definition>090600 - Disclosure - Certain Balance Sheet Components, Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails" id="CertainBalanceSheetComponentsAccruedExpensesDetails">
        <!--Parent Role: Certain Balance Sheet Components-->
        <link:definition>090602 - Disclosure - Certain Balance Sheet Components, Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" id="CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails">
        <!--Parent Role: Certain Balance Sheet Components-->
        <link:definition>090604 - Disclosure - Certain Balance Sheet Components, Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails" id="LongtermDebtFundingAgreementWithNovaquestDetails">
        <!--Parent Role: Long-Term Debt-->
        <link:definition>090700 - Disclosure - Long-Term Debt, Funding Agreement with NovaQuest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails" id="LongtermDebtCreditFacilityWithXyqLuxcoDetails">
        <!--Parent Role: Long-Term Debt-->
        <link:definition>090702 - Disclosure - Long-Term Debt, Credit Facility with XYQ Luxco (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails" id="LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails">
        <!--Parent Role: Long-Term Debt-->
        <link:definition>090704 - Disclosure - Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" id="LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2">
        <!--Parent Role: Long-Term Debt, Credit Facility with XYQ Luxco (Details)-->
        <link:definition>090704 - Disclosure - Long-Term Debt, Credit Facility with XYQ Luxco (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" id="LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2">
        <!--Parent Role: Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details)-->
        <link:definition>090706 - Disclosure - Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/ShareholdersEquityDetails" id="ShareholdersEquityDetails">
        <!--Parent Role: Shareholders' Equity-->
        <link:definition>090800 - Disclosure - Shareholders' Equity - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails" id="SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails">
        <!--Parent Role: Share-Based Compensation-->
        <link:definition>090900 - Disclosure - Share-Based Compensation, Stock Options and Performance Stock Options under RSL Equity Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails" id="SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails">
        <!--Parent Role: Share-Based Compensation-->
        <link:definition>090902 - Disclosure - Share-Based Compensation, Restricted Stock Units and Performance Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails" id="SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails">
        <!--Parent Role: Share-Based Compensation-->
        <link:definition>090904 - Disclosure - Share-Based Compensation, CVARs, Employee Stock Purchase Plan and Subsidiary Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091000 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>091100 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails" id="EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails">
        <!--Parent Role: Earn-Out Shares, Public Warrants and Private Placement Warrants-->
        <link:definition>091200 - Disclosure - Earn-Out Shares, Public Warrants and Private Placement Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails" id="FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails">
        <!--Parent Role: Fair Value Measurements-->
        <link:definition>091300 - Disclosure - Fair Value Measurements, Assets and Liabilities are Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails" id="FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails">
        <!--Parent Role: Fair Value Measurements-->
        <link:definition>091302 - Disclosure - Fair Value Measurements, Changes in Fair Value of the Level 3 Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" id="FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails">
        <!--Parent Role: Fair Value Measurements-->
        <link:definition>091304 - Disclosure - Fair Value Measurements, Changes in Fair Value of the Level 3 Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails" id="FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails">
        <!--Parent Role: Fair Value Measurements-->
        <link:definition>091306 - Disclosure - Fair Value Measurements, Fair Value of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://roivant.com/role/NetIncomeLossPerCommonShareDetails" id="NetIncomeLossPerCommonShareDetails">
        <!--Parent Role: Net Income (Loss) per Common Share-->
        <link:definition>091400 - Disclosure - Net Income (Loss) per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xs:element name="CappedValueAppreciationRightsMember" id="roiv_CappedValueAppreciationRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="November2021CappedValueAppreciationRightsGrantsMember" id="roiv_November2021CappedValueAppreciationRightsGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SubsidiaryEquityIncentivePlansMember" id="roiv_SubsidiaryEquityIncentivePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RoivantSciencesLtd2021EquityIncentivePlanMember" id="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SubsidiaryEquityIncentivePlansAbstract" id="roiv_SubsidiaryEquityIncentivePlansAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityInstrumentsVestedAndSettledShares" id="roiv_EquityInstrumentsVestedAndSettledShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="March2020CappedValueAppreciationRightsGrantsMember" id="roiv_March2020CappedValueAppreciationRightsGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DescriptionOfBusinessAndLiquidityAbstract" id="roiv_DescriptionOfBusinessAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CertainBalanceSheetComponentsAbstract" id="roiv_CertainBalanceSheetComponentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DermavantMember" id="roiv_DermavantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FundingAgreementWithNovaQuestAbstract" id="roiv_FundingAgreementWithNovaQuestAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentQuarterlyPaymentsMade" id="roiv_DebtInstrumentQuarterlyPaymentsMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" id="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MaximumMilestonePaymentOffsetAmount" id="roiv_MaximumMilestonePaymentOffsetAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="FundingAgreementWithNovaQuestMember" id="roiv_FundingAgreementWithNovaQuestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumMilestonePaymentObligation" id="roiv_MaximumMilestonePaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ExerciseOfPrivatePlacementWarrantsValue" id="roiv_ExerciseOfPrivatePlacementWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="OtherOfOtherAssetsCurrent" id="roiv_OtherOfOtherAssetsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" id="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CreditFacilityWithXYQLuxcoMember" id="roiv_CreditFacilityWithXYQLuxcoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ArbutusBiopharmaCorporationMember" id="roiv_ArbutusBiopharmaCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InvestmentsDisclosureAbstract" id="roiv_InvestmentsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanAndCreditAgreementsByDermavantAbstract" id="roiv_LoanAndCreditAgreementsByDermavantAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentExitFeeAndEndOfTermCharge" id="roiv_DebtInstrumentExitFeeAndEndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DebtInstrumentExitFee" id="roiv_DebtInstrumentExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RevenueInterestPurchaseAndSaleAgreementAbstract" id="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommittedFundingUnderRIPSA" id="roiv_CommittedFundingUnderRIPSA" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueNetIssuanceCosts" id="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CapitalContributionsToSubsidiaries" id="roiv_CapitalContributionsToSubsidiaries" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" id="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesNetIssuanceCosts" id="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" id="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RedeemableNoncontrollingInterestMember" id="roiv_RedeemableNoncontrollingInterestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DividendDeclaredBySubsidiary" id="roiv_DividendDeclaredBySubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" id="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" id="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NoncontrollingInterestIncreaseDecreaseFromDisposition" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RestrictedStockAndPerformanceStockUnitsMember" id="roiv_RestrictedStockAndPerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RoivantSciencesLtdEquityPlansMember" id="roiv_RoivantSciencesLtdEquityPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RecentTransactionsAbstract" id="roiv_RecentTransactionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RecentTransactionsTextBlock" id="roiv_RecentTransactionsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EarnoutSharesMember" id="roiv_EarnoutSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrivatePlacementWarrantsMember" id="roiv_PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FairValueMeasurementInputsAndValuationTechniquesAbstract" id="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FairValueAssetMeasurementInput" id="roiv_FairValueAssetMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="FairValueEarnoutSharesMeasurementInput" id="roiv_FairValueEarnoutSharesMeasurementInput" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DatavantHoldingsIncMember" id="roiv_DatavantHoldingsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PublicWarrantsMember" id="roiv_PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiabilityInstrumentsMeasuredAtFairValueMember" id="roiv_LiabilityInstrumentsMeasuredAtFairValueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" id="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" id="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LiabilityInstrumentsMeasuredAtFairValue" id="roiv_LiabilityInstrumentsMeasuredAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CioxParentMember" id="roiv_CioxParentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PalantirTechnologiesIncMember" id="roiv_PalantirTechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GSKMember" id="roiv_GSKMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CashBonusProgramMember" id="roiv_CashBonusProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProprietarySoftwareSubscriptionPeriod" id="roiv_ProprietarySoftwareSubscriptionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RemainingMinimumPurchaseCommitmentRelatedToAgreement" id="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PeriodOfRightToTerminateTheProductServiceAgreement" id="roiv_PeriodOfRightToTerminateTheProductServiceAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SamsungBiologicsCo.Ltd.Member" id="roiv_SamsungBiologicsCo.Ltd.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PeriodToPurchaseAdditionalBatchesOfBatoclimab" id="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfBonusPayableInNext30DaysOfGrantDate" id="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="FiftyPercentBonusPayablePeriodFromGrantDate" id="roiv_FiftyPercentBonusPayablePeriodFromGrantDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DescriptionOfBusinessAbstract" id="roiv_DescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiquidityAbstract" id="roiv_LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GainLossOnSaleOfAssets" id="roiv_GainLossOnSaleOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TelavantHoldingsIncMember" id="roiv_TelavantHoldingsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaymentsOfSubsidiaryDividends" id="roiv_PaymentsOfSubsidiaryDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromSubsidiaryDebtFinancingsNet" id="roiv_ProceedsFromSubsidiaryDebtFinancingsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MilestonePayments" id="roiv_MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromSaleOfAssets" id="roiv_ProceedsFromSaleOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PaymentForOfferingAndLoanCosts" id="roiv_PaymentForOfferingAndLoanCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" id="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" id="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NoncashOther" id="roiv_NoncashOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" id="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentForWarrantRedemptions" id="roiv_PaymentForWarrantRedemptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NonCashAcquiredInProcessResearchAndDevelopment" id="roiv_NonCashAcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GainLossOnFairValueOfDebtAndLiabilityInstruments" id="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentsOfTaxesForTheRepurchaseOfEquity" id="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CashlessExerciseOfTheCompanyCommonStockWarrants" id="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PfizerMember" id="roiv_PfizerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RSLMember" id="roiv_RSLMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupAbstract" id="roiv_DisposalGroupAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncomeLossFromDisposalGroupBeforeIncomeTax" id="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" id="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupNetAssetsLiabilities" id="roiv_DisposalGroupNetAssetsLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="FutureMilestoneToBeReceivedFromSaleOfAssets" id="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupAssets" id="roiv_DisposalGroupAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="OwnershipPercentage" id="roiv_OwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DisposalGroupLiabilities" id="roiv_DisposalGroupLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DisposalGroupConsiderationAbstract" id="roiv_DisposalGroupConsiderationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupNoncontrollingInterestDerecognizedValue" id="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ConsiderationReceivedForSaleOfAssets" id="roiv_ConsiderationReceivedForSaleOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="UpfrontCashPaymentReceivedForSaleOfAssets" id="roiv_UpfrontCashPaymentReceivedForSaleOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RocheTransactionMember" id="roiv_RocheTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PublicWarrantsAndPrivatePlacementWarrantsMember" id="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PatientSquareCapitalLimitedLiabilityCompanyMember" id="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TwentyPercentEarnOutSharesMember" id="roiv_TwentyPercentEarnOutSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PublicWarrantsAndPrivatePlacementWarrantsAbstract" id="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" id="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CashExercisePrice" id="roiv_CashExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfTradingDays" id="roiv_NumberOfTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" id="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightRedemptionPrice" id="roiv_ClassOfWarrantOrRightRedemptionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockIssuedDuringPeriodSharesCashWarrantExercises" id="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EarnOutSharesAbstract" id="roiv_EarnOutSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfEarnOutShares" id="roiv_PercentageOfEarnOutShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfEarnOutSharesVested" id="roiv_NumberOfEarnOutSharesVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="EarnOutSharePrice" id="roiv_EarnOutSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" id="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesCashlessWarrantExercises" id="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PublicWarrantCashExercised" id="roiv_PublicWarrantCashExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PeriodToExerciseWarrantsAfterBusinessCombination" id="roiv_PeriodToExerciseWarrantsAfterBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TenPercentEarnOutSharesMember" id="roiv_TenPercentEarnOutSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePrice" id="roiv_ExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" id="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CashlessPublicWarrantExercised" id="roiv_CashlessPublicWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AcquiredInProcessResearchAndDevelopmentExpense" id="roiv_AcquiredInProcessResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="InterestIncome" id="roiv_InterestIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LicenseMilestoneAndOtherRevenueMember" id="roiv_LicenseMilestoneAndOtherRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OperatingCosts" id="roiv_OperatingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockOptionsAndPerformanceStockOptionsMember" id="roiv_StockOptionsAndPerformanceStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OtherStockBasedAwardsAndInstrumentsIssuedMember" id="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EarnOutSharesNonvestedMember" id="roiv_EarnOutSharesNonvestedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfEquityIncentivePlans" id="roiv_NumberOfEquityIncentivePlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="UnderwrittenPublicOfferingMember" id="roiv_UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ImmunovantIncMember" id="roiv_ImmunovantIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RoivantParticipationOfImmunovantStockOfferingMember" id="roiv_RoivantParticipationOfImmunovantStockOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonSharesOfferingPriceAuthorized" id="roiv_CommonSharesOfferingPriceAuthorized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="EstimatedNetProceedsFromIssuanceOfCommonStock" id="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockPurchasedDuringPeriodByEntityShares" id="roiv_StockPurchasedDuringPeriodByEntityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NetProceedsFromIssuanceOfCommonStock" id="roiv_NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EquityOfferingsAtTheMarketMember" id="roiv_EquityOfferingsAtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OptionToPurchaseAdditionalSharesOfCommonStock" id="roiv_OptionToPurchaseAdditionalSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" id="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CowenAndCompanyLLCMember" id="roiv_CowenAndCompanyLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" id="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" id="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" id="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" id="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProteovantSciencesIncMember" id="roiv_ProteovantSciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SKIncMember" id="roiv_SKIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SKBiopharmaceuticalsCoLtdMember" id="roiv_SKBiopharmaceuticalsCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeconsolidationOfSubsidiariesAbstract" id="roiv_DeconsolidationOfSubsidiariesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" id="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MilestonePaymentPayable" id="roiv_MilestonePaymentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NewlyFormedSubsidiaryMember" id="roiv_NewlyFormedSubsidiaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UpfrontCashPayment" id="roiv_UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="VantAIPreferredFinancingMember" id="roiv_VantAIPreferredFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccruedSalesAllowancesCurrent" id="roiv_AccruedSalesAllowancesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedResearchAndDevelopmentExpensesCurrent" id="roiv_AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="WelichemBiotechIncMember" id="roiv_WelichemBiotechIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IntangibleAssetAbstract" id="roiv_IntangibleAssetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MilestonePayable" id="roiv_MilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="MilestonePaid" id="roiv_MilestonePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" id="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" id="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>roiv-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtCreditFacilityWithXyqLuxcoDetails" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtFundingAgreementWithNovaquestDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsAccruedExpensesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsOtherCurrentAssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactionsTelavantDispositionDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactionsTelavantDispositionDetails" />
  <link:roleRef roleURI="http://roivant.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="InvestmentsFairValueDisclosure" xlink:title="calculation: Assets to InvestmentsFairValueDisclosure" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="OtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to OtherAssetsCurrent" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="LiabilityInstrumentsMeasuredAtFairValue" xlink:title="LiabilityInstrumentsMeasuredAtFairValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilityInstrumentsMeasuredAtFairValue" xlink:title="calculation: Liabilities to LiabilityInstrumentsMeasuredAtFairValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LongTermDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to LongTermDebtCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OtherLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to OtherLiabilitiesCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermDebt" xlink:title="calculation: Liabilities to LongTermDebt" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="MinorityInterest" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to MinorityInterest" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="StockholdersEquity" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to StockholdersEquity" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="GainLossOnFairValueOfDebtAndLiabilityInstruments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to GainLossOnFairValueOfDebtAndLiabilityInstruments" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="DeconsolidationGainOrLossAmount" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to DeconsolidationGainOrLossAmount" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OtherNonoperatingIncomeExpense" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InterestIncome" xlink:label="InterestIncome" xlink:title="InterestIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestIncome" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestIncome" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GainLossOnSaleOfAssets" xlink:title="calculation: OperatingIncomeLoss to GainLossOnSaleOfAssets" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="calculation: OperatingIncomeLoss to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OperatingCosts" xlink:label="OperatingCosts" xlink:title="OperatingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="OperatingCosts" xlink:title="calculation: OperatingExpenses to OperatingCosts" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="AcquiredInProcessResearchAndDevelopmentExpense" xlink:title="AcquiredInProcessResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="AcquiredInProcessResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to AcquiredInProcessResearchAndDevelopmentExpense" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to SellingGeneralAndAdministrativeExpense" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestExpense" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="GainLossOnInvestments" xlink:title="GainLossOnInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="GainLossOnInvestments" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to GainLossOnInvestments" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: ProfitLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: ProfitLoss to IncomeTaxExpenseBenefit" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="ProfitLoss" xlink:title="calculation: NetIncomeLoss to ProfitLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to NetIncomeLossAttributableToNoncontrollingInterest" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="calculation: ComprehensiveIncomeNetOfTax to ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="calculation: OtherComprehensiveIncomeLossNetOfTax to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="OtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to OtherComprehensiveIncomeLossNetOfTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="ProfitLoss" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to ProfitLoss" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="calculation: ComprehensiveIncomeNetOfTax to ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="19.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OtherNoncashIncomeExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OtherNoncashIncomeExpense" order="23.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="NonCashAcquiredInProcessResearchAndDevelopment" xlink:title="NonCashAcquiredInProcessResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NonCashAcquiredInProcessResearchAndDevelopment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NonCashAcquiredInProcessResearchAndDevelopment" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableTrade" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableTrade" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOperatingLeaseLiability" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDispositionOfAssets1" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DeconsolidationGainOrLossAmount" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DeconsolidationGainOrLossAmount" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="GainLossOnInvestments" xlink:title="GainLossOnInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnInvestments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnInvestments" order="20.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ProfitLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ProfitLoss" order="18.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="IncreaseDecreaseInOtherOperatingCapitalNet" xlink:title="IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingCapitalNet" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingCapitalNet" order="16.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="IncreaseDecreaseInOtherCurrentAssets" xlink:title="IncreaseDecreaseInOtherCurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherCurrentAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherCurrentAssets" order="13.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilities" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationDepletionAndAmortization" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="GainLossOnFairValueOfDebtAndLiabilityInstruments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnFairValueOfDebtAndLiabilityInstruments" order="21.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentForWarrantRedemptions" xlink:label="PaymentForWarrantRedemptions" xlink:title="PaymentForWarrantRedemptions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentForWarrantRedemptions" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentForWarrantRedemptions" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromWarrantExercises" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromWarrantExercises" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentsOfSubsidiaryDividends" xlink:label="PaymentsOfSubsidiaryDividends" xlink:title="PaymentsOfSubsidiaryDividends" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfSubsidiaryDividends" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfSubsidiaryDividends" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentForOfferingAndLoanCosts" xlink:label="PaymentForOfferingAndLoanCosts" xlink:title="PaymentForOfferingAndLoanCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentForOfferingAndLoanCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentForOfferingAndLoanCosts" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:label="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:title="PaymentsOfTaxesForTheRepurchaseOfEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfTaxesForTheRepurchaseOfEquity" order="16.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="ProceedsFromStockPlans" xlink:title="ProceedsFromStockPlans" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockPlans" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockPlans" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:title="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="12.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:title="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:title="ProceedsFromSubsidiaryDebtFinancingsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromSubsidiaryDebtFinancingsNet" order="17.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="CashDivestedFromDeconsolidation" xlink:title="CashDivestedFromDeconsolidation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="CashDivestedFromDeconsolidation" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to CashDivestedFromDeconsolidation" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromSaleOfAssets" xlink:label="ProceedsFromSaleOfAssets" xlink:title="ProceedsFromSaleOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfAssets" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="MilestonePayments" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to MilestonePayments" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="PaymentsForProceedsFromOtherInvestingActivities" xlink:title="PaymentsForProceedsFromOtherInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsForProceedsFromOtherInvestingActivities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsForProceedsFromOtherInvestingActivities" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:label="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:title="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to CashAndCashEquivalentsAtCarryingValue" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="RestrictedCashCurrent" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to RestrictedCashCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="RestrictedCashNoncurrent" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to RestrictedCashNoncurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/IntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="calculation: IntangibleAssetsNetExcludingGoodwill to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="calculation: IntangibleAssetsNetExcludingGoodwill to FiniteLivedIntangibleAssetsGross" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactionsTelavantDispositionDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupNetAssetsLiabilities" xlink:label="DisposalGroupNetAssetsLiabilities" xlink:title="DisposalGroupNetAssetsLiabilities" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupLiabilities" xlink:label="DisposalGroupLiabilities" xlink:title="DisposalGroupLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DisposalGroupNetAssetsLiabilities" xlink:to="DisposalGroupLiabilities" xlink:title="calculation: DisposalGroupNetAssetsLiabilities to DisposalGroupLiabilities" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupAssets" xlink:label="DisposalGroupAssets" xlink:title="DisposalGroupAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DisposalGroupNetAssetsLiabilities" xlink:to="DisposalGroupAssets" xlink:title="calculation: DisposalGroupNetAssetsLiabilities to DisposalGroupAssets" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="PrepaidExpenseCurrent" xlink:title="PrepaidExpenseCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherAssetsCurrent" xlink:to="PrepaidExpenseCurrent" xlink:title="calculation: OtherAssetsCurrent to PrepaidExpenseCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherAssetsCurrent" xlink:to="RestrictedCashCurrent" xlink:title="calculation: OtherAssetsCurrent to RestrictedCashCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="IncomeTaxesReceivable" xlink:title="IncomeTaxesReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherAssetsCurrent" xlink:to="IncomeTaxesReceivable" xlink:title="calculation: OtherAssetsCurrent to IncomeTaxesReceivable" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherAssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: OtherAssetsCurrent to InventoryNet" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherAssetsCurrent" xlink:to="ReceivablesNetCurrent" xlink:title="calculation: OtherAssetsCurrent to ReceivablesNetCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherOfOtherAssetsCurrent" xlink:label="OtherOfOtherAssetsCurrent" xlink:title="OtherOfOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherAssetsCurrent" xlink:to="OtherOfOtherAssetsCurrent" xlink:title="calculation: OtherAssetsCurrent to OtherOfOtherAssetsCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="InterestReceivable" xlink:title="InterestReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherAssetsCurrent" xlink:to="InterestReceivable" xlink:title="calculation: OtherAssetsCurrent to InterestReceivable" order="6.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="AccruedResearchAndDevelopmentExpensesCurrent" xlink:title="AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentExpensesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentExpensesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AccruedSalesAllowancesCurrent" xlink:label="AccruedSalesAllowancesCurrent" xlink:title="AccruedSalesAllowancesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedSalesAllowancesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedSalesAllowancesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to OtherAccruedLiabilitiesCurrent" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="OtherSundryLiabilitiesCurrent" xlink:title="OtherSundryLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherLiabilitiesCurrent" xlink:to="OtherSundryLiabilitiesCurrent" xlink:title="calculation: OtherLiabilitiesCurrent to OtherSundryLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherLiabilitiesCurrent" xlink:to="DeferredRevenueCurrent" xlink:title="calculation: OtherLiabilitiesCurrent to DeferredRevenueCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherLiabilitiesCurrent" xlink:to="TaxesPayableCurrent" xlink:title="calculation: OtherLiabilitiesCurrent to TaxesPayableCurrent" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="DebtInstrumentFairValue" xlink:title="DebtInstrumentFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="ShorttermDebtFairValue" xlink:title="ShorttermDebtFairValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtInstrumentFairValue" xlink:to="ShorttermDebtFairValue" xlink:title="calculation: DebtInstrumentFairValue to ShorttermDebtFairValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtInstrumentFairValue" xlink:to="LongTermDebtFairValue" xlink:title="calculation: DebtInstrumentFairValue to LongTermDebtFairValue" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="LongTermDebtCurrent" xlink:title="calculation: LongTermDebt to LongTermDebtCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="LongTermDebtNoncurrent" xlink:title="calculation: LongTermDebt to LongTermDebtNoncurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentCarryingAmount" xlink:title="calculation: LongTermDebt to DebtInstrumentCarryingAmount" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentExitFee" xlink:title="calculation: LongTermDebt to DebtInstrumentExitFee" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="calculation: LongTermDebt to DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentCarryingAmount" xlink:title="calculation: LongTermDebt to DebtInstrumentCarryingAmount" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="calculation: LongTermDebt to DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1.0" weight="-1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>roiv-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:roleRef roleURI="http://roivant.com/role/NetIncomeLossPerCommonShareDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#NetIncomeLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails" />
  <link:roleRef roleURI="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails" />
  <link:roleRef roleURI="http://roivant.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#ShareholdersEquityDetails" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtCreditFacilityWithXyqLuxcoDetails" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtFundingAgreementWithNovaquestDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsAccruedExpensesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsOtherCurrentAssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactionsTelavantDispositionDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactionsTelavantDispositionDetails" />
  <link:roleRef roleURI="http://roivant.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#EquityMethodInvestmentsInvestmentInDatavantDetails" />
  <link:roleRef roleURI="http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#EquityMethodInvestmentsInvestmentInArbutusDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#DescriptionOfBusinessAndLiquidityDetails" />
  <link:roleRef roleURI="http://roivant.com/role/NetIncomeLossPerCommonShareTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#NetIncomeLossPerCommonShareTables" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsTables" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationTables" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtTables" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsTables" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactionsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactionsTables" />
  <link:roleRef roleURI="http://roivant.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://roivant.com/role/NetIncomeLossPerCommonShare" xlink:type="simple" xlink:href="roiv-20231231.xsd#NetIncomeLossPerCommonShare" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurements" />
  <link:roleRef roleURI="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants" xlink:type="simple" xlink:href="roiv-20231231.xsd#EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants" />
  <link:roleRef roleURI="http://roivant.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="roiv-20231231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://roivant.com/role/IncomeTaxes" xlink:type="simple" xlink:href="roiv-20231231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensation" />
  <link:roleRef roleURI="http://roivant.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="roiv-20231231.xsd#ShareholdersEquity" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebt" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebt" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponents" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponents" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactions" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactions" />
  <link:roleRef roleURI="http://roivant.com/role/IntangibleAssets" xlink:type="simple" xlink:href="roiv-20231231.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://roivant.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="roiv-20231231.xsd#EquityMethodInvestments" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" xlink:type="simple" xlink:href="roiv-20231231.xsd#DescriptionOfBusinessAndLiquidity" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://roivant.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="roiv-20231231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="definition: StatementLineItems to RevenuesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingExpensesAbstract" xlink:title="definition: StatementLineItems to OperatingExpensesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainLossOnSaleOfAssets" xlink:title="definition: StatementLineItems to GainLossOnSaleOfAssets" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: StatementLineItems to OperatingIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="GainLossOnInvestments" xlink:title="GainLossOnInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainLossOnInvestments" xlink:title="definition: StatementLineItems to GainLossOnInvestments" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="GainLossOnFairValueOfDebtAndLiabilityInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="definition: StatementLineItems to GainLossOnFairValueOfDebtAndLiabilityInstruments" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DeconsolidationGainOrLossAmount" xlink:title="definition: StatementLineItems to DeconsolidationGainOrLossAmount" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InterestIncome" xlink:label="InterestIncome" xlink:title="InterestIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestIncome" xlink:title="definition: StatementLineItems to InterestIncome" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="definition: StatementLineItems to InterestExpense" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="definition: StatementLineItems to OtherNonoperatingIncomeExpense" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="definition: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="definition: StatementLineItems to IncomeTaxExpenseBenefit" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProfitLoss" xlink:title="definition: StatementLineItems to ProfitLoss" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="definition: StatementLineItems to NetIncomeLossAttributableToNoncontrollingInterest" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="definition: StatementLineItems to EarningsPerShareAbstract" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingAbstract" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: StatementLineItems to EarningsPerShareBasic" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: StatementLineItems to EarningsPerShareDiluted" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OperatingCosts" xlink:label="OperatingCosts" xlink:title="OperatingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingCosts" xlink:title="definition: StatementLineItems to OperatingCosts" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: StatementLineItems to ResearchAndDevelopmentExpense" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="AcquiredInProcessResearchAndDevelopmentExpense" xlink:title="AcquiredInProcessResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AcquiredInProcessResearchAndDevelopmentExpense" xlink:title="definition: StatementLineItems to AcquiredInProcessResearchAndDevelopmentExpense" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="definition: StatementLineItems to SellingGeneralAndAdministrativeExpense" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingExpenses" xlink:title="definition: StatementLineItems to OperatingExpenses" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: StatementLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="28.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: StatementTable to ProductOrServiceAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ProductMember" xlink:title="definition: ProductsAndServicesDomain to ProductMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LicenseMilestoneAndOtherRevenueMember" xlink:label="LicenseMilestoneAndOtherRevenueMember" xlink:title="LicenseMilestoneAndOtherRevenueMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseMilestoneAndOtherRevenueMember" xlink:title="definition: ProductsAndServicesDomain to LicenseMilestoneAndOtherRevenueMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensation" xlink:title="definition: StatementLineItems to ShareBasedCompensation" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: StatementTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="definition: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInTemporaryEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="definition: StatementLineItems to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:label="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:title="NoncontrollingInterestIncreaseDecreaseFromDisposition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:title="definition: StatementLineItems to NoncontrollingInterestIncreaseDecreaseFromDisposition" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:title="StockIssuedDuringPeriodValueNetIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNetIssuanceCosts" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:title="StockIssuedDuringPeriodSharesNetIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNetIssuanceCosts" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:title="definition: StatementLineItems to IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:title="definition: StatementLineItems to IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:label="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:title="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:label="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:title="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:label="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:title="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:title="definition: StatementLineItems to NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:label="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:title="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:label="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:title="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:title="definition: StatementLineItems to IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:label="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:title="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:title="definition: StatementLineItems to APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="CapitalContributionsToSubsidiaries" xlink:title="CapitalContributionsToSubsidiaries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CapitalContributionsToSubsidiaries" xlink:title="definition: StatementLineItems to CapitalContributionsToSubsidiaries" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DividendDeclaredBySubsidiary" xlink:label="DividendDeclaredBySubsidiary" xlink:title="DividendDeclaredBySubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DividendDeclaredBySubsidiary" xlink:title="definition: StatementLineItems to DividendDeclaredBySubsidiary" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:title="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:title="definition: StatementLineItems to NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="definition: StatementLineItems to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProfitLoss" xlink:title="definition: StatementLineItems to ProfitLoss" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:title="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:title="definition: StatementLineItems to TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:title="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:title="definition: StatementLineItems to DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="35.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="RedeemableNoncontrollingInterestMember" xlink:title="RedeemableNoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RedeemableNoncontrollingInterestMember" xlink:title="definition: EquityComponentDomain to RedeemableNoncontrollingInterestMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="NoncontrollingInterestMember" xlink:title="NoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="NoncontrollingInterestMember" xlink:title="definition: EquityComponentDomain to NoncontrollingInterestMember" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/EquityMethodInvestments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IntangibleAssets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebt" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/NetIncomeLossPerCommonShare" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IntangibleAssetsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactionsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ScheduleOfDebtInstrumentsTextBlock" xlink:title="definition: DebtInstrumentLineItems to ScheduleOfDebtInstrumentsTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: DebtInstrumentTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to DermavantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: DebtInstrumentTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestMember" xlink:label="FundingAgreementWithNovaQuestMember" xlink:title="FundingAgreementWithNovaQuestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="FundingAgreementWithNovaQuestMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to FundingAgreementWithNovaQuestMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CreditFacilityWithXYQLuxcoMember" xlink:label="CreditFacilityWithXYQLuxcoMember" xlink:title="CreditFacilityWithXYQLuxcoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CreditFacilityWithXYQLuxcoMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CreditFacilityWithXYQLuxcoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:label="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DatavantHoldingsIncMember" xlink:label="DatavantHoldingsIncMember" xlink:title="DatavantHoldingsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="DatavantHoldingsIncMember" xlink:title="definition: EquityMethodInvesteeNameDomain to DatavantHoldingsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnoutSharesMember" xlink:label="EarnoutSharesMember" xlink:title="EarnoutSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="EarnoutSharesMember" xlink:title="definition: EquityComponentDomain to EarnoutSharesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/NetIncomeLossPerCommonShareTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="LiquidityAbstract" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to LiquidityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="GainLossOnSaleOfAssets" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to GainLossOnSaleOfAssets" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to CashAndCashEquivalentsAtCarryingValue" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to RetainedEarningsAccumulatedDeficit" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ProfitLoss" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to ProfitLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to ScheduleOfEquityMethodInvestmentsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TelavantHoldingsIncMember" xlink:label="TelavantHoldingsIncMember" xlink:title="TelavantHoldingsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="TelavantHoldingsIncMember" xlink:title="definition: EquityMethodInvesteeNameDomain to TelavantHoldingsIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InvestmentsDisclosureAbstract" xlink:label="InvestmentsDisclosureAbstract" xlink:title="InvestmentsDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="InvestmentsDisclosureAbstract" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to InvestmentsDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to CommonStockSharesOutstanding" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to EquityMethodInvestmentOwnershipPercentage" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="InvestmentsFairValueDisclosure" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to InvestmentsFairValueDisclosure" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to UnrealizedGainLossOnInvestments" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="SharePrice" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to SharePrice" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to ScheduleOfEquityMethodInvestmentsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="ArbutusBiopharmaCorporationMember" xlink:title="ArbutusBiopharmaCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="ArbutusBiopharmaCorporationMember" xlink:title="definition: EquityMethodInvesteeNameDomain to ArbutusBiopharmaCorporationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InvestmentsDisclosureAbstract" xlink:label="InvestmentsDisclosureAbstract" xlink:title="InvestmentsDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="InvestmentsDisclosureAbstract" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to InvestmentsDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to EquityMethodInvestmentOwnershipPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="InvestmentsFairValueDisclosure" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to InvestmentsFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to UnrealizedGainLossOnInvestments" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to ScheduleOfEquityMethodInvestmentsTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CioxParentMember" xlink:label="CioxParentMember" xlink:title="CioxParentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="CioxParentMember" xlink:title="definition: EquityMethodInvesteeNameDomain to CioxParentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:title="AcquiredFiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IntangibleAssetAbstract" xlink:label="IntangibleAssetAbstract" xlink:title="IntangibleAssetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="IntangibleAssetAbstract" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to IntangibleAssetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePayable" xlink:label="MilestonePayable" xlink:title="MilestonePayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="MilestonePayable" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to MilestonePayable" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePaid" xlink:label="MilestonePaid" xlink:title="MilestonePaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="MilestonePaid" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to MilestonePaid" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:title="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsGross" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to IntangibleAssetsNetExcludingGoodwill" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:title="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:title="definition: AcquiredFiniteLivedIntangibleAssetsLineItems to ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable to CounterpartyNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:label="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:title="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_WelichemBiotechIncMember" xlink:label="WelichemBiotechIncMember" xlink:title="WelichemBiotechIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="WelichemBiotechIncMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to WelichemBiotechIncMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable to IncomeStatementLocationAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="definition: IncomeStatementLocationDomain to CostOfSalesMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactionsTelavantDispositionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupAbstract" xlink:label="DisposalGroupAbstract" xlink:title="DisposalGroupAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OwnershipPercentage" xlink:label="OwnershipPercentage" xlink:title="OwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="OwnershipPercentage" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to OwnershipPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:label="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:title="IncomeLossFromDisposalGroupBeforeIncomeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to IncomeLossFromDisposalGroupBeforeIncomeTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupConsiderationAbstract" xlink:label="DisposalGroupConsiderationAbstract" xlink:title="DisposalGroupConsiderationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupConsiderationAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupConsiderationAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupAssets" xlink:label="DisposalGroupAssets" xlink:title="DisposalGroupAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupAssets" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupLiabilities" xlink:label="DisposalGroupLiabilities" xlink:title="DisposalGroupLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupLiabilities" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupLiabilities" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupNetAssetsLiabilities" xlink:label="DisposalGroupNetAssetsLiabilities" xlink:title="DisposalGroupNetAssetsLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupNetAssetsLiabilities" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupNetAssetsLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="GainLossOnSaleOfAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to GainLossOnSaleOfAssets" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UpfrontCashPaymentReceivedForSaleOfAssets" xlink:label="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:title="UpfrontCashPaymentReceivedForSaleOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to UpfrontCashPaymentReceivedForSaleOfAssets" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:label="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:title="FutureMilestoneToBeReceivedFromSaleOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to FutureMilestoneToBeReceivedFromSaleOfAssets" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:label="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:title="DisposalGroupNoncontrollingInterestDerecognizedValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupNoncontrollingInterestDerecognizedValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ConsiderationReceivedForSaleOfAssets" xlink:label="ConsiderationReceivedForSaleOfAssets" xlink:title="ConsiderationReceivedForSaleOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ConsiderationReceivedForSaleOfAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to ConsiderationReceivedForSaleOfAssets" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TelavantHoldingsIncMember" xlink:label="TelavantHoldingsIncMember" xlink:title="TelavantHoldingsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="TelavantHoldingsIncMember" xlink:title="definition: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to TelavantHoldingsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RocheTransactionMember" xlink:label="RocheTransactionMember" xlink:title="RocheTransactionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="RocheTransactionMember" xlink:title="definition: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to RocheTransactionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RSLMember" xlink:label="RSLMember" xlink:title="RSLMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RSLMember" xlink:title="definition: EquityComponentDomain to RSLMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PfizerMember" xlink:label="PfizerMember" xlink:title="PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="PfizerMember" xlink:title="definition: EquityComponentDomain to PfizerMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="AssetAcquisitionLineItems" xlink:title="AssetAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="AssetAcquisitionAbstract" xlink:title="AssetAcquisitionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="AssetAcquisitionAbstract" xlink:title="definition: AssetAcquisitionLineItems to AssetAcquisitionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DeconsolidationOfSubsidiariesAbstract" xlink:label="DeconsolidationOfSubsidiariesAbstract" xlink:title="DeconsolidationOfSubsidiariesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="DeconsolidationOfSubsidiariesAbstract" xlink:title="definition: AssetAcquisitionLineItems to DeconsolidationOfSubsidiariesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:title="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:title="definition: AssetAcquisitionLineItems to PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: AssetAcquisitionLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="DeconsolidationGainOrLossAmount" xlink:title="definition: AssetAcquisitionLineItems to DeconsolidationGainOrLossAmount" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="InvestmentsFairValueDisclosure" xlink:title="definition: AssetAcquisitionLineItems to InvestmentsFairValueDisclosure" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UpfrontCashPayment" xlink:label="UpfrontCashPayment" xlink:title="UpfrontCashPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="UpfrontCashPayment" xlink:title="definition: AssetAcquisitionLineItems to UpfrontCashPayment" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:label="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:title="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:title="definition: AssetAcquisitionLineItems to AssetAcquisitionResearchAndDevelopmentExpenseInProcess" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePaymentPayable" xlink:label="MilestonePaymentPayable" xlink:title="MilestonePaymentPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionLineItems" xlink:to="MilestonePaymentPayable" xlink:title="definition: AssetAcquisitionLineItems to MilestonePaymentPayable" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="AssetAcquisitionTable" xlink:title="AssetAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AssetAcquisitionLineItems" xlink:to="AssetAcquisitionTable" xlink:title="definition: AssetAcquisitionLineItems to AssetAcquisitionTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="AssetAcquisitionTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: AssetAcquisitionTable to SubsidiarySaleOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_VantAIPreferredFinancingMember" xlink:label="VantAIPreferredFinancingMember" xlink:title="VantAIPreferredFinancingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="VantAIPreferredFinancingMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to VantAIPreferredFinancingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="AssetAcquisitionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: AssetAcquisitionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SKIncMember" xlink:label="SKIncMember" xlink:title="SKIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="SKIncMember" xlink:title="definition: RelatedPartyDomain to SKIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SKBiopharmaceuticalsCoLtdMember" xlink:label="SKBiopharmaceuticalsCoLtdMember" xlink:title="SKBiopharmaceuticalsCoLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="SKBiopharmaceuticalsCoLtdMember" xlink:title="definition: RelatedPartyDomain to SKBiopharmaceuticalsCoLtdMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="AssetAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: AssetAcquisitionTable to BusinessAcquisitionAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProteovantSciencesIncMember" xlink:label="ProteovantSciencesIncMember" xlink:title="ProteovantSciencesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="ProteovantSciencesIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to ProteovantSciencesIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NewlyFormedSubsidiaryMember" xlink:label="NewlyFormedSubsidiaryMember" xlink:title="NewlyFormedSubsidiaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NewlyFormedSubsidiaryMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NewlyFormedSubsidiaryMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="AssetAcquisitionTable" xlink:to="RangeAxis" xlink:title="definition: AssetAcquisitionTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestAbstract" xlink:label="FundingAgreementWithNovaQuestAbstract" xlink:title="FundingAgreementWithNovaQuestAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FundingAgreementWithNovaQuestAbstract" xlink:title="definition: DebtInstrumentLineItems to FundingAgreementWithNovaQuestAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermDebtCurrentAndNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="definition: DebtInstrumentLineItems to LongtermDebtCurrentAndNoncurrentAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="DebtInstrumentFairValue" xlink:title="DebtInstrumentFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFairValue" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFairValue" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="ShorttermDebtFairValue" xlink:title="ShorttermDebtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ShorttermDebtFairValue" xlink:title="definition: DebtInstrumentLineItems to ShorttermDebtFairValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtFairValue" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtFairValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromIssuanceOfDebt" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromIssuanceOfDebt" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFrequencyOfPeriodicPayment" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:label="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:title="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:title="definition: DebtInstrumentLineItems to TotalRequiredDebtInstrumentQuarterlyPaymentsMade" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTerm" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="MaximumMilestonePaymentObligation" xlink:title="MaximumMilestonePaymentObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="MaximumMilestonePaymentObligation" xlink:title="definition: DebtInstrumentLineItems to MaximumMilestonePaymentObligation" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="MaximumMilestonePaymentOffsetAmount" xlink:title="MaximumMilestonePaymentOffsetAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="MaximumMilestonePaymentOffsetAmount" xlink:title="definition: DebtInstrumentLineItems to MaximumMilestonePaymentOffsetAmount" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentQuarterlyPaymentsMade" xlink:label="DebtInstrumentQuarterlyPaymentsMade" xlink:title="DebtInstrumentQuarterlyPaymentsMade" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentQuarterlyPaymentsMade" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentQuarterlyPaymentsMade" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: DebtInstrumentTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to DermavantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: DebtInstrumentTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestMember" xlink:label="FundingAgreementWithNovaQuestMember" xlink:title="FundingAgreementWithNovaQuestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="FundingAgreementWithNovaQuestMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to FundingAgreementWithNovaQuestMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="definition: DebtInstrumentTable to StatementScenarioAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LoanAndCreditAgreementsByDermavantAbstract" xlink:label="LoanAndCreditAgreementsByDermavantAbstract" xlink:title="LoanAndCreditAgreementsByDermavantAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LoanAndCreditAgreementsByDermavantAbstract" xlink:title="definition: DebtInstrumentLineItems to LoanAndCreditAgreementsByDermavantAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromLinesOfCredit" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromLinesOfCredit" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTerm" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:title="DebtInstrumentExitFeeAndEndOfTermCharge" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentExitFeeAndEndOfTermCharge" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFeeAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFeeAmount" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtAbstract" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtAbstract" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentExitFee" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentExitFee" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebt" xlink:title="definition: DebtInstrumentLineItems to LongTermDebt" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtCurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtCurrent" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtNoncurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtNoncurrent" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: DebtInstrumentTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to DermavantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: DebtInstrumentTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CreditFacilityWithXYQLuxcoMember" xlink:label="CreditFacilityWithXYQLuxcoMember" xlink:title="CreditFacilityWithXYQLuxcoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CreditFacilityWithXYQLuxcoMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CreditFacilityWithXYQLuxcoMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:label="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:title="RevenueInterestPurchaseAndSaleAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:title="definition: DebtInstrumentLineItems to RevenueInterestPurchaseAndSaleAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:label="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:title="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:title="definition: DebtInstrumentLineItems to CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRIPSA" xlink:label="CommittedFundingUnderRIPSA" xlink:title="CommittedFundingUnderRIPSA" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CommittedFundingUnderRIPSA" xlink:title="definition: DebtInstrumentLineItems to CommittedFundingUnderRIPSA" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:label="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:title="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:title="definition: DebtInstrumentLineItems to CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtAbstract" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebt" xlink:title="definition: DebtInstrumentLineItems to LongTermDebt" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtCurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtCurrent" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtNoncurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtNoncurrent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: DebtInstrumentTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to DermavantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: DebtInstrumentTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:label="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="definition: ClassOfStockLineItems to StockholdersEquityNoteAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesOfferingPriceAuthorized" xlink:label="CommonSharesOfferingPriceAuthorized" xlink:title="CommonSharesOfferingPriceAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonSharesOfferingPriceAuthorized" xlink:title="definition: ClassOfStockLineItems to CommonSharesOfferingPriceAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:label="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:title="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:title="definition: ClassOfStockLineItems to CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesNewIssues" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="SaleOfStockPricePerShare" xlink:title="definition: ClassOfStockLineItems to SaleOfStockPricePerShare" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NetProceedsFromIssuanceOfCommonStock" xlink:label="NetProceedsFromIssuanceOfCommonStock" xlink:title="NetProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="NetProceedsFromIssuanceOfCommonStock" xlink:title="definition: ClassOfStockLineItems to NetProceedsFromIssuanceOfCommonStock" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockPurchasedDuringPeriodByEntityShares" xlink:label="StockPurchasedDuringPeriodByEntityShares" xlink:title="StockPurchasedDuringPeriodByEntityShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockPurchasedDuringPeriodByEntityShares" xlink:title="definition: ClassOfStockLineItems to StockPurchasedDuringPeriodByEntityShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OptionToPurchaseAdditionalSharesOfCommonStock" xlink:label="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:title="OptionToPurchaseAdditionalSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:title="definition: ClassOfStockLineItems to OptionToPurchaseAdditionalSharesOfCommonStock" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:label="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:title="EstimatedNetProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:title="definition: ClassOfStockLineItems to EstimatedNetProceedsFromIssuanceOfCommonStock" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OwnershipPercentage" xlink:label="OwnershipPercentage" xlink:title="OwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="OwnershipPercentage" xlink:title="definition: ClassOfStockLineItems to OwnershipPercentage" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: ScheduleOfStockByClassTable to RelatedPartyTransactionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CowenAndCompanyLLCMember" xlink:label="CowenAndCompanyLLCMember" xlink:title="CowenAndCompanyLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="CowenAndCompanyLLCMember" xlink:title="definition: RelatedPartyTransactionDomain to CowenAndCompanyLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EquityOfferingsAtTheMarketMember" xlink:label="EquityOfferingsAtTheMarketMember" xlink:title="EquityOfferingsAtTheMarketMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="EquityOfferingsAtTheMarketMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to EquityOfferingsAtTheMarketMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="UnderwrittenPublicOfferingMember" xlink:title="UnderwrittenPublicOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="UnderwrittenPublicOfferingMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to UnderwrittenPublicOfferingMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantParticipationOfImmunovantStockOfferingMember" xlink:label="RoivantParticipationOfImmunovantStockOfferingMember" xlink:title="RoivantParticipationOfImmunovantStockOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="RoivantParticipationOfImmunovantStockOfferingMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to RoivantParticipationOfImmunovantStockOfferingMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="PrivatePlacementMember" xlink:title="PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="PrivatePlacementMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to PrivatePlacementMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfStockByClassTable to TitleOfIndividualAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfStockByClassTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ImmunovantIncMember" xlink:label="ImmunovantIncMember" xlink:title="ImmunovantIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="ImmunovantIncMember" xlink:title="definition: EquityMethodInvesteeNameDomain to ImmunovantIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfStockByClassTable to ConsolidatedEntitiesAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RSLMember" xlink:label="RSLMember" xlink:title="RSLMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="RSLMember" xlink:title="definition: ConsolidatedEntitiesDomain to RSLMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfEquityIncentivePlans" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfEquityIncentivePlans" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="StockOptionsAndPerformanceStockOptionsMember" xlink:title="StockOptionsAndPerformanceStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionsAndPerformanceStockOptionsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionsAndPerformanceStockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtdEquityPlansMember" xlink:label="RoivantSciencesLtdEquityPlansMember" xlink:title="RoivantSciencesLtdEquityPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="RoivantSciencesLtdEquityPlansMember" xlink:title="definition: PlanNameDomain to RoivantSciencesLtdEquityPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:label="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="RoivantSciencesLtd2021EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RoivantSciencesLtdEquityPlansMember" xlink:to="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="definition: RoivantSciencesLtdEquityPlansMember to RoivantSciencesLtd2021EquityIncentivePlanMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="RestrictedStockAndPerformanceStockUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockAndPerformanceStockUnitsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtdEquityPlansMember" xlink:label="RoivantSciencesLtdEquityPlansMember" xlink:title="RoivantSciencesLtdEquityPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="RoivantSciencesLtdEquityPlansMember" xlink:title="definition: PlanNameDomain to RoivantSciencesLtdEquityPlansMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SubsidiaryEquityIncentivePlansAbstract" xlink:label="SubsidiaryEquityIncentivePlansAbstract" xlink:title="SubsidiaryEquityIncentivePlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SubsidiaryEquityIncentivePlansAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SubsidiaryEquityIncentivePlansAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EquityInstrumentsVestedAndSettledShares" xlink:label="EquityInstrumentsVestedAndSettledShares" xlink:title="EquityInstrumentsVestedAndSettledShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EquityInstrumentsVestedAndSettledShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EquityInstrumentsVestedAndSettledShares" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="CappedValueAppreciationRightsMember" xlink:title="CappedValueAppreciationRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="CappedValueAppreciationRightsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to CappedValueAppreciationRightsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:label="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="RoivantSciencesLtd2021EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to RoivantSciencesLtd2021EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SubsidiaryEquityIncentivePlansMember" xlink:label="SubsidiaryEquityIncentivePlansMember" xlink:title="SubsidiaryEquityIncentivePlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="SubsidiaryEquityIncentivePlansMember" xlink:title="definition: PlanNameDomain to SubsidiaryEquityIncentivePlansMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardDateAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardDateAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain" xlink:title="definition: AwardDateAxis to AwardDateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain_2" xlink:title="AwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain_2" xlink:title="definition: AwardDateAxis to AwardDateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_March2020CappedValueAppreciationRightsGrantsMember" xlink:label="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="March2020CappedValueAppreciationRightsGrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AwardDateDomain" xlink:to="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="definition: AwardDateDomain to March2020CappedValueAppreciationRightsGrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_November2021CappedValueAppreciationRightsGrantsMember" xlink:label="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="November2021CappedValueAppreciationRightsGrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AwardDateDomain" xlink:to="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="definition: AwardDateDomain to November2021CappedValueAppreciationRightsGrantsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="LongTermPurchaseCommitmentLineItems" xlink:title="LongTermPurchaseCommitmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:label="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:title="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:title="definition: LongTermPurchaseCommitmentLineItems to LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="LongtermPurchaseCommitmentPeriod" xlink:title="LongtermPurchaseCommitmentPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="LongtermPurchaseCommitmentPeriod" xlink:title="definition: LongTermPurchaseCommitmentLineItems to LongtermPurchaseCommitmentPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:label="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:title="RemainingMinimumPurchaseCommitmentRelatedToAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:title="definition: LongTermPurchaseCommitmentLineItems to RemainingMinimumPurchaseCommitmentRelatedToAgreement" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodOfRightToTerminateTheProductServiceAgreement" xlink:label="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:title="PeriodOfRightToTerminateTheProductServiceAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:title="definition: LongTermPurchaseCommitmentLineItems to PeriodOfRightToTerminateTheProductServiceAgreement" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" xlink:title="PurchaseObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PurchaseObligation" xlink:title="definition: LongTermPurchaseCommitmentLineItems to PurchaseObligation" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:label="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:title="PeriodToPurchaseAdditionalBatchesOfBatoclimab" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:title="definition: LongTermPurchaseCommitmentLineItems to PeriodToPurchaseAdditionalBatchesOfBatoclimab" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProprietarySoftwareSubscriptionPeriod" xlink:label="ProprietarySoftwareSubscriptionPeriod" xlink:title="ProprietarySoftwareSubscriptionPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="ProprietarySoftwareSubscriptionPeriod" xlink:title="definition: LongTermPurchaseCommitmentLineItems to ProprietarySoftwareSubscriptionPeriod" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:title="PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:title="definition: LongTermPurchaseCommitmentLineItems to PurchaseCommitmentRemainingMinimumAmountCommitted" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="definition: LongTermPurchaseCommitmentLineItems to EmployeeRelatedLiabilitiesCurrent" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="definition: LongTermPurchaseCommitmentLineItems to SellingGeneralAndAdministrativeExpense" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: LongTermPurchaseCommitmentLineItems to ResearchAndDevelopmentExpense" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:label="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:title="PercentageOfBonusPayableInNext30DaysOfGrantDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:title="definition: LongTermPurchaseCommitmentLineItems to PercentageOfBonusPayableInNext30DaysOfGrantDate" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FiftyPercentBonusPayablePeriodFromGrantDate" xlink:label="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:title="FiftyPercentBonusPayablePeriodFromGrantDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:title="definition: LongTermPurchaseCommitmentLineItems to FiftyPercentBonusPayablePeriodFromGrantDate" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="LongTermPurchaseCommitmentTable" xlink:title="LongTermPurchaseCommitmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="LongTermPurchaseCommitmentTable" xlink:title="definition: LongTermPurchaseCommitmentLineItems to LongTermPurchaseCommitmentTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LongTermPurchaseCommitmentTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SamsungBiologicsCo.Ltd.Member" xlink:label="SamsungBiologicsCo.Ltd.Member" xlink:title="SamsungBiologicsCo.Ltd.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SamsungBiologicsCo.Ltd.Member" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SamsungBiologicsCo.Ltd.Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PalantirTechnologiesIncMember" xlink:label="PalantirTechnologiesIncMember" xlink:title="PalantirTechnologiesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PalantirTechnologiesIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PalantirTechnologiesIncMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashBonusProgramMember" xlink:label="CashBonusProgramMember" xlink:title="CashBonusProgramMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CashBonusProgramMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CashBonusProgramMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="definition: LongTermPurchaseCommitmentTable to LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="definition: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" xlink:title="definition: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GSKMember" xlink:label="GSKMember" xlink:title="GSKMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="GSKMember" xlink:title="definition: LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain to GSKMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: LongTermPurchaseCommitmentTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="ChiefFinancialOfficerMember" xlink:title="ChiefFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefFinancialOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefFinancialOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: LongTermPurchaseCommitmentTable to SubsequentEventTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesAbstract" xlink:label="EarnOutSharesAbstract" xlink:title="EarnOutSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="EarnOutSharesAbstract" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to EarnOutSharesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:label="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="PublicWarrantsAndPrivatePlacementWarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to PublicWarrantsAndPrivatePlacementWarrantsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to ClassOfWarrantOrRightOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodToExerciseWarrantsAfterBusinessCombination" xlink:label="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:title="PeriodToExerciseWarrantsAfterBusinessCombination" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to PeriodToExerciseWarrantsAfterBusinessCombination" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to WarrantsAndRightsOutstandingTerm" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ClassOfWarrantOrRightRedemptionPrice" xlink:label="ClassOfWarrantOrRightRedemptionPrice" xlink:title="ClassOfWarrantOrRightRedemptionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="ClassOfWarrantOrRightRedemptionPrice" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to ClassOfWarrantOrRightRedemptionPrice" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="SaleOfStockPricePerShare" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to SaleOfStockPricePerShare" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDays" xlink:label="NumberOfTradingDays" xlink:title="NumberOfTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="NumberOfTradingDays" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to NumberOfTradingDays" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashExercisePrice" xlink:label="CashExercisePrice" xlink:title="CashExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="CashExercisePrice" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to CashExercisePrice" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ExercisePrice" xlink:label="ExercisePrice" xlink:title="ExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="ExercisePrice" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to ExercisePrice" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:label="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:title="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantCashExercised" xlink:label="PublicWarrantCashExercised" xlink:title="PublicWarrantCashExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="PublicWarrantCashExercised" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to PublicWarrantCashExercised" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashlessPublicWarrantExercised" xlink:label="CashlessPublicWarrantExercised" xlink:title="CashlessPublicWarrantExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="CashlessPublicWarrantExercised" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to CashlessPublicWarrantExercised" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:label="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:title="StockIssuedDuringPeriodSharesCashWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to StockIssuedDuringPeriodSharesCashWarrantExercises" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:label="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:title="StockIssuedDuringPeriodSharesCashlessWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to StockIssuedDuringPeriodSharesCashlessWarrantExercises" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:label="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:title="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to ClassOfWarrantOrRightUnexercisedPriceOfWarrants" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to StockIssuedDuringPeriodSharesNewIssues" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PercentageOfEarnOutShares" xlink:label="PercentageOfEarnOutShares" xlink:title="PercentageOfEarnOutShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="PercentageOfEarnOutShares" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to PercentageOfEarnOutShares" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharePrice" xlink:label="EarnOutSharePrice" xlink:title="EarnOutSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="EarnOutSharePrice" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to EarnOutSharePrice" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:label="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:title="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:label="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:title="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfEarnOutSharesVested" xlink:label="NumberOfEarnOutSharesVested" xlink:title="NumberOfEarnOutSharesVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="NumberOfEarnOutSharesVested" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to NumberOfEarnOutSharesVested" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:label="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:title="PatientSquareCapitalLimitedLiabilityCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:title="definition: RelatedPartyDomain to PatientSquareCapitalLimitedLiabilityCompanyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to ClassOfWarrantOrRightAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsMember" xlink:label="PublicWarrantsMember" xlink:title="PublicWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PublicWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:label="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:title="PublicWarrantsAndPrivatePlacementWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PublicWarrantsAndPrivatePlacementWarrantsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to StatementEquityComponentsAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TwentyPercentEarnOutSharesMember" xlink:label="TwentyPercentEarnOutSharesMember" xlink:title="TwentyPercentEarnOutSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="TwentyPercentEarnOutSharesMember" xlink:title="definition: EquityComponentDomain to TwentyPercentEarnOutSharesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TenPercentEarnOutSharesMember" xlink:label="TenPercentEarnOutSharesMember" xlink:title="TenPercentEarnOutSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="TenPercentEarnOutSharesMember" xlink:title="definition: EquityComponentDomain to TenPercentEarnOutSharesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to StatementClassOfStockAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="RangeAxis" xlink:title="definition: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to RangeAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosureAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FinancialLiabilitiesFairValueDisclosure" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosure" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:label="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:title="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="DebtInstrumentFairValue" xlink:title="DebtInstrumentFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DebtInstrumentFairValue" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DebtInstrumentFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="DerivativeLiabilities" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to DerivativeLiabilities" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="InvestmentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to InvestmentsFairValueDisclosure" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByAssetClassAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByAssetClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="MoneyMarketFundsMember" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to MoneyMarketFundsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="CommonStockMember" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to CommonStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="OtherInvestmentCompaniesMember" xlink:title="OtherInvestmentCompaniesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="OtherInvestmentCompaniesMember" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to OtherInvestmentCompaniesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DatavantHoldingsIncMember" xlink:label="DatavantHoldingsIncMember" xlink:title="DatavantHoldingsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="DatavantHoldingsIncMember" xlink:title="definition: EquityMethodInvesteeNameDomain to DatavantHoldingsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="ArbutusBiopharmaCorporationMember" xlink:title="ArbutusBiopharmaCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="ArbutusBiopharmaCorporationMember" xlink:title="definition: EquityMethodInvesteeNameDomain to ArbutusBiopharmaCorporationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FinancialInstrumentAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:title="LiabilityInstrumentsMeasuredAtFairValueMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to LiabilityInstrumentsMeasuredAtFairValueMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:label="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:title="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsMember" xlink:label="PublicWarrantsMember" xlink:title="PublicWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PublicWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to StatementEquityComponentsAxis" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnoutSharesMember" xlink:label="EarnoutSharesMember" xlink:title="EarnoutSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="EarnoutSharesMember" xlink:title="definition: EquityComponentDomain to EarnoutSharesMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:label="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:title="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="RepaymentsOfLongTermDebt" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to RepaymentsOfLongTermDebt" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ExerciseOfPrivatePlacementWarrantsValue" xlink:label="ExerciseOfPrivatePlacementWarrantsValue" xlink:title="ExerciseOfPrivatePlacementWarrantsValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="ExerciseOfPrivatePlacementWarrantsValue" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to ExerciseOfPrivatePlacementWarrantsValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:title="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:label="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:title="FairValueMeasurementInputsAndValuationTechniquesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to FairValueMeasurementInputsAndValuationTechniquesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueAssetMeasurementInput" xlink:label="FairValueAssetMeasurementInput" xlink:title="FairValueAssetMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueAssetMeasurementInput" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to FairValueAssetMeasurementInput" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueEarnoutSharesMeasurementInput" xlink:label="FairValueEarnoutSharesMeasurementInput" xlink:title="FairValueEarnoutSharesMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueEarnoutSharesMeasurementInput" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to FairValueEarnoutSharesMeasurementInput" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to WarrantsAndRightsOutstandingMeasurementInput" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to WarrantsAndRightsOutstandingTerm" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to LiabilitiesFairValueDisclosure" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:title="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to MeasurementInputTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to ClassOfWarrantOrRightAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to StatementEquityComponentsAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnoutSharesMember" xlink:label="EarnoutSharesMember" xlink:title="EarnoutSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="EarnoutSharesMember" xlink:title="definition: EquityComponentDomain to EarnoutSharesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DatavantHoldingsIncMember" xlink:label="DatavantHoldingsIncMember" xlink:title="DatavantHoldingsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="DatavantHoldingsIncMember" xlink:title="definition: EquityMethodInvesteeNameDomain to DatavantHoldingsIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/NetIncomeLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="NetIncomeLossAbstract" xlink:title="NetIncomeLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="NetIncomeLossAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to NetIncomeLossAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareBasic" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDiluted" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to NetIncomeLoss" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="StockOptionsAndPerformanceStockOptionsMember" xlink:title="StockOptionsAndPerformanceStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsAndPerformanceStockOptionsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to StockOptionsAndPerformanceStockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="RestrictedStockAndPerformanceStockUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockAndPerformanceStockUnitsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_March2020CappedValueAppreciationRightsGrantsMember" xlink:label="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="March2020CappedValueAppreciationRightsGrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to March2020CappedValueAppreciationRightsGrantsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_November2021CappedValueAppreciationRightsGrantsMember" xlink:label="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="November2021CappedValueAppreciationRightsGrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to November2021CappedValueAppreciationRightsGrantsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesNonvestedMember" xlink:label="EarnOutSharesNonvestedMember" xlink:title="EarnOutSharesNonvestedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EarnOutSharesNonvestedMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EarnOutSharesNonvestedMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to PrivatePlacementWarrantsMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsMember" xlink:label="PublicWarrantsMember" xlink:title="PublicWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="PublicWarrantsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to PublicWarrantsMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:label="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:title="OtherStockBasedAwardsAndInstrumentsIssuedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to OtherStockBasedAwardsAndInstrumentsIssuedMember" order="9.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="GainLossOnFairValueOfDebtAndLiabilityInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementAbstract" xlink:to="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="definition: IncomeStatementAbstract to GainLossOnFairValueOfDebtAndLiabilityInstruments" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="LiabilityInstrumentsMeasuredAtFairValue" xlink:title="LiabilityInstrumentsMeasuredAtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="LiabilityInstrumentsMeasuredAtFairValue" xlink:title="definition: LiabilitiesAbstract to LiabilityInstrumentsMeasuredAtFairValue" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>roiv-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Less: accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:title="AcquiredFiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xlink:title="label: AcquiredFiniteLivedIntangibleAssetsLineItems to us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:title="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xlink:title="label: ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable to us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl1">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">Consolidated Balance Sheets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">Net income (loss) per common share - basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl1">Net income (loss) per common share, basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAxis_lbl">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:title="label: BusinessAcquisitionAxis to us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAcquireeDomain_lbl">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:title="label: BusinessAcquisitionAcquireeDomain to us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:title="label: CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy to us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl1">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl1" xlink:title="label: CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy to us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="CashDivestedFromDeconsolidation" xlink:title="CashDivestedFromDeconsolidation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashDivestedFromDeconsolidation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_CashDivestedFromDeconsolidation_lbl" xml:lang="en-US" id="us-gaap_CashDivestedFromDeconsolidation_lbl">Cash decrease upon deconsolidation of subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashDivestedFromDeconsolidation" xlink:to="us-gaap_CashDivestedFromDeconsolidation_lbl" xlink:title="label: CashDivestedFromDeconsolidation to us-gaap_CashDivestedFromDeconsolidation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashDivestedFromDeconsolidation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashDivestedFromDeconsolidation_lbl1" xml:lang="en-US" id="us-gaap_CashDivestedFromDeconsolidation_lbl1">Cash Divested from Deconsolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashDivestedFromDeconsolidation" xlink:to="us-gaap_CashDivestedFromDeconsolidation_lbl1" xlink:title="label: CashDivestedFromDeconsolidation to us-gaap_CashDivestedFromDeconsolidation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableTrade to us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayableTrade to us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in assets and liabilities, net of effects from acquisition and divestiture:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccruedLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl1">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccruedLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl1">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Number of shares acquired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 804,890,910 and 760,143,393 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl1" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl1">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl">Comprehensive income (loss) attributable to Roivant Sciences Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount_lbl">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtInstrumentCarryingAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount_lbl1">Carrying balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl1" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentCarryingAmount_lbl2" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount_lbl2">Long-Term Debt, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl2" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl">Face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="DebtInstrumentFairValue" xlink:title="DebtInstrumentFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFairValue_lbl">Fair value of long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:title="label: DebtInstrumentFairValue to us-gaap_DebtInstrumentFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtInstrumentFairValue_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFairValue_lbl1">Debt issued by Dermavant to NovaQuest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl1" xlink:title="label: DebtInstrumentFairValue to us-gaap_DebtInstrumentFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFairValue_lbl2" xml:lang="en-US" id="us-gaap_DebtInstrumentFairValue_lbl2">Debt Instrument, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl2" xlink:title="label: DebtInstrumentFairValue to us-gaap_DebtInstrumentFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFeeAmount_lbl">Reduction in exit fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:title="label: DebtInstrumentFeeAmount to us-gaap_DebtInstrumentFeeAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFeeAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFeeAmount_lbl1">Debt Instrument, Fee Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl1" xlink:title="label: DebtInstrumentFeeAmount to us-gaap_DebtInstrumentFeeAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl">Frequency of periodic payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:title="label: DebtInstrumentFrequencyOfPeriodicPayment to us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueCurrent_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:title="label: DeferredRevenueCurrent to us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueCurrent_lbl1" xml:lang="en-US" id="us-gaap_DeferredRevenueCurrent_lbl1">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl1" xlink:title="label: DeferredRevenueCurrent to us-gaap_DeferredRevenueCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl" xml:lang="en-US" id="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl">Liability instruments measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl" xlink:title="label: DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue to us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl1" xml:lang="en-US" id="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl1">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl1" xlink:title="label: DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue to us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Net income (loss) per common share - diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl1">Net income (loss) per common share, diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="EquityMethodInvestmentsDisclosureTextBlock" xlink:title="EquityMethodInvestmentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl">Equity Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:title="label: EquityMethodInvestmentsDisclosureTextBlock to us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl1">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl1" xlink:title="label: EquityMethodInvestmentsDisclosureTextBlock to us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl1">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl">Disposal Group Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:title="label: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl">Disposal Group Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Share-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl1">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl">Number of shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl">Equity method investment ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1">Equity Method Investment, Ownership Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="GainLossOnInvestments" xlink:title="GainLossOnInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US" id="us-gaap_GainLossOnInvestments_lbl">Change in fair value of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:title="label: GainLossOnInvestments to us-gaap_GainLossOnInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnInvestments_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnInvestments_lbl1">Gain (Loss) on Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl1" xlink:title="label: GainLossOnInvestments to us-gaap_GainLossOnInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">Condensed Consolidated Statements of Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="IncomeTaxesReceivable" xlink:title="IncomeTaxesReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxesReceivable_lbl">Income tax receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:title="label: IncomeTaxesReceivable to us-gaap_IncomeTaxesReceivable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" id="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl">Effect of dilutive common stock equivalents (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:title="label: IncrementalCommonSharesAttributableToShareBasedPaymentArrangements to us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1">Net book value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl2" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl2">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl2" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Gross amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1">Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl">Recognized Intangible Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="InterestReceivable" xlink:title="InterestReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestReceivable_lbl" xml:lang="en-US" id="us-gaap_InterestReceivable_lbl">Interest receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:title="label: InterestReceivable to us-gaap_InterestReceivable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="us-gaap_InventoryNet_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="InvestmentPolicyTextBlock" xlink:title="InvestmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_InvestmentPolicyTextBlock_lbl">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:title="label: InvestmentPolicyTextBlock to us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InvestmentPolicyTextBlock_lbl1">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl1" xlink:title="label: InvestmentPolicyTextBlock to us-gaap_InvestmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">Liabilities and Shareholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtCurrent_lbl">Less: current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:title="label: LongTermDebtCurrent to us-gaap_LongTermDebtCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongTermDebtCurrent_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtCurrent_lbl1">Current portion of long-term debt (includes $26,950 and $26,940 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl1" xlink:title="label: LongTermDebtCurrent to us-gaap_LongTermDebtCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtCurrent_lbl2" xml:lang="en-US" id="us-gaap_LongTermDebtCurrent_lbl2">Long-Term Debt, Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl2" xlink:title="label: LongTermDebtCurrent to us-gaap_LongTermDebtCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtNoncurrent_lbl">Total long-term debt, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:title="label: LongTermDebtNoncurrent to us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="us-gaap_LongTermDebt_lbl">Total debt, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:title="label: LongTermDebt to us-gaap_LongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LongTermDebt_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebt_lbl1">Long-term debt, net of current portion (includes $194,560 and $180,700 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl1" xlink:title="label: LongTermDebt to us-gaap_LongTermDebt_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebt_lbl2" xml:lang="en-US" id="us-gaap_LongTermDebt_lbl2">Long-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl2" xlink:title="label: LongTermDebt to us-gaap_LongTermDebt_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MinorityInterest_lbl" xml:lang="en-US" id="us-gaap_MinorityInterest_lbl">Noncontrolling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:title="label: MinorityInterest to us-gaap_MinorityInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterest_lbl1" xml:lang="en-US" id="us-gaap_MinorityInterest_lbl1">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl1" xlink:title="label: MinorityInterest to us-gaap_MinorityInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="us-gaap_MoneyMarketFundsMember_lbl">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:title="label: MoneyMarketFundsMember to us-gaap_MoneyMarketFundsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net income (loss) attributable to Roivant Sciences Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net income (loss) attributable to Roivant Sciences Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="ProceedsFromStockPlans" xlink:title="ProceedsFromStockPlans" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockPlans_lbl">Proceeds from issuance of the Company's common shares under employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xlink:title="label: ProceedsFromStockPlans to us-gaap_ProceedsFromStockPlans_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Income (loss) from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenuesAbstract_lbl">Revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:title="label: RevenuesAbstract to us-gaap_RevenuesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="IncreaseDecreaseInOtherOperatingCapitalNet" xlink:title="IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:title="label: IncreaseDecreaseInOtherOperatingCapitalNet to us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl1">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl1" xlink:title="label: IncreaseDecreaseInOtherOperatingCapitalNet to us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="OtherComprehensiveIncomeLossTaxAbstract" xlink:title="OtherComprehensiveIncomeLossTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl">Other comprehensive (loss) income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:title="label: OtherComprehensiveIncomeLossTaxAbstract to us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl1">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl1" xlink:title="label: OtherComprehensiveIncomeLossTaxAbstract to us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl">Total other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl1">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl1" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsCurrent_lbl2" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl2">Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl2" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="OtherSundryLiabilitiesCurrent" xlink:title="OtherSundryLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherSundryLiabilitiesCurrent_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xlink:title="label: OtherSundryLiabilitiesCurrent to us-gaap_OtherSundryLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="PaymentsForProceedsFromOtherInvestingActivities" xlink:title="PaymentsForProceedsFromOtherInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:title="label: PaymentsForProceedsFromOtherInvestingActivities to us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl1">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl1" xlink:title="label: PaymentsForProceedsFromOtherInvestingActivities to us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl1">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="PrepaidExpenseCurrent" xlink:title="PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseCurrent_lbl">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:title="label: PrepaidExpenseCurrent to us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="PrivatePlacementMember" xlink:title="PrivatePlacementMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="us-gaap_PrivatePlacementMember_lbl">Private Placement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:title="label: PrivatePlacementMember to us-gaap_PrivatePlacementMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:label="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:title="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl">Proceeds from sale of subsidiary interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl" xlink:title="label: ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries to us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from issuance of the Company's common shares, net of issuance costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl">Purchase of equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromLinesOfCredit_lbl">Proceeds from Lines of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:title="label: ProceedsFromLinesOfCredit to us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Proceeds from exercise of the Company's and subsidiary stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" id="us-gaap_ReceivablesNetCurrent_lbl">Trade receivables, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:title="label: ReceivablesNetCurrent to us-gaap_ReceivablesNetCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebt_lbl">Payments related to long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:title="label: RepaymentsOfLongTermDebt to us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermDebt_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebt_lbl1">Repayments of Long-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl1" xlink:title="label: RepaymentsOfLongTermDebt to us-gaap_RepaymentsOfLongTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:title="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl">Contributions from issuance of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xlink:title="label: PaymentsForRepurchaseOfPreferredStockAndPreferenceStock to us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Retained earnings / (accumulated deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockNameOfTransactionDomain_lbl">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:title="label: SaleOfStockNameOfTransactionDomain to us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockPricePerShare_lbl">Purchase price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:title="label: SaleOfStockPricePerShare to us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockPricePerShare_lbl1">Sale price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1" xlink:title="label: SaleOfStockPricePerShare to us-gaap_SaleOfStockPricePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:label="ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:title="ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_lbl">Recognized Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_lbl" xlink:title="label: ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock to us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl">Long-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:title="label: ScheduleOfDebtInstrumentsTextBlock to us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" xlink:title="label: ScheduleOfDebtInstrumentsTextBlock to us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense_lbl">Selling, general and administrative (includes $46,944 and $50,741 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $128,445 and $165,771 for the nine months ended December 31, 2023 and 2022, respectively)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1">Selling, general and administrative expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Non-vested balance, beginning (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Non-vested balance, ending (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Options outstanding, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl">Options exercisable at September 30, 2023 (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl">Condensed Consolidated Statements of Comprehensive Income (Loss) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:title="label: StatementOfIncomeAndComprehensiveIncomeAbstract to us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Shareholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">Equity, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl">Shareholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl1">Stockholders' Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl1" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl">Class of warrant outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Shareholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Equity [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis_lbl">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestorMember_lbl" xml:lang="en-US" id="us-gaap_InvestorMember_lbl">Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:title="label: InvestorMember to us-gaap_InvestorMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockMember_lbl1" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl1">Common Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl2" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl2">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development (includes $7,475 and $6,888 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $24,305 and $26,548 for the nine months ended December 31, 2023 and 2022, respectively)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="OtherLiabilitiesCurrentAbstract" xlink:title="OtherLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrentAbstract_lbl">Other Current Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xlink:title="label: OtherLiabilitiesCurrentAbstract to us-gaap_OtherLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl">Total other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl1">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl2">Other Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl2" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl1">Other Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:title="label: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl1" xml:lang="en-US" id="us-gaap_StatementTable_lbl1">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl1" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosure_lbl">Aggregate fair value investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:title="label: InvestmentsFairValueDisclosure to us-gaap_InvestmentsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="us-gaap_InvestmentsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosure_lbl1">Investments measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl1" xlink:title="label: InvestmentsFairValueDisclosure to us-gaap_InvestmentsFairValueDisclosure_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InvestmentsFairValueDisclosure_lbl2" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosure_lbl2">Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl2" xlink:title="label: InvestmentsFairValueDisclosure to us-gaap_InvestmentsFairValueDisclosure_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsFairValueDisclosure_lbl3" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosure_lbl3">Retained investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl3" xlink:title="label: InvestmentsFairValueDisclosure to us-gaap_InvestmentsFairValueDisclosure_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl1" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl1">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl1" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl">Changes in Fair Value of the Level 3 Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable to us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl1">Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl2" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl2">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl2" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl">Changes in Fair Value of the Level 3 Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl">Changes in fair value of debt and liability instruments, included in net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis_lbl">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain_lbl">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl1">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl1">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">Shareholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:label="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:title="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract_lbl" xml:lang="en-US" id="us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract_lbl">Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract_lbl" xlink:title="label: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="LongTermPurchaseCommitmentTable" xlink:title="LongTermPurchaseCommitmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermPurchaseCommitmentTable_lbl" xml:lang="en-US" id="us-gaap_LongTermPurchaseCommitmentTable_lbl">Long-Term Purchase Commitment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:title="label: LongTermPurchaseCommitmentTable to us-gaap_LongTermPurchaseCommitmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US" id="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl">Category of Item Purchased [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:title="label: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US" id="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:title="label: LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain to us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="LongTermPurchaseCommitmentLineItems" xlink:title="LongTermPurchaseCommitmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US" id="us-gaap_LongTermPurchaseCommitmentLineItems_lbl">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:title="label: LongTermPurchaseCommitmentLineItems to us-gaap_LongTermPurchaseCommitmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl">Net income (loss) per common share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl1">Net Income (Loss) per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl1" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl">Net Income (Loss) per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl">Schedule of Equity Method Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:title="label: ScheduleOfEquityMethodInvestmentsTable to us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl1">Schedule of Equity Method Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl1" xlink:title="label: ScheduleOfEquityMethodInvestmentsTable to us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:title="label: ScheduleOfEquityMethodInvestmentsLineItems to us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl1">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl1" xlink:title="label: ScheduleOfEquityMethodInvestmentsLineItems to us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtAbstract_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtAbstract_lbl">Outstanding Debt Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtAbstract_lbl" xlink:title="label: LongTermDebtAbstract to us-gaap_LongTermDebtAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LongTermDebtAbstract_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtAbstract_lbl1">Carrying Balance [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtAbstract_lbl1" xlink:title="label: LongTermDebtAbstract to us-gaap_LongTermDebtAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl1">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl">Common shares available for future grants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Shareholders' equity attributable to Roivant Sciences Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" id="us-gaap_DerivativeLiabilities_lbl">Total liabilities at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:title="label: DerivativeLiabilities to us-gaap_DerivativeLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DerivativeLiabilities_lbl1">Derivative Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl1" xlink:title="label: DerivativeLiabilities to us-gaap_DerivativeLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl1" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl1">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl1" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">(Accumulated Deficit) / Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl1" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityComponentDomain_lbl1" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl1">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl1" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl">Forfeited/Canceled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl">Long-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl1">Long-Term Debt [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl1" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl">Issuance of the Company's common shares under employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:title="label: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan to us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl">Sale of common shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Common shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl">Issuance of the Company's common shares under employee stock purchase plan (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="CommitmentsAndContingenciesPolicyTextBlock" xlink:title="CommitmentsAndContingenciesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl">Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesPolicyTextBlock to us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesPolicyTextBlock to us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl">Non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Capped Value Appreciation Rights [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl">Net Income (Loss) per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl1">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl1" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProfitLoss_lbl" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProfitLoss_lbl1" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl1">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ProfitLoss_lbl2" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl2">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProfitLoss_lbl3" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl3">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl3" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl">Net loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl">Denominator [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasicAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl">Weighted average shares outstanding:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl">Comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl">Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:title="label: ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl">Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1">Total shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="NoncontrollingInterestMember" xlink:title="NoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" id="us-gaap_NoncontrollingInterestMember_lbl">Noncontrolling Interests [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:title="label: NoncontrollingInterestMember to us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncontrollingInterestMember_lbl1" xml:lang="en-US" id="us-gaap_NoncontrollingInterestMember_lbl1">Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl1" xlink:title="label: NoncontrollingInterestMember to us-gaap_NoncontrollingInterestMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl1" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl1">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl1" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl1">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl1" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies (Note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl1" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeconsolidationGainOrLossAmount_lbl" xml:lang="en-US" id="us-gaap_DeconsolidationGainOrLossAmount_lbl">Gain on deconsolidation of subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:title="label: DeconsolidationGainOrLossAmount to us-gaap_DeconsolidationGainOrLossAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeconsolidationGainOrLossAmount_lbl1" xml:lang="en-US" id="us-gaap_DeconsolidationGainOrLossAmount_lbl1">Gain on deconsolidation of subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl1" xlink:title="label: DeconsolidationGainOrLossAmount to us-gaap_DeconsolidationGainOrLossAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:title="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl" xml:lang="en-US" id="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl">Deconsolidation of subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl" xlink:title="label: DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount to us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl1" xml:lang="en-US" id="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl1">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl1" xlink:title="label: DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount to us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermDebtCurrentAndNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl">Carrying Balance of Debt Issued [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" xlink:title="label: LongtermDebtCurrentAndNoncurrentAbstract to us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl1" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Total accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl">Compensation-related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl">Other expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_TaxesPayableCurrent_lbl">Income tax payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xlink:title="label: TaxesPayableCurrent to us-gaap_TaxesPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:title="label: AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1">Accrued Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xlink:title="label: AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl1" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="NetIncomeLossAbstract" xlink:title="NetIncomeLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAbstract_lbl">Numerator [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xlink:title="label: NetIncomeLossAbstract to us-gaap_NetIncomeLossAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl">Net income (loss) before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl">Other Current Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl1">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInTemporaryEquityRollForward to us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl">Total assets at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl1">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl">Non financial liabilities at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl1">Liabilities, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain_lbl">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain_lbl1">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl1" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl1">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl1" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl">Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl1">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromWarrantExercises_lbl">Proceeds from exercise of the Company's warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:title="label: ProceedsFromWarrantExercises to us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl">Fair value of liability instrument issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl">Asset Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProductMember_lbl" xml:lang="en-US" id="us-gaap_ProductMember_lbl">Product Revenue, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:title="label: ProductMember to us-gaap_ProductMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:title="BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl">Description of Business and Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:title="label: BusinessDescriptionAndBasisOfPresentationTextBlock to us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl1" xml:lang="en-US" id="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl1">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl1" xlink:title="label: BusinessDescriptionAndBasisOfPresentationTextBlock to us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl">Balance at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1">Balance at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfDebt_lbl">Proceeds from issuance of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:title="label: ProceedsFromIssuanceOfDebt to us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfDebt_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfDebt_lbl1">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl1" xlink:title="label: ProceedsFromIssuanceOfDebt to us-gaap_ProceedsFromIssuanceOfDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByAssetClassAxis_lbl">Asset Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:title="label: FairValueByAssetClassAxis to us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl1" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl1">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl1" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis_lbl">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_lbl1" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis_lbl1">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl1" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl">Assets and Liabilities are Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl1">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl1" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:title="ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:title="label: ScheduleOfCashAndCashEquivalentsTableTextBlock to us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" xlink:title="label: ScheduleOfCashAndCashEquivalentsTableTextBlock to us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">Intangible Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract_lbl">Fair Value Measurements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract_lbl">Long-Term Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtFairValue_lbl">Total long-term debt, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xlink:title="label: LongTermDebtFairValue to us-gaap_LongTermDebtFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongTermDebtFairValue_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtFairValue_lbl1">Long term debt accounted under fair value option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl1" xlink:title="label: LongTermDebtFairValue to us-gaap_LongTermDebtFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtFairValue_lbl2" xml:lang="en-US" id="us-gaap_LongTermDebtFairValue_lbl2">Long-Term Debt, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl2" xlink:title="label: LongTermDebtFairValue to us-gaap_LongTermDebtFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="ShorttermDebtFairValue" xlink:title="ShorttermDebtFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShorttermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShorttermDebtFairValue_lbl" xml:lang="en-US" id="us-gaap_ShorttermDebtFairValue_lbl">Less: current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_lbl" xlink:title="label: ShorttermDebtFairValue to us-gaap_ShorttermDebtFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShorttermDebtFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShorttermDebtFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShorttermDebtFairValue_lbl1">Current portion of long-term debt accounted for under fair value option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_lbl1" xlink:title="label: ShorttermDebtFairValue to us-gaap_ShorttermDebtFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShorttermDebtFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShorttermDebtFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShorttermDebtFairValue_lbl2">Short-Term Debt, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_lbl2" xlink:title="label: ShorttermDebtFairValue to us-gaap_ShorttermDebtFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">Share-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl">Restricted Common Stock (Non-vested) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl1">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosureAbstract_lbl">Assets: [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:title="label: AssetsFairValueDisclosureAbstract to us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl1">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl1" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl">Fair Value Calculation Using Significant Unobservable Inputs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl1" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl">Liabilities: [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:title="label: LiabilitiesFairValueDisclosureAbstract to us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl">Recurring Fair Value Measurements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:title="EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl">Equity Method Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:title="label: EquityMethodInvestmentsAndJointVenturesAbstract to us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNoncashIncomeExpense_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:title="label: OtherNoncashIncomeExpense to us-gaap_OtherNoncashIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNoncashIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNoncashIncomeExpense_lbl1">Other Noncash Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl1" xlink:title="label: OtherNoncashIncomeExpense to us-gaap_OtherNoncashIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl">Certain Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:title="label: SupplementalBalanceSheetDisclosuresTextBlock to us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" xlink:title="label: SupplementalBalanceSheetDisclosuresTextBlock to us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="IncreaseDecreaseInOtherCurrentAssets" xlink:title="IncreaseDecreaseInOtherCurrentAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:title="label: IncreaseDecreaseInOtherCurrentAssets to us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl1">Increase (Decrease) in Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl1" xlink:title="label: IncreaseDecreaseInOtherCurrentAssets to us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnInvestments_lbl">Unrealized gain (losses) on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:title="label: UnrealizedGainLossOnInvestments to us-gaap_UnrealizedGainLossOnInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrealizedGainLossOnInvestments_lbl1" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnInvestments_lbl1">Unrealized Gain (Loss) on Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl1" xlink:title="label: UnrealizedGainLossOnInvestments to us-gaap_UnrealizedGainLossOnInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl">Computations for Basic and Diluted Net Income (Loss) Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:title="ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl">Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfOtherCurrentAssetsTableTextBlock to us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharePrice_lbl" xml:lang="en-US" id="us-gaap_SharePrice_lbl">Closing price of common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice_lbl1" xml:lang="en-US" id="us-gaap_SharePrice_lbl1">Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl1" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_FinancialInstrumentAxis_lbl">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:title="label: FinancialInstrumentAxis to us-gaap_FinancialInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:title="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl">Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:title="label: TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests to us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl1" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl1">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl1" xlink:title="label: TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests to us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl2" xml:lang="en-US" id="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl2">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl2" xlink:title="label: TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests to us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl1" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl1">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl1" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl1" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl1">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl1" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl1" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl1">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl1" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Events [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl">Remaining weighted average estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Significant Accounting Policies /Recently Adopted/ Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl">Concentrations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl">Future amortization expense, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl">Future amortization expense, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl">Future amortization expense, 2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl">Future amortization expense, 2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl">Future amortization expense, remainder of 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl1">Number of Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl1" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfReportableSegments_lbl">Number of reporting segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:title="label: NumberOfReportableSegments to us-gaap_NumberOfReportableSegments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfReportableSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfReportableSegments_lbl1">Number of Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl1" xlink:title="label: NumberOfReportableSegments to us-gaap_NumberOfReportableSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl">Selling, General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" xlink:title="PurchaseObligation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" id="us-gaap_PurchaseObligation_lbl">Additional minimum purchase obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:title="label: PurchaseObligation to us-gaap_PurchaseObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PurchaseObligation_lbl1" xml:lang="en-US" id="us-gaap_PurchaseObligation_lbl1">Purchase Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl1" xlink:title="label: PurchaseObligation to us-gaap_PurchaseObligation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl">Changes in fair value of investment in Datavant, included in net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl">Total other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossNetOfTax to us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeLossNetOfTax to us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesMember_lbl">Cost of Revenues [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:title="label: CostOfSalesMember to us-gaap_CostOfSalesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="OtherInvestmentCompaniesMember" xlink:title="OtherInvestmentCompaniesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherInvestmentCompaniesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherInvestmentCompaniesMember_lbl" xml:lang="en-US" id="us-gaap_OtherInvestmentCompaniesMember_lbl">Other Investments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherInvestmentCompaniesMember" xlink:to="us-gaap_OtherInvestmentCompaniesMember_lbl" xlink:title="label: OtherInvestmentCompaniesMember to us-gaap_OtherInvestmentCompaniesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherInvestmentCompaniesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherInvestmentCompaniesMember_lbl1" xml:lang="en-US" id="us-gaap_OtherInvestmentCompaniesMember_lbl1">Other Investment Companies [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherInvestmentCompaniesMember" xlink:to="us-gaap_OtherInvestmentCompaniesMember_lbl1" xlink:title="label: OtherInvestmentCompaniesMember to us-gaap_OtherInvestmentCompaniesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:title="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" xml:lang="en-US" id="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl">Issuance of subsidiary preferred shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" xlink:title="label: NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance to us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl">Gain on sale of Telavant net assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl1">Gain (Loss) on Disposition of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl">Warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:title="PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" id="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl">Remaining minimum payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:title="label: PurchaseCommitmentRemainingMinimumAmountCommitted to us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="OtherCurrentLiabilitiesTableTextBlock" xlink:title="OtherCurrentLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl">Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:title="label: OtherCurrentLiabilitiesTableTextBlock to us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm_lbl">Debt instrument, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl">Financial liabilities at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1">Financial Liabilities Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" id="us-gaap_AwardDateAxis_lbl">Award Date [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:title="label: AwardDateAxis to us-gaap_AwardDateAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" id="us-gaap_AwardDateDomain_lbl">Award Date [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xlink:title="label: AwardDateDomain to us-gaap_AwardDateDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionAxis_lbl">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:title="label: RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDomain_lbl">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:title="label: RelatedPartyTransactionDomain to us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="LongtermPurchaseCommitmentPeriod" xlink:title="LongtermPurchaseCommitmentPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" id="us-gaap_LongtermPurchaseCommitmentPeriod_lbl">Purchase certain quantities of inventory over period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:title="label: LongtermPurchaseCommitmentPeriod to us-gaap_LongtermPurchaseCommitmentPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl">Less: unamortized discount and debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet to us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl1">Less: unamortized issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet to us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl2" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl2">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl2" xlink:title="label: DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet to us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl1">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl">Revenue, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl">Cash, Cash Equivalents, and Restricted Cash [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" id="us-gaap_RestrictedCashCurrent_lbl">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:title="label: RestrictedCashCurrent to us-gaap_RestrictedCashCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedCashCurrent_lbl1" xml:lang="en-US" id="us-gaap_RestrictedCashCurrent_lbl1">Restricted cash (included in "Other current assets")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl1" xlink:title="label: RestrictedCashCurrent to us-gaap_RestrictedCashCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedCashCurrent_lbl2" xml:lang="en-US" id="us-gaap_RestrictedCashCurrent_lbl2">Restricted Cash, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl2" xlink:title="label: RestrictedCashCurrent to us-gaap_RestrictedCashCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" id="us-gaap_RestrictedCashNoncurrent_lbl">Restricted cash (included in "Other assets")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xlink:title="label: RestrictedCashNoncurrent to us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedCashNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_RestrictedCashNoncurrent_lbl1">Restricted Cash, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl1" xlink:title="label: RestrictedCashNoncurrent to us-gaap_RestrictedCashNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl3" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl3">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl3" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl">Payments on principal portion of finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl">Operating lease liabilities, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1">Operating Lease, Liability, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeAxis_lbl">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:title="label: MeasurementInputTypeAxis to us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedTermMember_lbl">Term (in years) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:title="label: MeasurementInputExpectedTermMember to us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedTermMember_lbl1" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedTermMember_lbl1">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl1" xlink:title="label: MeasurementInputExpectedTermMember to us-gaap_MeasurementInputExpectedTermMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputPriceVolatilityMember_lbl">Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:title="label: MeasurementInputPriceVolatilityMember to us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputPriceVolatilityMember_lbl1" xml:lang="en-US" id="us-gaap_MeasurementInputPriceVolatilityMember_lbl1">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl1" xlink:title="label: MeasurementInputPriceVolatilityMember to us-gaap_MeasurementInputPriceVolatilityMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl">Risk-free Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:title="label: MeasurementInputRiskFreeInterestRateMember to us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1" xml:lang="en-US" id="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1" xlink:title="label: MeasurementInputRiskFreeInterestRateMember to us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeDomain_lbl">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xlink:title="label: MeasurementInputTypeDomain to us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl">Private placement warrants, measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:title="label: WarrantsAndRightsOutstandingMeasurementInput to us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl1">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl1" xlink:title="label: WarrantsAndRightsOutstandingMeasurementInput to us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl">Private placement warrants, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1">Warrants expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:label="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:title="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" id="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_lbl">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_lbl" xlink:title="label: FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList to us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:title="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" id="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:title="label: FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList to us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl">Non-cash lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiability to us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl1">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl1" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiability to us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="AssetAcquisitionAbstract" xlink:title="AssetAcquisitionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetAcquisitionAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionAbstract_lbl">Asset Acquisition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl" xlink:title="label: AssetAcquisitionAbstract to us-gaap_AssetAcquisitionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetAcquisitionAbstract_lbl1">Asset Acquisition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl1" xlink:title="label: AssetAcquisitionAbstract to us-gaap_AssetAcquisitionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="AssetAcquisitionTable" xlink:title="AssetAcquisitionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionTable_lbl">Asset Acquisition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xlink:title="label: AssetAcquisitionTable to us-gaap_AssetAcquisitionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="AssetAcquisitionLineItems" xlink:title="AssetAcquisitionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionLineItems_lbl">Asset Acquisition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xlink:title="label: AssetAcquisitionLineItems to us-gaap_AssetAcquisitionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:title="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US" id="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:title="label: DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration to us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" id="srt_EquityMethodInvesteeNameDomain_lbl">Investment, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xlink:title="label: EquityMethodInvesteeNameDomain to srt_EquityMethodInvesteeNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_DirectorMember_lbl" xml:lang="en-US" id="srt_DirectorMember_lbl">Independent Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:title="label: DirectorMember to srt_DirectorMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="ChiefFinancialOfficerMember" xlink:title="ChiefFinancialOfficerMember" />
    <link:label xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="srt_ChiefFinancialOfficerMember_lbl">Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:title="label: ChiefFinancialOfficerMember to srt_ChiefFinancialOfficerMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="srt_ScenarioUnspecifiedDomain_lbl">Scenario [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to srt_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioForecastMember_lbl" xml:lang="en-US" id="srt_ScenarioForecastMember_lbl">Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:title="label: ScenarioForecastMember to srt_ScenarioForecastMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementScenarioAxis_lbl" xml:lang="en-US" id="srt_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to srt_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" id="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl">Investment, Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:title="label: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_RangeAxis_lbl1" xml:lang="en-US" id="srt_RangeAxis_lbl1">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl1" xlink:title="label: RangeAxis to srt_RangeAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_RangeMember_lbl1" xml:lang="en-US" id="srt_RangeMember_lbl1">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl1" xlink:title="label: RangeMember to srt_RangeMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" id="srt_CounterpartyNameAxis_lbl">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:title="label: CounterpartyNameAxis to srt_CounterpartyNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="srt_RepurchaseAgreementCounterpartyNameDomain_lbl">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:title="label: RepurchaseAgreementCounterpartyNameDomain to srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="srt_TitleOfIndividualAxis_lbl">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US" id="srt_ConsolidatedEntitiesAxis_lbl">Consolidated Entities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:title="label: ConsolidatedEntitiesAxis to srt_ConsolidatedEntitiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US" id="srt_ConsolidatedEntitiesDomain_lbl">Consolidated Entities [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" xlink:title="label: ConsolidatedEntitiesDomain to srt_ConsolidatedEntitiesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="srt_ProductsAndServicesDomain_lbl">Product and Service [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xlink:title="label: ProductsAndServicesDomain to srt_ProductsAndServicesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="srt_ProductOrServiceAxis_lbl">Product and Service [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:title="label: ProductOrServiceAxis to srt_ProductOrServiceAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" id="dei_DocumentQuarterlyReport_lbl">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:label xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="dei_EntityExTransitionPeriod_lbl">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:title="label: EntityExTransitionPeriod to dei_EntityExTransitionPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="CountryRegion" xlink:title="CountryRegion" />
    <link:label xlink:type="resource" xlink:label="dei_CountryRegion_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CountryRegion_lbl" xml:lang="en-US" id="dei_CountryRegion_lbl">Country Region</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:title="label: CountryRegion to dei_CountryRegion_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:label="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:title="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" />
    <link:label xlink:type="resource" xlink:label="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl" xml:lang="en-US" id="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl">The name of entity acquired intangibles assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:to="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl" xlink:title="label: GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember to roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl1" xml:lang="en-US" id="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl1">GlaxoSmithKline Intellectual Property Development Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:to="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl1" xlink:title="label: GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember to roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl2" xml:lang="en-US" id="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl2">GSK [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:to="roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl2" xlink:title="label: GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember to roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePaid" xlink:label="MilestonePaid" xlink:title="MilestonePaid" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_MilestonePaid_lbl" xml:lang="en-US" id="roiv_MilestonePaid_lbl">Payment made during the period for achieving the milestone or milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaid" xlink:to="roiv_MilestonePaid_lbl" xlink:title="label: MilestonePaid to roiv_MilestonePaid_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_MilestonePaid_lbl1" xml:lang="en-US" id="roiv_MilestonePaid_lbl1">Milestone Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaid" xlink:to="roiv_MilestonePaid_lbl1" xlink:title="label: MilestonePaid to roiv_MilestonePaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePaid_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_MilestonePaid_lbl2" xml:lang="en-US" id="roiv_MilestonePaid_lbl2">Milestone amount paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaid" xlink:to="roiv_MilestonePaid_lbl2" xlink:title="label: MilestonePaid to roiv_MilestonePaid_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePayable" xlink:label="MilestonePayable" xlink:title="MilestonePayable" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_MilestonePayable_lbl" xml:lang="en-US" id="roiv_MilestonePayable_lbl">Amount of milestone payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayable" xlink:to="roiv_MilestonePayable_lbl" xlink:title="label: MilestonePayable to roiv_MilestonePayable_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_MilestonePayable_lbl1" xml:lang="en-US" id="roiv_MilestonePayable_lbl1">Milestone Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayable" xlink:to="roiv_MilestonePayable_lbl1" xlink:title="label: MilestonePayable to roiv_MilestonePayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_MilestonePayable_lbl2" xml:lang="en-US" id="roiv_MilestonePayable_lbl2">Milestone payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayable" xlink:to="roiv_MilestonePayable_lbl2" xlink:title="label: MilestonePayable to roiv_MilestonePayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IntangibleAssetAbstract" xlink:label="IntangibleAssetAbstract" xlink:title="IntangibleAssetAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_IntangibleAssetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_IntangibleAssetAbstract_lbl1" xml:lang="en-US" id="roiv_IntangibleAssetAbstract_lbl1">Intangible Asset [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetAbstract" xlink:to="roiv_IntangibleAssetAbstract_lbl1" xlink:title="label: IntangibleAssetAbstract to roiv_IntangibleAssetAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_IntangibleAssetAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_IntangibleAssetAbstract_lbl2" xml:lang="en-US" id="roiv_IntangibleAssetAbstract_lbl2">Intangible Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetAbstract" xlink:to="roiv_IntangibleAssetAbstract_lbl2" xlink:title="label: IntangibleAssetAbstract to roiv_IntangibleAssetAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_WelichemBiotechIncMember" xlink:label="WelichemBiotechIncMember" xlink:title="WelichemBiotechIncMember" />
    <link:label xlink:type="resource" xlink:label="roiv_WelichemBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_WelichemBiotechIncMember_lbl" xml:lang="en-US" id="roiv_WelichemBiotechIncMember_lbl">The name of entity acquired intangibles assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WelichemBiotechIncMember" xlink:to="roiv_WelichemBiotechIncMember_lbl" xlink:title="label: WelichemBiotechIncMember to roiv_WelichemBiotechIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_WelichemBiotechIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_WelichemBiotechIncMember_lbl1" xml:lang="en-US" id="roiv_WelichemBiotechIncMember_lbl1">Welichem Biotech Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WelichemBiotechIncMember" xlink:to="roiv_WelichemBiotechIncMember_lbl1" xlink:title="label: WelichemBiotechIncMember to roiv_WelichemBiotechIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_WelichemBiotechIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_WelichemBiotechIncMember_lbl2" xml:lang="en-US" id="roiv_WelichemBiotechIncMember_lbl2">Welichem Biotech Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WelichemBiotechIncMember" xlink:to="roiv_WelichemBiotechIncMember_lbl2" xlink:title="label: WelichemBiotechIncMember to roiv_WelichemBiotechIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="AccruedResearchAndDevelopmentExpensesCurrent" xlink:title="AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:label xlink:type="resource" xlink:label="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US" id="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:title="label: AccruedResearchAndDevelopmentExpensesCurrent to roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl1" xml:lang="en-US" id="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl1">Accrued Research and Development Expenses, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl1" xlink:title="label: AccruedResearchAndDevelopmentExpensesCurrent to roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl2" xml:lang="en-US" id="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl2">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl2" xlink:title="label: AccruedResearchAndDevelopmentExpensesCurrent to roiv_AccruedResearchAndDevelopmentExpensesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AccruedSalesAllowancesCurrent" xlink:label="AccruedSalesAllowancesCurrent" xlink:title="AccruedSalesAllowancesCurrent" />
    <link:label xlink:type="resource" xlink:label="roiv_AccruedSalesAllowancesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_AccruedSalesAllowancesCurrent_lbl" xml:lang="en-US" id="roiv_AccruedSalesAllowancesCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to sales allowances, due within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedSalesAllowancesCurrent" xlink:to="roiv_AccruedSalesAllowancesCurrent_lbl" xlink:title="label: AccruedSalesAllowancesCurrent to roiv_AccruedSalesAllowancesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_AccruedSalesAllowancesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_AccruedSalesAllowancesCurrent_lbl1" xml:lang="en-US" id="roiv_AccruedSalesAllowancesCurrent_lbl1">Accrued Sales Allowances Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedSalesAllowancesCurrent" xlink:to="roiv_AccruedSalesAllowancesCurrent_lbl1" xlink:title="label: AccruedSalesAllowancesCurrent to roiv_AccruedSalesAllowancesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_AccruedSalesAllowancesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_AccruedSalesAllowancesCurrent_lbl2" xml:lang="en-US" id="roiv_AccruedSalesAllowancesCurrent_lbl2">Sales allowances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedSalesAllowancesCurrent" xlink:to="roiv_AccruedSalesAllowancesCurrent_lbl2" xlink:title="label: AccruedSalesAllowancesCurrent to roiv_AccruedSalesAllowancesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_VantAIPreferredFinancingMember" xlink:label="VantAIPreferredFinancingMember" xlink:title="VantAIPreferredFinancingMember" />
    <link:label xlink:type="resource" xlink:label="roiv_VantAIPreferredFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_VantAIPreferredFinancingMember_lbl" xml:lang="en-US" id="roiv_VantAIPreferredFinancingMember_lbl">Preferred financing in exchange for shares of VantAI's Series Spin Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VantAIPreferredFinancingMember" xlink:to="roiv_VantAIPreferredFinancingMember_lbl" xlink:title="label: VantAIPreferredFinancingMember to roiv_VantAIPreferredFinancingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_VantAIPreferredFinancingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_VantAIPreferredFinancingMember_lbl1" xml:lang="en-US" id="roiv_VantAIPreferredFinancingMember_lbl1">VantAI Preferred Financing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VantAIPreferredFinancingMember" xlink:to="roiv_VantAIPreferredFinancingMember_lbl1" xlink:title="label: VantAIPreferredFinancingMember to roiv_VantAIPreferredFinancingMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UpfrontCashPayment" xlink:label="UpfrontCashPayment" xlink:title="UpfrontCashPayment" />
    <link:label xlink:type="resource" xlink:label="roiv_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_UpfrontCashPayment_lbl" xml:lang="en-US" id="roiv_UpfrontCashPayment_lbl">The cash outflow associated with the upfront cash payment during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontCashPayment" xlink:to="roiv_UpfrontCashPayment_lbl" xlink:title="label: UpfrontCashPayment to roiv_UpfrontCashPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_UpfrontCashPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_UpfrontCashPayment_lbl1" xml:lang="en-US" id="roiv_UpfrontCashPayment_lbl1">Upfront Cash Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontCashPayment" xlink:to="roiv_UpfrontCashPayment_lbl1" xlink:title="label: UpfrontCashPayment to roiv_UpfrontCashPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_UpfrontCashPayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_UpfrontCashPayment_lbl2" xml:lang="en-US" id="roiv_UpfrontCashPayment_lbl2">Upfront cash payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontCashPayment" xlink:to="roiv_UpfrontCashPayment_lbl2" xlink:title="label: UpfrontCashPayment to roiv_UpfrontCashPayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NewlyFormedSubsidiaryMember" xlink:label="NewlyFormedSubsidiaryMember" xlink:title="NewlyFormedSubsidiaryMember" />
    <link:label xlink:type="resource" xlink:label="roiv_NewlyFormedSubsidiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NewlyFormedSubsidiaryMember_lbl" xml:lang="en-US" id="roiv_NewlyFormedSubsidiaryMember_lbl">a newly-formed subsidiary in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewlyFormedSubsidiaryMember" xlink:to="roiv_NewlyFormedSubsidiaryMember_lbl" xlink:title="label: NewlyFormedSubsidiaryMember to roiv_NewlyFormedSubsidiaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NewlyFormedSubsidiaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NewlyFormedSubsidiaryMember_lbl1" xml:lang="en-US" id="roiv_NewlyFormedSubsidiaryMember_lbl1">Newly-Formed Subsidiary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewlyFormedSubsidiaryMember" xlink:to="roiv_NewlyFormedSubsidiaryMember_lbl1" xlink:title="label: NewlyFormedSubsidiaryMember to roiv_NewlyFormedSubsidiaryMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePaymentPayable" xlink:label="MilestonePaymentPayable" xlink:title="MilestonePaymentPayable" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePaymentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_MilestonePaymentPayable_lbl" xml:lang="en-US" id="roiv_MilestonePaymentPayable_lbl">Amount of milestone payment payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentPayable" xlink:to="roiv_MilestonePaymentPayable_lbl" xlink:title="label: MilestonePaymentPayable to roiv_MilestonePaymentPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePaymentPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_MilestonePaymentPayable_lbl1" xml:lang="en-US" id="roiv_MilestonePaymentPayable_lbl1">Milestone Payment Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentPayable" xlink:to="roiv_MilestonePaymentPayable_lbl1" xlink:title="label: MilestonePaymentPayable to roiv_MilestonePaymentPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePaymentPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_MilestonePaymentPayable_lbl2" xml:lang="en-US" id="roiv_MilestonePaymentPayable_lbl2">Milestone payment payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentPayable" xlink:to="roiv_MilestonePaymentPayable_lbl2" xlink:title="label: MilestonePaymentPayable to roiv_MilestonePaymentPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:label="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:title="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" />
    <link:label xlink:type="resource" xlink:label="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl" xml:lang="en-US" id="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl">Amount of asset acquisition research and development expense in-process.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:to="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl" xlink:title="label: AssetAcquisitionResearchAndDevelopmentExpenseInProcess to roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl1" xml:lang="en-US" id="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl1">Asset Acquisition, Research and Development Expense in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:to="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl1" xlink:title="label: AssetAcquisitionResearchAndDevelopmentExpenseInProcess to roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl2" xml:lang="en-US" id="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl2">Acquired in process research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:to="roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl2" xlink:title="label: AssetAcquisitionResearchAndDevelopmentExpenseInProcess to roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DeconsolidationOfSubsidiariesAbstract" xlink:label="DeconsolidationOfSubsidiariesAbstract" xlink:title="DeconsolidationOfSubsidiariesAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_DeconsolidationOfSubsidiariesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DeconsolidationOfSubsidiariesAbstract_lbl1" xml:lang="en-US" id="roiv_DeconsolidationOfSubsidiariesAbstract_lbl1">Deconsolidation of Subsidiaries [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeconsolidationOfSubsidiariesAbstract" xlink:to="roiv_DeconsolidationOfSubsidiariesAbstract_lbl1" xlink:title="label: DeconsolidationOfSubsidiariesAbstract to roiv_DeconsolidationOfSubsidiariesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SKBiopharmaceuticalsCoLtdMember" xlink:label="SKBiopharmaceuticalsCoLtdMember" xlink:title="SKBiopharmaceuticalsCoLtdMember" />
    <link:label xlink:type="resource" xlink:label="roiv_SKBiopharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_SKBiopharmaceuticalsCoLtdMember_lbl" xml:lang="en-US" id="roiv_SKBiopharmaceuticalsCoLtdMember_lbl">SK Biopharmaceuticals Co., Ltd. ("SK Bio"), a subsidiary of SK Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SKBiopharmaceuticalsCoLtdMember" xlink:to="roiv_SKBiopharmaceuticalsCoLtdMember_lbl" xlink:title="label: SKBiopharmaceuticalsCoLtdMember to roiv_SKBiopharmaceuticalsCoLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_SKBiopharmaceuticalsCoLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_SKBiopharmaceuticalsCoLtdMember_lbl1" xml:lang="en-US" id="roiv_SKBiopharmaceuticalsCoLtdMember_lbl1">SK Biopharmaceuticals Co Ltd [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SKBiopharmaceuticalsCoLtdMember" xlink:to="roiv_SKBiopharmaceuticalsCoLtdMember_lbl1" xlink:title="label: SKBiopharmaceuticalsCoLtdMember to roiv_SKBiopharmaceuticalsCoLtdMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SKIncMember" xlink:label="SKIncMember" xlink:title="SKIncMember" />
    <link:label xlink:type="resource" xlink:label="roiv_SKIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_SKIncMember_lbl" xml:lang="en-US" id="roiv_SKIncMember_lbl">Name of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SKIncMember" xlink:to="roiv_SKIncMember_lbl" xlink:title="label: SKIncMember to roiv_SKIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_SKIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_SKIncMember_lbl1" xml:lang="en-US" id="roiv_SKIncMember_lbl1">SK, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SKIncMember" xlink:to="roiv_SKIncMember_lbl1" xlink:title="label: SKIncMember to roiv_SKIncMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProteovantSciencesIncMember" xlink:label="ProteovantSciencesIncMember" xlink:title="ProteovantSciencesIncMember" />
    <link:label xlink:type="resource" xlink:label="roiv_ProteovantSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ProteovantSciencesIncMember_lbl" xml:lang="en-US" id="roiv_ProteovantSciencesIncMember_lbl">The name of entity owned or controlled subsidiary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProteovantSciencesIncMember" xlink:to="roiv_ProteovantSciencesIncMember_lbl" xlink:title="label: ProteovantSciencesIncMember to roiv_ProteovantSciencesIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ProteovantSciencesIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ProteovantSciencesIncMember_lbl1" xml:lang="en-US" id="roiv_ProteovantSciencesIncMember_lbl1">ProteoVant Sciences, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProteovantSciencesIncMember" xlink:to="roiv_ProteovantSciencesIncMember_lbl1" xlink:title="label: ProteovantSciencesIncMember to roiv_ProteovantSciencesIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ProteovantSciencesIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ProteovantSciencesIncMember_lbl2" xml:lang="en-US" id="roiv_ProteovantSciencesIncMember_lbl2">Proteovant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProteovantSciencesIncMember" xlink:to="roiv_ProteovantSciencesIncMember_lbl2" xlink:title="label: ProteovantSciencesIncMember to roiv_ProteovantSciencesIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl">Tabular disclosure of Share Based Compensation Restricted Stock And Performance Stock Units Award Activity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:to="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock to roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl1" xml:lang="en-US" id="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl1">Schedule Of Share Based Compensation Restricted Stock And Performance Stock Units Award Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:to="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock to roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl2" xml:lang="en-US" id="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl2">Activity for Restricted Stock Units and Performance Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:to="roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl2" xlink:title="label: ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock to roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl">Schedule Of Share Based Compensation Stock Options And Performance Options Activity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:to="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock to roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl1" xml:lang="en-US" id="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl1">Schedule Of Share Based Compensation Stock Options And Performance Options Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:to="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock to roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl2" xml:lang="en-US" id="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl2">Activity for Stock Options and Performance Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:to="roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl2" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock to roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:label="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl">Tabular disclosure of the November 2021 capped value appreciation rights stock units activity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:to="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock to roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl1" xml:lang="en-US" id="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl1">Schedule of November 2021 Capped Value Appreciation Rights Stock Units Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:to="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl1" xlink:title="label: ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock to roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl2" xml:lang="en-US" id="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl2">Activity for Capped Value Appreciation Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:to="roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl2" xlink:title="label: ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock to roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:label="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:title="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl" xml:lang="en-US" id="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl">Tabular disclosure of information related to the calculation of the gain on sale of assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:to="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl" xlink:title="label: ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock to roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl1" xml:lang="en-US" id="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl1">Schedule of Gain on Sale of Assets Calculation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:to="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl1" xlink:title="label: ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock to roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl2" xml:lang="en-US" id="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl2">Calculation of Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:to="roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl2" xlink:title="label: ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock to roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CowenAndCompanyLLCMember" xlink:label="CowenAndCompanyLLCMember" xlink:title="CowenAndCompanyLLCMember" />
    <link:label xlink:type="resource" xlink:label="roiv_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CowenAndCompanyLLCMember_lbl" xml:lang="en-US" id="roiv_CowenAndCompanyLLCMember_lbl">An affiliate with whom the entity entered into a sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CowenAndCompanyLLCMember" xlink:to="roiv_CowenAndCompanyLLCMember_lbl" xlink:title="label: CowenAndCompanyLLCMember to roiv_CowenAndCompanyLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CowenAndCompanyLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CowenAndCompanyLLCMember_lbl1" xml:lang="en-US" id="roiv_CowenAndCompanyLLCMember_lbl1">Cowen and Company, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CowenAndCompanyLLCMember" xlink:to="roiv_CowenAndCompanyLLCMember_lbl1" xlink:title="label: CowenAndCompanyLLCMember to roiv_CowenAndCompanyLLCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CowenAndCompanyLLCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CowenAndCompanyLLCMember_lbl2" xml:lang="en-US" id="roiv_CowenAndCompanyLLCMember_lbl2">Cowen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CowenAndCompanyLLCMember" xlink:to="roiv_CowenAndCompanyLLCMember_lbl2" xlink:title="label: CowenAndCompanyLLCMember to roiv_CowenAndCompanyLLCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:label="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:title="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl" xml:lang="en-US" id="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl">The common shares aggregate offering price authorized remaining capacity to issue under equity offering program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:to="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl" xlink:title="label: CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable to roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl1" xml:lang="en-US" id="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl1">Common Shares Aggregate Offering Price Authorized, Remaining Capacity Available</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:to="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl1" xlink:title="label: CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable to roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl2" xml:lang="en-US" id="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl2">Common shares aggregate offering price authorized, remaining capacity available</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:to="roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl2" xlink:title="label: CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable to roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OptionToPurchaseAdditionalSharesOfCommonStock" xlink:label="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:title="OptionToPurchaseAdditionalSharesOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl" xml:lang="en-US" id="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl">Number of additional shares of common stock option to purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:to="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl" xlink:title="label: OptionToPurchaseAdditionalSharesOfCommonStock to roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl1" xml:lang="en-US" id="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl1">Option to Purchase Additional Shares of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:to="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl1" xlink:title="label: OptionToPurchaseAdditionalSharesOfCommonStock to roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl2" xml:lang="en-US" id="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl2">Option purchase additional shares of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:to="roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl2" xlink:title="label: OptionToPurchaseAdditionalSharesOfCommonStock to roiv_OptionToPurchaseAdditionalSharesOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EquityOfferingsAtTheMarketMember" xlink:label="EquityOfferingsAtTheMarketMember" xlink:title="EquityOfferingsAtTheMarketMember" />
    <link:label xlink:type="resource" xlink:label="roiv_EquityOfferingsAtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EquityOfferingsAtTheMarketMember_lbl" xml:lang="en-US" id="roiv_EquityOfferingsAtTheMarketMember_lbl">Offering of "at-the-market" shares as per equity distribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityOfferingsAtTheMarketMember" xlink:to="roiv_EquityOfferingsAtTheMarketMember_lbl" xlink:title="label: EquityOfferingsAtTheMarketMember to roiv_EquityOfferingsAtTheMarketMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EquityOfferingsAtTheMarketMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EquityOfferingsAtTheMarketMember_lbl1" xml:lang="en-US" id="roiv_EquityOfferingsAtTheMarketMember_lbl1">Equity Offerings at the Market [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityOfferingsAtTheMarketMember" xlink:to="roiv_EquityOfferingsAtTheMarketMember_lbl1" xlink:title="label: EquityOfferingsAtTheMarketMember to roiv_EquityOfferingsAtTheMarketMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EquityOfferingsAtTheMarketMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EquityOfferingsAtTheMarketMember_lbl2" xml:lang="en-US" id="roiv_EquityOfferingsAtTheMarketMember_lbl2">At-the-Market Equity Offering Program[Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityOfferingsAtTheMarketMember" xlink:to="roiv_EquityOfferingsAtTheMarketMember_lbl2" xlink:title="label: EquityOfferingsAtTheMarketMember to roiv_EquityOfferingsAtTheMarketMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NetProceedsFromIssuanceOfCommonStock" xlink:label="NetProceedsFromIssuanceOfCommonStock" xlink:title="NetProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="roiv_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="roiv_NetProceedsFromIssuanceOfCommonStock_lbl">The net cash inflow from the additional capital contribution to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromIssuanceOfCommonStock" xlink:to="roiv_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: NetProceedsFromIssuanceOfCommonStock to roiv_NetProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NetProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NetProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="roiv_NetProceedsFromIssuanceOfCommonStock_lbl1">Net Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromIssuanceOfCommonStock" xlink:to="roiv_NetProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: NetProceedsFromIssuanceOfCommonStock to roiv_NetProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NetProceedsFromIssuanceOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NetProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US" id="roiv_NetProceedsFromIssuanceOfCommonStock_lbl2">Net proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromIssuanceOfCommonStock" xlink:to="roiv_NetProceedsFromIssuanceOfCommonStock_lbl2" xlink:title="label: NetProceedsFromIssuanceOfCommonStock to roiv_NetProceedsFromIssuanceOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockPurchasedDuringPeriodByEntityShares" xlink:label="StockPurchasedDuringPeriodByEntityShares" xlink:title="StockPurchasedDuringPeriodByEntityShares" />
    <link:label xlink:type="resource" xlink:label="roiv_StockPurchasedDuringPeriodByEntityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockPurchasedDuringPeriodByEntityShares_lbl" xml:lang="en-US" id="roiv_StockPurchasedDuringPeriodByEntityShares_lbl">Number of new stock purchased during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockPurchasedDuringPeriodByEntityShares" xlink:to="roiv_StockPurchasedDuringPeriodByEntityShares_lbl" xlink:title="label: StockPurchasedDuringPeriodByEntityShares to roiv_StockPurchasedDuringPeriodByEntityShares_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockPurchasedDuringPeriodByEntityShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockPurchasedDuringPeriodByEntityShares_lbl1" xml:lang="en-US" id="roiv_StockPurchasedDuringPeriodByEntityShares_lbl1">Stock Purchased During Period by Entity, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockPurchasedDuringPeriodByEntityShares" xlink:to="roiv_StockPurchasedDuringPeriodByEntityShares_lbl1" xlink:title="label: StockPurchasedDuringPeriodByEntityShares to roiv_StockPurchasedDuringPeriodByEntityShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockPurchasedDuringPeriodByEntityShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockPurchasedDuringPeriodByEntityShares_lbl2" xml:lang="en-US" id="roiv_StockPurchasedDuringPeriodByEntityShares_lbl2">Common shares purchased by RSL (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockPurchasedDuringPeriodByEntityShares" xlink:to="roiv_StockPurchasedDuringPeriodByEntityShares_lbl2" xlink:title="label: StockPurchasedDuringPeriodByEntityShares to roiv_StockPurchasedDuringPeriodByEntityShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:label="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:title="EstimatedNetProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl">The estimated net cash inflow from the additional capital contribution to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:to="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: EstimatedNetProceedsFromIssuanceOfCommonStock to roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl1">Estimated Net Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:to="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: EstimatedNetProceedsFromIssuanceOfCommonStock to roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US" id="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl2">Net proceeds of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:to="roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl2" xlink:title="label: EstimatedNetProceedsFromIssuanceOfCommonStock to roiv_EstimatedNetProceedsFromIssuanceOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesOfferingPriceAuthorized" xlink:label="CommonSharesOfferingPriceAuthorized" xlink:title="CommonSharesOfferingPriceAuthorized" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesOfferingPriceAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CommonSharesOfferingPriceAuthorized_lbl" xml:lang="en-US" id="roiv_CommonSharesOfferingPriceAuthorized_lbl">The common shares aggregate offering price authorized to issue under equity offering program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesOfferingPriceAuthorized" xlink:to="roiv_CommonSharesOfferingPriceAuthorized_lbl" xlink:title="label: CommonSharesOfferingPriceAuthorized to roiv_CommonSharesOfferingPriceAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesOfferingPriceAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CommonSharesOfferingPriceAuthorized_lbl1" xml:lang="en-US" id="roiv_CommonSharesOfferingPriceAuthorized_lbl1">Common Shares Offering Price Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesOfferingPriceAuthorized" xlink:to="roiv_CommonSharesOfferingPriceAuthorized_lbl1" xlink:title="label: CommonSharesOfferingPriceAuthorized to roiv_CommonSharesOfferingPriceAuthorized_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesOfferingPriceAuthorized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CommonSharesOfferingPriceAuthorized_lbl2" xml:lang="en-US" id="roiv_CommonSharesOfferingPriceAuthorized_lbl2">Common shares aggregate offering price authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesOfferingPriceAuthorized" xlink:to="roiv_CommonSharesOfferingPriceAuthorized_lbl2" xlink:title="label: CommonSharesOfferingPriceAuthorized to roiv_CommonSharesOfferingPriceAuthorized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantParticipationOfImmunovantStockOfferingMember" xlink:label="RoivantParticipationOfImmunovantStockOfferingMember" xlink:title="RoivantParticipationOfImmunovantStockOfferingMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RoivantParticipationOfImmunovantStockOfferingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RoivantParticipationOfImmunovantStockOfferingMember_lbl1" xml:lang="en-US" id="roiv_RoivantParticipationOfImmunovantStockOfferingMember_lbl1">Roivant participation of Immunovant Stock offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoivantParticipationOfImmunovantStockOfferingMember" xlink:to="roiv_RoivantParticipationOfImmunovantStockOfferingMember_lbl1" xlink:title="label: RoivantParticipationOfImmunovantStockOfferingMember to roiv_RoivantParticipationOfImmunovantStockOfferingMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ImmunovantIncMember" xlink:label="ImmunovantIncMember" xlink:title="ImmunovantIncMember" />
    <link:label xlink:type="resource" xlink:label="roiv_ImmunovantIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ImmunovantIncMember_lbl" xml:lang="en-US" id="roiv_ImmunovantIncMember_lbl">Name of subsidiary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImmunovantIncMember" xlink:to="roiv_ImmunovantIncMember_lbl" xlink:title="label: ImmunovantIncMember to roiv_ImmunovantIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ImmunovantIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ImmunovantIncMember_lbl1" xml:lang="en-US" id="roiv_ImmunovantIncMember_lbl1">Immunovant, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImmunovantIncMember" xlink:to="roiv_ImmunovantIncMember_lbl1" xlink:title="label: ImmunovantIncMember to roiv_ImmunovantIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ImmunovantIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ImmunovantIncMember_lbl2" xml:lang="en-US" id="roiv_ImmunovantIncMember_lbl2">Immunovant, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImmunovantIncMember" xlink:to="roiv_ImmunovantIncMember_lbl2" xlink:title="label: ImmunovantIncMember to roiv_ImmunovantIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="UnderwrittenPublicOfferingMember" xlink:title="UnderwrittenPublicOfferingMember" />
    <link:label xlink:type="resource" xlink:label="roiv_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" id="roiv_UnderwrittenPublicOfferingMember_lbl">Public offering in which the Common Stock is offered and sold on a firm commitment basis through one or more underwriters.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnderwrittenPublicOfferingMember" xlink:to="roiv_UnderwrittenPublicOfferingMember_lbl" xlink:title="label: UnderwrittenPublicOfferingMember to roiv_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_UnderwrittenPublicOfferingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_UnderwrittenPublicOfferingMember_lbl1" xml:lang="en-US" id="roiv_UnderwrittenPublicOfferingMember_lbl1">Underwritten Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnderwrittenPublicOfferingMember" xlink:to="roiv_UnderwrittenPublicOfferingMember_lbl1" xlink:title="label: UnderwrittenPublicOfferingMember to roiv_UnderwrittenPublicOfferingMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_UnderwrittenPublicOfferingMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_UnderwrittenPublicOfferingMember_lbl2" xml:lang="en-US" id="roiv_UnderwrittenPublicOfferingMember_lbl2">Underwritten Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnderwrittenPublicOfferingMember" xlink:to="roiv_UnderwrittenPublicOfferingMember_lbl2" xlink:title="label: UnderwrittenPublicOfferingMember to roiv_UnderwrittenPublicOfferingMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfEquityIncentivePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" id="roiv_NumberOfEquityIncentivePlans_lbl">The number of equity incentive plans for the company during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityIncentivePlans" xlink:to="roiv_NumberOfEquityIncentivePlans_lbl" xlink:title="label: NumberOfEquityIncentivePlans to roiv_NumberOfEquityIncentivePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfEquityIncentivePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NumberOfEquityIncentivePlans_lbl1" xml:lang="en-US" id="roiv_NumberOfEquityIncentivePlans_lbl1">Number of Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityIncentivePlans" xlink:to="roiv_NumberOfEquityIncentivePlans_lbl1" xlink:title="label: NumberOfEquityIncentivePlans to roiv_NumberOfEquityIncentivePlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfEquityIncentivePlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NumberOfEquityIncentivePlans_lbl2" xml:lang="en-US" id="roiv_NumberOfEquityIncentivePlans_lbl2">Number of equity incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityIncentivePlans" xlink:to="roiv_NumberOfEquityIncentivePlans_lbl2" xlink:title="label: NumberOfEquityIncentivePlans to roiv_NumberOfEquityIncentivePlans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesNonvestedMember" xlink:label="EarnOutSharesNonvestedMember" xlink:title="EarnOutSharesNonvestedMember" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesNonvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EarnOutSharesNonvestedMember_lbl" xml:lang="en-US" id="roiv_EarnOutSharesNonvestedMember_lbl">Earnout or earn-out refers to a pricing structure in mergers and acquisitions where the sellers must "earn" part of the purchase price based on the performance of the business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesNonvestedMember" xlink:to="roiv_EarnOutSharesNonvestedMember_lbl" xlink:title="label: EarnOutSharesNonvestedMember to roiv_EarnOutSharesNonvestedMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesNonvestedMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnOutSharesNonvestedMember_lbl1" xml:lang="en-US" id="roiv_EarnOutSharesNonvestedMember_lbl1">Earn Out Shares Nonvested [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesNonvestedMember" xlink:to="roiv_EarnOutSharesNonvestedMember_lbl1" xlink:title="label: EarnOutSharesNonvestedMember to roiv_EarnOutSharesNonvestedMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesNonvestedMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EarnOutSharesNonvestedMember_lbl2" xml:lang="en-US" id="roiv_EarnOutSharesNonvestedMember_lbl2">Earn-Out Shares (Non-vested) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesNonvestedMember" xlink:to="roiv_EarnOutSharesNonvestedMember_lbl2" xlink:title="label: EarnOutSharesNonvestedMember to roiv_EarnOutSharesNonvestedMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:label="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:title="OtherStockBasedAwardsAndInstrumentsIssuedMember" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl" xml:lang="en-US" id="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl">The other stock based awards and instruments issued related to the awards consisting of stock units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:to="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl" xlink:title="label: OtherStockBasedAwardsAndInstrumentsIssuedMember to roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl1" xml:lang="en-US" id="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl1">Other Stock Based Awards and Instruments Issued [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:to="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl1" xlink:title="label: OtherStockBasedAwardsAndInstrumentsIssuedMember to roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl2" xml:lang="en-US" id="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl2">Other Stock Based Awards and Instruments Issued [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:to="roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl2" xlink:title="label: OtherStockBasedAwardsAndInstrumentsIssuedMember to roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="StockOptionsAndPerformanceStockOptionsMember" xlink:title="StockOptionsAndPerformanceStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl" xml:lang="en-US" id="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time and Share-based payment arrangement awarded for meeting performance target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAndPerformanceStockOptionsMember" xlink:to="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl" xlink:title="label: StockOptionsAndPerformanceStockOptionsMember to roiv_StockOptionsAndPerformanceStockOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl1" xml:lang="en-US" id="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl1">Stock Options and Performance Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAndPerformanceStockOptionsMember" xlink:to="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl1" xlink:title="label: StockOptionsAndPerformanceStockOptionsMember to roiv_StockOptionsAndPerformanceStockOptionsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl2" xml:lang="en-US" id="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl2">Stock Options and Performance Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAndPerformanceStockOptionsMember" xlink:to="roiv_StockOptionsAndPerformanceStockOptionsMember_lbl2" xlink:title="label: StockOptionsAndPerformanceStockOptionsMember to roiv_StockOptionsAndPerformanceStockOptionsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OperatingCosts" xlink:label="OperatingCosts" xlink:title="OperatingCosts" />
    <link:label xlink:type="resource" xlink:label="roiv_OperatingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_OperatingCosts_lbl" xml:lang="en-US" id="roiv_OperatingCosts_lbl">The total amount of operating cost and expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingCosts" xlink:to="roiv_OperatingCosts_lbl" xlink:title="label: OperatingCosts to roiv_OperatingCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_OperatingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_OperatingCosts_lbl1" xml:lang="en-US" id="roiv_OperatingCosts_lbl1">Operating Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingCosts" xlink:to="roiv_OperatingCosts_lbl1" xlink:title="label: OperatingCosts to roiv_OperatingCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_OperatingCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_OperatingCosts_lbl2" xml:lang="en-US" id="roiv_OperatingCosts_lbl2">Cost of revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingCosts" xlink:to="roiv_OperatingCosts_lbl2" xlink:title="label: OperatingCosts to roiv_OperatingCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LicenseMilestoneAndOtherRevenueMember" xlink:label="LicenseMilestoneAndOtherRevenueMember" xlink:title="LicenseMilestoneAndOtherRevenueMember" />
    <link:label xlink:type="resource" xlink:label="roiv_LicenseMilestoneAndOtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_LicenseMilestoneAndOtherRevenueMember_lbl" xml:lang="en-US" id="roiv_LicenseMilestoneAndOtherRevenueMember_lbl">Represents the license, milestone, and other revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseMilestoneAndOtherRevenueMember" xlink:to="roiv_LicenseMilestoneAndOtherRevenueMember_lbl" xlink:title="label: LicenseMilestoneAndOtherRevenueMember to roiv_LicenseMilestoneAndOtherRevenueMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_LicenseMilestoneAndOtherRevenueMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_LicenseMilestoneAndOtherRevenueMember_lbl1" xml:lang="en-US" id="roiv_LicenseMilestoneAndOtherRevenueMember_lbl1">License, Milestone and Other Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseMilestoneAndOtherRevenueMember" xlink:to="roiv_LicenseMilestoneAndOtherRevenueMember_lbl1" xlink:title="label: LicenseMilestoneAndOtherRevenueMember to roiv_LicenseMilestoneAndOtherRevenueMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_LicenseMilestoneAndOtherRevenueMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_LicenseMilestoneAndOtherRevenueMember_lbl2" xml:lang="en-US" id="roiv_LicenseMilestoneAndOtherRevenueMember_lbl2">License, Milestone and Other Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseMilestoneAndOtherRevenueMember" xlink:to="roiv_LicenseMilestoneAndOtherRevenueMember_lbl2" xlink:title="label: LicenseMilestoneAndOtherRevenueMember to roiv_LicenseMilestoneAndOtherRevenueMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InterestIncome" xlink:label="InterestIncome" xlink:title="InterestIncome" />
    <link:label xlink:type="resource" xlink:label="roiv_InterestIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_InterestIncome_lbl" xml:lang="en-US" id="roiv_InterestIncome_lbl">Interest income on nonoperating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncome" xlink:to="roiv_InterestIncome_lbl" xlink:title="label: InterestIncome to roiv_InterestIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_InterestIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_InterestIncome_lbl1" xml:lang="en-US" id="roiv_InterestIncome_lbl1">Interest Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncome" xlink:to="roiv_InterestIncome_lbl1" xlink:title="label: InterestIncome to roiv_InterestIncome_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_InterestIncome_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_InterestIncome_lbl2" xml:lang="en-US" id="roiv_InterestIncome_lbl2">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncome" xlink:to="roiv_InterestIncome_lbl2" xlink:title="label: InterestIncome to roiv_InterestIncome_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="AcquiredInProcessResearchAndDevelopmentExpense" xlink:title="AcquiredInProcessResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl">Amount of acquired in-process research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquiredInProcessResearchAndDevelopmentExpense" xlink:to="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl" xlink:title="label: AcquiredInProcessResearchAndDevelopmentExpense to roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl1">Acquired in Process Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquiredInProcessResearchAndDevelopmentExpense" xlink:to="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl1" xlink:title="label: AcquiredInProcessResearchAndDevelopmentExpense to roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl2" xml:lang="en-US" id="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl2">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquiredInProcessResearchAndDevelopmentExpense" xlink:to="roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl2" xlink:title="label: AcquiredInProcessResearchAndDevelopmentExpense to roiv_AcquiredInProcessResearchAndDevelopmentExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashlessPublicWarrantExercised" xlink:label="CashlessPublicWarrantExercised" xlink:title="CashlessPublicWarrantExercised" />
    <link:label xlink:type="resource" xlink:label="roiv_CashlessPublicWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CashlessPublicWarrantExercised_lbl" xml:lang="en-US" id="roiv_CashlessPublicWarrantExercised_lbl">Number of cashless public warrants exercised during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashlessPublicWarrantExercised" xlink:to="roiv_CashlessPublicWarrantExercised_lbl" xlink:title="label: CashlessPublicWarrantExercised to roiv_CashlessPublicWarrantExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CashlessPublicWarrantExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CashlessPublicWarrantExercised_lbl1" xml:lang="en-US" id="roiv_CashlessPublicWarrantExercised_lbl1">Cashless Public Warrant Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashlessPublicWarrantExercised" xlink:to="roiv_CashlessPublicWarrantExercised_lbl1" xlink:title="label: CashlessPublicWarrantExercised to roiv_CashlessPublicWarrantExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CashlessPublicWarrantExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CashlessPublicWarrantExercised_lbl2" xml:lang="en-US" id="roiv_CashlessPublicWarrantExercised_lbl2">Cashless warrant exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashlessPublicWarrantExercised" xlink:to="roiv_CashlessPublicWarrantExercised_lbl2" xlink:title="label: CashlessPublicWarrantExercised to roiv_CashlessPublicWarrantExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:label="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:title="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl" xml:lang="en-US" id="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl">Number of trading days allowed to calculate earnout share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:to="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl" xlink:title="label: NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold to roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl1" xml:lang="en-US" id="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl1">Number of Trading Days Allowed to Calculate Earn-Out Share Price Threshold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:to="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl1" xlink:title="label: NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold to roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl2" xml:lang="en-US" id="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl2">Trading day period for earn-out shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:to="roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl2" xlink:title="label: NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold to roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ExercisePrice" xlink:label="ExercisePrice" xlink:title="ExercisePrice" />
    <link:label xlink:type="resource" xlink:label="roiv_ExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ExercisePrice_lbl" xml:lang="en-US" id="roiv_ExercisePrice_lbl">The exercise price per Common Share on a cashless basis to exercise warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePrice" xlink:to="roiv_ExercisePrice_lbl" xlink:title="label: ExercisePrice to roiv_ExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ExercisePrice_lbl1" xml:lang="en-US" id="roiv_ExercisePrice_lbl1">Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePrice" xlink:to="roiv_ExercisePrice_lbl1" xlink:title="label: ExercisePrice to roiv_ExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ExercisePrice_lbl2" xml:lang="en-US" id="roiv_ExercisePrice_lbl2">Cashless exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePrice" xlink:to="roiv_ExercisePrice_lbl2" xlink:title="label: ExercisePrice to roiv_ExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TenPercentEarnOutSharesMember" xlink:label="TenPercentEarnOutSharesMember" xlink:title="TenPercentEarnOutSharesMember" />
    <link:label xlink:type="resource" xlink:label="roiv_TenPercentEarnOutSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_TenPercentEarnOutSharesMember_lbl" xml:lang="en-US" id="roiv_TenPercentEarnOutSharesMember_lbl">The percentage of earn-out shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenPercentEarnOutSharesMember" xlink:to="roiv_TenPercentEarnOutSharesMember_lbl" xlink:title="label: TenPercentEarnOutSharesMember to roiv_TenPercentEarnOutSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_TenPercentEarnOutSharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_TenPercentEarnOutSharesMember_lbl1" xml:lang="en-US" id="roiv_TenPercentEarnOutSharesMember_lbl1">Ten Percent Earn-Out Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenPercentEarnOutSharesMember" xlink:to="roiv_TenPercentEarnOutSharesMember_lbl1" xlink:title="label: TenPercentEarnOutSharesMember to roiv_TenPercentEarnOutSharesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_TenPercentEarnOutSharesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_TenPercentEarnOutSharesMember_lbl2" xml:lang="en-US" id="roiv_TenPercentEarnOutSharesMember_lbl2">10 % Earn-Out [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenPercentEarnOutSharesMember" xlink:to="roiv_TenPercentEarnOutSharesMember_lbl2" xlink:title="label: TenPercentEarnOutSharesMember to roiv_TenPercentEarnOutSharesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodToExerciseWarrantsAfterBusinessCombination" xlink:label="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:title="PeriodToExerciseWarrantsAfterBusinessCombination" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl" xml:lang="en-US" id="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl">Period after the completion of a business combination when warrants will become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:to="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl" xlink:title="label: PeriodToExerciseWarrantsAfterBusinessCombination to roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl1" xml:lang="en-US" id="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl1">Period to Exercise Warrants After Business Combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:to="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl1" xlink:title="label: PeriodToExerciseWarrantsAfterBusinessCombination to roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl2" xml:lang="en-US" id="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl2">Period to exercise warrants after business combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:to="roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl2" xlink:title="label: PeriodToExerciseWarrantsAfterBusinessCombination to roiv_PeriodToExerciseWarrantsAfterBusinessCombination_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantCashExercised" xlink:label="PublicWarrantCashExercised" xlink:title="PublicWarrantCashExercised" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantCashExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PublicWarrantCashExercised_lbl" xml:lang="en-US" id="roiv_PublicWarrantCashExercised_lbl">Number of Public warrants cash exercised during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantCashExercised" xlink:to="roiv_PublicWarrantCashExercised_lbl" xlink:title="label: PublicWarrantCashExercised to roiv_PublicWarrantCashExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantCashExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PublicWarrantCashExercised_lbl1" xml:lang="en-US" id="roiv_PublicWarrantCashExercised_lbl1">Public Warrant Cash Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantCashExercised" xlink:to="roiv_PublicWarrantCashExercised_lbl1" xlink:title="label: PublicWarrantCashExercised to roiv_PublicWarrantCashExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantCashExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PublicWarrantCashExercised_lbl2" xml:lang="en-US" id="roiv_PublicWarrantCashExercised_lbl2">Warrant exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantCashExercised" xlink:to="roiv_PublicWarrantCashExercised_lbl2" xlink:title="label: PublicWarrantCashExercised to roiv_PublicWarrantCashExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:label="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:title="StockIssuedDuringPeriodSharesCashlessWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl">Aggregate number of shares exchanged on a cashless basis during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:to="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl" xlink:title="label: StockIssuedDuringPeriodSharesCashlessWarrantExercises to roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl1">Stock Issued During Period Shares Cashless Warrant Exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:to="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesCashlessWarrantExercises to roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl2">Aggregate value of shares exchanged on a cashless basis (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:to="roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesCashlessWarrantExercises to roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:label="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:title="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl" xml:lang="en-US" id="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl">The number of trading days that are allowed to meet earn-out share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:to="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl" xlink:title="label: NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold to roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl1" xml:lang="en-US" id="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl1">Number of Trading Days to be used to Meet Earn-Out Share Price Threshold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:to="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl1" xlink:title="label: NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold to roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl2" xml:lang="en-US" id="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl2">Number of trading days to meet earn-out price threshold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:to="roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl2" xlink:title="label: NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold to roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharePrice" xlink:label="EarnOutSharePrice" xlink:title="EarnOutSharePrice" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EarnOutSharePrice_lbl" xml:lang="en-US" id="roiv_EarnOutSharePrice_lbl">The share price of earn-out share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharePrice" xlink:to="roiv_EarnOutSharePrice_lbl" xlink:title="label: EarnOutSharePrice to roiv_EarnOutSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnOutSharePrice_lbl1" xml:lang="en-US" id="roiv_EarnOutSharePrice_lbl1">Earn-Out Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharePrice" xlink:to="roiv_EarnOutSharePrice_lbl1" xlink:title="label: EarnOutSharePrice to roiv_EarnOutSharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EarnOutSharePrice_lbl2" xml:lang="en-US" id="roiv_EarnOutSharePrice_lbl2">Earn-out share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharePrice" xlink:to="roiv_EarnOutSharePrice_lbl2" xlink:title="label: EarnOutSharePrice to roiv_EarnOutSharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfEarnOutSharesVested" xlink:label="NumberOfEarnOutSharesVested" xlink:title="NumberOfEarnOutSharesVested" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfEarnOutSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NumberOfEarnOutSharesVested_lbl" xml:lang="en-US" id="roiv_NumberOfEarnOutSharesVested_lbl">Number of earn-out shares vested during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEarnOutSharesVested" xlink:to="roiv_NumberOfEarnOutSharesVested_lbl" xlink:title="label: NumberOfEarnOutSharesVested to roiv_NumberOfEarnOutSharesVested_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfEarnOutSharesVested_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NumberOfEarnOutSharesVested_lbl1" xml:lang="en-US" id="roiv_NumberOfEarnOutSharesVested_lbl1">Number of Earn-Out Shares Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEarnOutSharesVested" xlink:to="roiv_NumberOfEarnOutSharesVested_lbl1" xlink:title="label: NumberOfEarnOutSharesVested to roiv_NumberOfEarnOutSharesVested_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfEarnOutSharesVested_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NumberOfEarnOutSharesVested_lbl2" xml:lang="en-US" id="roiv_NumberOfEarnOutSharesVested_lbl2">Number of earn-out shares vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEarnOutSharesVested" xlink:to="roiv_NumberOfEarnOutSharesVested_lbl2" xlink:title="label: NumberOfEarnOutSharesVested to roiv_NumberOfEarnOutSharesVested_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PercentageOfEarnOutShares" xlink:label="PercentageOfEarnOutShares" xlink:title="PercentageOfEarnOutShares" />
    <link:label xlink:type="resource" xlink:label="roiv_PercentageOfEarnOutShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PercentageOfEarnOutShares_lbl" xml:lang="en-US" id="roiv_PercentageOfEarnOutShares_lbl">The collective percentage of earn-out shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfEarnOutShares" xlink:to="roiv_PercentageOfEarnOutShares_lbl" xlink:title="label: PercentageOfEarnOutShares to roiv_PercentageOfEarnOutShares_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PercentageOfEarnOutShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PercentageOfEarnOutShares_lbl1" xml:lang="en-US" id="roiv_PercentageOfEarnOutShares_lbl1">Percentage of Earn-Out Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfEarnOutShares" xlink:to="roiv_PercentageOfEarnOutShares_lbl1" xlink:title="label: PercentageOfEarnOutShares to roiv_PercentageOfEarnOutShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PercentageOfEarnOutShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PercentageOfEarnOutShares_lbl2" xml:lang="en-US" id="roiv_PercentageOfEarnOutShares_lbl2">Percentage of earn-out shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfEarnOutShares" xlink:to="roiv_PercentageOfEarnOutShares_lbl2" xlink:title="label: PercentageOfEarnOutShares to roiv_PercentageOfEarnOutShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesAbstract" xlink:label="EarnOutSharesAbstract" xlink:title="EarnOutSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnOutSharesAbstract_lbl1" xml:lang="en-US" id="roiv_EarnOutSharesAbstract_lbl1">Earn-Out Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesAbstract" xlink:to="roiv_EarnOutSharesAbstract_lbl1" xlink:title="label: EarnOutSharesAbstract to roiv_EarnOutSharesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EarnOutSharesAbstract_lbl2" xml:lang="en-US" id="roiv_EarnOutSharesAbstract_lbl2">Earn-Out Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesAbstract" xlink:to="roiv_EarnOutSharesAbstract_lbl2" xlink:title="label: EarnOutSharesAbstract to roiv_EarnOutSharesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:label="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:title="StockIssuedDuringPeriodSharesCashWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl">Aggregate number of shares exchanged during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:to="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl" xlink:title="label: StockIssuedDuringPeriodSharesCashWarrantExercises to roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl1">Stock Issued During Period Shares Cash Warrant Exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:to="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesCashWarrantExercises to roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl2">Aggregate value of shares exchanged (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:to="roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesCashWarrantExercises to roiv_StockIssuedDuringPeriodSharesCashWarrantExercises_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ClassOfWarrantOrRightRedemptionPrice" xlink:label="ClassOfWarrantOrRightRedemptionPrice" xlink:title="ClassOfWarrantOrRightRedemptionPrice" />
    <link:label xlink:type="resource" xlink:label="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl" xml:lang="en-US" id="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl">Redemption price per share or per unit of warrants or rights outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightRedemptionPrice" xlink:to="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl" xlink:title="label: ClassOfWarrantOrRightRedemptionPrice to roiv_ClassOfWarrantOrRightRedemptionPrice_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl1" xml:lang="en-US" id="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl1">Class of Warrant or Right Redemption Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightRedemptionPrice" xlink:to="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl1" xlink:title="label: ClassOfWarrantOrRightRedemptionPrice to roiv_ClassOfWarrantOrRightRedemptionPrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl2" xml:lang="en-US" id="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl2">Redemption price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightRedemptionPrice" xlink:to="roiv_ClassOfWarrantOrRightRedemptionPrice_lbl2" xlink:title="label: ClassOfWarrantOrRightRedemptionPrice to roiv_ClassOfWarrantOrRightRedemptionPrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:label="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:title="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" />
    <link:label xlink:type="resource" xlink:label="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl" xml:lang="en-US" id="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl">Number of shares unexercised of warrant redeemed during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:to="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl" xlink:title="label: ClassOfWarrantOrRightUnexercisedPriceOfWarrants to roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl1" xml:lang="en-US" id="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl1">Class of Warrant or Right Unexercised Price of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:to="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl1" xlink:title="label: ClassOfWarrantOrRightUnexercisedPriceOfWarrants to roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl2" xml:lang="en-US" id="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl2">Unexercised public warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:to="roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl2" xlink:title="label: ClassOfWarrantOrRightUnexercisedPriceOfWarrants to roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDays" xlink:label="NumberOfTradingDays" xlink:title="NumberOfTradingDays" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NumberOfTradingDays_lbl" xml:lang="en-US" id="roiv_NumberOfTradingDays_lbl">Number of trading days for common stock price to exceed threshold, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDays" xlink:to="roiv_NumberOfTradingDays_lbl" xlink:title="label: NumberOfTradingDays to roiv_NumberOfTradingDays_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDays_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NumberOfTradingDays_lbl1" xml:lang="en-US" id="roiv_NumberOfTradingDays_lbl1">Number of Trading Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDays" xlink:to="roiv_NumberOfTradingDays_lbl1" xlink:title="label: NumberOfTradingDays to roiv_NumberOfTradingDays_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NumberOfTradingDays_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NumberOfTradingDays_lbl2" xml:lang="en-US" id="roiv_NumberOfTradingDays_lbl2">Number of trading days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTradingDays" xlink:to="roiv_NumberOfTradingDays_lbl2" xlink:title="label: NumberOfTradingDays to roiv_NumberOfTradingDays_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashExercisePrice" xlink:label="CashExercisePrice" xlink:title="CashExercisePrice" />
    <link:label xlink:type="resource" xlink:label="roiv_CashExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CashExercisePrice_lbl" xml:lang="en-US" id="roiv_CashExercisePrice_lbl">The exercise price per common share on a cash basis to exercise warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashExercisePrice" xlink:to="roiv_CashExercisePrice_lbl" xlink:title="label: CashExercisePrice to roiv_CashExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CashExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CashExercisePrice_lbl1" xml:lang="en-US" id="roiv_CashExercisePrice_lbl1">Cash Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashExercisePrice" xlink:to="roiv_CashExercisePrice_lbl1" xlink:title="label: CashExercisePrice to roiv_CashExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CashExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_CashExercisePrice_lbl2" xml:lang="en-US" id="roiv_CashExercisePrice_lbl2">Cash exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashExercisePrice" xlink:to="roiv_CashExercisePrice_lbl2" xlink:title="label: CashExercisePrice to roiv_CashExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:label="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:title="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl">Number of common shares issued to surrendering holder per warrant during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:to="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl" xlink:title="label: StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant to roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl1">Stock Issued During Period Number of Shares Issued to Surrendering Holder Per Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:to="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl1" xlink:title="label: StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant to roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl2">Number of common shares issued to surrendering holder per warrant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:to="roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl2" xlink:title="label: StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant to roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:label="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="PublicWarrantsAndPrivatePlacementWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" xml:lang="en-US" id="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1">Public Warrants and Private Placement Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" xlink:title="label: PublicWarrantsAndPrivatePlacementWarrantsAbstract to roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl2" xml:lang="en-US" id="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl2">Public Warrants and Private Placement Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl2" xlink:title="label: PublicWarrantsAndPrivatePlacementWarrantsAbstract to roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl1" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl1">Earn-Out Shares, Public Warrants and Private Placement Warrants [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl1" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TwentyPercentEarnOutSharesMember" xlink:label="TwentyPercentEarnOutSharesMember" xlink:title="TwentyPercentEarnOutSharesMember" />
    <link:label xlink:type="resource" xlink:label="roiv_TwentyPercentEarnOutSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_TwentyPercentEarnOutSharesMember_lbl" xml:lang="en-US" id="roiv_TwentyPercentEarnOutSharesMember_lbl">The percentage of earnout shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwentyPercentEarnOutSharesMember" xlink:to="roiv_TwentyPercentEarnOutSharesMember_lbl" xlink:title="label: TwentyPercentEarnOutSharesMember to roiv_TwentyPercentEarnOutSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_TwentyPercentEarnOutSharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_TwentyPercentEarnOutSharesMember_lbl1" xml:lang="en-US" id="roiv_TwentyPercentEarnOutSharesMember_lbl1">Twenty Percent Earn-Out Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwentyPercentEarnOutSharesMember" xlink:to="roiv_TwentyPercentEarnOutSharesMember_lbl1" xlink:title="label: TwentyPercentEarnOutSharesMember to roiv_TwentyPercentEarnOutSharesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_TwentyPercentEarnOutSharesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_TwentyPercentEarnOutSharesMember_lbl2" xml:lang="en-US" id="roiv_TwentyPercentEarnOutSharesMember_lbl2">20% Earn-Out [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwentyPercentEarnOutSharesMember" xlink:to="roiv_TwentyPercentEarnOutSharesMember_lbl2" xlink:title="label: TwentyPercentEarnOutSharesMember to roiv_TwentyPercentEarnOutSharesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:label="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:title="PatientSquareCapitalLimitedLiabilityCompanyMember" />
    <link:label xlink:type="resource" xlink:label="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl" xml:lang="en-US" id="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl">Name of the sponsor company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:to="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl" xlink:title="label: PatientSquareCapitalLimitedLiabilityCompanyMember to roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl1" xml:lang="en-US" id="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl1">Patient Square Capital Limited Liability Company [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:to="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl1" xlink:title="label: PatientSquareCapitalLimitedLiabilityCompanyMember to roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl2" xml:lang="en-US" id="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl2">MAAC Sponsor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:to="roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl2" xlink:title="label: PatientSquareCapitalLimitedLiabilityCompanyMember to roiv_PatientSquareCapitalLimitedLiabilityCompanyMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:label="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:title="PublicWarrantsAndPrivatePlacementWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl" xml:lang="en-US" id="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl">Security that gives the holder the right to purchase one share of Class A common stock at a specific exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:to="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl" xlink:title="label: PublicWarrantsAndPrivatePlacementWarrantsMember to roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl1" xml:lang="en-US" id="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl1">Public Warrants and Private Placement Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:to="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl1" xlink:title="label: PublicWarrantsAndPrivatePlacementWarrantsMember to roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl2" xml:lang="en-US" id="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl2">Public and Private Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:to="roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl2" xlink:title="label: PublicWarrantsAndPrivatePlacementWarrantsMember to roiv_PublicWarrantsAndPrivatePlacementWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl">Schedule for earn-out shares, public warrants and private placement warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl1" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl1">Earn-Out Shares, Public Warrants and Private Placement Warrants [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl1" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl">The entire disclosure of earn-out shares, public warrants and private placement warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl1" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl1">Earn-Out Shares, Public Warrants and Private Placement Warrants [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl1" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl2" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl2">Earn-Out Shares, Public Warrants and Private Placement Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl2" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" xml:lang="en-US" id="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1">Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" xlink:title="label: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract to roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RocheTransactionMember" xlink:label="RocheTransactionMember" xlink:title="RocheTransactionMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RocheTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RocheTransactionMember_lbl" xml:lang="en-US" id="roiv_RocheTransactionMember_lbl">Name of business transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RocheTransactionMember" xlink:to="roiv_RocheTransactionMember_lbl" xlink:title="label: RocheTransactionMember to roiv_RocheTransactionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RocheTransactionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RocheTransactionMember_lbl1" xml:lang="en-US" id="roiv_RocheTransactionMember_lbl1">Roche Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RocheTransactionMember" xlink:to="roiv_RocheTransactionMember_lbl1" xlink:title="label: RocheTransactionMember to roiv_RocheTransactionMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UpfrontCashPaymentReceivedForSaleOfAssets" xlink:label="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:title="UpfrontCashPaymentReceivedForSaleOfAssets" />
    <link:label xlink:type="resource" xlink:label="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl" xml:lang="en-US" id="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl">Amount of upfront cash payment received for sale of assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:to="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl" xlink:title="label: UpfrontCashPaymentReceivedForSaleOfAssets to roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl1" xml:lang="en-US" id="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl1">Upfront Cash Payment Received for Sale of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:to="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl1" xlink:title="label: UpfrontCashPaymentReceivedForSaleOfAssets to roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl2" xml:lang="en-US" id="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl2">Upfront cash payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:to="roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl2" xlink:title="label: UpfrontCashPaymentReceivedForSaleOfAssets to roiv_UpfrontCashPaymentReceivedForSaleOfAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ConsiderationReceivedForSaleOfAssets" xlink:label="ConsiderationReceivedForSaleOfAssets" xlink:title="ConsiderationReceivedForSaleOfAssets" />
    <link:label xlink:type="resource" xlink:label="roiv_ConsiderationReceivedForSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ConsiderationReceivedForSaleOfAssets_lbl" xml:lang="en-US" id="roiv_ConsiderationReceivedForSaleOfAssets_lbl">Amount of consideration received for sale of assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsiderationReceivedForSaleOfAssets" xlink:to="roiv_ConsiderationReceivedForSaleOfAssets_lbl" xlink:title="label: ConsiderationReceivedForSaleOfAssets to roiv_ConsiderationReceivedForSaleOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ConsiderationReceivedForSaleOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ConsiderationReceivedForSaleOfAssets_lbl1" xml:lang="en-US" id="roiv_ConsiderationReceivedForSaleOfAssets_lbl1">Consideration received for sale of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsiderationReceivedForSaleOfAssets" xlink:to="roiv_ConsiderationReceivedForSaleOfAssets_lbl1" xlink:title="label: ConsiderationReceivedForSaleOfAssets to roiv_ConsiderationReceivedForSaleOfAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ConsiderationReceivedForSaleOfAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_ConsiderationReceivedForSaleOfAssets_lbl2" xml:lang="en-US" id="roiv_ConsiderationReceivedForSaleOfAssets_lbl2">Total consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsiderationReceivedForSaleOfAssets" xlink:to="roiv_ConsiderationReceivedForSaleOfAssets_lbl2" xlink:title="label: ConsiderationReceivedForSaleOfAssets to roiv_ConsiderationReceivedForSaleOfAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:label="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:title="DisposalGroupNoncontrollingInterestDerecognizedValue" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl" xml:lang="en-US" id="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl">The carrying amount of noncontrolling interest derecognized attributable to disposal group held for sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:to="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl" xlink:title="label: DisposalGroupNoncontrollingInterestDerecognizedValue to roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl1" xml:lang="en-US" id="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl1">Disposal Group, Noncontrolling Interest, Derecognized Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:to="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl1" xlink:title="label: DisposalGroupNoncontrollingInterestDerecognizedValue to roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl2" xml:lang="en-US" id="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl2">Carrying amount of noncontrolling interest derecognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:to="roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl2" xlink:title="label: DisposalGroupNoncontrollingInterestDerecognizedValue to roiv_DisposalGroupNoncontrollingInterestDerecognizedValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupConsiderationAbstract" xlink:label="DisposalGroupConsiderationAbstract" xlink:title="DisposalGroupConsiderationAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupConsiderationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DisposalGroupConsiderationAbstract_lbl1" xml:lang="en-US" id="roiv_DisposalGroupConsiderationAbstract_lbl1">Disposal Group, Consideration [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupConsiderationAbstract" xlink:to="roiv_DisposalGroupConsiderationAbstract_lbl1" xlink:title="label: DisposalGroupConsiderationAbstract to roiv_DisposalGroupConsiderationAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupConsiderationAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DisposalGroupConsiderationAbstract_lbl2" xml:lang="en-US" id="roiv_DisposalGroupConsiderationAbstract_lbl2">Consideration [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupConsiderationAbstract" xlink:to="roiv_DisposalGroupConsiderationAbstract_lbl2" xlink:title="label: DisposalGroupConsiderationAbstract to roiv_DisposalGroupConsiderationAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupLiabilities" xlink:label="DisposalGroupLiabilities" xlink:title="DisposalGroupLiabilities" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DisposalGroupLiabilities_lbl" xml:lang="en-US" id="roiv_DisposalGroupLiabilities_lbl">Amount classified as liabilities attributable to disposal group held for sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupLiabilities" xlink:to="roiv_DisposalGroupLiabilities_lbl" xlink:title="label: DisposalGroupLiabilities to roiv_DisposalGroupLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DisposalGroupLiabilities_lbl1" xml:lang="en-US" id="roiv_DisposalGroupLiabilities_lbl1">Disposal Group, Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupLiabilities" xlink:to="roiv_DisposalGroupLiabilities_lbl1" xlink:title="label: DisposalGroupLiabilities to roiv_DisposalGroupLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DisposalGroupLiabilities_lbl2" xml:lang="en-US" id="roiv_DisposalGroupLiabilities_lbl2">Liabilities transferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupLiabilities" xlink:to="roiv_DisposalGroupLiabilities_lbl2" xlink:title="label: DisposalGroupLiabilities to roiv_DisposalGroupLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OwnershipPercentage" xlink:label="OwnershipPercentage" xlink:title="OwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="roiv_OwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_OwnershipPercentage_lbl" xml:lang="en-US" id="roiv_OwnershipPercentage_lbl">The percentage of ownership interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipPercentage" xlink:to="roiv_OwnershipPercentage_lbl" xlink:title="label: OwnershipPercentage to roiv_OwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_OwnershipPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_OwnershipPercentage_lbl1" xml:lang="en-US" id="roiv_OwnershipPercentage_lbl1">Ownership Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipPercentage" xlink:to="roiv_OwnershipPercentage_lbl1" xlink:title="label: OwnershipPercentage to roiv_OwnershipPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_OwnershipPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_OwnershipPercentage_lbl2" xml:lang="en-US" id="roiv_OwnershipPercentage_lbl2">Ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipPercentage" xlink:to="roiv_OwnershipPercentage_lbl2" xlink:title="label: OwnershipPercentage to roiv_OwnershipPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupAssets" xlink:label="DisposalGroupAssets" xlink:title="DisposalGroupAssets" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DisposalGroupAssets_lbl" xml:lang="en-US" id="roiv_DisposalGroupAssets_lbl">Amount classified as assets attributable to disposal group held for sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupAssets" xlink:to="roiv_DisposalGroupAssets_lbl" xlink:title="label: DisposalGroupAssets to roiv_DisposalGroupAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DisposalGroupAssets_lbl1" xml:lang="en-US" id="roiv_DisposalGroupAssets_lbl1">Disposal Group, Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupAssets" xlink:to="roiv_DisposalGroupAssets_lbl1" xlink:title="label: DisposalGroupAssets to roiv_DisposalGroupAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DisposalGroupAssets_lbl2" xml:lang="en-US" id="roiv_DisposalGroupAssets_lbl2">Assets sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupAssets" xlink:to="roiv_DisposalGroupAssets_lbl2" xlink:title="label: DisposalGroupAssets to roiv_DisposalGroupAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:label="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:title="FutureMilestoneToBeReceivedFromSaleOfAssets" />
    <link:label xlink:type="resource" xlink:label="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl" xml:lang="en-US" id="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl">The future milestone to be received from sale of assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:to="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl" xlink:title="label: FutureMilestoneToBeReceivedFromSaleOfAssets to roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl1" xml:lang="en-US" id="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl1">Future Milestone to be Received from Sale of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:to="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl1" xlink:title="label: FutureMilestoneToBeReceivedFromSaleOfAssets to roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl2" xml:lang="en-US" id="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl2">Consideration to be received from milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:to="roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl2" xlink:title="label: FutureMilestoneToBeReceivedFromSaleOfAssets to roiv_FutureMilestoneToBeReceivedFromSaleOfAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupNetAssetsLiabilities" xlink:label="DisposalGroupNetAssetsLiabilities" xlink:title="DisposalGroupNetAssetsLiabilities" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupNetAssetsLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DisposalGroupNetAssetsLiabilities_lbl" xml:lang="en-US" id="roiv_DisposalGroupNetAssetsLiabilities_lbl">Amount classified as net assets (liabilities) attributable to disposal group held for sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNetAssetsLiabilities" xlink:to="roiv_DisposalGroupNetAssetsLiabilities_lbl" xlink:title="label: DisposalGroupNetAssetsLiabilities to roiv_DisposalGroupNetAssetsLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupNetAssetsLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DisposalGroupNetAssetsLiabilities_lbl1" xml:lang="en-US" id="roiv_DisposalGroupNetAssetsLiabilities_lbl1">Disposal Group, Net Assets (Liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNetAssetsLiabilities" xlink:to="roiv_DisposalGroupNetAssetsLiabilities_lbl1" xlink:title="label: DisposalGroupNetAssetsLiabilities to roiv_DisposalGroupNetAssetsLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupNetAssetsLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="roiv_DisposalGroupNetAssetsLiabilities_lbl2" xml:lang="en-US" id="roiv_DisposalGroupNetAssetsLiabilities_lbl2">Net liabilities sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNetAssetsLiabilities" xlink:to="roiv_DisposalGroupNetAssetsLiabilities_lbl2" xlink:title="label: DisposalGroupNetAssetsLiabilities to roiv_DisposalGroupNetAssetsLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl1" xml:lang="en-US" id="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl1">Disposal Groups, Including Discontinued Operations, Calculation of Gain [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:to="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl1" xlink:title="label: DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract to roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl2" xml:lang="en-US" id="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl2">Calculation of Gain [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:to="roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl2" xlink:title="label: DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract to roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:label="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:title="IncomeLossFromDisposalGroupBeforeIncomeTax" />
    <link:label xlink:type="resource" xlink:label="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl" xml:lang="en-US" id="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl">Amount of before tax of income (loss) from a disposal group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:to="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl" xlink:title="label: IncomeLossFromDisposalGroupBeforeIncomeTax to roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl1" xml:lang="en-US" id="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl1">Income (Loss) from Disposal Group, before Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:to="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl1" xlink:title="label: IncomeLossFromDisposalGroupBeforeIncomeTax to roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl2" xml:lang="en-US" id="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl2">Pretax loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:to="roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl2" xlink:title="label: IncomeLossFromDisposalGroupBeforeIncomeTax to roiv_IncomeLossFromDisposalGroupBeforeIncomeTax_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupAbstract" xlink:label="DisposalGroupAbstract" xlink:title="DisposalGroupAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DisposalGroupAbstract_lbl1" xml:lang="en-US" id="roiv_DisposalGroupAbstract_lbl1">Disposal Group [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupAbstract" xlink:to="roiv_DisposalGroupAbstract_lbl1" xlink:title="label: DisposalGroupAbstract to roiv_DisposalGroupAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DisposalGroupAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DisposalGroupAbstract_lbl2" xml:lang="en-US" id="roiv_DisposalGroupAbstract_lbl2">Telavant Disposition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupAbstract" xlink:to="roiv_DisposalGroupAbstract_lbl2" xlink:title="label: DisposalGroupAbstract to roiv_DisposalGroupAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RSLMember" xlink:label="RSLMember" xlink:title="RSLMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RSLMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RSLMember_lbl1" xml:lang="en-US" id="roiv_RSLMember_lbl1">RSL [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RSLMember" xlink:to="roiv_RSLMember_lbl1" xlink:title="label: RSLMember to roiv_RSLMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PfizerMember" xlink:label="PfizerMember" xlink:title="PfizerMember" />
    <link:label xlink:type="resource" xlink:label="roiv_PfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PfizerMember_lbl" xml:lang="en-US" id="roiv_PfizerMember_lbl">Name of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PfizerMember" xlink:to="roiv_PfizerMember_lbl" xlink:title="label: PfizerMember to roiv_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PfizerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PfizerMember_lbl1" xml:lang="en-US" id="roiv_PfizerMember_lbl1">Pfizer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PfizerMember" xlink:to="roiv_PfizerMember_lbl1" xlink:title="label: PfizerMember to roiv_PfizerMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:label="CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:title="CashlessExerciseOfTheCompanyCommonStockWarrants" />
    <link:label xlink:type="resource" xlink:label="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl" xml:lang="en-US" id="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl">Amount of cashless exercise of the company's common stock warrants in noncash investing or financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:to="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl" xlink:title="label: CashlessExerciseOfTheCompanyCommonStockWarrants to roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl1" xml:lang="en-US" id="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl1">Cashless Exercise of the Company Common Stock Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:to="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl1" xlink:title="label: CashlessExerciseOfTheCompanyCommonStockWarrants to roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl2" xml:lang="en-US" id="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl2">Cashless exercise of the Company's warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:to="roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl2" xlink:title="label: CashlessExerciseOfTheCompanyCommonStockWarrants to roiv_CashlessExerciseOfTheCompanyCommonStockWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:label="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:title="PaymentsOfTaxesForTheRepurchaseOfEquity" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl" xml:lang="en-US" id="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl">Payments of Taxes for the Repurchase of Equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:to="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl" xlink:title="label: PaymentsOfTaxesForTheRepurchaseOfEquity to roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl1" xml:lang="en-US" id="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl1">Payments of Taxes for the Repurchase of Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:to="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl1" xlink:title="label: PaymentsOfTaxesForTheRepurchaseOfEquity to roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl2" xml:lang="en-US" id="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl2">Taxes paid related to net settlement of equity awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:to="roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl2" xlink:title="label: PaymentsOfTaxesForTheRepurchaseOfEquity to roiv_PaymentsOfTaxesForTheRepurchaseOfEquity_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="GainLossOnFairValueOfDebtAndLiabilityInstruments" />
    <link:label xlink:type="resource" xlink:label="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl" xml:lang="en-US" id="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl">Amount of gain (loss) on fair value of debt and liability instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:to="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl" xlink:title="label: GainLossOnFairValueOfDebtAndLiabilityInstruments to roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl1" xml:lang="en-US" id="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl1">Gain (Loss) on Fair Value of Debt and Liability Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:to="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl1" xlink:title="label: GainLossOnFairValueOfDebtAndLiabilityInstruments to roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl2" xml:lang="en-US" id="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl2">Change in fair value of debt and liability instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:to="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl2" xlink:title="label: GainLossOnFairValueOfDebtAndLiabilityInstruments to roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="NonCashAcquiredInProcessResearchAndDevelopment" xlink:title="NonCashAcquiredInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl" xml:lang="en-US" id="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl">The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashAcquiredInProcessResearchAndDevelopment" xlink:to="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl" xlink:title="label: NonCashAcquiredInProcessResearchAndDevelopment to roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl1" xml:lang="en-US" id="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl1">Non-Cash Acquired In-Process Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashAcquiredInProcessResearchAndDevelopment" xlink:to="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl1" xlink:title="label: NonCashAcquiredInProcessResearchAndDevelopment to roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl2" xml:lang="en-US" id="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl2">Non-cash acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashAcquiredInProcessResearchAndDevelopment" xlink:to="roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl2" xlink:title="label: NonCashAcquiredInProcessResearchAndDevelopment to roiv_NonCashAcquiredInProcessResearchAndDevelopment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentForWarrantRedemptions" xlink:label="PaymentForWarrantRedemptions" xlink:title="PaymentForWarrantRedemptions" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentForWarrantRedemptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PaymentForWarrantRedemptions_lbl" xml:lang="en-US" id="roiv_PaymentForWarrantRedemptions_lbl">The cash outflow associated with the warrant redemptions during period of the time.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForWarrantRedemptions" xlink:to="roiv_PaymentForWarrantRedemptions_lbl" xlink:title="label: PaymentForWarrantRedemptions to roiv_PaymentForWarrantRedemptions_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentForWarrantRedemptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PaymentForWarrantRedemptions_lbl1" xml:lang="en-US" id="roiv_PaymentForWarrantRedemptions_lbl1">Payment for Warrant Redemptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForWarrantRedemptions" xlink:to="roiv_PaymentForWarrantRedemptions_lbl1" xlink:title="label: PaymentForWarrantRedemptions to roiv_PaymentForWarrantRedemptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentForWarrantRedemptions_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_PaymentForWarrantRedemptions_lbl2" xml:lang="en-US" id="roiv_PaymentForWarrantRedemptions_lbl2">Payment for redemptions of the Company's warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForWarrantRedemptions" xlink:to="roiv_PaymentForWarrantRedemptions_lbl2" xlink:title="label: PaymentForWarrantRedemptions to roiv_PaymentForWarrantRedemptions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:title="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
    <link:label xlink:type="resource" xlink:label="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl" xml:lang="en-US" id="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl">The cash outflow for debt repayment of long-term debt and convertible debt by subsidiary during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:to="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl" xlink:title="label: RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary to roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl1" xml:lang="en-US" id="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl1">Repayment of Long Term Debt and Convertible Debt by Subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:to="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl1" xlink:title="label: RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary to roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl2" xml:lang="en-US" id="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl2">Repayment of debt by subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:to="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl2" xlink:title="label: RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary to roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncashOther" xlink:label="NoncashOther" xlink:title="NoncashOther" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncashOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NoncashOther_lbl" xml:lang="en-US" id="roiv_NoncashOther_lbl">Amount of expense or loss included in net income that result in no cash flow, classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOther" xlink:to="roiv_NoncashOther_lbl" xlink:title="label: NoncashOther to roiv_NoncashOther_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncashOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NoncashOther_lbl1" xml:lang="en-US" id="roiv_NoncashOther_lbl1">Noncash, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOther" xlink:to="roiv_NoncashOther_lbl1" xlink:title="label: NoncashOther to roiv_NoncashOther_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncashOther_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_NoncashOther_lbl2" xml:lang="en-US" id="roiv_NoncashOther_lbl2">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOther" xlink:to="roiv_NoncashOther_lbl2" xlink:title="label: NoncashOther to roiv_NoncashOther_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:title="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl" xml:lang="en-US" id="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl">The net cash inflows from issuance of subsidiary common shares, net of issuance costs paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:to="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl" xlink:title="label: ProceedsFromIssuanceOfSubsidiaryCommonSharesNet to roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl1" xml:lang="en-US" id="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl1">Proceeds from Issuance of Subsidiary Common Shares, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:to="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl1" xlink:title="label: ProceedsFromIssuanceOfSubsidiaryCommonSharesNet to roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl2" xml:lang="en-US" id="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl2">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:to="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl2" xlink:title="label: ProceedsFromIssuanceOfSubsidiaryCommonSharesNet to roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:label="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:title="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl" xml:lang="en-US" id="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl">Amount of common shares and other consideration issued for the purchase of property and equipment in noncash investing or financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:to="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl" xlink:title="label: CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment to roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl1" xml:lang="en-US" id="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl1">Common Shares and Other Consideration Issued for Purchase of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:to="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl1" xlink:title="label: CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment to roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl2" xml:lang="en-US" id="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl2">Issuance of the Company's common shares and other consideration for an acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:to="roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl2" xlink:title="label: CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment to roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentForOfferingAndLoanCosts" xlink:label="PaymentForOfferingAndLoanCosts" xlink:title="PaymentForOfferingAndLoanCosts" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentForOfferingAndLoanCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PaymentForOfferingAndLoanCosts_lbl" xml:lang="en-US" id="roiv_PaymentForOfferingAndLoanCosts_lbl">The cash outflow associated with payment for offering and loan costs during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForOfferingAndLoanCosts" xlink:to="roiv_PaymentForOfferingAndLoanCosts_lbl" xlink:title="label: PaymentForOfferingAndLoanCosts to roiv_PaymentForOfferingAndLoanCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentForOfferingAndLoanCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PaymentForOfferingAndLoanCosts_lbl1" xml:lang="en-US" id="roiv_PaymentForOfferingAndLoanCosts_lbl1">Payment for Offering and Loan Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForOfferingAndLoanCosts" xlink:to="roiv_PaymentForOfferingAndLoanCosts_lbl1" xlink:title="label: PaymentForOfferingAndLoanCosts to roiv_PaymentForOfferingAndLoanCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentForOfferingAndLoanCosts_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_PaymentForOfferingAndLoanCosts_lbl2" xml:lang="en-US" id="roiv_PaymentForOfferingAndLoanCosts_lbl2">Payment of offering costs and loan origination costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForOfferingAndLoanCosts" xlink:to="roiv_PaymentForOfferingAndLoanCosts_lbl2" xlink:title="label: PaymentForOfferingAndLoanCosts to roiv_PaymentForOfferingAndLoanCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromSaleOfAssets" xlink:label="ProceedsFromSaleOfAssets" xlink:title="ProceedsFromSaleOfAssets" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ProceedsFromSaleOfAssets_lbl" xml:lang="en-US" id="roiv_ProceedsFromSaleOfAssets_lbl">The cash inflow from the sale of assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfAssets" xlink:to="roiv_ProceedsFromSaleOfAssets_lbl" xlink:title="label: ProceedsFromSaleOfAssets to roiv_ProceedsFromSaleOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromSaleOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ProceedsFromSaleOfAssets_lbl1" xml:lang="en-US" id="roiv_ProceedsFromSaleOfAssets_lbl1">Proceeds from Sale of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfAssets" xlink:to="roiv_ProceedsFromSaleOfAssets_lbl1" xlink:title="label: ProceedsFromSaleOfAssets to roiv_ProceedsFromSaleOfAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromSaleOfAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_ProceedsFromSaleOfAssets_lbl2" xml:lang="en-US" id="roiv_ProceedsFromSaleOfAssets_lbl2">Proceeds from sale of Telavant net assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfAssets" xlink:to="roiv_ProceedsFromSaleOfAssets_lbl2" xlink:title="label: ProceedsFromSaleOfAssets to roiv_ProceedsFromSaleOfAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_MilestonePayments_lbl" xml:lang="en-US" id="roiv_MilestonePayments_lbl">Payment made during the period for achieving the milestone or milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="roiv_MilestonePayments_lbl" xlink:title="label: MilestonePayments to roiv_MilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_MilestonePayments_lbl1" xml:lang="en-US" id="roiv_MilestonePayments_lbl1">Milestone Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="roiv_MilestonePayments_lbl1" xlink:title="label: MilestonePayments to roiv_MilestonePayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_MilestonePayments_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_MilestonePayments_lbl2" xml:lang="en-US" id="roiv_MilestonePayments_lbl2">Milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="roiv_MilestonePayments_lbl2" xlink:title="label: MilestonePayments to roiv_MilestonePayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:title="ProceedsFromSubsidiaryDebtFinancingsNet" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl" xml:lang="en-US" id="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl">The cash inflow associated with the aggregate amount received by the entity through subsidiary debt financings, net during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:to="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl" xlink:title="label: ProceedsFromSubsidiaryDebtFinancingsNet to roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl1" xml:lang="en-US" id="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl1">Proceeds from Subsidiary Debt Financings, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:to="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl1" xlink:title="label: ProceedsFromSubsidiaryDebtFinancingsNet to roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl2" xml:lang="en-US" id="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl2">Proceeds from subsidiary debt financings, net of financing costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:to="roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl2" xlink:title="label: ProceedsFromSubsidiaryDebtFinancingsNet to roiv_ProceedsFromSubsidiaryDebtFinancingsNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentsOfSubsidiaryDividends" xlink:label="PaymentsOfSubsidiaryDividends" xlink:title="PaymentsOfSubsidiaryDividends" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentsOfSubsidiaryDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PaymentsOfSubsidiaryDividends_lbl" xml:lang="en-US" id="roiv_PaymentsOfSubsidiaryDividends_lbl">Cash outflow in the form of capital distributions and subsidiary dividends to common shareholders, preferred shareholders and noncontrolling interests.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfSubsidiaryDividends" xlink:to="roiv_PaymentsOfSubsidiaryDividends_lbl" xlink:title="label: PaymentsOfSubsidiaryDividends to roiv_PaymentsOfSubsidiaryDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentsOfSubsidiaryDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PaymentsOfSubsidiaryDividends_lbl1" xml:lang="en-US" id="roiv_PaymentsOfSubsidiaryDividends_lbl1">Payments of Subsidiary Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfSubsidiaryDividends" xlink:to="roiv_PaymentsOfSubsidiaryDividends_lbl1" xlink:title="label: PaymentsOfSubsidiaryDividends to roiv_PaymentsOfSubsidiaryDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PaymentsOfSubsidiaryDividends_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_PaymentsOfSubsidiaryDividends_lbl2" xml:lang="en-US" id="roiv_PaymentsOfSubsidiaryDividends_lbl2">Payment of subsidiary dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfSubsidiaryDividends" xlink:to="roiv_PaymentsOfSubsidiaryDividends_lbl2" xlink:title="label: PaymentsOfSubsidiaryDividends to roiv_PaymentsOfSubsidiaryDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TelavantHoldingsIncMember" xlink:label="TelavantHoldingsIncMember" xlink:title="TelavantHoldingsIncMember" />
    <link:label xlink:type="resource" xlink:label="roiv_TelavantHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_TelavantHoldingsIncMember_lbl" xml:lang="en-US" id="roiv_TelavantHoldingsIncMember_lbl">Name of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TelavantHoldingsIncMember" xlink:to="roiv_TelavantHoldingsIncMember_lbl" xlink:title="label: TelavantHoldingsIncMember to roiv_TelavantHoldingsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_TelavantHoldingsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_TelavantHoldingsIncMember_lbl1" xml:lang="en-US" id="roiv_TelavantHoldingsIncMember_lbl1">Telavant Holdings, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TelavantHoldingsIncMember" xlink:to="roiv_TelavantHoldingsIncMember_lbl1" xlink:title="label: TelavantHoldingsIncMember to roiv_TelavantHoldingsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_TelavantHoldingsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_TelavantHoldingsIncMember_lbl2" xml:lang="en-US" id="roiv_TelavantHoldingsIncMember_lbl2">Telavant Holdings, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TelavantHoldingsIncMember" xlink:to="roiv_TelavantHoldingsIncMember_lbl2" xlink:title="label: TelavantHoldingsIncMember to roiv_TelavantHoldingsIncMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="roiv_TelavantHoldingsIncMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_TelavantHoldingsIncMember_lbl3" xml:lang="en-US" id="roiv_TelavantHoldingsIncMember_lbl3">Telavant Holdings, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TelavantHoldingsIncMember" xlink:to="roiv_TelavantHoldingsIncMember_lbl3" xlink:title="label: TelavantHoldingsIncMember to roiv_TelavantHoldingsIncMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:label xlink:type="resource" xlink:label="roiv_GainLossOnSaleOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_GainLossOnSaleOfAssets_lbl" xml:lang="en-US" id="roiv_GainLossOnSaleOfAssets_lbl">Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfAssets" xlink:to="roiv_GainLossOnSaleOfAssets_lbl" xlink:title="label: GainLossOnSaleOfAssets to roiv_GainLossOnSaleOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_GainLossOnSaleOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_GainLossOnSaleOfAssets_lbl1" xml:lang="en-US" id="roiv_GainLossOnSaleOfAssets_lbl1">Gain (Loss) on Sale of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfAssets" xlink:to="roiv_GainLossOnSaleOfAssets_lbl1" xlink:title="label: GainLossOnSaleOfAssets to roiv_GainLossOnSaleOfAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_GainLossOnSaleOfAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_GainLossOnSaleOfAssets_lbl2" xml:lang="en-US" id="roiv_GainLossOnSaleOfAssets_lbl2">Gain on sale of Telavant net assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfAssets" xlink:to="roiv_GainLossOnSaleOfAssets_lbl2" xlink:title="label: GainLossOnSaleOfAssets to roiv_GainLossOnSaleOfAssets_lbl2" />
    <link:label xlink:type="resource" xlink:label="roiv_GainLossOnSaleOfAssets_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_GainLossOnSaleOfAssets_lbl3" xml:lang="en-US" id="roiv_GainLossOnSaleOfAssets_lbl3">Gain on sale of net assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfAssets" xlink:to="roiv_GainLossOnSaleOfAssets_lbl3" xlink:title="label: GainLossOnSaleOfAssets to roiv_GainLossOnSaleOfAssets_lbl3" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_LiquidityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_LiquidityAbstract_lbl1" xml:lang="en-US" id="roiv_LiquidityAbstract_lbl1">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAbstract" xlink:to="roiv_LiquidityAbstract_lbl1" xlink:title="label: LiquidityAbstract to roiv_LiquidityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_LiquidityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_LiquidityAbstract_lbl2" xml:lang="en-US" id="roiv_LiquidityAbstract_lbl2">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAbstract" xlink:to="roiv_LiquidityAbstract_lbl2" xlink:title="label: LiquidityAbstract to roiv_LiquidityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DescriptionOfBusinessAbstract" xlink:label="DescriptionOfBusinessAbstract" xlink:title="DescriptionOfBusinessAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_DescriptionOfBusinessAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DescriptionOfBusinessAbstract_lbl1" xml:lang="en-US" id="roiv_DescriptionOfBusinessAbstract_lbl1">Description of Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfBusinessAbstract" xlink:to="roiv_DescriptionOfBusinessAbstract_lbl1" xlink:title="label: DescriptionOfBusinessAbstract to roiv_DescriptionOfBusinessAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DescriptionOfBusinessAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DescriptionOfBusinessAbstract_lbl2" xml:lang="en-US" id="roiv_DescriptionOfBusinessAbstract_lbl2">Description of Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfBusinessAbstract" xlink:to="roiv_DescriptionOfBusinessAbstract_lbl2" xlink:title="label: DescriptionOfBusinessAbstract to roiv_DescriptionOfBusinessAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FiftyPercentBonusPayablePeriodFromGrantDate" xlink:label="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:title="FiftyPercentBonusPayablePeriodFromGrantDate" />
    <link:label xlink:type="resource" xlink:label="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl" xml:lang="en-US" id="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl">Period of fifty percent bonus payable from grant date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:to="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl" xlink:title="label: FiftyPercentBonusPayablePeriodFromGrantDate to roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl1" xml:lang="en-US" id="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl1">Fifty Percent Bonus Payable Period from Grant Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:to="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl1" xlink:title="label: FiftyPercentBonusPayablePeriodFromGrantDate to roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl2" xml:lang="en-US" id="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl2">Period of bonus payable from grant date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:to="roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl2" xlink:title="label: FiftyPercentBonusPayablePeriodFromGrantDate to roiv_FiftyPercentBonusPayablePeriodFromGrantDate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:label="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:title="PercentageOfBonusPayableInNext30DaysOfGrantDate" />
    <link:label xlink:type="resource" xlink:label="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl" xml:lang="en-US" id="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl">The percentage of bonus payable in next 30 days of the grant date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:to="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl" xlink:title="label: PercentageOfBonusPayableInNext30DaysOfGrantDate to roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl1" xml:lang="en-US" id="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl1">Percentage of Bonus Payable in Next 30 Days of Grant Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:to="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl1" xlink:title="label: PercentageOfBonusPayableInNext30DaysOfGrantDate to roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl2" xml:lang="en-US" id="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl2">Percentage of bonus payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:to="roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl2" xlink:title="label: PercentageOfBonusPayableInNext30DaysOfGrantDate to roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:label="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:title="PeriodToPurchaseAdditionalBatchesOfBatoclimab" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl" xml:lang="en-US" id="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl">The period to purchase additional batches of batoclimab, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:to="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl" xlink:title="label: PeriodToPurchaseAdditionalBatchesOfBatoclimab to roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl1" xml:lang="en-US" id="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl1">Period to Purchase Additional Batches of Batoclimab</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:to="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl1" xlink:title="label: PeriodToPurchaseAdditionalBatchesOfBatoclimab to roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl2" xml:lang="en-US" id="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl2">Period to purchase additional batches of batoclimab</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:to="roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl2" xlink:title="label: PeriodToPurchaseAdditionalBatchesOfBatoclimab to roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SamsungBiologicsCo.Ltd.Member" xlink:label="SamsungBiologicsCo.Ltd.Member" xlink:title="SamsungBiologicsCo.Ltd.Member" />
    <link:label xlink:type="resource" xlink:label="roiv_SamsungBiologicsCo.Ltd.Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_SamsungBiologicsCo.Ltd.Member_lbl" xml:lang="en-US" id="roiv_SamsungBiologicsCo.Ltd.Member_lbl">Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SamsungBiologicsCo.Ltd.Member" xlink:to="roiv_SamsungBiologicsCo.Ltd.Member_lbl" xlink:title="label: SamsungBiologicsCo.Ltd.Member to roiv_SamsungBiologicsCo.Ltd.Member_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_SamsungBiologicsCo.Ltd.Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_SamsungBiologicsCo.Ltd.Member_lbl1" xml:lang="en-US" id="roiv_SamsungBiologicsCo.Ltd.Member_lbl1">Samsung Biologics Co., Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SamsungBiologicsCo.Ltd.Member" xlink:to="roiv_SamsungBiologicsCo.Ltd.Member_lbl1" xlink:title="label: SamsungBiologicsCo.Ltd.Member to roiv_SamsungBiologicsCo.Ltd.Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_SamsungBiologicsCo.Ltd.Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_SamsungBiologicsCo.Ltd.Member_lbl2" xml:lang="en-US" id="roiv_SamsungBiologicsCo.Ltd.Member_lbl2">Samsung [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SamsungBiologicsCo.Ltd.Member" xlink:to="roiv_SamsungBiologicsCo.Ltd.Member_lbl2" xlink:title="label: SamsungBiologicsCo.Ltd.Member to roiv_SamsungBiologicsCo.Ltd.Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodOfRightToTerminateTheProductServiceAgreement" xlink:label="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:title="PeriodOfRightToTerminateTheProductServiceAgreement" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl" xml:lang="en-US" id="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl">The period of right to terminate the product service agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:to="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl" xlink:title="label: PeriodOfRightToTerminateTheProductServiceAgreement to roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl1" xml:lang="en-US" id="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl1">Period of Right to Terminate the Product Service Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:to="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl1" xlink:title="label: PeriodOfRightToTerminateTheProductServiceAgreement to roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl2" xml:lang="en-US" id="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl2">Period of right to terminate the product service agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:to="roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl2" xlink:title="label: PeriodOfRightToTerminateTheProductServiceAgreement to roiv_PeriodOfRightToTerminateTheProductServiceAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:label="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:title="RemainingMinimumPurchaseCommitmentRelatedToAgreement" />
    <link:label xlink:type="resource" xlink:label="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl" xml:lang="en-US" id="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl">The remaining minimum amount of purchase commitment related to agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:to="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl" xlink:title="label: RemainingMinimumPurchaseCommitmentRelatedToAgreement to roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl1" xml:lang="en-US" id="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl1">Remaining Minimum Purchase Commitment Related to Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:to="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl1" xlink:title="label: RemainingMinimumPurchaseCommitmentRelatedToAgreement to roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl2" xml:lang="en-US" id="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl2">Remaining minimum purchase commitment related to agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:to="roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl2" xlink:title="label: RemainingMinimumPurchaseCommitmentRelatedToAgreement to roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProprietarySoftwareSubscriptionPeriod" xlink:label="ProprietarySoftwareSubscriptionPeriod" xlink:title="ProprietarySoftwareSubscriptionPeriod" />
    <link:label xlink:type="resource" xlink:label="roiv_ProprietarySoftwareSubscriptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ProprietarySoftwareSubscriptionPeriod_lbl" xml:lang="en-US" id="roiv_ProprietarySoftwareSubscriptionPeriod_lbl">Proprietary software subscription period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProprietarySoftwareSubscriptionPeriod" xlink:to="roiv_ProprietarySoftwareSubscriptionPeriod_lbl" xlink:title="label: ProprietarySoftwareSubscriptionPeriod to roiv_ProprietarySoftwareSubscriptionPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ProprietarySoftwareSubscriptionPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ProprietarySoftwareSubscriptionPeriod_lbl1" xml:lang="en-US" id="roiv_ProprietarySoftwareSubscriptionPeriod_lbl1">Proprietary Software Subscription Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProprietarySoftwareSubscriptionPeriod" xlink:to="roiv_ProprietarySoftwareSubscriptionPeriod_lbl1" xlink:title="label: ProprietarySoftwareSubscriptionPeriod to roiv_ProprietarySoftwareSubscriptionPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ProprietarySoftwareSubscriptionPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ProprietarySoftwareSubscriptionPeriod_lbl2" xml:lang="en-US" id="roiv_ProprietarySoftwareSubscriptionPeriod_lbl2">Proprietary software subscription period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProprietarySoftwareSubscriptionPeriod" xlink:to="roiv_ProprietarySoftwareSubscriptionPeriod_lbl2" xlink:title="label: ProprietarySoftwareSubscriptionPeriod to roiv_ProprietarySoftwareSubscriptionPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashBonusProgramMember" xlink:label="CashBonusProgramMember" xlink:title="CashBonusProgramMember" />
    <link:label xlink:type="resource" xlink:label="roiv_CashBonusProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CashBonusProgramMember_lbl" xml:lang="en-US" id="roiv_CashBonusProgramMember_lbl">The company approved a special one-time cash retention bonus award to its employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashBonusProgramMember" xlink:to="roiv_CashBonusProgramMember_lbl" xlink:title="label: CashBonusProgramMember to roiv_CashBonusProgramMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CashBonusProgramMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CashBonusProgramMember_lbl1" xml:lang="en-US" id="roiv_CashBonusProgramMember_lbl1">Cash Bonus Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashBonusProgramMember" xlink:to="roiv_CashBonusProgramMember_lbl1" xlink:title="label: CashBonusProgramMember to roiv_CashBonusProgramMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CashBonusProgramMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CashBonusProgramMember_lbl2" xml:lang="en-US" id="roiv_CashBonusProgramMember_lbl2">Cash Bonus Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashBonusProgramMember" xlink:to="roiv_CashBonusProgramMember_lbl2" xlink:title="label: CashBonusProgramMember to roiv_CashBonusProgramMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GSKMember" xlink:label="GSKMember" xlink:title="GSKMember" />
    <link:label xlink:type="resource" xlink:label="roiv_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_GSKMember_lbl" xml:lang="en-US" id="roiv_GSKMember_lbl">GSK Solutions Inc. is a cutting edge, no-nonsense cyber security company who provides security software, services, and consulting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GSKMember" xlink:to="roiv_GSKMember_lbl" xlink:title="label: GSKMember to roiv_GSKMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_GSKMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_GSKMember_lbl1" xml:lang="en-US" id="roiv_GSKMember_lbl1">GSK [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GSKMember" xlink:to="roiv_GSKMember_lbl1" xlink:title="label: GSKMember to roiv_GSKMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_GSKMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_GSKMember_lbl2" xml:lang="en-US" id="roiv_GSKMember_lbl2">GSK [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GSKMember" xlink:to="roiv_GSKMember_lbl2" xlink:title="label: GSKMember to roiv_GSKMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PalantirTechnologiesIncMember" xlink:label="PalantirTechnologiesIncMember" xlink:title="PalantirTechnologiesIncMember" />
    <link:label xlink:type="resource" xlink:label="roiv_PalantirTechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PalantirTechnologiesIncMember_lbl" xml:lang="en-US" id="roiv_PalantirTechnologiesIncMember_lbl">Palantir Technologies is a public American software company that specializes in big data analytics.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PalantirTechnologiesIncMember" xlink:to="roiv_PalantirTechnologiesIncMember_lbl" xlink:title="label: PalantirTechnologiesIncMember to roiv_PalantirTechnologiesIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PalantirTechnologiesIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PalantirTechnologiesIncMember_lbl1" xml:lang="en-US" id="roiv_PalantirTechnologiesIncMember_lbl1">Palantir Technologies Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PalantirTechnologiesIncMember" xlink:to="roiv_PalantirTechnologiesIncMember_lbl1" xlink:title="label: PalantirTechnologiesIncMember to roiv_PalantirTechnologiesIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PalantirTechnologiesIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PalantirTechnologiesIncMember_lbl2" xml:lang="en-US" id="roiv_PalantirTechnologiesIncMember_lbl2">Palantirs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PalantirTechnologiesIncMember" xlink:to="roiv_PalantirTechnologiesIncMember_lbl2" xlink:title="label: PalantirTechnologiesIncMember to roiv_PalantirTechnologiesIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CioxParentMember" xlink:label="CioxParentMember" xlink:title="CioxParentMember" />
    <link:label xlink:type="resource" xlink:label="roiv_CioxParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CioxParentMember_lbl" xml:lang="en-US" id="roiv_CioxParentMember_lbl">The name of combined merged entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CioxParentMember" xlink:to="roiv_CioxParentMember_lbl" xlink:title="label: CioxParentMember to roiv_CioxParentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CioxParentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CioxParentMember_lbl1" xml:lang="en-US" id="roiv_CioxParentMember_lbl1">Ciox Parent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CioxParentMember" xlink:to="roiv_CioxParentMember_lbl1" xlink:title="label: CioxParentMember to roiv_CioxParentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CioxParentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CioxParentMember_lbl2" xml:lang="en-US" id="roiv_CioxParentMember_lbl2">Datavant Merger [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CioxParentMember" xlink:to="roiv_CioxParentMember_lbl2" xlink:title="label: CioxParentMember to roiv_CioxParentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="LiabilityInstrumentsMeasuredAtFairValue" xlink:title="LiabilityInstrumentsMeasuredAtFairValue" />
    <link:label xlink:type="resource" xlink:label="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl" xml:lang="en-US" id="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl">Amount of liability instruments measured at fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityInstrumentsMeasuredAtFairValue" xlink:to="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl" xlink:title="label: LiabilityInstrumentsMeasuredAtFairValue to roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl1" xml:lang="en-US" id="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl1">Liability Instruments Measured at Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityInstrumentsMeasuredAtFairValue" xlink:to="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl1" xlink:title="label: LiabilityInstrumentsMeasuredAtFairValue to roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl2" xml:lang="en-US" id="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl2">Liability instruments measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityInstrumentsMeasuredAtFairValue" xlink:to="roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl2" xlink:title="label: LiabilityInstrumentsMeasuredAtFairValue to roiv_LiabilityInstrumentsMeasuredAtFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:label="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:title="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl" xml:lang="en-US" id="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl">Fair value of other liability instruments measured at fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:to="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl" xlink:title="label: OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement to roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl1" xml:lang="en-US" id="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl1">Other Liability Instruments Measured At Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:to="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl1" xlink:title="label: OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement to roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl2" xml:lang="en-US" id="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl2">Other Liability instruments measured at fair value measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:to="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl2" xlink:title="label: OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement to roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:label="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:title="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl" xml:lang="en-US" id="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl">Represents other liability instruments measured at fair value measurement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:to="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl" xlink:title="label: OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember to roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl1" xml:lang="en-US" id="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl1">Other Liability Instruments Measured At Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:to="roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl1" xlink:title="label: OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember to roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:title="LiabilityInstrumentsMeasuredAtFairValueMember" />
    <link:label xlink:type="resource" xlink:label="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl" xml:lang="en-US" id="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl">The fair value of liability instruments measured at fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:to="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl" xlink:title="label: LiabilityInstrumentsMeasuredAtFairValueMember to roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl1" xml:lang="en-US" id="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl1">Liability Instruments Measured At Fair Value [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:to="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl1" xlink:title="label: LiabilityInstrumentsMeasuredAtFairValueMember to roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl2" xml:lang="en-US" id="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl2">Liability Instruments Measured at Fair Value [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:to="roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl2" xlink:title="label: LiabilityInstrumentsMeasuredAtFairValueMember to roiv_LiabilityInstrumentsMeasuredAtFairValueMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsMember" xlink:label="PublicWarrantsMember" xlink:title="PublicWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PublicWarrantsMember_lbl" xml:lang="en-US" id="roiv_PublicWarrantsMember_lbl">In finance, a warrant is a security that entitles the holder to buy or sell stock, typically the stock of the issuing company, at a fixed price called the exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsMember" xlink:to="roiv_PublicWarrantsMember_lbl" xlink:title="label: PublicWarrantsMember to roiv_PublicWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PublicWarrantsMember_lbl1" xml:lang="en-US" id="roiv_PublicWarrantsMember_lbl1">Public Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsMember" xlink:to="roiv_PublicWarrantsMember_lbl1" xlink:title="label: PublicWarrantsMember to roiv_PublicWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_PublicWarrantsMember_lbl2" xml:lang="en-US" id="roiv_PublicWarrantsMember_lbl2">Public Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsMember" xlink:to="roiv_PublicWarrantsMember_lbl2" xlink:title="label: PublicWarrantsMember to roiv_PublicWarrantsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="roiv_PublicWarrantsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_PublicWarrantsMember_lbl3" xml:lang="en-US" id="roiv_PublicWarrantsMember_lbl3">Public Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicWarrantsMember" xlink:to="roiv_PublicWarrantsMember_lbl3" xlink:title="label: PublicWarrantsMember to roiv_PublicWarrantsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DatavantHoldingsIncMember" xlink:label="DatavantHoldingsIncMember" xlink:title="DatavantHoldingsIncMember" />
    <link:label xlink:type="resource" xlink:label="roiv_DatavantHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DatavantHoldingsIncMember_lbl" xml:lang="en-US" id="roiv_DatavantHoldingsIncMember_lbl">The name of related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DatavantHoldingsIncMember" xlink:to="roiv_DatavantHoldingsIncMember_lbl" xlink:title="label: DatavantHoldingsIncMember to roiv_DatavantHoldingsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DatavantHoldingsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DatavantHoldingsIncMember_lbl1" xml:lang="en-US" id="roiv_DatavantHoldingsIncMember_lbl1">Datavant Holdings, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DatavantHoldingsIncMember" xlink:to="roiv_DatavantHoldingsIncMember_lbl1" xlink:title="label: DatavantHoldingsIncMember to roiv_DatavantHoldingsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DatavantHoldingsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DatavantHoldingsIncMember_lbl2" xml:lang="en-US" id="roiv_DatavantHoldingsIncMember_lbl2">Datavant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DatavantHoldingsIncMember" xlink:to="roiv_DatavantHoldingsIncMember_lbl2" xlink:title="label: DatavantHoldingsIncMember to roiv_DatavantHoldingsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueEarnoutSharesMeasurementInput" xlink:label="FairValueEarnoutSharesMeasurementInput" xlink:title="FairValueEarnoutSharesMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueEarnoutSharesMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_FairValueEarnoutSharesMeasurementInput_lbl" xml:lang="en-US" id="roiv_FairValueEarnoutSharesMeasurementInput_lbl">The fair value measurement input for Earn-out shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueEarnoutSharesMeasurementInput" xlink:to="roiv_FairValueEarnoutSharesMeasurementInput_lbl" xlink:title="label: FairValueEarnoutSharesMeasurementInput to roiv_FairValueEarnoutSharesMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueEarnoutSharesMeasurementInput_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FairValueEarnoutSharesMeasurementInput_lbl1" xml:lang="en-US" id="roiv_FairValueEarnoutSharesMeasurementInput_lbl1">Fair Value Earnout Shares Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueEarnoutSharesMeasurementInput" xlink:to="roiv_FairValueEarnoutSharesMeasurementInput_lbl1" xlink:title="label: FairValueEarnoutSharesMeasurementInput to roiv_FairValueEarnoutSharesMeasurementInput_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueEarnoutSharesMeasurementInput_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_FairValueEarnoutSharesMeasurementInput_lbl2" xml:lang="en-US" id="roiv_FairValueEarnoutSharesMeasurementInput_lbl2">Earn-out share, measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueEarnoutSharesMeasurementInput" xlink:to="roiv_FairValueEarnoutSharesMeasurementInput_lbl2" xlink:title="label: FairValueEarnoutSharesMeasurementInput to roiv_FairValueEarnoutSharesMeasurementInput_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueAssetMeasurementInput" xlink:label="FairValueAssetMeasurementInput" xlink:title="FairValueAssetMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueAssetMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_FairValueAssetMeasurementInput_lbl" xml:lang="en-US" id="roiv_FairValueAssetMeasurementInput_lbl">Fair value asset, measurement input.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetMeasurementInput" xlink:to="roiv_FairValueAssetMeasurementInput_lbl" xlink:title="label: FairValueAssetMeasurementInput to roiv_FairValueAssetMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueAssetMeasurementInput_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FairValueAssetMeasurementInput_lbl1" xml:lang="en-US" id="roiv_FairValueAssetMeasurementInput_lbl1">Fair Value Asset, Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetMeasurementInput" xlink:to="roiv_FairValueAssetMeasurementInput_lbl1" xlink:title="label: FairValueAssetMeasurementInput to roiv_FairValueAssetMeasurementInput_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueAssetMeasurementInput_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_FairValueAssetMeasurementInput_lbl2" xml:lang="en-US" id="roiv_FairValueAssetMeasurementInput_lbl2">Investment in equity securities, measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetMeasurementInput" xlink:to="roiv_FairValueAssetMeasurementInput_lbl2" xlink:title="label: FairValueAssetMeasurementInput to roiv_FairValueAssetMeasurementInput_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:label="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:title="FairValueMeasurementInputsAndValuationTechniquesAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl1" xml:lang="en-US" id="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl1">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl1" xlink:title="label: FairValueMeasurementInputsAndValuationTechniquesAbstract to roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl2" xml:lang="en-US" id="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl2">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl2" xlink:title="label: FairValueMeasurementInputsAndValuationTechniquesAbstract to roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" id="roiv_PrivatePlacementWarrantsMember_lbl">Security that gives the holder the right to purchase one share of common stock at a specific exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementWarrantsMember" xlink:to="roiv_PrivatePlacementWarrantsMember_lbl" xlink:title="label: PrivatePlacementWarrantsMember to roiv_PrivatePlacementWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_PrivatePlacementWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_PrivatePlacementWarrantsMember_lbl1" xml:lang="en-US" id="roiv_PrivatePlacementWarrantsMember_lbl1">Private Placement Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementWarrantsMember" xlink:to="roiv_PrivatePlacementWarrantsMember_lbl1" xlink:title="label: PrivatePlacementWarrantsMember to roiv_PrivatePlacementWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_PrivatePlacementWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_PrivatePlacementWarrantsMember_lbl2" xml:lang="en-US" id="roiv_PrivatePlacementWarrantsMember_lbl2">Private Placement Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementWarrantsMember" xlink:to="roiv_PrivatePlacementWarrantsMember_lbl2" xlink:title="label: PrivatePlacementWarrantsMember to roiv_PrivatePlacementWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnoutSharesMember" xlink:label="EarnoutSharesMember" xlink:title="EarnoutSharesMember" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnoutSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EarnoutSharesMember_lbl" xml:lang="en-US" id="roiv_EarnoutSharesMember_lbl">The fair value of earn-out shares issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnoutSharesMember" xlink:to="roiv_EarnoutSharesMember_lbl" xlink:title="label: EarnoutSharesMember to roiv_EarnoutSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnoutSharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EarnoutSharesMember_lbl1" xml:lang="en-US" id="roiv_EarnoutSharesMember_lbl1">Earnout Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnoutSharesMember" xlink:to="roiv_EarnoutSharesMember_lbl1" xlink:title="label: EarnoutSharesMember to roiv_EarnoutSharesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EarnoutSharesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EarnoutSharesMember_lbl2" xml:lang="en-US" id="roiv_EarnoutSharesMember_lbl2">Earn-Out Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarnoutSharesMember" xlink:to="roiv_EarnoutSharesMember_lbl2" xlink:title="label: EarnoutSharesMember to roiv_EarnoutSharesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RecentTransactionsTextBlock" xlink:label="RecentTransactionsTextBlock" xlink:title="RecentTransactionsTextBlock" />
    <link:label xlink:type="resource" xlink:label="roiv_RecentTransactionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RecentTransactionsTextBlock_lbl" xml:lang="en-US" id="roiv_RecentTransactionsTextBlock_lbl">The entire disclosure for recent transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecentTransactionsTextBlock" xlink:to="roiv_RecentTransactionsTextBlock_lbl" xlink:title="label: RecentTransactionsTextBlock to roiv_RecentTransactionsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RecentTransactionsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RecentTransactionsTextBlock_lbl1" xml:lang="en-US" id="roiv_RecentTransactionsTextBlock_lbl1">Recent Transactions [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecentTransactionsTextBlock" xlink:to="roiv_RecentTransactionsTextBlock_lbl1" xlink:title="label: RecentTransactionsTextBlock to roiv_RecentTransactionsTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RecentTransactionsTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_RecentTransactionsTextBlock_lbl2" xml:lang="en-US" id="roiv_RecentTransactionsTextBlock_lbl2">Recent Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecentTransactionsTextBlock" xlink:to="roiv_RecentTransactionsTextBlock_lbl2" xlink:title="label: RecentTransactionsTextBlock to roiv_RecentTransactionsTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RecentTransactionsAbstract" xlink:label="RecentTransactionsAbstract" xlink:title="RecentTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_RecentTransactionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RecentTransactionsAbstract_lbl1" xml:lang="en-US" id="roiv_RecentTransactionsAbstract_lbl1">Recent Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecentTransactionsAbstract" xlink:to="roiv_RecentTransactionsAbstract_lbl1" xlink:title="label: RecentTransactionsAbstract to roiv_RecentTransactionsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtdEquityPlansMember" xlink:label="RoivantSciencesLtdEquityPlansMember" xlink:title="RoivantSciencesLtdEquityPlansMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RoivantSciencesLtdEquityPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RoivantSciencesLtdEquityPlansMember_lbl" xml:lang="en-US" id="roiv_RoivantSciencesLtdEquityPlansMember_lbl">The Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "RSL 2021 EIP"), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (collectively, the "RSL Equity Plans").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoivantSciencesLtdEquityPlansMember" xlink:to="roiv_RoivantSciencesLtdEquityPlansMember_lbl" xlink:title="label: RoivantSciencesLtdEquityPlansMember to roiv_RoivantSciencesLtdEquityPlansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RoivantSciencesLtdEquityPlansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RoivantSciencesLtdEquityPlansMember_lbl1" xml:lang="en-US" id="roiv_RoivantSciencesLtdEquityPlansMember_lbl1">Roivant Sciences Ltd Equity Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoivantSciencesLtdEquityPlansMember" xlink:to="roiv_RoivantSciencesLtdEquityPlansMember_lbl1" xlink:title="label: RoivantSciencesLtdEquityPlansMember to roiv_RoivantSciencesLtdEquityPlansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RoivantSciencesLtdEquityPlansMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_RoivantSciencesLtdEquityPlansMember_lbl2" xml:lang="en-US" id="roiv_RoivantSciencesLtdEquityPlansMember_lbl2">RSL Equity Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoivantSciencesLtdEquityPlansMember" xlink:to="roiv_RoivantSciencesLtdEquityPlansMember_lbl2" xlink:title="label: RoivantSciencesLtdEquityPlansMember to roiv_RoivantSciencesLtdEquityPlansMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="RestrictedStockAndPerformanceStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl" xml:lang="en-US" id="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl">Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and Share-based payment arrangement awarded for meeting performance target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockAndPerformanceStockUnitsMember" xlink:to="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl" xlink:title="label: RestrictedStockAndPerformanceStockUnitsMember to roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl1" xml:lang="en-US" id="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl1">Restricted Stock and Performance Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockAndPerformanceStockUnitsMember" xlink:to="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl1" xlink:title="label: RestrictedStockAndPerformanceStockUnitsMember to roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl2" xml:lang="en-US" id="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl2">Restricted Stock and Performance Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockAndPerformanceStockUnitsMember" xlink:to="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl2" xlink:title="label: RestrictedStockAndPerformanceStockUnitsMember to roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl3" xml:lang="en-US" id="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl3">Restricted Stock Units and Performance Stock Units (Non-vested) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockAndPerformanceStockUnitsMember" xlink:to="roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl3" xlink:title="label: RestrictedStockAndPerformanceStockUnitsMember to roiv_RestrictedStockAndPerformanceStockUnitsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:label="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:title="NoncontrollingInterestIncreaseDecreaseFromDisposition" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl" xml:lang="en-US" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl">The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the disposition of subsidiary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:to="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl" xlink:title="label: NoncontrollingInterestIncreaseDecreaseFromDisposition to roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl1" xml:lang="en-US" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl1">Noncontrolling Interest, Increase Decrease from Disposition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:to="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl1" xlink:title="label: NoncontrollingInterestIncreaseDecreaseFromDisposition to roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl2" xml:lang="en-US" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl2">Disposition of Telavant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:to="roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl2" xlink:title="label: NoncontrollingInterestIncreaseDecreaseFromDisposition to roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl">The amount of subsidiary stock issued as a result of stock options exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:to="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised to roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl1">Stock Issued During Period, Value, Subsidiary, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:to="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised to roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl2">Subsidiary stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:to="roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl2" xlink:title="label: StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised to roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl">The value of stock issued in connection with equity incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl1">Stock Issued During Period, Value, in Connection with Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl1" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl2">Issuance of the Company's common shares in connection with equity incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl2" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:label="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:title="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl" xml:lang="en-US" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl">The amount of the increase in or (reduction or elimination) during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:to="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl" xlink:title="label: NoncontrollingInterestIncreaseDecreaseFromDeconsolidation to roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl1" xml:lang="en-US" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl1">Noncontrolling Interest, Increase Decrease from Deconsolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:to="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl1" xlink:title="label: NoncontrollingInterestIncreaseDecreaseFromDeconsolidation to roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl2" xml:lang="en-US" id="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl2">Deconsolidation of subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:to="roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl2" xlink:title="label: NoncontrollingInterestIncreaseDecreaseFromDeconsolidation to roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl">The amount of common shares issued related to settlement of transaction consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:to="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" xlink:title="label: StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration to roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1">Stock Issued During Period, Value, Common Shares Related to Settlement of Transaction Consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:to="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" xlink:title="label: StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration to roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2">Issuance of the Company's common shares related to settlement of transaction consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:to="roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" xlink:title="label: StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration to roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DividendDeclaredBySubsidiary" xlink:label="DividendDeclaredBySubsidiary" xlink:title="DividendDeclaredBySubsidiary" />
    <link:label xlink:type="resource" xlink:label="roiv_DividendDeclaredBySubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DividendDeclaredBySubsidiary_lbl" xml:lang="en-US" id="roiv_DividendDeclaredBySubsidiary_lbl">Dividend declared by subsidiary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendDeclaredBySubsidiary" xlink:to="roiv_DividendDeclaredBySubsidiary_lbl" xlink:title="label: DividendDeclaredBySubsidiary to roiv_DividendDeclaredBySubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DividendDeclaredBySubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DividendDeclaredBySubsidiary_lbl1" xml:lang="en-US" id="roiv_DividendDeclaredBySubsidiary_lbl1">Dividend Declared by Subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendDeclaredBySubsidiary" xlink:to="roiv_DividendDeclaredBySubsidiary_lbl1" xlink:title="label: DividendDeclaredBySubsidiary to roiv_DividendDeclaredBySubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DividendDeclaredBySubsidiary_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_DividendDeclaredBySubsidiary_lbl2" xml:lang="en-US" id="roiv_DividendDeclaredBySubsidiary_lbl2">Dividend declared by subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendDeclaredBySubsidiary" xlink:to="roiv_DividendDeclaredBySubsidiary_lbl2" xlink:title="label: DividendDeclaredBySubsidiary to roiv_DividendDeclaredBySubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl">The value of stock issued in connection with equity incentive plans and tax withholding payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1">Stock Issued During Period Value In Connection With Equity Incentive Plans And Tax Withholding Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="RedeemableNoncontrollingInterestMember" xlink:title="RedeemableNoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RedeemableNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RedeemableNoncontrollingInterestMember_lbl" xml:lang="en-US" id="roiv_RedeemableNoncontrollingInterestMember_lbl">Noncontrolling interests that are mandatorily redeemable upon a certain date or event occurring.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemableNoncontrollingInterestMember" xlink:to="roiv_RedeemableNoncontrollingInterestMember_lbl" xlink:title="label: RedeemableNoncontrollingInterestMember to roiv_RedeemableNoncontrollingInterestMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RedeemableNoncontrollingInterestMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RedeemableNoncontrollingInterestMember_lbl1" xml:lang="en-US" id="roiv_RedeemableNoncontrollingInterestMember_lbl1">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemableNoncontrollingInterestMember" xlink:to="roiv_RedeemableNoncontrollingInterestMember_lbl1" xlink:title="label: RedeemableNoncontrollingInterestMember to roiv_RedeemableNoncontrollingInterestMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RedeemableNoncontrollingInterestMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_RedeemableNoncontrollingInterestMember_lbl2" xml:lang="en-US" id="roiv_RedeemableNoncontrollingInterestMember_lbl2">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemableNoncontrollingInterestMember" xlink:to="roiv_RedeemableNoncontrollingInterestMember_lbl2" xlink:title="label: RedeemableNoncontrollingInterestMember to roiv_RedeemableNoncontrollingInterestMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl">The number of shares issued in connection with equity incentive plans and tax withholding payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1">Stock Issued During Period, Shares, in Connection with Equity Incentive Plans and Tax Withholding Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:label="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:title="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl">Number of shares issued common share related to settlement of warrants shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:to="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl" xlink:title="label: StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares to roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl1">Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:to="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl1" xlink:title="label: StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares to roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl2">Issuance of the Company's common shares related to settlement of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:to="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl2" xlink:title="label: StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares to roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl">The number of common shares issued related to settlement of transaction consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:to="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" xlink:title="label: StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration to roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1">Stock Issued During Period, Shares, Common Shares Related to Settlement of Transaction Consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:to="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration to roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2">Issuance of the Company's common shares related to settlement of transaction consideration (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:to="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration to roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:label="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:title="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl">The number of stock issuance of common shares and other consideration for acquisition during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:to="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares to roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl1">Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:to="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl1" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares to roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl2">Issuance of the Company's common shares and other consideration for an acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:to="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl2" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares to roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:label="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:title="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl">Value of stock issuance of common shares and other consideration for acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:to="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue to roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl1">Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:to="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl1" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue to roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl2">Issuance of the Company's common shares and other consideration for an acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:to="roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl2" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue to roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:label="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:title="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl">Aggregate change in value issuance of the company's common share related to settlement of warrants value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:to="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl" xlink:title="label: StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue to roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl1">Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:to="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl1" xlink:title="label: StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue to roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl2">Issuance of the Company's common shares related to settlement of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:to="roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl2" xlink:title="label: StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue to roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl">The value of stock issued in connection with equity incentive plans net of forfeitures and tax withholding payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1">Stock Issued During Period, Value, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2">Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl">The amount net common shares issued of subsidiary to the company and cash contributions to majority-owned subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl1" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl1">Issuance of Subsidiary Common Shares to the Company and Capital Contributions to Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl1" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl2" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl2">Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl2" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:title="StockIssuedDuringPeriodSharesNetIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl">Number of stock issued during the period net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:to="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNetIssuanceCosts to roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl1">Stock Issued During Period, Shares, Net Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:to="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNetIssuanceCosts to roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl2">Issuance of the Company's common shares, net of issuance costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:to="roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNetIssuanceCosts to roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:label="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:title="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" />
    <link:label xlink:type="resource" xlink:label="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl" xml:lang="en-US" id="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl">Amount of increase to additional paid-in capital (APIC) and Noncontrolling Interest for recognition of cost for award under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:to="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl" xlink:title="label: APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition to roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl1" xml:lang="en-US" id="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl1">APIC and Noncontrolling Interest, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:to="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl1" xlink:title="label: APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition to roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl2" xml:lang="en-US" id="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl2">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:to="roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl2" xlink:title="label: APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition to roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl">Number of common shares issuance of subsidiary to the Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyShares to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl1" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl1">Issuance of Subsidiary Common Shares to the Company, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl1" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyShares to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl2" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl2">Issuance of subsidiary common shares to the Company (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl2" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyShares to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="CapitalContributionsToSubsidiaries" xlink:title="CapitalContributionsToSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="roiv_CapitalContributionsToSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CapitalContributionsToSubsidiaries_lbl" xml:lang="en-US" id="roiv_CapitalContributionsToSubsidiaries_lbl">Capital Contributions To Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionsToSubsidiaries" xlink:to="roiv_CapitalContributionsToSubsidiaries_lbl" xlink:title="label: CapitalContributionsToSubsidiaries to roiv_CapitalContributionsToSubsidiaries_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CapitalContributionsToSubsidiaries_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CapitalContributionsToSubsidiaries_lbl1" xml:lang="en-US" id="roiv_CapitalContributionsToSubsidiaries_lbl1">Capital Contributions To Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionsToSubsidiaries" xlink:to="roiv_CapitalContributionsToSubsidiaries_lbl1" xlink:title="label: CapitalContributionsToSubsidiaries to roiv_CapitalContributionsToSubsidiaries_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CapitalContributionsToSubsidiaries_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CapitalContributionsToSubsidiaries_lbl2" xml:lang="en-US" id="roiv_CapitalContributionsToSubsidiaries_lbl2">Cash contributions to majority-owned subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalContributionsToSubsidiaries" xlink:to="roiv_CapitalContributionsToSubsidiaries_lbl2" xlink:title="label: CapitalContributionsToSubsidiaries to roiv_CapitalContributionsToSubsidiaries_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl">The number of shares issued in connection with equity incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl1">Stock Issued During Period, Shares, in Connection with Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl2">Issuance of the Company's common shares in connection with equity incentive plans (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl">The number of shares issued in connection with equity incentive plans net of forfeitures and tax withholding payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1">Stock Issued During Period, Shares, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2">Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:to="roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments to roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:title="StockIssuedDuringPeriodValueNetIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl">Stock issued during the period value, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:to="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl" xlink:title="label: StockIssuedDuringPeriodValueNetIssuanceCosts to roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl1" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl1">Stock Issued During Period, Value, Net Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:to="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNetIssuanceCosts to roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl2" xml:lang="en-US" id="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl2">Issuance of the Company's common shares, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:to="roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl2" xlink:title="label: StockIssuedDuringPeriodValueNetIssuanceCosts to roiv_StockIssuedDuringPeriodValueNetIssuanceCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl">The amount net common shares issued of subsidiary to the company, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl1" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl1">Issuance of Subsidiary Common Shares to the Company Net Issuance Costs, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl1" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl2" xml:lang="en-US" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl2">Issuance of subsidiary common shares to the Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:to="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl2" xlink:title="label: IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue to roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:label="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:title="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl" xml:lang="en-US" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl">The committed funding under revenue interest purchase and sale agreement received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:to="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl" xlink:title="label: CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived to roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl1" xml:lang="en-US" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl1">Committed Funding under Revenue Interest Purchase and Sale Agreement Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:to="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl1" xlink:title="label: CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived to roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl2" xml:lang="en-US" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl2">Committed funding under revenue interest purchase and sale agreement received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:to="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl2" xlink:title="label: CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived to roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:label="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:title="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl" xml:lang="en-US" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl">The committed funding under revenue interest purchase and sale agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:to="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl" xlink:title="label: CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement to roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl1" xml:lang="en-US" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl1">Committed Funding under Revenue Interest Purchase and Sale Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:to="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl1" xlink:title="label: CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement to roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl2" xml:lang="en-US" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl2">Face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:to="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl2" xlink:title="label: CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement to roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRIPSA" xlink:label="CommittedFundingUnderRIPSA" xlink:title="CommittedFundingUnderRIPSA" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRIPSA_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CommittedFundingUnderRIPSA_lbl" xml:lang="en-US" id="roiv_CommittedFundingUnderRIPSA_lbl">The committed funding under revenue interest purchase and sale agreement (RIPSA).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRIPSA" xlink:to="roiv_CommittedFundingUnderRIPSA_lbl" xlink:title="label: CommittedFundingUnderRIPSA to roiv_CommittedFundingUnderRIPSA_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRIPSA_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CommittedFundingUnderRIPSA_lbl1" xml:lang="en-US" id="roiv_CommittedFundingUnderRIPSA_lbl1">Committed Funding under RIPSA</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRIPSA" xlink:to="roiv_CommittedFundingUnderRIPSA_lbl1" xlink:title="label: CommittedFundingUnderRIPSA to roiv_CommittedFundingUnderRIPSA_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CommittedFundingUnderRIPSA_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CommittedFundingUnderRIPSA_lbl2" xml:lang="en-US" id="roiv_CommittedFundingUnderRIPSA_lbl2">Royalties entitled to receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommittedFundingUnderRIPSA" xlink:to="roiv_CommittedFundingUnderRIPSA_lbl2" xlink:title="label: CommittedFundingUnderRIPSA to roiv_CommittedFundingUnderRIPSA_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:label="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:title="RevenueInterestPurchaseAndSaleAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl1" xml:lang="en-US" id="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl1">Revenue Interest Purchase and Sale Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:to="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl1" xlink:title="label: RevenueInterestPurchaseAndSaleAgreementAbstract to roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl2" xml:lang="en-US" id="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl2">Revenue Interest Purchase and Sale Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:to="roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl2" xlink:title="label: RevenueInterestPurchaseAndSaleAgreementAbstract to roiv_RevenueInterestPurchaseAndSaleAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DebtInstrumentExitFee_lbl" xml:lang="en-US" id="roiv_DebtInstrumentExitFee_lbl">Amount of expenses associated with exit fee of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="roiv_DebtInstrumentExitFee_lbl" xlink:title="label: DebtInstrumentExitFee to roiv_DebtInstrumentExitFee_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentExitFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DebtInstrumentExitFee_lbl1" xml:lang="en-US" id="roiv_DebtInstrumentExitFee_lbl1">Debt Instrument, Exit Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="roiv_DebtInstrumentExitFee_lbl1" xlink:title="label: DebtInstrumentExitFee to roiv_DebtInstrumentExitFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentExitFee_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DebtInstrumentExitFee_lbl2" xml:lang="en-US" id="roiv_DebtInstrumentExitFee_lbl2">Exit fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="roiv_DebtInstrumentExitFee_lbl2" xlink:title="label: DebtInstrumentExitFee to roiv_DebtInstrumentExitFee_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:title="DebtInstrumentExitFeeAndEndOfTermCharge" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl" xml:lang="en-US" id="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl">The amount of expenses associated with exit fee and end of term charge of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:to="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl" xlink:title="label: DebtInstrumentExitFeeAndEndOfTermCharge to roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl1" xml:lang="en-US" id="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl1">Debt Instrument, Exit Fee and End of Term Charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:to="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl1" xlink:title="label: DebtInstrumentExitFeeAndEndOfTermCharge to roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl2" xml:lang="en-US" id="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl2">Debt instrument exit fee and end of term charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:to="roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl2" xlink:title="label: DebtInstrumentExitFeeAndEndOfTermCharge to roiv_DebtInstrumentExitFeeAndEndOfTermCharge_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LoanAndCreditAgreementsByDermavantAbstract" xlink:label="LoanAndCreditAgreementsByDermavantAbstract" xlink:title="LoanAndCreditAgreementsByDermavantAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl1" xml:lang="en-US" id="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl1">Loan and Credit Agreements by Dermavant [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl1" xlink:title="label: LoanAndCreditAgreementsByDermavantAbstract to roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl2" xml:lang="en-US" id="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl2">Loan and Credit Agreements by Dermavant [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl2" xlink:title="label: LoanAndCreditAgreementsByDermavantAbstract to roiv_LoanAndCreditAgreementsByDermavantAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InvestmentsDisclosureAbstract" xlink:label="InvestmentsDisclosureAbstract" xlink:title="InvestmentsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_InvestmentsDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_InvestmentsDisclosureAbstract_lbl1" xml:lang="en-US" id="roiv_InvestmentsDisclosureAbstract_lbl1">Investments Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsDisclosureAbstract" xlink:to="roiv_InvestmentsDisclosureAbstract_lbl1" xlink:title="label: InvestmentsDisclosureAbstract to roiv_InvestmentsDisclosureAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_InvestmentsDisclosureAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_InvestmentsDisclosureAbstract_lbl2" xml:lang="en-US" id="roiv_InvestmentsDisclosureAbstract_lbl2">Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsDisclosureAbstract" xlink:to="roiv_InvestmentsDisclosureAbstract_lbl2" xlink:title="label: InvestmentsDisclosureAbstract to roiv_InvestmentsDisclosureAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="ArbutusBiopharmaCorporationMember" xlink:title="ArbutusBiopharmaCorporationMember" />
    <link:label xlink:type="resource" xlink:label="roiv_ArbutusBiopharmaCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ArbutusBiopharmaCorporationMember_lbl" xml:lang="en-US" id="roiv_ArbutusBiopharmaCorporationMember_lbl">The name of related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArbutusBiopharmaCorporationMember" xlink:to="roiv_ArbutusBiopharmaCorporationMember_lbl" xlink:title="label: ArbutusBiopharmaCorporationMember to roiv_ArbutusBiopharmaCorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ArbutusBiopharmaCorporationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ArbutusBiopharmaCorporationMember_lbl1" xml:lang="en-US" id="roiv_ArbutusBiopharmaCorporationMember_lbl1">Arbutus Biopharma Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArbutusBiopharmaCorporationMember" xlink:to="roiv_ArbutusBiopharmaCorporationMember_lbl1" xlink:title="label: ArbutusBiopharmaCorporationMember to roiv_ArbutusBiopharmaCorporationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ArbutusBiopharmaCorporationMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ArbutusBiopharmaCorporationMember_lbl2" xml:lang="en-US" id="roiv_ArbutusBiopharmaCorporationMember_lbl2">Arbutus Biopharma Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArbutusBiopharmaCorporationMember" xlink:to="roiv_ArbutusBiopharmaCorporationMember_lbl2" xlink:title="label: ArbutusBiopharmaCorporationMember to roiv_ArbutusBiopharmaCorporationMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CreditFacilityWithXYQLuxcoMember" xlink:label="CreditFacilityWithXYQLuxcoMember" xlink:title="CreditFacilityWithXYQLuxcoMember" />
    <link:label xlink:type="resource" xlink:label="roiv_CreditFacilityWithXYQLuxcoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CreditFacilityWithXYQLuxcoMember_lbl" xml:lang="en-US" id="roiv_CreditFacilityWithXYQLuxcoMember_lbl">An senior secured credit facility entered by Dermavant and certain of its subsidiaries with XYQ Luxco S.A.R.L ("XYQ Luxco"),.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityWithXYQLuxcoMember" xlink:to="roiv_CreditFacilityWithXYQLuxcoMember_lbl" xlink:title="label: CreditFacilityWithXYQLuxcoMember to roiv_CreditFacilityWithXYQLuxcoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CreditFacilityWithXYQLuxcoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CreditFacilityWithXYQLuxcoMember_lbl1" xml:lang="en-US" id="roiv_CreditFacilityWithXYQLuxcoMember_lbl1">Credit Facility with XYQ Luxco [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityWithXYQLuxcoMember" xlink:to="roiv_CreditFacilityWithXYQLuxcoMember_lbl1" xlink:title="label: CreditFacilityWithXYQLuxcoMember to roiv_CreditFacilityWithXYQLuxcoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CreditFacilityWithXYQLuxcoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CreditFacilityWithXYQLuxcoMember_lbl2" xml:lang="en-US" id="roiv_CreditFacilityWithXYQLuxcoMember_lbl2">Credit Facility with XYQ Luxco [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityWithXYQLuxcoMember" xlink:to="roiv_CreditFacilityWithXYQLuxcoMember_lbl2" xlink:title="label: CreditFacilityWithXYQLuxcoMember to roiv_CreditFacilityWithXYQLuxcoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:label="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl" xml:lang="en-US" id="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl">A revenue interest purchase and sale agreement between Dermavant and XYQ Luxco, NovaQuest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:to="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl" xlink:title="label: RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember to roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl1" xml:lang="en-US" id="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl1">Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:to="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl1" xlink:title="label: RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember to roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl2" xml:lang="en-US" id="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl2">Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:to="roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl2" xlink:title="label: RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember to roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherOfOtherAssetsCurrent" xlink:label="OtherOfOtherAssetsCurrent" xlink:title="OtherOfOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherOfOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_OtherOfOtherAssetsCurrent_lbl" xml:lang="en-US" id="roiv_OtherOfOtherAssetsCurrent_lbl">Amount of other current assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOfOtherAssetsCurrent" xlink:to="roiv_OtherOfOtherAssetsCurrent_lbl" xlink:title="label: OtherOfOtherAssetsCurrent to roiv_OtherOfOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherOfOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_OtherOfOtherAssetsCurrent_lbl1" xml:lang="en-US" id="roiv_OtherOfOtherAssetsCurrent_lbl1">Other of Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOfOtherAssetsCurrent" xlink:to="roiv_OtherOfOtherAssetsCurrent_lbl1" xlink:title="label: OtherOfOtherAssetsCurrent to roiv_OtherOfOtherAssetsCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_OtherOfOtherAssetsCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_OtherOfOtherAssetsCurrent_lbl2" xml:lang="en-US" id="roiv_OtherOfOtherAssetsCurrent_lbl2">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOfOtherAssetsCurrent" xlink:to="roiv_OtherOfOtherAssetsCurrent_lbl2" xlink:title="label: OtherOfOtherAssetsCurrent to roiv_OtherOfOtherAssetsCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ExerciseOfPrivatePlacementWarrantsValue" xlink:label="ExerciseOfPrivatePlacementWarrantsValue" xlink:title="ExerciseOfPrivatePlacementWarrantsValue" />
    <link:label xlink:type="resource" xlink:label="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl" xml:lang="en-US" id="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl">The cash outflow associated with the amount received from entity's raising of capital via private rather than public placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExerciseOfPrivatePlacementWarrantsValue" xlink:to="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl" xlink:title="label: ExerciseOfPrivatePlacementWarrantsValue to roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl1" xml:lang="en-US" id="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl1">Exercise of Private Placement Warrants Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExerciseOfPrivatePlacementWarrantsValue" xlink:to="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl1" xlink:title="label: ExerciseOfPrivatePlacementWarrantsValue to roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl2" xml:lang="en-US" id="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl2">Exercise of Private Placement Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExerciseOfPrivatePlacementWarrantsValue" xlink:to="roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl2" xlink:title="label: ExerciseOfPrivatePlacementWarrantsValue to roiv_ExerciseOfPrivatePlacementWarrantsValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="MaximumMilestonePaymentObligation" xlink:title="MaximumMilestonePaymentObligation" />
    <link:label xlink:type="resource" xlink:label="roiv_MaximumMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_MaximumMilestonePaymentObligation_lbl" xml:lang="en-US" id="roiv_MaximumMilestonePaymentObligation_lbl">The maximum milestone payment obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMilestonePaymentObligation" xlink:to="roiv_MaximumMilestonePaymentObligation_lbl" xlink:title="label: MaximumMilestonePaymentObligation to roiv_MaximumMilestonePaymentObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_MaximumMilestonePaymentObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_MaximumMilestonePaymentObligation_lbl1" xml:lang="en-US" id="roiv_MaximumMilestonePaymentObligation_lbl1">Maximum Milestone Payment Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMilestonePaymentObligation" xlink:to="roiv_MaximumMilestonePaymentObligation_lbl1" xlink:title="label: MaximumMilestonePaymentObligation to roiv_MaximumMilestonePaymentObligation_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_MaximumMilestonePaymentObligation_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_MaximumMilestonePaymentObligation_lbl2" xml:lang="en-US" id="roiv_MaximumMilestonePaymentObligation_lbl2">Maximum milestone payment obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMilestonePaymentObligation" xlink:to="roiv_MaximumMilestonePaymentObligation_lbl2" xlink:title="label: MaximumMilestonePaymentObligation to roiv_MaximumMilestonePaymentObligation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestMember" xlink:label="FundingAgreementWithNovaQuestMember" xlink:title="FundingAgreementWithNovaQuestMember" />
    <link:label xlink:type="resource" xlink:label="roiv_FundingAgreementWithNovaQuestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_FundingAgreementWithNovaQuestMember_lbl" xml:lang="en-US" id="roiv_FundingAgreementWithNovaQuestMember_lbl">An asset purchase funding agreement between Dermavant and NovaQuest Co-Investment Fund VIII, L.P (the "NovaQuest Agreement").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FundingAgreementWithNovaQuestMember" xlink:to="roiv_FundingAgreementWithNovaQuestMember_lbl" xlink:title="label: FundingAgreementWithNovaQuestMember to roiv_FundingAgreementWithNovaQuestMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_FundingAgreementWithNovaQuestMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FundingAgreementWithNovaQuestMember_lbl1" xml:lang="en-US" id="roiv_FundingAgreementWithNovaQuestMember_lbl1">Funding Agreement with NovaQuest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FundingAgreementWithNovaQuestMember" xlink:to="roiv_FundingAgreementWithNovaQuestMember_lbl1" xlink:title="label: FundingAgreementWithNovaQuestMember to roiv_FundingAgreementWithNovaQuestMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_FundingAgreementWithNovaQuestMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_FundingAgreementWithNovaQuestMember_lbl2" xml:lang="en-US" id="roiv_FundingAgreementWithNovaQuestMember_lbl2">Funding Agreement with NovaQuest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FundingAgreementWithNovaQuestMember" xlink:to="roiv_FundingAgreementWithNovaQuestMember_lbl2" xlink:title="label: FundingAgreementWithNovaQuestMember to roiv_FundingAgreementWithNovaQuestMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="MaximumMilestonePaymentOffsetAmount" xlink:title="MaximumMilestonePaymentOffsetAmount" />
    <link:label xlink:type="resource" xlink:label="roiv_MaximumMilestonePaymentOffsetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_MaximumMilestonePaymentOffsetAmount_lbl" xml:lang="en-US" id="roiv_MaximumMilestonePaymentOffsetAmount_lbl">The maximum milestone payment offset amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMilestonePaymentOffsetAmount" xlink:to="roiv_MaximumMilestonePaymentOffsetAmount_lbl" xlink:title="label: MaximumMilestonePaymentOffsetAmount to roiv_MaximumMilestonePaymentOffsetAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_MaximumMilestonePaymentOffsetAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_MaximumMilestonePaymentOffsetAmount_lbl1" xml:lang="en-US" id="roiv_MaximumMilestonePaymentOffsetAmount_lbl1">Maximum Milestone Payment Offset Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMilestonePaymentOffsetAmount" xlink:to="roiv_MaximumMilestonePaymentOffsetAmount_lbl1" xlink:title="label: MaximumMilestonePaymentOffsetAmount to roiv_MaximumMilestonePaymentOffsetAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_MaximumMilestonePaymentOffsetAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_MaximumMilestonePaymentOffsetAmount_lbl2" xml:lang="en-US" id="roiv_MaximumMilestonePaymentOffsetAmount_lbl2">Right to offset of commercial milestones payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMilestonePaymentOffsetAmount" xlink:to="roiv_MaximumMilestonePaymentOffsetAmount_lbl2" xlink:title="label: MaximumMilestonePaymentOffsetAmount to roiv_MaximumMilestonePaymentOffsetAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:label="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:title="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" />
    <link:label xlink:type="resource" xlink:label="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl" xml:lang="en-US" id="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl">Total required debt instrument quarterly payments made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:to="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl" xlink:title="label: TotalRequiredDebtInstrumentQuarterlyPaymentsMade to roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl1" xml:lang="en-US" id="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl1">Total Required Debt Instrument Quarterly Payments Made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:to="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl1" xlink:title="label: TotalRequiredDebtInstrumentQuarterlyPaymentsMade to roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl2" xml:lang="en-US" id="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl2">Periodic payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:to="roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl2" xlink:title="label: TotalRequiredDebtInstrumentQuarterlyPaymentsMade to roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentQuarterlyPaymentsMade" xlink:label="DebtInstrumentQuarterlyPaymentsMade" xlink:title="DebtInstrumentQuarterlyPaymentsMade" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl" xml:lang="en-US" id="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl">Amount of quarterly payments made under the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentQuarterlyPaymentsMade" xlink:to="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl" xlink:title="label: DebtInstrumentQuarterlyPaymentsMade to roiv_DebtInstrumentQuarterlyPaymentsMade_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl1" xml:lang="en-US" id="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl1">Debt Instrument, Quarterly Payments Made</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentQuarterlyPaymentsMade" xlink:to="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl1" xlink:title="label: DebtInstrumentQuarterlyPaymentsMade to roiv_DebtInstrumentQuarterlyPaymentsMade_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl2" xml:lang="en-US" id="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl2">Quarterly payments made</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentQuarterlyPaymentsMade" xlink:to="roiv_DebtInstrumentQuarterlyPaymentsMade_lbl2" xlink:title="label: DebtInstrumentQuarterlyPaymentsMade to roiv_DebtInstrumentQuarterlyPaymentsMade_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestAbstract" xlink:label="FundingAgreementWithNovaQuestAbstract" xlink:title="FundingAgreementWithNovaQuestAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_FundingAgreementWithNovaQuestAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FundingAgreementWithNovaQuestAbstract_lbl1" xml:lang="en-US" id="roiv_FundingAgreementWithNovaQuestAbstract_lbl1">Funding Agreement with NovaQuest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="roiv_FundingAgreementWithNovaQuestAbstract_lbl1" xlink:title="label: FundingAgreementWithNovaQuestAbstract to roiv_FundingAgreementWithNovaQuestAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:label xlink:type="resource" xlink:label="roiv_DermavantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_DermavantMember_lbl" xml:lang="en-US" id="roiv_DermavantMember_lbl">Name of the acquiree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DermavantMember" xlink:to="roiv_DermavantMember_lbl" xlink:title="label: DermavantMember to roiv_DermavantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_DermavantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DermavantMember_lbl1" xml:lang="en-US" id="roiv_DermavantMember_lbl1">Dermavant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DermavantMember" xlink:to="roiv_DermavantMember_lbl1" xlink:title="label: DermavantMember to roiv_DermavantMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_DermavantMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_DermavantMember_lbl2" xml:lang="en-US" id="roiv_DermavantMember_lbl2">Dermavant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DermavantMember" xlink:to="roiv_DermavantMember_lbl2" xlink:title="label: DermavantMember to roiv_DermavantMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CertainBalanceSheetComponentsAbstract" xlink:label="CertainBalanceSheetComponentsAbstract" xlink:title="CertainBalanceSheetComponentsAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_CertainBalanceSheetComponentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CertainBalanceSheetComponentsAbstract_lbl1" xml:lang="en-US" id="roiv_CertainBalanceSheetComponentsAbstract_lbl1">Certain Balance Sheet Components [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="roiv_CertainBalanceSheetComponentsAbstract_lbl1" xlink:title="label: CertainBalanceSheetComponentsAbstract to roiv_CertainBalanceSheetComponentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DescriptionOfBusinessAndLiquidityAbstract" xlink:label="DescriptionOfBusinessAndLiquidityAbstract" xlink:title="DescriptionOfBusinessAndLiquidityAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_DescriptionOfBusinessAndLiquidityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_DescriptionOfBusinessAndLiquidityAbstract_lbl1" xml:lang="en-US" id="roiv_DescriptionOfBusinessAndLiquidityAbstract_lbl1">Description of Business and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfBusinessAndLiquidityAbstract" xlink:to="roiv_DescriptionOfBusinessAndLiquidityAbstract_lbl1" xlink:title="label: DescriptionOfBusinessAndLiquidityAbstract to roiv_DescriptionOfBusinessAndLiquidityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" />
    <link:label xlink:type="resource" xlink:label="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl" xml:lang="en-US" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl">The number of share-based compensation arrangement by share-based payment award equity-based payment instruments, other than options, outstanding shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:to="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares to roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl1" xml:lang="en-US" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:to="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares to roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl2" xml:lang="en-US" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl2">Number of shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:to="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares to roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_March2020CappedValueAppreciationRightsGrantsMember" xlink:label="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="March2020CappedValueAppreciationRightsGrantsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl" xml:lang="en-US" id="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl">Grant date of Capped Value Appreciation Rights (CVARs).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March2020CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl" xlink:title="label: March2020CappedValueAppreciationRightsGrantsMember to roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl1" xml:lang="en-US" id="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl1">March 2020 Capped Value Appreciation Rights Grants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March2020CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl1" xlink:title="label: March2020CappedValueAppreciationRightsGrantsMember to roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl2" xml:lang="en-US" id="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl2">March 2020 CVAR Grants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March2020CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl2" xlink:title="label: March2020CappedValueAppreciationRightsGrantsMember to roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl3" xml:lang="en-US" id="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl3">March 2020 CVARs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="March2020CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl3" xlink:title="label: March2020CappedValueAppreciationRightsGrantsMember to roiv_March2020CappedValueAppreciationRightsGrantsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EquityInstrumentsVestedAndSettledShares" xlink:label="EquityInstrumentsVestedAndSettledShares" xlink:title="EquityInstrumentsVestedAndSettledShares" />
    <link:label xlink:type="resource" xlink:label="roiv_EquityInstrumentsVestedAndSettledShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_EquityInstrumentsVestedAndSettledShares_lbl" xml:lang="en-US" id="roiv_EquityInstrumentsVestedAndSettledShares_lbl">The number of equity instruments vested and settled during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInstrumentsVestedAndSettledShares" xlink:to="roiv_EquityInstrumentsVestedAndSettledShares_lbl" xlink:title="label: EquityInstrumentsVestedAndSettledShares to roiv_EquityInstrumentsVestedAndSettledShares_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_EquityInstrumentsVestedAndSettledShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_EquityInstrumentsVestedAndSettledShares_lbl1" xml:lang="en-US" id="roiv_EquityInstrumentsVestedAndSettledShares_lbl1">Equity Instruments Vested and Settled, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInstrumentsVestedAndSettledShares" xlink:to="roiv_EquityInstrumentsVestedAndSettledShares_lbl1" xlink:title="label: EquityInstrumentsVestedAndSettledShares to roiv_EquityInstrumentsVestedAndSettledShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_EquityInstrumentsVestedAndSettledShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_EquityInstrumentsVestedAndSettledShares_lbl2" xml:lang="en-US" id="roiv_EquityInstrumentsVestedAndSettledShares_lbl2">Equity instruments vested and settled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInstrumentsVestedAndSettledShares" xlink:to="roiv_EquityInstrumentsVestedAndSettledShares_lbl2" xlink:title="label: EquityInstrumentsVestedAndSettledShares to roiv_EquityInstrumentsVestedAndSettledShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SubsidiaryEquityIncentivePlansAbstract" xlink:label="SubsidiaryEquityIncentivePlansAbstract" xlink:title="SubsidiaryEquityIncentivePlansAbstract" />
    <link:label xlink:type="resource" xlink:label="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl1" xml:lang="en-US" id="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl1">Subsidiary Equity Incentive Plans [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryEquityIncentivePlansAbstract" xlink:to="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl1" xlink:title="label: SubsidiaryEquityIncentivePlansAbstract to roiv_SubsidiaryEquityIncentivePlansAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl2" xml:lang="en-US" id="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl2">Subsidiary Equity Incentive Plans [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryEquityIncentivePlansAbstract" xlink:to="roiv_SubsidiaryEquityIncentivePlansAbstract_lbl2" xlink:title="label: SubsidiaryEquityIncentivePlansAbstract to roiv_SubsidiaryEquityIncentivePlansAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:label="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="RoivantSciencesLtd2021EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl" xml:lang="en-US" id="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl">The Roivant Sciences Ltd Equity Incentive Plan 2021 also known as (the "RSL 2021 EIP").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:to="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl" xlink:title="label: RoivantSciencesLtd2021EquityIncentivePlanMember to roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl1">Roivant Sciences Ltd 2021 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:to="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl1" xlink:title="label: RoivantSciencesLtd2021EquityIncentivePlanMember to roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl2" xml:lang="en-US" id="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl2">RSL 2021 EIP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:to="roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl2" xlink:title="label: RoivantSciencesLtd2021EquityIncentivePlanMember to roiv_RoivantSciencesLtd2021EquityIncentivePlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SubsidiaryEquityIncentivePlansMember" xlink:label="SubsidiaryEquityIncentivePlansMember" xlink:title="SubsidiaryEquityIncentivePlansMember" />
    <link:label xlink:type="resource" xlink:label="roiv_SubsidiaryEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_SubsidiaryEquityIncentivePlansMember_lbl" xml:lang="en-US" id="roiv_SubsidiaryEquityIncentivePlansMember_lbl">Subsidiary equity incentive plans is a plan adopted by wholly owned and majority-owned or controlled subsidiaries of Roivant Sciences Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryEquityIncentivePlansMember" xlink:to="roiv_SubsidiaryEquityIncentivePlansMember_lbl" xlink:title="label: SubsidiaryEquityIncentivePlansMember to roiv_SubsidiaryEquityIncentivePlansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_SubsidiaryEquityIncentivePlansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_SubsidiaryEquityIncentivePlansMember_lbl1" xml:lang="en-US" id="roiv_SubsidiaryEquityIncentivePlansMember_lbl1">Subsidiary Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryEquityIncentivePlansMember" xlink:to="roiv_SubsidiaryEquityIncentivePlansMember_lbl1" xlink:title="label: SubsidiaryEquityIncentivePlansMember to roiv_SubsidiaryEquityIncentivePlansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_SubsidiaryEquityIncentivePlansMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_SubsidiaryEquityIncentivePlansMember_lbl2" xml:lang="en-US" id="roiv_SubsidiaryEquityIncentivePlansMember_lbl2">Subsidiary Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryEquityIncentivePlansMember" xlink:to="roiv_SubsidiaryEquityIncentivePlansMember_lbl2" xlink:title="label: SubsidiaryEquityIncentivePlansMember to roiv_SubsidiaryEquityIncentivePlansMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_November2021CappedValueAppreciationRightsGrantsMember" xlink:label="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="November2021CappedValueAppreciationRightsGrantsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl" xml:lang="en-US" id="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl">Grant date of Capped Value Appreciation Rights (CVARs).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="November2021CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl" xlink:title="label: November2021CappedValueAppreciationRightsGrantsMember to roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl1" xml:lang="en-US" id="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl1">November 2021 Capped Value Appreciation Rights Grants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="November2021CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl1" xlink:title="label: November2021CappedValueAppreciationRightsGrantsMember to roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl2" xml:lang="en-US" id="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl2">November 2021 CVAR Grants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="November2021CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl2" xlink:title="label: November2021CappedValueAppreciationRightsGrantsMember to roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl3" xml:lang="en-US" id="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl3">November 2021 CVARs (Non-vested) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="November2021CappedValueAppreciationRightsGrantsMember" xlink:to="roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl3" xlink:title="label: November2021CappedValueAppreciationRightsGrantsMember to roiv_November2021CappedValueAppreciationRightsGrantsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="CappedValueAppreciationRightsMember" xlink:title="CappedValueAppreciationRightsMember" />
    <link:label xlink:type="resource" xlink:label="roiv_CappedValueAppreciationRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_CappedValueAppreciationRightsMember_lbl" xml:lang="en-US" id="roiv_CappedValueAppreciationRightsMember_lbl">Capped value appreciation rights to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CappedValueAppreciationRightsMember" xlink:to="roiv_CappedValueAppreciationRightsMember_lbl" xlink:title="label: CappedValueAppreciationRightsMember to roiv_CappedValueAppreciationRightsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_CappedValueAppreciationRightsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_CappedValueAppreciationRightsMember_lbl1" xml:lang="en-US" id="roiv_CappedValueAppreciationRightsMember_lbl1">Capped Value Appreciation Rights [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CappedValueAppreciationRightsMember" xlink:to="roiv_CappedValueAppreciationRightsMember_lbl1" xlink:title="label: CappedValueAppreciationRightsMember to roiv_CappedValueAppreciationRightsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_CappedValueAppreciationRightsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_CappedValueAppreciationRightsMember_lbl2" xml:lang="en-US" id="roiv_CappedValueAppreciationRightsMember_lbl2">CVARs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CappedValueAppreciationRightsMember" xlink:to="roiv_CappedValueAppreciationRightsMember_lbl2" xlink:title="label: CappedValueAppreciationRightsMember to roiv_CappedValueAppreciationRightsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:title="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" />
    <link:label xlink:type="resource" xlink:label="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl" xml:lang="en-US" id="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl">Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl" xlink:title="label: FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour to roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl1" xml:lang="en-US" id="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl1">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl1" xlink:title="label: FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour to roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl1" />
    <link:label xlink:type="resource" xlink:label="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl2" xml:lang="en-US" id="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl2">Future amortization expense, thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl2" xlink:title="label: FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour to roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>roiv-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://roivant.com/role/NetIncomeLossPerCommonShareDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#NetIncomeLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails" />
  <link:roleRef roleURI="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails" />
  <link:roleRef roleURI="http://roivant.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#ShareholdersEquityDetails" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtCreditFacilityWithXyqLuxcoDetails" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtFundingAgreementWithNovaquestDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsAccruedExpensesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsOtherCurrentAssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactionsTelavantDispositionDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactionsTelavantDispositionDetails" />
  <link:roleRef roleURI="http://roivant.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#EquityMethodInvestmentsInvestmentInDatavantDetails" />
  <link:roleRef roleURI="http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#EquityMethodInvestmentsInvestmentInArbutusDetails" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails" xlink:type="simple" xlink:href="roiv-20231231.xsd#DescriptionOfBusinessAndLiquidityDetails" />
  <link:roleRef roleURI="http://roivant.com/role/NetIncomeLossPerCommonShareTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#NetIncomeLossPerCommonShareTables" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurementsTables" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensationTables" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebtTables" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponentsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponentsTables" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactionsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactionsTables" />
  <link:roleRef roleURI="http://roivant.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://roivant.com/role/NetIncomeLossPerCommonShare" xlink:type="simple" xlink:href="roiv-20231231.xsd#NetIncomeLossPerCommonShare" />
  <link:roleRef roleURI="http://roivant.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="roiv-20231231.xsd#FairValueMeasurements" />
  <link:roleRef roleURI="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants" xlink:type="simple" xlink:href="roiv-20231231.xsd#EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants" />
  <link:roleRef roleURI="http://roivant.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="roiv-20231231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://roivant.com/role/IncomeTaxes" xlink:type="simple" xlink:href="roiv-20231231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://roivant.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="roiv-20231231.xsd#SharebasedCompensation" />
  <link:roleRef roleURI="http://roivant.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="roiv-20231231.xsd#ShareholdersEquity" />
  <link:roleRef roleURI="http://roivant.com/role/LongtermDebt" xlink:type="simple" xlink:href="roiv-20231231.xsd#LongtermDebt" />
  <link:roleRef roleURI="http://roivant.com/role/CertainBalanceSheetComponents" xlink:type="simple" xlink:href="roiv-20231231.xsd#CertainBalanceSheetComponents" />
  <link:roleRef roleURI="http://roivant.com/role/RecentTransactions" xlink:type="simple" xlink:href="roiv-20231231.xsd#RecentTransactions" />
  <link:roleRef roleURI="http://roivant.com/role/IntangibleAssets" xlink:type="simple" xlink:href="roiv-20231231.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://roivant.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="roiv-20231231.xsd#EquityMethodInvestments" />
  <link:roleRef roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="roiv-20231231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" xlink:type="simple" xlink:href="roiv-20231231.xsd#DescriptionOfBusinessAndLiquidity" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="roiv-20231231.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://roivant.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="roiv-20231231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="CountryRegion" xlink:title="CountryRegion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CountryRegion" xlink:title="presentation: CoverAbstract to CountryRegion" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityExTransitionPeriod" xlink:title="presentation: CoverAbstract to EntityExTransitionPeriod" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="InvestmentsFairValueDisclosure" xlink:title="presentation: AssetsAbstract to InvestmentsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LongTermDebtCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="LiabilityInstrumentsMeasuredAtFairValue" xlink:title="LiabilityInstrumentsMeasuredAtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilityInstrumentsMeasuredAtFairValue" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilityInstrumentsMeasuredAtFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermDebt" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="MinorityInterest" xlink:title="presentation: StockholdersEquityAbstract to MinorityInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="ShorttermDebtFairValue" xlink:title="ShorttermDebtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ShorttermDebtFairValue" xlink:title="presentation: LiabilitiesCurrentAbstract to ShorttermDebtFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermDebtFairValue" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermDebtFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to StockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ProductMember" xlink:title="presentation: ProductsAndServicesDomain to ProductMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LicenseMilestoneAndOtherRevenueMember" xlink:label="LicenseMilestoneAndOtherRevenueMember" xlink:title="LicenseMilestoneAndOtherRevenueMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseMilestoneAndOtherRevenueMember" xlink:title="presentation: ProductsAndServicesDomain to LicenseMilestoneAndOtherRevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: StatementTable to ProductOrServiceAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: RevenuesAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="presentation: StatementLineItems to RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OperatingCosts" xlink:label="OperatingCosts" xlink:title="OperatingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingCosts" xlink:title="presentation: OperatingExpensesAbstract to OperatingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="AcquiredInProcessResearchAndDevelopmentExpense" xlink:title="AcquiredInProcessResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="AcquiredInProcessResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to AcquiredInProcessResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to SellingGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: StatementLineItems to OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GainLossOnSaleOfAssets" xlink:title="presentation: StatementLineItems to GainLossOnSaleOfAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="presentation: StatementLineItems to OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="GainLossOnInvestments" xlink:title="GainLossOnInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GainLossOnInvestments" xlink:title="presentation: StatementLineItems to GainLossOnInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="GainLossOnFairValueOfDebtAndLiabilityInstruments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="presentation: StatementLineItems to GainLossOnFairValueOfDebtAndLiabilityInstruments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DeconsolidationGainOrLossAmount" xlink:title="presentation: StatementLineItems to DeconsolidationGainOrLossAmount" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InterestIncome" xlink:label="InterestIncome" xlink:title="InterestIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="InterestIncome" xlink:title="presentation: StatementLineItems to InterestIncome" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="presentation: StatementLineItems to InterestExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: StatementLineItems to OtherNonoperatingIncomeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: StatementLineItems to IncomeTaxExpenseBenefit" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProfitLoss" xlink:title="presentation: StatementLineItems to ProfitLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="presentation: StatementLineItems to NetIncomeLossAttributableToNoncontrollingInterest" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: StatementLineItems to NetIncomeLoss" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: StatementLineItems to EarningsPerShareAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfSharesOutstandingAbstract" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: StatementTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensation" xlink:title="presentation: StatementLineItems to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ProfitLoss" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="OtherComprehensiveIncomeLossTaxAbstract" xlink:title="OtherComprehensiveIncomeLossTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossTaxAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeLossTaxAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossTaxAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeLossTaxAbstract to OtherComprehensiveIncomeLossNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="OtherComprehensiveIncomeLossTaxAbstract" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to OtherComprehensiveIncomeLossTaxAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ComprehensiveIncomeNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="RedeemableNoncontrollingInterestMember" xlink:title="RedeemableNoncontrollingInterestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RedeemableNoncontrollingInterestMember" xlink:title="presentation: StatementEquityComponentsAxis to RedeemableNoncontrollingInterestMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="presentation: StatementEquityComponentsAxis to AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="NoncontrollingInterestMember" xlink:title="NoncontrollingInterestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="NoncontrollingInterestMember" xlink:title="presentation: StatementEquityComponentsAxis to NoncontrollingInterestMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:title="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:title="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2" xlink:title="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2" xlink:title="presentation: IncreaseDecreaseInTemporaryEquityRollForward to TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInTemporaryEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:label="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:title="NoncontrollingInterestIncreaseDecreaseFromDisposition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NoncontrollingInterestIncreaseDecreaseFromDisposition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NoncontrollingInterestIncreaseDecreaseFromDisposition" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:title="StockIssuedDuringPeriodValueNetIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNetIssuanceCosts" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNetIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:title="StockIssuedDuringPeriodSharesNetIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNetIssuanceCosts" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNetIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to IssuanceOfSubsidiaryCommonSharesToTheCompanyShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:label="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:title="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:label="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:title="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:label="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:title="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NoncontrollingInterestIncreaseDecreaseFromDeconsolidation" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:label="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:title="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:label="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:title="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:label="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:title="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:label="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:title="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:label="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:title="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="CapitalContributionsToSubsidiaries" xlink:title="CapitalContributionsToSubsidiaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CapitalContributionsToSubsidiaries" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CapitalContributionsToSubsidiaries" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DividendDeclaredBySubsidiary" xlink:label="DividendDeclaredBySubsidiary" xlink:title="DividendDeclaredBySubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DividendDeclaredBySubsidiary" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DividendDeclaredBySubsidiary" order="26.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:title="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ProfitLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ProfitLoss" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ProfitLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="NonCashAcquiredInProcessResearchAndDevelopment" xlink:title="NonCashAcquiredInProcessResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NonCashAcquiredInProcessResearchAndDevelopment" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NonCashAcquiredInProcessResearchAndDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="GainLossOnInvestments" xlink:title="GainLossOnInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnInvestments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="GainLossOnFairValueOfDebtAndLiabilityInstruments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnFairValueOfDebtAndLiabilityInstruments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DeconsolidationGainOrLossAmount" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DeconsolidationGainOrLossAmount" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets1" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherNoncashIncomeExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherNoncashIncomeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="IncreaseDecreaseInOtherCurrentAssets" xlink:title="IncreaseDecreaseInOtherCurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherCurrentAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableTrade" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableTrade" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="IncreaseDecreaseInOtherOperatingCapitalNet" xlink:title="IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingCapitalNet" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingCapitalNet" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="MilestonePayments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to MilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:label="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:title="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromSaleOfAssets" xlink:label="ProceedsFromSaleOfAssets" xlink:title="ProceedsFromSaleOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="CashDivestedFromDeconsolidation" xlink:title="CashDivestedFromDeconsolidation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="CashDivestedFromDeconsolidation" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to CashDivestedFromDeconsolidation" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="PaymentsForProceedsFromOtherInvestingActivities" xlink:title="PaymentsForProceedsFromOtherInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsForProceedsFromOtherInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsForProceedsFromOtherInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:title="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:title="ProceedsFromSubsidiaryDebtFinancingsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromSubsidiaryDebtFinancingsNet" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromSubsidiaryDebtFinancingsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentsOfSubsidiaryDividends" xlink:label="PaymentsOfSubsidiaryDividends" xlink:title="PaymentsOfSubsidiaryDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfSubsidiaryDividends" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfSubsidiaryDividends" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:title="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentForOfferingAndLoanCosts" xlink:label="PaymentForOfferingAndLoanCosts" xlink:title="PaymentForOfferingAndLoanCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentForOfferingAndLoanCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentForOfferingAndLoanCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:label="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:title="PaymentsOfTaxesForTheRepurchaseOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfTaxesForTheRepurchaseOfEquity" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfTaxesForTheRepurchaseOfEquity" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="ProceedsFromStockPlans" xlink:title="ProceedsFromStockPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockPlans" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockPlans" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromWarrantExercises" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PaymentForWarrantRedemptions" xlink:label="PaymentForWarrantRedemptions" xlink:title="PaymentForWarrantRedemptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentForWarrantRedemptions" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentForWarrantRedemptions" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:label="CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:title="CashlessExerciseOfTheCompanyCommonStockWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CashlessExerciseOfTheCompanyCommonStockWarrants" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to CashlessExerciseOfTheCompanyCommonStockWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:label="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:title="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NoncashOther" xlink:label="NoncashOther" xlink:title="NoncashOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NoncashOther" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to NoncashOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidity">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DescriptionOfBusinessAndLiquidityAbstract" xlink:label="DescriptionOfBusinessAndLiquidityAbstract" xlink:title="DescriptionOfBusinessAndLiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:title="BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessAndLiquidityAbstract" xlink:to="BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:title="presentation: DescriptionOfBusinessAndLiquidityAbstract to BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/EquityMethodInvestments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:title="EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="EquityMethodInvestmentsDisclosureTextBlock" xlink:title="EquityMethodInvestmentsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="EquityMethodInvestmentsDisclosureTextBlock" xlink:title="presentation: EquityMethodInvestmentsAndJointVenturesAbstract to EquityMethodInvestmentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IntangibleAssets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactions">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RecentTransactionsAbstract" xlink:label="RecentTransactionsAbstract" xlink:title="RecentTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RecentTransactionsTextBlock" xlink:label="RecentTransactionsTextBlock" xlink:title="RecentTransactionsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RecentTransactionsAbstract" xlink:to="RecentTransactionsTextBlock" xlink:title="presentation: RecentTransactionsAbstract to RecentTransactionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponents">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CertainBalanceSheetComponentsAbstract" xlink:label="CertainBalanceSheetComponentsAbstract" xlink:title="CertainBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="presentation: CertainBalanceSheetComponentsAbstract to SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract to EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetIncomeLossPerCommonShare">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConsolidationPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="CommitmentsAndContingenciesPolicyTextBlock" xlink:title="CommitmentsAndContingenciesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CommitmentsAndContingenciesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CommitmentsAndContingenciesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="InvestmentPolicyTextBlock" xlink:title="InvestmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InvestmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InvestmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to FairValueMeasurementPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:title="ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IntangibleAssetsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:label="ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:title="ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactionsTables">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RecentTransactionsAbstract" xlink:label="RecentTransactionsAbstract" xlink:title="RecentTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:label="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:title="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RecentTransactionsAbstract" xlink:to="ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" xlink:title="presentation: RecentTransactionsAbstract to ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsTables">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CertainBalanceSheetComponentsAbstract" xlink:label="CertainBalanceSheetComponentsAbstract" xlink:title="CertainBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:title="ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:title="presentation: CertainBalanceSheetComponentsAbstract to ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: CertainBalanceSheetComponentsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="OtherCurrentLiabilitiesTableTextBlock" xlink:title="OtherCurrentLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="OtherCurrentLiabilitiesTableTextBlock" xlink:title="presentation: CertainBalanceSheetComponentsAbstract to OtherCurrentLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to DermavantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: DebtInstrumentTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestMember" xlink:label="FundingAgreementWithNovaQuestMember" xlink:title="FundingAgreementWithNovaQuestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="FundingAgreementWithNovaQuestMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to FundingAgreementWithNovaQuestMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CreditFacilityWithXYQLuxcoMember" xlink:label="CreditFacilityWithXYQLuxcoMember" xlink:title="CreditFacilityWithXYQLuxcoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CreditFacilityWithXYQLuxcoMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CreditFacilityWithXYQLuxcoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:label="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: DebtInstrumentTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="ScheduleOfDebtInstrumentsTextBlock" xlink:title="presentation: DebtInstrumentLineItems to ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:label="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DatavantHoldingsIncMember" xlink:label="DatavantHoldingsIncMember" xlink:title="DatavantHoldingsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="DatavantHoldingsIncMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to DatavantHoldingsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnoutSharesMember" xlink:label="EarnoutSharesMember" xlink:title="EarnoutSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="EarnoutSharesMember" xlink:title="presentation: EquityComponentDomain to EarnoutSharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetIncomeLossPerCommonShareTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DescriptionOfBusinessAndLiquidityAbstract" xlink:label="DescriptionOfBusinessAndLiquidityAbstract" xlink:title="DescriptionOfBusinessAndLiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DescriptionOfBusinessAbstract" xlink:label="DescriptionOfBusinessAbstract" xlink:title="DescriptionOfBusinessAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: DescriptionOfBusinessAbstract to NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessAbstract" xlink:to="NumberOfReportableSegments" xlink:title="presentation: DescriptionOfBusinessAbstract to NumberOfReportableSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessAndLiquidityAbstract" xlink:to="DescriptionOfBusinessAbstract" xlink:title="presentation: DescriptionOfBusinessAndLiquidityAbstract to DescriptionOfBusinessAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TelavantHoldingsIncMember" xlink:label="TelavantHoldingsIncMember" xlink:title="TelavantHoldingsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="TelavantHoldingsIncMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to TelavantHoldingsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="GainLossOnSaleOfAssets" xlink:title="presentation: LiquidityAbstract to GainLossOnSaleOfAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: LiquidityAbstract to CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: LiquidityAbstract to RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="ProfitLoss" xlink:title="presentation: LiquidityAbstract to ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="LiquidityAbstract" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to LiquidityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessAndLiquidityAbstract" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="presentation: DescriptionOfBusinessAndLiquidityAbstract to ScheduleOfEquityMethodInvestmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="RestrictedCashCurrent" xlink:title="presentation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract to RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="RestrictedCashNoncurrent" xlink:title="presentation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract to RestrictedCashNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:title="presentation: AccountingPoliciesAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:title="EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="ArbutusBiopharmaCorporationMember" xlink:title="ArbutusBiopharmaCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="ArbutusBiopharmaCorporationMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to ArbutusBiopharmaCorporationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InvestmentsDisclosureAbstract" xlink:label="InvestmentsDisclosureAbstract" xlink:title="InvestmentsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: InvestmentsDisclosureAbstract to CommonStockSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: InvestmentsDisclosureAbstract to EquityMethodInvestmentOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="InvestmentsFairValueDisclosure" xlink:title="presentation: InvestmentsDisclosureAbstract to InvestmentsFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="presentation: InvestmentsDisclosureAbstract to UnrealizedGainLossOnInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="SharePrice" xlink:title="presentation: InvestmentsDisclosureAbstract to SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="InvestmentsDisclosureAbstract" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to InvestmentsDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="presentation: EquityMethodInvestmentsAndJointVenturesAbstract to ScheduleOfEquityMethodInvestmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:title="EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CioxParentMember" xlink:label="CioxParentMember" xlink:title="CioxParentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="CioxParentMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to CioxParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_InvestmentsDisclosureAbstract" xlink:label="InvestmentsDisclosureAbstract" xlink:title="InvestmentsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: InvestmentsDisclosureAbstract to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="InvestmentsFairValueDisclosure" xlink:title="presentation: InvestmentsDisclosureAbstract to InvestmentsFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDisclosureAbstract" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="presentation: InvestmentsDisclosureAbstract to UnrealizedGainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="InvestmentsDisclosureAbstract" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to InvestmentsDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="presentation: EquityMethodInvestmentsAndJointVenturesAbstract to ScheduleOfEquityMethodInvestmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:title="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:label="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:title="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_WelichemBiotechIncMember" xlink:label="WelichemBiotechIncMember" xlink:title="WelichemBiotechIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="WelichemBiotechIncMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to WelichemBiotechIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable to CounterpartyNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="presentation: IncomeStatementLocationDomain to CostOfSalesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable to IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:title="AcquiredFiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IntangibleAssetAbstract" xlink:label="IntangibleAssetAbstract" xlink:title="IntangibleAssetAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePayable" xlink:label="MilestonePayable" xlink:title="MilestonePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="MilestonePayable" xlink:title="presentation: IntangibleAssetAbstract to MilestonePayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePaid" xlink:label="MilestonePaid" xlink:title="MilestonePaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="MilestonePaid" xlink:title="presentation: IntangibleAssetAbstract to MilestonePaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to IntangibleAssetsNetExcludingGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: IntangibleAssetAbstract to FiniteLivedIntangibleAssetsNetAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: IntangibleAssetAbstract to AmortizationOfIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="presentation: IntangibleAssetAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="presentation: IntangibleAssetAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="presentation: IntangibleAssetAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="presentation: IntangibleAssetAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="presentation: IntangibleAssetAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:title="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetAbstract" xlink:to="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:title="presentation: IntangibleAssetAbstract to FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="IntangibleAssetAbstract" xlink:title="presentation: AcquiredFiniteLivedIntangibleAssetsLineItems to IntangibleAssetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable to AcquiredFiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactionsTelavantDispositionDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RecentTransactionsAbstract" xlink:label="RecentTransactionsAbstract" xlink:title="RecentTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TelavantHoldingsIncMember" xlink:label="TelavantHoldingsIncMember" xlink:title="TelavantHoldingsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="TelavantHoldingsIncMember" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to TelavantHoldingsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RocheTransactionMember" xlink:label="RocheTransactionMember" xlink:title="RocheTransactionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="RocheTransactionMember" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to RocheTransactionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RSLMember" xlink:label="RSLMember" xlink:title="RSLMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="RSLMember" xlink:title="presentation: EquityComponentDomain to RSLMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PfizerMember" xlink:label="PfizerMember" xlink:title="PfizerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="PfizerMember" xlink:title="presentation: EquityComponentDomain to PfizerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupAbstract" xlink:label="DisposalGroupAbstract" xlink:title="DisposalGroupAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OwnershipPercentage" xlink:label="OwnershipPercentage" xlink:title="OwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupAbstract" xlink:to="OwnershipPercentage" xlink:title="presentation: DisposalGroupAbstract to OwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupConsiderationAbstract" xlink:label="DisposalGroupConsiderationAbstract" xlink:title="DisposalGroupConsiderationAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UpfrontCashPaymentReceivedForSaleOfAssets" xlink:label="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:title="UpfrontCashPaymentReceivedForSaleOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupConsiderationAbstract" xlink:to="UpfrontCashPaymentReceivedForSaleOfAssets" xlink:title="presentation: DisposalGroupConsiderationAbstract to UpfrontCashPaymentReceivedForSaleOfAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:label="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:title="FutureMilestoneToBeReceivedFromSaleOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupConsiderationAbstract" xlink:to="FutureMilestoneToBeReceivedFromSaleOfAssets" xlink:title="presentation: DisposalGroupConsiderationAbstract to FutureMilestoneToBeReceivedFromSaleOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:label="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:title="DisposalGroupNoncontrollingInterestDerecognizedValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupConsiderationAbstract" xlink:to="DisposalGroupNoncontrollingInterestDerecognizedValue" xlink:title="presentation: DisposalGroupConsiderationAbstract to DisposalGroupNoncontrollingInterestDerecognizedValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ConsiderationReceivedForSaleOfAssets" xlink:label="ConsiderationReceivedForSaleOfAssets" xlink:title="ConsiderationReceivedForSaleOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupConsiderationAbstract" xlink:to="ConsiderationReceivedForSaleOfAssets" xlink:title="presentation: DisposalGroupConsiderationAbstract to ConsiderationReceivedForSaleOfAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:to="DisposalGroupConsiderationAbstract" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract to DisposalGroupConsiderationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupAssets" xlink:label="DisposalGroupAssets" xlink:title="DisposalGroupAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:to="DisposalGroupAssets" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract to DisposalGroupAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupLiabilities" xlink:label="DisposalGroupLiabilities" xlink:title="DisposalGroupLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:to="DisposalGroupLiabilities" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract to DisposalGroupLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DisposalGroupNetAssetsLiabilities" xlink:label="DisposalGroupNetAssetsLiabilities" xlink:title="DisposalGroupNetAssetsLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:to="DisposalGroupNetAssetsLiabilities" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract to DisposalGroupNetAssetsLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GainLossOnSaleOfAssets" xlink:label="GainLossOnSaleOfAssets" xlink:title="GainLossOnSaleOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:to="GainLossOnSaleOfAssets" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract to GainLossOnSaleOfAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupAbstract" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" xlink:title="presentation: DisposalGroupAbstract to DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:label="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:title="IncomeLossFromDisposalGroupBeforeIncomeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupAbstract" xlink:to="IncomeLossFromDisposalGroupBeforeIncomeTax" xlink:title="presentation: DisposalGroupAbstract to IncomeLossFromDisposalGroupBeforeIncomeTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupAbstract" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RecentTransactionsAbstract" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="presentation: RecentTransactionsAbstract to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RecentTransactionsAbstract" xlink:label="RecentTransactionsAbstract" xlink:title="RecentTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="AssetAcquisitionTable" xlink:title="AssetAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_VantAIPreferredFinancingMember" xlink:label="VantAIPreferredFinancingMember" xlink:title="VantAIPreferredFinancingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="VantAIPreferredFinancingMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to VantAIPreferredFinancingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: AssetAcquisitionTable to SubsidiarySaleOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SKIncMember" xlink:label="SKIncMember" xlink:title="SKIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="SKIncMember" xlink:title="presentation: RelatedPartyDomain to SKIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SKBiopharmaceuticalsCoLtdMember" xlink:label="SKBiopharmaceuticalsCoLtdMember" xlink:title="SKBiopharmaceuticalsCoLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="SKBiopharmaceuticalsCoLtdMember" xlink:title="presentation: RelatedPartyDomain to SKBiopharmaceuticalsCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: AssetAcquisitionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProteovantSciencesIncMember" xlink:label="ProteovantSciencesIncMember" xlink:title="ProteovantSciencesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="ProteovantSciencesIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to ProteovantSciencesIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NewlyFormedSubsidiaryMember" xlink:label="NewlyFormedSubsidiaryMember" xlink:title="NewlyFormedSubsidiaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NewlyFormedSubsidiaryMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NewlyFormedSubsidiaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: AssetAcquisitionTable to BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionTable" xlink:to="RangeAxis" xlink:title="presentation: AssetAcquisitionTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="AssetAcquisitionLineItems" xlink:title="AssetAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="AssetAcquisitionAbstract" xlink:title="AssetAcquisitionAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UpfrontCashPayment" xlink:label="UpfrontCashPayment" xlink:title="UpfrontCashPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAbstract" xlink:to="UpfrontCashPayment" xlink:title="presentation: AssetAcquisitionAbstract to UpfrontCashPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:label="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:title="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAbstract" xlink:to="AssetAcquisitionResearchAndDevelopmentExpenseInProcess" xlink:title="presentation: AssetAcquisitionAbstract to AssetAcquisitionResearchAndDevelopmentExpenseInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MilestonePaymentPayable" xlink:label="MilestonePaymentPayable" xlink:title="MilestonePaymentPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAbstract" xlink:to="MilestonePaymentPayable" xlink:title="presentation: AssetAcquisitionAbstract to MilestonePaymentPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionLineItems" xlink:to="AssetAcquisitionAbstract" xlink:title="presentation: AssetAcquisitionLineItems to AssetAcquisitionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DeconsolidationOfSubsidiariesAbstract" xlink:label="DeconsolidationOfSubsidiariesAbstract" xlink:title="DeconsolidationOfSubsidiariesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:title="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeconsolidationOfSubsidiariesAbstract" xlink:to="PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:title="presentation: DeconsolidationOfSubsidiariesAbstract to PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeconsolidationOfSubsidiariesAbstract" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: DeconsolidationOfSubsidiariesAbstract to ProceedsFromIssuanceOrSaleOfEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="DeconsolidationGainOrLossAmount" xlink:title="DeconsolidationGainOrLossAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeconsolidationOfSubsidiariesAbstract" xlink:to="DeconsolidationGainOrLossAmount" xlink:title="presentation: DeconsolidationOfSubsidiariesAbstract to DeconsolidationGainOrLossAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeconsolidationOfSubsidiariesAbstract" xlink:to="InvestmentsFairValueDisclosure" xlink:title="presentation: DeconsolidationOfSubsidiariesAbstract to InvestmentsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionLineItems" xlink:to="DeconsolidationOfSubsidiariesAbstract" xlink:title="presentation: AssetAcquisitionLineItems to DeconsolidationOfSubsidiariesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionTable" xlink:to="AssetAcquisitionLineItems" xlink:title="presentation: AssetAcquisitionTable to AssetAcquisitionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RecentTransactionsAbstract" xlink:to="AssetAcquisitionTable" xlink:title="presentation: RecentTransactionsAbstract to AssetAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CertainBalanceSheetComponentsAbstract" xlink:label="CertainBalanceSheetComponentsAbstract" xlink:title="CertainBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="PrepaidExpenseCurrent" xlink:title="PrepaidExpenseCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidExpenseCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ReceivablesNetCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to ReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="RestrictedCashCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to RestrictedCashCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="IncomeTaxesReceivable" xlink:title="IncomeTaxesReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="IncomeTaxesReceivable" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to IncomeTaxesReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="InterestReceivable" xlink:title="InterestReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="InterestReceivable" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to InterestReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherOfOtherAssetsCurrent" xlink:label="OtherOfOtherAssetsCurrent" xlink:title="OtherOfOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="OtherOfOtherAssetsCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to OtherOfOtherAssetsCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="OtherAssetsCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to OtherAssetsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="presentation: CertainBalanceSheetComponentsAbstract to PrepaidExpenseAndOtherAssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CertainBalanceSheetComponentsAbstract" xlink:label="CertainBalanceSheetComponentsAbstract" xlink:title="CertainBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="AccruedResearchAndDevelopmentExpensesCurrent" xlink:title="AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedResearchAndDevelopmentExpensesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedResearchAndDevelopmentExpensesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_AccruedSalesAllowancesCurrent" xlink:label="AccruedSalesAllowancesCurrent" xlink:title="AccruedSalesAllowancesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedSalesAllowancesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedSalesAllowancesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to OtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="AccruedLiabilitiesCurrentAbstract" xlink:title="presentation: CertainBalanceSheetComponentsAbstract to AccruedLiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CertainBalanceSheetComponentsAbstract" xlink:label="CertainBalanceSheetComponentsAbstract" xlink:title="CertainBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="OtherLiabilitiesCurrentAbstract" xlink:title="OtherLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="presentation: OtherLiabilitiesCurrentAbstract to DeferredRevenueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesCurrentAbstract" xlink:to="TaxesPayableCurrent" xlink:title="presentation: OtherLiabilitiesCurrentAbstract to TaxesPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="OtherSundryLiabilitiesCurrent" xlink:title="OtherSundryLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesCurrentAbstract" xlink:to="OtherSundryLiabilitiesCurrent" xlink:title="presentation: OtherLiabilitiesCurrentAbstract to OtherSundryLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="presentation: OtherLiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainBalanceSheetComponentsAbstract" xlink:to="OtherLiabilitiesCurrentAbstract" xlink:title="presentation: CertainBalanceSheetComponentsAbstract to OtherLiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to DermavantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: DebtInstrumentTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestMember" xlink:label="FundingAgreementWithNovaQuestMember" xlink:title="FundingAgreementWithNovaQuestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="FundingAgreementWithNovaQuestMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to FundingAgreementWithNovaQuestMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: DebtInstrumentTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: DebtInstrumentTable to StatementScenarioAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FundingAgreementWithNovaQuestAbstract" xlink:label="FundingAgreementWithNovaQuestAbstract" xlink:title="FundingAgreementWithNovaQuestAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="ProceedsFromIssuanceOfDebt" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to ProceedsFromIssuanceOfDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to DebtInstrumentFrequencyOfPeriodicPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:label="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:title="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="TotalRequiredDebtInstrumentQuarterlyPaymentsMade" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to TotalRequiredDebtInstrumentQuarterlyPaymentsMade" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to DebtInstrumentTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="MaximumMilestonePaymentObligation" xlink:title="MaximumMilestonePaymentObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="MaximumMilestonePaymentObligation" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to MaximumMilestonePaymentObligation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="MaximumMilestonePaymentOffsetAmount" xlink:title="MaximumMilestonePaymentOffsetAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="MaximumMilestonePaymentOffsetAmount" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to MaximumMilestonePaymentOffsetAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentQuarterlyPaymentsMade" xlink:label="DebtInstrumentQuarterlyPaymentsMade" xlink:title="DebtInstrumentQuarterlyPaymentsMade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FundingAgreementWithNovaQuestAbstract" xlink:to="DebtInstrumentQuarterlyPaymentsMade" xlink:title="presentation: FundingAgreementWithNovaQuestAbstract to DebtInstrumentQuarterlyPaymentsMade" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="FundingAgreementWithNovaQuestAbstract" xlink:title="presentation: DebtInstrumentLineItems to FundingAgreementWithNovaQuestAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermDebtCurrentAndNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="DebtInstrumentFairValue" xlink:title="DebtInstrumentFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentFairValue" xlink:title="presentation: LongtermDebtCurrentAndNoncurrentAbstract to DebtInstrumentFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="ShorttermDebtFairValue" xlink:title="ShorttermDebtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="ShorttermDebtFairValue" xlink:title="presentation: LongtermDebtCurrentAndNoncurrentAbstract to ShorttermDebtFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="LongTermDebtFairValue" xlink:title="presentation: LongtermDebtCurrentAndNoncurrentAbstract to LongTermDebtFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="presentation: DebtInstrumentLineItems to LongtermDebtCurrentAndNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to DermavantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: DebtInstrumentTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CreditFacilityWithXYQLuxcoMember" xlink:label="CreditFacilityWithXYQLuxcoMember" xlink:title="CreditFacilityWithXYQLuxcoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CreditFacilityWithXYQLuxcoMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CreditFacilityWithXYQLuxcoMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: DebtInstrumentTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LoanAndCreditAgreementsByDermavantAbstract" xlink:label="LoanAndCreditAgreementsByDermavantAbstract" xlink:title="LoanAndCreditAgreementsByDermavantAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="ProceedsFromLinesOfCredit" xlink:title="ProceedsFromLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="ProceedsFromLinesOfCredit" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to ProceedsFromLinesOfCredit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to DebtInstrumentTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to DebtInstrumentInterestRateStatedPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:title="DebtInstrumentExitFeeAndEndOfTermCharge" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="DebtInstrumentExitFeeAndEndOfTermCharge" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to DebtInstrumentExitFeeAndEndOfTermCharge" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="DebtInstrumentFeeAmount" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to DebtInstrumentFeeAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="DebtInstrumentCarryingAmount" xlink:title="presentation: LongTermDebtAbstract to DebtInstrumentCarryingAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="DebtInstrumentExitFee" xlink:title="presentation: LongTermDebtAbstract to DebtInstrumentExitFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="presentation: LongTermDebtAbstract to DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebt" xlink:title="presentation: LongTermDebtAbstract to LongTermDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebtCurrent" xlink:title="presentation: LongTermDebtAbstract to LongTermDebtCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebtNoncurrent" xlink:title="presentation: LongTermDebtAbstract to LongTermDebtNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndCreditAgreementsByDermavantAbstract" xlink:to="LongTermDebtAbstract" xlink:title="presentation: LoanAndCreditAgreementsByDermavantAbstract to LongTermDebtAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LoanAndCreditAgreementsByDermavantAbstract" xlink:title="presentation: DebtInstrumentLineItems to LoanAndCreditAgreementsByDermavantAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DermavantMember" xlink:label="DermavantMember" xlink:title="DermavantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="DermavantMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to DermavantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: DebtInstrumentTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:label="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: DebtInstrumentTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:label="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:title="RevenueInterestPurchaseAndSaleAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:label="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:title="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:to="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:title="presentation: RevenueInterestPurchaseAndSaleAgreementAbstract to CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRIPSA" xlink:label="CommittedFundingUnderRIPSA" xlink:title="CommittedFundingUnderRIPSA" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:to="CommittedFundingUnderRIPSA" xlink:title="presentation: RevenueInterestPurchaseAndSaleAgreementAbstract to CommittedFundingUnderRIPSA" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:label="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:title="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:to="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" xlink:title="presentation: RevenueInterestPurchaseAndSaleAgreementAbstract to CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="DebtInstrumentCarryingAmount" xlink:title="presentation: LongTermDebtAbstract to DebtInstrumentCarryingAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:title="presentation: LongTermDebtAbstract to DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebt" xlink:title="presentation: LongTermDebtAbstract to LongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebtCurrent" xlink:title="presentation: LongTermDebtAbstract to LongTermDebtCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebtNoncurrent" xlink:title="presentation: LongTermDebtAbstract to LongTermDebtNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:to="LongTermDebtAbstract" xlink:title="presentation: RevenueInterestPurchaseAndSaleAgreementAbstract to LongTermDebtAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="RevenueInterestPurchaseAndSaleAgreementAbstract" xlink:title="presentation: DebtInstrumentLineItems to RevenueInterestPurchaseAndSaleAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CowenAndCompanyLLCMember" xlink:label="CowenAndCompanyLLCMember" xlink:title="CowenAndCompanyLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="CowenAndCompanyLLCMember" xlink:title="presentation: RelatedPartyTransactionDomain to CowenAndCompanyLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RelatedPartyTransactionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EquityOfferingsAtTheMarketMember" xlink:label="EquityOfferingsAtTheMarketMember" xlink:title="EquityOfferingsAtTheMarketMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="EquityOfferingsAtTheMarketMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to EquityOfferingsAtTheMarketMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="UnderwrittenPublicOfferingMember" xlink:title="UnderwrittenPublicOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="UnderwrittenPublicOfferingMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to UnderwrittenPublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantParticipationOfImmunovantStockOfferingMember" xlink:label="RoivantParticipationOfImmunovantStockOfferingMember" xlink:title="RoivantParticipationOfImmunovantStockOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="RoivantParticipationOfImmunovantStockOfferingMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to RoivantParticipationOfImmunovantStockOfferingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="PrivatePlacementMember" xlink:title="PrivatePlacementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="PrivatePlacementMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to PrivatePlacementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfStockByClassTable to TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ImmunovantIncMember" xlink:label="ImmunovantIncMember" xlink:title="ImmunovantIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="ImmunovantIncMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to ImmunovantIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfStockByClassTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RSLMember" xlink:label="RSLMember" xlink:title="RSLMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="RSLMember" xlink:title="presentation: ConsolidatedEntitiesDomain to RSLMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfStockByClassTable to ConsolidatedEntitiesAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesOfferingPriceAuthorized" xlink:label="CommonSharesOfferingPriceAuthorized" xlink:title="CommonSharesOfferingPriceAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="CommonSharesOfferingPriceAuthorized" xlink:title="presentation: StockholdersEquityNoteAbstract to CommonSharesOfferingPriceAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:label="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:title="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" xlink:title="presentation: StockholdersEquityNoteAbstract to CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: StockholdersEquityNoteAbstract to StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="SaleOfStockPricePerShare" xlink:title="presentation: StockholdersEquityNoteAbstract to SaleOfStockPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NetProceedsFromIssuanceOfCommonStock" xlink:label="NetProceedsFromIssuanceOfCommonStock" xlink:title="NetProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="NetProceedsFromIssuanceOfCommonStock" xlink:title="presentation: StockholdersEquityNoteAbstract to NetProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockPurchasedDuringPeriodByEntityShares" xlink:label="StockPurchasedDuringPeriodByEntityShares" xlink:title="StockPurchasedDuringPeriodByEntityShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockPurchasedDuringPeriodByEntityShares" xlink:title="presentation: StockholdersEquityNoteAbstract to StockPurchasedDuringPeriodByEntityShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OptionToPurchaseAdditionalSharesOfCommonStock" xlink:label="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:title="OptionToPurchaseAdditionalSharesOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="OptionToPurchaseAdditionalSharesOfCommonStock" xlink:title="presentation: StockholdersEquityNoteAbstract to OptionToPurchaseAdditionalSharesOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:label="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:title="EstimatedNetProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="EstimatedNetProceedsFromIssuanceOfCommonStock" xlink:title="presentation: StockholdersEquityNoteAbstract to EstimatedNetProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OwnershipPercentage" xlink:label="OwnershipPercentage" xlink:title="OwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="OwnershipPercentage" xlink:title="presentation: StockholdersEquityNoteAbstract to OwnershipPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="presentation: ClassOfStockLineItems to StockholdersEquityNoteAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="StockOptionsAndPerformanceStockOptionsMember" xlink:title="StockOptionsAndPerformanceStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionsAndPerformanceStockOptionsMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionsAndPerformanceStockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtdEquityPlansMember" xlink:label="RoivantSciencesLtdEquityPlansMember" xlink:title="RoivantSciencesLtdEquityPlansMember" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:label="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="RoivantSciencesLtd2021EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoivantSciencesLtdEquityPlansMember" xlink:to="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="presentation: RoivantSciencesLtdEquityPlansMember to RoivantSciencesLtd2021EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="RoivantSciencesLtdEquityPlansMember" xlink:title="presentation: PlanNameDomain to RoivantSciencesLtdEquityPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="NumberOfEquityIncentivePlans" xlink:title="presentation: ShareBasedCompensationAbstract to NumberOfEquityIncentivePlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: ShareBasedCompensationAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="RestrictedStockAndPerformanceStockUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockAndPerformanceStockUnitsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtdEquityPlansMember" xlink:label="RoivantSciencesLtdEquityPlansMember" xlink:title="RoivantSciencesLtdEquityPlansMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="RoivantSciencesLtdEquityPlansMember" xlink:title="presentation: PlanNameDomain to RoivantSciencesLtdEquityPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="CappedValueAppreciationRightsMember" xlink:title="CappedValueAppreciationRightsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="CappedValueAppreciationRightsMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to CappedValueAppreciationRightsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:label="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="RoivantSciencesLtd2021EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="RoivantSciencesLtd2021EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to RoivantSciencesLtd2021EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SubsidiaryEquityIncentivePlansMember" xlink:label="SubsidiaryEquityIncentivePlansMember" xlink:title="SubsidiaryEquityIncentivePlansMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="SubsidiaryEquityIncentivePlansMember" xlink:title="presentation: PlanNameDomain to SubsidiaryEquityIncentivePlansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_March2020CappedValueAppreciationRightsGrantsMember" xlink:label="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="March2020CappedValueAppreciationRightsGrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateDomain" xlink:to="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="presentation: AwardDateDomain to March2020CappedValueAppreciationRightsGrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_November2021CappedValueAppreciationRightsGrantsMember" xlink:label="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="November2021CappedValueAppreciationRightsGrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateDomain" xlink:to="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="presentation: AwardDateDomain to November2021CappedValueAppreciationRightsGrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain" xlink:title="presentation: AwardDateAxis to AwardDateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardDateAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardDateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EquityInstrumentsVestedAndSettledShares" xlink:label="EquityInstrumentsVestedAndSettledShares" xlink:title="EquityInstrumentsVestedAndSettledShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="EquityInstrumentsVestedAndSettledShares" xlink:title="presentation: ShareBasedCompensationAbstract to EquityInstrumentsVestedAndSettledShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SubsidiaryEquityIncentivePlansAbstract" xlink:label="SubsidiaryEquityIncentivePlansAbstract" xlink:title="SubsidiaryEquityIncentivePlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryEquityIncentivePlansAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: SubsidiaryEquityIncentivePlansAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SubsidiaryEquityIncentivePlansAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SubsidiaryEquityIncentivePlansAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="LongTermPurchaseCommitmentTable" xlink:title="LongTermPurchaseCommitmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_SamsungBiologicsCo.Ltd.Member" xlink:label="SamsungBiologicsCo.Ltd.Member" xlink:title="SamsungBiologicsCo.Ltd.Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SamsungBiologicsCo.Ltd.Member" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SamsungBiologicsCo.Ltd.Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PalantirTechnologiesIncMember" xlink:label="PalantirTechnologiesIncMember" xlink:title="PalantirTechnologiesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PalantirTechnologiesIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PalantirTechnologiesIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashBonusProgramMember" xlink:label="CashBonusProgramMember" xlink:title="CashBonusProgramMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CashBonusProgramMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CashBonusProgramMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LongTermPurchaseCommitmentTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_GSKMember" xlink:label="GSKMember" xlink:title="GSKMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="GSKMember" xlink:title="presentation: LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain to GSKMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="presentation: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="presentation: LongTermPurchaseCommitmentTable to LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="ChiefFinancialOfficerMember" xlink:title="ChiefFinancialOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefFinancialOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefFinancialOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: LongTermPurchaseCommitmentTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: LongTermPurchaseCommitmentTable to SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="LongTermPurchaseCommitmentLineItems" xlink:title="LongTermPurchaseCommitmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:label="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:title="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="LongtermPurchaseCommitmentPeriod" xlink:title="LongtermPurchaseCommitmentPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="LongtermPurchaseCommitmentPeriod" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to LongtermPurchaseCommitmentPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:label="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:title="RemainingMinimumPurchaseCommitmentRelatedToAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="RemainingMinimumPurchaseCommitmentRelatedToAgreement" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to RemainingMinimumPurchaseCommitmentRelatedToAgreement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodOfRightToTerminateTheProductServiceAgreement" xlink:label="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:title="PeriodOfRightToTerminateTheProductServiceAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="PeriodOfRightToTerminateTheProductServiceAgreement" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to PeriodOfRightToTerminateTheProductServiceAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" xlink:title="PurchaseObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="PurchaseObligation" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to PurchaseObligation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:label="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:title="PeriodToPurchaseAdditionalBatchesOfBatoclimab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="PeriodToPurchaseAdditionalBatchesOfBatoclimab" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to PeriodToPurchaseAdditionalBatchesOfBatoclimab" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ProprietarySoftwareSubscriptionPeriod" xlink:label="ProprietarySoftwareSubscriptionPeriod" xlink:title="ProprietarySoftwareSubscriptionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="ProprietarySoftwareSubscriptionPeriod" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to ProprietarySoftwareSubscriptionPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:title="PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to PurchaseCommitmentRemainingMinimumAmountCommitted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to EmployeeRelatedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to SellingGeneralAndAdministrativeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to ResearchAndDevelopmentExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:label="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:title="PercentageOfBonusPayableInNext30DaysOfGrantDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="PercentageOfBonusPayableInNext30DaysOfGrantDate" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to PercentageOfBonusPayableInNext30DaysOfGrantDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FiftyPercentBonusPayablePeriodFromGrantDate" xlink:label="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:title="FiftyPercentBonusPayablePeriodFromGrantDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:to="FiftyPercentBonusPayablePeriodFromGrantDate" xlink:title="presentation: LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract to FiftyPercentBonusPayablePeriodFromGrantDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" xlink:title="presentation: LongTermPurchaseCommitmentLineItems to LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LongTermPurchaseCommitmentLineItems" xlink:title="presentation: LongTermPurchaseCommitmentTable to LongTermPurchaseCommitmentLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LongTermPurchaseCommitmentTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LongTermPurchaseCommitmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:label="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:title="PatientSquareCapitalLimitedLiabilityCompanyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="PatientSquareCapitalLimitedLiabilityCompanyMember" xlink:title="presentation: RelatedPartyDomain to PatientSquareCapitalLimitedLiabilityCompanyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsMember" xlink:label="PublicWarrantsMember" xlink:title="PublicWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PublicWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:label="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:title="PublicWarrantsAndPrivatePlacementWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicWarrantsAndPrivatePlacementWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PublicWarrantsAndPrivatePlacementWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TwentyPercentEarnOutSharesMember" xlink:label="TwentyPercentEarnOutSharesMember" xlink:title="TwentyPercentEarnOutSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="TwentyPercentEarnOutSharesMember" xlink:title="presentation: EquityComponentDomain to TwentyPercentEarnOutSharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_TenPercentEarnOutSharesMember" xlink:label="TenPercentEarnOutSharesMember" xlink:title="TenPercentEarnOutSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="TenPercentEarnOutSharesMember" xlink:title="presentation: EquityComponentDomain to TenPercentEarnOutSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="RangeAxis" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:label="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:title="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesAbstract" xlink:label="EarnOutSharesAbstract" xlink:title="EarnOutSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: EarnOutSharesAbstract to StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PercentageOfEarnOutShares" xlink:label="PercentageOfEarnOutShares" xlink:title="PercentageOfEarnOutShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesAbstract" xlink:to="PercentageOfEarnOutShares" xlink:title="presentation: EarnOutSharesAbstract to PercentageOfEarnOutShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharePrice" xlink:label="EarnOutSharePrice" xlink:title="EarnOutSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesAbstract" xlink:to="EarnOutSharePrice" xlink:title="presentation: EarnOutSharesAbstract to EarnOutSharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:label="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:title="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesAbstract" xlink:to="NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" xlink:title="presentation: EarnOutSharesAbstract to NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:label="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:title="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesAbstract" xlink:to="NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" xlink:title="presentation: EarnOutSharesAbstract to NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfEarnOutSharesVested" xlink:label="NumberOfEarnOutSharesVested" xlink:title="NumberOfEarnOutSharesVested" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesAbstract" xlink:to="NumberOfEarnOutSharesVested" xlink:title="presentation: EarnOutSharesAbstract to NumberOfEarnOutSharesVested" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="EarnOutSharesAbstract" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to EarnOutSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:label="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="PublicWarrantsAndPrivatePlacementWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PeriodToExerciseWarrantsAfterBusinessCombination" xlink:label="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:title="PeriodToExerciseWarrantsAfterBusinessCombination" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="PeriodToExerciseWarrantsAfterBusinessCombination" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to PeriodToExerciseWarrantsAfterBusinessCombination" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to WarrantsAndRightsOutstandingTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ClassOfWarrantOrRightRedemptionPrice" xlink:label="ClassOfWarrantOrRightRedemptionPrice" xlink:title="ClassOfWarrantOrRightRedemptionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="ClassOfWarrantOrRightRedemptionPrice" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to ClassOfWarrantOrRightRedemptionPrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="SaleOfStockPricePerShare" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to SaleOfStockPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_NumberOfTradingDays" xlink:label="NumberOfTradingDays" xlink:title="NumberOfTradingDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="NumberOfTradingDays" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to NumberOfTradingDays" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashExercisePrice" xlink:label="CashExercisePrice" xlink:title="CashExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="CashExercisePrice" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to CashExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ExercisePrice" xlink:label="ExercisePrice" xlink:title="ExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="ExercisePrice" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to ExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:label="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:title="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantCashExercised" xlink:label="PublicWarrantCashExercised" xlink:title="PublicWarrantCashExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="PublicWarrantCashExercised" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to PublicWarrantCashExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_CashlessPublicWarrantExercised" xlink:label="CashlessPublicWarrantExercised" xlink:title="CashlessPublicWarrantExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="CashlessPublicWarrantExercised" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to CashlessPublicWarrantExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:label="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:title="StockIssuedDuringPeriodSharesCashWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="StockIssuedDuringPeriodSharesCashWarrantExercises" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to StockIssuedDuringPeriodSharesCashWarrantExercises" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:label="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:title="StockIssuedDuringPeriodSharesCashlessWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="StockIssuedDuringPeriodSharesCashlessWarrantExercises" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to StockIssuedDuringPeriodSharesCashlessWarrantExercises" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:label="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:title="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="ClassOfWarrantOrRightUnexercisedPriceOfWarrants" xlink:title="presentation: PublicWarrantsAndPrivatePlacementWarrantsAbstract to ClassOfWarrantOrRightUnexercisedPriceOfWarrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:to="PublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems to PublicWarrantsAndPrivatePlacementWarrantsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:to="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable to EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract" xlink:to="EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" xlink:title="presentation: EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract to EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="MoneyMarketFundsMember" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to MoneyMarketFundsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="CommonStockMember" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="OtherInvestmentCompaniesMember" xlink:title="OtherInvestmentCompaniesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="OtherInvestmentCompaniesMember" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to OtherInvestmentCompaniesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="presentation: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByAssetClassAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DatavantHoldingsIncMember" xlink:label="DatavantHoldingsIncMember" xlink:title="DatavantHoldingsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="DatavantHoldingsIncMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to DatavantHoldingsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="ArbutusBiopharmaCorporationMember" xlink:title="ArbutusBiopharmaCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="ArbutusBiopharmaCorporationMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to ArbutusBiopharmaCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:title="LiabilityInstrumentsMeasuredAtFairValueMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="LiabilityInstrumentsMeasuredAtFairValueMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to LiabilityInstrumentsMeasuredAtFairValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:label="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:title="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FinancialInstrumentAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsMember" xlink:label="PublicWarrantsMember" xlink:title="PublicWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PublicWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PublicWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnoutSharesMember" xlink:label="EarnoutSharesMember" xlink:title="EarnoutSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="EarnoutSharesMember" xlink:title="presentation: EquityComponentDomain to EarnoutSharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: AssetsFairValueDisclosureAbstract to CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="InvestmentsFairValueDisclosure" xlink:title="presentation: AssetsFairValueDisclosureAbstract to InvestmentsFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: AssetsFairValueDisclosureAbstract to AssetsFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosureAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="DebtInstrumentFairValue" xlink:title="DebtInstrumentFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="DebtInstrumentFairValue" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to DebtInstrumentFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:title="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="DerivativeLiabilities" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to DerivativeLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to FinancialLiabilitiesFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to LiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:label="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:title="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:label="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:title="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="RepaymentsOfLongTermDebt" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to RepaymentsOfLongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_ExerciseOfPrivatePlacementWarrantsValue" xlink:label="ExerciseOfPrivatePlacementWarrantsValue" xlink:title="ExerciseOfPrivatePlacementWarrantsValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="ExerciseOfPrivatePlacementWarrantsValue" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to ExerciseOfPrivatePlacementWarrantsValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:title="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to MeasurementInputTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PrivatePlacementWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnoutSharesMember" xlink:label="EarnoutSharesMember" xlink:title="EarnoutSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="EarnoutSharesMember" xlink:title="presentation: EquityComponentDomain to EarnoutSharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_DatavantHoldingsIncMember" xlink:label="DatavantHoldingsIncMember" xlink:title="DatavantHoldingsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="DatavantHoldingsIncMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to DatavantHoldingsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:label="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:title="FairValueMeasurementInputsAndValuationTechniquesAbstract" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueAssetMeasurementInput" xlink:label="FairValueAssetMeasurementInput" xlink:title="FairValueAssetMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="FairValueAssetMeasurementInput" xlink:title="presentation: FairValueMeasurementInputsAndValuationTechniquesAbstract to FairValueAssetMeasurementInput" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_FairValueEarnoutSharesMeasurementInput" xlink:label="FairValueEarnoutSharesMeasurementInput" xlink:title="FairValueEarnoutSharesMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="FairValueEarnoutSharesMeasurementInput" xlink:title="presentation: FairValueMeasurementInputsAndValuationTechniquesAbstract to FairValueEarnoutSharesMeasurementInput" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="presentation: FairValueMeasurementInputsAndValuationTechniquesAbstract to WarrantsAndRightsOutstandingMeasurementInput" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: FairValueMeasurementInputsAndValuationTechniquesAbstract to WarrantsAndRightsOutstandingTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueMeasurementInputsAndValuationTechniquesAbstract to LiabilitiesFairValueDisclosure" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:title="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:to="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:title="presentation: FairValueMeasurementInputsAndValuationTechniquesAbstract to DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueMeasurementInputsAndValuationTechniquesAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems to FairValueMeasurementInputsAndValuationTechniquesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetIncomeLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="StockOptionsAndPerformanceStockOptionsMember" xlink:title="StockOptionsAndPerformanceStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsAndPerformanceStockOptionsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to StockOptionsAndPerformanceStockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="RestrictedStockAndPerformanceStockUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockAndPerformanceStockUnitsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockAndPerformanceStockUnitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_March2020CappedValueAppreciationRightsGrantsMember" xlink:label="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="March2020CappedValueAppreciationRightsGrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="March2020CappedValueAppreciationRightsGrantsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to March2020CappedValueAppreciationRightsGrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_November2021CappedValueAppreciationRightsGrantsMember" xlink:label="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="November2021CappedValueAppreciationRightsGrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="November2021CappedValueAppreciationRightsGrantsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to November2021CappedValueAppreciationRightsGrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_EarnOutSharesNonvestedMember" xlink:label="EarnOutSharesNonvestedMember" xlink:title="EarnOutSharesNonvestedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EarnOutSharesNonvestedMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EarnOutSharesNonvestedMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="PrivatePlacementWarrantsMember" xlink:title="PrivatePlacementWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="PrivatePlacementWarrantsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to PrivatePlacementWarrantsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_PublicWarrantsMember" xlink:label="PublicWarrantsMember" xlink:title="PublicWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="PublicWarrantsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to PublicWarrantsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="roiv-20231231.xsd#roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:label="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:title="OtherStockBasedAwardsAndInstrumentsIssuedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="OtherStockBasedAwardsAndInstrumentsIssuedMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to OtherStockBasedAwardsAndInstrumentsIssuedMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="NetIncomeLossAbstract" xlink:title="NetIncomeLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetIncomeLossAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="NetIncomeLossAbstract" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to NetIncomeLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingBasicAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingBasicAbstract to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingBasicAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to EarningsPerShareDiluted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936714224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROIVANT SCIENCES LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001635088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1173944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">50 Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SW1H 0DB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400 3347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, $0.0000000341740141 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ROIV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,846,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658938734208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,670,810<span></span>
</td>
<td class="nump">$ 1,676,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">135,923<span></span>
</td>
<td class="nump">121,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,806,733<span></span>
</td>
<td class="nump">1,798,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,857<span></span>
</td>
<td class="nump">39,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">46,898<span></span>
</td>
<td class="nump">53,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments measured at fair value</a></td>
<td class="nump">239,927<span></span>
</td>
<td class="nump">304,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">150,415<span></span>
</td>
<td class="nump">144,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">46,849<span></span>
</td>
<td class="nump">49,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,312,679<span></span>
</td>
<td class="nump">2,389,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">35,226<span></span>
</td>
<td class="nump">37,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">122,148<span></span>
</td>
<td class="nump">167,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">10,477<span></span>
</td>
<td class="nump">11,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt (includes $26,950 and $26,940 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)</a></td>
<td class="nump">45,706<span></span>
</td>
<td class="nump">40,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">31,342<span></span>
</td>
<td class="nump">15,076<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">244,899<span></span>
</td>
<td class="nump">272,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_LiabilityInstrumentsMeasuredAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="nump">28,374<span></span>
</td>
<td class="nump">63,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">47,059<span></span>
</td>
<td class="nump">53,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion (includes $194,560 and $180,700 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)</a></td>
<td class="nump">403,337<span></span>
</td>
<td class="nump">375,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">17,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">728,097<span></span>
</td>
<td class="nump">782,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 804,890,910 and 760,143,393 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">5,390,260<span></span>
</td>
<td class="nump">4,933,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings / (accumulated deficit)</a></td>
<td class="nump">727,287<span></span>
</td>
<td class="num">(3,772,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(27,784)<span></span>
</td>
<td class="num">(2,617)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity attributable to Roivant Sciences Ltd.</a></td>
<td class="nump">6,089,763<span></span>
</td>
<td class="nump">1,157,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">494,819<span></span>
</td>
<td class="nump">449,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="nump">6,584,582<span></span>
</td>
<td class="nump">1,607,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 7,312,679<span></span>
</td>
<td class="nump">$ 2,389,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LiabilityInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability instruments measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LiabilityInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936673968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Current portion of long-term debt accounted for under fair value option</a></td>
<td class="nump">$ 26,950<span></span>
</td>
<td class="nump">$ 26,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long term debt accounted under fair value option</a></td>
<td class="nump">$ 194,560<span></span>
</td>
<td class="nump">$ 180,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0000000341740141<span></span>
</td>
<td class="nump">$ 0.0000000341740141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">7,000,000,000<span></span>
</td>
<td class="nump">7,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">804,890,910<span></span>
</td>
<td class="nump">760,143,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">804,890,910<span></span>
</td>
<td class="nump">760,143,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936926704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 37,140<span></span>
</td>
<td class="nump">$ 17,052<span></span>
</td>
<td class="nump">$ 95,865<span></span>
</td>
<td class="nump">$ 33,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_OperatingCosts', window );">Cost of revenues</a></td>
<td class="nump">3,668<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
<td class="nump">11,148<span></span>
</td>
<td class="nump">8,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (includes $7,475 and $6,888 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $24,305 and $26,548 for the nine months ended December 31, 2023 and 2022, respectively)</a></td>
<td class="nump">123,717<span></span>
</td>
<td class="nump">125,533<span></span>
</td>
<td class="nump">380,834<span></span>
</td>
<td class="nump">393,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,749<span></span>
</td>
<td class="nump">26,450<span></span>
</td>
<td class="nump">97,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (includes $46,944 and $50,741 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $128,445 and $165,771 for the nine months ended December 31, 2023 and 2022, respectively)</a></td>
<td class="nump">197,282<span></span>
</td>
<td class="nump">168,261<span></span>
</td>
<td class="nump">517,827<span></span>
</td>
<td class="nump">474,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">324,667<span></span>
</td>
<td class="nump">395,129<span></span>
</td>
<td class="nump">936,259<span></span>
</td>
<td class="nump">975,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnSaleOfAssets', window );">Gain on sale of Telavant net assets</a></td>
<td class="nump">5,348,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,348,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">5,060,883<span></span>
</td>
<td class="num">(378,077)<span></span>
</td>
<td class="nump">4,508,016<span></span>
</td>
<td class="num">(941,152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="nump">10,467<span></span>
</td>
<td class="num">(25,948)<span></span>
</td>
<td class="nump">63,880<span></span>
</td>
<td class="nump">53,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">9,331<span></span>
</td>
<td class="nump">62,360<span></span>
</td>
<td class="nump">85,376<span></span>
</td>
<td class="nump">90,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,514)<span></span>
</td>
<td class="num">(17,354)<span></span>
</td>
<td class="num">(29,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_InterestIncome', window );">Interest income</a></td>
<td class="num">(31,953)<span></span>
</td>
<td class="num">(10,249)<span></span>
</td>
<td class="num">(62,967)<span></span>
</td>
<td class="num">(17,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">9,444<span></span>
</td>
<td class="nump">8,446<span></span>
</td>
<td class="nump">27,603<span></span>
</td>
<td class="nump">19,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(34,743)<span></span>
</td>
<td class="num">(18,095)<span></span>
</td>
<td class="num">(33,405)<span></span>
</td>
<td class="num">(11,060)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="nump">5,098,337<span></span>
</td>
<td class="num">(382,077)<span></span>
</td>
<td class="nump">4,444,883<span></span>
</td>
<td class="num">(1,045,618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">25,672<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">31,181<span></span>
</td>
<td class="nump">8,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">5,072,665<span></span>
</td>
<td class="num">(384,896)<span></span>
</td>
<td class="nump">4,413,702<span></span>
</td>
<td class="num">(1,054,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(23,519)<span></span>
</td>
<td class="num">(32,882)<span></span>
</td>
<td class="num">(86,339)<span></span>
</td>
<td class="num">(79,188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Roivant Sciences Ltd.</a></td>
<td class="nump">$ 5,096,184<span></span>
</td>
<td class="num">$ (352,014)<span></span>
</td>
<td class="nump">$ 4,500,041<span></span>
</td>
<td class="num">$ (975,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share - basic (in dollars per share)</a></td>
<td class="nump">$ 6.37<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share - diluted (in dollars per share)</a></td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">800,587,716<span></span>
</td>
<td class="nump">713,319,399<span></span>
</td>
<td class="nump">776,759,728<span></span>
</td>
<td class="nump">703,054,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">844,461,685<span></span>
</td>
<td class="nump">713,319,399<span></span>
</td>
<td class="nump">824,310,013<span></span>
</td>
<td class="nump">703,054,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 20,666<span></span>
</td>
<td class="nump">$ 9,244<span></span>
</td>
<td class="nump">$ 55,749<span></span>
</td>
<td class="nump">$ 14,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=roiv_LicenseMilestoneAndOtherRevenueMember', window );">License, Milestone and Other Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 16,474<span></span>
</td>
<td class="nump">$ 7,808<span></span>
</td>
<td class="nump">$ 40,116<span></span>
</td>
<td class="nump">$ 19,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquired in-process research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AcquiredInProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on fair value of debt and liability instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_InterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on nonoperating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_InterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of operating cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=roiv_LicenseMilestoneAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=roiv_LicenseMilestoneAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658940421248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,903<span></span>
</td>
<td class="nump">$ 192,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 7,475<span></span>
</td>
<td class="nump">$ 6,888<span></span>
</td>
<td class="nump">24,305<span></span>
</td>
<td class="nump">26,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 46,944<span></span>
</td>
<td class="nump">$ 50,741<span></span>
</td>
<td class="nump">$ 128,445<span></span>
</td>
<td class="nump">$ 165,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658942133168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 5,072,665<span></span>
</td>
<td class="num">$ (384,896)<span></span>
</td>
<td class="nump">$ 4,413,702<span></span>
</td>
<td class="num">$ (1,054,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(25,066)<span></span>
</td>
<td class="num">(8,972)<span></span>
</td>
<td class="num">(25,612)<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(25,066)<span></span>
</td>
<td class="num">(8,972)<span></span>
</td>
<td class="num">(25,612)<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">5,047,599<span></span>
</td>
<td class="num">(393,868)<span></span>
</td>
<td class="nump">4,388,090<span></span>
</td>
<td class="num">(1,054,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(23,873)<span></span>
</td>
<td class="num">(32,036)<span></span>
</td>
<td class="num">(86,784)<span></span>
</td>
<td class="num">(78,858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Roivant Sciences Ltd.</a></td>
<td class="nump">$ 5,071,472<span></span>
</td>
<td class="num">$ (361,832)<span></span>
</td>
<td class="nump">$ 4,474,874<span></span>
</td>
<td class="num">$ (975,196)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931964128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Redeemable Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>(Accumulated Deficit) / Retained Earnings [Member]</div></th>
<th class="th"><div>Noncontrolling Interests [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">$ 22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,421,614<span></span>
</td>
<td class="num">$ (946)<span></span>
</td>
<td class="num">$ (2,763,724)<span></span>
</td>
<td class="nump">$ 381,999<span></span>
</td>
<td class="nump">$ 2,038,943<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,975,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(8,329)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,739,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue', window );">Issuance of subsidiary common shares to the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(251)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares', window );">Issuance of subsidiary common shares to the Company (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration', window );">Issuance of the Company's common shares related to settlement of transaction consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration', window );">Issuance of the Company's common shares related to settlement of transaction consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">61,590<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,204<span></span>
</td>
<td class="nump">72,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,966<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="nump">5,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(331,809)<span></span>
</td>
<td class="num">(21,975)<span></span>
</td>
<td class="num">(353,784)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,474,624<span></span>
</td>
<td class="nump">5,020<span></span>
</td>
<td class="num">(3,095,533)<span></span>
</td>
<td class="nump">371,280<span></span>
</td>
<td class="nump">1,755,391<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,171,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,421,614<span></span>
</td>
<td class="num">(946)<span></span>
</td>
<td class="num">(2,763,724)<span></span>
</td>
<td class="nump">381,999<span></span>
</td>
<td class="nump">2,038,943<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,975,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054,601)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,695,386<span></span>
</td>
<td class="num">(729)<span></span>
</td>
<td class="num">(3,739,137)<span></span>
</td>
<td class="nump">471,618<span></span>
</td>
<td class="nump">1,427,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726,804,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation of subsidiaries</a></td>
<td class="num">(22,491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,474,624<span></span>
</td>
<td class="nump">5,020<span></span>
</td>
<td class="num">(3,095,533)<span></span>
</td>
<td class="nump">371,280<span></span>
</td>
<td class="nump">1,755,391<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,171,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation', window );">Deconsolidation of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans', window );">Issuance of the Company's common shares in connection with equity incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans', window );">Issuance of the Company's common shares in connection with equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue', window );">Issuance of the Company's common shares and other consideration for an acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,836<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">8,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares', window );">Issuance of the Company's common shares and other consideration for an acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries', window );">Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,240)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,415<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,564<span></span>
</td>
<td class="nump">61,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="nump">3,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(291,590)<span></span>
</td>
<td class="num">(24,331)<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,538,635<span></span>
</td>
<td class="nump">9,089<span></span>
</td>
<td class="num">(3,387,123)<span></span>
</td>
<td class="nump">353,548<span></span>
</td>
<td class="nump">1,514,149<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704,386,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueNetIssuanceCosts', window );">Issuance of the Company's common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">94,735<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">94,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts', window );">Issuance of the Company's common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,417,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue', window );">Issuance of subsidiary common shares to the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">19,599<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,129<span></span>
</td>
<td class="nump">67,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation', window );">Deconsolidation of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised', window );">Subsidiary stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries', window );">Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,822)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,961<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,770<span></span>
</td>
<td class="nump">57,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Issuance of subsidiary preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,818)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="num">(8,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,014)<span></span>
</td>
<td class="num">(32,882)<span></span>
</td>
<td class="num">(384,896)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,695,386<span></span>
</td>
<td class="num">(729)<span></span>
</td>
<td class="num">(3,739,137)<span></span>
</td>
<td class="nump">471,618<span></span>
</td>
<td class="nump">1,427,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726,804,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,933,137<span></span>
</td>
<td class="num">(2,617)<span></span>
</td>
<td class="num">(3,772,754)<span></span>
</td>
<td class="nump">449,821<span></span>
</td>
<td class="nump">1,607,587<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,143,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">14,395<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,994,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised', window );">Subsidiary stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,498<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,762<span></span>
</td>
<td class="nump">49,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contributions to majority-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(623)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DividendDeclaredBySubsidiary', window );">Dividend declared by subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,993)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(4,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(291,816)<span></span>
</td>
<td class="num">(36,029)<span></span>
</td>
<td class="num">(327,845)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,981,910<span></span>
</td>
<td class="num">(6,610)<span></span>
</td>
<td class="num">(4,064,570)<span></span>
</td>
<td class="nump">423,409<span></span>
</td>
<td class="nump">1,334,139<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,137,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,933,137<span></span>
</td>
<td class="num">(2,617)<span></span>
</td>
<td class="num">(3,772,754)<span></span>
</td>
<td class="nump">449,821<span></span>
</td>
<td class="nump">1,607,587<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,143,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,413,702<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,390,260<span></span>
</td>
<td class="num">(27,784)<span></span>
</td>
<td class="nump">727,287<span></span>
</td>
<td class="nump">494,819<span></span>
</td>
<td class="nump">6,584,582<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,890,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,981,910<span></span>
</td>
<td class="num">(6,610)<span></span>
</td>
<td class="num">(4,064,570)<span></span>
</td>
<td class="nump">423,409<span></span>
</td>
<td class="nump">1,334,139<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,137,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueNetIssuanceCosts', window );">Issuance of the Company's common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">199,822<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">199,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts', window );">Issuance of the Company's common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,402,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue', window );">Issuance of the Company's common shares related to settlement of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">83,264<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares', window );">Issuance of the Company's common shares related to settlement of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,554,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of the Company's common shares under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of the Company's common shares under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation', window );">Deconsolidation of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(35,050)<span></span>
</td>
<td class="num">(35,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised', window );">Subsidiary stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,831<span></span>
</td>
<td class="nump">49,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contributions to majority-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,538<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">3,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(304,327)<span></span>
</td>
<td class="num">(26,791)<span></span>
</td>
<td class="num">(331,118)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,320,503<span></span>
</td>
<td class="num">(3,072)<span></span>
</td>
<td class="num">(4,368,897)<span></span>
</td>
<td class="nump">377,099<span></span>
</td>
<td class="nump">1,325,633<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,792,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition', window );">Disposition of Telavant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(87,500)<span></span>
</td>
<td class="num">(87,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments', window );">Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,098,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue', window );">Issuance of subsidiary common shares to the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">129,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,970<span></span>
</td>
<td class="nump">238,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares', window );">Issuance of subsidiary common shares to the Company (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised', window );">Subsidiary stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries', window );">Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(104,172)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,551<span></span>
</td>
<td class="nump">54,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,712)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="num">(25,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,096,184<span></span>
</td>
<td class="num">(23,519)<span></span>
</td>
<td class="nump">5,072,665<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,390,260<span></span>
</td>
<td class="num">$ (27,784)<span></span>
</td>
<td class="nump">$ 727,287<span></span>
</td>
<td class="nump">$ 494,819<span></span>
</td>
<td class="nump">$ 6,584,582<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,890,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) and Noncontrolling Interest for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CapitalContributionsToSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Contributions To Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CapitalContributionsToSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DividendDeclaredBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend declared by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DividendDeclaredBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount net common shares issued of subsidiary to the company and cash contributions to majority-owned subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount net common shares issued of subsidiary to the company, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuance of subsidiary to the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the increase in or (reduction or elimination) during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the disposition of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of stock issuance of common shares and other consideration for acquisition during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issuance of common shares and other consideration for acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common shares issued related to settlement of transaction consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in connection with equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in connection with equity incentive plans and tax withholding payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in connection with equity incentive plans net of forfeitures and tax withholding payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued common share related to settlement of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value issuance of the company's common share related to settlement of warrants value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of common shares issued related to settlement of transaction consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued in connection with equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued in connection with equity incentive plans and tax withholding payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued in connection with equity incentive plans net of forfeitures and tax withholding payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period value, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subsidiary stock issued as a result of stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658938600720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,413,702<span></span>
</td>
<td class="num">$ (1,054,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NonCashAcquiredInProcessResearchAndDevelopment', window );">Non-cash acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">152,903<span></span>
</td>
<td class="nump">192,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="nump">63,880<span></span>
</td>
<td class="nump">53,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">85,376<span></span>
</td>
<td class="nump">90,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiaries</a></td>
<td class="num">(17,354)<span></span>
</td>
<td class="num">(29,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of Telavant net assets</a></td>
<td class="num">(5,348,410)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">16,811<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">5,047<span></span>
</td>
<td class="nump">6,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(31,846)<span></span>
</td>
<td class="num">(8,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisition and divestiture:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(18,767)<span></span>
</td>
<td class="num">(31,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">13,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(15,785)<span></span>
</td>
<td class="nump">5,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(6,151)<span></span>
</td>
<td class="num">(6,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="nump">41,986<span></span>
</td>
<td class="nump">3,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(656,811)<span></span>
</td>
<td class="num">(664,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(140,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,033)<span></span>
</td>
<td class="num">(11,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Proceeds from sale of subsidiary interests</a></td>
<td class="nump">47,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ProceedsFromSaleOfAssets', window );">Proceeds from sale of Telavant net assets, net</a></td>
<td class="nump">5,233,396<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Cash decrease upon deconsolidation of subsidiaries</a></td>
<td class="num">(83,679)<span></span>
</td>
<td class="num">(6,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">5,196,695<span></span>
</td>
<td class="num">(157,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of the Company's common shares, net of issuance costs paid</a></td>
<td class="nump">199,822<span></span>
</td>
<td class="nump">94,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet', window );">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</a></td>
<td class="nump">238,733<span></span>
</td>
<td class="nump">67,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ProceedsFromSubsidiaryDebtFinancingsNet', window );">Proceeds from subsidiary debt financings, net of financing costs paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PaymentsOfSubsidiaryDividends', window );">Payment of subsidiary dividend</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary', window );">Repayment of debt by subsidiary</a></td>
<td class="num">(21,815)<span></span>
</td>
<td class="num">(22,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PaymentForOfferingAndLoanCosts', window );">Payment of offering costs and loan origination costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on principal portion of finance lease obligations</a></td>
<td class="num">(1,225)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of the Company's and subsidiary stock options</a></td>
<td class="nump">51,023<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PaymentsOfTaxesForTheRepurchaseOfEquity', window );">Taxes paid related to net settlement of equity awards</a></td>
<td class="num">(9,101)<span></span>
</td>
<td class="num">(9,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of the Company's common shares under employee stock purchase plan</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of the Company's warrants</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PaymentForWarrantRedemptions', window );">Payment for redemptions of the Company's warrants</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">451,988<span></span>
</td>
<td class="nump">289,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">4,993,343<span></span>
</td>
<td class="num">(532,997)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">1,692,115<span></span>
</td>
<td class="nump">2,074,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">6,685,458<span></span>
</td>
<td class="nump">1,541,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CashlessExerciseOfTheCompanyCommonStockWarrants', window );">Cashless exercise of the Company's warrants</a></td>
<td class="nump">83,258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment', window );">Issuance of the Company's common shares and other consideration for an acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NoncashOther', window );">Other</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="nump">$ 7,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CashlessExerciseOfTheCompanyCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cashless exercise of the company's common stock warrants in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CashlessExerciseOfTheCompanyCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common shares and other consideration issued for the purchase of property and equipment in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on fair value of debt and liability instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made during the period for achieving the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NonCashAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NonCashAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NoncashOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NoncashOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentForOfferingAndLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with payment for offering and loan costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentForOfferingAndLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentForWarrantRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the warrant redemptions during period of the time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentForWarrantRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentsOfSubsidiaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and subsidiary dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentsOfSubsidiaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentsOfTaxesForTheRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of Taxes for the Repurchase of Equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentsOfTaxesForTheRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflows from issuance of subsidiary common shares, net of issuance costs paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromSubsidiaryDebtFinancingsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through subsidiary debt financings, net during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromSubsidiaryDebtFinancingsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt repayment of long-term debt and convertible debt by subsidiary during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658941160672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DescriptionOfBusinessAndLiquidityAbstract', window );"><strong>Description of Business and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Liquidity</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 1&#8212;Description of Business and Liquidity</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) Description of Business</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;RSL&#8221;) aims to improve health by rapidly delivering innovative
          medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization. In addition to
          biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April 7, 2014 as a Bermuda exempted limited company.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">VTAMA&#174; (tapinarof) was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) in May 2022 for the treatment of plaque psoriasis in
          adult patients.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has determined that it has one
          operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#8220;Equity
          Method Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">On September 30, 2021, RSL completed its business combination (the &#8220;Business Combination&#8221;) with Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;), a
          special purpose acquisition company, and began trading on Nasdaq under the ticker symbol &#8220;ROIV.&#8221;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(B) Liquidity</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">The













          <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">Company has incurred significant operating
            losses and negative cash flows from operations since its inception. In December 2023, the Company recognized a gain of approximately $5.3
            billion on the sale of Telavant net assets.&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company had cash and cash equivalents of approximately&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$6.7 billion</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and
            its retained earnings was&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$727.3 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. For the&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine months ended</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">2022</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company incurred net income of approximately&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$4.4
            billion</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and a net loss of approximately&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$1.1 billion</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively. The Company has historically financed its operations primarily through the sale
            of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. Through its subsidiary, Dermavant Sciences Ltd., the Company has launched its first commercial product,
            VTAMA, following approval by the FDA in May 2022</span>.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to
          commercialization of products, regulatory approvals to market its product candidates, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property
          rights. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may require additional capital to fully implement its business plan.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure
          requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DescriptionOfBusinessAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DescriptionOfBusinessAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658940989520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 2&#8212;Summary of Significant Accounting Policies</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) Basis of Presentation and Principles of Consolidation</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s fiscal year ends on March 31, and its fiscal quarters end on June 30, September 30, and December 31.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
          accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and follow the requirements of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Accordingly, these unaudited condensed
          consolidated financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be
          condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial
          statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the SEC. The unaudited condensed consolidated balance sheet at March 31, 2023 has been derived from the audited
          consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial
          position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the nine months ended December 31,
          2023 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2024, for any other interim period, or for any other future year.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting
          Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Updates (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in
          which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to
          noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents
          noncontrolling interests as a component of shareholders&#8217; equity on its unaudited condensed consolidated balance sheets.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying
          amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest
          is adjusted is recognized within shareholders&#8217; equity attributable to RSL.</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(B) Use of Estimates</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts
          reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development
          costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
          values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">(C) Concentrations</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company
          maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and
          liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has long-lived assets in different geographic locations. As of December 31, 2023 and March 31, 2023, a majority of the Company&#8217;s
          long-lived assets were located in the United States.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">(D) Cash, Cash
          Equivalents, and Restricted Cash</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company
          considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted
          cash as presented on the accompanying condensed consolidated balance sheets as follows (in thousands):</div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> December 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Cash and cash equivalents</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>6,670,810</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>1,676,813</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Restricted cash (included in &#8220;Other current assets&#8221;)<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,165</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,011</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt">Restricted cash (included in &#8220;Other assets&#8221;)<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">9,483</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">10,291</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div>Cash, cash equivalents and restricted cash</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>6,685,458</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1,692,115</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(E) Contingencies</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually
          assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at
          which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the
          Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(F) Investments</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Investments in equity securities may be accounted for using (i) the fair value option, if elected, (ii) fair value through earnings if fair value
          is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the
          measurement alternative is made for each eligible investment.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company
          believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Equity Method Investments.&#8221;</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(G) Fair Value Measurements</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance
          establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are
          inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market
          participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received
          to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a
          three-tier fair value hierarchy that distinguishes among the following:</div>

<div><br/></div>

<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                  <div style="text-align: left;">&#8226;</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">Level 1-Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</div>
                </td>

  </tr>


</table>
        </div>

<div><br/></div>

<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                    <div>&#8226;</div>
                  </td>

    <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">Level 2-Valuations are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models
                      for which all significant inputs are observable, either directly or indirectly.</div>
                  </td>

  </tr>


</table>
          </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div>
              <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                      <div>&#8226;</div>
                    </td>

    <td style="vertical-align: top; width: auto;">
                      <div style="text-align: justify;">Level 3-Valuations are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement.</div>
                    </td>

  </tr>


</table>
            </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value
          requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the
          lowest level of any input that is significant to the fair value measurement.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of common stock of
          Heracles Parent, L.L.C., the parent entity of Datavant, (as defined and discussed in Note 3, &#8220;Equity Method Investments&#8221;); liability instruments issued, including warrant and earn-out shares liabilities issued in connection with the Company&#8217;s
          business combination with MAAC (as discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private Placement Warrants&#8221;); its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and
          long-term debt.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;">The shares of Arbutus common stock and
          investments in common stock with a readily determinable fair value are classified as Level 1, and their fair value is determined based upon quoted market prices in an active market. The shares of common stock of Heracles Parent, L.L.C., the
          parent entity of Datavant (as defined and discussed in Note 3, &#8220;Equity Method Investments&#8221;) and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private
          Placement Warrants&#8221;), are classified as Level 3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Prior to their settlement, the Public Warrants were publicly traded and
          therefore were classified as Level 1 as the Public Warrants had a readily determinable fair value. Cash and accounts payable are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature.
          Money market funds are included in Level 1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly
          owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level 2 of the fair value hierarchy. Long-term debt issued
          by Dermavant for which the fair value option has been elected is included in Level 3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
        <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(H) Significant Accounting Policies</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">There were no significant changes to the Company&#8217;s significant accounting policies from those disclosed in the Company&#8217;s Form 10-K for the year ended March 31, 2023.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(I) Recently Adopted Accounting Pronouncements</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">The Company did not adopt any material accounting pronouncements during the nine months ended December 31, 2023.</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(J) Recently Issued Accounting Pronouncements Not Yet Adopted<br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In
            November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&#8221; which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant
            segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU is applicable to the Company&#8217;s Annual Report on Form 10-K
            for the fiscal year ended March 31, 2025, and subsequent interim periods, with early adoption permitted. These amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently
            evaluating the impact of adopting this ASU on its consolidated financial statements</span>.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 18pt; text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In December 2023, the FASB issued ASU 2023-09, &#8220;Income
            Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; which includes updates to the income tax disclosures related to the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments are effective for fiscal
            years beginning after December 15, 2024 and is applicable to the Company&#8217;s fiscal year beginning April 1, 2025, with early adoption permitted. The amendments should be applied prospectively, however retrospective application is permitted. The
            Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span>  </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936624640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 3&#8212;Equity Method Investments</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">The Company maintains equity method investments in certain entities. As of December 31, 2023 and March 31, 2023, the most significant of these were our
            investments in Arbutus and Datavant (as defined below), which are accounted for using the fair value option.</span> </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">The </span><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company determined that it does not control these entities and as a result does not consolidate these entities. Due to the Company&#8217;s significant influence over operating and financial policies of
            these entities, the entities are considered related parties of the Company.</span><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Investment in Arbutus</div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company holds an investment in Arbutus in the form of 38,847,462 common shares of Arbutus. As of December 31, 2023, RSL held approximately 23% of issued
          and outstanding shares of Arbutus.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">At <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">March 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the aggregate fair value of the Company&#8217;s investment in Arbutus was&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$97.1 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$117.7 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
              Company recognized an unrealized gain of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$18.3 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and an unrealized loss of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$20.6 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;on its investment in Arbutus, respectively, in the accompanying condensed consolidated statements of operations. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2022</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
              Company recognized an unrealized gain of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$16.3 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and an unrealized loss of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$25.3 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;on its investment in Arbutus, respectively, in the accompanying condensed consolidated statements of operations. The fair value of the Company&#8217;s investment was
              determined using the closing price of Arbutus&#8217;s common stock on&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">March 31, 2023</span> of $2.50 and $3.03, respectively. </span><br/>
        </div>

<div><br/></div>

<div style="text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Investment
















            in Datavant </span> </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In June 2021, Datavant and Heracles Parent, L.L.C. (referred to herein as &#8220;Ciox Parent&#8221; and, after the closing of the Datavant Merger (as defined below), &#8220;Datavant&#8221;), primarily through its wholly owned subsidiary CIOX
            Health, LLC, entered into a definitive agreement to merge Datavant with and into a newly formed wholly owned subsidiary of Ciox Parent (the &#8220;Datavant Merger&#8221;). As of December 31, 2023, the Company&#8217;s minority equity interest represented
            approximately 9% of the outstanding Class A units in Ciox Parent. Ciox Parent&#8217;s capital structure includes several classes of
            preferred units that, among other features, have liquidation preferences and conversion rights. Upon conversion of such preferred units into Class A units, the Company&#8217;s ownership interest would be diluted. </span><br/>
        </div>

<div style="text-align: left;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">As
          <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">March 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
            fair value of the Company&#8217;s investment was&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$135.9 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$178.6
            million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company recognized unrealized losses on its investment in Datavant of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$28.4
            million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$42.6 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, respectively, in the accompanying condensed consolidated statements of operations. During the three and&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">nine</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;months ended&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2022</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the
            Company recognized an unrealized gain on of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$7.5 million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;and an unrealized loss of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">$21.4
            million</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;on its investment in Datavant, respectively, in the accompanying condensed consolidated statements of operations</span><span style="letter-spacing: normal; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The fair value of the Company&#8217;s investment was determined using valuation models that incorporate significant unobservable inputs and is
          classified as a Level 3 measurement within the fair value hierarchy. Refer to Note 13, &#8220;Fair Value Measurements&#8221; for more information.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 323<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org//323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936624768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 4&#8212;Intangible Assets</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In July 2018, Dermavant acquired the worldwide rights (other than for China) with respect to certain intellectual property rights retained by
          Welichem Biotech Inc. (&#8220;Welichem&#8221;) to VTAMA and related compounds from Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Ltd. (collectively, &#8220;GSK&#8221;) pursuant to an asset purchase agreement. GSK previously acquired rights to
          a predecessor formulation from Welichem pursuant to an asset purchase agreement between GSK and Welichem entered into in May 2012. The Company evaluated the agreement and determined that the acquired assets did not meet the definition of a
          business and thus the transaction was accounted for as an asset acquisition.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Following the FDA approval of VTAMA in May 2022, the Company became obligated to pay a regulatory milestone to GSK of &#163;100.0 million (approximately $126
          million on the date of achievement) following the receipt of marketing approval of VTAMA in the United States. The milestone was paid in July 2022.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Additionally, the first sale of VTAMA in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$25.0 million (approximately $20
          million on the date of achievement). The milestone was paid in August 2022.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Both of the above milestones were capitalized as intangible assets upon achievement and are being amortized over their estimated useful lives. As
          of December 31, 2023, the remaining weighted average estimated useful lives of the intangible assets was 14.8 years.<br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The following table summarizes the Company&#8217;s recognized intangible assets (in thousands):<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">December 31, 2023</span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="text-align: center;">

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Gross amount</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">166,471</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>152,629</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Less: accumulated amortization</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(16,056</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(7,748</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt;">Net book value</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">150,415</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>144,881</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Amortization expense was $2.4
          million and $2.2 million for the three months ended December 31, 2023 and 2022, respectively, and $7.2 million and $5.2 million for the
          nine months ended December 31, 2023 and 2022, respectively. Amortization expense was recorded as part of &#8220;Cost of revenues&#8221; in the accompanying condensed consolidated statement of operations. Future amortization expense is approximately $2.5 million for the remainder of the year ended March 31, 2024, $10.1 million for each of the years ended from March 31, 2025 through March 31, 2028 and $107.5
          million thereafter. The Company&#8217;s intangible assets are denominated in currencies other than U.S. dollar and therefore are subject to foreign currency movements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931620832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_RecentTransactionsAbstract', window );"><strong>Recent Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_RecentTransactionsTextBlock', window );">Recent Transactions</a></td>
<td class="text">
<div style="font-weight: bold; text-align: justify;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note
          5&#8212;Recent Transactions</span></div>

<div><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(A) Telavant Disposition</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">On December 14, 2023 (the &#8220;Transaction Date&#8221;), the Company completed the sale of its entire equity interest in its majority-owned subsidiary, Telavant
      Holdings, Inc. (&#8220;Telavant&#8221;), to Roche Holdings, Inc. (&#8220;Roche&#8221;) (the &#8220;Roche Transaction&#8221;). The Roche Transaction was made pursuant to a Stock Purchase Agreement dated October 22, 2023 among the Company, Telavant, Pfizer Inc. (&#8220;Pfizer&#8221;), and Roche (the
      &#8220;Stock Purchase Agreement&#8221;). Telavant was jointly formed by the Company and Pfizer in November 2022 to develop and commercialize RVT-3101, an anti-TL1A antibody in development for ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease, in the United States
      and Japan. Prior to the Roche Transaction, the Company held&#160;75% of the issued and outstanding shares of common stock and preferred stock of
      Telavant, and Pfizer owned the remaining&#160;25%, in each case on an as-converted basis.</div>

<div><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Pursuant to the Stock Purchase Agreement, Roche acquired all of the issued and outstanding shares of capital stock of Telavant in exchange for
      approximately $7.1 billion in cash at the closing of the Roche Transaction and a one-time milestone payment of $150 million in cash payable upon the initiation of a Phase 3 trial in UC. The $7.1 billion in closing consideration was paid to all of Telavant&#8217;s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant
      prior to the closing of the Roche Transaction, and this same treatment will be applied to the one-time milestone payment. The Company received an upfront payment of approximately $5.2 billion in cash as its pro rata portion of the consideration upon closing of the Roche Transaction. Additionally, the Company is eligible to receive approximately $110 million for its pro rata portion of the one-time milestone payment if the milestone payment condition is satisfied.</div>

<div>&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">At the closing of the Roche Transaction, Roche acquired the full rights to further develop and manufacture RVT-3101 and commercialize it in the United
      States and Japan pending clinical and regulatory success. Outside of the United States and Japan, Pfizer holds commercialization rights. In addition, following the closing of the Roche Transaction, Roche acquired Telavant&#8217;s option to enter into a
      global collaboration with Pfizer on a next generation p40/TL1A directed bispecific antibody, currently in Phase 1.</div>

<div>&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Telavant entity that was sold did not meet the definition of a
        business, and therefore the Company concluded that the Roche Transaction was a sale of non-financial assets, with control transferred at closing.</span> The sale of Telavant did not meet the criteria for reporting discontinued operations as the
      sale does not represent a strategic shift in the Company<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8217;s</span> business. <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The
        Company recognized a gain on sale of Telavant net assets of approximately </span>$5.3 billion<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> during the </span>three<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> and </span>nine<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> months ended December </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</span>2023<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> in the
        accompanying condensed consolidated statements of operations. The gain does not include the Company&#8217;s portion of the </span>one<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">-time milestone payment, which will
        be recognized in the period it is achieved. The gain on sale of Telavant net assets qualifies under the substantial shareholding exemption and consequently is not subject to the corporation income tax. </span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">The table below summarizes
      the calculation of the gain.</span></div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(in</span><span style="font-weight: bold;"> thousand</span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);"><span style="font-weight: bold;">s</span>)</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Consideration:</div>
          </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Upfront cash payment</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">5,234,373</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Carrying amount of noncontrolling interest derecognized</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">87,500</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total consideration</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5,321,873</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Assets sold</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,253</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Liabilities transferred</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">29,790</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Net liabilities sold</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(26,537</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">)</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Gain on sale of Telavant net assets</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,348,410</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">The pretax loss generated by Telavant was $27.3
      million for the period from October 1, 2023 to the Transaction Date and $71.1 million for the period from April 1, 2023 to the Transaction
      Date. The pretax loss generated by Telavant for the period from inception on November 14, 2022 to December 31, 2022 was $89.4 million. The
      entirety of the Telavant pretax losses was attributable to the Company.</div>

<div><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(B) Asset Acquisition</div>

<div>&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In July 2023, a
        newly-formed subsidiary in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment. The
        transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The acquired rights represent in-process research and development assets, which were determined to have no alternative future
        use. Accordingly, the Company recorded $14.0 million as acquired in-process research and development expense in the accompanying
        condensed consolidated statements of operations for the nine months ended December 31, 2023.</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Additionally,


          the newly-formed subsidiary agreed to pay up to $280 million of future development, regulatory, and commercial milestone payments and
          tiered high-single digit sales-based royalties.</span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
       <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>&#160;
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(C) Deconsolidation of Subsidiaries</div>

<div>&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In July 2023, VantAI
        Holdings, Inc. (&#8220;VantAI&#8221;), a wholly-owned subsidiary of the Company, completed a transaction pursuant to which SK, Inc. (&#8220;SK&#8221;) contributed $6.0
        million to VantAI in exchange for preferred shares in VantAI (the &#8220;VantAI Preferred Financing&#8221;). In August 2023, the Company and SK Biopharmaceuticals Co., Ltd. (&#8220;SK Bio&#8221;), a subsidiary of SK, completed a transaction pursuant to which SK Bio
        purchased all of the Company&#8217;s shares in Proteovant Sciences, Inc. (&#8220;Proteovant&#8221;) in exchange for $47.5 million (the &#8220;Proteovant Sale&#8221;).</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">As a result of changes in
        governance and voting rights, the Company determined that it no longer held a controlling financial interest in VantAI. Accordingly, the Company deconsolidated VantAI as of July 2023. The Company recorded a $17.4 million gain on deconsolidation of Proteovant and VantAI in the accompanying condensed consolidated statements of operations for the nine months ended December 31, 2023.</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">Upon deconsolidation, the
        Company recorded its $9.0 million retained investment in VantAI based upon the fair value of the preferred shares held by the Company.
        Due to the Company&#8217;s significant influence over the operating and financial policies of VantAI, the Company will account for its retained interest under the equity method of accounting.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RecentTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RecentTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RecentTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for recent transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RecentTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931588288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CertainBalanceSheetComponentsAbstract', window );"><strong>Certain Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Components</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 6&#8212;<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Certain Balance Sheet Components</span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">(A) Other Current Assets</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;">Other current assets at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 24.5pt;"> <br/>
          </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';">March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Prepaid expenses</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">52,642</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">60,827</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Trade receivables, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">41,078</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">30,379</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">Restricted cash</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">5,165</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">5,011</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; font-weight: normal;" valign="bottom">Inventory <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom">5,240</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom">2,761</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Income tax receivable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">3,209</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">2,356</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom">Interest receivable</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">18,901</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,909</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">9,688</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">15,531</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; text-align: justify;">Total other current assets</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">135,923</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">121,774</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">(B) Accrued Expenses</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Accrued expenses at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> December 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Research and development expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>43,627</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>76,278</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Compensation-related expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>41,406</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>55,186</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">Sales allowances</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">16,808</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">17,569</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Other expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>20,307</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>18,096</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt;">Total accrued expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>122,148</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>167,129</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
        </div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">(C) Other Current
          Liabilities</div>

<div> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Other current liabilities at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">December 31, 2023<br/>
                  </div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">March 31, 2023<br/>
                  </div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Deferred revenue</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>4,695</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>12,444</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Income tax payable</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>25,223</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>542</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div>1,424</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div>2,090</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-align: left; text-indent: 0pt; margin-left: 9pt;">Total other current liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>31,342</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>15,076</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
            </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CertainBalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CertainBalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658942083312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 7&#8212;Long-Term Debt</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Dermavant</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Funding Agreement with NovaQuest</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In connection with Dermavant&#8217;s acquisition of tapinarof from GSK pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;), Dermavant and
          NovaQuest Co-Investment Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $100.0 million in August 2018 and $17.5 million in October 2018.
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In exchange for the $117.5 million
          in total funding from NovaQuest, Dermavant agreed to make fixed payments to NovaQuest under the NovaQuest Agreement upon regulatory approval of tapinarof. For each of the atopic dermatitis and psoriasis indications, Dermavant is required to make
          quarterly payments to NovaQuest totaling $176.3
          million per indication over a six-year period following regulatory approval of tapinarof for the applicable indication in the United
          States. In the event that Dermavant receives regulatory approval for one indication, and Dermavant terminates the development of the other indication for any reason other than a Technical Failure (as defined below), then Dermavant will be
          required to make the above-referenced quarterly payments to NovaQuest up to $440.6 million over a 15-year period for the approved indication, which are referred to as 15-year Payments. A Technical Failure is deemed to occur for an indication if the development program for such indication is terminated due to (1) significant safety concerns, (2) material adverse developments or
          (3) the receipt by Dermavant of a complete response letter or a final non-approval letter from the FDA is expected to result in significant delay in or cost to reach commercialization for the applicable indication. In addition, Dermavant is
          required to make up to $141.0 million in payments to NovaQuest upon achievement of certain commercial milestones. In the event that
          Dermavant is required to start making 15-year Payments, then Dermavant has the right to offset such amounts by up to $88.1 million of the commercial milestone payments, with such offset being applied to the quarterly payments in reverse chronological order (such that
          the final quarterly payments owed will be used first to offset the commercial milestone payments). The NovaQuest Agreement does not contain any royalty payment requirements on commercialization of tapinarof. Upon receiving FDA approval for the
          psoriasis indication, Dermavant made its first quarterly payment of $7.3 million under the NovaQuest Agreement in May 2022 and has made
          cumulative quarterly payments totaling $51.4
          million as of December 31, 2023.&#160; </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In
          lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the statements of operations at the end of each reporting period.
          Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of December 31, 2023 and March 31, 2023, the fair value of the debt was $221.5 million and $207.6 million, respectively. Refer to Note
          13, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The carrying balance of the debt issued to NovaQuest was as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Fair value of long-term debt</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>221,510</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>207,640</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Less: current portion</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(26,950</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(26,940</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Total long-term debt, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>194,560</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>180,700</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Credit Facility with XYQ Luxco</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">In May 2021, Dermavant and certain of its subsidiaries entered into a $40.0 million senior secured credit facility (the &#8220;Credit Facility&#8221;) with XYQ Luxco S.A.R.L (&#8220;XYQ Luxco&#8221;), as lender, and U.S. Bank National Association, as collateral agent. The Credit
          Facility has a five-year maturity and bears an interest rate of 10.0% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the
          maturity date. Dermavant is also obligated to pay an exit fee of $5.0 million. The exit fee can be reduced to $4.0 million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of December 31, 2023. In connection
          with the funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase 1,199,072 common shares of Dermavant at
          an exercise price of $0.01 per common share.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Outstanding debt obligations to XYQ Luxco were as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Principal amount</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Exit fee</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Less: unamortized discount and debt issuance costs</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(8,221</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(10,170</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Total debt, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>36,779</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>34,830</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Less: current portion</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div>Total long-term debt, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>36,779</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>34,830</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Revenue Interest Purchase and Sale Agreement</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In
          May 2021, Dermavant, as seller, entered into a $160.0 million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its
          investigational product tapinarof with XYQ Luxco, NovaQuest Co-Investment Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P., together with U.S. Bank
          National Association, as collateral agent. Under the terms of the RIPSA, Dermavant is obligated to pay royalties based on a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States, up
          to a cap of $344.0 million, in exchange for the $160.0 million in committed funding, which was paid to Dermavant in June 2022 following the approval of tapinarof by the FDA.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><br/></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">The













          transaction is accounted for as debt. Over the term of the arrangement, the effective interest rate will be updated prospectively each reporting period based on the carrying amount of the note, payments made to date, and the estimated remaining
          cash flows related to the note.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0px;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The RIPSA carrying balance was as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
                </td>

    <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div>Carrying balance</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>195,297</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>178,571</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Less: unamortized issuance costs</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(4,543</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(4,806</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div>Total debt, net</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>190,754</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div><br/>
                    </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>173,765</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div><br/>
                    </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>
                    <div>Less: current portion</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(18,756</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(13,780</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div>Total long-term debt, net</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>171,998</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>159,985</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
        </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931669120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 8&#8212;Shareholders&#8217; Equity</div>

<div><br/></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(A) At-the-Market Equity Offering Program</span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;">On September 19, 2022, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC
            (&#8220;Cowen&#8221;) to sell its common shares having an aggregate offering price of up to $400.0 million from time to time through an
            &#8220;at-the-market&#8221; equity offering program under which Cowen acts as the Company&#8217;s agent (the &#8220;ATM Facility&#8221;).</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;">As of December 31, 2023, the Company had $400.0 million of remaining capacity available under the ATM Facility.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">(B) Common Share
              Purchase and Share Agreements</div>

<div style="text-align: left; font-weight: normal; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In September 2023, the Company entered into common share purchase and sale agreements with certain institutional investors, pursuant to which the Company sold an aggregate of 19,600,685 of its common shares at a purchase price of $10.21
              per share. Net proceeds to the Company were approximately $199.8 million after deducting offering expenses.</div>

<div style="text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
              </span></div>

<div style="text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(C) Consolidated Vant Equity Transaction</span></div>

<div style="text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                  </span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Immunovant</span></span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">In <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">October 2023, the Company&#8217;s subsidiary, Immunovant, Inc. (&#8220;Immunovant&#8221;), completed an underwritten public offering of 8,475,500
                shares of its common stock (including 1,526,316 shares of common stock purchased by the Company on the same terms as other
                investors in the offering and the full exercise of the underwriters&#8217; option to purchase 1,105,500 additional shares of common
                stock) at a price to the public of $38.00 per share. Concurrent with the public offering, the Company purchased 4,473,684 shares of Immunovant&#8217;s common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as
                amended, at the same price per share as investors in the public offering of $38.00 per share. The net proceeds to Immunovant were
                approximately $466.7 million after deducting underwriting discounts and commissions, placement agent fees and offering expenses.
                The Company&#8217;s equity ownership interest in Immunovant is approximately 55% as of&#160;</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, and the Company continues to consolidate
                Immunovant</span>. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658941186464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 9&#8212;Share-Based Compensation</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) RSL Equity Incentive Plans</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">RSL has three equity incentive
          plans: the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#8220;RSL 2021 EIP&#8221;), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan
          (collectively, the &#8220;RSL Equity Plans&#8221;). The RSL 2021 EIP was approved and adopted in connection with the Business Combination and became effective immediately prior to closing. At December 31, 2023, a total of 41,986,389 common shares were available for future grants under the RSL 2021 EIP.</div>

<div><br/></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Stock Options and Performance Stock Options</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for stock options and performance stock options under the RSL Equity Plans for the nine months ended December 31, 2023 was as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of Options</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Options outstanding at&#160;March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>154,271,791</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>4,497,911</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: 0pt; margin-left: 9pt; width: 88%; background-color: #CCEEFF;" valign="bottom">Exercised<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(10,796,348</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited/Canceled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(604,245</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Options outstanding at December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>147,369,109</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Options exercisable at&#160;December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>91,671,364</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Restricted Stock Units and Performance Stock Units</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for restricted stock units and performance stock units under the RSL Equity Plans for the nine months ended December 31, 2023 was as
          follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Non-vested balance at&#160;March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>20,700,788</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>4,199,120</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Vested</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(5,498,323</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(1,175,450</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Non-vested balance at&#160;December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>18,226,135</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Capped Value Appreciation Rights</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">March 2020 CVAR Grants</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">As <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of&#160;</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">December 31, 2023</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, 27,531,825 CVARs remain outstanding and subject to
              the applicable hurdle price and knock-in condition. All outstanding capped value appreciation rights</span> (&#8220;CVARs&#8221;) <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">relating to the March 2020 grants had met the service vesting condition as of December 31, 2023. During the&#160;</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">nine months ended December 31, 2023</span>,
            4,499,113 service-vested CVARs satisfied their applicable hurdle price and the knock-in condition, if relevant, on the applicable
            measurement date, and as a result, 1,445,420 common shares were issued upon their settlement</span>.<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">November 2021 CVAR Grants</span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for CVARs under the RSL 2021 EIP for the nine months ended December 31, 2023 was as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of CVARs</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Non-vested balance at&#160;March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>3,222,645</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Vested</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(955,782</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Forfeited</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(128,377</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Non-vested balance at&#160;December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>2,138,486</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">During the nine months ended December 31, 2023, 955,782 common shares were issued upon their settlement.</span><br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: bold;"> </span> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="font-weight: bold;">(B) Subsidiary Equity Incentive Plans</span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: bold;"> <span style="font-weight: normal;"><br/>
            </span></span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain subsidiaries of
              RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive non-qualified and incentive
              stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. The Company recorded share-based compensation expense of $23.3 million and $53.1 million for
              the three and nine months ended December 31, 2023, respectively, and $13.7 million and $37.8 million for the three and nine months ended December 31, 2022, respectively, related to subsidiary EIPs.</span><br/>
          </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140659029117120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 10&#8212;Income Taxes</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s effective tax rate for the three and nine <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">months













            ended <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">December 31</span>, 2023 was </span>0.5%
          and 0.7%, respectively, and the effective tax rate for the three and nine months ended December 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> was (0.7)% and (0.9)%, </span>respectively. The effective tax rates for three and nine months ended December 31, 2023 are driven by the Company&#8217;s gain on sale of Telavant net assets,
          which qualifies for the substantial shareholding exemption and consequently is not subject to the corporation income tax, as well as the jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net
          deferred tax assets. The effective tax rates for three and nine months ended December 31, 2022 are driven by the jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company assesses the realizability of its deferred tax assets at each balance sheet date based on available positive and negative evidence in
          order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658941019712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 11&#8212;Commitments and Contingencies</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(A) Commitments</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has entered into commitments under various asset acquisition and license agreements. Additionally, the Company enters into agreements with contract service providers to assist in the performance of its
            research and development activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods
            and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and
            supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company also has commitments relating to its long-term debt and leases. Refer to Note 7, &#8220;Long-Term Debt&#8221; for further information. There have been no material changes to the commitments relating to the Company&#8217;s
              leases during the nine months ended December 31, 2023 outside the ordinary course of business. For further information regarding the Company&#8217;s lease commitments, refer to Note 15, &#8220;Leases&#8221; in the Company&#8217;s Annual Report on Form 10-K for the
              year ended March 31, 2023. </span></span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
        </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Purchase Commitments</span><br/>
            </span></span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 18pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
            </span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-variant: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-transform: none;">In conjunction with Dermavant&#8217;s entry into the GSK
            Agreement in 2018, Dermavant entered into a clinical supply agreement pursuant to which GSK would provide a supply of tapinarof and clinical product at an agreed upon price during the Company&#8217;s clinical trials. In April 2019, Dermavant entered
            into a commercial supply agreement with GSK to continue to provide certain quantities of tapinarof and commercial product at agreed upon minimum quantities and price. The commercial supply agreement commenced in April 2022 upon completion of
            certain quality and regulatory conditions. In July 2022, Dermavant and GSK amended the terms of the clinical supply and commercial supply agreements which released GSK of certain commitments to supply tapinarof and released Dermavant of certain
            commitments to purchase tapinarof in exchange for a supplementary fee. Other supply and purchase commitments under the agreements remain in effect. In addition, Dermavant and Thermo Fisher Scientific (&#8220;TFS&#8221;) entered into a Commercial
            Manufacturing and Supply Agreement for which TFS agreed to provide a supply of tapinarof to Dermavant at an agreed upon price. The agreements discussed above require Dermavant to purchase certain quantities of inventory over a period</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> of five years. As of December 31, 2023, the remaining minimum purchase commitment related to these agreements was estimated to be approximately $43.1 million. </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">In
        November 2021, the Company&#8217;s subsidiary, Immunovant, entered into a Product Service Agreement (&#8220;PSA&#8221;) with Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) by which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial
        sale and perform other manufacturing-related services with respect to batoclimab. As of December 31, 2023, the remaining minimum purchase commitment related to this agreement was estimated to be approximately $18.3 million. Immunovant had the right to terminate the PSA with 30 days&#8217; written notice to Samsung, exercisable no later than January 2024, in the event Immunovant decided to stop all development of, and all attempts to obtain regulatory approval for,
        batoclimab; subject to payment to Samsung of non-cancellable service fees and costs incurred by Samsung for all batches of batoclimab scheduled to be manufactured during the two-year period following such termination. Because efforts to develop and
        obtain regulatory approval for batoclimab remain ongoing, Immunovant did not exercise that early termination right and it has lapsed. As a result, Immunovant has an additional minimum obligation to Samsung of approximately $28.0 million to purchase additional batches of batoclimab in the four-year period of 2026 through 2029.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><br/></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In May 2021, the Company entered into a master subscription agreement with Palantir Technologies Inc. (&#8220;Palantir&#8221;) for access to Palantir&#8217;s proprietary software for a five-year period. As of December 31, 2023, the remaining minimum payments for this software subscription were $19.1 million.</span><br/>
        </div>

<div> <br/>
        </div>

<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify;"> <span style="font-weight: bold; font-style: italic; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash
          Bonus Program</span><br/>
      </div>

<div> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023, the Company approved a special one-time cash retention bonus award to its employees in the aggregate amount of $76.9 million (the &#8220;<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash Bonus Program&#8221;)</span>. During the three and nine months ended December 31, 2023, the Company recognized selling, general and administrative expense and research and development expense of $27.2 million and $8.1
            million, respectively, representing the portion of the bonus award that was vested and payable immediately. The remaining portion will be recognized over the applicable service period of the award. In February 2024, the Company expanded this
            Cash Bonus Program to include an award to its Chief Financial Officer on similar terms as the other awards previously made to other employees. The Chief Financial Officer did not receive a payment from the Cash Bonus Program approved in
            December. This award to the Chief Financial Officer was in the aggregate amount of $2.8 million. Fifty percent of the bonus will be payable within 30 days of the grant date, with the balance subject to vesting tied to the employee&#8217;s continued service to the Company, as described in more detail in Part II, Item 5 of this Quarterly Report.</span><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">(B) Loss Contingencies</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable
            that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim,
            including an estimable range, if possible. </span></div>

<div><br/></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;">Immunovant Securities
          Litigation</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In February 2021, a putative securities class action complaint was filed against Immunovant and certain of its current and former officers in the U.S. District Court for the Eastern District of New
              York on behalf of a class consisting of those who acquired Immunovant&#8217;s securities from October 2, 2019 and February 1, 2021. The complaint alleged that Immunovant and certain of its officers violated Sections 10(b) and 20(a) of the
              Securities Exchange Act of 1934, as amended, by making false and misleading statements regarding the safety of batoclimab and sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including
              reasonable attorneys&#8217; fees. In December 2021, the U.S. District Court appointed a lead plaintiff. In March 2022, the lead plaintiff filed an amended complaint adding both (i) the Company and (ii) Immunovant&#8217;s directors and underwriters as
              defendants, and asserting additional claims under Section 11, 12(a)(2), and 15 of the Securities Act of 1933, as amended, on behalf of a putative class consisting of those who purchased or otherwise acquired Immunovant&#8217;s securities pursuant
              and/or traceable to Immunovant&#8217;s follow-on public offering on or about September 2, 2020. In February 2023, after further briefing on the amended complaint the U.S. District Court issued an order permitting the lead plaintiff to file a second
              amended complaint. That second amended complaint was filed in March 2023. The defendants&#8217; served motions to dismiss the second amended complaint on April 28, 2023. The fully briefed motions to dismiss, including defendants&#8217; opening briefs,
              lead plaintiff&#8217;s opposition and defendants&#8217; replies, were filed with the court on June 30, 2023. No hearing date has yet been set. The Company intends to continue to vigorously defend the case and has not recorded a liability related to this
              lawsuit because, at this time, the Company is unable to reasonably estimate possible losses or determine whether an unfavorable outcome is either probable or remote.</span> </span> <span style="font-size: 10pt;"> </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"> </span><br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;">Acuitas Declaratory
          Judgment Action</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In March 2022,
              Acuitas Therapeutics Inc. (&#8220;Acuitas&#8221;) filed a lawsuit in the U.S. District Court for the Southern District of New York (&#8220;SDNY&#8221;) against two of the Company&#8217;s affiliates, Genevant and Arbutus, seeking a declaratory judgment that certain patents
              held by Arbutus and licensed by Genevant are not infringed by the manufacture, use, offer for sale, sale or importation into the United States of COMIRNATY, Pfizer&#8217;s and BioNTech&#8217;s vaccine for COVID-19 and are otherwise invalid. On September
              6, 2022, Acuitas filed a First Amended Complaint. In response, on October 4, 2022, Genevant and Arbutus filed a motion to dismiss the first amended complaint for lack of a controversy and supporting brief. Briefing on this motion was
              completed in mid-November. On August 4, 2023, Acuitas voluntarily dismissed the action in the SDNY and re-filed a complaint in the U.S. District Court for the District of New Jersey. On October 13, 2023, Genevant and Arbutus filed a motion to
              dismiss the re-filed complaint. No hearing date has been set. Each of Genevant and Arbutus intends to continue to vigorously defend the case.</span> </span> </div>

<div><br/></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">(C) Indemnification
          Agreements</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the
            occurrence of certain events. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company also indemnifies each of its directors and officers for certain events or occurrences,
            subject to certain limits. The maximum amount of potential future indemnification is unlimited; however, the Company currently maintains director and officer liability insurance, which may cover certain liabilities arising from the Company&#8217;s
            obligation to indemnify its directors and officers. To date, the Company has not incurred any material costs related to these indemnification obligations and has not accrued any liabilities related to such obligations in the condensed
            consolidated financial statements as of December 31, 2023 and March 31, 2023. </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658941212304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earn-Out Shares, Public Warrants and Private Placement Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock', window );">Earn-Out Shares, Public Warrants and Private Placement Warrants</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 12&#8212;Earn-Out Shares, Public Warrants and Private Placement Warrants</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Earn-Out Shares</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">In connection with the Business Combination, the Company issued the following: </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="c2d6ce1f9431483b81d4e2da22271795" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 27pt;"></td>

    <td style="vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(a)<br/>
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify;">2,033,591 common shares to Patient Square Capital LLC (the &#8220;MAAC Sponsor&#8221;) and 10,000 common shares issued to each of MAAC&#8217;s independent directors (collectively, the &#8220;20% Earn-Out Shares&#8221;), which will vest if the closing price of the Company&#8217;s common shares is greater than or equal to $15.00 over any <span style="-sec-ix-hidden:Fact_2cef63e668c241b7bc426da933f7f568">twenty</span> out of <span style="-sec-ix-hidden:Fact_d2125a9df960461aa915b45e9db9e81b">thirty</span> trading day period during the Vesting Period (defined below).</div>
              </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="c759375f6a474886b6c60be6cd797d32" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 27pt;"></td>

    <td style="vertical-align: top; width: 36pt;">(b)<br/>
              </td>

    <td style="vertical-align: top; width: auto; text-align: justify;">1,016,796 common shares issued to the MAAC Sponsor and 5,000 common shares issued to each of MAAC&#8217;s independent directors (collectively, the &#8220;10% Earn-Out Shares&#8221; and, together with the 20% Earn-Out Shares, the
                &#8220;Earn-Out Shares&#8221;), each in respect of its MAAC Class B Shares, will vest if the closing price of the Company&#8217;s common shares is greater than or equal to $20.00 over any <span style="-sec-ix-hidden:Fact_227cc2a973b342cdadc7924eb0824d99">twenty</span> out of <span style="-sec-ix-hidden:Fact_938065e85885426b93d64ce0a73dd639">thirty</span> trading day period during the Vesting Period (as defined below).</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ad9db901fae345a298e6d370b7b21acf" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 27pt;"></td>

    <td style="vertical-align: top; width: 36pt;">(c)<br/>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify;">The remaining number of common shares issued to the MAAC Sponsor and each of MAAC&#8217;s independent director are not subject to the vesting conditions described above (the &#8220;Retained Shares&#8221;).</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Vesting Period commenced on November 9, 2021 and ends no later than September 30, 2026 (the &#8220;Vesting Period&#8221;). The Vesting Period will, if a definitive purchase agreement with respect to a Sale (as defined in the
            Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs
            during such Vesting Period, then all of the Earn-Out Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any Earn-Out Shares have not vested on or prior to the end of such Vesting
            Period, then such Earn-Out Shares will be forfeited. </span></div>

<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">
          The Earn-Out Shares require liability classification and are classified as &#8220;Liability instruments measured at fair value&#8221; on the condensed consolidated balance sheets. The Earn-Out Shares liability is subject to remeasurement at each balance
          sheet date with changes in fair value recognized in the Company&#8217;s statements of operations. As of December 31, 2023, no Earn-Out
          Shares have vested. </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt;"><br/>
          </span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Public Warrants and Private Placement Warrants</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Immediately following the Business Combination, the Company had 10,214,365 outstanding warrants for the
            purchase of one of the Company&#8217;s common shares, which were held by the MAAC Sponsor at an exercise price of $11.50 (the &#8220;Private
            Placement Warrants&#8221;), and 20,535,896 outstanding warrants for the purchase of one of the Company&#8217;s common shares, which were held by
            MAAC&#8217;s shareholders at an exercise price of $11.50<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;(the &#8220;Public Warrants&#8221; and, together with the Private Placement
              Warrants, the &#8220;Warrants&#8221;). Pursuant to the Warrant Agreement, dated October 6, 2020, by and between the Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;) and Continental Stock Transfer &amp; Trust Company, as predecessor warrant agent, as modified
              by the Warrant Assumption Agreement, dated September 30, 2021, by and among MAAC, the Company and American Stock Transfer &amp; Trust Company, LLC as successor warrant agent (as modified, the &#8220;Warrant Agreement&#8221;), the Warrants </span>became
            exercisable 30 days following the completion of the Business Combination and would expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation. </span></div>

<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span>
         <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Prior to their settlement, the Warrants required liability classification and were classified as &#8220;Liability instruments measured at fair value&#8221; on the condensed consolidated balance sheets. The Private Placement
              Warrants liability and Public Warrants liability were subject to remeasurement with changes in fair value recognized in the Company&#8217;s statements of operations. The Warrants were remeasured immediately prior to settlement. These remeasurements
              were recognized in &#8220;Change in fair value of debt and liability instruments&#8221; in the accompanying condensed consolidated statements of operations. </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 18pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Under the terms of the Warrant Agreement, the Company was entitled to redeem the Public Warrants at a redemption price of $0.10
            per Public Warrant because the last reported sales price (the &#8220;Reference Value&#8221;) of the Company&#8217;s common shares was at least $10.00
            per share for any twenty (20) trading days within the thirty (30) trading-day period ending on the third trading day prior to the date on which RSL gave a Notice of Redemption. In addition, because the Reference Value was less than $18.00 per share, the outstanding Private Placement Warrants were also required to be concurrently called for redemption on the same terms as the
            outstanding Public Warrants. This share price performance requirement was satisfied as of July 28, 2023. On August 2, 2023, the Company announced that it would redeem all Warrants that remain outstanding on September 1, 2023 (the &#8220;Redemption
            Date&#8221;).</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;">Prior
















          to the Redemption Date, Warrant holders were permitted to exercise the Warrants (i) for cash, at an exercise price of $11.50 per common
          share, or (ii) on a &#8220;cashless basis&#8221; whereby, in lieu of paying the Company the $11.50 exercise price per common share, the
          surrendering holder would receive approximately 0.2495 common shares per Warrant as determined in accordance with the terms of the
          Warrant Agreement.</div>

<div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Of the 20,475,875 Public Warrants that were outstanding as of June 30, 2023, 397 Public Warrants were exercised for cash at an exercise price of $11.50 per common share in exchange for an aggregate of 397 common shares and 20,061,507 were exercised on a cashless basis in exchange for an aggregate of 5,005,531 common shares. The remaining 413,971 unexercised Public Warrants
            were redeemed at the $0.10 redemption price. In addition, all of the Private Placement Warrants were exercised on a cashless basis in
            exchange for an aggregate of 2,548,621 common shares.</span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of earn-out shares, public warrants and private placement warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140659029117120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 13&#8212;Fair Value Measurements</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Recurring Fair Value Measurements</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The
      following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and March 31, 2023, by level, within the fair value hierarchy (in thousands): </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 9pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 1</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 2</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 3</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Balance as of</div>
            <div style="text-align: center; font-weight: bold;">December 31,</div>
            <div style="text-align: center; font-weight: bold;">2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 1</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 2</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 3</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Balance as <br/>
            </div>
            <div style="text-align: center; font-weight: bold;">of March 31,</div>
            <div style="text-align: center; font-weight: bold;">2023 </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Assets:</div>
          </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Money market funds</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,513,936</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,513,936</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,496,726</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,496,726</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Investment in Datavant Class A units</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Investment in Arbutus common shares</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>97,119</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>97,119</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>117,708</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>117,708</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Other investments</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>6,874</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>6,874</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>8,030</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>8,030</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Total assets at fair value</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,617,929</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,753,863</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,622,464</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,801,043</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Liabilities:</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Debt issued by Dermavant to NovaQuest</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>221,510</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>221,510</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>207,640</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>207,640</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Liability instruments measured at fair value<sup>(1)</sup></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>28,374</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>28,374</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>29,895</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>33,651</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>63,546</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Total liabilities at fair value</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>249,884</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>249,884</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>29,895</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>241,291</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>271,186</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
    </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
            <div style="font-style: normal;"><sup>(1)</sup></div>
          </td>

    <td style="width: 96%; vertical-align: top;">
            <div style="text-align: justify;">At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $24.9 million and other liability instruments issued of $3.5 million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $29.9
              million, and Level 3 includes the fair value of the Earn-Out Shares of $15.2 million, Private Placement Warrants of $15.2 million, and other liability instruments issued of $3.3 million.</div>
          </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy that occurred during the nine months ended December 31, 2023. </span> </div>

<div><br/></div>

<div style="font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Level 3 Disclosures</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company measures its Level 3 assets and liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. The
        valuation of the Level 3 assets and liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as
        additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </span></div>

<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span> </div>

<div><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"> The
      fair value of Level 3 assets and liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information,
      considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value
      amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      <br/>
    </div>

<div><span style="font-size: 10pt;"> </span>
  <span style="font-size: 10pt;"> </span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The changes in fair value of the Level 3
      assets during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">193,963</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_5ffcc6c700034d4587790a5e791d733c">Changes in fair value of investment in Datavant, included in net loss</span></span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(21,452</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">172,511</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_1bcdc2e95f0b40ac8041dbfa7444510a">Changes in fair value of investment in Datavant, included in net loss</span></span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>(42,645</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The
      changes in fair value of the Level 3 liabilities during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Balance at <span style="text-indent: 0pt;">March 31</span>, </span><span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>204,293</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">Fair value of liability instrument issued <br/>
            </div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">248</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Payments related to long-term
                debt</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(22,031</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_93006666e195494db2e26107da08a25a">Changes in fair value of debt and liability instruments, included in net loss</span></span> </span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
            <div>68,328</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>250,838</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>241,291</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Payments related to long-term
                debt</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(22,031</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Exercise of Private Placement Warrants</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(28,090</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_ca3f4592024941f287ede17a07ff606d">Changes in fair value of debt and liability instruments, included in net loss</span></span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">58,714</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">249,884</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Investment in Datavant</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method
        (&#8220;OPM&#8221;). The OPM allows for the allocation of a company&#8217;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#8217; liquidation preferences, participation rights, dividend
        policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The fair value was calculated using significant unobservable inputs including the following: </span></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="font-weight: bold; font-style: normal;">Input</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
            <div>Volatility</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: center;">95.0%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: center;">100.0%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
            <div>Risk-free rate</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="text-align: center;">4.46%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="text-align: center;">4.02%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>


</table>

<div><br/></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Debt issued by Dermavant to NovaQuest</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt;"><br/>
      </span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The fair value of the debt instrument as of December 31, 2023 and March 31, 2023 represents the fair value of amounts payable to NovaQuest calculated using the Monte Carlo simulation method under the income approach
        determined by using probability assessments of the expected future payments through 2032. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The
        estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Earn-Out Shares</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The fair value of the Earn-Out Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the lock-up periods to
        which the Earn-Out Shares are subject. Refer to Note 12, &#8220;Earn-Out Shares, Public Warrants and Private Placement Warrants&#8221; for additional details. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Significant unobservable inputs used to calculate the fair value of the Earn-Out Shares included the following: </span></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="font-weight: bold;">Input</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
            <div>Volatility</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">61.9%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">79.9%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
            <div>Risk-free rate</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">4.07%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">3.76%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2023 and March 31, 2023, the fair value of the Earn-Out Shares was $24.9 million and $15.2 million, respectively. Earn-Out Shares were included in &#8220;<span style="-sec-ix-hidden:Fact_896fc6f03cbf47ba9500416e14491b89">Liability instruments measured at fair value</span>&#8221; in the accompanying condensed consolidated balance sheets. </span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0px;"><span style="font-size: 10pt;"> </span><br/>
    </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Private Placement Warrants</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Prior to their settlement, the fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured
        to incorporate the redemption features as discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private Placement Warrants&#8221; and the added restriction by which the Company could not redeem the Private Placement Warrants if the Reference Value
        was greater than $18.00. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Significant unobservable
        inputs used to calculate the fair value of the Private Placement Warrants included the following: </span></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="font-weight: bold;">Input</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div>Volatility</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-align: center;">50.5%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.43%;" valign="bottom">
            <div>Risk-free rate</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%;" valign="bottom">
            <div style="text-align: center;">3.76%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div>Term (in years)</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-align: center;">3.50</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In August 2023, the Company announced that it would redeem all Warrants that remain outstanding on September 1, 2023. All of the Private Placement Warrants were exercised. As of March 31, 2023, the fair value of the Private Placement
        Warrants was $15.2 million, which was included in &#8220;<span style="-sec-ix-hidden:Fact_8076c0698f4040ad9216b28dd1dd2471">Liability instruments measured at fair value</span>&#8221; in the accompanying condensed consolidated balance sheets. </span>  </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931589744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Income (Loss) per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) per Common Share</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Note 14&#8212;Net Income (Loss) per Common Share</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Basic net income (loss) per common share is computed by dividing net income (loss) attributable to Roivant Sciences Ltd. by the
          weighted-average number of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common
          stock outstanding during the period.</span> <span style="font-size: 10pt;"> </span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"><br/>
        </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The computations for basic and diluted net income (loss) per common share were as follows (in thousands, except share and per share amounts):</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Three Months Ended December 31,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Nine Months Ended December 31,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2022</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2023</div>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2022</div>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Numerator:</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Net income (loss) attributable to Roivant Sciences Ltd.<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">5,096,184</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(352,014</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">4,500,041</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(975,413</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 52%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Denominator:</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Weighted average shares outstanding, basic</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">800,587,716<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">713,319,399</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">776,759,728<br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">703,054,773</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Effect of dilutive common stock equivalents</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">43,873,969<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">47,550,285<br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Weighted average shares outstanding, diluted</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">844,461,685<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">713,319,399</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">824,310,013<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">703,054,773</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net income (loss) per common share, basic</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">6.37<br/>
              </span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(0.49</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$<br/>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">5.79<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(1.39</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net income (loss) per common share, diluted</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">6.03<br/>
              </span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(0.49</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">5.46<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(1.39</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>


</table>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
    </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. For the three and nine months ended
          December 31, 2022, all outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss. </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt;"><br/>
        </span> </div>

<div><span style="font-size: 10pt;"> </span></div>

<div><span style="font-size: 10pt;"> </span>
    <span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As
        of December 31, 2023 and 2022, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net income (loss) per common share because including them would have been anti-dilutive: </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">December 31, 2022</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Stock options and performance stock options</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>65,518,394</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>154,631,025</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Restricted stock units and performance stock units (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>5,422,465</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>22,153,774</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">March 2020 CVARs<sup>(1)</sup></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>17,548,368</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>32,011,996</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">November 2021 CVARs (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>359,730</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>3,609,021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Restricted common stock (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>238,059</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>730,522</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Earn-Out Shares (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>3,080,387</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>3,080,387</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Private Placement Warrants</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>&#8212;</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>10,214,365</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Public Warrants</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>&#8212;</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>20,475,875</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="margin-left: 9pt; text-indent: -9pt;">Other stock based awards and instruments issued</div>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">4,147,404</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">6,178,990</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
              <div><sup>(1)</sup></div>
            </td>

    <td style="width: 96%; vertical-align: top;">
              <div style="text-align: justify;">Refer to Note 9, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs.</div>
            </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658927128768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s fiscal year ends on March 31, and its fiscal quarters end on June 30, September 30, and December 31.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
          accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and follow the requirements of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Accordingly, these unaudited condensed
          consolidated financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be
          condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial
          statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the SEC. The unaudited condensed consolidated balance sheet at March 31, 2023 has been derived from the audited
          consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial
          position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the nine months ended December 31,
          2023 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2024, for any other interim period, or for any other future year.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting
          Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Updates (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in
          which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to
          noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents
          noncontrolling interests as a component of shareholders&#8217; equity on its unaudited condensed consolidated balance sheets.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying
          amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest
          is adjusted is recognized within shareholders&#8217; equity attributable to RSL.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(B) Use of Estimates</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts
          reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development
          costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
          values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">(C) Concentrations</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company
          maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and
          liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has long-lived assets in different geographic locations. As of December 31, 2023 and March 31, 2023, a majority of the Company&#8217;s
          long-lived assets were located in the United States.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">(D) Cash, Cash
          Equivalents, and Restricted Cash</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company
          considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted
          cash as presented on the accompanying condensed consolidated balance sheets as follows (in thousands):</div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> December 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Cash and cash equivalents</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>6,670,810</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>1,676,813</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Restricted cash (included in &#8220;Other current assets&#8221;)<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,165</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,011</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt">Restricted cash (included in &#8220;Other assets&#8221;)<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">9,483</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">10,291</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div>Cash, cash equivalents and restricted cash</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>6,685,458</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1,692,115</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(E) Contingencies</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually
          assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at
          which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the
          Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(F) Investments</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Investments in equity securities may be accounted for using (i) the fair value option, if elected, (ii) fair value through earnings if fair value
          is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the
          measurement alternative is made for each eligible investment.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company
          believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Equity Method Investments.&#8221;</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">(G) Fair Value Measurements</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance
          establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are
          inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market
          participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received
          to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a
          three-tier fair value hierarchy that distinguishes among the following:</div>

<div><br/></div>

<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                  <div style="text-align: left;">&#8226;</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">Level 1-Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</div>
                </td>

  </tr>


</table>
        </div>

<div><br/></div>

<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                    <div>&#8226;</div>
                  </td>

    <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">Level 2-Valuations are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models
                      for which all significant inputs are observable, either directly or indirectly.</div>
                  </td>

  </tr>


</table>
          </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div>
              <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 36pt;">
                      <div>&#8226;</div>
                    </td>

    <td style="vertical-align: top; width: auto;">
                      <div style="text-align: justify;">Level 3-Valuations are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement.</div>
                    </td>

  </tr>


</table>
            </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value
          requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the
          lowest level of any input that is significant to the fair value measurement.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of common stock of
          Heracles Parent, L.L.C., the parent entity of Datavant, (as defined and discussed in Note 3, &#8220;Equity Method Investments&#8221;); liability instruments issued, including warrant and earn-out shares liabilities issued in connection with the Company&#8217;s
          business combination with MAAC (as discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private Placement Warrants&#8221;); its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and
          long-term debt.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;">The shares of Arbutus common stock and
          investments in common stock with a readily determinable fair value are classified as Level 1, and their fair value is determined based upon quoted market prices in an active market. The shares of common stock of Heracles Parent, L.L.C., the
          parent entity of Datavant (as defined and discussed in Note 3, &#8220;Equity Method Investments&#8221;) and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 12, &#8220;Earn-Out Shares, Public Warrants and Private
          Placement Warrants&#8221;), are classified as Level 3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Prior to their settlement, the Public Warrants were publicly traded and
          therefore were classified as Level 1 as the Public Warrants had a readily determinable fair value. Cash and accounts payable are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature.
          Money market funds are included in Level 1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly
          owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level 2 of the fair value hierarchy. Long-term debt issued
          by Dermavant for which the fair value option has been elected is included in Level 3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Significant Accounting Policies /Recently Adopted/ Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(H) Significant Accounting Policies</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">There were no significant changes to the Company&#8217;s significant accounting policies from those disclosed in the Company&#8217;s Form 10-K for the year ended March 31, 2023.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(I) Recently Adopted Accounting Pronouncements</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">The Company did not adopt any material accounting pronouncements during the nine months ended December 31, 2023.</div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(J) Recently Issued Accounting Pronouncements Not Yet Adopted<br/>
        </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In
            November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&#8221; which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant
            segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU is applicable to the Company&#8217;s Annual Report on Form 10-K
            for the fiscal year ended March 31, 2025, and subsequent interim periods, with early adoption permitted. These amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently
            evaluating the impact of adopting this ASU on its consolidated financial statements</span>.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 18pt; text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In December 2023, the FASB issued ASU 2023-09, &#8220;Income
            Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; which includes updates to the income tax disclosures related to the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments are effective for fiscal
            years beginning after December 15, 2024 and is applicable to the Company&#8217;s fiscal year beginning April 1, 2025, with early adoption permitted. The amendments should be applied prospectively, however retrospective application is permitted. The
            Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span>  </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140659028924800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted
          cash as presented on the accompanying condensed consolidated balance sheets as follows (in thousands):</div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> December 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Cash and cash equivalents</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>6,670,810</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>1,676,813</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Restricted cash (included in &#8220;Other current assets&#8221;)<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,165</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,011</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt">Restricted cash (included in &#8220;Other assets&#8221;)<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">9,483</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">10,291</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div>Cash, cash equivalents and restricted cash</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>6,685,458</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>1,692,115</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936606816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Recognized Intangible Assets</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The following table summarizes the Company&#8217;s recognized intangible assets (in thousands):<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">December 31, 2023</span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="text-align: center;">

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Gross amount</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">166,471</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>152,629</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Less: accumulated amortization</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(16,056</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(7,748</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt;">Net book value</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">150,415</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>144,881</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658941186464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_RecentTransactionsAbstract', window );"><strong>Recent Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock', window );">Calculation of Gain</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">The table below summarizes
      the calculation of the gain.</span>
<div>&#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(in</span><span style="font-weight: bold;"> thousand</span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);"><span style="font-weight: bold;">s</span>)</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Consideration:</div>
          </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Upfront cash payment</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">5,234,373</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Carrying amount of noncontrolling interest derecognized</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">87,500</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total consideration</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5,321,873</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Assets sold</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,253</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Liabilities transferred</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">29,790</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Net liabilities sold</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(26,537</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">)</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Gain on sale of Telavant net assets</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman';">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
            <div><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,348,410</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RecentTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RecentTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to the calculation of the gain on sale of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931783376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CertainBalanceSheetComponentsAbstract', window );"><strong>Certain Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other Current Assets</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;">Other current assets at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 24.5pt;"> <br/>
          </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';">March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Prepaid expenses</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">52,642</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">60,827</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Trade receivables, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">41,078</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">30,379</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">Restricted cash</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">5,165</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom">5,011</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; font-weight: normal;" valign="bottom">Inventory <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom">5,240</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom">2,761</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Income tax receivable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">3,209</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">2,356</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom">Interest receivable</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">18,901</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,909</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">9,688</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;">15,531</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; text-align: justify;">Total other current assets</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">135,923</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">$</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-weight: normal;"><span style="color: rgb(0, 0, 0);">121,774</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Accrued expenses at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> December 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Research and development expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>43,627</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>76,278</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Compensation-related expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>41,406</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>55,186</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">Sales allowances</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">16,808</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">17,569</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Other expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>20,307</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>18,096</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt;">Total accrued expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>122,148</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>167,129</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Other current liabilities at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 24.5pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">December 31, 2023<br/>
                  </div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">March 31, 2023<br/>
                  </div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Deferred revenue</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>4,695</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>12,444</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Income tax payable</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>25,223</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>542</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div>1,424</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div>2,090</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-align: left; text-indent: 0pt; margin-left: 9pt;">Total other current liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>31,342</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>15,076</div>
                </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
            </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CertainBalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CertainBalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658927151680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables) - Dermavant [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Funding Agreement with NovaQuest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-Term Debt</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The carrying balance of the debt issued to NovaQuest was as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Fair value of long-term debt</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>221,510</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>207,640</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Less: current portion</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(26,950</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(26,940</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Total long-term debt, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>194,560</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>180,700</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Credit Facility with XYQ Luxco [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-Term Debt</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Outstanding debt obligations to XYQ Luxco were as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
              </td>

    <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Principal amount</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Exit fee</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Less: unamortized discount and debt issuance costs</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(8,221</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(10,170</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div>Total debt, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>36,779</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>34,830</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Less: current portion</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div>Total long-term debt, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>36,779</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>34,830</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-Term Debt</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">The RIPSA carrying balance was as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
                </td>

    <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;">March 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div>Carrying balance</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>195,297</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>178,571</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>Less: unamortized issuance costs</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(4,543</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(4,806</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div>Total debt, net</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>190,754</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div><br/>
                    </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>173,765</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div><br/>
                    </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div>
                    <div>Less: current portion</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(18,756</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>(13,780</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div>Total long-term debt, net</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>171,998</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>159,985</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
        </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_FundingAgreementWithNovaQuestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_FundingAgreementWithNovaQuestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_CreditFacilityWithXYQLuxcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_CreditFacilityWithXYQLuxcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931480960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock', window );">Activity for Stock Options and Performance Stock Options</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for stock options and performance stock options under the RSL Equity Plans for the nine months ended December 31, 2023 was as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of Options</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Options outstanding at&#160;March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>154,271,791</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>4,497,911</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; text-indent: 0pt; margin-left: 9pt; width: 88%; background-color: #CCEEFF;" valign="bottom">Exercised<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(10,796,348</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited/Canceled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(604,245</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Options outstanding at December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>147,369,109</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Options exercisable at&#160;December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>91,671,364</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock', window );">Activity for Restricted Stock Units and Performance Stock Units</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for restricted stock units and performance stock units under the RSL Equity Plans for the nine months ended December 31, 2023 was as
          follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Non-vested balance at&#160;March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>20,700,788</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>4,199,120</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Vested</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(5,498,323</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>(1,175,450</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Non-vested balance at&#160;December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>18,226,135</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock', window );">Activity for Capped Value Appreciation Rights</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;">Activity for CVARs under the RSL 2021 EIP for the nine months ended December 31, 2023 was as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of CVARs</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Non-vested balance at&#160;March 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>3,222,645</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Vested</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>(955,782</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Forfeited</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(128,377</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Non-vested balance at&#160;December 31, 2023</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>2,138,486</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the November 2021 capped value appreciation rights stock units activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Share Based Compensation Restricted Stock And Performance Stock Units Award Activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation Stock Options And Performance Options Activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658937969856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities are Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The
      following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and March 31, 2023, by level, within the fair value hierarchy (in thousands): </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 9pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 1</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 2</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 3</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Balance as of</div>
            <div style="text-align: center; font-weight: bold;">December 31,</div>
            <div style="text-align: center; font-weight: bold;">2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 1</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 2</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Level 3</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Balance as <br/>
            </div>
            <div style="text-align: center; font-weight: bold;">of March 31,</div>
            <div style="text-align: center; font-weight: bold;">2023 </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Assets:</div>
          </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Money market funds</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,513,936</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,513,936</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,496,726</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,496,726</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Investment in Datavant Class A units</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Investment in Arbutus common shares</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>97,119</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>97,119</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>117,708</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>117,708</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Other investments</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>6,874</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>6,874</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>8,030</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>8,030</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Total assets at fair value</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,617,929</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>6,753,863</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,622,464</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>1,801,043</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Liabilities:</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Debt issued by Dermavant to NovaQuest</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>221,510</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>221,510</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>207,640</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>207,640</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Liability instruments measured at fair value<sup>(1)</sup></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>28,374</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>28,374</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>29,895</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>33,651</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>63,546</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Total liabilities at fair value</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>249,884</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>249,884</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>29,895</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>241,291</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>271,186</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
    </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
            <div style="font-style: normal;"><sup>(1)</sup></div>
          </td>

    <td style="width: 96%; vertical-align: top;">
            <div style="text-align: justify;">At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $24.9 million and other liability instruments issued of $3.5 million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $29.9
              million, and Level 3 includes the fair value of the Earn-Out Shares of $15.2 million, Private Placement Warrants of $15.2 million, and other liability instruments issued of $3.3 million.</div>
          </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Fair Value of the Level 3 Assets</a></td>
<td class="text">
<div><span style="font-size: 10pt;"> </span>
  <span style="font-size: 10pt;"> </span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The changes in fair value of the Level 3
      assets during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">193,963</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_5ffcc6c700034d4587790a5e791d733c">Changes in fair value of investment in Datavant, included in net loss</span></span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(21,452</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">172,511</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>178,579</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_1bcdc2e95f0b40ac8041dbfa7444510a">Changes in fair value of investment in Datavant, included in net loss</span></span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div>(42,645</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>135,934</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Fair Value of the Level 3 Liabilities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;">The
      changes in fair value of the Level 3 liabilities during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Balance at <span style="text-indent: 0pt;">March 31</span>, </span><span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>204,293</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">Fair value of liability instrument issued <br/>
            </div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">248</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Payments related to long-term
                debt</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(22,031</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_93006666e195494db2e26107da08a25a">Changes in fair value of debt and liability instruments, included in net loss</span></span> </span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
            <div>68,328</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2022</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>250,838</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>$</div>
          </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div>241,291</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Payments related to long-term
                debt</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(22,031</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Exercise of Private Placement Warrants</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(28,090</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;"><span style="text-indent: 0pt;"><span style="-sec-ix-hidden:Fact_ca3f4592024941f287ede17a07ff606d">Changes in fair value of debt and liability instruments, included in net loss</span></span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">58,714</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-indent: -9pt; margin-left: 9pt;">Balance at&#160;<span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2023</span></div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">249,884</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Calculation Using Significant Unobservable Inputs</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Significant unobservable
        inputs used to calculate the fair value of the Private Placement Warrants included the following: </span></span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="font-weight: bold;">Input</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div>Volatility</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-align: center;">50.5%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.43%;" valign="bottom">
            <div>Risk-free rate</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%;" valign="bottom">
            <div style="text-align: center;">3.76%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div>Term (in years)</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom">
            <div style="text-align: center;">3.50</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember', window );">Earn-Out Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Calculation Using Significant Unobservable Inputs</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Significant unobservable inputs used to calculate the fair value of the Earn-Out Shares included the following: </span></span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="font-weight: bold;">Input</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
            <div>Volatility</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">61.9%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">79.9%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
            <div>Risk-free rate</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">4.07%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="text-align: center;">3.76%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_DatavantHoldingsIncMember', window );">Datavant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Calculation Using Significant Unobservable Inputs</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The fair value was calculated using significant unobservable inputs including the following: </span></span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Point Estimate Used</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="font-weight: bold; font-style: normal;">Input</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of December 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-weight: bold;">As of March 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
            <div>Volatility</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: center;">95.0%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: center;">100.0%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
            <div>Risk-free rate</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="text-align: center;">4.46%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="text-align: center;">4.02%</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div><br/>
            </div>
          </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_DatavantHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_DatavantHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658941954880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Income (Loss) per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computations for Basic and Diluted Net Income (Loss) Per Common Share</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The computations for basic and diluted net income (loss) per common share were as follows (in thousands, except share and per share amounts):</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Three Months Ended December 31,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Nine Months Ended December 31,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2023</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2022</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2023</div>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">2022</div>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Numerator:</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Net income (loss) attributable to Roivant Sciences Ltd.<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">5,096,184</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(352,014</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">4,500,041</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(975,413</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 52%;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Denominator:</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Weighted average shares outstanding, basic</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">800,587,716<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">713,319,399</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">776,759,728<br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">703,054,773</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Effect of dilutive common stock equivalents</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">43,873,969<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">47,550,285<br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Weighted average shares outstanding, diluted</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">844,461,685<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">713,319,399</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">824,310,013<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">703,054,773</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="margin-left: 9pt; text-indent: -9pt;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net income (loss) per common share, basic</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">6.37<br/>
              </span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(0.49</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$<br/>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">5.79<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(1.39</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net income (loss) per common share, diluted</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">6.03<br/>
              </span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(0.49</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-size: 10pt;">5.46<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">$</span></div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">(1.39</span></div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-size: 10pt;"><span style="color: rgb(0, 0, 0);">)</span></div>
          </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) per Common Share</a></td>
<td class="text">
<div><span style="font-size: 10pt;"> </span>
    <span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 18pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As
        of December 31, 2023 and 2022, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net income (loss) per common share because including them would have been anti-dilutive: </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">December 31, 2023</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">December 31, 2022</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Stock options and performance stock options</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>65,518,394</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>154,631,025</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Restricted stock units and performance stock units (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>5,422,465</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>22,153,774</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">March 2020 CVARs<sup>(1)</sup></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>17,548,368</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>32,011,996</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">November 2021 CVARs (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>359,730</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>3,609,021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Restricted common stock (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>238,059</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>730,522</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Earn-Out Shares (non-vested)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>3,080,387</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>3,080,387</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Private Placement Warrants</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>&#8212;</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div>10,214,365</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="text-indent: -9pt; margin-left: 9pt;">Public Warrants</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>&#8212;</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div>20,475,875</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="margin-left: 9pt; text-indent: -9pt;">Other stock based awards and instruments issued</div>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">4,147,404</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">6,178,990</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
              <div><sup>(1)</sup></div>
            </td>

    <td style="width: 96%; vertical-align: top;">
              <div style="text-align: justify;">Refer to Note 9, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs.</div>
            </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926582768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Liquidity (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DescriptionOfBusinessAbstract', window );"><strong>Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnSaleOfAssets', window );">Gain on sale of net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,348,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,348,410<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,670,810<span></span>
</td>
<td class="nump">6,670,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,670,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,676,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">727,287<span></span>
</td>
<td class="nump">727,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,772,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,072,665<span></span>
</td>
<td class="num">$ (331,118)<span></span>
</td>
<td class="num">$ (327,845)<span></span>
</td>
<td class="num">$ (384,896)<span></span>
</td>
<td class="num">$ (315,921)<span></span>
</td>
<td class="num">$ (353,784)<span></span>
</td>
<td class="nump">$ 4,413,702<span></span>
</td>
<td class="num">$ (1,054,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_TelavantHoldingsIncMember', window );">Telavant Holdings, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnSaleOfAssets', window );">Gain on sale of net assets</a></td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_TelavantHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_TelavantHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931781264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,670,810<span></span>
</td>
<td class="nump">$ 1,676,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash (included in "Other current assets")</a></td>
<td class="nump">5,165<span></span>
</td>
<td class="nump">5,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (included in "Other assets")</a></td>
<td class="nump">9,483<span></span>
</td>
<td class="nump">10,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 6,685,458<span></span>
</td>
<td class="nump">$ 1,692,115<span></span>
</td>
<td class="nump">$ 1,541,037<span></span>
</td>
<td class="nump">$ 2,074,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931723296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments, Investment in Arbutus (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_InvestmentsDisclosureAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares acquired (in shares)</a></td>
<td class="nump">804,890,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,890,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,143,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="nump">$ 239,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_InvestmentsDisclosureAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="nump">$ 97,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (losses) on investments</a></td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="num">$ (20,600)<span></span>
</td>
<td class="num">$ (25,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of common stock (in dollars per share)</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_InvestmentsDisclosureAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares acquired (in shares)</a></td>
<td class="nump">38,847,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,847,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_InvestmentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_InvestmentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658938738656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments, Investment in Datavant (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_InvestmentsDisclosureAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="nump">$ 239,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_CioxParentMember', window );">Datavant Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_InvestmentsDisclosureAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="nump">$ 135,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (losses) on investments</a></td>
<td class="num">$ (28,400)<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="num">$ (42,600)<span></span>
</td>
<td class="num">$ (21,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_InvestmentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_InvestmentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_CioxParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_CioxParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926170960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details)<br> $ in Thousands, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Recognized Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Remaining weighted average estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,748)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Future amortization expense, remainder of 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future amortization expense, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future amortization expense, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future amortization expense, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future amortization expense, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Future amortization expense, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Recognized Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember', window );">GSK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IntangibleAssetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MilestonePayable', window );">Milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">&#163; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MilestonePaid', window );">Milestone amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=roiv_WelichemBiotechIncMember', window );">Welichem Biotech Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IntangibleAssetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MilestonePayable', window );">Milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MilestonePaid', window );">Milestone amount paid</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IntangibleAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IntangibleAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made during the period for achieving the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=roiv_WelichemBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=roiv_WelichemBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926951920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Transactions, Telavant Disposition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 14, 2023</div></th>
<th class="th"><div>Dec. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupConsiderationAbstract', window );"><strong>Consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnSaleOfAssets', window );">Gain on sale of Telavant net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,348,410<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,348,410<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_TelavantHoldingsIncMember', window );">Telavant Holdings, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupConsiderationAbstract', window );"><strong>Consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_IncomeLossFromDisposalGroupBeforeIncomeTax', window );">Pretax loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,300)<span></span>
</td>
<td class="num">$ (89,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_TelavantHoldingsIncMember', window );">Telavant Holdings, Inc. [Member] | RSL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupAbstract', window );"><strong>Telavant Disposition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupConsiderationAbstract', window );"><strong>Consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnSaleOfAssets', window );">Gain on sale of Telavant net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_TelavantHoldingsIncMember', window );">Telavant Holdings, Inc. [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupAbstract', window );"><strong>Telavant Disposition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_RocheTransactionMember', window );">Roche Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupConsiderationAbstract', window );"><strong>Consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_UpfrontCashPaymentReceivedForSaleOfAssets', window );">Upfront cash payment</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FutureMilestoneToBeReceivedFromSaleOfAssets', window );">Consideration to be received from milestone</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_RocheTransactionMember', window );">Roche Transaction [Member] | RSL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupConsiderationAbstract', window );"><strong>Consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_UpfrontCashPaymentReceivedForSaleOfAssets', window );">Upfront cash payment</a></td>
<td class="nump">5,234,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FutureMilestoneToBeReceivedFromSaleOfAssets', window );">Consideration to be received from milestone</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupNoncontrollingInterestDerecognizedValue', window );">Carrying amount of noncontrolling interest derecognized</a></td>
<td class="nump">87,500<span></span>
</td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ConsiderationReceivedForSaleOfAssets', window );">Total consideration</a></td>
<td class="nump">5,321,873<span></span>
</td>
<td class="nump">5,321,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupAssets', window );">Assets sold</a></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupLiabilities', window );">Liabilities transferred</a></td>
<td class="nump">29,790<span></span>
</td>
<td class="nump">29,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DisposalGroupNetAssetsLiabilities', window );">Net liabilities sold</a></td>
<td class="num">(26,537)<span></span>
</td>
<td class="num">$ (26,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_GainLossOnSaleOfAssets', window );">Gain on sale of Telavant net assets</a></td>
<td class="nump">$ 5,348,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ConsiderationReceivedForSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received for sale of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ConsiderationReceivedForSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupNetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as net assets (liabilities) attributable to disposal group held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupNetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupNoncontrollingInterestDerecognizedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of noncontrolling interest derecognized attributable to disposal group held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupNoncontrollingInterestDerecognizedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FutureMilestoneToBeReceivedFromSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The future milestone to be received from sale of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FutureMilestoneToBeReceivedFromSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncomeLossFromDisposalGroupBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of before tax of income (loss) from a disposal group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncomeLossFromDisposalGroupBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_UpfrontCashPaymentReceivedForSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront cash payment received for sale of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_UpfrontCashPaymentReceivedForSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_TelavantHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_TelavantHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_RSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_RSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_RocheTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_RocheTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658937077840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Transactions, Asset Acquisition and Deconsolidation of Subsidiaries (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiariesAbstract', window );"><strong>Deconsolidation of Subsidiaries [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,514<span></span>
</td>
<td class="nump">$ 17,354<span></span>
</td>
<td class="nump">$ 29,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Retained investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_NewlyFormedSubsidiaryMember', window );">Newly-Formed Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess', window );">Acquired in process research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_NewlyFormedSubsidiaryMember', window );">Newly-Formed Subsidiary [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MilestonePaymentPayable', window );">Milestone payment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SKBiopharmaceuticalsCoLtdMember', window );">SK Biopharmaceuticals Co Ltd [Member] | Proteovant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiariesAbstract', window );"><strong>Deconsolidation of Subsidiaries [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Purchase of equity</a></td>
<td class="nump">$ 47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_VantAIPreferredFinancingMember', window );">VantAI Preferred Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiariesAbstract', window );"><strong>Deconsolidation of Subsidiaries [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Retained investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_VantAIPreferredFinancingMember', window );">VantAI Preferred Financing [Member] | SK, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiariesAbstract', window );"><strong>Deconsolidation of Subsidiaries [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock', window );">Contributions from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquisition research and development expense in-process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeconsolidationOfSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeconsolidationOfSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the upfront cash payment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_NewlyFormedSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_NewlyFormedSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SKBiopharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SKBiopharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_ProteovantSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_ProteovantSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_VantAIPreferredFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=roiv_VantAIPreferredFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SKIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SKIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658942122448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Components, Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 52,642<span></span>
</td>
<td class="nump">$ 60,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">41,078<span></span>
</td>
<td class="nump">30,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash</a></td>
<td class="nump">5,165<span></span>
</td>
<td class="nump">5,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">5,240<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">18,901<span></span>
</td>
<td class="nump">4,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_OtherOfOtherAssetsCurrent', window );">Other</a></td>
<td class="nump">9,688<span></span>
</td>
<td class="nump">15,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 135,923<span></span>
</td>
<td class="nump">$ 121,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OtherOfOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OtherOfOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658942019760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Components, Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 43,627<span></span>
</td>
<td class="nump">$ 76,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related expenses</a></td>
<td class="nump">41,406<span></span>
</td>
<td class="nump">55,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_AccruedSalesAllowancesCurrent', window );">Sales allowances</a></td>
<td class="nump">16,808<span></span>
</td>
<td class="nump">17,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">20,307<span></span>
</td>
<td class="nump">18,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 122,148<span></span>
</td>
<td class="nump">$ 167,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AccruedSalesAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to sales allowances, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AccruedSalesAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936576576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Components, Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 12,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">25,223<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 31,342<span></span>
</td>
<td class="nump">$ 15,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926823312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Funding Agreement with NovaQuest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">19 Months Ended</th>
<th class="th" colspan="1">71 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2028</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Carrying Balance of Debt Issued [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Less: current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,950)<span></span>
</td>
<td class="num">$ (26,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,560<span></span>
</td>
<td class="nump">194,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Dermavant [Member] | Funding Agreement with NovaQuest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FundingAgreementWithNovaQuestAbstract', window );"><strong>Funding Agreement with NovaQuest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade', window );">Periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DebtInstrumentQuarterlyPaymentsMade', window );">Quarterly payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Carrying Balance of Debt Issued [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,510<span></span>
</td>
<td class="nump">221,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Less: current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,950)<span></span>
</td>
<td class="num">(26,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,560<span></span>
</td>
<td class="nump">$ 194,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Dermavant [Member] | Funding Agreement with NovaQuest [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FundingAgreementWithNovaQuestAbstract', window );"><strong>Funding Agreement with NovaQuest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade', window );">Periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Dermavant [Member] | Funding Agreement with NovaQuest [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FundingAgreementWithNovaQuestAbstract', window );"><strong>Funding Agreement with NovaQuest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentObligation', window );">Maximum milestone payment obligation</a></td>
<td class="nump">$ 440,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentOffsetAmount', window );">Right to offset of commercial milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentQuarterlyPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of quarterly payments made under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentQuarterlyPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FundingAgreementWithNovaQuestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FundingAgreementWithNovaQuestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum milestone payment obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumMilestonePaymentOffsetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum milestone payment offset amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumMilestonePaymentOffsetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total required debt instrument quarterly payments made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_FundingAgreementWithNovaQuestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_FundingAgreementWithNovaQuestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926823152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Credit Facility with XYQ Luxco (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Outstanding Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,337<span></span>
</td>
<td class="nump">$ 375,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,706)<span></span>
</td>
<td class="num">(40,720)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Dermavant [Member] | Credit Facility with XYQ Luxco [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_LoanAndCreditAgreementsByDermavantAbstract', window );"><strong>Loan and Credit Agreements by Dermavant [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge', window );">Debt instrument exit fee and end of term charge</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Reduction in exit fee</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issued (in shares)</a></td>
<td class="nump">1,199,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Outstanding Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,221)<span></span>
</td>
<td class="num">(10,170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,779<span></span>
</td>
<td class="nump">34,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,779<span></span>
</td>
<td class="nump">$ 34,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit fee of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses associated with exit fee and end of term charge of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentExitFeeAndEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LoanAndCreditAgreementsByDermavantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LoanAndCreditAgreementsByDermavantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_CreditFacilityWithXYQLuxcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_CreditFacilityWithXYQLuxcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926051936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Carrying Balance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,337<span></span>
</td>
<td class="nump">$ 375,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,706)<span></span>
</td>
<td class="num">(40,720)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember', window );">Dermavant [Member] | Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_RevenueInterestPurchaseAndSaleAgreementAbstract', window );"><strong>Revenue Interest Purchase and Sale Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CommittedFundingUnderRIPSA', window );">Royalties entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived', window );">Committed funding under revenue interest purchase and sale agreement received</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Carrying Balance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,297<span></span>
</td>
<td class="nump">178,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,543)<span></span>
</td>
<td class="num">(4,806)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,754<span></span>
</td>
<td class="nump">173,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,756)<span></span>
</td>
<td class="num">(13,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,998<span></span>
</td>
<td class="nump">$ 159,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommittedFundingUnderRIPSA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The committed funding under revenue interest purchase and sale agreement (RIPSA).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommittedFundingUnderRIPSA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The committed funding under revenue interest purchase and sale agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The committed funding under revenue interest purchase and sale agreement received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RevenueInterestPurchaseAndSaleAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RevenueInterestPurchaseAndSaleAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_DermavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926937696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 19, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ImmunovantIncMember', window );">Immunovant, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Immunovant, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EstimatedNetProceedsFromIssuanceOfCommonStock', window );">Net proceeds of common stock</a></td>
<td class="nump">$ 466.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Common Stock [Member] | Immunovant, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares (in shares)</a></td>
<td class="nump">8,475,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_RoivantParticipationOfImmunovantStockOfferingMember', window );">Roivant participation of Immunovant Stock offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockPurchasedDuringPeriodByEntityShares', window );">Common shares purchased by RSL (in shares)</a></td>
<td class="nump">1,526,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_OptionToPurchaseAdditionalSharesOfCommonStock', window );">Option purchase additional shares of common stock (in shares)</a></td>
<td class="nump">1,105,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member] | Immunovant, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockPurchasedDuringPeriodByEntityShares', window );">Common shares purchased by RSL (in shares)</a></td>
<td class="nump">4,473,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=roiv_CowenAndCompanyLLCMember', window );">Cowen [Member] | At-the-Market Equity Offering Program[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CommonSharesOfferingPriceAuthorized', window );">Common shares aggregate offering price authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable', window );">Common shares aggregate offering price authorized, remaining capacity available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The common shares aggregate offering price authorized remaining capacity to issue under equity offering program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommonSharesOfferingPriceAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The common shares aggregate offering price authorized to issue under equity offering program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommonSharesOfferingPriceAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EstimatedNetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EstimatedNetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OptionToPurchaseAdditionalSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares of common stock option to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OptionToPurchaseAdditionalSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockPurchasedDuringPeriodByEntityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock purchased during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockPurchasedDuringPeriodByEntityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ImmunovantIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ImmunovantIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_RoivantParticipationOfImmunovantStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=roiv_RoivantParticipationOfImmunovantStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=roiv_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=roiv_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_EquityOfferingsAtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=roiv_EquityOfferingsAtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658938692624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation, Stock Options and Performance Stock Options under RSL Equity Plans (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>IncentivePlans </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | IncentivePlans</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_RoivantSciencesLtd2021EquityIncentivePlanMember', window );">RSL 2021 EIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares available for future grants (in shares)</a></td>
<td class="nump">41,986,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember', window );">Stock Options and Performance Stock Options [Member] | RSL Equity Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">154,271,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4,497,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(10,796,348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Canceled (in shares)</a></td>
<td class="num">(604,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">147,369,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at September 30, 2023 (in shares)</a></td>
<td class="nump">91,671,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NumberOfEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity incentive plans for the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NumberOfEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_RoivantSciencesLtd2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_RoivantSciencesLtd2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_RoivantSciencesLtdEquityPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_RoivantSciencesLtdEquityPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658942777056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation, Restricted Stock Units and Performance Stock Units (Details) - Restricted Stock and Performance Stock Units [Member] - RSL Equity Plans [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning (in shares)</a></td>
<td class="nump">20,700,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,199,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(5,498,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,175,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending (in shares)</a></td>
<td class="nump">18,226,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_RestrictedStockAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_RestrictedStockAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_RoivantSciencesLtdEquityPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_RoivantSciencesLtdEquityPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658936735520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation, CVARs, Employee Stock Purchase Plan and Subsidiary Equity Incentive Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlansMember', window );">Subsidiary Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_SubsidiaryEquityIncentivePlansAbstract', window );"><strong>Subsidiary Equity Incentive Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 23.3<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="nump">$ 53.1<span></span>
</td>
<td class="nump">$ 37.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">CVARs [Member] | March 2020 CVAR Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares', window );">Number of shares outstanding (in shares)</a></td>
<td class="nump">27,531,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,531,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EquityInstrumentsVestedAndSettledShares', window );">Equity instruments vested and settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,499,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">CVARs [Member] | November 2021 CVAR Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">CVARs [Member] | RSL 2021 EIP [Member] | November 2021 CVAR Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Capped Value Appreciation Rights [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,222,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(955,782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending (in shares)</a></td>
<td class="nump">2,138,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EquityInstrumentsVestedAndSettledShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments vested and settled during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EquityInstrumentsVestedAndSettledShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share-based compensation arrangement by share-based payment award equity-based payment instruments, other than options, outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SubsidiaryEquityIncentivePlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SubsidiaryEquityIncentivePlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=roiv_March2020CappedValueAppreciationRightsGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=roiv_March2020CappedValueAppreciationRightsGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=roiv_November2021CappedValueAppreciationRightsGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=roiv_November2021CappedValueAppreciationRightsGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_RoivantSciencesLtd2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_RoivantSciencesLtd2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658942607328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658931928528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,282<span></span>
</td>
<td class="nump">$ 168,261<span></span>
</td>
<td class="nump">517,827<span></span>
</td>
<td class="nump">$ 474,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,717<span></span>
</td>
<td class="nump">$ 125,533<span></span>
</td>
<td class="nump">$ 380,834<span></span>
</td>
<td class="nump">$ 393,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=roiv_GSKMember', window );">GSK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase certain quantities of inventory over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement', window );">Remaining minimum purchase commitment related to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_SamsungBiologicsCo.Ltd.Member', window );">Samsung [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement', window );">Remaining minimum purchase commitment related to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PeriodOfRightToTerminateTheProductServiceAgreement', window );">Period of right to terminate the product service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Additional minimum purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab', window );">Period to purchase additional batches of batoclimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_PalantirTechnologiesIncMember', window );">Palantirs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ProprietarySoftwareSubscriptionPeriod', window );">Proprietary software subscription period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Remaining minimum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_CashBonusProgramMember', window );">Cash Bonus Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_CashBonusProgramMember', window );">Cash Bonus Program [Member] | Chief Financial Officer [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related expenses</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate', window );">Percentage of bonus payable</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FiftyPercentBonusPayablePeriodFromGrantDate', window );">Period of bonus payable from grant date</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FiftyPercentBonusPayablePeriodFromGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of fifty percent bonus payable from grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FiftyPercentBonusPayablePeriodFromGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of bonus payable in next 30 days of the grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PeriodOfRightToTerminateTheProductServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of right to terminate the product service agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PeriodOfRightToTerminateTheProductServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period to purchase additional batches of batoclimab, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProprietarySoftwareSubscriptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proprietary software subscription period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProprietarySoftwareSubscriptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining minimum amount of purchase commitment related to agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=roiv_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=roiv_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_SamsungBiologicsCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_SamsungBiologicsCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_PalantirTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_PalantirTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_CashBonusProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_CashBonusProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658925198560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earn-Out Shares, Public Warrants and Private Placement Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ClassOfWarrantOrRightRedemptionPrice', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CashlessPublicWarrantExercised', window );">Cashless warrant exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,061,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants', window );">Unexercised public warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises', window );">Aggregate value of shares exchanged on a cashless basis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,475,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ClassOfWarrantOrRightRedemptionPrice', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantCashExercised', window );">Warrant exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesCashWarrantExercises', window );">Aggregate value of shares exchanged (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises', window );">Aggregate value of shares exchanged on a cashless basis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfTradingDays', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfTradingDays', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CashExercisePrice', window );">Cash exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member] | Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsAndPrivatePlacementWarrantsMember', window );">Public and Private Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_CashExercisePrice', window );">Cash exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ExercisePrice', window );">Cashless exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant', window );">Number of common shares issued to surrendering holder per warrant (in shares)</a></td>
<td class="nump">0.2495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesAbstract', window );"><strong>Earn-Out Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfEarnOutSharesVested', window );">Number of earn-out shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PeriodToExerciseWarrantsAfterBusinessCombination', window );">Period to exercise warrants after business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | 20% Earn-Out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesAbstract', window );"><strong>Earn-Out Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,033,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PercentageOfEarnOutShares', window );">Percentage of earn-out shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | 10 % Earn-Out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesAbstract', window );"><strong>Earn-Out Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PercentageOfEarnOutShares', window );">Percentage of earn-out shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | Independent Directors [Member] | 20% Earn-Out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesAbstract', window );"><strong>Earn-Out Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold', window );">Number of trading days to meet earn-out price threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold', window );">Trading day period for earn-out shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | Independent Directors [Member] | 20% Earn-Out [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesAbstract', window );"><strong>Earn-Out Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharePrice', window );">Earn-out share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | Independent Directors [Member] | 10 % Earn-Out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesAbstract', window );"><strong>Earn-Out Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold', window );">Number of trading days to meet earn-out price threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold', window );">Trading day period for earn-out shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | Independent Directors [Member] | 10 % Earn-Out [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharesAbstract', window );"><strong>Earn-Out Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_EarnOutSharePrice', window );">Earn-out share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,214,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember', window );">MAAC Sponsor [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract', window );"><strong>Public Warrants and Private Placement Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,535,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CashExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price per common share on a cash basis to exercise warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CashExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CashlessPublicWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of cashless public warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CashlessPublicWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ClassOfWarrantOrRightRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ClassOfWarrantOrRightRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares unexercised of warrant redeemed during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EarnOutSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The share price of earn-out share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EarnOutSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EarnOutSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EarnOutSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price per Common Share on a cashless basis to exercise warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NumberOfEarnOutSharesVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of earn-out shares vested during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NumberOfEarnOutSharesVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trading days for common stock price to exceed threshold, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trading days allowed to calculate earnout share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of trading days that are allowed to meet earn-out share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageOfEarnOutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The collective percentage of earn-out shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageOfEarnOutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PeriodToExerciseWarrantsAfterBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after the completion of a business combination when warrants will become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PeriodToExerciseWarrantsAfterBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PublicWarrantCashExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Public warrants cash exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PublicWarrantCashExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued to surrendering holder per warrant during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesCashWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of shares exchanged during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesCashWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of shares exchanged on a cashless basis during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsAndPrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsAndPrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_PatientSquareCapitalLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_TwentyPercentEarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_TwentyPercentEarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_TenPercentEarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_TenPercentEarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926289136">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Assets and Liabilities are Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 239,927<span></span>
</td>
<td class="nump">$ 304,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember', window );">Earn-Out Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Recurring Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Non financial liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,900<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Recurring Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Non financial liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97,100<span></span>
</td>
<td class="nump">117,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Warrant [Member] | Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Recurring Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Earn-Out Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Recurring Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Non financial liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,900<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Warrant [Member] | Private Placement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Recurring Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Other Liability Instruments Measured At Fair Value Measurement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Recurring Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement', window );">Other Liability instruments measured at fair value measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,753,863<span></span>
</td>
<td class="nump">1,801,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221,510<span></span>
</td>
<td class="nump">207,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">28,374<span></span>
</td>
<td class="nump">63,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">249,884<span></span>
</td>
<td class="nump">271,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,513,936<span></span>
</td>
<td class="nump">1,496,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Common Shares [Member] | Datavant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">135,934<span></span>
</td>
<td class="nump">178,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97,119<span></span>
</td>
<td class="nump">117,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Other Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,874<span></span>
</td>
<td class="nump">8,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,617,929<span></span>
</td>
<td class="nump">1,622,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,513,936<span></span>
</td>
<td class="nump">1,496,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member] | Common Shares [Member] | Datavant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97,119<span></span>
</td>
<td class="nump">117,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member] | Other Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,874<span></span>
</td>
<td class="nump">8,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member] | Common Shares [Member] | Datavant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member] | Other Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">135,934<span></span>
</td>
<td class="nump">178,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221,510<span></span>
</td>
<td class="nump">207,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">28,374<span></span>
</td>
<td class="nump">33,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">249,884<span></span>
</td>
<td class="nump">241,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 3 [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 3 [Member] | Common Shares [Member] | Datavant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">135,934<span></span>
</td>
<td class="nump">178,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 3 [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 3 [Member] | Other Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets: [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $24.9 million and other liability instruments issued of $3.5 million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $29.9
              million, and Level 3 includes the fair value of the Earn-Out Shares of $15.2 million, Private Placement Warrants of $15.2 million, and other liability instruments issued of $3.3 million.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of other liability instruments measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_DatavantHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_DatavantHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926528896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Changes in Fair Value of the Level 3 Assets (Details) - Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning Balance</a></td>
<td class="nump">$ 178,579<span></span>
</td>
<td class="nump">$ 193,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Changes in fair value of investment in Datavant, included in net loss</a></td>
<td class="num">$ (42,645)<span></span>
</td>
<td class="num">$ (21,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Gain (Loss) on Fair Value of Debt and Liability Instruments<span></span>
</td>
<td class="text">Gain (Loss) on Fair Value of Debt and Liability Instruments<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending Balance</a></td>
<td class="nump">$ 135,934<span></span>
</td>
<td class="nump">$ 172,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658942898352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Changes in Fair Value of the Level 3 Liabilities (Details) - Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning of period</a></td>
<td class="nump">$ 241,291<span></span>
</td>
<td class="nump">$ 204,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value of liability instrument issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments related to long-term debt</a></td>
<td class="num">(22,031)<span></span>
</td>
<td class="num">(22,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_ExerciseOfPrivatePlacementWarrantsValue', window );">Exercise of Private Placement Warrants</a></td>
<td class="num">(28,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of debt and liability instruments, included in net loss</a></td>
<td class="nump">$ 58,714<span></span>
</td>
<td class="nump">$ 68,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Gain (Loss) on Fair Value of Debt and Liability Instruments<span></span>
</td>
<td class="text">Gain (Loss) on Fair Value of Debt and Liability Instruments<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of period</a></td>
<td class="nump">$ 249,884<span></span>
</td>
<td class="nump">$ 250,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ExerciseOfPrivatePlacementWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ExerciseOfPrivatePlacementWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658937060928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Fair Value of Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember', window );">Earn-Out Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Non financial liabilities at fair value</a></td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liability Instruments Measured at Fair Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Non financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liability Instruments Measured at Fair Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | Datavant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Investment in equity securities, measurement input</a></td>
<td class="nump">0.95<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | Earn-Out Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueEarnoutSharesMeasurementInput', window );">Earn-out share, measurement input</a></td>
<td class="nump">61.90%<span></span>
</td>
<td class="nump">79.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Private placement warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Rate [Member] | Datavant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Investment in equity securities, measurement input</a></td>
<td class="nump">0.0446<span></span>
</td>
<td class="nump">0.0402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Rate [Member] | Earn-Out Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueEarnoutSharesMeasurementInput', window );">Earn-out share, measurement input</a></td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Rate [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Private placement warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term (in years) [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Private placement warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value asset, measurement input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueEarnoutSharesMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value measurement input for Earn-out shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueEarnoutSharesMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_DatavantHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_DatavantHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140658926863248">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Roivant Sciences Ltd.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,096,184<span></span>
</td>
<td class="num">$ (352,014)<span></span>
</td>
<td class="nump">$ 4,500,041<span></span>
</td>
<td class="num">$ (975,413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">800,587,716<span></span>
</td>
<td class="nump">713,319,399<span></span>
</td>
<td class="nump">776,759,728<span></span>
</td>
<td class="nump">703,054,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive common stock equivalents (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,873,969<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,550,285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">844,461,685<span></span>
</td>
<td class="nump">713,319,399<span></span>
</td>
<td class="nump">824,310,013<span></span>
</td>
<td class="nump">703,054,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.37<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_StockOptionsAndPerformanceStockOptionsMember', window );">Stock Options and Performance Stock Options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,518,394<span></span>
</td>
<td class="nump">154,631,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_RestrictedStockAndPerformanceStockUnitsMember', window );">Restricted Stock Units and Performance Stock Units (Non-vested) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,422,465<span></span>
</td>
<td class="nump">22,153,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_March2020CappedValueAppreciationRightsGrantsMember', window );">March 2020 CVARs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,548,368<span></span>
</td>
<td class="nump">32,011,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_November2021CappedValueAppreciationRightsGrantsMember', window );">November 2021 CVARs (Non-vested) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,730<span></span>
</td>
<td class="nump">3,609,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Common Stock (Non-vested) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,059<span></span>
</td>
<td class="nump">730,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_EarnOutSharesNonvestedMember', window );">Earn-Out Shares (Non-vested) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080,387<span></span>
</td>
<td class="nump">3,080,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,214,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,475,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember', window );">Other Stock Based Awards and Instruments Issued [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,147,404<span></span>
</td>
<td class="nump">6,178,990<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Refer to Note 9, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_StockOptionsAndPerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_StockOptionsAndPerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_RestrictedStockAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_RestrictedStockAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_March2020CappedValueAppreciationRightsGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_March2020CappedValueAppreciationRightsGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_November2021CappedValueAppreciationRightsGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_November2021CappedValueAppreciationRightsGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_EarnOutSharesNonvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_EarnOutSharesNonvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:PC5*Z%ZI[73QRV3BLOH%3WQC9#*Q@=;*;FUXH&JAGC]$J]_&MXCEZ$P$U:
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M?7^9O^O/3Y389*_+%T(I$6>':\X"+LT%^ONE$&I_8FY0_N)B] ]02P,$%
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MY/E$SQ(\*!-^!0=,#WO??#3N23&"%PLKDIQ.P#L13O**U3\#CP3/Y8S0C <
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MU-(?; J=MRE?I!/P$3A[81H8 8M6Z"VH25NW57>NNI%;52H77_RA'>'@1_*
MN,*X"\8A-)W8,-+!N-!YX_+^!*H^V$-=PX+9^7/[!W "VL8Y-W0B%Y3S?.Q8
MHG'9%.6RP;&P><<2(QV8_<ZHN];Y32!R&GW1ZD& "[@%'FY*6#6?W.8R>O89
MNI,,YP7/Q@=VD4!"4LZS"2/#!B/#YHW,S^"R0#:,KBJ_D!68$5BC$T>U$>=0
M)#D9FZY87%+D=.*@A@W.@<T[AX,LV\@81.&&YB!+\R3-QWN)2"#P-9\\#V4G
M!^'?Z",Z4GQU >&9=_Q@)Q(8/]A9G;R_\2_/@)[O8>< ]GL++?$EASXPA_=1
MAQNG]]TKG3OMG*Z[RYT4 -P'P/=;#2:CO_%OB8YO!=?_ 5!+ P04    " #X
M.4U8/<+",R\#   )"@  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V6
M;6_:,!#'OXJ555LKM>21AW2 M%)-F[1)J*S;:Y,<Q*H3I[8#[3[]S@ED/ 0*
M4GE![.3N[_N=SP_]I9!/*@'0Y"7EF1I8B=;YK6VK*(&4JI;((<,O,R%3JK$K
MY[;*)="X=$JY[3E.QTXIRZQAOWPWEL.^*#1G&8PE446:4OEZ!UPL!Y9KK5\\
ML'FBS0M[V,_I'":@'_.QQ)Y=J\0LA4PQD1$)LX'UQ;T=A<:^-/C-8*DVVL20
M3(5X,IWO\<!R3$# (=)&@>)C 2/@W AA&,\K3:L>TCANMM?J7TMV9)E2!2/!
M_[!8)P.K9Y$89K3@^D$LO\&*IVWT(L%5^4^6E6TWM$A4*"W2E3-&D+*L>M*7
M51XV'#S_@(.W<O!.=?!7#GX)6D568MU338=]*99$&FM4,XTR-Z4WTK#,S.)$
M2_S*T$\/1R*+<4X@)MA2@K.8:NS<44ZS",C$""MR.:82,IV 9A'E5^2&/$[N
MR>7%%;D@+"._$E$HFL6J;VN,R2C;T6K\NVI\[\#X]Q"UB.]>$\_Q_ ;WT7'W
MGU0><K<Q$W4ZO#H=7JGG'TI'(0THX8Q.&6>:@;IM@JI4@F85L_)N54XC&%BX
MM!3(!5C#CQ_<CO.Y"?&=Q+: _1K8/Z9> ^="ELM*S @7V?Q&@TQQ.4PU+K1(
M%)DI"MPS2('E(LF,,DD6E!= 1&[\FG)4#=PI!S:;R6+H=<*VT[<7F_"-5L%_
MJRVJH*8*CE+]0 32A'!&^,%>8&X8M#N[\3>8]9RN<P"@70.TC];A),$%EPB.
MT:I/!)X+IE\;"[']GH7X3F);Q)V:N'.\$$6:8OWAAA<]79.<KB?H$O>76'!.
MI2(YSITRF;EJ2D6EW]V8";\5N-W <0,7;IS>SL2=;+Z%TZUQNF?@E$$K0@N=
M",G^8B$:K.IM(TLEWMX(#DMJ]=OA.,ETBZ%7,_3.9V!*%6_'W]L+JN<$O= )
MW=WP]RV['9P"WP_]YNC#.OKP_.CQ'J,TGE0,]X<W$,*3$?8M#R'8&P>UN23A
M\35GF2(<9NCKM+HH(JN+1]71(B_/[JG0>!,HFPG>U4 : _P^$T*O.^8Z4-_^
MAO\ 4$L#!!0    ( /@Y35B.O/Q>  D  /DL   8    >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&ULM5IK;]LX%OTKA+=83 $[YDNO;!*@M36[!:8[1=/9^;#8
M#XK-Q,+(DD>BG?;?[Z7\D$U>,>FN6B"U)1]>ZCYY+L6;YZK^HUDII<G7=5$V
MMZ.5UIOKZ;19K-0Z:ZZJC2KAE\>J7F<:+NNG:;.I5;9L!ZV+*:<TG*ZSO!S=
MW;3W/M5W-]56%WFI/M6DV:[76?WMO2JJY]L1&QUO?,Z?5MK<F-[=;+(G=:_T
M;YM/-5Q-3U*6^5J535Z5I%:/MZ-W[#H5@1G0(OZ5J^?F[#LQJCQ4U1_FXL/R
M=D3-$ZE"+;01D<''3LU441A)\!Q_'H2.3G.:@>??C])_;I4'91ZR1LVJXO=\
MJ5>WHWA$ENHQVQ;Z<_7\#W50J'W 154T[?_D^8"E([+8-KI:'P;#$ZSS<O^9
M?3T8XFP R,$'\,, ;@^0/0/$88!X[0SR,$"^=H;@,*!5?;K7O37</-/9W4U=
M/9/:H$&:^=):OQT-]LI+$RCWNH9?<QBG[V95N02WJR6!;TU5Y,M,P\6]A@^(
M!]V0ZI'\NE%U9OS:D GY[7Y.?GKSEKPA>4F^K*IMDY7+YF:JX6F,S.GB,//[
M_<R\9V9!/E:E7C4DA2=8(N/G_O&)9_P4K' R!3^:XCWW"IRKQ141;$PXY0)Y
MGMGKAW-,G?]O]O1_GOW"&.(4%Z*5)WKD?58[56Y5<XTY=C]4XD--:;MN-ME"
MW8Z@=C6JWJG1W5__PD+Z-\RJ0PJ;#RDL'4C8A?WER?[2)_UH_S$IE<9<L!\=
MMJ/-8K"[$Q&3]&:Z.[>MBV(1#?@E:NZBDB .@TM4BLPH$BI/J LU@Y.:@3?,
M#I6E?"+JZ\;4(3S@@B$#;DAA\R&%I0,)N_!$>/)$Z VX6=5H4^OK0^)C;MA+
M",Y#( QC*^80$$23%7(NB#$F+5&IBXJ30. 1%YWTC%Y(K$9E]6)%8-4"1K$#
MJK0Q"QWY*2\7Q7:I&O(F&LLH: %OPG$<Q\8NS2JKU<1PDB595&L3K.V2> Q<
M J2-Z)6"OUHILMZO3<JL302*LUH_J/I4WUO9IE+O)^%R+.AA0AZ. QF?I)7P
M^*\5-@;G-1O54J_BVUO,@Y%K=PZ%([)\B,&"0 C+BRY,Q#06TG(C DL$! 7N
MR/CDR-CKR'>+/[=Y#0;)R\FFKA:J:8S^J',Q4\3.4]G5TT4D4203RP@NBH<R
ML&2E+\FZ,$%R,D'B-<$]\&NHG6/RI$JHHT6K=K8$FI@WVM35G3H/:QF.$RGW
M81;0<239CPYLQN.QE(?(9F$PCB+VHT([<6,VB7AL+78S!!;&/&265UU8P**8
M6XF2NC )7DU"W*^,=JR<>CW[I=+@SLI9'5&:3=W\XC(,[:3&<$G N!W0""X1
M(0\L7(KAHH &?<J?M23,J_S?H;\E$(!-5B@3H5]4D>TR*-' A4C6-$KC=F"N
MSX2,);/S&@%2VP:OE)5Z95WJSSO]N5?_#R7D(61N437-6_)85^MC)$ 'AFK.
MW:>E(8UC86ON B<BBFD4V?J[0*AI,66AK3\B,9&,G9',2RMT#0CS\NN[V2HK
MGY1I,A^SO":[K-BVT9"7.]7HMC=%;2'<!*?23087-H$0MRG(',&%(HZ=,'!A
M@>!G9KTT0M<%,'\;T&>$I7K0;7$L\NPA+W+]#3!0\[?]=I%(5@MFF\5%A5R$
M3GJXL#@0D1,<R)R4BK[0Z)H&YF7"IP*Q5(O3IH59L<QJMGUH\F6>U7E/L0Q>
M7/81R 3H#Y.V$3!<) *;_F XGO"HKTYVC)WY*?N'4BM8%C6XWA0,5%V70D\$
M.R?1!YT1'*/<(3L8+N2)G5XI*B\"Y_?HW+%WYJ?O)YT/*R*JM$LX@?=(6V47
M%4MI-RH("CQ'A:TOPI@38+D]ZG8<E_E)[J] E.J#?WOW IA++B<">(CC9 3'
M8IH$MLZ8/"&IO2. RF,T['-R1VN9G]?^4QUC^K@(/BA@C>IX4V=?>[(;H6TT
MB85PRK\+G(B8(PLAPO#@G[.TIIA$6'B"D/7T.;PC@]Q/!C^<M/9%/7?I& _"
MR.:_&"QF=IXC*,%8;"T7*0*+D[@GZGE' +F? #K^1_5%*!J->&AO7,T0(/A:
MQHF=ZPA02B8BRFVU$8F,!C*DK$?UCOMQ/_<SJAN52:9UG3]L=?8 )%A7I*S
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MY%UYPW%F-BQQFD,A4E80#HNQ<6D/9X&RUP;?4MB(K3%1F=PS]J FG^.Q8:F
M((-(*@:*KS5,(<L4$8;QJ^8T&I<*N#U^8O^@<\=<[JF *<N^I[%,QD;?(#$L
MZ"J3MVSS">I\/,47L4SH)]G4MI9!HI60+*_!&$&>%M6;/M9UV (@3SO J0'.
M/L!]!M"K ;V7>G!K@/M2#UX-T*F;5>ZZ<"&5=#+B;$.XLD8V-=#5UVBL5UHH
MG<PEQZ\IXN1DRHH8=QUB@B/!LC2F$B=SB2^4@Q2$+<B7$CA5^RK(Z0WEN)R
M3".:O2/GY&X>DM.3=^2$I 7YFK"5H$4L1J;$Z)0/,ZHCN:HB<9Z)I$>N&1(+
M,L.(XA9\>!P_.((WL2I-:9RGTEPY1PE#B"Y(SSXCCN7T6N*9OASNM*7S?]YG
M_^Q]IQB]1B<]S><^PS=/<-_/U9&,2<1RO*:$5D3;/A]E4A??4)0T@K&!-YL
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M \E9!MX+32LDOE6@-@:2YS%@$;,P8 4[9>!4[$D&2,\ .<O \7'QS;V)G'J
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MN.P^CIO587YO^-RB4[7 >QW88/;&,[[,ZW90B08D?EMU$#0-JK5&>=@:C5D
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M2D"RY,IU""J<I"$2R]SWF4$JP>:6N4MKD,FP07;6K$68$1L B:]IQ"4E+JD
MR;BHKF".S:XA(<\3KZX'U*6R$#./!=*:8#)L@H5?*@>Z7F%B=%#PM^1*WQ@S
MMW2FF!<:H.HFSUU9!<E$DHO,G=S64,LI%^[+ 6M QS@7C,^LJI/6,I)1BQX#
M>];!L2+UB*1?1R-SR;@LW!J$%6G#)2FM(J5I4EI-19NFFS6 9-@ >MZT11@:
MG66X:2-]DP2>M@"$T+0%)(.G+:"6H6D+0!><MI#6R)%A(^?ETQ;A!J+#Y9LO
M<],6I V7I+2*E*9):345;9IQUGZ1V1><MI"DM@PI;45**TEI%2E-D])J*MHT
M0:TE)<.6U'G/$J1>%"EM14HK26D5*4V3TFH)O6[:C *2F:(Z:<TU&?4V9Z=$
M"+ZMDEII1UIP%.0[5QE7B5]J#PB7J3Q])?DQU,!;HU.9NL:R!G1""?-$Y@Z"
M /\M,P^M<PO>I#789%2Q7:":"PX5J=DF?>=J+.52B?>$NB)MN"2E5:0T34JK
MJ6C3=+,>H@Q[B.CV_G"6D=J'1UJP0P#V+H.-$L#4@XP2R/N#C1*@9= H\75!
MHZ2P?F(16W 7ZY6$&X@-5^%;=G->"6G#)2FM(J5I4EI-19MFG+5."_8%'XL*
M4E>5E+8BI96DM(J4IDEI-15MFJ#6.R["WC']-C'A!J.3%-]/KP"6=RKE+SL$
M=.[-#)=H7%+C)S0-EG5>"Y+2NV=N%!-N/#IP@+FI\B3)"_?5-:3MEJ2TBI2F
M26DU%6V:C-9C+KYPL>!3VMYT_4V[&1X.J1Q;'!H^Z^@L%GCWXWO;:5)(MUH%
MD'F]#RK1N*1&SV<:;^OP%N$"N]]!O-$>C-0V+OS2N%PD:>%W8*2.,"FM(J5I
M4EI-19LFM'6$"YIW8/3MMAG:]5@XMV^'8=N.N3@>9,;I?3/7#9$ZR06^65X!
M+"_FJ;LI>0G(O&X(KVK$)35Z/M.H6=.UH'GU!1HUM#,AM6H+P#;-,I$)]X4Z
MI,V6I+2*E*9):345;9J6UFPN:+;->]B99_Y%>W>_[3ZU[;%4_?ZAO[X=78+Q
MO@CF(JD77>"+P O?KLY<B[\$1%Y?@I=^XI(:.9MIR*QA6]!LB(>'#.U*2$W>
MPO='5<[]40GIHG!26D5*TZ2TFHHVR4IE/6H5]JBCMU$+\V*32^'KP15>_XI+
M*ERB <F29XF[J6.-ZZ:QL.ZM"A>^/F]-41@:'1!\7SM PMP](DJ<4^$2#4C<
M5Q'7T.G,;9VBK%&ID&WM(I84A5'1$< WLP,D7 COAHF3*ERB 0GS-P6I 9E0
MG,T4Y2MK0JJP"4FRI"C<1G2$\*WI ,DRD]Y%@J_@Q24:D'A-U4'.-#36DE-A
M2^X%RUC"Y.B H#;5"I>4@(1GW-UZ"P=I0.*]K0MJ+)^K$5+6-5-AU^RLLK,P
M(_K+]WTK[\M')24NJ0#)DB>"IVXM$"1,<ZF\:P("<L9F.RWK]:BPUQ-^+Q0X
MU1\F1@<%=W"4[YAD/$W\Y<& T'SO,G7# \@$SXM">?$!5L1*F;C[%-> CO$T
MR_F,N:RLJZ.B2ND"+X:"8T7JU2C?JRF21*J4NV.=%6G#)2FM(J5I4EI-19NF
MFW5KU*-C\&7*,A2I.T-*6Y'22E):14K3I+2:BC9-4.M-J; WM=KL[[OCFYF[
MF\7/[;;YT,R,W$C-)857$"I\ 3(NJ7")!B1+:"M;7#>) DNL&3/^_$4G/:/G
MLY$SC(WO9UPHP)\UDREDD;G[?T(R-\IG:/09FAH])2?"["3"88_G][7G$7*V
M\=$&%B<GJLB$.Y"A;;BDQ56T.$V+J\EP3A*G)TE\?A7?"]Z/@C03GWUX\=YG
MS>29(E4R=Q]Z(*'?V^#N&=A@8IZ)_"X'>$,%+^3<PPY+^$F\Z%\+@?8<I);:
M9US(1:!MLJ3%5;0X38NKR7!.#HJ3' R;A<^;W$"H\6F&%]A]UDRN6,E<[Q:2
M^1T$;A:"S0EOT G)1JMJKG/(3@)S?J'=%W]G#')R\?'%S4A(LS1?+W,=K?(,
M6G6&1D,:J,$Z#',BG)]$F&Y[/(05'Q!\@SQ(PY7R7EMV!JLZ0Z,A#1-9YMK#
MD,Z,9.?F>5DB3R(2]A]?,'."H.,#A.^/=X:FA#3+5$CFVL1GP#0(X^[&)S7<
M9I;DL\]IQ4F$P@569TVD()#X6.!;Y)VA*<_05) F2U3.W!78&E(N4YYY2ZMA
MI$SS?&9+,):HDWA$O2OCG!75"#(^.KA7!6G@]>^0$EP #PG!%?"0$%P"#PF#
M:^ 9.W&P6-C!>N$J> 0?'3/F^SASZ^!IFRYI<14M3M/B:C+<8]Y=[F_;=E@U
M0_/FU7WSOOVAZ=]OS/ARV]X8?/+-N+=+OWE_^_3+T-V;-+U8O.N&H;L[_'C;
M-NNV'P7FWV^Z;OC\RZ7A?^SZ7PYMO/E_4$L#!!0    ( /@Y35CW4#O[10D
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M%FZ'9Q/^+(C_>L,D7ZK27T7@7>##CBE&<4',+  HP45,9C@=8@5.8NH&FD]
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M   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULI5AK;QNW$OVN7T&H1>$
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M($L?W9JBA+DK*TG L@[(05"YB8!H;/DJ/>& >5# ::S=GN?XC+)A<WYWZI8
MM'(!M4>'TJ#0ID!)@CA+O)TY;M&1(CXO$. &-#OTUK/FU<.&'DD; Q+CGHJ
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MYVXV(H$88&C[:H1O0 R*MJW5BZYENVY-4ILZUED0G1V"@M6].QGMWSB@ 4I
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MG/X&*9)4:LQR%59+ZF&XL3><1J,MP[;IE'$A>GOQ(#IHZ/ C_0/^;GO26]<
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M^J=OWX33X.@%7<>=KN.7T%\7CY<A/FM'8OSVS2P*HZ-MVS\4XH\JNX=SP]E
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M#-F84NXUNNGS2^<_>,ZW6,ZU@DY4!8%[/,PT:.>U$W$:AQP;,:,I3YS/2A2
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M1"Y1P_4\=(SL^BMQ(PU>L'VSQ!<-*#L!Q[<23\"Q8Q<XOI$6_P)02P,$%
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M[[BAB!J%KA_YT2;L37OC!:%OD86]2HN.Y0!\,KQ8E>>$1KM0&4_[6&D:;BV
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MP= "S"\U/-J\$(/V0^WY_P!02P,$%     @ ^#E-6!+AG:EP!0  XPP  !D
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M4>P^$_HO!#5OH/65HN=./> #VO]KYO\"4$L#!!0    ( /@Y35CBF%F.0P8
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M\'#XS$$@;O>"3)1(U![VD%-_X!V\)OF%$5[0'_G1<.('O4E-!*5(%[J]1)/
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M#0]A3(%$18[WR$]@AP=K)> 0MAW6/C]@=\7,"!Q>>O/:7G(!VE+ZFBVF $H
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M01,"PN<*WQ+5@034?T X^P]02P,$%     @ ^#E-6/'PZ936 @  $@8  !D
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MG,ZG8G&R.+V'WFDO[RG3._U?Y!7_/E]:U\)3_K-/=$_Y;#]EBIX?;",S]>(
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M'8'!:N3TL$@F&^W */@PT!T9(Q50EM9PX*3;6E5*BCD2FRPZ$,_5TOGS%(P
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MEH;H![,4_6[;Q NZ&VU]HJ3W87JD1@C/]#WC/N+]8)<8U"I<X]"G$@-O?'5
MS8')?)/EOZR(V,/32QMO%>*DH9*W?FYB>%)!@S:^@D_2U!@90XW)A^NQ9E/!
M.$&%H_?<O?<[(8H*-M=NMQ3N^R(>>H_DX.*REQ.E0S(GC2O1L.@H<91S:/[O
M2+PK#8O -%3^3*S-!B>W.Y]>^&:VI 9+LY$'$5()$FUB2==2AY]^Y)#Q;<S
MMU_,=YCID&7?9?]X]#BXS->U"848CKVQ++%42>8EV^1S!&[/[ESJ[.HL_80E
MK7_\V,?33,5+"+)'I?OC1S>H1SDQ3JCC,"5_7),#>6IHD6]#A_Y5[A\6,BN[
M7P#L^TSL./FTKU+MBC]@I%8'/N._\NN?]M](GOM/ X?E_@-+'+<B=RA5@:TG
ML\</#_S$.?YPIN$/!=$N.E/QGP!&Q!8MP/O"P$'##SJ@_W+TY7\!4$L#!!0
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MG#D<SWQH,BSS+6U[],$3OA]J=],\XU$2#V#*UA:TIE36@)&D(8$==A/A)3=
MO&R0T#\8H&J)[8LOG:S=?]E!BGR!D84B5:\2.CFQ57R;ITSG"+4WCO>)QO(H
M CNVG(<A$OY\)?8FFS6_$(/V?)MH'^W2F\595U2?(S*MH8<@/*<^W;X7"R(8
M$F<9%P#\U((ZHB<G,O-GJ*@'X!8T[&U!A((//*^2$SHHMN[Z*'?'[1.LA?-:
M%E9O6A*,GW&; (6'5H<Z(9:-.X1C)PL""%:NFL23EBE*3W<_E:B\\C"90Q+
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M G/) QL[ *XA<8I;!#'XB.MV;]<;\[JR)<5I,.E6B#@K6R ;.>]LM"<R6_M
MV0RR^09+G;\QU&0HW0E]1"3^EX$WPA4+'3R0K*236^H"J['+" -96M=4UR22
MNX(![9 ,D95,+=:'P$N]#)[B"P"PAH#1X:=QY@>AY$ZR 0*O3P?PX^96:QE&
M.5[=I$7;I:^ "B1(PZ8U8Q\(KDI-WH4JOR'8A02I/=M*XFVQY#*+@OMWC]K
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M(!GD="WLG=I\@3:?H>-C2AC_)9O&=S@("%L;JZH6C HJ+IL_?6KKL 48QQ\
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M:=#=]3+'<0K*)N#Y6DJS#6R!;D#'?P!02P,$%     @ ^#E-6*X\V<S7 @
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M0YQ/WMY,VH5DM;X-;)C$NX5^S/ R!UPYH'W+F#PN5(+N>CC]'U!+ P04
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M!8*PH=F,\B9TM/ KPN-5TV6BV2-*Z3U-3>"=7"6Y!M=2L$HH5TL>T;X>9(4
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MYW*2 "Q,8A:[$8E=G_ENROPTI7$<L3A,6>PE)'9\YH0!BV.?7,WGZ(=4SKM
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M+LK3JID"CH'*">+YFA!^Z$B!]BO)XG]02P,$%     @ ^#E-6*:G17MW!P
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ME>)I?K@$&H/0 7A_SKG:GN@&JJ\SD_\ 4$L#!!0    ( /@Y35A*AP5MP@0
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M7EKOO-<GG*RKK>49X9SDU>$*L'CADPW$]PM"^.Y$=M#^_C'^%U!+ P04
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MV*2TQJ>UYN2.X'@[IX_ F"G4@E!I^C->E"H%]-*.6;,/H)X$3>.H-!VD$JJ
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M:"[RZA?DSY^RK'Q[4570?IS#]'=02P,$%     @ ^#E-6!)PJ/_^"@  D5\
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MQJ==Q3T&W?A -SY.-SAQ^UU(Z0R_F(AN%!",CY=;3D[=XTL<N&76G3L&$?E
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MJN14+1%0M_3K!YX^<*&=.LW-G#MW@J(%H&@A%%HW8+0-& 5:S31 4"&!1 M
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M/3OLH)I'@]9A+]MW64]K#W5V#O85+QTAN5:HH&:A8B_Q??J:7T7H^40'JBV
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M 3/K!I_D2OFR%MK>187R]LUC).;U?I/WF7J5-FFUF_=]46Q4J9'O0+-^4+0
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MGWKG<MJE?.WY7N/U_Y/J<CXW72]_67[O'-WC%YP#_&_Q^ 502P,$%     @
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MK779'/)9][G$Y!-02P$"% ,4    " #X.4U8!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /@Y35B#
M$?U&[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( /@Y35B97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ^#E-6"/"YA<?!@
M?2$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( /@Y35@ YU *^P8  "$<   8              " @6,.
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #X.4U8/<+"
M,R\#   )"@  &               @(&4%0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ ^#E-6(Z\_%X "0  ^2P  !@
M ("!^1@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( /@Y
M35C0T.Y9.0,  -4+   8              " @2\B  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " #X.4U823\=ZO,#  #Z#@  &
M        @(&>)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ ^#E-6/HV;#OJ%0  W^$  !@              ("!QRD  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /@Y35CW4#O[10D  "DJ   8
M              " @><_  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " #X.4U8$)[YS^$'   1$@  &               @(%B20  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ^#E-6'H&(=43%
M:ST  !D              ("!>5$  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " #X.4U88-:@QU@&  !%$@  &0              @('#
M90  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /@Y35@J
MRS]$1 8  (4.   9              " @5)L  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ ^#E-6&A9 FC7"@  ZQP  !D
M     ("!S7(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /@Y35CQ\.F4U@(  !(&   9              "
M@;.9  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ^#E-
M6.ZG]WBA#P  12H  !D              ("!P)P  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " #X.4U87CA$LX()  !R'   &0
M        @(&8K   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( /@Y35AS*J^^( L  / B   9              " @5&V  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ^#E-6-)\?>&]!0  B@X
M !D              ("!J,$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " #X.4U80S\1#K44  "E00  &0              @(&<QP
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /@Y35AC%K=F
M$P,  !<'   9              " @8C<  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ ^#E-6'[VRARC @  K 4  !D
M ("!TM\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #X
M.4U8KCS9S-<"   $!@  &0              @(&LX@  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /@Y35C^Q4@:V ,  .X)   9
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M970S,2YX;6Q02P$"% ,4    " #X.4U8Z7HG1E8%  !A*@  &0
M    @(&H_@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M /@Y35@1B+6P%0,   D+   9              " @34$ 0!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ ^#E-6(;B-A2F!   \AD  !D
M             ("!@0<! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " #X.4U8!A,4V9X#   Q$0  &0              @(%># $ >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( /@Y35BFIT5[=P<
M !Q/   9              " @3,0 0!X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ ^#E-6"]KJ'6!!P  24X  !D              ("!
MX1<! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #X.4U8
MVZT1)4$&  "<-P  &0              @(&9'P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( /@Y35@Z46CU(0,  'X)   9
M      " @1$F 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ ^#E-6(6@X1+& @  N0<  !D              ("!:2D! 'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #X.4U8J^^W/Z,"   )!P
M&0              @(%F+ $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( /@Y35COZ^'"Z 8  ,T_   9              " @4 O 0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ^#E-6,^5>P0V
M!0  J1D  !D              ("!7S8! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " #X.4U82H<%;<($   +&0  &0
M@(',.P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /@Y
M35@6FV#Y*P8  +<O   9              " @<5  0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ ^#E-6*?7*+>[ P  50P  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( /@Y35AJZ;:MQ D  -IA   9
M  " @>Q= 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
M^#E-6!)PJ/_^"@  D5\  !D              ("!YV<! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " #X.4U8BR>O>&\#  !A"0  &0
M            @($<<P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( /@Y35CJ:5P&] ,  /X+   9              " @<)V 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ ^#E-6%O0.V0B!0
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M96QS+RYR96QS4$L! A0#%     @ ^#E-6#8\+#ZQ!   D"4   \
M     ( !&HT! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /@Y35@,/Y#\
MY0$  '\A   :              "  ?B1 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( /@Y35B/X;=ITP$  #8A   3
M  "  164 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $  =Q$  !F6
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>317</ContextCount>
  <ElementCount>343</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>020100 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>030000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>040000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>050000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Description of Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DescriptionOfBusinessAndLiquidity</Role>
      <ShortName>Description of Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Recent Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RecentTransactions</Role>
      <ShortName>Recent Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Certain Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CertainBalanceSheetComponents</Role>
      <ShortName>Certain Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongtermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SharebasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Earn-Out Shares, Public Warrants and Private Placement Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants</Role>
      <ShortName>Earn-Out Shares, Public Warrants and Private Placement Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061300 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>061400 - Disclosure - Net Income (Loss) per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetIncomeLossPerCommonShare</Role>
      <ShortName>Net Income (Loss) per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Recent Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RecentTransactionsTables</Role>
      <ShortName>Recent Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/RecentTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Certain Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CertainBalanceSheetComponentsTables</Role>
      <ShortName>Certain Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/CertainBalanceSheetComponents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongtermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/LongtermDebt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>080900 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/SharebasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>081300 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>081400 - Disclosure - Net Income (Loss) per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetIncomeLossPerCommonShareTables</Role>
      <ShortName>Net Income (Loss) per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/NetIncomeLossPerCommonShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Description of Business and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails</Role>
      <ShortName>Description of Business and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/DescriptionOfBusinessAndLiquidity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Equity Method Investments, Investment in Arbutus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails</Role>
      <ShortName>Equity Method Investments, Investment in Arbutus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090302 - Disclosure - Equity Method Investments, Investment in Datavant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails</Role>
      <ShortName>Equity Method Investments, Investment in Datavant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/IntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Recent Transactions, Telavant Disposition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RecentTransactionsTelavantDispositionDetails</Role>
      <ShortName>Recent Transactions, Telavant Disposition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090502 - Disclosure - Recent Transactions, Asset Acquisition and Deconsolidation of Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails</Role>
      <ShortName>Recent Transactions, Asset Acquisition and Deconsolidation of Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Certain Balance Sheet Components, Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Components, Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090602 - Disclosure - Certain Balance Sheet Components, Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Components, Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090604 - Disclosure - Certain Balance Sheet Components, Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Certain Balance Sheet Components, Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Long-Term Debt, Funding Agreement with NovaQuest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails</Role>
      <ShortName>Long-Term Debt, Funding Agreement with NovaQuest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Long-Term Debt, Credit Facility with XYQ Luxco (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails</Role>
      <ShortName>Long-Term Debt, Credit Facility with XYQ Luxco (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090704 - Disclosure - Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails</Role>
      <ShortName>Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Shareholders' Equity - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/ShareholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Share-Based Compensation, Stock Options and Performance Stock Options under RSL Equity Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails</Role>
      <ShortName>Share-Based Compensation, Stock Options and Performance Stock Options under RSL Equity Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090902 - Disclosure - Share-Based Compensation, Restricted Stock Units and Performance Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails</Role>
      <ShortName>Share-Based Compensation, Restricted Stock Units and Performance Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090904 - Disclosure - Share-Based Compensation, CVARs, Employee Stock Purchase Plan and Subsidiary Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails</Role>
      <ShortName>Share-Based Compensation, CVARs, Employee Stock Purchase Plan and Subsidiary Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Earn-Out Shares, Public Warrants and Private Placement Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails</Role>
      <ShortName>Earn-Out Shares, Public Warrants and Private Placement Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>091300 - Disclosure - Fair Value Measurements, Assets and Liabilities are Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements, Assets and Liabilities are Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>091302 - Disclosure - Fair Value Measurements, Changes in Fair Value of the Level 3 Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails</Role>
      <ShortName>Fair Value Measurements, Changes in Fair Value of the Level 3 Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>091304 - Disclosure - Fair Value Measurements, Changes in Fair Value of the Level 3 Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements, Changes in Fair Value of the Level 3 Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>091306 - Disclosure - Fair Value Measurements, Fair Value of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements, Fair Value of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ef20015327_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>091400 - Disclosure - Net Income (Loss) per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetIncomeLossPerCommonShareDetails</Role>
      <ShortName>Net Income (Loss) per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/NetIncomeLossPerCommonShareTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ef20015327_10q.htm">ef20015327_10q.htm</File>
    <File>roiv-20231231.xsd</File>
    <File>roiv-20231231_cal.xml</File>
    <File>roiv-20231231_def.xml</File>
    <File>roiv-20231231_lab.xml</File>
    <File>roiv-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="732">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20015327_10q.htm": {
   "nsprefix": "roiv",
   "nsuri": "http://roivant.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ef20015327_10q.htm"
     ]
    },
    "schema": {
     "local": [
      "roiv-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "roiv-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "roiv-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "roiv-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "roiv-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 233,
   "keyCustom": 110,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 47,
   "hidden": {
    "total": 17,
    "http://roivant.com/20231231": 4,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 8
   },
   "contextCount": 317,
   "entityCount": 1,
   "segmentCount": 84,
   "elementCount": 578,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 732,
    "http://xbrl.sec.gov/dei/2023": 32
   },
   "report": {
    "R1": {
     "role": "http://roivant.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "010000 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:ShorttermDebtFairValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "16",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
     "longName": "020000 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
     "longName": "020100 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
     "longName": "030000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
     "longName": "040000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c20220331_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember",
      "name": "roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "050000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:NonCashAcquiredInProcessResearchAndDevelopment",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://roivant.com/role/DescriptionOfBusinessAndLiquidity",
     "longName": "060100 - Disclosure - Description of Business and Liquidity",
     "shortName": "Description of Business and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "060200 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://roivant.com/role/EquityMethodInvestments",
     "longName": "060300 - Disclosure - Equity Method Investments",
     "shortName": "Equity Method Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://roivant.com/role/IntangibleAssets",
     "longName": "060400 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://roivant.com/role/RecentTransactions",
     "longName": "060500 - Disclosure - Recent Transactions",
     "shortName": "Recent Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:RecentTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:RecentTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://roivant.com/role/CertainBalanceSheetComponents",
     "longName": "060600 - Disclosure - Certain Balance Sheet Components",
     "shortName": "Certain Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://roivant.com/role/LongtermDebt",
     "longName": "060700 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://roivant.com/role/ShareholdersEquity",
     "longName": "060800 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://roivant.com/role/SharebasedCompensation",
     "longName": "060900 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://roivant.com/role/IncomeTaxes",
     "longName": "061000 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://roivant.com/role/CommitmentsAndContingencies",
     "longName": "061100 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants",
     "longName": "061200 - Disclosure - Earn-Out Shares, Public Warrants and Private Placement Warrants",
     "shortName": "Earn-Out Shares, Public Warrants and Private Placement Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://roivant.com/role/FairValueMeasurements",
     "longName": "061300 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://roivant.com/role/NetIncomeLossPerCommonShare",
     "longName": "061400 - Disclosure - Net Income (Loss) per Common Share",
     "shortName": "Net Income (Loss) per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "070200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "080200 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://roivant.com/role/IntangibleAssetsTables",
     "longName": "080400 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://roivant.com/role/RecentTransactionsTables",
     "longName": "080500 - Disclosure - Recent Transactions (Tables)",
     "shortName": "Recent Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://roivant.com/role/CertainBalanceSheetComponentsTables",
     "longName": "080600 - Disclosure - Certain Balance Sheet Components (Tables)",
     "shortName": "Certain Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://roivant.com/role/LongtermDebtTables",
     "longName": "080700 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://roivant.com/role/SharebasedCompensationTables",
     "longName": "080900 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://roivant.com/role/FairValueMeasurementsTables",
     "longName": "081300 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://roivant.com/role/NetIncomeLossPerCommonShareTables",
     "longName": "081400 - Disclosure - Net Income (Loss) per Common Share (Tables)",
     "shortName": "Net Income (Loss) per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
     "longName": "090100 - Disclosure - Description of Business and Liquidity (Details)",
     "shortName": "Description of Business and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "090200 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
     "longName": "090300 - Disclosure - Equity Method Investments, Investment in Arbutus (Details)",
     "shortName": "Equity Method Investments, Investment in Arbutus (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails",
     "longName": "090302 - Disclosure - Equity Method Investments, Investment in Datavant (Details)",
     "shortName": "Equity Method Investments, Investment in Datavant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://roivant.com/role/IntangibleAssetsDetails",
     "longName": "090400 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230331",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails",
     "longName": "090500 - Disclosure - Recent Transactions, Telavant Disposition (Details)",
     "shortName": "Recent Transactions, Telavant Disposition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "roiv:GainLossOnSaleOfAssets",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember",
      "name": "roiv:IncomeLossFromDisposalGroupBeforeIncomeTax",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails",
     "longName": "090502 - Disclosure - Recent Transactions, Asset Acquisition and Deconsolidation of Subsidiaries (Details)",
     "shortName": "Recent Transactions, Asset Acquisition and Deconsolidation of Subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230701to20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember",
      "name": "roiv:UpfrontCashPayment",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails",
     "longName": "090600 - Disclosure - Certain Balance Sheet Components, Other Current Assets (Details)",
     "shortName": "Certain Balance Sheet Components, Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails",
     "longName": "090602 - Disclosure - Certain Balance Sheet Components, Accrued Expenses (Details)",
     "shortName": "Certain Balance Sheet Components, Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "roiv:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "roiv:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails",
     "longName": "090604 - Disclosure - Certain Balance Sheet Components, Other Current Liabilities (Details)",
     "shortName": "Certain Balance Sheet Components, Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:DeferredRevenueCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:DeferredRevenueCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
     "longName": "090700 - Disclosure - Long-Term Debt, Funding Agreement with NovaQuest (Details)",
     "shortName": "Long-Term Debt, Funding Agreement with NovaQuest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:ShorttermDebtFairValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
     "longName": "090702 - Disclosure - Long-Term Debt, Credit Facility with XYQ Luxco (Details)",
     "shortName": "Long-Term Debt, Credit Facility with XYQ Luxco (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
     "longName": "090704 - Disclosure - Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details)",
     "shortName": "Long-Term Debt, Revenue Interest Purchase and Sale Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember",
      "name": "roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://roivant.com/role/ShareholdersEquityDetails",
     "longName": "090800 - Disclosure - Shareholders' Equity - (Details)",
     "shortName": "Shareholders' Equity - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember",
      "name": "roiv:OwnershipPercentage",
      "unitRef": "U005",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember",
      "name": "roiv:OwnershipPercentage",
      "unitRef": "U005",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails",
     "longName": "090900 - Disclosure - Share-Based Compensation, Stock Options and Performance Stock Options under RSL Equity Plans (Details)",
     "shortName": "Share-Based Compensation, Stock Options and Performance Stock Options under RSL Equity Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:NumberOfEquityIncentivePlans",
      "unitRef": "U008",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231",
      "name": "roiv:NumberOfEquityIncentivePlans",
      "unitRef": "U008",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
     "longName": "090902 - Disclosure - Share-Based Compensation, Restricted Stock Units and Performance Stock Units (Details)",
     "shortName": "Share-Based Compensation, Restricted Stock Units and Performance Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c20230331_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230331_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
     "longName": "090904 - Disclosure - Share-Based Compensation, CVARs, Employee Stock Purchase Plan and Subsidiary Equity Incentive Plans (Details)",
     "shortName": "Share-Based Compensation, CVARs, Employee Stock Purchase Plan and Subsidiary Equity Incentive Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c20231001to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://roivant.com/role/IncomeTaxesDetails",
     "longName": "091000 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "U005",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "U005",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://roivant.com/role/CommitmentsAndContingenciesDetails",
     "longName": "091100 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230401to20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember",
      "name": "us-gaap:LongtermPurchaseCommitmentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
     "longName": "091200 - Disclosure - Earn-Out Shares, Public Warrants and Private Placement Warrants (Details)",
     "shortName": "Earn-Out Shares, Public Warrants and Private Placement Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c20230630",
      "name": "roiv:ClassOfWarrantOrRightRedemptionPrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230630",
      "name": "roiv:ClassOfWarrantOrRightRedemptionPrice",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "091300 - Disclosure - Fair Value Measurements, Assets and Liabilities are Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements, Assets and Liabilities are Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230331_ClassOfWarrantOrRightAxis_PublicWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FinancialInstrumentAxis_WarrantMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "link:footnote",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails",
     "longName": "091302 - Disclosure - Fair Value Measurements, Changes in Fair Value of the Level 3 Assets (Details)",
     "shortName": "Fair Value Measurements, Changes in Fair Value of the Level 3 Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails",
     "longName": "091304 - Disclosure - Fair Value Measurements, Changes in Fair Value of the Level 3 Liabilities (Details)",
     "shortName": "Fair Value Measurements, Changes in Fair Value of the Level 3 Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
     "longName": "091306 - Disclosure - Fair Value Measurements, Fair Value of Significant Unobservable Inputs (Details)",
     "shortName": "Fair Value Measurements, Fair Value of Significant Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c20231231_StatementEquityComponentsAxis_EarnoutSharesMember",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember",
      "name": "roiv:FairValueAssetMeasurementInput",
      "unitRef": "U005",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://roivant.com/role/NetIncomeLossPerCommonShareDetails",
     "longName": "091400 - Disclosure - Net Income (Loss) per Common Share (Details)",
     "shortName": "Net Income (Loss) per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231001to20231231",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20015327_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "roiv_APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) and Noncontrolling Interest for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC and Noncontrolling Interest, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r701"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses [Abstract]",
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued Research and Development Expenses, Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_AccruedSalesAllowancesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "AccruedSalesAllowancesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to sales allowances, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued Sales Allowances Current",
        "terseLabel": "Sales allowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r108",
      "r167",
      "r529",
      "r557",
      "r558"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r36",
      "r429",
      "r432",
      "r468",
      "r553",
      "r554",
      "r742",
      "r743",
      "r744",
      "r755",
      "r756",
      "r757"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_AcquiredInProcessResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "AcquiredInProcessResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquired in-process research and development expense.",
        "label": "Acquired in Process Research and Development Expense",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r701",
      "r829"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r571",
      "r755",
      "r756",
      "r757",
      "r807",
      "r831"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r403"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49",
      "r52"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Potentially dilutive common stock were excluded from computation of diluted net income (loss) per common share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "roiv_ArbutusBiopharmaCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ArbutusBiopharmaCorporationMember",
     "presentation": [
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of related party.",
        "label": "Arbutus Biopharma Corporation [Member]",
        "terseLabel": "Arbutus Biopharma Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails",
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAbstract",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Abstract]",
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "AssetAcquisitionResearchAndDevelopmentExpenseInProcess",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset acquisition research and development expense in-process.",
        "label": "Asset Acquisition, Research and Development Expense in Process",
        "verboseLabel": "Acquired in process research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r161",
      "r193",
      "r231",
      "r239",
      "r243",
      "r282",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r421",
      "r425",
      "r449",
      "r526",
      "r612",
      "r701",
      "r714",
      "r773",
      "r774",
      "r815"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r171",
      "r193",
      "r282",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r421",
      "r425",
      "r449",
      "r701",
      "r773",
      "r774",
      "r815"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets: [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r695",
      "r696"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r418",
      "r695",
      "r696"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Liquidity",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r119",
      "r120"
     ]
    },
    "roiv_CapitalContributionsToSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CapitalContributionsToSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Contributions To Subsidiaries",
        "label": "Capital Contributions To Subsidiaries",
        "terseLabel": "Cash contributions to majority-owned subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CappedValueAppreciationRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CappedValueAppreciationRightsMember",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped value appreciation rights to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Capped Value Appreciation Rights [Member]",
        "terseLabel": "CVARs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r158",
      "r673"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r134"
     ]
    },
    "roiv_CashBonusProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CashBonusProgramMember",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The company approved a special one-time cash retention bonus award to its employees.",
        "label": "Cash Bonus Program [Member]",
        "terseLabel": "Cash Bonus Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r116",
      "r190"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash [Abstract]",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r116"
     ]
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashDivestedFromDeconsolidation",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash decrease upon deconsolidation of subsidiaries",
        "label": "Cash Divested from Deconsolidation",
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "roiv_CashExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CashExercisePrice",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exercise price per common share on a cash basis to exercise warrants.",
        "label": "Cash Exercise Price",
        "verboseLabel": "Cash exercise price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CashlessExerciseOfTheCompanyCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CashlessExerciseOfTheCompanyCommonStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cashless exercise of the company's common stock warrants in noncash investing or financing activities.",
        "label": "Cashless Exercise of the Company Common Stock Warrants",
        "terseLabel": "Cashless exercise of the Company's warrants"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CashlessPublicWarrantExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CashlessPublicWarrantExercised",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of cashless public warrants exercised during the period.",
        "label": "Cashless Public Warrant Exercised",
        "terseLabel": "Cashless warrant exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CertainBalanceSheetComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CertainBalanceSheetComponentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Balance Sheet Components [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "roiv_CioxParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CioxParentMember",
     "presentation": [
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of combined merged entity.",
        "label": "Ciox Parent [Member]",
        "terseLabel": "Datavant Merger [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r164",
      "r165",
      "r166",
      "r193",
      "r215",
      "r219",
      "r221",
      "r223",
      "r229",
      "r230",
      "r282",
      "r306",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r336",
      "r337",
      "r340",
      "r343",
      "r350",
      "r449",
      "r563",
      "r564",
      "r565",
      "r566",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r600",
      "r621",
      "r640",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r723",
      "r751",
      "r759"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r229",
      "r336",
      "r337",
      "r338",
      "r340",
      "r343",
      "r348",
      "r350",
      "r563",
      "r564",
      "r565",
      "r566",
      "r690",
      "r723",
      "r751"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants issued (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ClassOfWarrantOrRightRedemptionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ClassOfWarrantOrRightRedemptionPrice",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right Redemption Price",
        "verboseLabel": "Redemption price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ClassOfWarrantOrRightUnexercisedPriceOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ClassOfWarrantOrRightUnexercisedPriceOfWarrants",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares unexercised of warrant redeemed during the period.",
        "label": "Class of Warrant or Right Unexercised Price of Warrants",
        "terseLabel": "Unexercised public warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r85",
      "r527",
      "r599"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r300",
      "r301",
      "r667",
      "r769"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r668"
     ]
    },
    "roiv_CommittedFundingUnderRIPSA": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CommittedFundingUnderRIPSA",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The committed funding under revenue interest purchase and sale agreement (RIPSA).",
        "label": "Committed Funding under RIPSA",
        "terseLabel": "Royalties entitled to receive"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The committed funding under revenue interest purchase and sale agreement.",
        "label": "Committed Funding under Revenue Interest Purchase and Sale Agreement",
        "terseLabel": "Face amount"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The committed funding under revenue interest purchase and sale agreement received.",
        "label": "Committed Funding under Revenue Interest Purchase and Sale Agreement Received",
        "terseLabel": "Committed funding under revenue interest purchase and sale agreement received"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The common shares aggregate offering price authorized remaining capacity to issue under equity offering program.",
        "label": "Common Shares Aggregate Offering Price Authorized, Remaining Capacity Available",
        "terseLabel": "Common shares aggregate offering price authorized, remaining capacity available"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common shares and other consideration issued for the purchase of property and equipment in noncash investing or financing activities.",
        "label": "Common Shares and Other Consideration Issued for Purchase of Property and Equipment",
        "verboseLabel": "Issuance of the Company's common shares and other consideration for an acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CommonSharesOfferingPriceAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CommonSharesOfferingPriceAuthorized",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The common shares aggregate offering price authorized to issue under equity offering program.",
        "label": "Common Shares Offering Price Authorized",
        "terseLabel": "Common shares aggregate offering price authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares available for future grants (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock [Member]",
        "terseLabel": "Common Shares [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r755",
      "r756",
      "r807",
      "r826",
      "r831"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r600"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares acquired (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102",
      "r600",
      "r618",
      "r831",
      "r832"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 804,890,910 and 760,143,393 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r528",
      "r701"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss) attributable to Roivant Sciences Ltd.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r176",
      "r178",
      "r186",
      "r522",
      "r542"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r69",
      "r75",
      "r176",
      "r178",
      "r185",
      "r521",
      "r541"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r131",
      "r176",
      "r178",
      "r184",
      "r520",
      "r540"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r147"
     ]
    },
    "roiv_ConsiderationReceivedForSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ConsiderationReceivedForSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received for sale of assets.",
        "label": "Consideration received for sale of Assets",
        "verboseLabel": "Total consideration"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r421",
      "r422",
      "r425",
      "r426",
      "r472",
      "r669",
      "r772",
      "r775",
      "r776"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r421",
      "r422",
      "r425",
      "r426",
      "r472",
      "r669",
      "r772",
      "r775",
      "r776"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r679"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenues [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r318",
      "r338",
      "r471",
      "r676",
      "r678"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CowenAndCompanyLLCMember",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An affiliate with whom the entity entered into a sales agreement.",
        "label": "Cowen and Company, LLC [Member]",
        "terseLabel": "Cowen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_CreditFacilityWithXYQLuxcoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "CreditFacilityWithXYQLuxcoMember",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An senior secured credit facility entered by Dermavant and certain of its subsidiaries with XYQ Luxco S.A.R.L (\"XYQ Luxco\"),.",
        "label": "Credit Facility with XYQ Luxco [Member]",
        "terseLabel": "Credit Facility with XYQ Luxco [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DatavantHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DatavantHoldingsIncMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of related party.",
        "label": "Datavant Holdings, Inc [Member]",
        "terseLabel": "Datavant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 0.0
      },
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "verboseLabel": "Carrying balance",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r136",
      "r332"
     ]
    },
    "roiv_DebtInstrumentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DebtInstrumentExitFee",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit fee of debt instrument.",
        "label": "Debt Instrument, Exit Fee",
        "terseLabel": "Exit fee"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DebtInstrumentExitFeeAndEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DebtInstrumentExitFeeAndEndOfTermCharge",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses associated with exit fee and end of term charge of debt instrument.",
        "label": "Debt Instrument, Exit Fee and End of Term Charge",
        "terseLabel": "Debt instrument exit fee and end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83",
      "r315",
      "r463",
      "r686",
      "r687"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair value of long-term debt",
        "verboseLabel": "Debt issued by Dermavant to NovaQuest",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r448",
      "r686",
      "r687"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in exit fee",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Frequency of periodic payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r87"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r316"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r463",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r752"
     ]
    },
    "roiv_DebtInstrumentQuarterlyPaymentsMade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DebtInstrumentQuarterlyPaymentsMade",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of quarterly payments made under the agreement.",
        "label": "Debt Instrument, Quarterly Payments Made",
        "terseLabel": "Quarterly payments made"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r58",
      "r61",
      "r80",
      "r81",
      "r83",
      "r86",
      "r128",
      "r129",
      "r197",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r463",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r752"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      },
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: unamortized discount and debt issuance costs",
        "negatedLabel": "Less: unamortized issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r321",
      "r333",
      "r686",
      "r687"
     ]
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 8.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on deconsolidation of subsidiaries",
        "label": "Gain on deconsolidation of subsidiaries",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "roiv_DeconsolidationOfSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DeconsolidationOfSubsidiariesAbstract",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deconsolidation of Subsidiaries [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deconsolidation of subsidiaries",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue, Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r235"
     ]
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability instruments measured at fair value",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value",
        "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities at fair value",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r448",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r613",
      "r615",
      "r616",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r678",
      "r827"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "roiv_DermavantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DermavantMember",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the acquiree.",
        "label": "Dermavant [Member]",
        "terseLabel": "Dermavant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DescriptionOfBusinessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DescriptionOfBusinessAbstract",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business [Abstract]",
        "terseLabel": "Description of Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DescriptionOfBusinessAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DescriptionOfBusinessAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Independent Directors [Member]"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r828"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r369",
      "r397",
      "r398",
      "r399",
      "r698"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DisposalGroupAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DisposalGroupAbstract",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group [Abstract]",
        "terseLabel": "Telavant Disposition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DisposalGroupAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DisposalGroupAssets",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails": {
       "parentTag": "roiv_DisposalGroupNetAssetsLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale.",
        "label": "Disposal Group, Assets",
        "terseLabel": "Assets sold"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DisposalGroupConsiderationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DisposalGroupConsiderationAbstract",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Consideration [Abstract]",
        "terseLabel": "Consideration [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DisposalGroupLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DisposalGroupLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails": {
       "parentTag": "roiv_DisposalGroupNetAssetsLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale.",
        "label": "Disposal Group, Liabilities",
        "terseLabel": "Liabilities transferred"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DisposalGroupNetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DisposalGroupNetAssetsLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as net assets (liabilities) attributable to disposal group held for sale.",
        "label": "Disposal Group, Net Assets (Liabilities)",
        "totalLabel": "Net liabilities sold"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DisposalGroupNoncontrollingInterestDerecognizedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DisposalGroupNoncontrollingInterestDerecognizedValue",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of noncontrolling interest derecognized attributable to disposal group held for sale.",
        "label": "Disposal Group, Noncontrolling Interest, Derecognized Value",
        "terseLabel": "Carrying amount of noncontrolling interest derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsCalculationOfGainAbstract",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations, Calculation of Gain [Abstract]",
        "terseLabel": "Calculation of Gain [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696"
     ]
    },
    "roiv_DividendDeclaredBySubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "DividendDeclaredBySubsidiary",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend declared by subsidiary.",
        "label": "Dividend Declared by Subsidiary",
        "negatedLabel": "Dividend declared by subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EarnOutSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnOutSharePrice",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The share price of earn-out share.",
        "label": "Earn-Out Share Price",
        "terseLabel": "Earn-out share price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EarnOutSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnOutSharesAbstract",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-Out Shares [Abstract]",
        "terseLabel": "Earn-Out Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EarnOutSharesNonvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnOutSharesNonvestedMember",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout or earn-out refers to a pricing structure in mergers and acquisitions where the sellers must \"earn\" part of the purchase price based on the performance of the business.",
        "label": "Earn Out Shares Nonvested [Member]",
        "terseLabel": "Earn-Out Shares (Non-vested) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsLineItems",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earn-Out Shares, Public Warrants and Private Placement Warrants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTable",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for earn-out shares, public warrants and private placement warrants.",
        "label": "Earn-Out Shares, Public Warrants and Private Placement Warrants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of earn-out shares, public warrants and private placement warrants.",
        "label": "Earn-Out Shares, Public Warrants and Private Placement Warrants [Text Block]",
        "terseLabel": "Earn-Out Shares, Public Warrants and Private Placement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share:",
        "label": "Net Income (Loss) per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share - basic (in dollars per share)",
        "label": "Net income (loss) per common share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r213",
      "r215",
      "r221",
      "r222",
      "r223",
      "r227",
      "r437",
      "r438",
      "r523",
      "r543",
      "r680"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share - diluted (in dollars per share)",
        "label": "Net income (loss) per common share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r215",
      "r221",
      "r222",
      "r223",
      "r227",
      "r437",
      "r438",
      "r523",
      "r543",
      "r680"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) per Common Share [Abstract]",
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) per Common Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r224",
      "r225",
      "r226"
     ]
    },
    "roiv_EarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EarnoutSharesMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of earn-out shares issued.",
        "label": "Earnout Shares [Member]",
        "terseLabel": "Earn-Out Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails",
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation-related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r153",
      "r179",
      "r180",
      "r181",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r210",
      "r228",
      "r284",
      "r285",
      "r352",
      "r400",
      "r401",
      "r402",
      "r411",
      "r412",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r468",
      "r553",
      "r554",
      "r555",
      "r571",
      "r640"
     ]
    },
    "roiv_EquityInstrumentsVestedAndSettledShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EquityInstrumentsVestedAndSettledShares",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments vested and settled during the period.",
        "label": "Equity Instruments Vested and Settled, Shares",
        "terseLabel": "Equity instruments vested and settled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r281"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity method investment ownership percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://roivant.com/role/EquityMethodInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r280",
      "r283",
      "r724"
     ]
    },
    "roiv_EquityOfferingsAtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EquityOfferingsAtTheMarketMember",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering of \"at-the-market\" shares as per equity distribution agreement.",
        "label": "Equity Offerings at the Market [Member]",
        "terseLabel": "At-the-Market Equity Offering Program[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_EstimatedNetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "EstimatedNetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net cash inflow from the additional capital contribution to the entity.",
        "label": "Estimated Net Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ExerciseOfPrivatePlacementWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ExerciseOfPrivatePlacementWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Exercise of Private Placement Warrants Value",
        "negatedLabel": "Exercise of Private Placement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ExercisePrice",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exercise price per Common Share on a cashless basis to exercise warrants.",
        "label": "Exercise Price",
        "terseLabel": "Cashless exercise price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_FairValueAssetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FairValueAssetMeasurementInput",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value asset, measurement input.",
        "label": "Fair Value Asset, Measurement Input",
        "terseLabel": "Investment in equity securities, measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r446"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r446"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Calculation Using Significant Unobservable Inputs",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r79"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in Fair Value of the Level 3 Assets",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r79"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r79"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails",
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r441",
      "r477",
      "r478",
      "r479",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r443",
      "r444",
      "r447"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "roiv_FairValueEarnoutSharesMeasurementInput": {
     "xbrltype": "percentItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FairValueEarnoutSharesMeasurementInput",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value measurement input for Earn-out shares.",
        "label": "Fair Value Earnout Shares Measurement Input",
        "terseLabel": "Earn-out share, measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r356",
      "r361",
      "r441",
      "r477",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r356",
      "r361",
      "r441",
      "r478",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails",
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r441",
      "r479",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r79"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in Fair Value of the Level 3 Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r79"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_FairValueMeasurementInputsAndValuationTechniquesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FairValueMeasurementInputsAndValuationTechniquesAbstract",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value of investment in Datavant, included in net loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in fair value of debt and liability instruments, included in net loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of liability instrument issued",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails",
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r477",
      "r478",
      "r479",
      "r686",
      "r687",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r447"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3AssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "roiv_FiftyPercentBonusPayablePeriodFromGrantDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FiftyPercentBonusPayablePeriodFromGrantDate",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of fifty percent bonus payable from grant date.",
        "label": "Fifty Percent Bonus Payable Period from Grant Date",
        "terseLabel": "Period of bonus payable from grant date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on principal portion of finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r467"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r331",
      "r348",
      "r434",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r539",
      "r684",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r763",
      "r764",
      "r765",
      "r766"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at fair value",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "terseLabel": "Future amortization expense, thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining weighted average estimated useful lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/IntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r297"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, remainder of 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/IntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r506"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_FundingAgreementWithNovaQuestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FundingAgreementWithNovaQuestAbstract",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funding Agreement with NovaQuest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_FundingAgreementWithNovaQuestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FundingAgreementWithNovaQuestMember",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An asset purchase funding agreement between Dermavant and NovaQuest Co-Investment Fund VIII, L.P (the \"NovaQuest Agreement\").",
        "label": "Funding Agreement with NovaQuest [Member]",
        "terseLabel": "Funding Agreement with NovaQuest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_FutureMilestoneToBeReceivedFromSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "FutureMilestoneToBeReceivedFromSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The future milestone to be received from sale of assets.",
        "label": "Future Milestone to be Received from Sale of Assets",
        "terseLabel": "Consideration to be received from milestone"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_GSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "GSKMember",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Solutions Inc. is a cutting edge, no-nonsense cyber security company who provides security software, services, and consulting.",
        "label": "GSK [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of Telavant net assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "GainLossOnFairValueOfDebtAndLiabilityInstruments",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on fair value of debt and liability instruments.",
        "label": "Gain (Loss) on Fair Value of Debt and Liability Instruments",
        "negatedLabel": "Change in fair value of debt and liability instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of investments",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r722"
     ]
    },
    "roiv_GainLossOnSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "GainLossOnSaleOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Sale of Assets",
        "terseLabel": "Gain on sale of Telavant net assets",
        "verboseLabel": "Gain on sale of net assets"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of entity acquired intangibles assets.",
        "label": "GlaxoSmithKline Intellectual Property Development Ltd. [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ImmunovantIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ImmunovantIncMember",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of subsidiary.",
        "label": "Immunovant, Inc. [Member]",
        "terseLabel": "Immunovant, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r109",
      "r140",
      "r231",
      "r238",
      "r242",
      "r244",
      "r524",
      "r534",
      "r682"
     ]
    },
    "roiv_IncomeLossFromDisposalGroupBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "IncomeLossFromDisposalGroupBeforeIncomeTax",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of before tax of income (loss) from a disposal group.",
        "label": "Income (Loss) from Disposal Group, before Income Tax",
        "terseLabel": "Pretax loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r17",
      "r20",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r124"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r624"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r624"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://roivant.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r405",
      "r408",
      "r409",
      "r410",
      "r413",
      "r415",
      "r416",
      "r417",
      "r568"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r150",
      "r209",
      "r210",
      "r236",
      "r406",
      "r414",
      "r545"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax receivable",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r741"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities, net of effects from acquisition and divestiture:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r748"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of dilutive common stock equivalents (in shares)",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r223",
      "r368"
     ]
    },
    "roiv_IntangibleAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "IntangibleAssetAbstract",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset [Abstract]",
        "terseLabel": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://roivant.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://roivant.com/role/IntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net book value",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r142",
      "r182",
      "r234",
      "r462",
      "r625",
      "r712",
      "r830"
     ]
    },
    "roiv_InterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "InterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income on nonoperating activities.",
        "label": "Interest Income",
        "negatedLabel": "Interest income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r833"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r674",
      "r701"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r559",
      "r560",
      "r561",
      "r562",
      "r647",
      "r648"
     ]
    },
    "roiv_InvestmentsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "InvestmentsDisclosureAbstract",
     "presentation": [
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Disclosure [Abstract]",
        "terseLabel": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fair value investment",
        "positiveLabel": "Investments measured at fair value",
        "verboseLabel": "Investment",
        "label": "Retained investment",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r812"
     ]
    },
    "roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount net common shares issued of subsidiary to the company and cash contributions to majority-owned subsidiaries.",
        "label": "Issuance of Subsidiary Common Shares to the Company and Capital Contributions to Subsidiaries",
        "terseLabel": "Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount net common shares issued of subsidiary to the company, net of issuance costs.",
        "label": "Issuance of Subsidiary Common Shares to the Company Net Issuance Costs, Value",
        "terseLabel": "Issuance of subsidiary common shares to the Company"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "IssuanceOfSubsidiaryCommonSharesToTheCompanyShares",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuance of subsidiary to the Company.",
        "label": "Issuance of Subsidiary Common Shares to the Company, Shares",
        "terseLabel": "Issuance of subsidiary common shares to the Company (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r193",
      "r282",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r422",
      "r425",
      "r426",
      "r449",
      "r598",
      "r681",
      "r714",
      "r773",
      "r815",
      "r816"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r139",
      "r532",
      "r701",
      "r753",
      "r767",
      "r810"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities and Shareholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r157",
      "r193",
      "r282",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r422",
      "r425",
      "r426",
      "r449",
      "r701",
      "r773",
      "r815",
      "r816"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non financial liabilities at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities: [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_LiabilityInstrumentsMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "LiabilityInstrumentsMeasuredAtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability instruments measured at fair value.",
        "label": "Liability Instruments Measured at Fair Value",
        "verboseLabel": "Liability instruments measured at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_LiabilityInstrumentsMeasuredAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "LiabilityInstrumentsMeasuredAtFairValueMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liability instruments measured at fair value.",
        "label": "Liability Instruments Measured At Fair Value [Member]",
        "terseLabel": "Liability Instruments Measured at Fair Value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_LicenseMilestoneAndOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "LicenseMilestoneAndOtherRevenueMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license, milestone, and other revenue.",
        "label": "License, Milestone and Other Revenue [Member]",
        "terseLabel": "License, Milestone and Other Revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "LiquidityAbstract",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]",
        "terseLabel": "Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_LoanAndCreditAgreementsByDermavantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "LoanAndCreditAgreementsByDermavantAbstract",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan and Credit Agreements by Dermavant [Abstract]",
        "terseLabel": "Loan and Credit Agreements by Dermavant [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt, net",
        "verboseLabel": "Long-term debt, net of current portion (includes $194,560 and $180,700 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r136",
      "r322",
      "r334",
      "r686",
      "r687",
      "r824"
     ]
    },
    "us-gaap_LongTermDebtAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAbstract",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Debt Obligations [Abstract]",
        "verboseLabel": "Carrying Balance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of long-term debt (includes $26,950 and $26,940 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total long-term debt, net",
        "terseLabel": "Long term debt accounted under fair value option",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total long-term debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://roivant.com/role/LongtermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentTable",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment [Table]",
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying Balance of Debt Issued [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase certain quantities of inventory over period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_March2020CappedValueAppreciationRightsGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "March2020CappedValueAppreciationRightsGrantsMember",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails",
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date of Capped Value Appreciation Rights (CVARs).",
        "label": "March 2020 Capped Value Appreciation Rights Grants [Member]",
        "terseLabel": "March 2020 CVAR Grants [Member]",
        "verboseLabel": "March 2020 CVARs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r363",
      "r504",
      "r552",
      "r590",
      "r591",
      "r646",
      "r649",
      "r650",
      "r651",
      "r659",
      "r670",
      "r671",
      "r683",
      "r690",
      "r697",
      "r703",
      "r777",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "roiv_MaximumMilestonePaymentObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "MaximumMilestonePaymentObligation",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum milestone payment obligation.",
        "label": "Maximum Milestone Payment Obligation",
        "verboseLabel": "Maximum milestone payment obligation"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_MaximumMilestonePaymentOffsetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "MaximumMilestonePaymentOffsetAmount",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum milestone payment offset amount.",
        "label": "Maximum Milestone Payment Offset Amount",
        "terseLabel": "Right to offset of commercial milestones payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Term (in years) [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_MilestonePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "MilestonePaid",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made during the period for achieving the milestone or milestones.",
        "label": "Milestone Paid",
        "terseLabel": "Milestone amount paid"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_MilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "MilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payable.",
        "label": "Milestone Payable",
        "terseLabel": "Milestone payable"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_MilestonePaymentPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "MilestonePaymentPayable",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment payable.",
        "label": "Milestone Payment Payable",
        "terseLabel": "Milestone payment payable"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made during the period for achieving the milestone or milestones.",
        "label": "Milestone Payments",
        "negatedLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r363",
      "r504",
      "r552",
      "r590",
      "r591",
      "r646",
      "r649",
      "r650",
      "r651",
      "r659",
      "r670",
      "r671",
      "r683",
      "r690",
      "r697",
      "r703",
      "r777",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r138",
      "r193",
      "r282",
      "r306",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r449",
      "r531",
      "r602"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to Roivant Sciences Ltd.",
        "terseLabel": "Net income (loss) attributable to Roivant Sciences Ltd.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r118",
      "r141",
      "r155",
      "r174",
      "r177",
      "r181",
      "r193",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r220",
      "r231",
      "r238",
      "r242",
      "r244",
      "r282",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r438",
      "r449",
      "r537",
      "r620",
      "r638",
      "r639",
      "r682",
      "r712",
      "r773"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r133",
      "r174",
      "r177",
      "r209",
      "r210",
      "r536",
      "r744"
     ]
    },
    "roiv_NetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow from the additional capital contribution to the entity.",
        "label": "Net Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from sale of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies /Recently Adopted/ Issued Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NewlyFormedSubsidiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NewlyFormedSubsidiaryMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "a newly-formed subsidiary in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment.",
        "label": "Newly-Formed Subsidiary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NonCashAcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NonCashAcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Non-Cash Acquired In-Process Research and Development",
        "terseLabel": "Non-cash acquired in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NoncashOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NoncashOther",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Noncash, Other",
        "terseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NoncontrollingInterestIncreaseDecreaseFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NoncontrollingInterestIncreaseDecreaseFromDeconsolidation",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the increase in or (reduction or elimination) during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Increase Decrease from Deconsolidation",
        "negatedLabel": "Deconsolidation of subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NoncontrollingInterestIncreaseDecreaseFromDisposition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NoncontrollingInterestIncreaseDecreaseFromDisposition",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the disposition of subsidiary.",
        "label": "Noncontrolling Interest, Increase Decrease from Disposition",
        "negatedLabel": "Disposition of Telavant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of subsidiary preferred shares",
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r132"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests [Member]",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r352",
      "r755",
      "r756",
      "r757",
      "r831"
     ]
    },
    "roiv_November2021CappedValueAppreciationRightsGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "November2021CappedValueAppreciationRightsGrantsMember",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails",
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date of Capped Value Appreciation Rights (CVARs).",
        "label": "November 2021 Capped Value Appreciation Rights Grants [Member]",
        "terseLabel": "November 2021 CVAR Grants [Member]",
        "verboseLabel": "November 2021 CVARs (Non-vested) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NumberOfEarnOutSharesVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NumberOfEarnOutSharesVested",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of earn-out shares vested during period.",
        "label": "Number of Earn-Out Shares Vested",
        "terseLabel": "Number of earn-out shares vested (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NumberOfEquityIncentivePlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NumberOfEquityIncentivePlans",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity incentive plans for the company during the period.",
        "label": "Number of Equity Incentive Plans",
        "terseLabel": "Number of equity incentive plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "roiv_NumberOfTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NumberOfTradingDays",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days for common stock price to exceed threshold, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Trading Days",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days allowed to calculate earnout share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Trading Days Allowed to Calculate Earn-Out Share Price Threshold",
        "terseLabel": "Trading day period for earn-out shares"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of trading days that are allowed to meet earn-out share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Trading Days to be used to Meet Earn-Out Share Price Threshold",
        "terseLabel": "Number of trading days to meet earn-out price threshold"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_OperatingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "OperatingCosts",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of operating cost and expense.",
        "label": "Operating Costs",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r238",
      "r242",
      "r244",
      "r682"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "roiv_OptionToPurchaseAdditionalSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "OptionToPurchaseAdditionalSharesOfCommonStock",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares of common stock option to purchase.",
        "label": "Option to Purchase Additional Shares of Common Stock",
        "terseLabel": "Option purchase additional shares of common stock (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other current assets",
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r701"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r11",
      "r131"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r108",
      "r450",
      "r451",
      "r453"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r18",
      "r175",
      "r178",
      "r183",
      "r454",
      "r455",
      "r460",
      "r519",
      "r538",
      "r742",
      "r743"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income:",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestmentCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestmentCompaniesMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Investments [Member]",
        "label": "Other Investment Companies [Member]",
        "documentation": "Investment in other investment companies (as defined)."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other current liabilities",
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r701"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrentAbstract",
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of other liability instruments measured at fair value.",
        "label": "Other Liability Instruments Measured At Fair Value",
        "terseLabel": "Other Liability instruments measured at fair value measurement"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other liability instruments measured at fair value measurement.",
        "label": "Other Liability Instruments Measured At Fair Value Measurement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "roiv_OtherOfOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "OtherOfOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other current assets classified as other.",
        "label": "Other of Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_OtherStockBasedAwardsAndInstrumentsIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "OtherStockBasedAwardsAndInstrumentsIssuedMember",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The other stock based awards and instruments issued related to the awards consisting of stock units.",
        "label": "Other Stock Based Awards and Instruments Issued [Member]",
        "terseLabel": "Other Stock Based Awards and Instruments Issued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r54"
     ]
    },
    "roiv_OwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "OwnershipPercentage",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership interest.",
        "label": "Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PalantirTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PalantirTechnologiesIncMember",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palantir Technologies is a public American software company that specializes in big data analytics.",
        "label": "Palantir Technologies Inc. [Member]",
        "terseLabel": "Palantirs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PatientSquareCapitalLimitedLiabilityCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PatientSquareCapitalLimitedLiabilityCompanyMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the sponsor company.",
        "label": "Patient Square Capital Limited Liability Company [Member]",
        "terseLabel": "MAAC Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PaymentForOfferingAndLoanCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PaymentForOfferingAndLoanCosts",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with payment for offering and loan costs during the period.",
        "label": "Payment for Offering and Loan Costs",
        "negatedLabel": "Payment of offering costs and loan origination costs"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PaymentForWarrantRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PaymentForWarrantRedemptions",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the warrant redemptions during period of the time.",
        "label": "Payment for Warrant Redemptions",
        "negatedLabel": "Payment for redemptions of the Company's warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r745"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions from issuance of shares",
        "documentation": "The cash outflow to reacquire preferred stock during the period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "roiv_PaymentsOfSubsidiaryDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PaymentsOfSubsidiaryDividends",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and subsidiary dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Subsidiary Dividends",
        "negatedLabel": "Payment of subsidiary dividend"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PaymentsOfTaxesForTheRepurchaseOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PaymentsOfTaxesForTheRepurchaseOfEquity",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of Taxes for the Repurchase of Equity.",
        "label": "Payments of Taxes for the Repurchase of Equity",
        "negatedLabel": "Taxes paid related to net settlement of equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "roiv_PercentageOfBonusPayableInNext30DaysOfGrantDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PercentageOfBonusPayableInNext30DaysOfGrantDate",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of bonus payable in next 30 days of the grant date.",
        "label": "Percentage of Bonus Payable in Next 30 Days of Grant Date",
        "terseLabel": "Percentage of bonus payable"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PercentageOfEarnOutShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PercentageOfEarnOutShares",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The collective percentage of earn-out shares.",
        "label": "Percentage of Earn-Out Shares",
        "terseLabel": "Percentage of earn-out shares"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PeriodOfRightToTerminateTheProductServiceAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PeriodOfRightToTerminateTheProductServiceAgreement",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of right to terminate the product service agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period of Right to Terminate the Product Service Agreement",
        "terseLabel": "Period of right to terminate the product service agreement"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PeriodToExerciseWarrantsAfterBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PeriodToExerciseWarrantsAfterBusinessCombination",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period after the completion of a business combination when warrants will become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period to Exercise Warrants After Business Combination",
        "verboseLabel": "Period to exercise warrants after business combination"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PeriodToPurchaseAdditionalBatchesOfBatoclimab": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PeriodToPurchaseAdditionalBatchesOfBatoclimab",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period to purchase additional batches of batoclimab, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period to Purchase Additional Batches of Batoclimab",
        "terseLabel": "Period to purchase additional batches of batoclimab"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PfizerMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity.",
        "label": "Pfizer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets [Abstract]",
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r294",
      "r295",
      "r675"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase one share of common stock at a specific exercise price.",
        "label": "Private Placement Warrants [Member]",
        "verboseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of subsidiary interests",
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of the Company's common shares, net of issuance costs paid",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ProceedsFromIssuanceOfSubsidiaryCommonSharesNet",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflows from issuance of subsidiary common shares, net of issuance costs paid.",
        "label": "Proceeds from Issuance of Subsidiary Common Shares, Net",
        "terseLabel": "Proceeds from issuance of subsidiary common shares, net of issuance costs paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r563"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r752"
     ]
    },
    "roiv_ProceedsFromSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ProceedsFromSaleOfAssets",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of assets.",
        "label": "Proceeds from Sale of Assets",
        "verboseLabel": "Proceeds from sale of Telavant net assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of the Company's and subsidiary stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of the Company's common shares under employee stock purchase plan",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "roiv_ProceedsFromSubsidiaryDebtFinancingsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ProceedsFromSubsidiaryDebtFinancingsNet",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through subsidiary debt financings, net during the period.",
        "label": "Proceeds from Subsidiary Debt Financings, Net",
        "terseLabel": "Proceeds from subsidiary debt financings, net of financing costs paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of the Company's warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Revenue, Net [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r505",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r672",
      "r691",
      "r702",
      "r729",
      "r770",
      "r771",
      "r778",
      "r825"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r505",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r672",
      "r691",
      "r702",
      "r729",
      "r770",
      "r771",
      "r778",
      "r825"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r174",
      "r177",
      "r188",
      "r193",
      "r201",
      "r209",
      "r210",
      "r231",
      "r238",
      "r242",
      "r244",
      "r282",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r420",
      "r423",
      "r424",
      "r438",
      "r449",
      "r524",
      "r535",
      "r570",
      "r620",
      "r638",
      "r639",
      "r682",
      "r699",
      "r700",
      "r713",
      "r744",
      "r773"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r525",
      "r533",
      "r701"
     ]
    },
    "roiv_ProprietarySoftwareSubscriptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ProprietarySoftwareSubscriptionPeriod",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proprietary software subscription period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Proprietary Software Subscription Period",
        "terseLabel": "Proprietary software subscription period"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ProteovantSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ProteovantSciencesIncMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of entity owned or controlled subsidiary.",
        "label": "ProteoVant Sciences, Inc [Member]",
        "terseLabel": "Proteovant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PublicWarrantCashExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PublicWarrantCashExercised",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Public warrants cash exercised during the period.",
        "label": "Public Warrant Cash Exercised",
        "terseLabel": "Warrant exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PublicWarrantsAndPrivatePlacementWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PublicWarrantsAndPrivatePlacementWarrantsAbstract",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants and Private Placement Warrants [Abstract]",
        "terseLabel": "Public Warrants and Private Placement Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PublicWarrantsAndPrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PublicWarrantsAndPrivatePlacementWarrantsMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase one share of Class A common stock at a specific exercise price.",
        "label": "Public Warrants and Private Placement Warrants [Member]",
        "terseLabel": "Public and Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In finance, a warrant is a security that entitles the holder to buy or sell stock, typically the stock of the issuing company, at a fixed price called the exercise price.",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants [Member]",
        "verboseLabel": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining minimum payments",
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r137"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional minimum purchase obligation",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RSLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RSLMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSL [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r355",
      "r363",
      "r392",
      "r393",
      "r394",
      "r480",
      "r504",
      "r552",
      "r590",
      "r591",
      "r646",
      "r649",
      "r650",
      "r651",
      "r659",
      "r670",
      "r671",
      "r683",
      "r690",
      "r697",
      "r703",
      "r706",
      "r768",
      "r777",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r355",
      "r363",
      "r392",
      "r393",
      "r394",
      "r480",
      "r504",
      "r552",
      "r590",
      "r591",
      "r646",
      "r649",
      "r650",
      "r651",
      "r659",
      "r670",
      "r671",
      "r683",
      "r690",
      "r697",
      "r703",
      "r706",
      "r768",
      "r777",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables, net",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "roiv_RecentTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RecentTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RecentTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RecentTransactionsTextBlock",
     "presentation": [
      "http://roivant.com/role/RecentTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for recent transactions.",
        "label": "Recent Transactions [Text Block]",
        "terseLabel": "Recent Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RedeemableNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RedeemableNoncontrollingInterestMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interests that are mandatorily redeemable upon a certain date or event occurring.",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r469",
      "r470",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r617",
      "r619",
      "r645"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r814"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r469",
      "r470",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r617",
      "r619",
      "r645",
      "r814"
     ]
    },
    "roiv_RemainingMinimumPurchaseCommitmentRelatedToAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RemainingMinimumPurchaseCommitmentRelatedToAgreement",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining minimum amount of purchase commitment related to agreements.",
        "label": "Remaining Minimum Purchase Commitment Related to Agreement",
        "verboseLabel": "Remaining minimum purchase commitment related to agreement"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt repayment of long-term debt and convertible debt by subsidiary during the period.",
        "label": "Repayment of Long Term Debt and Convertible Debt by Subsidiary",
        "negatedLabel": "Repayment of debt by subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangesInFairValueOfLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments related to long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r566"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r318",
      "r338",
      "r471",
      "r677",
      "r678"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development (includes $7,475 and $6,888 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $24,305 and $26,548 for the nine months ended December 31, 2023 and 2022, respectively)",
        "label": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r404",
      "r823"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentAssetsDetails",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "verboseLabel": "Restricted cash (included in \"Other current assets\")",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r750"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash (included in \"Other assets\")",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r739",
      "r750"
     ]
    },
    "roiv_RestrictedStockAndPerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RestrictedStockAndPerformanceStockUnitsMember",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and Share-based payment arrangement awarded for meeting performance target.",
        "label": "Restricted Stock and Performance Stock Units [Member]",
        "terseLabel": "Restricted Stock and Performance Stock Units [Member]",
        "verboseLabel": "Restricted Stock Units and Performance Stock Units (Non-vested) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Common Stock (Non-vested) [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings / (accumulated deficit)",
        "label": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r130",
      "r530",
      "r556",
      "r558",
      "r567",
      "r601",
      "r701"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Accumulated Deficit) / Retained Earnings [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r210",
      "r284",
      "r285",
      "r400",
      "r401",
      "r402",
      "r411",
      "r412",
      "r428",
      "r430",
      "r431",
      "r433",
      "r436",
      "r553",
      "r555",
      "r571",
      "r831"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, net",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r237",
      "r240",
      "r241",
      "r245",
      "r246",
      "r247",
      "r353",
      "r354",
      "r505"
     ]
    },
    "roiv_RevenueInterestPurchaseAndSaleAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RevenueInterestPurchaseAndSaleAgreementAbstract",
     "presentation": [
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Purchase and Sale Agreement [Abstract]",
        "terseLabel": "Revenue Interest Purchase and Sale Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember",
     "presentation": [
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revenue interest purchase and sale agreement between Dermavant and XYQ Luxco, NovaQuest.",
        "label": "Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member]",
        "terseLabel": "Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RocheTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RocheTransactionMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of business transaction.",
        "label": "Roche Transaction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RoivantParticipationOfImmunovantStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RoivantParticipationOfImmunovantStockOfferingMember",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roivant participation of Immunovant Stock offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RoivantSciencesLtd2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RoivantSciencesLtd2021EquityIncentivePlanMember",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Roivant Sciences Ltd Equity Incentive Plan 2021 also known as (the \"RSL 2021 EIP\").",
        "label": "Roivant Sciences Ltd 2021 Equity Incentive Plan [Member]",
        "terseLabel": "RSL 2021 EIP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_RoivantSciencesLtdEquityPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "RoivantSciencesLtdEquityPlansMember",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Roivant Sciences Ltd. 2021 Equity Incentive Plan (the \"RSL 2021 EIP\"), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (collectively, the \"RSL Equity Plans\").",
        "label": "Roivant Sciences Ltd Equity Plans [Member]",
        "terseLabel": "RSL Equity Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_SKBiopharmaceuticalsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "SKBiopharmaceuticalsCoLtdMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SK Biopharmaceuticals Co., Ltd. (\"SK Bio\"), a subsidiary of SK Inc.",
        "label": "SK Biopharmaceuticals Co Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_SKIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "SKIncMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity.",
        "label": "SK, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price (in dollars per share)",
        "verboseLabel": "Sale price (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_SamsungBiologicsCo.Ltd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "SamsungBiologicsCo.Ltd.Member",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea.",
        "label": "Samsung Biologics Co., Ltd. [Member]",
        "terseLabel": "Samsung [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r364",
      "r758"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r364",
      "r725",
      "r758"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized Intangible Assets",
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) per Common Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r58",
      "r61",
      "r80",
      "r81",
      "r83",
      "r86",
      "r128",
      "r129",
      "r686",
      "r688",
      "r754"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computations for Basic and Diluted Net Income (Loss) Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r281"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r278",
      "r279",
      "r281",
      "r282",
      "r449"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Schedule of Equity Method Investments [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r193",
      "r278",
      "r279",
      "r281",
      "r282",
      "r449"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities are Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "roiv_ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to the calculation of the gain on sale of assets.",
        "label": "Schedule of Gain on Sale of Assets Calculation [Table Text Block]",
        "terseLabel": "Calculation of Gain"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the November 2021 capped value appreciation rights stock units activity.",
        "label": "Schedule of November 2021 Capped Value Appreciation Rights Stock Units Activity [Table Text Block]",
        "terseLabel": "Activity for Capped Value Appreciation Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "roiv_ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Share Based Compensation Restricted Stock And Performance Stock Units Award Activity.",
        "label": "Schedule Of Share Based Compensation Restricted Stock And Performance Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Activity for Restricted Stock Units and Performance Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share Based Compensation Stock Options And Performance Options Activity.",
        "label": "Schedule Of Share Based Compensation Stock Options And Performance Options Activity [Table Text Block]",
        "terseLabel": "Activity for Stock Options and Performance Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r128",
      "r129",
      "r130",
      "r164",
      "r165",
      "r166",
      "r229",
      "r336",
      "r337",
      "r338",
      "r340",
      "r343",
      "r348",
      "r350",
      "r563",
      "r564",
      "r565",
      "r566",
      "r690",
      "r723",
      "r751"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative (includes $46,944 and $50,741 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $128,445 and $165,771 for the nine months ended December 31, 2023 and 2022, respectively)",
        "terseLabel": "Selling, general and administrative expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expense [Member]",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation [Abstract]",
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Non-vested balance, beginning (in shares)",
        "periodEndLabel": "Non-vested balance, ending (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capped Value Appreciation Rights [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share-based compensation arrangement by share-based payment award equity-based payment instruments, other than options, outstanding shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding Shares",
        "terseLabel": "Number of shares outstanding (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable at September 30, 2023 (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails",
      "http://roivant.com/role/SharebasedCompensationRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing price of common stock (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShorttermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShorttermDebtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of long-term debt accounted for under fair value option",
        "label": "Short-Term Debt, Fair Value",
        "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r191"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r164",
      "r165",
      "r166",
      "r193",
      "r215",
      "r219",
      "r221",
      "r223",
      "r229",
      "r230",
      "r282",
      "r306",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r336",
      "r337",
      "r340",
      "r343",
      "r350",
      "r449",
      "r563",
      "r564",
      "r565",
      "r566",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r600",
      "r621",
      "r640",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r723",
      "r751",
      "r759"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r153",
      "r179",
      "r180",
      "r181",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r210",
      "r228",
      "r284",
      "r285",
      "r352",
      "r400",
      "r401",
      "r402",
      "r411",
      "r412",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r468",
      "r553",
      "r554",
      "r555",
      "r571",
      "r640"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r228",
      "r505",
      "r559",
      "r582",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r622",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r707"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r364",
      "r725",
      "r726",
      "r758"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r228",
      "r505",
      "r559",
      "r582",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r622",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r707"
     ]
    },
    "roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of stock issuance of common shares and other consideration for acquisition during the period.",
        "label": "Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Shares",
        "terseLabel": "Issuance of the Company's common shares and other consideration for an acquisition (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issuance of common shares and other consideration for acquisition.",
        "label": "Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Value",
        "terseLabel": "Issuance of the Company's common shares and other consideration for an acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issued to surrendering holder per warrant during the period.",
        "label": "Stock Issued During Period Number of Shares Issued to Surrendering Holder Per Warrant",
        "terseLabel": "Number of common shares issued to surrendering holder per warrant (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodSharesCashWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCashWarrantExercises",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of shares exchanged during the period.",
        "label": "Stock Issued During Period Shares Cash Warrant Exercises",
        "terseLabel": "Aggregate value of shares exchanged (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodSharesCashlessWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCashlessWarrantExercises",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of shares exchanged on a cashless basis during the period.",
        "label": "Stock Issued During Period Shares Cashless Warrant Exercises",
        "terseLabel": "Aggregate value of shares exchanged on a cashless basis (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common shares issued related to settlement of transaction consideration.",
        "label": "Stock Issued During Period, Shares, Common Shares Related to Settlement of Transaction Consideration",
        "terseLabel": "Issuance of the Company's common shares related to settlement of transaction consideration (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of the Company's common shares under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r101",
      "r102",
      "r130"
     ]
    },
    "roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in connection with equity incentive plans.",
        "label": "Stock Issued During Period, Shares, in Connection with Equity Incentive Plans",
        "verboseLabel": "Issuance of the Company's common shares in connection with equity incentive plans (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in connection with equity incentive plans and tax withholding payments.",
        "label": "Stock Issued During Period, Shares, in Connection with Equity Incentive Plans and Tax Withholding Payments",
        "terseLabel": "Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in connection with equity incentive plans net of forfeitures and tax withholding payments.",
        "label": "Stock Issued During Period, Shares, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments",
        "terseLabel": "Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodSharesNetIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesNetIssuanceCosts",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued during the period net of issuance costs.",
        "label": "Stock Issued During Period, Shares, Net Issuance Costs",
        "verboseLabel": "Issuance of the Company's common shares, net of issuance costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common shares (in shares)",
        "label": "Common shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r101",
      "r102",
      "r130",
      "r563",
      "r640",
      "r661"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r101",
      "r102",
      "r130",
      "r378"
     ]
    },
    "roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued common share related to settlement of warrants shares.",
        "label": "Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Shares",
        "terseLabel": "Issuance of the Company's common shares related to settlement of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value issuance of the company's common share related to settlement of warrants value.",
        "label": "Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Value",
        "terseLabel": "Issuance of the Company's common shares related to settlement of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of common shares issued related to settlement of transaction consideration.",
        "label": "Stock Issued During Period, Value, Common Shares Related to Settlement of Transaction Consideration",
        "terseLabel": "Issuance of the Company's common shares related to settlement of transaction consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of the Company's common shares under employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r101",
      "r102",
      "r130"
     ]
    },
    "roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of stock issued in connection with equity incentive plans.",
        "label": "Stock Issued During Period, Value, in Connection with Equity Incentive Plans",
        "terseLabel": "Issuance of the Company's common shares in connection with equity incentive plans"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of stock issued in connection with equity incentive plans and tax withholding payments.",
        "label": "Stock Issued During Period Value In Connection With Equity Incentive Plans And Tax Withholding Payments",
        "negatedLabel": "Issuance of the Company's common shares in connection with equity incentive plans and tax withholding payments"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of stock issued in connection with equity incentive plans net of forfeitures and tax withholding payments.",
        "label": "Stock Issued During Period, Value, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments",
        "terseLabel": "Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodValueNetIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueNetIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during the period value, net of issuance costs.",
        "label": "Stock Issued During Period, Value, Net Issuance Costs",
        "terseLabel": "Issuance of the Company's common shares, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsidiary stock issued as a result of stock options exercised.",
        "label": "Stock Issued During Period, Value, Subsidiary, Stock Options Exercised",
        "terseLabel": "Subsidiary stock options exercised"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockOptionsAndPerformanceStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockOptionsAndPerformanceStockOptionsMember",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails",
      "http://roivant.com/role/SharebasedCompensationStockOptionsAndPerformanceStockOptionsUnderRslEquityPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time and Share-based payment arrangement awarded for meeting performance target.",
        "label": "Stock Options and Performance Stock Options [Member]",
        "terseLabel": "Stock Options and Performance Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_StockPurchasedDuringPeriodByEntityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "StockPurchasedDuringPeriodByEntityShares",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock purchased during the period.",
        "label": "Stock Purchased During Period by Entity, Shares",
        "terseLabel": "Common shares purchased by RSL (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shareholders' equity attributable to Roivant Sciences Ltd.",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r105",
      "r106",
      "r121",
      "r602",
      "r618",
      "r641",
      "r642",
      "r701",
      "r714",
      "r753",
      "r767",
      "r810",
      "r831"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "totalLabel": "Total shareholders' equity",
        "periodStartLabel": "Beginning balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r73",
      "r153",
      "r154",
      "r180",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r284",
      "r285",
      "r352",
      "r400",
      "r401",
      "r402",
      "r411",
      "r412",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r454",
      "r456",
      "r460",
      "r468",
      "r554",
      "r555",
      "r569",
      "r602",
      "r618",
      "r641",
      "r642",
      "r665",
      "r713",
      "r753",
      "r767",
      "r810",
      "r831"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r192",
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r352",
      "r435",
      "r643",
      "r644",
      "r666"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r473"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r473"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r473"
     ]
    },
    "roiv_SubsidiaryEquityIncentivePlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "SubsidiaryEquityIncentivePlansAbstract",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary Equity Incentive Plans [Abstract]",
        "terseLabel": "Subsidiary Equity Incentive Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_SubsidiaryEquityIncentivePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "SubsidiaryEquityIncentivePlansMember",
     "presentation": [
      "http://roivant.com/role/SharebasedCompensationCvarsEmployeeStockPurchasePlanAndSubsidiaryEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary equity incentive plans is a plan adopted by wholly owned and majority-owned or controlled subsidiaries of Roivant Sciences Ltd.",
        "label": "Subsidiary Equity Incentive Plans [Member]",
        "terseLabel": "Subsidiary Equity Incentive Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://roivant.com/role/CertainBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "roiv_TelavantHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "TelavantHoldingsIncMember",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityDetails",
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity.",
        "label": "Telavant Holdings, Inc [Member]",
        "verboseLabel": "Telavant Holdings, Inc. [Member]",
        "terseLabel": "Telavant Holdings, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r193",
      "r282",
      "r449"
     ]
    },
    "roiv_TenPercentEarnOutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "TenPercentEarnOutSharesMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of earn-out shares.",
        "label": "Ten Percent Earn-Out Shares [Member]",
        "terseLabel": "10 % Earn-Out [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails",
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r813"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails",
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_TotalRequiredDebtInstrumentQuarterlyPaymentsMade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "TotalRequiredDebtInstrumentQuarterlyPaymentsMade",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total required debt instrument quarterly payments made.",
        "label": "Total Required Debt Instrument Quarterly Payments Made.",
        "terseLabel": "Periodic payment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r331",
      "r348",
      "r434",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r539",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r763",
      "r764",
      "r765",
      "r766"
     ]
    },
    "roiv_TwentyPercentEarnOutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "TwentyPercentEarnOutSharesMember",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of earnout shares.",
        "label": "Twenty Percent Earn-Out Shares [Member]",
        "terseLabel": "20% Earn-Out [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesDetails",
      "http://roivant.com/role/LongtermDebtCreditFacilityWithXyqLuxcoDetails",
      "http://roivant.com/role/LongtermDebtFundingAgreementWithNovaquestDetails",
      "http://roivant.com/role/LongtermDebtRevenueInterestPurchaseAndSaleAgreementDetails",
      "http://roivant.com/role/LongtermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "roiv_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering in which the Common Stock is offered and sold on a firm commitment basis through one or more underwriters.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInArbutusDetails",
      "http://roivant.com/role/EquityMethodInvestmentsInvestmentInDatavantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (losses) on investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "roiv_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "UpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the upfront cash payment during the period.",
        "label": "Upfront Cash Payment",
        "verboseLabel": "Upfront cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_UpfrontCashPaymentReceivedForSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "UpfrontCashPaymentReceivedForSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsTelavantDispositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront cash payment received for sale of assets.",
        "label": "Upfront Cash Payment Received for Sale of Assets",
        "verboseLabel": "Upfront cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r145",
      "r146",
      "r148",
      "r149"
     ]
    },
    "roiv_VantAIPreferredFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "VantAIPreferredFinancingMember",
     "presentation": [
      "http://roivant.com/role/RecentTransactionsAssetAcquisitionAndDeconsolidationOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred financing in exchange for shares of VantAI's Series Spin Preferred Stock",
        "label": "VantAI Preferred Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAssetsAndLiabilitiesAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement warrants, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://roivant.com/role/EarnoutSharesPublicWarrantsAndPrivatePlacementWarrantsDetails",
      "http://roivant.com/role/FairValueMeasurementsFairValueOfSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private placement warrants, term",
        "terseLabel": "Warrants expiration period",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r223"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r223"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://roivant.com/role/NetIncomeLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "roiv_WelichemBiotechIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://roivant.com/20231231",
     "localname": "WelichemBiotechIncMember",
     "presentation": [
      "http://roivant.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of entity acquired intangibles assets.",
        "label": "Welichem Biotech Inc [Member]",
        "terseLabel": "Welichem Biotech Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//323/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "323",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001140361-24-007260-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-007260-xbrl.zip
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MPH0-Q0XOX+_ A'7'#IN1B9?XC@(3=M%/U)XMW+RA/J4]+-J]3&)\0)HPE;F
M1Z4T:VFFJ-;O>7,KLX&+S7"9S&\4"JG++!129:O">-G19,'9M7-VW/VW%H9U
MV3G4Y&69^N?KL07S5ZS62ZQO%,K< GZ.Z.=;^6D*?FZ<G^;2^*DMX$;M(!>K
MVS; OJ665R_B!>/>DB2^S1/OQT[P;&(^V^#>+J)G@E%MT:@65+JM+LX2@+_5
M8?+S[#OQO*+'NDWPTB"\G-(N4NR!\H323O!RX7EN V,7,1 GOL\V]Y+HFH3^
M15QVZ]@-9LZ;VS88CD48>$-S$L;4QQWE #\M7X58D'/3)[4-+%LLARQ8MFTP
M*>S?6NS?VG51V+\V:^;8@JP(,=:Y7K.Q?1@OXKHPIOO":0'5>\IWX7NMSO?:
M0GD0.>UMX^]XL:70]W;H^\8*+>O"+&V!6@YA]U=0=+]H)9:VW$JL%^& X/MN
MZGL+ED);H0XO@T'A]NPVW(E$QO8"W,LX+1*5^\AU@=_;QM^7V6>!W]MKJ5\8
MD(H$Q=H2DML@#\*>[PK7ZSX1"VU)$7B_!$XOWOUA9(O*TCK"+,!IX;FMI>/+
M$OG[,DT6B<;]U&OAQZUOH6DS.# F#VU+/+>$+ (>U[X.TPJSV#9UV ZK(?S^
MG5$ X1^TQ#_8E.:_3!Y$'+AM_'T9LHL\WCZBO.#ZKNCZ2[J]"=N^QMA_,VW?
M7MC]3WCU^\%IX<7M-G^%/=])KK<M6=42LHC<[?ISMQOAN]@9M\JN$\ML3RNV
MN+6FG<A2^PZ+HJ U=6-:7BM:48V_U9V^Q;:HE>K9\EIXBRJKC70:7&;/[G:$
M6*L24%'FN4K(7[/%%HQJ@6T6"ZH;:/J\9, 7%GO=%GN9+I=8U%I+-+I$EHEH
M=,V0N=3$7EMJ9E<7 P@?>7N"-8$CZSU@:;V66RP0K*W?^!*3#**IV0;ZC:]Y
MA4< :VOMHJC[; ^P+OF$4)&LV,!!#FM>'Q*:N2Z79\F0VZZ8>.UG$POD:7&>
M6^SH7=-Y7.MUXP3+VF7?17_;M2Q&+#/6%<F*#2P +G4!7F2!U[X O]YDH8#,
M=J4'165_BZ+8-4.I6/EL"VBV+=VPYJ(Z@3!KRV O.0W1-L%=:DF"/G*"W^<B
M QN?92<>\#ACCC83WB\T[9$'> _GT;_O!GUZ%9RD*8GOF4QPK$TI..?GQ LC
MF,D_P[S[/__Z_6OQY"7MENP9LSXX3I/PX>/8W&>*[<*OFTJ\\F7/D7"92I.]
MNOW+4@]K6*8$WM '&A>T"BNNB]3KDHR>Q/XMB>C)?4K9O4VZ7B8/Y/>B]>'5
M/*%Y^ZS?+M3+T2$AQ7C7>1'[$&*-,&Y+Q+1%4+H %7=>#F]!"/PB AIQI^T;
MS;N)?Q$_  F&KESS6THO28]R824Y8];?DP@)F8'SUD[AR]+\XUMF6DGGK/GN
MO)B<1B3+KH)_$E2D_"J]">^['(JNT_ !WG,=$8\K$;^EY2FMF?,I.3U_5CO/
M[OF!*B;XDB*_[1)P)MK-YV="4L;K*=/9/08KZO)@_XY&>P7[,^>[0C$!WF]&
M3-XJ'">I6^1%]CE,^J!0/7*:I/TD)>CGE2[MEJ=CER14S]+I[;YORQ+&JUCE
M7JFD"LEK,?]E3?!_V_@O:TMLQC9V1*^0A)9+0C;:;'%3)_\N,?TAQ&;=8K.I
M\*EQW(00F^T3FQ>=5['4<$H6:+.]8J,M;J3:%H6?ALG3-4EIW-+5H"7)QO@T
M]R1R$=QM;5RR5,@7?-X10%]FU"&$0L040BAV-&)8:EI+",5N)*U4V< 2C*3
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M724>_%<) .IV<M:^*1NZX1&JFX9NJ@'PVB>Z;*BJ;5/9W5%>@R;30+=\Q0
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M\$4C1)I#FGK,??CFT,6O#DD (_XHD>B1#+*FAOS23:O;W23U:7I8LEON/X$
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MI:$+@@<C@WM*F]XD:6G<$8*N29I+%Q=@0?F&^!-TKIGT_U[ )0J&5[JAH"@
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M8?$3Q%A$BMD^30RV0/&*'BL)RG#_2H\EFB$>PVN/W=#K-C-#*05:_J]8WA(
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M$VL0@[*KT+..<K.@NZI9:2S*PNPQ[R\*KP7N"MP5N#N_AG%:1!^ T\C+17J
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M\$+EV4,H^4H[DEODY6F?.4][L9*P3DV7QF]2(&O*9(%O>QQ?(LTIZ=7,'BT
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MS[B85FU\+EN)\1U0K,YQ6.9=G:T@($M EH L 5ES_;0X>:!1/NCPWJ?T"6-
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M3V<Z7&Q\T_-&9KU($7(#%2%:4O3 MGPML'1758FJ6]0&W\60B0Y0N5('QNK
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MN:U,=U H"DJ&-S-Q"8 S8T,3'F^Z/3!. L.6?2;*0O[?\^W36:BD4,FQ4$E
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MO$_<6J,\<"F1M!3>(P/2.G6V#MI*WWM1*]XUIVJ0LM&1OE8051"U#+$+*U(
M"M$A<"*/GB45D)%GGL<>O0'W(\K44A5$%40=/J) *?"(5HL@0%J%H%,^KA@V
MPQE%5Y'G5MK;"5>+?;K5-D;40*+QMVST-_G&9?-YGLW()A6_J^_<@'V! V&-
M :Q[1S["1W)-ZS"\$K%%L<=JU"T:"\R#:X:2"HKH6&P2X0S%E!7@'I.V[R\(
MY;53797CAR8].SS$!R#Q!:F[0ZJ(HAD; R$E#C8R!")&)B$Y%P1V.>ZW8J6R
M6AS4'/&"U/WO]3-#JF4J*>^2] [0,A<LH06?C]K G>LQP?RA!!;76?]T:-)3
MD'H(ZSY$I *2C8XL.4&@R'D=B9QQ+OGD4NQHX;@5JYJ;VK$]5H!L$ZD[-+CO
ML*J74]7V:U8/FCV&31%]QEFOA*)C@JI-R?A 9#P""](ZC,VO*+S1B7;54-W5
M  ?CL2ZAU0*BVR#BZ%40%I,#:(HKI1#$E1<&8^"F0_/=BHUJ,X@.QDE=0%1
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M;YZNUOZIM[O0"U_V?GV/X,L5+M0V6UUH I*S$%CPS"F1=*9()Q)T#7S>6F,
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M$IT*'3Q3.M@9\'URBD?'0'( $LD21PE>!X&6C-UY0H35M;%[M(%*0D0![D$
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MS+ 8);$4@PA. I#S3H&*S2@J"LC!=4Y_? P6=Y"4P9VKK>@:)G=D$E; ^<S
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M=T7L!BUV]QR8W<II/A2GA#/*M-7^_T_3R?EG%+;:A]HK2XJD92*"%C(?AQ[
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M'CAYC< 58TJ HX3!AAB()V8<6IY*<&VPHEFXH'!!KUP )HKH8VQ:3  #89T
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MGKQ30@9#!%NK6_9PMM^.I3BJ8Q[]3*I75AD.JQR85!)R;X,K9UT#1.><PI1
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M6/"X#*24?)Q]K*-GE7YF+2OW5.YY%O=XQT)D7HDH$Q@&3B4#D2,F "79UJW
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M[Z&)S*)Q J1WGCR$/#J4A,K9F(3#3%3]DX@LFIO_XH$M8S>VW)X P1VZ/O@
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M(RA022#*J(%D:2QB&>Y(=_#ESJH92]5-?][#6E2?SY54]!X;>I$K[D%S*<B
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M],NK-S_\].J'7T8_GG__/.;;]DJZ6%ZVO89O_]>+%V?3\'XV?_'BL;_\U"Q
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M*NMT,[$/C_H94R6ZGZJ[C+ 9\N;0NABT>,Z@Y=[LXZ]G7X_N,(M=SHI\SJS
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MV2F9^!/^+._OP(MN'+#W;_]Q5;WZJ!PT*"Q$K'&AL]TE@Z) Y(1AH!]?V".
M!Z?$H,@/>>RA'S(H]D,>-/BSIA0B"'051%4*83\?;ET/HA3_K[ZR>VALOOL,
M)@*?M&[7PP&!-2G1BL'O8;KK;.3O.O\LY./JL6GUGI<P3SZ;@Q%E'\=+P:>M
MGT#T@]VMTTY ?BZ^1VMO\:UK00YH30;,R-PXC\TY+=B9F>WWBG;U[\]>M7V
M;"+F18'&%:Q5EF8"(W&-^=@YP1WGVBA$#3 !#8 !,0-LE([S+V L%OE=?2=V
M] 6E!<9BIHTEH:9-".DG)8Q21!.Y&QLJ8- PBO\'P^'.#<^T*:;=ZJ]@,\\4
MV(U_V9  ]5>XXQT,\OWD(QC5[]-K&&\7LD+)@'O,]UT_HE'"$R&8!'_$353
MF*U[-=CP;6O^CX_B5H%C#0\W9J:Q+1>FY>JW2OT*([S^FI5_?%)CCI'.O^4Z
M\E>^G8A?-"DV95BQQD>(^S!CKU;SJSH+F&3CL;9O)YKJ)3?']_6P8%5GVO:?
ME5=UWI,YT'\:C._4P@Z^&8-%Y?P;!AG1B9U@6LHXY[-*,CQ[=8VAQJ=(A&>O
MFOWG$VV4^D]K@KNL<E?ZW/(:J&TB5Q'=EB71TV2.->*UC1UT/5D&!;J>O>9%
M@8</_^!C/+]NP6J3Q&>14"0.*)$L5B(F@1_2F'NA#"VM:GOSN;>7A^'5*CI0
M+0.?UKKMPO.&;X'%.ZH!U72A9EP' Q4O$%4:81K*;Y+-?ZLH\7-%B&LAYG?S
M,<9Y?E)X@M8N?**NHDD:)0F-"?5#CS%* J9<'A/P>I4-B+B/QX.&Q\.^K&HO
MLFA]Y^Y;Y_(KYXTY,GF:_#O!Z=_! &]+Q!15\FE-<'=Y]K3F?S'2; KK::XT
MGN\^K3D-M\";8 1ZHO AOU,7NQL-D@]%GF8SC&VTX7=]SOQ(AFX:4BJYS]S4
MBU,6\#CPN'0M/6MV*)O<WLRF5ZOUUK:PP]-:LD$2S.&:LS&0=N'K]7SM1:['
M9$)HZE/I,T8P:"=#25Q7A6ZR5\%BAZ^WZ\5$KE;K@B],/<*D@:E"&%?@WFZR
M'0:6;[-REA>8##B^KQ()J@//5HQX6@")BVR,"5-%/K^Y;0*3'0F"/;YU8-4I
M%6@(?<X^:N*735K O:XO1-A]^%6J9+; FZT1^3^KR5PY-VJ"0\#"0@Q:CS.A
M)N4BH7 \YDE%(4>C<-U4%8<P23-*G,;BM2/G)P7T7TUB78XOE<Z8SR<80M9/
M2+.BG+42&#'+4<[%;-29O$XY&P'7C,?Y%SU(G6<&EU=Y9F]^NFXGBU4L>=0\
M!#(H7Y$\JH1%,BACD9Q=RF)[8V::;?\)NQ839XJL_+-! H//BSSCS)P0K.;U
MPK/A77JG56WU1DXRGV&5;Y,O.\M'F!RC"@RBX%:%?:=C)]VDX94$8YW3:'9
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M+>NAL]B!'4BP07!?SBW_K,"Q4!-P;!6X[1A$F^@'%U(;];H4@B^,H^E"$9J
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MA(-;XN'C#&0=+R2"1$A]4#1KH@8D_*'ZS_7'UY5>K/YCL.-:!TJ+Y_P^E8M
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MP W3:I&A/4%-S0:Y!L-$V623J%O2(4B'![/F!J4.V!/Y'V/>CCW)O_>NJ,?
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MF)I7Z%;8Q7<]$C1E,G 9]R+)/4J%'XLD]24A)/0%]\+T -4@C,@H"#WP4L*
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MGK*K].CBQ?43=@]9,^CP)=AX^-(O-@;(FG!_@;PLJ083+1ATDA)L/$GIG_\
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M]X:*ZMR:=@8K&G<5_$")6:E-$][/W;.!]4&Y*QQ_7E0!)'AMJ?!(X$XOM8V
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M!(]#<3>A5,2)<-T@ !_G"!6;SUX]_]L+YV/KO&Q!'T<3X\2X=N&@A(%P8\)
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M>EILLX/.(QMT'D8P-O'+!BLE,U>L_H I(:;EA196LZS$KE5'\WRLP+!]-]7
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M&:,7\&].=H=M;8$2,/EQSF>-]G]=Y;M7G.UHUG86Y>\6XZ#5.72+ ]A^)AW
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MX6#*8;A0.+*/>)&!%QEXD8';RL# C9- >FG* T7C,&$DB)E*0^&F'N>!%0#
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ME*L\Y=,T2BB"/@X3*#O+COY-777NJK=&C0I[%EV[]F"W04U4L=_*^G?VK^D
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M$QREDU:[R#ZZQ>M6QGCE?&A-%^^Q7-R>"+@D1?X%WOR7ODJJ9/9V4H)9@D\
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M!ZZ,1!*ZX&DR3CTB D^&,N"@4E=A.P9;:4<@L$5ZH,# 4[)EH:$ER4)R-.(
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M)S,O>6C(4"VLN7[T_62H9G!)KM5N_33]23_?@_EI'7ZDWZ.I=56=#\7/Q@R
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M@ON;ZO0\^*ZU.P!:GT^DL<NT6I9/[)7#!XO /U4F:5%K;A,US<:R-M7@P:*
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MXA"I(V,'QDWLP"M#(*])P_[(@>LGVH,ZW<CT'JBSX-'?!0YL_?A[3/IX>(0
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M=^351K'9G%[AJ3 H,#PKRNW2# IU.+0=RUNU2BWX>0MJ+ZRWR/P$XP#_F[5
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MK*R^A6"^Z!:XG[![Q[:F=L,9?P36]D$J W08UO<I<W%V*_T(4SJ;(8^8%]"
MB@"+$/NV#.'_5$2!P)2$,FRIE'9RH%]MR/M.CZ"VRD$= OC#2>^)%< *%%^
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M.L^7P'XJ]S*;-6OKJKCS/J9#'4X=2FV$78QE$(HH8(PS'@CX7UOC]V[EM2N
M=\*VO/83B.OE;":=(Q7FPXQYW5:MNBI6/5M/KUBM3J%M9R'UTA)H3A%+FU8
M5]S5;.EE2QEQE_F">3;V:<A\1EV'13Y!W+/;6GJ=,=U[30^4H%L9@)V%,>,8
M/#G'X M]*$KC-4KM#9+1[15,=#BSSNJ/D"PW-GZG+)W.6_%K,@F^RG')@I^C
M7X#QO@/?O0,V:Z@BU_=)0"6.'"8Q<D@8^IY+/.K8(8V8&UV0*G)ZMMNQ?/2M
M%[1CQX[6Y' 9E71I*FGO?+K0M6T/_D@4$AQBP1SI>,CV!;4#ZI!5^71*P<T4
MT9MI&+1)7IW53?UXT>=]8;!E#MNL3'982^XS@?.D5=2NX/*$O&:-!Y=RXG@T
MP"C"V&.!AQWN!A["+(A(5=KO$G2R%_1<I\U#[%)0;$_Q/;>.?GP)>!W=ZCA[
M,EZ7CP9?P!;)!2?I;;J+8E/FNDP0$88V#B,2<E B$<($D3 @W.OZH6*'V+W
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MH=*7\;CX2MM8\"DP>PR</"7*&'QL_M K!P2KD6;3Z]5JUTMB]9-[>$7"I11
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M!]NDG%<(X.!K4LM<UU+Q\4XG#_ 13AXL.8BA3N%>?9[DUC>5)YT=C0X['4G
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MF%M]7S/1TG;LD',12M\/<401#;S BQ!% ?7 (/%.XP-CMQ?X;B_T6LSV#KK
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MG9\%)?'\ _\Z>E'9LPKS :6R?G(_HV 8R/ 5X(?F;P6J$8"=/MA3.G,(6!_
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MW.+P_5V6.[W5P:\5H#<UZAM@5T^Z"7J-FQKC*M]0FJ]3TUE? M^F,X?E@<9
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M88^:2O;VJ&2LSSGK9BKSQ]Q[58N>:6[.H!(1N#7+TTGY&-W@IX"=B,:II8J
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M&*3?_3^%=ZAOW[Y[=W?WK;JHU<\HHUQC]"W=O#-#GH84(@RT8_DGY8;]IE!
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M&L-G$:QAW<^9FJ/UY$26!YX/ _J%S'-B_GH0?/43V E%B@?FLY!^1$3Q:%^
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MKA]7]^Q>IV.XVG#U!7'U-:8$]NO!U(>O[ELZ[HF__ 4^=6"KY1=\U''X@_J
MOSOS]5'+TUN\/OU;>)'C^M8R=(/06C+XS]1R%F $QY$U=QZ9-6;,!YMNXCE1
MY,Y<-K7B *CBSX)P07]-PA"M._'L$LT_/R;L4:-H%5L7F3%.Q=I^3Z+8G:T$
M.TN+M=.GXOU?=AF;\.$D9 2+&J^L5ZW&T%JXG@>SP\F_ JNB,5"?P)JL>,[@
M_T/&K 5LW3RR&(PXM7YE$[88L]#JM, 3:((Q0C K)^0; B_J-7K/>5&[H9CC
M[=SQ'V#*0 ]\&-\?^ PI$<QVF]7PV,1+< A'+=HBTA;ER.$K7[6:C:::<S";
M12S&78(7T=,TD^7&2UAZ15];-<XLR(29^2B-EOQ)$4=(Q?[-O/!O-YYO7*]-
M6ZKV96WU3TZ$0@ .D.NMK&GH/@+;PUXXV6=&VG+E?@#Y@STK,EC3A.'OQ5P"
MGQQM$A9XO6*$SV$0L^#1@?=\G;C,GS"8_WM_TK"N_^>[8;O=_"G]!7W0^NE[
MI-5M\@ ;)-C3\0+_ 91B/*?A0D8R[L;N?^5XUD1)OY@>S3I,'K2ILQDP,^X?
MYSO)&;@9G92P%G. -;4=D96[Z+&QZ@S?L.[GP,C:BYY8R$!?@SX#[;1*N5!M
M!FABR9"X1L%:-(&N1L#<V%A8W$:5#]-"VCJ3_R1N2,A\ZR.LC$00Q8\O3!^$
M+ZV0SJI7"*V#'ZH1?C%+0IT%Z)T+QT]FSB1.8(%R2GRY0'4^T6 RIT4II8"D
M.ZF0W-. VDIU =XN[IM%A$0-7'_05C>QNP#5Y43(#3&,C.\=!WX")'ARPJD%
MC.:+W62+I1>L&"KI)(3C>A^5J=ABPTX=O"'6?B?2Q /M2[;&7(5)X,"%,[:I
M!4ZDO4$?@O&"A^8O5V^^?+[[[#RP-[#K?]S"'YK506/D?G<7@'"'RMZ1=DVS
MB9>RV2D6O^!C@MM%(Q7MQX1A=@J^2[=SR%*8837;U8_67^^!C)'UD3T!DP(C
M_S5C20QQR9D(D _6@.-E$V/$9U>ON[ENS-FYB^&7,.^;,>[0C3.#Z?T("NS)
M644;MC%CN/T\#^5K."&X.=LDJT_;/6GSBL^:/UG24J( 8#[+9ST@J+[2V>'J
MA[V(\G?F3#=255\,F4F.!7(P^^7JN_O;-Q_>?;I[^^GC_;N/]U^+B+:-""([
M*4\];/2(ICYH@+?P#1H9BD9.QDA;%XLU,?EV(;P3]I(/UNL.NXM4*U?<01+N
M81;A*>M&J')@L3C(+/"\X GTS8\G5A]DXH.T>>C"3&# 7ZZ:5_1OX9_0OSE/
M\J\XQTQF,3UZ]0S1Y.I(GSX&<S<$<3?PX(G"U><OCG+L$?L[1]SS+N7@+,L"
M]5V<E)@+R7]$@?J-"]2[-8$ZFVM>D4H]Q^:']JX1S[^<*MU/U5_@=Q+X&"6-
MGBO;=!P:$;Y@"J.98PA\P03F$;_ZD/BT!\9)&>N;7M[<_?9C<$>1SY;CF&L*
M#@=)!/Y.M$^IC2/=K52(27;M]-$*>GPNC"2?K9A'C2W3LQ\;9J_,7KV$P@]7
MK]^HNY0+Z5=>!8#LX;,IH&7-X!^G6F>O:0];W1+!'S5 MQN6ORB6[P[M5M^P
MO&'YE\/R;;O?:UX4QY_/7CQALSS$F)CB&.6GPW=Z=JM=2@-Q4Q6A0FQ06AMY
MPP45XH).Q^X.*M^6^D+C)0JR:<(E%SJ;LU>(:X_LWJ@4M6[\O/K-IH3BK\W.
MA90PO$1^J-9LSJ\\VW:O7TI7#!,R6"/&O;-T?2<,9B9F4+Z;T![8_7*J=AMO
ML4)LT&G;@^I[B_4B3PW9X+IG-T<5T@:'S+U:+:!*+;OY)F3+8.+&KN^.*VOT
M&(/WE 9OWQZUC3]668:HUFS.SIY@;C2;ACTKRQ#5FLW9V1/-H&$IUK#IE[DV
M]^>;01\Q>3E!T*H)-)3N6HSL43GMFHV#62DNZ+9+*;YKN*!"7- =5AZ?\D(B
M!;)B5F5M'6/GGM#.!6W<,ST1*\L/U9K-V;FSU;('G5),1L.>]9O-^8,$;;M=
MOW[']0T2;"C2<1*SZ-.>I56K4&;Z] 6.#FX_4_W&,H=CJ<N)!U:D/HYAOS+9
M;]2W!X-2/&;#?H;]7E_W.W:['.CY ?QW88;-6:)"VYIMR<Y:Q97M*\,,%? \
M3'>^HR*UV_:H' B:Z5IIY**Z<M$9V;U!*=$P(Q=&+BHK%]>M/LA%*9<81Y>+
M^IJP9ZR/^4_?\;Q@0EUB7"QK"O\^<XW,EW:U?R9E:" :AH[5WE]#QQ<.E_DZ
M=T)V,Z;.CM@ID?D1];6K["V@N0$^99)-U^XT:W<#_'(8HEJS*2,'K-<U\*[*
M,D2U9E,*?J9;.WB7\=%SB_R\L7>K<<?+1]IC0^)F.=@!XP96B@^:]G#8-WQ0
MQW&.R0>CRN?@G3&44!KP8CONM,0#U%R:G4UP2[PTZ[3M;L]@+(Q8&+'(!4PZ
MO5)2(8U8&+&HK%CT[5:SE)S],TE%B09G]]M3F+9A> N;N7)8;\@BYH23.4]L
MTA*=JF1\=DL$]\/8UC1(QA[; SM?L_Y,IUMI9]BTAYTRNY(5\5"U#DG#U;7C
MZE$'+,.AX6K#U1?$U=>MMMUKUT17'[Z\[_=?V)H%*/[R%_C4@;V67XA1C]G2
MQ^(]?=["BQS7MY:A&X36DL%_II:S #,WCJRY\\BL,6,^6&T3SXDB=^:RJ14'
ML.W^+ @7]-<D#-%^$\\NT<#S8T(G-<069%8Q#G]0RUK[.F-^BK7]GD2Q.UL)
MAI4V::=/#8^^[#(GX<-)R @X-5Y9KUKM1L]:N)X'T\/9OP+#H3%4G\"BK'C.
M+!]VT5K ULTCB\&(4^M7-F&+,0NM3@ML_6:[8Q,0RPGYAKP"5=WH/N,];5L1
M'V@ %K;KK:QIPO"E<NJ1110JRH>S@ADLJM_HJZ%Q(Z(-<#'Z=;O1EC^V01*
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MS\_8*&2DM=<H,J_Q$P>K9X'U>0:;@SJ#1P[ALVD2$I'WRQZQ$'\OB$^9 =_
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M%]]+G&'_S17U\59R5L1&IV6/>ITZW5$?ODB#V##BL*<XM)IVNVMZ#1AQ,.)
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M-Y3%#%0?1='EF3(!^7Z14P@?N&$NW\SBT#]A5*EH4+;D1/IAROSNDO%Z#R+
MF7?SLR9^H0^0N>/*)A&?[]!1NEASOW-$WVBP1#E/"_EMY[KUTVBC>]^PWI.9
MO 2KPR5FTD1$$8$,E8R1G*9_"WM%*@[X+XL8(\84.>Y6+LUQGYT@GVD'8[I1
M>JK(G$EM&)5;LMUKW10K2KU%<1"D?OZ1,T[RMZG<R=!-#XWUG_/Z?> &IN]1
M+<!AO:8!A[T<<-@S@CC;%I6&=,AHEC4R]%;.4:9<2.9P3XUSZ7Q(?X$;1L+3
MSRLE?E\A=D0<K;MFF/BI^OO+^O_2W0RPU&$4:=H2#S!?#_,V"@7FZ-U/9=T'
M6P6X5:#O""&77/"'P\_4JPMC,X=15[<U05B"D(J&L[585]%5#T<-83&-(&>\
M:,51M@5LA>6_)8RT5Q!<W<J8V@87?:6<=RS8)$S<;-Z':B=2"):<P.N#!?9Q
MYYEL*1;? &T,V^W)=L(KT+C.H3.(+B[GJPC.'X<'!I"[$@<[%4C0%Z_3PE&1
MZ4_YO38O^[E=7QHV-6RZB4UYD3Z-4?.>)>\ /MG!8I:XTB+U&,!)#S86EN9S
MT7+!6D5^Q%^8<C6]B2?A43P376X!0DN]=L.ZAG6WL:ZX40,.XQ'^O5"SH&2W
M,[,*^&(C>QZ;PE#; [[<IW?P9'@8(5/H+0/5 6%XI'J#_*<N24"HEQL.P@?'
M%T:O4=*&T[=RNG"G<D"798#\S[VS&^#?12#++>&=F0_\-G>7EH-%Q2EM00>C
M\59/*K /CB;=6W"Q6E+3HDQ#)P*<.&&(_=MX#H0!\QJVW68"DY9+?!'D]SE8
MRTY1@6D9X#Q?;PP,; 9AZ*RMI?CPQF+5A06GB$2;1]S!L9QHX7:Z,^.741L*
MR=)91I$<V1)/ PG&08JZI!MK!1DE@ <\%.&="%U'AE->;56[;-/"/ZX_"QTX
MZI()OZ:Y#S+7SO(D%A="!"N4D-(-]^S:2;RQH"9H(.QU$&4".KO>F4*(-D.'
MQ(C9F!#>9-&E9+J3_#)+JT&20FTS[5LR?'825M$K;F\.TXF:JC)8AY=FD=[$
MSXW42_0"!,X8>QSGG590 (0P6V@=!S;%]6 RR%JRQ(\J(:SMT ;PB0C7K8NV
M*^JO9T\MQ.S"9#VZX\,UN;[6[)#W\ F*]XJ: A;/PEZK'XNU;2=_B [8X@#,
MH_:UGD*%LNFDU_)Y)"=AL9Y81E0EOHC736)_% /_9CH[[KJ7U&LV9[@X12,H
M,;25QX=EK=GFF\O4?,[(5V82*=VU.^8D1FG6XL]N+&  U/1ZO9J[%C>!S0G$
M_:SL0KD&I\[<@F*EC9P6R]6_H(83:^D"XLEMS%YP7A7R^9X![2+4U,XPM];K
M2YO\-A!7E 5OR0ZBT>Y+X4UP&E6L6[__+^Z+5=@J9%-/D,(6(B?7KIE R!8T
MG[K!TDUH@83;#'+'(U;@QM/>8 6P^8(*?G8^<P$T%+$"R$R(&[Q?EY9L+7U;
M2!X,*[NQ66#9$H\I+&GV12%;)K',LA$.-[R"I@?+01-&_#Y[D&0U)QX2O%BA
MA,"JNK"Z>Y'F?%"1<4>4^L[Z/9K4T>%#3=JI30H!B.0N"W VV@:B[M,?;)4M
MJO,[4 :4#JEE1S"@O67[A*4P9CJ_X_DEJY+1?A5U?B,P1@'C\Q>*!M08/]-:
M$GG'@\L?TN$C;52EHV>HIKNN7R2P6> ST^O5';HPA[6QB]&8Q26,)*",(UP4
M'ZP+WJE!6VF:#P>7:DAZ=>9KF4R4,-/Z29GM7'\Z4?KCPKO?HOM><1^L7W?>
MI_N?[]BXN;J[VCS.E6P-J:<.%?Q @JXRK4E$!VW.(\=E$.W7W\(K&QP!VK*"
MLUO?Q>Q\E'+.CI79]DU>A[Y)NVOP<X2<:#YAKJDO.UBRY<1T$9JH,EZU?&%'
M,PLCT0@J9Z"O%?'?::20+O')=?H:*\0A)EZ'OJAJYZUR>-*#:A694+<1@\WU
M*51!"C@ST^MN&\M)4)TK,L* IV12$H4._A][[]8DMW%EC;[/KZB8^![L"#0M
MR9[QS.B<$T&3DJRQ:/%(E/V,JD)50T0!90#5K9I?_^6^[TPDJJOI;EH>P0\S
M(MF-2V+GSGU9>RTN4Q<AK]E5D);@1H%TLMR<)Z"SAR8_G0LFM-(=0=\;W@)W
M0H2$XQC@J.6D7FQ[L>WY-DY8>E,Q<#%LV[77<+;[(=]UE.!#OA"B!.PI$OW5
M 3!Y"&Z,!M'=/#5QME@XXO#ZS=F&K7BJ7BAB/,$+2IY2U+(PA_X3@L,_7<#A
MOQQP^')D7'&%G]V1X08W+S"C#'7X4F6/TU3AHA<X4J#8A(4)ZP1D*I"4OLI)
MI-PF*#O2E&U+K#)"7A*)(EZLU<Q,G3F^$?G?+$7'$E\MF^6*W,$,[MB1*KJU
MNZB*"_JO9VZTP:Z /X4PB,"+) =,5>AT7B%[S7D#=SN5V$"NV:J+E2]6?@D,
M=NPKI.4 5H'MJ2]-6'J Z6&H(4')6,%AV'2E,0?OX#%77M7# *U!KWZ!Q1I-
MF?.6O=CH8J.7;)2S7>Q?'[&%8;WZ:3-[B(GP%E>YF.%3D=V&KU,HGP'^ 7D@
MB#B*:??6R&\"$&WJNY34PIZI=B@6@D;QA;(T)187[![\%M"5=NOPT"X(P1\J
MFV:.8]P]' 0?40DS#C@F\?/BII?]<9V;AA)@^#XM=R[=@%E4: <]M;'&!A)8
MX+8++MVAP+(10E147^QPL<-+=BB]3ZDQKQC)0Y5HY>_J(:9(QM3B"L:T+8\R
M%,.D"W2!CA2F(<"O0QMSWW7PTO"OX6A GQT>(L3?B*O+%EJX[\IHA0(8D)A/
MT<_.R_^4:B?#XYB(>85GA1!*L(%(6LN'SDB/]HH)7[Z"IWX3_?);'+4+A].O
M\"-_\OGFJS=O\3\__?S7R_9<MN?%[4FC<+I'KY:GD#&X1!E )N%LIBYL52<Q
M&RQ]WY<'8E6\!?#R&U0=X*E4^D.]G"J+V<Z:+<<NP0T?$'');G_"J+S8T&)#
M5Z*R5%F-\"4P/X.<O3E-"F;5Y.$%@(\$XWL\']MBG8MU7FF=Y5U7;Y.#=B0&
M]+'J07P="\9Y<]W<AK"S:O<H.C*GLP(S@#7C\^$KU8=E"'BQT:MS.^5UQ7/8
M6M#:UM8YC3;2<@=Q]X*&-Z!>]O.=YM4I1&%JAF+A_6V'F9KCXDY''[<5S&$&
M$P/X;ETU6Z4?'LM^7XT\LG6HXD;F $-RS#/OJ=%XF$<*Z(<J;.ZV'I!KFL9H
M$$/F!B/#[X=%.7C)&YIJJ_ODVJ+D@H^!Q2 :<D'$+^P)@/'8!:E:E'YI*F_2
MK#!>3UM5/$,3#2Z\6+VF\4B:59N9R1.V:!C@%,+H>;;H>;T;1UPCDP[C;8^D
MUY[U_('N6)[?,"DR1"S#^K;_*,T.XHAVTQ8U#7V)C G. .+GHP/BAL:VB-S^
M(X_=7!AS83PC[JT&=@]6DC*,OS'$GE5G9E[&$.YB"[@40^WXO&]LC"T:6.OL
MET3!K&_=Y)H)Q@3W1\]75TR\[>["*'QW%_DPNVX3_$#X"7D);*P- _/B>S)C
M1"/XZEJYZ3N8; M/@1.$*YR_8UQU7QYQ%!O<5TE;J!"KN*NK^X('9[?PF_T=
MB23A'Y'S>TOOH(,)W2YL<A%1L=>O$,B*W-#W-PA>%>01#\"*>PE+L7F_XN+5
MOOM-V]WL.RY@A<N0T,9 RE;P1RK8\7<+3W;;W1.=58<R">CB>'_Z-<)$D>?(
M<17#T8.#]F3\6U3[@!V#]Z@FE\P02.?47A!?6]LZK'&J"SXRZ';UX1)P[@63
MUNE] O7""C7,L5H?*/L(]@ 0=0)P\1"[AV>1?F_#5.Q.5\"KS^ 7!C/% ;_;
MX!R,C3[W MLN?"+,I>'GUT3T3ITT8(RA>S%6N2$R^)AK-1SG^O;2,28Q,]'N
MT:7&&56D&%4-!-;)<A1B]GNK#M\=Q"EQ*[UT<U:5B S3E;A7=Z+!=BPV1;]<
M*/D!U:!9M;@%2$4?WO:\V@/X/US;1CI)VV%S2U5I'5:?3IO;ZW?F@4I_!-ES
MXZ/E/).J>5U2UM*KLW7X[U8.^NF0)<"^4*$G9J(@H .!?05SOSPBI&-*Y.?T
M:Z@'2#G\]?UG9[[QZT]G85<OVS.MB&,P<D=2U^M9E7?H3CM7?2&%(AP\R<UD
MM)KA,^E(=7:$O;@P^*OSPPN%>OX"/S>4_&<+2OZ7@Y)_RMEY$'G*J '.QMH^
M>OL'A-07'AG[C!5S^[ #M)_Z2YD0R[T-T4@)$]JO.NR2@MN#'WKYM4PP5>&D
MZ."D S'5BCI*6)<O-[>4&F$0%3\--S_]G?YV@L-JQ)$\_<!'D ON#O4&?S0L
M(=7Z?P(Z(!&>(?3DF<D>>-3=V-!EZB^<[AD6(8BIXT>CX[!IG!(V9Z8RH0BW
M8.H,:%1W7>-ZN+0<""EFF+WRTWQK0G&2[W!^XY2QZ)/883J3XYR( VRH_%IK
MK +5!YX2T& !& 7K8=X@J0P>8D0H$\+;HTIF);,"N7"$$J$,QTENX@WC/]7Q
M _U UCACC@W>2RYW%P4T)]B9G_B4$!UF&2R]'ZJ,^2-5R606;UL=PID^LJX-
MLB;*O"FI'>S8L&<"-ZP=K!F3EB5Z0L(N/$\24I(:17B4+LE'D2)UK/$TV?LP
M.GUW'\/[O >U J=;FVS:U5943)D38D71R:S'Q,@PA+1$+LV0*/K+,UTY<;D0
M/WNV/([+HQ2",X$Y/S;FWZ^'"6+B#<3Q&' 8P(!5MDRFYP?9C4S32=ZOE'>F
M%K *?H$XUX:M7E,V>A_NH0K2M #=N6RH.<[EL5K5FV<X,"(X27;J)E?C@,OB
M B5)!.ZS-? T[OOPYNCS2) .X^D!!,6W#^MO2^.+D3*#$.E=^2BP@.&^MUB&
M0!XP%EB5=2GX2?3%30,7GX?][@.+BQ] SIG8'BBYT *F9%!<ZK-/>E:.U>1P
M,%:46(0;A+/"'U&D.L8@R8_YQ14$!#HYDJ!U$[^N?(*ZS5AX\;DU"2.STN$1
M*YECOC21@QT91YT2_PV54)1$ESQQ*B53S4PNDW/P_,[IP%DD_HR%"JHKITQ]
M\+M2/',:W?+UJBQQV;V4:HA8#SDS&)E.I&O(91;>&,LOA%BD)H/6/LQP"R);
M9$>FBG9Y[T#<4;P9LBP<T8ZX_!I21J%@Y!]1(L;BRSQ9:UBQS@X Z>-@PJLD
M6UQK].GS,\>T?V#MYE3E)B[5$-_?@2K^7*NQ6!#!AN\K;9""*5JQ,1Q;9:]D
M/1^^"BM98O%?N-06TDV7'$(5?0P)AD0]FF^-<-U6-K4#1>;#$;<=1$,NKJ-%
M<J#W41440@-CCBSIT ,1[:0TWL5%;;O!F3I\&6HW[H$YB4XJT4Y>HB!?0O53
MK' -3)97:97.+X+.1V%E,M7+DU'7K%/.@S5 Q1E[;D"0 ]<STT+:K]]_#D$(
MWI5X_#Q96(X$4M< 5QI*]"-WY>PRZ'Y%X\BM)RU&\%0BV'R /4VK@8O34D'9
MW!#7ZU' G(A-,W@5X'(N^\VM<'+FUX:>9K[[)5GP&;N=>"Q,CR%]^]GK2$F5
MJYHEB-[3RU98TF2^T.Q'A[X,618;.UN5&6[&P-CH>U 9!2N^M=*IN7I<^&FP
M+7E&=&(4JVAOT+IQN&+;W],B0J.U'"A2HE"S'GWM$D,X_+*8 P$=<,?E[1-C
MF]'##%TS#<-GPSF*X&YG/\6S^O&7VD%NSOH-Q-5X4ELI  ^)GQFRZ8\X/4::
M<FV"^E-1USKX8IR  'NS*DV(1"N R(A0%%6<N;_/>?,%,ESNA0^14JJV#8KD
MD+H]!5_BB&\QY!SKH0J!BC5HPSX8.MU<<<;%4TB1]XWZN!@-NDPC8_Z^3T]7
MAY>$=)L;B&[:?^K[S*-+9BIB U X9Q)5YLWDU\33KNW<S9CK*3F,Z@R/KR]C
MD&=*/:(MT 05JF9&_.C6#D "=>TZ^S.>]ZY](G)!8"FVD]5&G/N<2K&[9W0-
M&X0T<,M%ZG"N6?;SBPHAGUH99_QSER\?8C%V*!SL/N("<OF2-C\U:RJ!SM"L
M"=Q)J$^G).5*=.YD%]?A>(#Y0,>[#O?VC)A.R]V,0_SUH FC+A[F'GBOGO/)
MOC02\)E'PKS] '%K;T]N_UQD/A*U6H'A8(AC494L?G*@2O9SJF*T/.+@OP,<
M ^'?J?X4_"*"#B"7K6#<$N+>;8%=VHXF;Z(@?ZS*0\''N.Q_Q^J/B3-WW-DX
M2EN+W:DU7(?.X_BB-%%K^]*,CCL7,7FHY_W2!*'P2!9'=\K<K 4$.>""\'+I
MJ8#P@9"2-/:<!3/'4(4.[)X2$'T]9$#M79]];5E(.)?Z\>9T%.F.W"974+25
M%-KJ7E\>S8L1I?O>F/'AAZ!DO!%*&Z4:;I$^]B_80J!M"6\@ 3Q]:C7<0[>M
M.( /?W<V5N:,2= /$TGN:1"4B[^.K@%% 1.SH" JY6C5XTQ*4;-YVRWY?KSC
MJR^^'=+\$TP3*@?8<J[T1R%20/@MO S2#_J 4*\12Y_<2%4)MV_ZS%))H0GE
M#BK:P49"'($F?![&RK*<3;4]]1'9OB/H9X^)E9'C*1C"QI<DH:\2HSC6>.(C
M@XH3)]D*K@=XN;D?4@FV1U^ [ WK3J4N8G"X/:LG4#LD?M&F\YR\0]76'3E]
MO^7FXQKN_A.O^:204TH8Y>/H^ZY_SPXDV@5H>' M?6<K75+Y[">;'Z3'-50V
M+B 6(DZ#*BH'Q^%=I!@QPH1<N4)Z ,V9-HKF"^N*DYX'#Q,\"*%C;!^<[%VB
M. .J7 AY:4]&;LW1R%\)O8C<^@?A,,AS,PPC?!0D-Y_X"4^/3Q6@9+[?C><W
MY?W@VQAP&W/_Z?> DE+7 CI8"S>T)7A/I5['@+>.:7\"D_WP)5B0*/\42)3?
M+DB4!8ERM9@8X/_;?8.M%*E[FY.VJ#IXGR*\\SVS=GM*?W!X/<YK")(:N,]Z
M3^F'*,^H[#G_LY'C5DD:;FV$CQH"&XN9J1M-9.(E)3'N\3EPC4H */?5-M,)
MST*U%DK?]D?(XJ"=7]>=07[%US"303@6?(R=98O4%I/3*2JAC?9[VN/#DYS"
MV7QH C'/H4*19WW_\-<6%U*B1GA@%T'#[TGQ1AM/5D64RTNX-YWGPO.X(;SX
MQ3IT3NPFY5V8*<I/#WV?7!71T>\RIH\9 CRS0 A7<.YO.P@ON_M6(<6N_N![
MU_Y?:&60HPWJ16O\/IP/#-7FQ)03'-="0 [;X%ZD/S',KP:K<&S#!R0IKG"9
ML$P E-*?$@<@VPO]@ ODJ-;55M46,V3HR-S56S I]24:Y'.^:O :?L39=RBD
MZ0OZ7/B/!;(C*?0:&UPT8<6O,?\6E!X\]Y=U2F%2HJ!I$S_P00,.54638#@H
M(4(H&+2ON[+?HGV2F%/7$]*%^CPP$[+AM&"PGR@88V6?@%:_NX>5#SNPAC1M
M>Q+B5WM$#MAKPXLAG@+P_@!EX+0Y"FT]\3CL70QJN'P-USK@'2!$EID7A;:!
MX=-# ^I#2I;TG41#4M1A2L%TRU7(*;09)P"_10,&HO,XL7AORTYGC@W(U]S@
MVJ2R(=)5/U/_\C2%6>N 22]'0#$.K=(]7$Y]]G(N#M]<&*P:ST<X?M"P[KHF
MV,K_5'V'\4X(9U+<$+B6-6I&XBI<Q@=)JA[560SE*?<KY1=(<9EO)-SYKNB/
M='%2'Q,W'R%Q>H^ TX<;8BV*&<&C$2:>)A GI?!/;@]&2="K!AZ M)VA9JG)
M>-G2EMPR $L<2%/OJFB<*01^W4'J:(.SI. I;+"I0@W1[0GJXCOL2ZHUU;*J
M([T@Q80.10>=3NG$J#2GFX_9G6#4SX3:(;6N*MK%CF\/^\184)=B40>M8J?X
MNJUV):)ZR$?I=TTX^]B)P.XZ5FU8<#RX&(15F]KG@T4B1"J27^^\L%[8EMOR
M$$X5!B#%417ZU7I(P]72-+K<.A;>]JG<HU]"'70XK"E>URDS-[@3[L2])\&%
M0)(PT#B7^UNH*KE9'D6A)1$Z?@!Z%%Q^1EOYV2\_K68/@M\)T5$#]<6V\0G@
MAY^P$PO!,,N0R9<<-K?5]M1(_6SD4MR.7)Y<>%82-!QNEUV&OG_>BT:@-)Q0
M/%47Y05IG7CT20:G'+3;-6[G81:JK0J'&PXO_D-5!*-!,'<.F1[FON_NB6$-
M=T8LD0;CW(<C=S4&]#S]-$3DX0K6LW^Z-YX[IF;>KBE96G?R9N>+[Z7^7@O>
MZ -CMKI+<K]Z+6^)R-BHB:-A7#QZNB^/)+4,C?--Q;<0IFE"8SL45B$]E =2
M1XBO3C)NB45/NI=4N@=$J=$F+K?;'EH,B$%E_J9C=Y22JIPW^M49:>[>F<L)
MX2VZ'L).;#XP=-W!@QC%;GP',B;LUS@ORXM@=F& ]2U=AA$Y&GH808<)7H?9
M\\\:KN]0]+TC)_"0I"L>B0>E>7H&UM$A@6%]T:N5#LOK.U3Z/.#S=.&PC@#?
M;J1)4*]G&M,7B1XJ/[R7_T5R. FP20SX>7W0I<)>S'=0M7O(W;#)B?LV9)!Q
M>.GH+BPU:.J0]FPQ.94R/66AW,J173/@F>.L8UL/-*D<KLU%0G[IAQZ8#Q(K
M![W(%H*?F,H$YV/A5(;@+_Q_!<3(\//,NOF(-25) (Q0N.>(W4028Q<D @7[
MQU._N2T9OZ6-=- -CR&D,:1TER]O&>K&;Q\_[)2"B-K5ZVJ#A;C59Y]\]ENB
M%"%@.T19_CT1$ >ZZN^"D[USO6HH,D(VBD7$$SW_VUW8@R':#+_S7;>YY:[;
M?@_H8:B0<:JB8^7BJ?_/[U]\NEH#0R_S/T#7O.QOH!*(9<D;_$(6F&C8&G[W
MTW_[Q.II?(U?@7/@3BL]R3M[)>$"?;%ZZ?3E#20[V1RI0<2S#V0&53SE9\&.
MRZPB],2Q;KO=#@YX-2^9LPCI??C['U&B X?.>FJ=.C@EMK$%S!*N-Y@1>.-S
M( M*"UV(;V$G%WKY?:+W%QH<YP'@RQ  HVOW^(D\M&TH'-K$MYNQDE5SC8^X
M:J2FT5L9D"%TN:I9K.K[B@IHWT--ATIJ/A,-/XN(7CK.H117, O-'LRFJ95_
MI "D6X@2.'M1]V:3]<A&P@B8>51P,IV#RQ8U.\%B$& 9'@ANO5<U"\>ZP*U8
M4Y//EF+4-R=\ E94-RUY+FY&+LK7N7AR!L(&,61NO#>- -6UN\%1VJT0@3@U
M@\DN(QR7V^B%E4VEIL;0"IP.]$!4?FN(#2?QKN7 @ DO[[K>R+-L 91#BPL<
MD5'CU4! )!E.EB:U/)X_UA3[8H#T"?X3 53WX"S#_X]!<%R95HX68BYQ<S&P
M5*?#@;+)J,$E;0T/*@HVHQO;N:@$?IE.:1&X?NA/QY'/\G!6(];4IV8<69:"
MU2C0;&6B&-$5 $Z#E4?_KIS5MJR<D_"],5PBX5*-?\T:Z6Q"IK2&4 >X^6+O
MIR^)O6B"3M5Q\6F*6(2AZ. B#4D=_ $@RL(%0DY2]8 6U^'2FH#F,IZ$MF>P
MU2(AJ*9U4G&/-N)3FHM>79J"Y5\;B_%FCC46ND(\>4:+JD.X/QTQR'3E)UGB
M\&';6QX*3OC%[&B(=X20#^=W,N[;M'Y,M8C:1*BXI3&P1QZCFC<=-C!49YC1
MI+ 11P6HIW(GL^+1XW*YQ@8C@RUA\C;*3:/K4L1E"'@^(&&?O=R$) ".%&CH
M4FH"1<$UU/.-5(U+1A'7%5TZ'*?$JC1L^GH-H=,:Z&8D0\ > _0+L"J6;'>.
MMJ2R65)?P+\FS7O(3QH_S>-ZB%;6SU;PL]7^A<'EGQ$W\[L%-[/@9CZD;NF
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MDGR/4_@*#,%MRQ[P,L3R%X\#+PJ[R\YY1)GWT+4U&*_6K(1Q$1C(16=TA7W
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MHJ?^>8V(F=V1RGR.3DRH_MB\,+0;JZ/+HU!I4+8JCJGP\)\$;\AT'F*8U7"
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MU>:42%^T$$+%\ JL2=M[*?4N-!RE[5O&2A'PC%*MM\CSQ>K/0%@6;MW@0>O
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M%'O&@).'*%O>8>R.X;*(]_WWSZ^^%@B^Y*^URIGBO\87Y4\9PJ=I&TMM(W.
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MV$HM2M6%P#DEFFYE$IOPC1,F$7&\QX@L/.)SP3EMI BF"P)YC\R0$S]N.,J
M.'LFW)5-@ID7,(#A::;O[=[*P_[EE,'.RH&F;"V \#Y4PD-D%(&O<"QAM!7"
MG!LW5:0+EANS2_C](YC.@(LF,Y\X\IP=\K_J;/C:AA]C;;1YAN@"&YA X$&L
MMBCVBK414N\J\W'QV>(^?<4D\KMJ5(>GVH:AVY"&?/J%YM8S6L2IK <?U8ZH
MEKRZ#H[&-.P=^B:*+VC>][Z2J<4GG-4,E[X\D)E\JUB$06B"O%%S*D)&Z0XV
M9YS KCXZ$RWF3,PQ ,Q/[AJ%3? ++<^0,TN*&Z07M@PD,@>A73 QY>4=>*GZ
MGL@*^&NID@M;T(SE$C<X>)YGGX2>V3>L?AUO'J^R[5;5"%0D_"QT<TU-RJ>=
M%YV1$N]@6]<Y('!EL(G5&#@0PN=>/0PE3"C289IP2J@\,UG5];-7 B["P=-R
M$ZL0DM3D'K]@JGVR@:8"%JO\$>"9-6"O;'T9XU"50ZQ1C=/C T<E<+3CMX/1
MK],!OP"F:?@<T=I#5"\YC*0U?$G16(1G#4XK'/JL,'P$_JV66ND^6BO3(M@T
M6U3?.'-!)VM<JE-F5I^3DZ*1%;&5D, 6E7I.&7XF5J#L#N@$I3Q"<9U3C[Y&
M)&DA\/T9(OY_NR#^?SF(_P^J[RG?+>MP<+Y#_#JMX^V(VK7U0.+#PI0&I<OL
M+#UP:="\-\_=KRN'OY"TI*3;4M&HN9 _[8+O@U*3RS^=^Y/ZQ8[&U5GL<Z(,
M)$G1)9%%U?/:,1-O^OHH+\.>-:D 6H*.E \>OT5>7I26AO<U).Q>4>31]"JE
ME7@0EU7_[51QNF_: A1SA3-TCRD]Q*:.\1ZS,>5./$NIJ:_L$(VD<JQ0$&YR
M6Z^)(^]$I$P%$1KO@FT0X5+X3OR>P#6*6QO'%GNU&,/)%$Q4QO>U*KI<,[H>
MDR7I^T?T&@9\BS2_L$#G2LFM((L3_3?[E1![ HNDT H3+7-80&';&-+$TXJE
MPG%BP=>$\I&^ _%<-S,1%;+)X*.AM<I.H@<S0CF1>K5-E4PB,X5'S4]PVIX+
M[H.WY\3&?<J#=Q;R6A\1YHI*7+MF("Q&^G'<"/Q2H%[;G)G&QR4%W/*Z)%E*
MNYEJ:I8 6TZIJ16N3FV]JE(_W(;]T1Y]E16IDFZB:"+D4]D+[<5I"U<*?N%?
MUJ?MOAI3HD^G>!SC?<)YW!J/F?Z8Q;S3+T:6IX8X#$9A(G5>T4LEIFTA@%7!
M5/%]ZVJ\1Z(_?+O:=V_XE) >1TYZ0\/F;I<Q,.!A_ZO;Z-:[A>MMJP.1V8T"
M2HJ,U\J:N]6$-GGN92-QV'F%JX30>5"N^/C+>'ZYE!J>._G#JJG?@Q%@%4]%
MJ8U]$U9M0KN><&X;\_HSY[]4:\#:E]=2)F&PD/6$9[T-P4[5NU?T/SC*MO32
M*C,<F!%<#)S P.KPZG==03Q+J9JI.:6E_I@BFR("$/A5M3&'^O3B./%AYPF_
MZ,3,8JF=@+#0CQX45DUH/2 ,;JJX@$\3!7$M!6X9WAP3O[#2%W5M' GF?40I
M#1@,0+%Z0E$DM?SHK??OD/_G.X,"?F??_J743F!I7^4^,G3 WOH0B/^P>J4?
M]V._T+=8LIZ6?L"_(6DBJ#NTUF$&_L9V/]Z>"^2CIZXS07UN17O\U I9YU%D
MWZ69.G<FH@G@]V>>8M)$:*W.QR*&=DI&AGL!8 .NR=ESQ&R7Z@K-LH5F 0NQ
MI7\$^,)?76DWTF729Z:2)9?M66%LMAC(4FUW=74/3JK=6GJ49>9]82:>M&RN
MYU.SXMX@ED34E6T(I>"SD"([$8Q!P6V@I*0]A??M3H.X==_7]"<6Z*[UU0-U
M6**1UC)SU\!(1CR&K!WJ\7PD R\/P$&._!).%,^'$2@C9FTU(.%%_CJYD<]N
M.'3?BG@IG.? _A477G7IM2<]I74_K^[@;L1^&EFW9X^E8RU6&?$8-#KP-C46
M^L#"(+UASKLRDMITW*6DTR%-KYG-A^@-, @D@X.=N+.(YY3?;LC(7RBWW@C*
MCOC*X2R"C/ XA,^(V#+D!P2F491 KP'D-I Z+$9K1.VO9(B7W43\I.B@P@;T
M->(\/Z8KJC+FFTEWG?# !82>IVJ, \=.G?-#3VSDK@ES9TK2R/X#TF#VT9HS
M/0#YQ)\C6N.\^*>YQ3G@XO-Z1SO*(I76YSK4TC.-EO\A.LFY<\[.M6P'QC)2
MTAG01'^A"J0W^@4@M?-J8Y9<LLO+&4VP=\ 8H<E66!] "X>^FOE6];9EOZ](
M[5F=GXYOXDE5#BG'J7<4;/D04H2LNP854 ^>& JK/LT^:9$LP IFU"JG*L#=
M+N1O!ZV7S$,7E[JS"1YYODU7+P,ZRZ:\,)S_2%N*FKZN;A,!'Z1D-448)\H/
M/ ;DBACA"J#FE->[6PQY,>1+ANQ(^W,E&CAYL*@$/]N @2$4 G"#PSC)A@Q(
MN7$M")<X7KUE=DHA[4.ZQ9@78WY2K[RM!^1/L:X+L5@46-;> SXY?+K""N]]
M.AN0*P['T\AT)2Z;$IK%BV-A?%;VD#>EDR74=IC))N5_RU#QLCNNVQTD9<P]
ML[ZB2D"GMIUS_V/YON(I/9O-Z9Q\!D@R=$Z*C*6*5E7?=S3N#[B<S6TEJ/ZQ
M"]]0\H&)QB^F&IDVG.MJ<CUG>C@L]K_8_].>#JAC6G/)!RN]""IRM>!BE=$Y
MS,3PG@0HE\!'=F^%O7755KM:AOFFF7/8D=C;P728)HHFYP/*5WQLLN,%&OD1
MH)&_6Z"1OQQHY'+L7'&%_QW'3IR4X,0!Z&M#Q"8I!QY&"#!U"3?.8SEQR0\Y
MI[@M/X\G78*LQ=J?/,@B#D2R:A&QW0*T*)D\@='*(:8+@;\[<;?VGD9.H<WM
MU=RJZF!1%M[COASPOG8OU-:.Q]N^>O6V6%7C+6\9@;MV4V)(!WK%RT.:PQ-"
MP'6^;)EER\Q23<NX=;'ZPS>$D\JJ?R)>'R#IS Q!$!XHK2+GRET]P-YBG>"J
M*AY7<3T7!+OF/A]A\XH,M![VTQ"R^>VI4;Z7]-Y8+^;-*3#BR98Q6#%NU\Q%
M\!1"* 'D_X"J&<;)D'$TC=XGOZ1[_C$^*;\2?!X6F1%H>:3"'Y;^Z)V\^W5'
M,8,%C*9"@5I-N0Z[FKDI0K 0?GY],D%@I%ZP$8?%^RS>YUDZF;[=B/4)J#2L
MPJ\W)Z/-.2C'V(KJ'?OSZE?XKI]\_MT7;[['__ST\U^S6C>1HC"/ U;;0S!K
M>.)+^V^Q\\7.G[UCWPWCC56>Q7GS;/8QV'E%UT2GG-*;+XV:Q52?QU2U2!U"
MLP/8WKE(52):U><>*$D)\514DQ8"H(2U+ _X6BQXL> GM6 A0%N)=M.F-A:Z
M.6*_KD\H2&;YY#X//[N8[&*R3VFR/,Y!A&1E.EF"J?RV.XZ(0/>ST#];-N0O
M.^ J+0'?8O6#ICRUD/##W!IRCWY[#"G]"??F9Y]\]BE&Y%"BKD$D"R#&."P:
M I\#U=M@B*^#WY&A.)SS@;\=PB(S<5O9E]MZ?Z#!+3#CD"9@1N"2#,5!ACMN
M^W"GUB'+9%A&5RP<=INJ;P?77^4)#;T9!&?)@U#<)Y.N\(_,MT@U#_(RAR[\
M>/B<@-E1##(1K-:5(V8'7DTBPVW06F FL^IA)F*U)A8Y637P:O4=LAO+#.\[
MGH$/BQ'R_8Z9RA2FM*Z[F*=.7SQ\U!-% .4FW/]0EZZA/ "@ Z@@B6,S7KO5
MO@L/0)!P'+/13UH3]<'V#JNCI?](88EN(/R0(&/ZO76]<6&J0WAN\&E#LO;*
M>O03_&H%F/7P7INS9[,6TDR(=L)'D&GJB$O.$1DFKV%&+>%]!?2(QW!OQ*KL
M[+5RLS"&E)F^HV0" .G%61I(%&R,\9W,S0'[@3 Q#WY&'\>&@-H"7GU_JHD[
M5U@:>1Y;D&?NG<S@@XLI>P<ZBV?&M+@4K+LJ^["-+K\N+.FV F(463,4\-ZN
M7O?E;EQ])4\(UO*U6MRWM";R$*^[ 4B#PYW^> HG6G AU;#I:]0T"!<Z[>F]
M_F#S CHI*X,)[W14 69IZ7GKS>IU/0 (VM[^5_\=CGN8B0L^Z;>_QC& </35
M_OO"U("C644^$7A>F.+#!]6[#HY:CJ?U;. O65BB%<#X&;D@I"SJ"I.[SIT/
M^ <\$VQJ@>MVX1&>=U@*R'@)3,CS6CIO&3.@=NU#Q/3(&CAI'NZZ?G:\[\(8
M'@]5M9?H[U'22+]VSEZ!3"P2;HRNQCLFAG+.ODA*)^S)%DA\HV,R,L"MU7VZ
M7-)7TIGU'+/+ ;!U<6@+ 6TX.#E44+H,$K^Y\/:%HYSQS"_&18->UONP?+'Z
M4FL8J(^ 8(.;7#H#2D1+)YBUWA(I4MY[9G[+WSGOI90"4]\>)K+WB)@%D13
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MZ.=B)5A28.^.8<*4#^K4.NW2G^@[Z01[YBS/8K_L-/''KISTDC([8$MV;!>
MFKDI8S>H"^!_SI*C.=V//%N,L\2%&R;6!7AXJ/C%Z@MXB>G%)Q_)Z=]0-Q3\
MTVD0'#=<8@<\&GPOW172.3IV1XG],"'D!JC?/0MO[3\'./O?%G#V+P><_2&;
MT'*2BM2A@JN*F4A RF?D)/&\.H?5'Y0*O1K9F]4DFK0!BE:L=DW92UZLOF0B
M=;@BDIM'5/">D"A7YN"H]\7J#:C>76"U03^\KO8 IDR'N'K1WU 8T_I\:?AW
M>J(#VR(&92(X#JO5UQBZ(.,B%C%\K<8-D$WX6'DJDTY/4(>IID3GKBMJZ;*^
M>&8"[2,Q@:5,/IC:<'4[ ^C&: /+OUS]27]FRN(3HO"(5AFY^RDNU,(ZR2BQ
MWA?<HK71P.0&1!6I*Y=C&Q'./XWY-'AGO.,C<@@*+*!(:Y7OB-C$9]B/32H>
ME4G$29HN $2Z1%4-CY'9*MEZV]:S.>U/)4I:N $R[F!=3\PF&3)/%ZP\'P!6
MW;$<@=L'XMVH..8K35:^H"+HS&>)0BXKCK\)OPN2)H7=&^'@2E I6S!A]_.L
M5T8G"0H"KO-""-D+$I3N!K.$6TKRY6_Y8O6.$EVDE!KM,SA#("(S^:KZ_O#]
ME*"F,WKKQW] 5.EPRDVQ4VHTVLZ7!_&XB>2OX.%1^#TBDA/ZH;MPC,A7.8E&
MVZ2<:'O>GLSR9:7SO*84\ 7LDWLH#6>_S<#DI5NNJE^B=1;F\IZ%E)!JVK'T
M3;)-P=)*5LPDT+DKVTIA,9&N5&/90@ZQZ0+\0^H#5Y"Q,VU@[ ;Q'"'J/]P(
M1],%9(9P\ F:N7,NS\E_YML5$3DOZ8UL&<XL_3&+,%)@=+D.3]QYEGR'1,W6
M#4IE%17\]$H)1L3=A&/M>85(946YI%4B]_0:%RSE_[Z&.!\_!U_EY.B,"\FK
MZ;2WI2X4W "S UA%9UW4(CMHLXK.7:L8./^#S,JLHN J-[=E,XU$C&\YUFF\
M6"ADY2 (W.Q0V&'OMMW@O0:(*AFL5L9+'/X5&FT<N(";D_.UK\ QS5-_)YVL
M7+#+@57,SC$AD)T2%^0\&;GQ7(U!B9(=VSM5(D$53+NC-SW3$R-!@^S9,IQ6
MJ!*$J@98CD)*Y>"2H :-9P#\3"4_D8^FW,0378 Z/D1[B4*5: H8U"$LEN=7
MMMRD+7RGA:GJ#2N[Z4_U*%L7BTZF,5JU?=<T5B")\A_V+B@$M*F/JF28^YYH
MR6)TES2Q0P);'^;"-BI)1TOLCT=CWVUH#"4<J_\CFF-M2(>5"@D)^)"U$OAO
M:;QLMWNQBA X920U (X1"+%I>Q-A#.!O"F8"7X?'JJ$!_C4HDG8(7KKKFE,;
MODL=?O9(CF+;#3R:0Y< ,(9+"*3]!P:Y#D8:_N%0KFT!.L'W.X)6\',HJ(B8
M*0KFD5D$X"R;VZX)^6TETKC?O/Z&:*3B_ $51MCUD,8Q- *@)N('"O@HMCB$
M=S9V%JE@)J)FL%PG(F4GCWJ -L6QR>JH%'[1ZD$0&KA03H(TFQR'9[*%$IY<
M=[EM5]&L(01;&PX3I2F%"P5+TF%F3&W(&PA2'$=C2,\9_$-U<LQKDFR,@.:\
M25A%L1[>WZ2%Q_"T0!5'MRBW!Y"''DT%T=Z$&6HKUW@E%OVN!X$OK'5"B6%7
MWG44JFJ@T(;M=*RW<D]5;,;"0P_I.I]=Q)[-:H3(;FH_0I&(TRR?-"WG,S'-
M')_U.$\)^:<U?2*4OGA(&%A,HA,YK@?H0A/&X-22[23N'?IXQ%:%[1G7??0!
MO?:O0#2.CLUJR.H.+:RRJU\(W/4"J%54G46R.=@C4(T745SM\:ZQ%"<=M#PW
MLX(!K]6OX$PS18BIP#L+N_^:10N[9'X1' KD4M&@HP%UH<M"IRLZ2Q$.7 84
M%O/_ /,74*@S8R-,VZ# E9CZ8F&+A<U9F*N&1:Z,9)U%T[3C_-<YML(5\"AM
MR ^^)/K''&9 9M2UE"=!&PBDGHTKHUSQW.VZ*3?O5^ON)QZ^7=V7?<MW).T@
M!TTE677*DJ!NHMIAI]:5[EM&0B2+L9)+#^:Q.7"M00G^P+WN=3@5_!LM>VO9
M6Q_HO44J3;8@ICQ*F #$Q22&5:C:H#?1U/Q-T8NMURXEX-R(FL^=&[NZPII'
M>%MG_<G."2'/\?8\U"&+@7OQ2$>M@LJ3_70\K:' N^R/97]<EHQ89V5#86?<
M0Y]"+19D4;@.4/65U.#I0,)L=-K@F=3CW<4=-TFR+S(7FAFGQV)H?U?530-%
M^<78%V-_G+'WU;$JQT=0WHG:8R74(T/2473-/NG=RT"=7I<OUYM0($<TR&52
MHL;BON,X"PM@ZRHS]$*M_L7H%Z-_V.AQ(@_!ZA5B9Z@[AN;5'Z0W"#&&5H:9
M)(N4#'_DF: =%%01?C'6HQ98PC&P[WJNJQ  G+B(>QE!6*HLBY7.6JG%M6AQ
MPXA*U#@ NJ9T]+F2O8>XJ?4B_UR6%=E6WKH>;U\Y"WM:&WLV*]-\L#ZL04:3
MZK\YN%)TEN?,;6:?Q2;GUC\UNYSA70\97G#V?P?._M\7G/TO!V?_3^6OET@@
MCE=U!-UA_'C@L$GGOY;(<K&G67N*P)&4S>#X2P.CV3)R7]]5GT-JM-C18D<7
M[*BOCB>65< LY;3;5?W/EZ)K?C9>(-<G%G\H-[=U=:=]Q+J-A;(=Z%EA=0@K
M,OJ.&5'PP@^/([,*$RS0K// 6I)N? L?PNU97;*\Z'B$7GYX%/_G-(+_[C8O
MDS[IW"(9%,VM7SOJ 05$'?[&N3U =)T.0KP53?X%:X Q%;@PX>OV_/5C'B+]
M$IG!:1JR"<;5CCT"K:-Y&X4U)G-(]Y5.D\FD"..>HSLG W[A=J..D4TF;6(!
M7)903UDUZ#(=4APUC5CYTT];Y';E6^& ,D8 ?5L"++LWS6IUTZLG+UVM&(5N
M''# ZC&9.D=\:Y;1 3T!D*?=,/<K8*FGXQ1(IZ:V,%Z6S[[>9'DP/P]LG],G
M!\094 HJ\T"1E0&?C,6OOIN1OO$LS5.BIY#NK*W+JJ-PA$H&V0/<4] SDW$D
M(F]:5TUPK^3T_,U\?X$4X_)]!-S.X6\/B-#G9C3^@JM@Y EZU;2<KJ[-.>8_
M!0+:,4%UK$/!Y%(',(@I$JH>2 ZG5HD&6 W@7>KA5OU80^A!P*16?<<3*0 >
M3!@RN%-#O': _A G<[,^WXB_69<#2EX(IUV&E.3%ZJ4#(>;6V"V0P;#;X:1P
M6S>7-3^-'/FE.7\X"VM,:'JF3&/,;Y4XW$)8T5)1' 3VT+B&KW7A:7YQJ!JN
M[UZ!I"Y:#P+.3C_Z0R#C]&=^:[)@[F/980C&L2H/H%VN#Z63[W5[US5WB6 Z
M?6&9F"<#:^!C$Z>(,46ZW_(P=R1>0N449OEZH>__?56]G^%RF8PM17HH9/\#
M#RJ?A$UK0AY_'<U:/)R\II"J8<[+Z-0'EY??5+!\N+8A6H99%'2)\A'Q0*+_
M])]_?H(/O"(M/!\&4?ZEH];Z!6U0'VR'?[!8_>7=RS<OY>UN@<H%NI^>#4#V
MJA#GC)[[\=B4?SN%RPW!GM$W("T?>GP.&.$D*E;K$\Q<H)52V*B6:/-T<L^=
MFVS"(H2[4CPX'_O 2'\*SXRVY(],KI4/51R@MD?QL/R8N^ BDY#M7+XXSL3=
M5TKLY)WOG)^=>U ?B[M8#1D3*&>PSKKC*8,3.#NO-W\G//'0O@!6 C;$K$!\
M&DG8&.Z$TT1XI.6C/$H/,E&>C'J*H[A7+C>]_*GEJVP_>G: !W7, YH-!2=G
MR*.B[3[^)V29#$=FU]/TW%71^&6VR2>)U/%H X9GO:[2$'_\ /Z2PWIB#Y4+
MQ/!.ZG#(P28^*Y\JFR)W%+U'QO/T(=LN#21FXS0*ZELDCWEU9>3S@6&-/\A<
M>/.HL.90E4SWD/LMV6E*8?H/BG-H7LY^VAUBEK!<#'HH(*!C.^=O(M2X?ZSK
M=,O"V?Y@F#LA[_@[OKB_%L7;AS2;'N8#]"+KAG'#K*LH5EC%K6;A<!\YBUP-
M7;-5PI"8*N1K'G'=T#RTE:W$5U,NRTC-<"RF$^@# C61JE9Q.[H .BS_G#[R
M4GQL?BAS>%T9//]=4?-\T&R.,03/-T\;/']@T)QE*G+A\P-5Q,NKC5R<N'LK
M("*V^&ZG4\'#E&Y"XT\?H[Q8?8NN+=AHJ^%[-8FN'SBCHATD4?:TVN5CZB<,
MJ!]*;[,W>\H ^ZD"Z_D;U,.%L%K?_ZG"Z\@GR45IDGNAIOSG@,S\?H',_'(@
M,T^6O"JUQBS9\16D187FI9[;85=NF$8-N2\%)B\J=$D8WX4<9N^(NN5*_H><
MVX? UU-T62#BCP\7<1 ))_?-)E@#?%;N3:8\\2J;%Y7AG:ZX#WW^UR2T+UW!
M)1<"X,6Y+B#94X8\T[%08H!K@5OG; ._"=O'S%'L8XG=_!!M$8OTQ&V;P@:9
MPL\%QU/N\3_C6=V(;HHYI:B;$QXJ^)@"68#Z[?NJ.N+?AW1L4_&)ZU0.''N'
ME5UFI48G_P2<BTAUDRQ#,.3P0 7.&\/_Q\<=B1**M^>ADR(Y9.J>4]!Z=@6G
MKAT'@S K6:1?Z])7BFL'M)M%O7S2P,H&;+Z1160R2>Q%\:ZM!''\62V"JRGQ
MPD4CR/A4L$ZP<%(HD9W BJY.OPPJ5^$GQO0-"^>.W,;'T''SU9NWJY@-P_^J
M>_.&V*&P0N2,MU /P^U<^XMPMIUZ5N>"._?!S1T[DN7"@+-J!>M!-LDB%B(P
M5<0KFHA)1=0;.WI[V><#TE5-1UFQ)QY"=?2P\)N_X:]>DEJN8Q"Q1/:"A0I!
MZR!F0T@O]+V^YTRO=\-[#B_SU:NW\>OM9& ^1WQ_7^G.3&2\C(XRX[[2><=L
MQWN/U5M6U9KT(*>3.8D$/"66.)S,6@K.N7H:%KX2/29-=?(\FE(E#;%XO:OX
MM)$_95H65AXC4A?@N8+FS>7W9:F3(;-:133<7&Z(1@[+CL3.&#-RZI'E"#G1
M"/G82K0;KQ@01\[*R:RW'P6':E=YXG^(.CZ^DE,"CP*DT?2;!:PZNR/5-XCX
M$V@VML^_NVS'TA?3/3$RR<'$] _/&DB\RP ,'I;&Q$*5<ODD&X]K,_/#OSGB
M2#\0C'ZQ:T%6R0N6@&=U>B5JG-;B%1IT3R)()UW\+&EB#]^HWYHCQT@I9&0-
MS,U)#"J[:J@0H1)^; :?<7GYZ&O'>FP*L6/](@MAW44J.,U(Q ?+"%@3,.Y"
M;L;T7JY'N$D2F1(1-12:7%G'U>.- 2D+&RWE4FTACKN<<_ >7\X9/%@8M$%_
MACZB.;862G3"'"ENPFUJVV@D.)+[EO!;M9<12[AB&WDZ]!M1V(2E>#NT[)#B
M%HLG>RB10SNLSNY$OPGXJ1"P@&H2EB1?-F'E0.3E,JR'60NE%*9K6]H!K+VT
MS6U7;RI?!42_:7'^(:3!ZJ@FOP[> %C B%J+N"I_/&WW9&5S!7K:^&!;[9ZB
MG)C.*Y)FYGM-%@L^U\Y5_+@8%25D^8JCR0Y=- @HM;5(F=VVE1RB^DJ#0;PZ
M<.H7/IRGU_;AL&W(5<E] .,ZYR7_X@<%^OSP)]_/#0]^6Z^QLHL5:+8ZS&!,
M1?,&[1^_3.TZ1TS,&QQ^O3U1>;PC"8;.\JK;J@SVMF$@VJ["P!FU9_]2=TTY
M^OWPY>M7+_.M:3-1!PQLRGLIZ*ONL<$8XL:,CW9Y,YH'\._*VQ\C ]89FRXQ
M&TY[!ZTSJ1*8(S9_^+H"B)L$^/\-9^ F)&SX5JN78[" MCH/JZ\0>-7D7S.+
M?Y3=638-*&'L5W?1:L:KMZNV>GGDIN&OLL+/LNO+$U5JRS5$/K"L$<J)?H6:
M&M0M%BU"_0+)5W%0Q]S7>-98(@+"@<=BNN^P'UAA3-EN3^W[%O3YIH3.VA</
M;W08,FS9,Z#UR.=<X-8J2%4^#A2H]I]+3>/<#QN9*5'S5&KQ,FI=]4K.R"!T
M5Q(1*,L*+"R=JU_(>$IZ:H+5."M.P[,9RU\&Z18+>XR%^235DQ%>96Q/0C<X
M29DO,@X^DF$P60:%MRW;9-DFUVX3,<Z4D3B$:(L9+68T;T:NJN2DDZXNA"F=
MO(L_;[MF.XA(6?+SBS$NQGB%,5*Q]'%<[8MI+:8U9UI_M?#N!]"7@IG3;ZIQ
MY+Q;U(&2B,YI"CU05%YL;[&]6:H9EJ_("E/D2L4$A)>&PF):BVG-GYB[TT #
M_=Q66$%GI(ZE-IF]^,C]\L']^#;^.<$:D&3J8GF+Y<U;'BJ/$ 7K4NI;;.@#
M;&BA^%V,ZLF-BB3"!NSG09N*84O!=#HIY_:K."2;0L&>WL*6&9+GGR'YCV6&
MY)<S0[)XYRNN\+/SSBYA.8*^!<^EXC  @B5_HO_:78&?6** Q<YFHX"J_A_&
M(UQA2.&O%UM:;&G&E@"B=JH)Y?3CJ=UH245<UZ"B;IOZKB9H0%\?"/Q8A?_K
M1^N>U\(^! +WYZZ]<6-!Z_/J9.J-*'V-KIGG"SWOX\7I<X^[8/0# ^2Y$,_"
M<MU=O:\)0P\T!PC3S\]#FK;V9%7_[H6Y=N3TVU.$Q-.Y><:-U.V)P(+!+K <
M!]Y'YJ&<)/"1%9@(6<^T!88L1)::U>G(/523%Q<H[VF@X7CK13BD*6KLJ V)
MS@Z.[A"K0[MC+L[PX/2M8X5P/UN7U>I^5DCF_Y]9KB:$Z+!" (>DL?^^,VZT
M&#:I('TH)KBIL$&G&^&G)GUL)LK D9>*Q<SI*R9<P1&1!&!DJ_ZNWO ?<.;-
M<SRX81!/%#DYF?*SR<A;-U35^\C8RO#V:R"#N6!9!!WGL9^!^!-T7'K==V6X
M'<RN](@ Y@LMZ,W_U2>9\[_>5F<&PW<YM$>\U1 XS(10P8KV7:<-!;"/8P]N
M*5SJ5PR[^^JGMPRX^_7J5]6+_8L"YB##__GF+0U%OGFKHR/;7R_""XM-/]:F
MT5]CS $0_@'.;L22-,TJ&!]UP6KH^K/Y$=@3@'..-R$Y3_I]V?+\&?GI5]]]
MN\!-%J.<-TH=UA>S]&(')9$F[9$[N;APE _G8:P.D1].''!!!GT&@C9F<HH!
MH,>*" *&17=DL=A+%HL$,'<T](93RDB^46E83#F 4CV$GQ8"_"H$#-VYJG@D
MFOSK"A'T/$''D[+\RS_?1!AS.\IR60!W19.F"F9UQ&06C!O=SV-2OQ>KEYZ;
M1^8#0DA6)91 DA76[7#D23IE!9&QA8:P;#9*&([%:@3&P*'DBD5<O@AO<!M2
MZ&AX9^H^+F12DTJ'NQ%/TX=WXW%'Z+]1X1=QG7LXFULA<D#^"4?;!(\1(DC@
M.^+NL >ZFTN+&WGVZM8!A)_0'B#<NOJ)Z5'R=P/>H+!*[BL'C]7CA-SLMT(+
MB,4B: [_+$.\2CZ >;DEU,=3."(VR+J#O,LA.<=<C!/V!_-T5\S4=X]8K3+T
M4DKV=,;BBI=Y;LI@'+<\=V@Y*<[?R),IZ9YL$Z!^B#DA9FH9DTJ&%7.4IT#(
M<4DS Q)D_=8?O<Z#W;_QML?1]W>WX3F.Y]7K"LI1;-%?EN'4?M?#'%'T]]]5
M+(P W_@-34%7JY?;.TBJMKEKP8?\MC\"H^5KV&7^GQQ?@R,3F6!1U0 BVAF1
M!6>&%Z68F=093+=!IIC+U2Z\'TS#6EQ<Q*4^),[QI#D\KUHPBP\3&+<5_&78
MA:DN4U._KYKZ%G)&Q)UEGXQFSYFU)4=Q0R4@??]XE%F7[.,-% O+V0"6,ZJX
M=2P@!16=8O5SL3$,,$/X@'7,W0-$ZR]67V*?#AF6D#+@OT_ARW[VR6>?%JNO
M 3[=H6W>E\HL%.Z--\8C9.MN[!G;$N*W=;"R$/0>RG6>!^[-5R3+$R[Q\K2'
M #H\P6<%,!^SL<S?5@&V7YSZX&+"C\"L,].5>?V%AQ_BA7_E8U/2R8H%NP?O
MGGE5IJ'Z^LU?WMU\^KM//@-B)Z0&@O\+9,M"> %<-<%A#S7$VJ1+\\"EE#X#
MA8G<4^OQE#ZU+L,VL95+#YQ=)]J#CN]"F29>_( 53GV&;7B,CH@;\7>NJY(F
MNVNR:+9 6Z1_&[IG=0$O5VN_LT?>C<B)NT.6=A"#T;]'YU>;=%3PGPUP)!(7
MR*8[K&M>?"(6H'\Z ,^WT-_!A4C<JJ.5#Y<?*IK1#S_;U+OJ)CQ.^(<*P\40
MY:$;IJZ%.WW=QJ\:#.QZQTBF&E["]\6(8?S@_#;P*;T0F-< X\B8S"*$!Q:/
MZ2M@H.#>4.X=##YB5FZWQ_ IQX%5JH!WPMW(K(_"CW#9-93IP])798\'D>-6
MM!/.T3)U;EWI+=&MHT",; CZDIF/7=/8<3@_6:YLPKP3+C3>P[4\K0[V"HYA
MZ;I>1@6P[HJ-L=NJ.2*%"MA:L#WJ?'3#2#T%#!E#Z'@;UVU]62N$:<%;  ?_
M@000X0HM@K@\X9TVC(*'V2"=D05^$"="/,QM##0PYOU#0L)P'Z)#Y(6[9J6\
MZU='L Z18]AJM4BE(W4?Q-]&V(>\_ U+4!DAGC_9<)_-;4;834GT -0??94(
MS(6L /F9PHHU9PNJG.!:EJR_ AYL)+$*SPT$3.2 KGFZ(EJ/\%#EON<$.R2!
M(X1HVVH$_$R+]#F4C[YGXC!W"Q+Z"G$5YO!T63P>CU05U1=_*!29E8:1N-&E
MJYG(T4+#3-A(;##5ELEVV"B@W1A,O9>P57[ZU&Z1\*;%9AT27L%"X0VV)Z$J
MT>@3>QR5$HRE0G6VW^$[1V0P\IUS;XW)X X9=:[[ALPL4VUH='%>@;"%)FV[
MA[31#,B(W& I^.:&9O67%1HXEM7 7X"'R*P[1-;Z_J+N%Y*'L-47WO2Y"_S<
M,*__N6!>?SF8UP_9A-]5&Q3@+3@@5I4[^CZPUU?AT#N%,$QDG+,'*\86P6H*
MEG8%OM$0;[VO8-H?&FKEEA#VS'#=@Q+-@?@9__C'[U??0L2 J_(UU3'#SPB1
M&3Q3B$K&FCHB&.27?7AHJVLQ-2;^*SCU<)A(=G';W:NO55+8X<$72=S]]UQ:
M_>UGGWXBZ_ *0C&4. J_CQI*1RXF#B$F".=IR#E_2V?:0#*8#]S1D2F&  2X
MV :B80N'_!9]\"9D7_LJ.IH@JMV6/9^#F>M#UILGQ&8\UJ#K \EI6'P)'Y.3
M1<4_$OH'A<@@9#>ZFK#7XG$FC,4=B=H%LPAOS:S+8U=(P1:#!'J,>B,'%7JF
MPMY)7U_?@2-C8G7&-F\EA7"*4:?/3,5V"%CA7,4S&(5C/OV/3U9;A!3!7>U#
M83\#J=_T)W#7T(^=0L#11&]:]I4W38C!&&KCR=J(4N/RXM*NVIY\+!IV=R7L
MV<E%:4"3XSF^KJR%8VDL-Z)2$^+%\-N#CY,T/H'J"6&#X-)24L>-EK/FCBK>
M/QVK+=X$LVM,X_&3H[E2,!*)"W*+@K\>I?-2('+WL4JF_"(D=@@\PSCW&#9_
M</FT19--!)_#0(=-V$FG<L^!$3$O#5&.)1'3&7]3%]+6%[@,D>:.K4S'M\FH
MH*-0(D&G$5?,&%K,+SNU,X\78WL+[F*D=X2 #DM;-06U>$2&= Y>"^G\"@Q4
M6W+R0R0"0>24++SP< T^7WXON-> CON9"1EWKC3BJB+YRM+E,H>]E6PAN;"K
M4 S,_RNM#=?U.;6'RCAFVZK:"I%K/?C"B;NR>6VV,<QHL4>/H7BVH&LLQG@Z
M(SC/I:+WMQ45PWI)]JAEAH^Q]77AD#CGTU-3SLY2P$>I]O2R]PC-=>G4N3M9
MN@'/C>*:KF!("8D\:#U&.N7;3@OZ<P7N>\LL??_ "6K]76GFA?31O@4\@#K#
M_(/""]6C++3?Q+PV4;5[<-D="Z>3X@F)LB/9R&FF=J-=XYD'H9)A1I,USA9E
M$X7WTX)P6EIQ:_&<&_V[&:)FYK*/.C8>2YZG^XW*^5^$[]L=0FP!>=KJ5_!O
M#$#\XHN7 D LN%3)!2HA\@[76M<A)=G7&PF*&N%.'0Z (Y/^[+$[*H]PZ2F<
MM8).PH^3!T[*._H$I>H'R!-@>:&-6@ED<=XQNIIOCWK&V>(NXX&3&G3N9[D;
MQX73774OA]EGGWQ2A!0M(G$.;N$$94%]_2PA,XP/>$T(*LRW*.\VA$T(K@?V
M]H94!E:LA3#0.10L,9QWFUL.9&Q3>-4%L>SL&[$8)LAPW&%):7V.90MH:3./
M_D*2%,B@HFH0!FSZ<<SWI?T>"U^0<Y[E)S">JT.PE.MIRKLX#DI;OO_+WKLV
MQW$<::-_9>*$?8*,:&!)2O)E=>*-@$A*HF6:"%[DX_W6,],#M-#3/>X+H-&O
M?RN?O%16=\\0E 797L]^6(O 8+JK*BNO3SY9]K 2XU2?#O#DER.=KCQ'J.:*
MEYUT.Q<_ACO5T8B=O<H'QJD:8!P5*E)+_&8,7O-COSW0W1&)V *Z?%M,A3KY
MK<CV:*FL0&,>Z]!%*G5P<9J?[*.%\7<G6;"YOC:ZT7$]1WH4&0@=LY')NFSU
MQ]>4:;N0\V7QO3K2M;LF9FD.G'S)8\#R6W9)Z0;,OJ2]#ALOC\ ^?NPD)QT\
MAGU!G0#S-^#"^+&$[]Y]0_1W5M?! >:*3JSOO;S@5YJIM&;*J\K5.7;F4,9
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MF%XNP'-OI,,Z(( \(\:<$/[>GUS9K]Y' S">ZN'\OI'BF+>$; X.[PI>D,,
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MGO/@&VDN'7Z3'J">ZCDPM_2PNH\IB[ /;6\;I9^-ZIO&V^>8"D7HU'%V$N^
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M21R/B:-C(VLHNT0VORNBWD2,%\SN NE82:4!S4JDU"?I.DG7)TE7;FVNA24
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M,"Q^1":&C<<TQQ5B[.VN%SW*GX7>[%;7X>IS[51K!7M_PY9%76S*WA)B3 (
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M.L$SN0OF)D1$:T8%AS_3PO:2^=KN>$/2''/LVS:/^ 5EHM_BKZS$C+/.J]7
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MM'DF/+P@[6*.4)3:5_6&;;/MPEOR$;%6Z2G""%1%\+]Z:QU%#VI-WI44:%$
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MD9X8 :17/^N2&<%'FG$FYH;WGC HKVO"&(-=!/3NO7$?^0UF A>>XY5,^'(
MI@D9W(QT/RK.K\X99C.2A/$1PF5EK-!C-)T3=H12ZVT/U.:K^HC$ [=E[^@@
MNE&#V&@C0DIW\>I^C)%3#@=[\'/.1IL[2IJ.1O3C4KLPXEW[-IIB_?&#9B8U
MR;_8EGC5<,#!8-'\)["JA64/=0G?3(K=.F-5=5GZHN#BZP1V,=4W\(5&/PL*
M=!5D5419^\\**<GN<I[\FX)59W?']F[F&<VF![2!@-V[QGF%MA997AX'$C%\
M,#=/LBMZY6@L6QHP=&PC%'KGL$>TSDYP4E=N6J:8BO'&QF Q_6:=[N=N>%[O
MQ^;V'A)IB@=,_Z3@@4([6^[/@$9;$EYV!',.AQ24YYU4T94:*.RJC!- 9RC4
MHXXT)&'G)K5]XUJXZ+4!P\R ^,1O8U-405"(LC8&'UEM^N>Y+4DGI,?:<.=(
MP%WYD)<,]33^RNR(9<Z,0$:>>+YX$=8[*!P(@X$G!O7RJ]= &YG2Q7IAA+1#
M#-U= IGE@5;N-6<7+7N&OMG-(JP#'H;#0;,T$3C3<3H!HT <*B%@'X,A\^D]
M=0?!(GOD#("BLA'U)>C&E6;D@-9OO?"I@)XO7A+I#B1/S[_H;'=X, ;YGX?W
M)M)RT$MEV!>]1O:'^7[:6*BGRW]&HY[1JU0R5:0@DZ7923]G"U!J-'>4*/((
MW[!#M(IGY#C%9?MP]^(C.-(A[\)M! - SI*>D]R&8-#+V.KK@N4-'GMT=.S-
MP;"'%&?;8(XHX?F&0NFC$&^G+[C<FX%G#6E#.<X7E_J+N^MFP2V\-@?.^:0;
M:^LPQ(-Y'D):I'\(H&WB%<0=@0J'CSW6\;9\[+[(VT*H5#UGG4T97T\H/MUJ
MV%<4=!"HY)- \7X67S"X)J7>-9O:#/*<G%N+OT)T[;CJB4(]=FLJPX!'Q<<7
MG+Z2:^WDB(!:MJE7@OL3]SNF7V <C/([P@YD9A5;CCQH>W9K1@=C);=EIV.B
MIF;_'8/SV;&4_L>(&#M4>+_7'G-3[4C_24_6$='\] ?1%Y .ZHJP-FY;=&/)
M5(>X(S%K\= TU>$Y:-="NXZH# S9%7TTH^*/J5%;O<Y-D 5K%)D^T+E%DM2"
MWG!B"#9E]=WTHXGH1[>7F\6)%A#<Z<G+BBN8V.&7D97]WO'<7!RL@_7\8*MV
M%.(R[ZY1Z=(_.0B,0YH<8#/\' Q*I60$8E9N(R2GVF8;-=>U$0J$7[97+%8F
MC>#1"[_?P@ZUDG7HE;8W>4FF[&6WN>J*.XUCQI@_"L[B&\_MC:M.\-GE_>%)
M=2I0X:6D(Y]@96K%UJ[+'K(4!*)WBLO(.:"097L2V9*.9-L/:>&!1[=,BRC:
M_(;I;AV:R_BMFR+\JMF6*TR9$O(0N6/I22F,]Y KOA'+0NFPO)7A53*Y( +K
M,'E$O=%[!'LSV1L9A*)W2K/&:1I3(]JI4=$O$I<(??[(($Q6),].0O8C40ZX
M..?TN/9JF4;(D@6POHWN^F&]B]3-?9)GJIW=8J7],^XC&GNI!4JF6K*&L!$Q
MFC65_-"1C/%T+4<#+3TO@73^BDUB_9@5_0 %^D%T,UTDP-MQFM/1!+.43ZP(
M!?G>3V<EN'D&LXD;[\LD>>5/V_=SZ7JXQP0&'+\,/:D2F9[>^)_Q$J"OP9B2
M>^61[G,Q7.+0M?#(_#S8I+QK:N/WK8F#MPN&(S,BAOW<%Z A/M)8S+ISV4B5
M84]&=O>@:AE=4!FC.><+6/<B1PG:!W),XEC88&% '\!F[V?D9"'A3;7FMR;%
M@-$VGS KX^>6.T[$B?^"^*K?G_!5_SGXJG\@>_[R0V;%<%)?<(^SA3F<(^LC
M_@ G2$:=(O-JYDCA^AXQ+!JY%2FAO1+<M.%,;L')TZ;V'OG!7J&T2RI94>R'
M$V=PW%,FPZ >0K$BU69<-6GO1QD/R[*U20R6<CT!..(GW4C!T[)3&B8<K7E*
M;QZ:+ZE"MJ4-E4%^\#DP#ZN7;*1UDTVV#,W:?]%?QW#5CQG65W.Y-;B 5+HO
M6F:6+%TI-_4W\M5UY"J;;N'"T#0?77/:XR?-;>'V\.FX$UF";)FGE==49BQ%
M?K8L=FK/L0I&GC @2,=A*87?IQP#@@E;NHT-E"TPRG%S.+X3=R)?W!1[\YER
MXR>G0''<D<GE+&0M-!6*C='$5&R:MB/ED6N+=WR$N++R^-Y(O2G<S677"/9%
M2]>9*B,1&"\80"6;#I\$W\B[AL/?)A2P-L\!)^@'CR>NWE(P/3X[S7F!_9A$
M6_/21Y:M?)X$UM#8&R0?P%JXU<8:--XN[,VRN94\-A&04:9[)TO7JG3G.&+=
ME4CRF[B$Q1U7'C#K.NXDI6$P8;#27DH1O)QRU$4E,\M(P_-V*I &TV.T2TU3
M)C9:B+S,+>ZZM<[9.=D7E9T6C[)P_KU)0TQ4*\$5\5 9U24>4WLE+X4[R!?7
MR3%6AF1:GSZJ!4M?,_4T3^%O?IJH;"1'B!W1*^Q'4SZ6>[G4W C/4_5&UQQS
ME6CTVUK;\XJ2.)APSSLA"TY!#+TRB843JBJCJDEGP<W;V)^#"/MG(L'>,@^R
M\K8D%+QH\K A',)A0ZB19C4R&4#=46Z.8S  -M3*B>JB-!T-P"1&TGA"F!XQ
M(R.Q^BE_$U%+HZ!,JU%=C+5H> ?PD>)W"(GJW'-28!JWTU?3IDT_UA7327BT
MS4/F7R0CN<FEQU79;F?#UI\)R],\O-#F\;32]:&SBF2^4JH<=;LV]2&6FIAG
M/3AS+R(IB/VMU<Y=C#I0#K/7KVV44V0MWD46. /[2J8)V6POC39@6U@GY'4)
M:A(Y;ZG\VE0%P?G:^.-XP_D+PS.*G#BB,&I8:39JVW!7(>7#JR-OBNT+-OIY
M7N?K/(OB+"RP"7^WW^CSE(2#WFE^I99S@ 64UG0=E()93<0JTR<,D**RB<.(
MBOY!-^K)(Z.M0QY11Z&.9\I#.<ATV=T8235&_AH$0+& 0$INBCZZ#-CRE"@U
M+58F(&!?&_/ ,1[5"]S@FSHL:-<++]-G2H(S62@M$I@5'F#)RUT96$0Y?MBT
M-(YRTW_CUR\N>*D\RFY,KL,L5E:V]H=D&Q 'VRUF*-Z=D.AT$\#7[3F93UZ]
M"K<[B.%[*D[*FY>1D5HX %*&/W<+QN+/Z/AN6))F]_*U2QAT),&KV[$!<-M*
M60G=UOGBG<Z7LO7[,=7CI2446W:4RI!L]2G*3NQHDF7E*/KI$@QE#"!Q2UZ4
M,OCV>=!VAI6-/T8BH!JV2P+KMSR\!$S$]0]#S<G,ECIK-\+?!J3Y/ <RK4!)
M#>A9Z[+;EMUX?B/1+4\(.EV!W<-EP\=8$CP_)9Z3<K/1#;L::+ -O0?^A*0"
M.HE0KL&P,97O-9WH53&Y-%]XYBA8?B4Q92G@"KW(G08?0OP5]<ZRB.,,'3N<
MJU=YRJ=W0H+V](_/?J];^*X!##?\:L"$=C('^9B72P"1]$3A.^TCVQ\>+ 9D
M2?1*GM^=G/(+R3Z_]D@><# 1_1V\?">TG?<VZ(E)SGN67*GC7332(=[-<@RV
M(>J,00F?+)S1MV.&SU4(?@3U\YQT8$1Z"T'+.\,41.W$\4K*L1>9M)N@"1!-
M#KUPL ,-='TG5?()L966QY->&7M?O.?S8,+-:O_EQ?/(.\IU#WJML]12)AR<
M--,HB/Q5B>H3YH(P%5G#,$.*,CANST=^RE[\=ZJ3Y9VI'D4PTW1.S2&,_C#)
M:?'FT1 ,GHQT_PD7PL'3V>X[7#F4:]/><$%[HK0C[A3*VW.W)*J7V ^=(W+<
M9'@ZM=<\^#"J5Y(75J2>]5:)XN!#^+W7=8P,@: T$;WE: A?8BC?^N,6(VP0
M:1Y;N3+<L?KY/&/YC8?X=17^8YV;4S'W@!E+>W\+RP&)/&;$1,X!$!H'R,X0
M ^_9*SZ#MVPG;(@AQY0S9'FT'GQ#>-6:%"1)88*[]:]MO.!PN,\YMDA9H"7=
MH6^OMQSORO?:9JXM_L"[NA!F1J3N)=\A \KR]=XR)N66$A6.MY1R 46UNX]Q
M*3>Q4&BOO4G8F<GB\3:#$E&Q)=GL1J1AI"S64Z!5^WD@?X0._./-<>]1Q;6D
M.YLA- ;0NFPN^\2)P2=-X3(>\*8FW'<"I[6%7](-J0N9)HIM38-J9/C#!=ON
M>FZ9(&+Y/ID!VHB28\MHC)],J9I^6T("G;J&YXL_NR^$5Z=4IEV<T*/5[>EQ
M85-%G41V0!E7X(_&>03_P!$=[N40O]?&' A>5$9/"!0H]OF=RJG_'N74/YS*
MJ:=RZJ=F/-] 4[XMNYLNV&UKJG@3U,17.B]$G#+$EK]V1O:OA;:"2CF ;$4(
M:P6VUMV$J,'Z3+NB+C$Y+5]'RN() HV)\=*1*(;-87,]Z6H,!H:@,E+]@FV@
M<E7P?+NFKHOJH9.?@C4#)S.Z@99DE'JV]08@EH5?E[N,7HUZ'ZRKC]."\SOE
M,\STVQ#OU<366"U>FJO/(UV#\_<Z[,5UT%C?$*-QPH#*5E>^VH($XO(TF9:1
M$U;H_#ZO!7"*%H0K*N=I*P(%)^'/>VF!HZE>A:Y&$%DL ^A:AX^)3_5E5\RO
M,VQ,V& :4M78R(]#EI-<%*5%<"\BY(EP_8=:9@>Y/;!V$%>S=RCZT>LEVZ#9
MU9EW;N1UV$LH5CHD!!E5_8=[XJB7-''<Z&H+"#-IM98I00FE&E,^AI^NAK9E
M:*J-\Z6-'(6)UL>F?!1-\'>NT*)1NP0GAXU45Z.9(*6/G'@K$6== ;5>%W?D
MO.S >4[9!!9#XR,76O:[@FL#.6C'"RX3M]!JG-L5CPYY(]<\YM=C+^.OP[J4
ME#8/IXK#C'M2YV"I!ZF"*A(06K<T47"3EQ4 RHWSYWA#<4\2_<&LM!TTF9;H
M.(5@^HXF<\;"!_<(C 5%4GL)*L.ND*4'2PED=3A<G(1&@4P0Q2*":PU?:$/<
M328F"V#@)4L>7^R'U(IOYA4^O56(!:IF7P@41KL><7UHJIBTBDF+X0"R82J5
M<A_?BSB#',,\'+8W?B^U4L0Q<;Q:CHOU%//D30230U#9144]"*V/[&0>C[=(
MN%D1!9]QQ"9-1 :UGGLUE^"F-T@PPNG8%ZL\?1?^O0Y2_(A^)HFJ#^??G5M]
MB3;V7=BMG\*U#?^MG?_4FIJ,%G&%=M0(VWMIMX)&8S1Q1^+]L%4=IPN(\_,2
MHX[.^@+S7&W\>@R(>-^I1?*M'X[8\<";VW(]Y$):NRPB/0<UJ%#3VKKLVF%G
ME6'+36"^F"2)> ZE#?%TP^TGYQ>EP3U;[IG=6X@K_3DY\&L>#RH.D)3QU$1Z
M7(B8A6QQE0/:$T-VY3*VUIFD6C]C%_VFI^H(R(@V,F)TML1=TU1S&D<VEETL
MWV5(WY,M@%;*3-V0?/7<->3RK*D+1E[$NF' !ZEZ^D,1YOA!375'RF0%GX]D
M]X#G8(0^)IH/VX=&%I3J)61$:4H:]'"\[-#(6VE&AJ%F<%#FV9NX!L)#!=&D
MVA&O",6GY)YEKO%<FBA5?Y 4$2O^'89G0;V3-0'?MFA+2@-A>AN,O;T7:23\
M<33[![_$&N(2,(NR=5!E94LU+P4_XG"N;:IM1/HLBWU3KV47>$R@7DVGX#$7
MK79L1ZB6#A2KDQJ&&JN&5<O(RX9P3))H4QB\0(R"I2BZ7=ES)*'LW&8BW8V>
MGELVEK;H663>GZ7W]VX=J\HYH\9?+2T!,U;M(C@$X(77PW9_ $B7<MR06ADF
MVE<EPF9'S?^Y-JIMG#;/0TR'*57V%\9.5>2*4Z 7E:V(0B3D7@5&JP[)&I.U
M>8\6Y1WV:+L9E];/(I"8SI0,A$6U#.&\""=+ZC4(X0\#:8-P;.7Z3&ABP$T#
M'1%GY%@<8*L_^H>CD]:@YI>/*C\AVN9RI?2Z"S*$;7EDD+=[Y4R.64BIS&)3
MV*8&[7_5-G?]=8HP$A,:4< /3L6RHEWE]+T)NDK$.KZCCU_8&AV9%>6CH\9R
MJT%[!9F3KI=HL*)L:TI79*<D0#N/+U ^82@E(!(UPHO5@)'@H)^SD%&,T<)G
M<6OIZV/M$I]CAJZ8M\=9D7ZQ_D]#-_MS'>^A&YV9T6[A?S5^BX!A+1""T"^:
M[*]YNWCK)3\OTP.<.8BZQ/,1HNA3Z@3?15,G6C1U=%6@]6UIFU;M0)._U5?(
MG(L!G(B&H'/GEQE455,",#EA=]&8?Q&T4.;#1>Z$$X>,0DH"\H8+@/H?R ?P
M).N()9R&A9C>AN[CV(QUOC_KF[,UV3?*744.L6 R,!S6YXD\3:KP$[@K2BI=
M#B%^EPG"*('FDV623 .^GY2%)9GL4H<O;!$3D0:O>TF91'["B'.Z*_*;6DEN
MG/WTI&/!C07HA)(H5'Z/ AY4;$<N.,:N<PQFD< H7Z._=_$<A)01V>+XTB;L
MA7.)?2Q,X3"W#V9GD\@OZS4C*7&@+2$1Y;;I($Z@XU0M*@)ATTM<OH!!B(D#
M$EZ/ICRY[GKN*$B2/[-=*F-7@]ELCIPJ9FB+5L3QH>E;PFJ;M V7":A25ILZ
M-&:.,CWG 2'TI;'^9,&9G$#F<D7K VW$QT.^?7(Z<2S,."EZ$*I\("E(VJLO
M5M>UL) Z2&.1;*!0*[0]Z&8.Y-=F=MS7OA/9>F *Q]JPCB)D*17!"(MN6[ ?
M(^[O"MN.G.)-0>5@</.FY)A8$D:B-$V)PMH@ 4S=.G9D\#]ZQMS+;<A<?P'E
M^-+&9K5J>;CF]57AD<K!$T'D6VIZ60)K"._ 16VA/6#F5/9F(>"<""Q258('
M+0LT&!$:5*D4:)>((82&=/)HP_/%NY@OFGR-1$!X4 C+PTX+F&8T]MH+H\.
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M8RIFO%/KP_U30?U0"9FX6/.>Q5[I[ 0J"2,0K%;9&Y,J@$.*&D^:Y;17W3;
M/5@G8^$^4 ,2()U8%G(I\8,RPM5-O(V&/VD*'6Q"KBW<>PZD=D8;86.)NHCG
M#K8YN!\5XY7MAQVUE/@A])G-H\L!K"KUQ^+#\,B,33(>VKZM)VCYJ$6Y(&
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M!AD*YATD((DD"_T/SHB5K&EA<>11'6"\Q+(;<[2CT9I8I5Z27CMY&%%3.>I
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M&Y+4C$XAO'PD\)<&3NHJ0@^&I/^86SS8IP[I?P'E;")*E=)J5A2E/H7;<CW
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M#L!.)NHF'KJ6=^'0, LTU?1):RB 7\?VQ3;* W!^GM=37*%L@496!WY<KZG
MH\1A1 0&"TKV'B/4A-\1):QPNZZ;.WJG+I6Z"9.$5!IBXJ)8Q\.7+5L;#1N[
M9&D.+NGQL9A^KCU@[@@TS>8'+4>?T^6-F2%5N0&59&UTUT#&8@[+>*UYRG/A
M.#907F"GSF&B;420,=3*T]GO6T6G&:E%Z\*%GEE;_[FP[CUH1/W"0R2T@$6Y
MA+@ARFY#(^"U&R/$!Y1#6(D[Z;TT80%AF!/AE>=V=(.ID4AD+0LC%Q"<C7!
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MI5-/)+,18BP(2KQQ7=$9I^J*PD_ZZ6#CZNK.(P#KAJT@7+O!CZ2:'F9L(%=
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M@6LO)X25-X %(*D(]R7%U].+P=3[>H3B#9,<&AKFL"G1:""&G@>V;BLJ+-^
M-1PE_ =+A\M!Z$2R+?R+9N$1N)#L08J0MNW*)06LI.(:DF6II57#ENZ,N@._
MF"05P=_1U_/U^;:CCH@JZ73HVD.Y!0WE,3BX6+. (]P27LDUS+=[M>>JB^62
M7+B]B>-=_A(+0LL#;2Q>&%=2T"[Z=04*;SCE*,>,&3$K<PF9OGN7;$<\7L7W
M(@1(M,=#L PN2=4MC((W$RZS5'7<(2+AK]+MTM 8!5BZNR]-W[B[CY*+TW.F
M3;I=!7W-:X_FBNZNKC+#EYJE5=VMQATW!:%N@=^O$=V^Y!W1"]C7:(%K*C>=
MQT<P-_O3^Y[3JK7WZMAE)QTHTAIY5[GB+'<]N>A?)F!O^ELG;9$F9KU-*<XR
MM]':GI%]]M*&5NHCAX6H >0T;@]JK8>6DI<C;C3^\YCKV*-L'!.L_ H@HV$F
M! /['#ZD:VDQV#KK9Y^822W(@4=1,):H[K!HLX:["B+Y3N\MGUGU5A>1@@U?
MU/00BP?%>78.L^Q @7*^5PCHI(+6>/FL*W?9<1E:"E]H1V!^1F8BQ8LL^U3"
MO=&04@<B<INC=ESC0;B6O"O+/>3;J"!9?[R1ZF2XRI$,Z.S1N5W'H T]6^XZ
MP\Y8O<'(?W4!5/3\L=F*T Z&K7:MDR:TCA_G>O+]!Y>8$:/N0J)EW;K1H6L[
MIXYB19,0]=R&\Q?^2[L3"B'8Z FG6_V\8%5<V)TLG_2/$6#A$K5",(.7&^3S
M%H>J[#BXH7N62GQ 7NI==:._I0#$Q+A$A)X$;%X;G/"MP-86/V!/:924^.N;
MUV]_L+0$W (8". 5#-NASR3%$0(<-O=-A^&<N_A<6X>HW'-A(UP1!U)OK '#
MOCUD/$*MYND/B>$OC^&@<H 5NZB(M&E7$</3($VR\EN3G)#@5IJ#6WN60^1Y
MJ6*F]?"[X?[;X4RYRX]J\P*?(A4U>BLY/$EA+@KXOQFA.EEJX3:\KR<U0GAS
M[ZR^$[_;5<-MNZ;1>>TCI)\9P\A 7OBP )0136V<$PN_A&[X@Q['']A+)7N#
MT^MZDWR X>LA G-+DB9\=8'+$GT5:16\*J$%2H *H/H69ZZR:2K^ 'X%SJF@
MM,-?^E;\JM8 ")P7,)&$^-/,DPX"(NQMN6>H]V9;&^,-UES-O,J(O..>,^IP
M@4:)H01&YB %/=,18)S/.3^'^@C[!]*7U'4"=]FVO FS?ELSKINLF&\-EP<5
MLQF;;-;57+KH!* %&0Y[L+M;/M+P\J@I1Q?*DR\D?XE%!H9.%L(;AY<G=LZA
M(6)Y1DQ5;40_E"]!D)/E!+/VETF+QUTE&'^:>7!#J4?#05 W==</4@I/,XW3
M=91^@F@EA2UK[L8V3-NQ5[)7P9ULQ?PHST@Y'_>2"?S A^2%I&,T8V-(ASAS
MPQUB(D89/C]6<42D\-#PLNFM&;LL9^(2+3$4YX3X%%#PY^^"+$#^/D!&%R\R
M6>#[HQF32.<D_OC%;8GP6:BMUGP;5NY2X!H&W-9=98K7Z8=.G$.[<6&61<H1
MOX)+ZMOL?+ +S5"4W(P2F&[U7=G@(>\3]G?PG.^P:[#?*K A<\?'4I]_KLK;
MP]6;'9B#:Y!A6Y7!.Z'FK.NP()^PMS3Y[&H0WTGZOJ1/A@VZM:_*A42,07T(
M7B"9)F\05^SC0&&FZ@%?\^5V3+=ML+K&2Y#>"V^GKX]*BN#,H+$"\LMP^X=W
M>%/MAPJJT(LGGQ>+IX^?/.'.1D1[@-UHL$@]D4;E[1J>A'ZH[4$A,>)'4)37
MV^UH<KYVV,I#?O2=31C$D,$AJX!;R%46^#A1' F.3F64HKP(5R8V7B(;K=!]
M6>X! CB?PU9[Z/I"TG&%C[=WM*P&5P_N_"ZLAK9JR6NR?XI>.&>O4K2OWQE8
M[(K8905<>/1--0Q;'OBG1*T6?5EH<+QB7][ &1$OIGV"<(W%8EK&CO,4'_\>
MC1):T$J*T_IM\HV[^ITKG3 F1,=_C3?\=XAS??(9;L)GA</^)3NYR!BX(;PR
MQ7I4SRGYJJ1+D))I>&?V!U!XUQIH@26M':TBAU5,5!4>/&(F,I:I[2!=P>\P
M\QM9V)50L<*=/&SCW*RSX;CV=G<GPI'BMY31GKOC2$>] _HZ90_5/W&I\ZEQ
MD'BPAI@$.<M<*M19NO>U<\Z^9>NOQ0R8-2ZY%N]E#@NI4V;%A(TE($,8-4,N
ME?!(7<!-OPEPTQ<7<-,%W'0J<YBM57(+;# +4AXI29@;4SQD_?O;>C^)IK"F
M$\51A184*%2$/TUB14Z"6'')@7@Z#FGXNB#RN--=D]0^2-RP7<2-QGC]F.5]
M&5$H^\L&VA]TDLS;Z8^X.Q"WA+>&:S1,C.(^<I&N,+C1C=B[WK*DU4DP5)2+
MA0DR5UI+IX5S/<"4.Q#'/^O73!PEC<XVP=6"N7&NCH8FX"A[]'&<%9'U3OK*
M.*QNHX!0_G+#X:CSIJ+ETLH^\:UK+^%<HL('\5S0I&1N O\MHP1UE-"$"DGE
M@X)^\8E/57_?!E?ZB^+Q9^'_?_YEL?BR>/;Y\^+YL\]PK;\LGC]^7CQY^KM/
M(]#0MM[7P(_7M,1N!^S5+13N\$J>$D64-S===:-1\O3K'(S\H6H(J_1FA10]
M_>(/N^4?L94NV$T(E] 43#_VYR&<)@D7Y9\M1M1*ZO9@4XPI@^MN&?9PO_A:
M^):"[>OV]BS^=TW5.^1W7"XX<P-_])&SH;29%[R;?>L2[U0AWP\!Q'=M.#U-
MB5FU<H]EDN EO6I6]J[\$7U7;M%R4,FW1 P85N5ZOZ_"?W[=!G]6\_%H'^1I
MK\,M8S-XAV'UNEIQ[(A),"C>!CM"IHM>7^KK:4CP FPE_!#]L)*++[X-063G
MTILOH%1?#U&UA#\C_R9O1<YS\H\>I_5)_2F2YG2[BO:AC DYCF0PM/7&/0*7
ML N%H*_A9>.#XL[)5^'9YSU<<0B8D!*6SME?L.,7]IW/^8)E#S_DUICT]&@=
MTY*R2VN[$A6\H0P4YG\;G!G,)$ U2U*!86#O,;+C\Z9FY-'B6N-HH'X($>*D
MY/+)-W]UW]4Y^.;UTZ>_^_+I9\_O98H2NW+:$-1]>K*!(\SP/W8\H]-9=6$J
MWP0+LE_\_\'R?K5XV=Z&&_$%=W]*%D%.,2^(#IW'RY7"'_3G=/0O:\K:/+*Q
M(-0/*:96E;/_F']O#H3, 8HXNBKPTD]N%2Y"2WM7]_"E8"FU;UI)UW"Y%JG,
MQ7/AG26);G?=L9@/U+RMP%E!+5^K].O*J^CZ_BKSCPJ_C'CMZNP)IQ6**/CL
M:I2/-G11,74."DI&+29T(;& ^?URY$H*5R%1&7 @"3W<R(IU0#*V+P_2I3<J
MUY[40R(U===.K&1E^FYI>YU/$\RWV<E+N([\R%E-/:CX[;@!&4Z<]1]CJVI)
M U)\F70S^.*N4'#X%FKG455]4OAF.IZ3 !H/7H*TIM)2G0)-HR$QP,W[8V!X
M!,H?/UVM6;VXF;WT:/$&^PV-)21&_K)<F!6?' P(?B.LSKHEFC+,PEC9QE$O
M'&MHF\,)9\M /E&410OW TR*JP.-0@.3%H0$7P:/QYY_%,F>(7*:!RM2@=
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MZNI0>%=?MM%E&QV[7S5+<>ZURISQF*B#?B%$IBE,B9ILLP^][,3+3CQFT+R
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M@;,N<"U5''&J83CY)%MBGS(P."PP\]1(C"&!Y6P7OU'QQLH#U ?$^21/06(
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MTJ=>L@ 'S3<1UA>R)0D_(>^<L)QXJR.U&R,4]"ZR%ZK%.[ J?ZH:>:Q)/@B
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MAM0SU#TSA#^X::1<,V PA09.BYA0D28>1!!%W?>4;4Y65A!O]GN4X%2#SAZ
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M4@1?;-X\+"OJ6S+1-A$78 '[ 3Q&U+PF=QPB@.9 &]:+::]#T/N.#AE4>XP
M/_NS_@9;.@D@DY) 9#T98R;+SCY(8&31O:8V_%W9H2)U=GJU,0I-LD?K+@\6
M/RPBPH0$ILP12H>YM#*M/"7.SI)$(8=N)&<!.F6:IA+ZC%WP-"O(R,$V7]7[
MDL3&V0H).P,F?NG/J?Q2TO= JIHLP V2[H?X?CNV];#2BJUN3$HS%\-0E4L2
MHZ(I[&Z%,OL#Z*9OZ"8!B;UIKD!_@&JQ,XY-.>D H"F-+RG/V@HKR8*7T9$Z
M.D;2'T @_OR'] #1'LY/J^0,8TH\$%E!10[QGRC#+-X.EB2<&+R['>1B\"D!
M<# 5\(V@ NK U_[2"MFQFK9)_9_<2O%^R13DU*[&S0'N&5Y>X=HGDIB5DJ7>
MR)%7]UVN<;PP$7K.^ 09>$Z<V&V H_W_'Y!>^X)O^Q?$MWUQP;==\&WO2?@0
MWVQL3[5N'B%]K:8:)Z2B\BM:KCOH6:;4W\@I5$MHS2)>R)+6R%@>W&OY\2Z#
M;_IPI/4_"N($1EP'MWT$H ? I#%;!]E&\,: !T+001#M-C72WPG@A%%9&BO$
MK7-0V9C5$8\3B!I5%%&-L/6]%NX?'NF\77,M&R$Q&50;:1/?UGLJU!UIMT"
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MM^3Q$M;*25@8S),[/3 )U;&R(\SEBW87/,'%&VA E<1&O(4F_);^S%%W+O8
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M(6D<#;6OTO4E%&%3[NQ W!FO\W*L@0D&0O7H(.Q K].ZL81I'$/F\+KM#O[
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MN;H=H7XDT TQNK"RL,'V9# 3_]/B0]M%\R<FQ!_@ @%Y/10UX3-DC]W@P[C
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M<HH $[2S"C LU+K;'"@L5JUSAB=#N?/,F-WS"6ZYS=I2WT-G_B!2R3X*$IC
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M%\;);TDY 5S#0-.E/;W;C92&"*8PC-F,M=<.,QL<.BXGY8Y\[V6Z_%'& ?!
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MLL'2KB7'CI"(&&7FSN@3)[/WEG.*3S*.#5[N#.2RKS0[UK =%T1$RR[8S_"
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M+:QL#T1XC%,,9Z@+ .#*@B/$J+N%_!.S.5QH3J!B(&>0Q>==ZQ%7 ;X=<O(
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M4+3FQG;2FJ0/O(T(_,(<>K:MN_OB=[LI*S#RP;SOQ9::0>;&(H"$V[7/B:
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MB/"F:E##)7=KA&A;##(2K);0<^I?F??"X6\F=+7<0XCK6"0ZO23@N\0G60+
M^(F]C)NI#(DV.9P7_PFK]  ;B/4K8G96,[K86*NB-XVQ4^X;=%@L@GT'?V71
ML7"L:;;.Y "^%Q(^MSKI.=+O>!IK644/BT5>ZL1V[A*2=H5\UY9[V\DG4"U(
M;RV+EWK ?G;*J]*>-,*DX7P8>;L(>_\R,M=8\ 1YJ&OQRUJ].*1) Q$VR6UX
M?ZIA'[Y)Y\L^8A;>2\9*KEIN9&K K&H?(G1 RFM*;0KX8RBA:CT0M+F*(4#
MQZ:'\P@O)E4?23W=OEV@)G=>\QX:*SQFE0Y(=3C"4Q +A</75B3LLN?1WHV8
M6U&!D.Z#HP*J5"=&VTJ@N17_(BAN4TP!)HAX])%?%<[_$J'03*S-(;!@@GYB
MPH/6ENZOVS//T$@ [G0L4+8!XED4#,'1[Y"7HR<)+3OE1_(^ %CKU4J<@(4
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M>CE#NI*Y@_&'33?Y:5E&]O$W4I/LR!DB\^^XAV*?>_*=ZM/-CU7Z"H3.6#L
M?):<U\EXA@RO#'WO[/U=,E??Q9YC8G[_G'VJGQX"SZ\_0_Q85^Q/R>":]38)
MWY+YUSZ&VN-CJ2=\&^C]M&\#-\:RWEYNC4_-MY9VH_FB]']02P,$%     @
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M2!A"GF(/>8*E;>L'/63<47R#K<J!!8%UMRC!1:TN6=<;DG8@IC>#!A4:B3+
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MC^X">PF+[V57BLJY>Z0;1SR43Q4WV1._*@E+HB4+;N["9ZZTDZ.38[#651H
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M/@YQLOX#)XL_U]^NTQ>?#"D;M)7MB[-U2080XC*-N#<I3<Y;^4*>O&\IP\5
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M3!8K-C77G&AWLM_R$\Q%"AW*\$6 9O&SWCX43UFTB8+T< [W>YA46CS"QQW
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M-3W16>ZUNQ1NH[Q*VMCK)N,/QW=4V@]> HPJ.=_ZW:*-:9SE,!ND[#L/TO2
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M9Y#O8&=+UE9M"&Y!\ARAE<4JRX"U:NX!ODW8.<JU5=$Y2/$(>A;$./[B80=
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MV;^ D?EJ"%J5R*B[E>Q].$"[O#O>A"<$ G"HZD:C4CD]_&<9&XJJ1L=#&P!
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M91,U\384HO>%.:&F<@@TFGR:U\<IZ/KR@HR1Y.=!MKL+#E@_?+""0P*N8,H
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M5[8F/HFM96SV4]=*YK;G?MX_W)"=C>'OC7]Q_-WI:]6T#@;IHH]?IQXP*3V
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M7OS+XLI[N(N#)'.8+:_4Y&RH22?#X]GA2'(7',HLI%^#='-#2:UGCF&S)6*
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MZ3R(PP(_XJ*#815N=!S+<3M)+&LTJ'T\RPG78-KPL4 C5T_%7T V?G9,@'*
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M1^1FJ6>*^A "YA0N+9N8:8X@D&T,97P(5.1%TO@3>AG T ) ]M4 3>=_>5'
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MV3I_;HVI%6V?3K;=#,IE(4 OLPXYJ6WB2$L$I?X<)N?,*K;/!I/O+^"%3&U
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MTQ634>UI$LB!3;69NW/'&^N UH+#I5G4TD*?;OD]\4P;<?70$P0>L2GKK'H
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M"W:Q-)4_QZOZ$K1E?0D:LTW_.*F<G/RT>/-C[?#D+XL___2WO;6,Y<TV-+9
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MIBG\Y8G9/23M]YBMWSY-OS __VQ.[8VI9V5* [.*#CT'?DG;D@OZY^!F,*E
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M:!A6.04,SOIW.\*(?2G9CP5M%B867X+M[((JR(RB;+],'D-JUQ549W9&6\[
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MMG,+!]-ZRK56X-O#.BH+5"FA3_5_9[/D/R6F%;FX?8,Z5(L4%X_O4_+Y ZT
M^F=UQ3@M)RWQ^R2+:6GIWZLR>>*9S,Z38I628I=CR=W&4.::ULO9G&ND<"P
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MQRBOD-NS7 J@BA_C[4;G.".;)&-8F\U"MQO""&"%=\/$*'/M4.%0GCE'"\=
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M#3B"RGSX;$$T/@W9J;0B2_DU+TIJ(2'FHTF=2;DH4Y804>UK&ASZ:"5T_@!
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M>X&2#Y(-OBGCDA_)NV1.V%S)L $VD#RD&I1+NB=VD]F&9(+>C2:)FU([JH^
M[250(S*+>&]2T\2Z2@;)V61*O9QL:MLSXHQP)&TDJ^8-T#A;:7T"[A@/P/7Z
M*O[,8MAF5NMZ#NE&[THU QXIQO93[99+2GR9/.'U15920"1W:753W>\%OM^E
ME\E]'\XV*H=]= 8J[IOJM$[ !Y,63C5[[LS,1!\Q PQ;,ON,DX='=A S?L)Y
M_( 1+LIDPS+U4M Q)912>X$7U*S 0L97YF##GE:[MWO/T-M$&(6[ ]["(01
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M?:B?B6%WB.Q PM8V"J7L\8Y80I+L27ZA *^9Q1-EDI=+LA*[TEH<G0,7)0?
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M/&A@1DFY;$.XT-&P>('8&U2\.M)^EPQSQAWON(P1"S5:NSSAY($H5B]R%88
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M->VE-F9XGE63)]P4]VX.!=FR1=D^%S9U_(8;+@D82CKGJE;RZ@-7A^9,8RQ
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M ^@5&GCCQAX'FBLS:OYMT\^E(RX>->6C7$'[?&_^J[*C&PP&5V-',QJ K<)
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MC7B28@%RJ!D:W@U**.CP;H:[4+9X4YJS'@@T#%LN2&WC0PT8&?8>':-AQ9"
M5[I+#=8BMZZFFGC;:0*4FWA4?F#NP\]2:X2\6MA..R38J1O6A'3W,O79;#!-
M &X3Y\P/N'V7E>A8A()"7@8"/%MUC+(-%N48NJY0*VN4E4 (\TO14GYDL2]=
M=/PCQ"S4M$Q0?*ND(,:7(BO5J/*!*HG42Z4"KQ4(;"H+*"L&'"T ]//UAQ
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MXAG O!8%Q>>>?LA-D&)^NE)D2ZWS%'5TT4Y)9I? 4W\/A]$Z"CLY%5/[?98
M-3Y1'O3YS 29'R:#^7OF"D<.'M+U]6SD&<=.S&,Z'!_EKB%#[C ?*US(CW=G
MIQT2['6@4!/C;\AVC0=R1_8,8H'N6>@$2!Q02Y)3#% A:?S8 *YX)K$_S;8
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M2C$3;SHZH[)G]"X(D0P'AB+[ X5=FZ8R&!^SF64SO%C-XLUJ(*QF:!*=PFJ
M;ZB,GH(,WVR#D#="'?.H15S=2:DF=KOD3"4;/B)21YWB7K-![N5=*Q3R,7KJ
MQ$&RVR*CQPT'4'6A++LNDN]O%85+=]20\VA('O7(*XBOHW!F<8YZ&"+&/=V]
M!$W%U[C];%B\7Z!"W0RIH\<!HOPN2$Z$*JK9!45!0TMZ\2,0MIRO>AQ2 %H_
M34^= \86KQ%CTDL<@3 &ZBUTS@$$+H*"HOB!0@H7,Q (!/< Y#JD>)>Q"-)
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M=GL2,U]1XKD9\905H/5XG.J9ZJB &[F,U,F+FNI+61:TJ"!&G!K5Y+/QW,P
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M HV-[%<W @'GS2;AAC[^RV6PW^,5+TEVL=\GF%7FI$W@*4KI7WF],N$YJ[V
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M50^&4"+V_=PI4*XGH"Y0;J)P) 0#7?5@IA "N^RJA_ZIQ>\U7 N.LUF<5(R
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M^LZ4:D5-OC.I93+*T0):[E0SO='W*(WP^BI9S]_P856F&O^8!^D"4!E7-EV
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MHQ3[IMKJ(Y1G4JEK2:Y_U,YRS7NMP-$<UV-P'VF6ZQD@Q\US_:-VHFL/W[J
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M6+)RYP>IU=Y0&[]+-U7C4E&Z>O%@?)L<KB9'W[$/)GMC0^NNL_>J-FE>FI\
MGV>C1]!/D%?1E@W0:\1KB)^27P[R5"-M[NXF'B)9,W:"EU$6QC@K4L2)&S#%
MK@/[:>S,G7S2ML0H:V\U5YNG+:+O$0;)>\<#O3Y\8YD#C=(=/2B5MC;@C0$
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M9ONN5-3>Q8U27^-)*AG<WD!J+C?X2C5Z:Q!H-IF\SB9C8Q5.ZY4NM\5$[5T
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M(ZB/W1U.@L,OW1,YIEW6+-U<6*N6-C?=7!?)FKY;^$+&<QF '^7;._P:_*-
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M9RA]I7+?)/LB)Y]Q0N/'*E=06>I]L]S9MG$Z]^,;HO-VP,R#U'CCO=RAMUH
MV*6IPW2&*H9CU6@51SQ@Y^N*I4:M40F^VDT'+5\K(]PFT6^%)-O<HG4:W*0
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M[RI5"O:N&F$%W<6BMOA O*GP]_SU8QNWWJ,]#RQ-X6(-'6^-CB70^"A=A\<
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M_WX>X?TV2'=!B(H\"H,XN\"W^9K3@R#JME<EU,[VM(J4L-Z7</0W-D_#SF*
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MZ4^;\YGF9O#6'$C=G9T-;\L-Q!M4@^2!;/^2@N,I)29JHPO81-;L&+1W,%#
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M+G"69W=(;$&TN3%AIL'-$T!.U9,.=#7JU#B'ZD="/#DTM0NF=,%4[C"D!!+
M\-%G,,<;5LOW,OO),P$%H\_M/W6FTO60M\T@")CR"K.3\4^'@!$!&L9$#$!T
MB;S !%<J=5AT6>D?8MCV5M';B@.V?5-VVFSV^@'WMI4,"AW3] Q1"!Z#U^"Y
MSYL[,62FTK:=8LC\B2&K'^=N;K+OBS3<!AF]8'P,8M2.O%- V;Q>0Z> LE-
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MBS?\:"\\7;.7L$3 05RZ6BW4%@RY^[MR%X]T/'6D2#3=S%C*E?BK<. T!K'
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M4+G4B#GK#_'9_!-[)HV-#0%)Z^G"(G$>!W+!U'J?R<]!7W[H- :  [@T$RF
MTGZ!2%4=$_ %J,KS#)#R-0-6F7<!NFY6U$*F7_W2&KJ6,[J2%E1Z2C%U2C%E
M/<74992BD+!BSIGLC[5(PX_NI"^"YXX2"C@Y7=20N[\6^)0ARL\I3SU[U,3I
M[J@R2Q&=E%)63_W1\V"<E!>QC/Q2$-K&J5=,:\7YOM\2Y@0HI&DNVM@TYO:
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M)O\@U+70,"<N?;YB/R\=OG["=2[%FE@<F6N:_ML_"US9=&WZ^-E*&2'K$F9
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M4*5JI88A3[)27ML3EF77TY=Y>]*=$<!M\O<450G32EWSU2'8(> "\>I[G,L
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MOV4:_BP_5;!-T M-NF@\ <S5&TK#*$.K#>]1-=8"4K%4\P@0M-37 6 ])5K
M,[BA&EX>IN#MVB*,[_HZ[\),7N\\BS51O5_'<+;5D?XOZD2BZK_/;#_[MIZ'
M[$@M2_B*ZU8ZR5]<O=*OS)(LV84VS<C,<GKY$JJWY\#&_,E/)\%SG01#W<M=
M7$/ SH(U'I5TS]%\CEM.O/Q%W6S@NF7ZG<\GU1$XG\_I<#'?I?R"[AE&A?B*
M'-+G\875]$HWUIBC<4WO>*0_1B])M(E"4F@\UYZ\TY>3<T)V55J^PBD*MTGT
M6X$R0$K+6:HR^-H(ORH;_=09/N78>")U,7S6962U?OADKLC&=$*7$PKDL^E>
M/FS/?1J%Z)^8KNKH;H'I:*Y4AB,WIXRUB1S0@5A/\O[<S*^'SLQ _OXZOPX%
M?(BR7Z]31&95TC*4Y0]!CD"8DQ?D $]4T#/T@74P!8*B2OQ-33.4\NIMC\(<
MK:D+ @A__ (<W+$*>(8WJ<Q3<,9BKI_61'2I95G/PS :\-)!KMTF2D;$\@@.
M9^9<I7,Z1#61KM'&\;K4XURZ%W&09:M-[1>S2A^BEVW.V#5(Z>K.$- Y(QYS
MXP"@%(DX8>O <73CN2XQ9T48<2V C-B:88'T 584MF\=!#70P2WC/,_3ZK8U
M/)P(X4,!H-QF*A0R/<V%LKD0:G^7G0P%K?+2X;WUS+CZK2#;_ N\V^.$'D<S
M9D00;=TK$EH;H@Y:PIP3A32-CS2;QJ##=Y FN,@?MV0,LB<_ 4732!:%-9LA
M5BN&"-0?YDR&I2,TBY'GL?BP<8=AZ.WK4<BZU">;Y6GZDDU?*L9RV2E,TC)W
M$KIF:=ZQZ^2O@TTG?_SK,=RB=1&CU:82Y!/*MWA]D[RB+#^(U_T5H;M@Q[HA
M,L&JF?@FL5I*=[Q6""9%&7%O=N03FYLF+X,\H/?J?\/QFGJBWR0A<[*4TM4M
M%]!9GCBEJL=P*5GS*(\_M18"OKY/JR8&/58<'H/I=T(3#K,SO^K3-"V=ILU9
M_H5G\4D-UT_V[(*_O5F5WL*>19NMNGG=<VXGI3CB3+TL![;*.XVTBM$(F9.8
M)AM!] *,S0P:*7MOV! ALGC$3%R,B>V;:-W>&V5+EFA"GD(14OTX.?*X6FM>
M+C)T#8XW8"@#%1JB35+H.%"GHID9T">IWE\?E^86B>BB/"#/5D0Q>9#0'80$
MM3I%ZQY2*^HU@B=HR1R.U1JA?Z[D,IJISY "@KOD -16Y$>+5(8VED%G5;&7
MFZ#.IH 1.#& (HRX5KV,V&L8*FG"' AEU>KGSK!M%"]1Z3D2O;:A7.^=*/_K
M* F2, KB>YQ%5#V'@/^KI-BAM-39\*#6(,OF3-<(2Z^1/X-6S8T/,XTSG#W"
M_V/.\1D3)T^!QFG+(L><M\RX<>6&>WY#L=0A^,(GG<L>E,\OG/XD[HSY47O4
M;,XHU4FOG!ENF(^QY7<HKU(LT;Q+]RB]P+L=3LHC)HN1XTVV.-*@LBF<"P$9
M6<>YC4UFQ86RO8D[2_)H'<4%7<\\4HR5,+QZJW+F79,A1YUMBJJ?5YNA&*SX
M\'F8CWQ5S#"WH?V)+3]_9S-@. DM4%/=+[/6Y$XG<1V.H.1"=<WC=/28X_#7
MU;Y,<T4F$Z+R#4YW9)>"NE^8?D@Z15MO:I6BUI83X'[#D[317R+(*JU<'E4J
M<^WV[P&1Z2VB$:IE:QD"?$XB3IB45MDV?;U262]@-T4?ZKA3K$W_PF]R)ET.
M]#X1[6_)S[^["/9[M*Z6VGO2MK!.%UR>K/_,#]/39] $LVLP\ *)DS6C#D>=
M*N<)A)^"R3O\6K:-?/F@"\M)/&K]:_+P IPF]*..3\U:]>_Q["<@'\P0Y73P
M\/@9,I>S:=ES]Y#6"Q"JR#MY;AYRMYC57A 6N&J\A>YPY=.[YL8'RD@[9RE\
M4B]PHB"M.DS$S/5OGN;9*GR%*114D#(ACP($*\!D"AJ9K^>R*??%<QR%8I0(
M2!IL,$G\0(1<.@T<,)G6O?]'=WI_E6]16LY^YT&&UF<TAS8]'[E)R-18E%EI
MR]?\V).,9NE:J\JEO8#3-)VH(TVYOAJ$?_+T1GR),WBL?  -Z3<C;:1=+F^;
MOU%_,]UV<7MTCLL;7H2G"8GX_6]($B\SNDW4R"TG_L\T6S.7>[>3XOF,7^1?
M4DG0NIR'Y%GA-4MSKOVEI6THJ.=_P5&#D*8Y76336!=))(I(!(NSBEC=6"Q$
MWYPS695'EWT6GCL>ZH[3H2Y!+J2*E8VT;<+=T^+L]0NB1]ID[4YV><$+NBOH
M0GVUJ0Z<.C$KU%<MY!B423R:."0]'LZK;(JJIJC(XO"=!@<\34G]P:W5E#)\
M2ZT)7@Y]8L,J;_8@[KAI9F=YGD;/9 5(5OQ/N%JUT]W]??5D_1D]5GJI'@T:
M@-L<P[HS33#T=Q@85Z>AL6&B75YF*^5HK%XQC!0',_VRTF+CSR_M+^ZG*6K>
M"8#?",.)"_U8;IM8^4U>CFLVPDL3-#I/8ZPQA32<PPS;:\8)&(2(.QECG$K<
MR58Z_1 -=E@&.Q0[#B2Q13:.I;8:+S-"3#Q0/MOA(AD>*!CE:>;@N^'I(Z[G
M4.?D46"H4?,XROESISR^Y^$;,N!%A]'[Y-MN*+URNSP_R';V0IEW.^CX[?'M
M,;R<+HTRQC/'W8I-=]=&FV[&[!'M]1?Z/\]!AO[7_P-02P$"% ,4    " #Y
M.4U8!MPCUIA ! #6_"P $@              @ $     968R,# Q-3,R-U\Q
M,'$N:'1M4$L! A0#%     @ ^3E-6)XJ)_\-"@  'CP  !4
M ( !R$ $ &5F,C P,34S,C=?97@S,2TQ+FAT;5!+ 0(4 Q0    ( /DY35@I
MSTZ4O D  %HZ   5              "  0A+! !E9C(P,#$U,S(W7V5X,S$M
M,BYH=&U02P$"% ,4    " #Y.4U8O!5_[Q &  #=%@  %0
M@ 'W5 0 968R,# Q-3,R-U]E>#,R+3$N:'1M4$L! A0#%     @ ^3E-6&\Y
MB60J!@  (Q@  !4              ( !.EL$ &5F,C P,34S,C=?97@S,BTR
M+FAT;5!+ 0(4 Q0    ( /DY35CV 06051D  *LP 0 1              "
M 9=A! !R;VEV+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( /DY35@=BG6>J!0
M "PC 0 5              "  1M[! !R;VEV+3(P,C,Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " #Y.4U8,0BMFCI3  !9T 4 %0              @ 'VCP0
M<F]I=BTR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ ^3E-6#BDVF%J\P
M6*(. !4              ( !8^,$ ')O:78M,C R,S$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( /DY35ADSJJOK7$   P#"  5              "  0#7!0!R
J;VEV+3(P,C,Q,C,Q7W!R92YX;6Q02P4&      H "@"7 @  X$@&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>ef20015327_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:roiv="http://roivant.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="roiv-20231231.xsd" xlink:type="simple"/>
    <context id="c20230401to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">roiv:LicenseMilestoneAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230701to20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231201to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_TelavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:CioxParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220531_CounterpartyNameAxis_WelichemBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:WelichemBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c20220531_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c20220701to20220731_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c20220801to20220831_CounterpartyNameAxis_WelichemBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:WelichemBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:RocheTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-14</startDate>
            <endDate>2023-12-14</endDate>
        </period>
    </context>
    <context id="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:RocheTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-14</startDate>
            <endDate>2023-12-14</endDate>
        </period>
    </context>
    <context id="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:RocheTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="c20230401to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221114to20221231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-14</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-14</endDate>
        </period>
    </context>
    <context id="c20231001to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">roiv:TelavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-14</endDate>
        </period>
    </context>
    <context id="c20230701to20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:NewlyFormedSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:NewlyFormedSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:NewlyFormedSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c20230701to20230731_RelatedPartyTransactionsByRelatedPartyAxis_SKIncMember_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SKIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:VantAIPreferredFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c20230801to20230831_BusinessAcquisitionAxis_ProteovantSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_SKBiopharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SKBiopharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:VantAIPreferredFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230731_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:VantAIPreferredFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c20180831_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="c20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-31</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-30</startDate>
            <endDate>2028-04-30</endDate>
        </period>
    </context>
    <context id="c20220530to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-30</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-31</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c20180831_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="c20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="c20220501to20220531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:FundingAgreementWithNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CreditFacilityWithXYQLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c20220601to20220630_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DermavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220919_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:EquityOfferingsAtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-19</instant>
        </period>
    </context>
    <context id="c20231231_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:EquityOfferingsAtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c20230901to20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:RoivantParticipationOfImmunovantStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:RoivantParticipationOfImmunovantStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ImmunovantIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtdEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230331_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RoivantSciencesLtd2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221001to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">roiv:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SamsungBiologicsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">roiv:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SamsungBiologicsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:PalantirTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:PalantirTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_TypeOfArrangementAxis_CashBonusProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="c20230401to20231231_TypeOfArrangementAxis_CashBonusProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231001to20231231_TypeOfArrangementAxis_CashBonusProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240209to20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:CashBonusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-09</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TwentyPercentEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TenPercentEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TwentyPercentEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TenPercentEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TwentyPercentEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:TenPercentEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:PatientSquareCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsAndPrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_ClassOfWarrantOrRightAxis_PublicWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FinancialInstrumentAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:EarnOutSharesNonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:March2020CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:OtherStockBasedAwardsAndInstrumentsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:OtherStockBasedAwardsAndInstrumentsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:EarnOutSharesNonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:November2021CappedValueAppreciationRightsGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>roiv:Segment</measure>
    </unit>
    <unit id="U005">
        <measure>pure</measure>
    </unit>
    <unit id="U006">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U007">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="U008">
        <measure>roiv:IncentivePlans</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20230401to20231231"
      id="Fact_b04ba911e6b545288f08ed06a343ecec">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20230401to20231231"
      id="Fact_ebff28a4b74b4ce8a505b0132b81ef8b">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20230401to20231231"
      id="Fact_5e0783854c1a48aa9316fd8bc24a4f3c">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20230401to20231231"
      id="Fact_2566ae06044d4426b5ae6761a06382ef">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20230401to20231231"
      id="Fact_f11308edf91b41dba61215563c4ebaa4">0001635088</dei:EntityCentralIndexKey>
    <roiv:NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_227cc2a973b342cdadc7924eb0824d99">P20D</roiv:NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold>
    <roiv:NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_2cef63e668c241b7bc426da933f7f568">P20D</roiv:NumberOfTradingDaysToBeUsedToMeetEarnOutSharePriceThreshold>
    <roiv:NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_d2125a9df960461aa915b45e9db9e81b">P30D</roiv:NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold>
    <roiv:NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_938065e85885426b93d64ce0a73dd639">P30D</roiv:NumberOfTradingDaysAllowedToCalculateEarnOutSharePriceThreshold>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
      contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      id="Fact_5ffcc6c700034d4587790a5e791d733c">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
      contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      id="Fact_1bcdc2e95f0b40ac8041dbfa7444510a">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      id="Fact_ca3f4592024941f287ede17a07ff606d">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      id="Fact_93006666e195494db2e26107da08a25a">http://roivant.com/20231231#GainLossOnFairValueOfDebtAndLiabilityInstruments</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="c20231231_StatementEquityComponentsAxis_EarnoutSharesMember"
      id="Fact_896fc6f03cbf47ba9500416e14491b89">http://roivant.com/20231231#LiabilityInstrumentsMeasuredAtFairValue</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"
      id="Fact_8076c0698f4040ad9216b28dd1dd2471">http://roivant.com/20231231#LiabilityInstrumentsMeasuredAtFairValue</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20231231"
      id="Fact_8ee3b8aa93764123a2f245e2aa34a8f5"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20230331"
      id="Fact_402b29cf8c3f4fd7af7fd8ece657ecb2"
      unitRef="U002"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="c20230401to20231231"
      id="Fact_d1342817f5fd478ea3b097c13cd06b0a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20230401to20231231"
      id="Fact_83eaf44af3864232b69230c1e42132dd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20230401to20231231"
      id="Fact_77d4677249404987841d457e305723d9">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20230401to20231231"
      id="Fact_75f253b62c2b402b8b74b8a9f66941c2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20230401to20231231"
      id="Fact_2a629753f68042b297a3a1e4c578891c">001-40782</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20230401to20231231"
      id="Fact_752bb2bc265449e1b4cbd30a8060733b">ROIVANT SCIENCES LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230401to20231231"
      id="Fact_75c417da4c33437ab9450b3b22d22eda">D0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230401to20231231"
      id="Fact_3e2157c9efb843bfb3da490e8798459d">98-1173944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230401to20231231"
      id="Fact_0d88b6bb100f493e80d2e056a1012bfb">7th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20230401to20231231"
      id="Fact_159378a8b4984b58914a5903658ec618">50 Broadway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20230401to20231231"
      id="Fact_d7c3ac5eaa6e49329c794117cbd5f3b2">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230401to20231231"
      id="Fact_624740da0a9f496dbfc64c1368f2f141">SW1H 0DB</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="c20230401to20231231"
      id="Fact_b726218524f74aacae742157aa2d3dbf">GB</dei:EntityAddressCountry>
    <dei:CountryRegion
      contextRef="c20230401to20231231"
      id="Fact_bcda329cae5648649295a7eb54b89a0a">44</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="c20230401to20231231"
      id="Fact_e16df5da524c4dda997faad239eac754">207</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230401to20231231"
      id="Fact_ff565a664deb47caab95dbb3e01a4877">400 3347</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20230401to20231231"
      id="Fact_c43c6edd5c7848d6b6ae30f60ee9d685">Common Shares, $0.0000000341740141 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230401to20231231"
      id="Fact_b15a695da37f40d2905c830c848fc6b4">ROIV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20230401to20231231"
      id="Fact_93787d461eab432ab015b941f63bbd3c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20230401to20231231"
      id="Fact_01e58743aef44d6a903dd1c6f565d9c7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20230401to20231231"
      id="Fact_74454031dc2a43afa76626665206821b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20230401to20231231"
      id="Fact_4b17c83cc4f14dbfab6b901defaa3964">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20230401to20231231"
      id="Fact_b6c15324254a40ad8e9d9bfd63050ec3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230401to20231231"
      id="Fact_437bdf416d774170ad1298670b6b698a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="c20230401to20231231"
      id="Fact_79b60e0e803b45e48b14293f8911ef71">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="c20230401to20231231"
      id="Fact_10cbe75a83d94b3d897a99c723a85fba">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20240209"
      decimals="INF"
      id="Fact_fdb219b6bf0a4b09a63f5cc8096bcda4"
      unitRef="U001">805846006</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_0fec7d5337b949e981f6d5f599087f4b"
      unitRef="U002">6670810000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_677c9a30422046339d8446f23f7c7f74"
      unitRef="U002">1676813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6cf02db0d8204894961d623f10f1b475"
      unitRef="U002">135923000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_7bda2315b1744dcea5a11e0052b7cd52"
      unitRef="U002">121774000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f40a3ed8727e48058e1092532bbdece6"
      unitRef="U002">6806733000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_9b08fc2146774e6e8686d64acee78f12"
      unitRef="U002">1798587000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_94bd5e8555e1409ea61b04ac85115f7f"
      unitRef="U002">21857000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20230331"
      decimals="-3"
      id="Fact_72dc39d07f7746f2a5f6c7521fcd1e05"
      unitRef="U002">39086000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20231231"
      decimals="-3"
      id="Fact_8260c01c307f44a29e3c3e01b9cfc0ca"
      unitRef="U002">46898000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20230331"
      decimals="-3"
      id="Fact_3326d4d6e2a7410ba6489cacb10aeeea"
      unitRef="U002">53251000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231"
      decimals="-3"
      id="Fact_bcbedd68e86b4ab4a246a2e11f1a1a46"
      unitRef="U002">239927000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331"
      decimals="-3"
      id="Fact_09f42b62729d496a86557c4d6f9f0049"
      unitRef="U002">304317000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20231231"
      decimals="-3"
      id="Fact_bc25a7ce6b004ff98d67e4ecfb27e8d6"
      unitRef="U002">150415000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20230331"
      decimals="-3"
      id="Fact_9ed2d71cceb54020ac97cac56f34e4bd"
      unitRef="U002">144881000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_637a50bfa7b5467991c992be3f4719dc"
      unitRef="U002">46849000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_4fda655ed0da46e0818834cce9aeca07"
      unitRef="U002">49482000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ac914f87d3f74b22a247e871950a4d0d"
      unitRef="U002">7312679000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20230331"
      decimals="-3"
      id="Fact_d76b1db0cff243d5bde95b11886922f4"
      unitRef="U002">2389604000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_181e14b15c484728af27ddebeba7b880"
      unitRef="U002">35226000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_8f9545e767fc456ea3aebfbc96ee9372"
      unitRef="U002">37830000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_d1c4c8979aa344f98e415f8d40b81d75"
      unitRef="U002">122148000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_32876a52fabf4b45b498aca7f950a1ec"
      unitRef="U002">167129000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3195308842d14e2f9bcb38a9561ce43a"
      unitRef="U002">10477000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_e265438a69534fdeaecf6d773ec8f0d6"
      unitRef="U002">11693000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ShorttermDebtFairValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4f5292ddbb0a4f53abd0ae3aed8e01ee"
      unitRef="U002">26950000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_8debdb7c757b4fd3a1be67cefd03cef8"
      unitRef="U002">26940000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:LongTermDebtCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a72a79b5985f4c38a71d8ae275978d5d"
      unitRef="U002">45706000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_3e6d4aabfa214d97ba9e3b723d20f80f"
      unitRef="U002">40720000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f558cfbeeb7e4d159fd6ad8397e98342"
      unitRef="U002">31342000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_155b6e9538704b6fbd1e5671a405c234"
      unitRef="U002">15076000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_dbcc5dbed3ae483e847e4029a70701b1"
      unitRef="U002">244899000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_6b89b1f111ce4d6b99e310fde8f88371"
      unitRef="U002">272448000</us-gaap:LiabilitiesCurrent>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_031ee54bd63c4f2ab34ca440b831ac3d"
      unitRef="U002">28374000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_d4b87d4a81a74cd6854cc32bb987feba"
      unitRef="U002">63546000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ceb15f21aa9a49dfa779e1e7a5f50f54"
      unitRef="U002">47059000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_ad52c8fd76a045b3a889640afdd015b2"
      unitRef="U002">53476000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6ecacae227d54822b14bff00c6cae596"
      unitRef="U002">194560000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_786022393a8644ba984ae9949833cc43"
      unitRef="U002">180700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebt
      contextRef="c20231231"
      decimals="-3"
      id="Fact_aef9ce15b41948d8b278591595b0acff"
      unitRef="U002">403337000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="c20230331"
      decimals="-3"
      id="Fact_9bda62f22a56495f810f44c4ae349920"
      unitRef="U002">375515000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c8063c4188e54ec183906fd782ceb445"
      unitRef="U002">4428000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_0c0b76bfcfc74a5ebe3576956c2404d9"
      unitRef="U002">17032000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_87d891c3f1db4ab49fbf318d1c6fc3a4"
      unitRef="U002">728097000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20230331"
      decimals="-3"
      id="Fact_3e4d49ee8c8f4f97a45654ed648c5b34"
      unitRef="U002">782017000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20230331"
      decimals="16"
      id="Fact_c1ae166fc6a04af29076967af6fac8c4"
      unitRef="U003">0.0000000341740141</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="16"
      id="Fact_3b2ad188219844fc93851d7aa67c8cb2"
      unitRef="U003">0.0000000341740141</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_c6cebf60ceb54eda8abec04250d574b4"
      unitRef="U001">7000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_ac8832e210384c48b424daddb2860c26"
      unitRef="U001">7000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_a98bb495e1f84e09b8f3921f312075a7"
      unitRef="U001">804890910</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20231231"
      decimals="0"
      id="Fact_94b85aa66db64c83aba1f0c940940594"
      unitRef="U001">804890910</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_93f11783b01b44c295f5c3342d23a6d2"
      unitRef="U001">760143393</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20230331"
      decimals="0"
      id="Fact_70feae7cdd324059ac6e2923bc0c1425"
      unitRef="U001">760143393</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_142a9fc04df1401892e8dc0cc3ddfce0"
      unitRef="U002">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_e7895281c9cd4ba78f4a789929e54aea"
      unitRef="U002">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6d8018da0ff14317ae8320b3a06c8a34"
      unitRef="U002">5390260000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20230331"
      decimals="-3"
      id="Fact_3e7aa5b3500e48798d87dc4cde45e5f5"
      unitRef="U002">4933137000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20231231"
      decimals="-3"
      id="Fact_76a2261bc9ab4d3898f65166c35e693f"
      unitRef="U002">727287000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20230331"
      decimals="-3"
      id="Fact_d0557b0bbb7e47ba809f5efcb3128521"
      unitRef="U002">-3772754000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c20231231"
      decimals="-3"
      id="Fact_73698f5f0df0411cb48ff4a1953094f6"
      unitRef="U002">-27784000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c20230331"
      decimals="-3"
      id="Fact_7f3e669f44df4337b939af3414673b89"
      unitRef="U002">-2617000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c8fa236275504df8b531ceb3ff46b828"
      unitRef="U002">6089763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="-3"
      id="Fact_2aecfa0b41ed4865922f00a0a32a8c50"
      unitRef="U002">1157766000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="c20231231"
      decimals="-3"
      id="Fact_8044d8dab214492c8492af9503fe1a00"
      unitRef="U002">494819000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="c20230331"
      decimals="-3"
      id="Fact_660057acf6694a89aa859141111d8a19"
      unitRef="U002">449821000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a2ef71e8f8e441078c3128412301e2ac"
      unitRef="U002">6584582000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230331"
      decimals="-3"
      id="Fact_ca263c1857fd45989516bc614868c52c"
      unitRef="U002">1607587000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6ddbeacac642464a89fbd7561202ce2a"
      unitRef="U002">7312679000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20230331"
      decimals="-3"
      id="Fact_ec7ffcfda6c8467c9651e42c4716fca7"
      unitRef="U002">2389604000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20231001to20231231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_2f7e881ea5e04b1b91d4f285d68ed405"
      unitRef="U002">20666000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20221001to20221231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_826779f1f0f946edb9d43c4e074b04c5"
      unitRef="U002">9244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230401to20231231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_797e51b866444af6ae8bef605a2bcc07"
      unitRef="U002">55749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220401to20221231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_88ba8887d63c435b9a9c12c8d99c80cc"
      unitRef="U002">14354000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20231001to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"
      decimals="-3"
      id="Fact_e334de77043545428ebdafe4cc6e9a50"
      unitRef="U002">16474000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20221001to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"
      decimals="-3"
      id="Fact_7e565ce2b3994c98b04ac4d4b9904aa7"
      unitRef="U002">7808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230401to20231231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"
      decimals="-3"
      id="Fact_434d5df4aa2b405dbb3b70e2521d0d77"
      unitRef="U002">40116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220401to20221231_ProductOrServiceAxis_LicenseMilestoneAndOtherRevenueMember"
      decimals="-3"
      id="Fact_b279eef936b04acf8d3b617c83e471a7"
      unitRef="U002">19550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_a1bd0f2c4b664e1c8b889d5f6a2e9803"
      unitRef="U002">37140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_d396da5a75a744369918e59b0cb42e91"
      unitRef="U002">17052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_deda963c97324f9197b528c1ea32fc95"
      unitRef="U002">95865000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_dcf048549b80441797870b6a74878509"
      unitRef="U002">33904000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <roiv:OperatingCosts
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_922aea593e234932b872acfb61c9bc33"
      unitRef="U002">3668000</roiv:OperatingCosts>
    <roiv:OperatingCosts
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_a081c49aec46490683afe22b2dc5ebb2"
      unitRef="U002">3586000</roiv:OperatingCosts>
    <roiv:OperatingCosts
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_0514b4c4ee6c493489d42869117a7f3a"
      unitRef="U002">11148000</roiv:OperatingCosts>
    <roiv:OperatingCosts
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_1608733c82be4fa7b8f86d5a186920bb"
      unitRef="U002">8953000</roiv:OperatingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="c20231001to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_0d5b0f13fd7a47b1ac16671e8b44c736"
      unitRef="U002">7475000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20221001to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_1d087111d5344ca78c929c818a2a4f92"
      unitRef="U002">6888000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230401to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_ac10694dfc604bc28f9e4af1d30567a0"
      unitRef="U002">24305000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220401to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_2032e0cbad77462a8f98c7f04916426e"
      unitRef="U002">26548000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_0dd22cade78340678dd7e000d8dde300"
      unitRef="U002">123717000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_1c858ccf7a44484f859d4a8eee73eb7b"
      unitRef="U002">125533000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_222795562f35467c99886732c9536b96"
      unitRef="U002">380834000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_f5573e2eb8e243aabc4c828ee52ef5b7"
      unitRef="U002">393358000</us-gaap:ResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_ff10bd2fb14b4fa9b220913fbc5b20c9"
      unitRef="U002">0</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_9298189c13034f8bac3a6dc137daaf33"
      unitRef="U002">97749000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_81068bdf59a04272a43120660c72b302"
      unitRef="U002">26450000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_6cb12d94c59d4b188c640531dc5eaeea"
      unitRef="U002">97749000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="c20231001to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_8f5bec98a170467db18300e3ef8da786"
      unitRef="U002">46944000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20221001to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_2704bf6f348a4571849998f5d29708bd"
      unitRef="U002">50741000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230401to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_3f96a76c63bd4fe4b69001419f689db8"
      unitRef="U002">128445000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220401to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_b14ddf35e0d3415e8e0678266bba1a23"
      unitRef="U002">165771000</us-gaap:ShareBasedCompensation>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_d1a927a6121e4fc5a68f9b054bb69265"
      unitRef="U002">197282000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_99e5353f5a3c46eda236515f84b7b646"
      unitRef="U002">168261000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_1b775a75551247eba2463bfabf24842a"
      unitRef="U002">517827000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_b7f79319b86a4c64913ef7a1cd425485"
      unitRef="U002">474996000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_78a6e9aa3a6646e68c47ff1941e260e2"
      unitRef="U002">324667000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_6c0371194ddb424ea9c131e516f5836d"
      unitRef="U002">395129000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_6fcb636d010c42b2914ce4fdcbbd9aa9"
      unitRef="U002">936259000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_5317186370ef4cb0aabafdcb39b728dd"
      unitRef="U002">975056000</us-gaap:OperatingExpenses>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_691d2d9298c9443f85a17f4d84b00794"
      unitRef="U002">5348410000</roiv:GainLossOnSaleOfAssets>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_f8f4b19c4c6a43978faf977e7c601fc2"
      unitRef="U002">0</roiv:GainLossOnSaleOfAssets>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_36b22b58f2114a889716826c3f369479"
      unitRef="U002">5348410000</roiv:GainLossOnSaleOfAssets>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_a4159fbb16f643ffac9c34e78a024df7"
      unitRef="U002">0</roiv:GainLossOnSaleOfAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_acce8183655f4d97a9152320d0e2a418"
      unitRef="U002">5060883000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_20d4fe13caaa48b2ab1d5d22cd3eb476"
      unitRef="U002">-378077000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_341e5d0285af469791201088d9346d78"
      unitRef="U002">4508016000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_eaa29dabf3114a148804e4ec8c6332f7"
      unitRef="U002">-941152000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_7b2ba8996d8b4405bb9eec6cd6419fc7"
      unitRef="U002">-10467000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_9823f730ea6f481ca62b3ebef11c9c1b"
      unitRef="U002">25948000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_a52aeb2d0fb145b58b3421995662eb4e"
      unitRef="U002">-63880000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_007a4fd161dd4a1e93ec4cd1fd5cf781"
      unitRef="U002">-53277000</us-gaap:GainLossOnInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_3c8c0da9f5ac4c38a71f31b3b396aff8"
      unitRef="U002">-9331000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_15aab40790ee439bacdc5e315be88cb5"
      unitRef="U002">-62360000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_788b43e751e54d5d90bc18c4da198304"
      unitRef="U002">-85376000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_7c1a9df679904436a09c367e1461eaf7"
      unitRef="U002">-90032000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_4f5f8e3091e54650966b27f507d52c6f"
      unitRef="U002">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_e3ebbf18875b4133ae632bba04e66fdd"
      unitRef="U002">12514000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_a282fc4ecd9a41eebab0f5ca0eb0b1d4"
      unitRef="U002">17354000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_4554baa862c24385a46f75b0a8300218"
      unitRef="U002">29276000</us-gaap:DeconsolidationGainOrLossAmount>
    <roiv:InterestIncome
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_1d7840b4971842eda90d56627edfa047"
      unitRef="U002">31953000</roiv:InterestIncome>
    <roiv:InterestIncome
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_2d286a44cff148d0a4ee0e7fae99c2a7"
      unitRef="U002">10249000</roiv:InterestIncome>
    <roiv:InterestIncome
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_2805f5b9f3b94a809c8ea84bd78c199e"
      unitRef="U002">62967000</roiv:InterestIncome>
    <roiv:InterestIncome
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_4ae8d9e8e92e45e9b6dee9799fbf9fd9"
      unitRef="U002">17900000</roiv:InterestIncome>
    <us-gaap:InterestExpense
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_18ff7bcee7ba40c389ad7ba4a2b76fe4"
      unitRef="U002">9444000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_11ab5c28af944145b322e15b27adc17e"
      unitRef="U002">8446000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_b3b88dd1ebbf4e51a02eb162d6d1903a"
      unitRef="U002">27603000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_78cd7b871e42451fa812aab3f36a490d"
      unitRef="U002">19393000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_1020c325ab3d40d2b93e2cbeddbfd7ae"
      unitRef="U002">34743000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_0d5314abfb0b48be918b4bd9e1e67b88"
      unitRef="U002">18095000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_816358231a5b493abfe57ee0a1c9714a"
      unitRef="U002">33405000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_4669b061834541a08e4d44a4c7e2a0c0"
      unitRef="U002">11060000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_fcb7578b825d400c896ac356cc30c231"
      unitRef="U002">5098337000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_573222d4c11a43d2a99ee4e340c9c077"
      unitRef="U002">-382077000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_48c05712046b411684d215fb4b688c52"
      unitRef="U002">4444883000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_9b4fb82dba37479d8e5db8794507e77f"
      unitRef="U002">-1045618000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_3928023734ac4e13b210a33320b01ccb"
      unitRef="U002">25672000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_03240dcd1b0e4fb5add3a1f4f0196dce"
      unitRef="U002">2819000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_d311ca4470d44c6a9b5dc2e879650f64"
      unitRef="U002">31181000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_7ebd1bf538414250912bac21bfd38cee"
      unitRef="U002">8983000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_34533d8890444bd58b2027870609e117"
      unitRef="U002">5072665000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_35c43e16743b4ae6869b2828e53a7b3c"
      unitRef="U002">-384896000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_c70b9d6a229445cb9f3aa5366531abac"
      unitRef="U002">4413702000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_e7b3b214e56a4ef0858f8115cd0b42d8"
      unitRef="U002">-1054601000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_b78698a44be5464195df09b90cd8cd81"
      unitRef="U002">-23519000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_e064108b79e1453698cad9947d65d780"
      unitRef="U002">-32882000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_175899089ee84fd1a2e358d81caafab1"
      unitRef="U002">-86339000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_043f5613a5f84da3b049e61ebbf81d6e"
      unitRef="U002">-79188000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_688b7a7cae984c0cb0952f604392f4dd"
      unitRef="U002">5096184000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_acff1ff96afd40399ff496a09d7adb99"
      unitRef="U002">-352014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_8423b53e54b143c7bbfb46d6b0e0b666"
      unitRef="U002">4500041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_91669f76f7bd4d25a559d97ea96e1fe6"
      unitRef="U002">-975413000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20231001to20231231"
      decimals="2"
      id="Fact_beae55c050564805855f41e6a7c677bd"
      unitRef="U003">6.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20221001to20221231"
      decimals="2"
      id="Fact_000c8fe481e44a4db6d24a1e0ee27553"
      unitRef="U003">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230401to20231231"
      decimals="2"
      id="Fact_d012f6bb764941f7af73a63934c67c0b"
      unitRef="U003">5.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220401to20221231"
      decimals="2"
      id="Fact_ebd7cf1f81474688a15a30920b82bd76"
      unitRef="U003">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20231001to20231231"
      decimals="2"
      id="Fact_331598902e644b4e8929213a44548f5f"
      unitRef="U003">6.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20221001to20221231"
      decimals="2"
      id="Fact_0e162eec5528444f89817f58b77e3ff1"
      unitRef="U003">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230401to20231231"
      decimals="2"
      id="Fact_76d68878a1464c23bf7ea9be5c693902"
      unitRef="U003">5.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220401to20221231"
      decimals="2"
      id="Fact_5f88740cfe5e4f88b6d5588f1b3077a6"
      unitRef="U003">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20231001to20231231"
      decimals="0"
      id="Fact_239b5e5c33cd4a68866dbaf2a17ec886"
      unitRef="U001">800587716</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20221001to20221231"
      decimals="0"
      id="Fact_7fbb1847974446c2b68dee23ec84e1e5"
      unitRef="U001">713319399</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230401to20231231"
      decimals="0"
      id="Fact_f2c2b094a278408297dac678753ab177"
      unitRef="U001">776759728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220401to20221231"
      decimals="0"
      id="Fact_e03409693f014749aa556864a613ce24"
      unitRef="U001">703054773</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20231001to20231231"
      decimals="0"
      id="Fact_016ff35f7f344711b58e28179c15d53c"
      unitRef="U001">844461685</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20221001to20221231"
      decimals="0"
      id="Fact_97c29fad90fa422fb5d9f4c925369014"
      unitRef="U001">713319399</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230401to20231231"
      decimals="0"
      id="Fact_14dd5ebafab448c3b5d7594376cc2d12"
      unitRef="U001">824310013</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220401to20221231"
      decimals="0"
      id="Fact_f5dd486d418c48848dbe86d1ceafd56c"
      unitRef="U001">703054773</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_5e98410819324493b36035938cefcf77"
      unitRef="U002">5072665000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_69e10c71b7284712950f81ab24987fb8"
      unitRef="U002">-384896000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_c55479e1541d4f359132bce3d36f0bc6"
      unitRef="U002">4413702000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_3c6f97a8354a49fda0a4fa3d7e8be1f2"
      unitRef="U002">-1054601000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_9f31ac1165f14d48849f30f5e7189b85"
      unitRef="U002">-25066000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_7f7de56f601444c28c8ff82263d361ad"
      unitRef="U002">-8972000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_2da1908d3cfc459cba075931c6844146"
      unitRef="U002">-25612000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_9c21ba8a52ae4aeab507601a2437ac6b"
      unitRef="U002">547000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_d8f98fcbe90142faa6cf9656a1338ed5"
      unitRef="U002">-25066000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_bb90bfae56f24dc7b9d4f6ea0d765a4b"
      unitRef="U002">-8972000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_d6d8faa647444a2894554d82364d18b1"
      unitRef="U002">-25612000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_a8fba159e9c64bfc86a2d4fc5857b3a5"
      unitRef="U002">547000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_09c12f6bf1184c7d968a64117895a4c8"
      unitRef="U002">5047599000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_0d6d353294854d92bef7fb7b175f31d1"
      unitRef="U002">-393868000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_405f72b339604cd488d1eebf2fa3463f"
      unitRef="U002">4388090000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_f8cd028dc05f42a79c63c8b8c00a9206"
      unitRef="U002">-1054054000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_88a9555ccbfb46adb229e81b53592819"
      unitRef="U002">-23873000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_7a1e56dd7b734763b9d7b794e45208c5"
      unitRef="U002">-32036000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_bf951d9043144e2f8e1a34b6c2a8e781"
      unitRef="U002">-86784000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_6dde2e70e3c040c39a5bb7aa3e3ef02b"
      unitRef="U002">-78858000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_597db978138a4eef9fb96176e272627f"
      unitRef="U002">5071472000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_3d617c64332e44c4a7f2ef489538cbb4"
      unitRef="U002">-361832000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_21c77e83ab684f80924b40c2cab701f6"
      unitRef="U002">4474874000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_c179b1bf8c744656b08f49fb62d230f4"
      unitRef="U002">-975196000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e71abf25db4a471bb7e6ade5aad2e64a"
      unitRef="U001">760143393</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_915ca5fe05084bf395ee797c46c161a5"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f7c6ab5560414fa8a351f64eb14465ac"
      unitRef="U002">4933137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a450b16a17424efda23f80884fd598c5"
      unitRef="U002">-2617000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_91ef67b491a44903ad1d1091ea74ab37"
      unitRef="U002">-3772754000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230331_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_b6b9ea5581e5432f82c842f17c164bf6"
      unitRef="U002">449821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230331"
      decimals="-3"
      id="Fact_82b5ab7bbdd14c3498477f356a3179e5"
      unitRef="U002">1607587000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a5e115da991a4a47ae270d489c7bea81"
      unitRef="U001">6994468</roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c329eee209ee48f9aba6c473cc7107a3"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7073fbecbdb7409a9aa5147d813a4be9"
      unitRef="U002">-14395000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_cf0986927542450e99b9b6813a1eeeb2"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_24f95ffd2bf34fb9a7429802a6d08ca2"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_62f0aba08ab242d5bc28e6969312f075"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_27449a6882ad4ca498a0c4142876b8ad"
      unitRef="U002">-14395000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2df0a42cefa14a23a1f49e3cfe53e7e0"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_4e2fe77eb27f4db4a1e28f89d59d853b"
      unitRef="U002">503000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_9d7d650420d74358a4e64dab37e7b63b"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d050f842ee5b48b3b4aee18ba7c5f66e"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_76d0432fb01442be89e77ee52513fc54"
      unitRef="U002">387000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_49b7d85c169048ada6735df548b21dfc"
      unitRef="U002">890000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_dc8c508d439543a2bcc028d0152b03ee"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d0ffb6fbe0334b4db32310ad5953a8c2"
      unitRef="U002">-623000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_3649d5504e824a50987f5ae07a4af3f4"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e74ea07d55ee49aa926495e2aff5098f"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_8341224682d64a3399083e04228fb663"
      unitRef="U002">623000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_4d550c2dccfc439d8fe9c71b656a5ccc"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:DividendDeclaredBySubsidiary
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_19070e6c76d74f4694fc6a05ddb1d83a"
      unitRef="U002">0</roiv:DividendDeclaredBySubsidiary>
    <roiv:DividendDeclaredBySubsidiary
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_105e8f8529934601bdf988da19f9601a"
      unitRef="U002">0</roiv:DividendDeclaredBySubsidiary>
    <roiv:DividendDeclaredBySubsidiary
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_3003ce1d8e714134adfde39a3167226a"
      unitRef="U002">0</roiv:DividendDeclaredBySubsidiary>
    <roiv:DividendDeclaredBySubsidiary
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_621bedb07ae744b8a26a3260c93d6f3a"
      unitRef="U002">0</roiv:DividendDeclaredBySubsidiary>
    <roiv:DividendDeclaredBySubsidiary
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_986e07e7dd2941beaf143d86a26fe97d"
      unitRef="U002">6000000</roiv:DividendDeclaredBySubsidiary>
    <roiv:DividendDeclaredBySubsidiary
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_fbfdaea85bcd4ce5abe8702d67fc9845"
      unitRef="U002">6000000</roiv:DividendDeclaredBySubsidiary>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_1faf259633fd49efabb0d74a11d59356"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_fbd05ab176a649829ced8b72a1223cb7"
      unitRef="U002">34498000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_333c0661dfd44b22a0916f8a851f31a9"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7fec9bc2dd534431bb922a93b75b6d76"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_b224110ae9494a028cc8f91fa21bc4ef"
      unitRef="U002">14762000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_72b051c977c949a88c2d63bab5d8fb73"
      unitRef="U002">49260000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2df20bf7a70c4612bb74aa92c560c3cc"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f12e1a4f9357493c93b5e15f03fd1a2c"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_8b7730ebda8e4803a13f45f1b7a4a9de"
      unitRef="U002">-3993000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_01f7670f818948b0b89dee53bb073988"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_6920f5b498b9495583418ae7a0112512"
      unitRef="U002">-155000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_aa136fcaa54448729b7097a6ad6dc317"
      unitRef="U002">-4148000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_cdcd8c249cee452e8a178dec237c60b8"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bdbf8661ed9841a3b024c29b30a44f8d"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_3104a86c2d7741e9909de6bc85ea3ae9"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c9ca7bed801749199cf4a0943eb428d5"
      unitRef="U002">-291816000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_5452c91014674d3dbaa21c2b8a41ad61"
      unitRef="U002">-36029000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_d73d55485eb94b2ab2e7bd051773a54a"
      unitRef="U002">-327845000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f73230a3032648e78f1f4757ec44b26f"
      unitRef="U001">767137861</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_713ff488fcca43ac90afab0722ff70b4"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_82007bb8cc224382a8bba24a1924af34"
      unitRef="U002">4981910000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_24d12dbb3401465f82d2b9653e1c1a03"
      unitRef="U002">-6610000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_63e9281ba9c14d34901f0be7d7ec6f80"
      unitRef="U002">-4064570000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_94791098a27f476486e8251414cad023"
      unitRef="U002">423409000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230630"
      decimals="-3"
      id="Fact_20ee4d5f0d5d4fc785698abe31b04bcf"
      unitRef="U002">1334139000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:StockIssuedDuringPeriodSharesNetIssuanceCosts
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ed96ba7ea89241248106485a283a946d"
      unitRef="U001">19600685</roiv:StockIssuedDuringPeriodSharesNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_41bb709882bf4aaa95c3cd9b6f8f8310"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d3e0fdc2c9344e9b9545db5d8eca1496"
      unitRef="U002">199822000</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_1c7980f31e2c43a5a5768b34643475c2"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e9f9e6008eb44d508fca1c7dc1793562"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_98590d3c1b8b4ddfbf84be853accc564"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_0550047e41b34a54a94c9f80562e06b5"
      unitRef="U002">199822000</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_13f38e1239cb44098d321e6e075a8782"
      unitRef="U001">7554549</roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsShares>
    <roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_5263a68a69834f1ab33586c3f357d4ab"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue>
    <roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_eb2249824d17405abedc28fc3244a4f0"
      unitRef="U002">83264000</roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue>
    <roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_2926ca25b5ad4ee3a51ddd300b6f7553"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue>
    <roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7cad236cbc5145b48c361fd96d68be77"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue>
    <roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_065ed85eb2a9492eb12ab2592b85b9ae"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue>
    <roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_990b66a084c841ed80f26bc5bea2583c"
      unitRef="U002">83264000</roiv:StockIssuedDuringPeriodValueCommonShareRelatedToSettlementOfWarrantsValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_faf9892337424fc6a74962f6ea7e6272"
      unitRef="U001">96385</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7bd9e3abf06d453a9edf4e4948d8830b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_73a3ed7b36d94bc1b1911320873fefe3"
      unitRef="U002">587000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_5478b944547644b28802902a3ad90f9e"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d506ce34726a402fb7c4ed32a1e96719"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_dd16cec4419f44be9b98d76f94c52d0b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_476a16ecb8a84c47a820b7e0089f1b7b"
      unitRef="U002">587000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_20526c6cebf5445bae8e69eb9728e7b2"
      unitRef="U001">6402885</roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_77714735125a442195b1ccd5ac79ded5"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_8c20501690c24c0f9c3c44379d1907b2"
      unitRef="U002">20873000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_ed483ffea4af41b09a38cb242ea0841d"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_76d85977d3d0455cb26c8ce288f992a4"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_896b621aa6194a29a2bfb09a705de137"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_0891d27528ca48afa0eb57f9af0122a4"
      unitRef="U002">20873000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansNetOfForfeituresAndTaxWithholdingPayments>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_1b58e5e3802d462391db4483cc0b4a52"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ffcf68693c574cdf813acc868d29dda4"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_d2f20735cd314b9d81f7a0d12243a2d7"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d539e16af3674962939f7677d385870b"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_5fdc2a45b8d64133a7aa5e958d982543"
      unitRef="U002">35050000</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_73930ce0fea14d068c8b939727fae57d"
      unitRef="U002">35050000</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_93d718f205634334bd81b760a895ca20"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7b7779bd7bb743b085397e0f181be1a4"
      unitRef="U002">131000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_d97c5ebd765048f09832e27a8f7040b1"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_1eb6a415005249efac8cdce1f079a81f"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_47d2dbddc24c4042892470fe980c8b90"
      unitRef="U002">65000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_e972e4bee38b49ad947d2cdf80f2c04c"
      unitRef="U002">196000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_625a638e9afe4d7b9969df35f713ab10"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f6631d8e7f7746378965da7efae67f4c"
      unitRef="U002">-571000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_8da24ce8ea7c46d9bb929e7b249e2f8a"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2e3e2574bd684d5aa6efa8b4078b809e"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_6c685dcfb3f240ab9d44fb1c9862767b"
      unitRef="U002">571000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_0120763eb319436b820355029b9568e2"
      unitRef="U002">0</roiv:CapitalContributionsToSubsidiaries>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6d74e8cd7e5848edb707fbe4b73aee1d"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7e45590da0e4485ab87a84148b994a70"
      unitRef="U002">34487000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_e041935a04424d20ba840a20e25f17bb"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c4090aa8f93c40a0a87b1986545ee9f1"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_181cf0d7ff01414999ad4868945368dc"
      unitRef="U002">14831000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_257d8fbde6e349bea7eca01920c268c9"
      unitRef="U002">49318000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_809627eb3a43491a8c6309e7a93ed9a5"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_12e604e50e85478b8760e3e9cf571250"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_bf8f548312c74de3a0dbb12149b2fe44"
      unitRef="U002">3538000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e55ecf03946345f5bc5c6b916341d55c"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_9cbd61f8ff7a4b048567eb46cd9b76c8"
      unitRef="U002">64000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_2a82bf9b4ae2487883c889306ddfea87"
      unitRef="U002">3602000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ae50de21a50b45e393a447af451fc78b"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9a0830162f1e4bf0b79d50d0c51ea743"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_8c80f7554ff4401d93e606ae57ce21a8"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2cbfcec626cc4603b6cb857342113081"
      unitRef="U002">-304327000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_de10b092dac74df48c34e5147817487e"
      unitRef="U002">-26791000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_51ea5cde89b14ffebee135e45ba7a727"
      unitRef="U002">-331118000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fc72818c37db41edaaa59fc97b56c0f4"
      unitRef="U001">800792365</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_9c35f3e2758148f1961b663e0a815eaf"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_af3bbdca0e414613966b0945ba7f8ddc"
      unitRef="U002">5320503000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_312eaca7b2194a80bd99465da9e42f45"
      unitRef="U002">-3072000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_81cf6f89c3fb446ba72043dff2cd5f81"
      unitRef="U002">-4368897000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_409624585c3944c6bee3806647016319"
      unitRef="U002">377099000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20230930"
      decimals="-3"
      id="Fact_34253fe81d51498e8e2f597da35a3188"
      unitRef="U002">1325633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8743744bb8d240879b257b88aeba7142"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cdaedc04fb6545c685c819e99dc54963"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_7be3705d420c44cb9fa399a10dd08d36"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3b1f7c3fa57844d88c67f1ea7685067f"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_be32d028481b45078394d6e64cbb14cb"
      unitRef="U002">87500000</roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_5f413dc98ddf4bfaa2f0c968c6ad55da"
      unitRef="U002">87500000</roiv:NoncontrollingInterestIncreaseDecreaseFromDisposition>
    <roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_52102239c47742459da93d65a5aebbee"
      unitRef="U001">4098545</roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c92e4c0408214454877e46ce6850d602"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_e6f0538723b045429db1134db459a586"
      unitRef="U002">-2456000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_2d8e1e62d92e40d49bab8f333b568e86"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_798eee2be1cd4dcdb49e798b5cba9027"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_428c956ffcac448fbf601f73ca3960bf"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_09c1c480d125440bbf2a47b59cbaa32d"
      unitRef="U002">-2456000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyShares
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="INF"
      id="Fact_51ef72d619114159a0d602cdd9afe860"
      unitRef="U001">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyShares>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_33bce87d81c6413488effeb6ffd589d1"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b17930d067cd48ad97e74cc9692ee52f"
      unitRef="U002">129763000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_cccc92f6586f48f0af549bd1fb146c8d"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3ea408f71e9c41629b5bb2bee4bfd037"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_f7c967e08f73427e8254cd794bfa8e70"
      unitRef="U002">108970000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_accfbc939d5e404894bcafaf8b9c7304"
      unitRef="U002">238733000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_82e15b68bbf949739ed5f98f3f69d4e2"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b56390b6f5964da1a4430c7bb9ff21c5"
      unitRef="U002">1711000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_6a5e3223693744f0815ef2a09acb8c64"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a29d233bc76b431cae8faa0d582e0573"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_3d40184dadab468d92a724798fa2eec1"
      unitRef="U002">1400000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_a7e57fdc96c04e46b047424e5e0ac1b7"
      unitRef="U002">3111000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_202ceffa99b249998357ab2f59106987"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_5087bbd9b980457bb006aa8fef50a669"
      unitRef="U002">-104172000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_38933e10c2c8496687770c2f84ae4208"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a3887815f1c042b5830151130c128746"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_eda4ea13e615426ab2b62eb936aff4c5"
      unitRef="U002">104172000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_ddf1bf2bb07e48dfb913817c28a05fd5"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ca7338cab8814096a09f6d83ce44cc82"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_5c831b8ec3e04eabb8a4bf20333e65f3"
      unitRef="U002">39999000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_3404f21ee07d42d9935ad1224a949746"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_624d09d5ffa245a7be6e8b92f56d8d45"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_122069116b924059b3d192fa8c01d9e9"
      unitRef="U002">14551000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_5908917e71734f8286389863420b117e"
      unitRef="U002">54550000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_158fa34f7d164ca6866480deb5099f1d"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_21b9052add0a411493648daa1f32b174"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_2790c9ef2e0242ec8ea2a1913f7f4020"
      unitRef="U002">-24712000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d2483002dcd84e45b97979a0777094f5"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_73ab505ec0dc4a6698386bcc8b2f39cb"
      unitRef="U002">-354000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_7652fd6364574ba3a657e1e64e578299"
      unitRef="U002">-25066000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_67a358642ac04a11975391410d0996fd"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_afd638093e0a4b3789eb8bd48084e916"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_655e8e614fd34e6cab43c8a69c8616dd"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_eb54de23617846bab63e64f16a46d71c"
      unitRef="U002">5096184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_096b829e29f341b4a8bdf15e5e837226"
      unitRef="U002">-23519000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_b6607040dc8f4a0bb5e9bcaba9534533"
      unitRef="U002">5072665000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_1c6c6346e2ab4bd6925c0f4b381224ae"
      unitRef="U001">804890910</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2ca88417ef1a41aeaa8cec9722800515"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_841a443c85fb4410a35fa32181412818"
      unitRef="U002">5390260000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_fb1ceef67a494647aee461ca62516de7"
      unitRef="U002">-27784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_25737093a960490580b7fb8c84b01c80"
      unitRef="U002">727287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_4e365a8fdbaf4e079beff6f1786fe6d5"
      unitRef="U002">494819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a8ea4e6045c34b7f94b7674d6ec10403"
      unitRef="U002">6584582000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="c20220331_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_1c74cffc9c9845c1addc97d9866b262a"
      unitRef="U002">22491000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f478373981c7438fa1cde1acf053ea1c"
      unitRef="U001">694975965</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_98d2f875edc54abbb57221e6a5251bf7"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_32810c6887d342ee8218e30ea2f378c3"
      unitRef="U002">4421614000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a930b9836aad41be88191d54dde640b2"
      unitRef="U002">-946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a4d9f82bbb90428186331c4b4d4029a6"
      unitRef="U002">-2763724000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220331_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_d620758959a147ee815b70ae8046daf0"
      unitRef="U002">381999000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220331"
      decimals="-3"
      id="Fact_53b88f6825ec444496efcda3383c71d5"
      unitRef="U002">2038943000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyShares
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="INF"
      id="Fact_b9bd3ff21c7a47af97bd145252d1c048"
      unitRef="U001">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyShares>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f331eafd9c544093922318e48f3d6d03"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_352ed7d511c642cea2467d99b490b176"
      unitRef="U002">-251000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_ba21476aa6f7407f801124bf79f75de2"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_27c7de02e109434bbf73e2f8e5a8c1d5"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_4467ee7c20da4f399a499d3385220b9c"
      unitRef="U002">251000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20220401to20220630"
      decimals="-3"
      id="Fact_02ce24610ddf4645b10267dd7fdd1a47"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0b6e7331db55471bb54b96f3af4d12b8"
      unitRef="U001">4739781</roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_be10ebf4be9b4ae08a97d8740e477d96"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_c91a9212eed148ccadfbeb9523c7ee43"
      unitRef="U002">8329000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_fa1b8c92bbbc4d9995aff42a4301d1ad"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_402ce26b7911474d89a3ab74e83a865c"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_97d1ad90ebbf480e92b798d634a70cf6"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20220401to20220630"
      decimals="-3"
      id="Fact_c0278ce2477d4c87bfe147832d99eb01"
      unitRef="U002">8329000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7abefcdf70e14e829fcc6ade022c3dbd"
      unitRef="U001">1455719</roiv:StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_1173c8baa47b44ddb656dee063623ad7"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_07c9d6825e9f41ec8c06a22ef34fec1f"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_6383c3410b7c4be085b0005968d0e4fd"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_53c54ebf01754ad0b6fc9c6473960cdc"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_34eb68992f784daa974cef93d1077558"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="c20220401to20220630"
      decimals="-3"
      id="Fact_0dd5b56628ca41f18a975f6a89fe1b79"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_38fcf214207e447fa4e71ca5806fbf28"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_57156ae30bb94c129aba396ae6526a19"
      unitRef="U002">61590000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_176322fca0bf4f93a1169c6193c52fb8"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d3cd1ef158184c65ab5cb836e69a7f4d"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_d971f341a2624e4ab3aeb91ad883888c"
      unitRef="U002">11204000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220401to20220630"
      decimals="-3"
      id="Fact_ff387284b15a48ff94a896e31979fee3"
      unitRef="U002">72794000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2bac2e8408334aed82b7c1d4c8c3b2f1"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_80f6d268fe2d40a197bccb767d7e8ec4"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_53479ff907a14c4899742557c6f75eba"
      unitRef="U002">5966000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_eaffc8d777574b85bfc936ddc7494f84"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_0c60d5899bf9460aa5ba5d4c4fbe16dc"
      unitRef="U002">-199000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220401to20220630"
      decimals="-3"
      id="Fact_ca61ef40c0cc413992caa08af08b9246"
      unitRef="U002">5767000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_53d6b43f8c524c339e56882794b3656d"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_55dab0bbc90540809f3566d9459f603b"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_28f970a45798430d987d11ab2a5d0e44"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6e03c8e61e504064b9a87396167e8a7b"
      unitRef="U002">-331809000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_b90cd0b52d3f470495f74d1aaf445307"
      unitRef="U002">-21975000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20220630"
      decimals="-3"
      id="Fact_68273f772800450e888c818e5c1e4a07"
      unitRef="U002">-353784000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="c20220630_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_9e3e57fce12242db9c11dda6fb15cff0"
      unitRef="U002">22491000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d369b890db1344aa8d66aaadb00e3258"
      unitRef="U001">701171465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_bce04d09c1254863bd35bca3c7a72006"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_42deea2348e347f3bda4b44bfd123aec"
      unitRef="U002">4474624000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220630_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_1c07574f1a364186b080b8efaf9cb5b7"
      unitRef="U002">5020000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_21059a223c57411d9c0fb473204b8c0d"
      unitRef="U002">-3095533000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220630_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_478f9eeb786d4d7c858e8539933eb4bd"
      unitRef="U002">371280000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220630"
      decimals="-3"
      id="Fact_4072e06180c043d3ad3381b9f0a3faed"
      unitRef="U002">1755391000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f1277ade95ee4fefba52b40c3ab8e666"
      unitRef="U001">1185639</roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlans>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_5ec62dfcf9a5413183a63823bc61eb81"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_40778632202f4a71a469dd6695a71289"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_660a81e249f244e8b2c9e066cec0e38b"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f0f15ac7d5ac4af19ad0be96e4f794af"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_adceb86951d045b68254f0d5f9f8637e"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_7bfaf9f656a543b989ed806febf9a10f"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlans>
    <roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e84b68e0c1f547008ecd9610dfcb81f6"
      unitRef="U001">2029877</roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionShares>
    <roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c8c73b879986468ca3a0aa4b88d86103"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue>
    <roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cc63470c131747bb86c55bc66ab580d9"
      unitRef="U002">8836000</roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue>
    <roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_4973b10a802141968dfe3862416b78a3"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue>
    <roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_90496b4574c842c7a50495a19bc816b8"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue>
    <roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_e2c9b4fbee2544419714cf3f4760fa75"
      unitRef="U002">112000</roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue>
    <roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_b86e7296911048bcb600b890e2afe38a"
      unitRef="U002">8948000</roiv:StockIssuedDuringPeriodCommonSharesAndOtherConsiderationForAcquisitionValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_fd26cccfb8c94ab69dbfe310244db0f0"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_995c501131cb4b9c962f2bc7d89a77a2"
      unitRef="U002">-2240000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_3195c165ebc7400bb7699c676a821647"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a463e1c7a6e448de8043bc94417cd4e2"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_5a9d7fd5c5b64452ae19cb57e2db63b9"
      unitRef="U002">2240000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_876166bd8ef84df992030b1b69a865d4"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_8b50cf32cb0549f1a3565254ed277bdd"
      unitRef="U002">-22491000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_82805b578708492da5a9dd73e33c41fd"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f337f16542f44c379385565dbd26a869"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_58071e0ea001415483c83a1b131c458a"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8acce353543c41cd87408e482b37d99d"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_418e253325804eb99743184e6c3ec575"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_ade991a66634409db139d1f818a03e1f"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_20c3c2d3812e4e14b4c273fe7c580913"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7598abbe07af46a18154f4e37aaf7f9a"
      unitRef="U002">57415000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_0d0f54bdf6014fea82fa83ca38b742e9"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_278b296c3f1946e098a9ceb52f33c310"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_786cffd35a0f45948908543ef048655b"
      unitRef="U002">4564000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_dbc9e85af47c41caa2e319c2530ec86a"
      unitRef="U002">61979000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b77c582260c74b25b01ed03642e96864"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_06872ed2a63c4557b515d633c5ecef5e"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_483232ab705f4e14b2eff8bebc24d536"
      unitRef="U002">4069000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_afd5619953474ccda4d09b231ac40870"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_070cdb5da1114eaba453f9cd55a3d55f"
      unitRef="U002">-317000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_5aa401cb11e04f0e8de7405f3358e51a"
      unitRef="U002">3752000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_471cf4170d8a4ab6aae70c803e826268"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3efc68f21e8840abac2fca931adfd5b7"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_4332f887aed74ce99d8e766656a03bc1"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_dab37501cdd04b44806b68b2c88cb076"
      unitRef="U002">-291590000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_44686c19c56b46ea87241282a057bcfc"
      unitRef="U002">-24331000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_527e598f16614bf58f716b595f9bbb8b"
      unitRef="U002">-315921000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="c20220930_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_8d3b4fbd4ee44ffc828d81943c501600"
      unitRef="U002">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_709006338d984097a5943441c841e82c"
      unitRef="U001">704386981</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8750e5488e4e447c8043cbe36b8afd8b"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_438f3284ac014756819dfbbfc8a2b184"
      unitRef="U002">4538635000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_ed5803f915fb4ca2b4891817c7fbc290"
      unitRef="U002">9089000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_9742e1f8415f4e35a48828036154e325"
      unitRef="U002">-3387123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220930_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_1e8d986e44b043f8ae4bbf19ad915255"
      unitRef="U002">353548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20220930"
      decimals="-3"
      id="Fact_26bc615472494be3af9b234cfbe1c78a"
      unitRef="U002">1514149000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:StockIssuedDuringPeriodSharesNetIssuanceCosts
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e4d50dd70f3a4a8592b766f7e320c55e"
      unitRef="U001">20000000</roiv:StockIssuedDuringPeriodSharesNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c43bbd4996ef439cac713f9096631b7a"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3d4c39120b994577b2b271071c085c30"
      unitRef="U002">94735000</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_48e26c49f3ac44a88316dd0bc4cab11c"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3ccc3b2f9e924d2a81faef8f65934d93"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_b729decce3ae4b50ab0c753648cd4963"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_00c0d1ef33264938a7f71329cbc76f65"
      unitRef="U002">94735000</roiv:StockIssuedDuringPeriodValueNetIssuanceCosts>
    <roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_22fdbbfac0d14bd9b16ec4f0febbf87c"
      unitRef="U001">2417850</roiv:StockIssuedDuringPeriodSharesInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f746f04910bc4bd1869341216f095b55"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_4c49caaaa6f44636ae7bb48ca82624be"
      unitRef="U002">982000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_edb84de6e1594e0dad551d04d410fbc4"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d3344269bee6423f8ff3cd4931492aee"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_1a9ca2d95b5f40f8a46a399417c74327"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_200fc7f5eba5428fa355e1693f4d3f68"
      unitRef="U002">982000</roiv:StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_02f77a4af86d4b0ea549c14e28d112cf"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7bcfaffec2084b07bdfa5236d6a6e280"
      unitRef="U002">-2822000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_34956b25cd994b9089214c643edba62d"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7e5b51b4d10f45d58e730c6c8f95dbd2"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_190ba1a228594ab8bc6695c241038168"
      unitRef="U002">2822000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_a1529149898247eda13ebbc2ed8501ae"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyAndCapitalContributionsToSubsidiaries>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6570954dad004db7ac0a5676647e9e24"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a5f6c5f6e8524fadb43c2b34d41517b8"
      unitRef="U002">19599000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_7c33b0d503e543ee9b5fb9ed6feece52"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_695123d21dfb4bc2a49e60000a499fe1"
      unitRef="U002">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_70927acae59c422f8bdc85d4a696e0ca"
      unitRef="U002">48129000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_eda624b7c1fd42bea6b8ac80fa793781"
      unitRef="U002">67728000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyNetIssuanceCostsValue>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ceddec870d2b46fdbb27df0b667887f5"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_c1719e20e2204e6eac20741941fb5774"
      unitRef="U002">260000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_e8dbbc37fdc740669737de12ba5f3d4b"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d252cf49ea2349e58c30ff21c2407085"
      unitRef="U002">0</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_0546f8ffa9fc4215a4cfab65e903eab4"
      unitRef="U002">177000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_6e42a80e7e97447abb6a5ab34a09dad8"
      unitRef="U002">437000</roiv:StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7099dcdf68ba4b00bd75dab8c1bca51d"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0cc79e44afbd45f9a4038000dd5c9b3b"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_da4edd84f02c4f69b459f7517b78e858"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6bed71de9ecf4120bdc489bb90c315fa"
      unitRef="U002">0</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_d67b855c784e4251909c4955a64ca112"
      unitRef="U002">292000</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_31dcb1e27ca8406ca0f1c50fa6eec542"
      unitRef="U002">292000</roiv:NoncontrollingInterestIncreaseDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7fd1882321db4724a8d2d8a92976a9a2"
      unitRef="U002">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a464ae02857b4da6ab64a66d17623e3d"
      unitRef="U002">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_435d9076ea9246808f112c926a44c16e"
      unitRef="U002">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_53c84f438ef3488198f96ed5251bdcfc"
      unitRef="U002">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_4042f245b24548ffa1f0f0e44c88e8f7"
      unitRef="U002">87500000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_150c6342409d4a768654132a5e5b8526"
      unitRef="U002">87500000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e44e3a41926447a28c7a760d2a87962d"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9924a2ca1f8442aa8b71aa1c8cb92126"
      unitRef="U002">45961000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_25898d6dfe7c4af28d7beb9f70a26cba"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c320420eb4464d2db4f8ddb4f5084192"
      unitRef="U002">0</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_a5800c2333f645bfac9757a623ac4cac"
      unitRef="U002">11770000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_51085ffa298643e5a3d114666dc73a8f"
      unitRef="U002">57731000</roiv:APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8869d4b87a5c4845b1afa6aa6edc0edc"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_c46f4d211a754f238d7b3244909340c0"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_8a79243b9beb4c238a3ea598df29a123"
      unitRef="U002">-9818000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_990775eb23044a99b3d44b19d0df0b53"
      unitRef="U002">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_47895eda84fe47ab98b06ffb9d09736d"
      unitRef="U002">846000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_d75350cd776d4940970885e46c6f12f8"
      unitRef="U002">-8972000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4ff4a5c379f44a75bc9a68e8ecd6f67b"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_410cb8785d5147c7989bfa03069ffb6a"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_4538f2f70d83416e8528ee1911405715"
      unitRef="U002">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e70663bb9ffd4be292eca41141baf8e6"
      unitRef="U002">-352014000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_2743168a685a4ad98e55578f42ac66a6"
      unitRef="U002">-32882000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_b9f55dfb5afb4d8ca480bb4105b4eac0"
      unitRef="U002">-384896000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="c20221231_StatementEquityComponentsAxis_RedeemableNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_293db412ad4e4f81a1ae00e55f63240b"
      unitRef="U002">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f437e7861e584d89b2ef0781fddd2d5c"
      unitRef="U001">726804831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_801a0b4831da40d5b2240160adb2bedb"
      unitRef="U002">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d0e44e03c0a84466a5c87ebe3b13e477"
      unitRef="U002">4695386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20221231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_39edc056ba3c49fa91a4d77db0389e37"
      unitRef="U002">-729000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e23ba3f69f1747cf91b1a48023372dcf"
      unitRef="U002">-3739137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20221231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_693288f8ee6c4e37a0fce62adaaf4b3e"
      unitRef="U002">471618000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20221231"
      decimals="-3"
      id="Fact_bf60ba0db6074abb9313aa9becaba159"
      unitRef="U002">1427138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_2a4b699f00c94f8f928830d7b9ebf524"
      unitRef="U002">4413702000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_3e704ce9d8424f73b804401f02092687"
      unitRef="U002">-1054601000</us-gaap:ProfitLoss>
    <roiv:NonCashAcquiredInProcessResearchAndDevelopment
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_7805e281fcac40abbf5bb25462221e1e"
      unitRef="U002">0</roiv:NonCashAcquiredInProcessResearchAndDevelopment>
    <roiv:NonCashAcquiredInProcessResearchAndDevelopment
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_f929b8a776dd4d8ebe46fa2c64be0395"
      unitRef="U002">87749000</roiv:NonCashAcquiredInProcessResearchAndDevelopment>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_cce46a527a0745fc8c070762b9a88eff"
      unitRef="U002">152903000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_b04c6e88da5345ab8f29a90cbabcb9f7"
      unitRef="U002">192504000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_88e948fe64ad4e2f8787933f4689b8d7"
      unitRef="U002">-63880000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_332a720fb50d41fbb61340a483c55f40"
      unitRef="U002">-53277000</us-gaap:GainLossOnInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_936c06c958414209a474396ac935cef7"
      unitRef="U002">-85376000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_40fe75641c0a4e218a0098a4edec570b"
      unitRef="U002">-90032000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_70570cca1d4545f2aa3d64e3dd2d80ae"
      unitRef="U002">17354000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_a151b46132e742e4a152ff616f902fd0"
      unitRef="U002">29276000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_b1b0204253c84956bbd321fea6aea5b5"
      unitRef="U002">5348410000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_93f1633809d04994a6d21494748eea52"
      unitRef="U002">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_098816723bca4735a1b61234ec1a22b4"
      unitRef="U002">16811000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_9c2e38073ea84edda34817d9195aba08"
      unitRef="U002">12904000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_9187303b4326483a869eb6e772476c8c"
      unitRef="U002">5047000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_65350038fc814bc7827720699e7a102f"
      unitRef="U002">6009000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_c1284585a1714bb69bb30b7117a3f648"
      unitRef="U002">31846000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_1a092a43481147179354063d85e80788"
      unitRef="U002">8066000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_e3f6c686498249ae867b7479ea7ce61a"
      unitRef="U002">18767000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_17ab5aed4e0b49818eb3720287dc4e47"
      unitRef="U002">31037000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_cf71c97a836042f798c68a5bc08e4663"
      unitRef="U002">1797000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_dcfca5fd29ec43a7b7ab80adf8ef320e"
      unitRef="U002">13970000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_3cb461b7fec246289ebaee71a4290d63"
      unitRef="U002">-15785000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_134e3b5397a443c397e5fdf96866c311"
      unitRef="U002">5702000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_91ef4c71ddcc4481b8335d96836cb569"
      unitRef="U002">-6151000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_7fcda848416e486c9a4df96896216482"
      unitRef="U002">-6814000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_9f24554f7b6245e98828262f7e56139f"
      unitRef="U002">-41986000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_fa3051800c6448209cbdcde7be83a6ea"
      unitRef="U002">-3342000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_44766c9ca5fb4d31b1b5060e898136e1"
      unitRef="U002">-656811000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_4d91d30999324b76a2a18f71005c9aae"
      unitRef="U002">-664305000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <roiv:MilestonePayments
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_6598e24980fd40e19d3748bf78afbe32"
      unitRef="U002">0</roiv:MilestonePayments>
    <roiv:MilestonePayments
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_83bda41e42ab4f1cab04c634a3a52035"
      unitRef="U002">140136000</roiv:MilestonePayments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_86cc706188a64936b495a4e5ec2167af"
      unitRef="U002">1033000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_410440e9c83b40b7afa4f53eb1067e52"
      unitRef="U002">11068000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_4ffcbfa025ff486bbaccb2f5abf64457"
      unitRef="U002">47500000</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_56352a7ad8244cbdb7305d6ad95e32dc"
      unitRef="U002">0</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <roiv:ProceedsFromSaleOfAssets
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_bcbfbc5c5ce7415eb83e31abac4e27f0"
      unitRef="U002">5233396000</roiv:ProceedsFromSaleOfAssets>
    <roiv:ProceedsFromSaleOfAssets
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_fbb87877cc4d44ae96315c34b8e8c7a4"
      unitRef="U002">0</roiv:ProceedsFromSaleOfAssets>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_009cd5993216450eb9061a94b38a29b1"
      unitRef="U002">83679000</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_21561966525945d69f069ced2c798780"
      unitRef="U002">6706000</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_eee223ac8788413d9451c7a6bd6576af"
      unitRef="U002">-511000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_b1b4d61cbaca484797034b57c519f5b2"
      unitRef="U002">-88000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_be3a39108dda48b7b4eb127fcf75f169"
      unitRef="U002">5196695000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_ca5ebf80e0c24888a43d694f1f088be0"
      unitRef="U002">-157822000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_aa4c30ec86504f649bce26659c2e6e57"
      unitRef="U002">199822000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_9e7c6c0b679b4531b760a6b6e5bd20e2"
      unitRef="U002">94735000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_24d8e50c13054299b354c0e9d93f09e9"
      unitRef="U002">238733000</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_1a18e91c80f7497f937006c3befc897c"
      unitRef="U002">67727000</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_d56bbe659cbc4b5a9214496c1dbb3b07"
      unitRef="U002">0</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_e3c865fae2634744b9a30543fb49a0a7"
      unitRef="U002">159899000</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:PaymentsOfSubsidiaryDividends
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_fbd6aa0cc8e046449b90531e89a1c497"
      unitRef="U002">6000000</roiv:PaymentsOfSubsidiaryDividends>
    <roiv:PaymentsOfSubsidiaryDividends
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_991cf6fa7ccb4754bcecc44abb0952e3"
      unitRef="U002">0</roiv:PaymentsOfSubsidiaryDividends>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_55716f5515dd4e9bb04d7be031cd408b"
      unitRef="U002">21815000</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_1a51035b24154f5e8fdb5278b3a9ca6c"
      unitRef="U002">22108000</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <roiv:PaymentForOfferingAndLoanCosts
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_2e931690534247ae8d1fb1234111cbe1"
      unitRef="U002">0</roiv:PaymentForOfferingAndLoanCosts>
    <roiv:PaymentForOfferingAndLoanCosts
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_9ebe73bdcdd4426cafdb430e713e61e8"
      unitRef="U002">2250000</roiv:PaymentForOfferingAndLoanCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_ab609be57db24ee8af4301a8bccdf7e7"
      unitRef="U002">1225000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_3efd99e3b6d94a3eb7b211406658b19b"
      unitRef="U002">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_86ed49e266724d2482d22c00074eb221"
      unitRef="U002">51023000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_2e63e065ab5f47dda017ae1faa8d4081"
      unitRef="U002">569000</us-gaap:ProceedsFromStockOptionsExercised>
    <roiv:PaymentsOfTaxesForTheRepurchaseOfEquity
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_185fbedcadfe46af95d59d084baa77bf"
      unitRef="U002">9101000</roiv:PaymentsOfTaxesForTheRepurchaseOfEquity>
    <roiv:PaymentsOfTaxesForTheRepurchaseOfEquity
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_38201011e8d34bf18500e8e7351b3d56"
      unitRef="U002">9442000</roiv:PaymentsOfTaxesForTheRepurchaseOfEquity>
    <us-gaap:ProceedsFromStockPlans
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_aa054c1f1f0941d09d486bd989f83996"
      unitRef="U002">587000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_4822ac96138b4d0fae0648d840e1270f"
      unitRef="U002">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_f5210bc60077499f87b9869af2bdd729"
      unitRef="U002">5000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_268cc33e25fa4ae2a9253eb3bea6407d"
      unitRef="U002">0</us-gaap:ProceedsFromWarrantExercises>
    <roiv:PaymentForWarrantRedemptions
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_1b948a3854ea433a92b88fde4128cf31"
      unitRef="U002">41000</roiv:PaymentForWarrantRedemptions>
    <roiv:PaymentForWarrantRedemptions
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_4bda51415a9446f8924b946ba3ea2cfe"
      unitRef="U002">0</roiv:PaymentForWarrantRedemptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_3819237778a2417fb2e6c0b7190af3df"
      unitRef="U002">451988000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_9c05357c33794217a10b96fa22dd47c4"
      unitRef="U002">289130000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_b9cc70bb369241f19adc0eba727cebef"
      unitRef="U002">1471000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_ee405ec1b7e74e09839ea69f3604091d"
      unitRef="U002">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_b774d9624e34446f8b5f5f96f7f2e2b5"
      unitRef="U002">4993343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_666e21af754a46f6ba129d8a827ff1e3"
      unitRef="U002">-532997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230331"
      decimals="-3"
      id="Fact_c5748371322c49b4bbb5273d2ae308b8"
      unitRef="U002">1692115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20220331"
      decimals="-3"
      id="Fact_44c5afb657f945759c8465b5d13ea8e4"
      unitRef="U002">2074034000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_8e6194be17634f5d897a9f7968fea706"
      unitRef="U002">6685458000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="-3"
      id="Fact_f5c174f9acc1418ba265db8fcc659357"
      unitRef="U002">1541037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <roiv:CashlessExerciseOfTheCompanyCommonStockWarrants
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_7d78d1daedc74d9ca9114b3ef34b16b5"
      unitRef="U002">83258000</roiv:CashlessExerciseOfTheCompanyCommonStockWarrants>
    <roiv:CashlessExerciseOfTheCompanyCommonStockWarrants
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_410017eb285f433bb72112b76541cee4"
      unitRef="U002">0</roiv:CashlessExerciseOfTheCompanyCommonStockWarrants>
    <roiv:CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_791ed4db9f174a14b850561d15db978c"
      unitRef="U002">0</roiv:CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment>
    <roiv:CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_3dd6a82cbbf64bd8b0e617bf39785944"
      unitRef="U002">9694000</roiv:CommonSharesAndOtherConsiderationIssuedForPurchaseOfPropertyAndEquipment>
    <roiv:NoncashOther
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_157c127a466d4c4aa3ffa4c03baa8a3c"
      unitRef="U002">301000</roiv:NoncashOther>
    <roiv:NoncashOther
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_e9020976598d437c92ab7489206b2b0c"
      unitRef="U002">7063000</roiv:NoncashOther>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="c20230401to20231231"
      id="Text_1d704520f5cf4bf8a54773c0831f66c0">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 1&#x2014;Description of Business and Liquidity&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(A) Description of Business&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#x201c;Company&#x201d; or &#x201c;RSL&#x201d;) aims to improve health by rapidly delivering innovative
          medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#x201c;Vants&#x201d;) and deploying technology to drive greater efficiency in research and development and commercialization. In addition to
          biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April 7, 2014 as a Bermuda exempted limited company.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;VTAMA&#xae; (tapinarof) was approved by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) in May 2022 for the treatment of plaque psoriasis in
          adult patients.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company has determined that it has one
          operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#x2019;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#x201c;Equity
          Method Investments&#x201d; for further discussion of the Company&#x2019;s investments in unconsolidated entities.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;On September 30, 2021, RSL completed its business combination (the &#x201c;Business Combination&#x201d;) with Montes Archimedes Acquisition Corp. (&#x201c;MAAC&#x201d;), a
          special purpose acquisition company, and began trading on Nasdaq under the ticker symbol &#x201c;ROIV.&#x201d;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(B) Liquidity&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;The













          &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;Company has incurred significant operating
            losses and negative cash flows from operations since its inception. In December 2023, the Company recognized a gain of approximately $5.3
            billion on the sale of Telavant net assets.&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the Company had cash and cash equivalents of approximately&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$6.7 billion&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and
            its retained earnings was&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$727.3 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;. For the&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;2022&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the Company incurred net income of approximately&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$4.4
            billion&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and a net loss of approximately&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$1.1 billion&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, respectively. The Company has historically financed its operations primarily through the sale
            of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. Through its subsidiary, Dermavant Sciences Ltd., the Company has launched its first commercial product,
            VTAMA, following approval by the FDA in May 2022&lt;/span&gt;.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to
          commercialization of products, regulatory approvals to market its product candidates, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property
          rights. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may require additional capital to fully implement its business plan.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure
          requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements.&lt;/div&gt;
</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c20230401to20231231"
      decimals="INF"
      id="Fact_34e78714195b4eadb74e957cc150c301"
      unitRef="U004">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20230401to20231231"
      decimals="INF"
      id="Fact_01bd28f6e54b488ea69ef765bc958c2d"
      unitRef="U004">1</us-gaap:NumberOfOperatingSegments>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20231201to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_TelavantHoldingsIncMember"
      decimals="-8"
      id="Fact_fed5a283303747babcc8dc300be5887d"
      unitRef="U002">5300000000</roiv:GainLossOnSaleOfAssets>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="-8"
      id="Fact_661b387ce19541d89ec9153649a26d6e"
      unitRef="U002">6700000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20231231"
      decimals="-5"
      id="Fact_40e4bf7bb4914362884158e0a91220e8"
      unitRef="U002">727300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProfitLoss
      contextRef="c20230401to20231231"
      decimals="-8"
      id="Fact_83a837d60f644da380f29f85a952ad03"
      unitRef="U002">4400000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20220401to20221231"
      decimals="-8"
      id="Fact_827028db14f34d38815a28d6d100e60b"
      unitRef="U002">-1100000000</us-gaap:ProfitLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20230401to20231231"
      id="Text_1cfef57290ff45639577d3d3deac9bed">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 2&#x2014;Summary of Significant Accounting Policies&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(A) Basis of Presentation and Principles of Consolidation&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company&#x2019;s fiscal year ends on March 31, and its fiscal quarters end on June 30, September 30, and December 31.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
          accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and follow the requirements of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial reporting. Accordingly, these unaudited condensed
          consolidated financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be
          condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial
          statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the SEC. The unaudited condensed consolidated balance sheet at March 31, 2023 has been derived from the audited
          consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial
          position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the nine months ended December 31,
          2023 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2024, for any other interim period, or for any other future year.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting
          Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) and Accounting Standards Updates (&#x2018;&#x2018;ASU&#x2019;&#x2019;) of the Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in
          which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to
          noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents
          noncontrolling interests as a component of shareholders&#x2019; equity on its unaudited condensed consolidated balance sheets.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying
          amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest
          is adjusted is recognized within shareholders&#x2019; equity attributable to RSL.&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(B) Use of Estimates&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts
          reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development
          costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
          values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;(C) Concentrations&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company
          maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and
          liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company has long-lived assets in different geographic locations. As of December 31, 2023 and March 31, 2023, a majority of the Company&#x2019;s
          long-lived assets were located in the United States.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;(D) Cash, Cash
          Equivalents, and Restricted Cash&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company
          considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted
          cash as presented on the accompanying condensed consolidated balance sheets as follows (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Cash and cash equivalents&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,670,810&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,676,813&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Restricted cash (included in &#x201c;Other current assets&#x201d;)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,165&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,011&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;Restricted cash (included in &#x201c;Other assets&#x201d;)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;9,483&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;10,291&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,685,458&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,692,115&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(E) Contingencies&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually
          assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at
          which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the
          Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(F) Investments&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Investments in equity securities may be accounted for using (i) the fair value option, if elected, (ii) fair value through earnings if fair value
          is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the
          measurement alternative is made for each eligible investment.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company
          believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#x201c;Equity Method Investments.&#x201d;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(G) Fair Value Measurements&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance
          establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are
          inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market
          participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received
          to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a
          three-tier fair value hierarchy that distinguishes among the following:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                  &lt;div style="text-align: left;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;div style="text-align: justify;"&gt;Level 1-Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                    &lt;div&gt;&#x2022;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                    &lt;div style="text-align: justify;"&gt;Level 2-Valuations are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models
                      for which all significant inputs are observable, either directly or indirectly.&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                      &lt;div&gt;&#x2022;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                      &lt;div style="text-align: justify;"&gt;Level 3-Valuations are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value
          requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the
          lowest level of any input that is significant to the fair value measurement.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of common stock of
          Heracles Parent, L.L.C., the parent entity of Datavant, (as defined and discussed in Note 3, &#x201c;Equity Method Investments&#x201d;); liability instruments issued, including warrant and earn-out shares liabilities issued in connection with the Company&#x2019;s
          business combination with MAAC (as discussed in Note 12, &#x201c;Earn-Out Shares, Public Warrants and Private Placement Warrants&#x201d;); its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and
          long-term debt.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;"&gt;The shares of Arbutus common stock and
          investments in common stock with a readily determinable fair value are classified as Level 1, and their fair value is determined based upon quoted market prices in an active market. The shares of common stock of Heracles Parent, L.L.C., the
          parent entity of Datavant (as defined and discussed in Note 3, &#x201c;Equity Method Investments&#x201d;) and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 12, &#x201c;Earn-Out Shares, Public Warrants and Private
          Placement Warrants&#x201d;), are classified as Level 3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Prior to their settlement, the Public Warrants were publicly traded and
          therefore were classified as Level 1 as the Public Warrants had a readily determinable fair value. Cash and accounts payable are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature.
          Money market funds are included in Level 1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly
          owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level 2 of the fair value hierarchy. Long-term debt issued
          by Dermavant for which the fair value option has been elected is included in Level 3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
        &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(H) Significant Accounting Policies&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;There were no significant changes to the Company&#x2019;s significant accounting policies from those disclosed in the Company&#x2019;s Form 10-K for the year ended March 31, 2023.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(I) Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;The Company did not adopt any material accounting pronouncements during the nine months ended December 31, 2023.&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(J) Recently Issued Accounting Pronouncements Not Yet Adopted&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In
            November 2023, the FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&#x201d; which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant
            segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU is applicable to the Company&#x2019;s Annual Report on Form 10-K
            for the fiscal year ended March 31, 2025, and subsequent interim periods, with early adoption permitted. These amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently
            evaluating the impact of adopting this ASU on its consolidated financial statements&lt;/span&gt;.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 18pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income
            Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; which includes updates to the income tax disclosures related to the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments are effective for fiscal
            years beginning after December 15, 2024 and is applicable to the Company&#x2019;s fiscal year beginning April 1, 2025, with early adoption permitted. The amendments should be applied prospectively, however retrospective application is permitted. The
            Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt;  &lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20230401to20231231"
      id="Text_971156c9275b4805b34f2eafb7e7a4fe">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company&#x2019;s fiscal year ends on March 31, and its fiscal quarters end on June 30, September 30, and December 31.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
          accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and follow the requirements of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial reporting. Accordingly, these unaudited condensed
          consolidated financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be
          condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial
          statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the SEC. The unaudited condensed consolidated balance sheet at March 31, 2023 has been derived from the audited
          consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial
          position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the nine months ended December 31,
          2023 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2024, for any other interim period, or for any other future year.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting
          Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) and Accounting Standards Updates (&#x2018;&#x2018;ASU&#x2019;&#x2019;) of the Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in
          which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation.&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="c20230401to20231231"
      id="Text_941c61e16cb34594af99645f097cbe72">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to
          noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents
          noncontrolling interests as a component of shareholders&#x2019; equity on its unaudited condensed consolidated balance sheets.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying
          amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest
          is adjusted is recognized within shareholders&#x2019; equity attributable to RSL.&lt;/div&gt;
</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20230401to20231231"
      id="Text_88f5b331ff484d8185f4d396e889a6b3">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(B) Use of Estimates&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts
          reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development
          costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
          values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20230401to20231231"
      id="Text_659064c4fa2b47b29093588ea31292fa">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;(C) Concentrations&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company
          maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and
          liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company has long-lived assets in different geographic locations. As of December 31, 2023 and March 31, 2023, a majority of the Company&#x2019;s
          long-lived assets were located in the United States.&lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="c20230401to20231231"
      id="Text_db6a625a60eb427aa97f4a884e8f6f9d">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;(D) Cash, Cash
          Equivalents, and Restricted Cash&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company
          considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted
          cash as presented on the accompanying condensed consolidated balance sheets as follows (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Cash and cash equivalents&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,670,810&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,676,813&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Restricted cash (included in &#x201c;Other current assets&#x201d;)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,165&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,011&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;Restricted cash (included in &#x201c;Other assets&#x201d;)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;9,483&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;10,291&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,685,458&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,692,115&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_4eefbee7bfa44190aa164ffc19182145">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted
          cash as presented on the accompanying condensed consolidated balance sheets as follows (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Cash and cash equivalents&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,670,810&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,676,813&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Restricted cash (included in &#x201c;Other current assets&#x201d;)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,165&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,011&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;Restricted cash (included in &#x201c;Other assets&#x201d;)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;9,483&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;10,291&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,685,458&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,692,115&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5f943e018ced4135b46c99ee18e00047"
      unitRef="U002">6670810000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20230331"
      decimals="-3"
      id="Fact_6ef1ef3ab96c4c31b60695c6b300be6c"
      unitRef="U002">1676813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_66ae039e743646f6a4b3fe9ddd07b5cb"
      unitRef="U002">5165000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_6d0eb19c615341ca9cd4c08374c0569b"
      unitRef="U002">5011000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_08a040975ba3433bbe90cde0074b96e8"
      unitRef="U002">9483000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_3bd0759ad3044abc90d6dd815577cd31"
      unitRef="U002">10291000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4611a28f316141a58ca576eb960d69a4"
      unitRef="U002">6685458000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230331"
      decimals="-3"
      id="Fact_de1bc92c78a14a65af65267f54ac93f1"
      unitRef="U002">1692115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="c20230401to20231231"
      id="Text_48d508a27da244c39cbf3d11163ca26f">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(E) Contingencies&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually
          assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at
          which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the
          Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="c20230401to20231231"
      id="Text_d263b7e9970d4177810738840f5ce099">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(F) Investments&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Investments in equity securities may be accounted for using (i) the fair value option, if elected, (ii) fair value through earnings if fair value
          is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the
          measurement alternative is made for each eligible investment.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company
          believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#x201c;Equity Method Investments.&#x201d;&lt;/div&gt;
</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="c20230401to20231231"
      id="Text_074d415c01634e328a6a0f65df6fd107">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(G) Fair Value Measurements&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance
          establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are
          inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market
          participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received
          to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a
          three-tier fair value hierarchy that distinguishes among the following:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                  &lt;div style="text-align: left;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;div style="text-align: justify;"&gt;Level 1-Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                    &lt;div&gt;&#x2022;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                    &lt;div style="text-align: justify;"&gt;Level 2-Valuations are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models
                      for which all significant inputs are observable, either directly or indirectly.&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                      &lt;div&gt;&#x2022;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                      &lt;div style="text-align: justify;"&gt;Level 3-Valuations are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value
          requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the
          lowest level of any input that is significant to the fair value measurement.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of common stock of
          Heracles Parent, L.L.C., the parent entity of Datavant, (as defined and discussed in Note 3, &#x201c;Equity Method Investments&#x201d;); liability instruments issued, including warrant and earn-out shares liabilities issued in connection with the Company&#x2019;s
          business combination with MAAC (as discussed in Note 12, &#x201c;Earn-Out Shares, Public Warrants and Private Placement Warrants&#x201d;); its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and
          long-term debt.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;"&gt;The shares of Arbutus common stock and
          investments in common stock with a readily determinable fair value are classified as Level 1, and their fair value is determined based upon quoted market prices in an active market. The shares of common stock of Heracles Parent, L.L.C., the
          parent entity of Datavant (as defined and discussed in Note 3, &#x201c;Equity Method Investments&#x201d;) and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 12, &#x201c;Earn-Out Shares, Public Warrants and Private
          Placement Warrants&#x201d;), are classified as Level 3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Prior to their settlement, the Public Warrants were publicly traded and
          therefore were classified as Level 1 as the Public Warrants had a readily determinable fair value. Cash and accounts payable are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature.
          Money market funds are included in Level 1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly
          owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level 2 of the fair value hierarchy. Long-term debt issued
          by Dermavant for which the fair value option has been elected is included in Level 3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market.&lt;/div&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20230401to20231231"
      id="Text_bbcb6500ac0442ceae9687f35c093fcb">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(H) Significant Accounting Policies&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;There were no significant changes to the Company&#x2019;s significant accounting policies from those disclosed in the Company&#x2019;s Form 10-K for the year ended March 31, 2023.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(I) Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;The Company did not adopt any material accounting pronouncements during the nine months ended December 31, 2023.&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(J) Recently Issued Accounting Pronouncements Not Yet Adopted&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt; text-align: justify;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In
            November 2023, the FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&#x201d; which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant
            segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU is applicable to the Company&#x2019;s Annual Report on Form 10-K
            for the fiscal year ended March 31, 2025, and subsequent interim periods, with early adoption permitted. These amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently
            evaluating the impact of adopting this ASU on its consolidated financial statements&lt;/span&gt;.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 18pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income
            Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; which includes updates to the income tax disclosures related to the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments are effective for fiscal
            years beginning after December 15, 2024 and is applicable to the Company&#x2019;s fiscal year beginning April 1, 2025, with early adoption permitted. The amendments should be applied prospectively, however retrospective application is permitted. The
            Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt;  &lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="c20230401to20231231"
      id="Text_a96f05fdbfaf42e8bc6cc4c592fd6dec">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 3&#x2014;Equity Method Investments&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"&gt;The Company maintains equity method investments in certain entities. As of December 31, 2023 and March 31, 2023, the most significant of these were our
            investments in Arbutus and Datavant (as defined below), which are accounted for using the fair value option.&lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"&gt;The &lt;/span&gt;&lt;span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Company determined that it does not control these entities and as a result does not consolidate these entities. Due to the Company&#x2019;s significant influence over operating and financial policies of
            these entities, the entities are considered related parties of the Company.&lt;/span&gt;&lt;span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Investment in Arbutus&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company holds an investment in Arbutus in the form of 38,847,462 common shares of Arbutus. As of December 31, 2023, RSL held approximately 23% of issued
          and outstanding shares of Arbutus.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;At &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;March 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the aggregate fair value of the Company&#x2019;s investment in Arbutus was&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$97.1 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$117.7 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, respectively. During the three and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;nine&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;months ended&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the
              Company recognized an unrealized gain of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$18.3 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and an unrealized loss of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$20.6 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;on its investment in Arbutus, respectively, in the accompanying condensed consolidated statements of operations. During the three and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;nine&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;months ended&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the
              Company recognized an unrealized gain of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$16.3 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and an unrealized loss of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$25.3 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;on its investment in Arbutus, respectively, in the accompanying condensed consolidated statements of operations. The fair value of the Company&#x2019;s investment was
              determined using the closing price of Arbutus&#x2019;s common stock on&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;March 31, 2023&lt;/span&gt; of $2.50 and $3.03, respectively. &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Investment
















            in Datavant &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In June 2021, Datavant and Heracles Parent, L.L.C. (referred to herein as &#x201c;Ciox Parent&#x201d; and, after the closing of the Datavant Merger (as defined below), &#x201c;Datavant&#x201d;), primarily through its wholly owned subsidiary CIOX
            Health, LLC, entered into a definitive agreement to merge Datavant with and into a newly formed wholly owned subsidiary of Ciox Parent (the &#x201c;Datavant Merger&#x201d;). As of December 31, 2023, the Company&#x2019;s minority equity interest represented
            approximately 9% of the outstanding Class A units in Ciox Parent. Ciox Parent&#x2019;s capital structure includes several classes of
            preferred units that, among other features, have liquidation preferences and conversion rights. Upon conversion of such preferred units into Class A units, the Company&#x2019;s ownership interest would be diluted. &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;As
          &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;March 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the
            fair value of the Company&#x2019;s investment was&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$135.9 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$178.6
            million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, respectively. During the three and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;nine&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;months ended&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the Company recognized unrealized losses on its investment in Datavant of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$28.4
            million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$42.6 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, respectively, in the accompanying condensed consolidated statements of operations. During the three and&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;nine&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;months ended&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the
            Company recognized an unrealized gain on of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$7.5 million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;and an unrealized loss of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;$21.4
            million&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;on its investment in Datavant, respectively, in the accompanying condensed consolidated statements of operations&lt;/span&gt;&lt;span style="letter-spacing: normal; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The fair value of the Company&#x2019;s investment was determined using valuation models that incorporate significant unobservable inputs and is
          classified as a Level 3 measurement within the fair value hierarchy. Refer to Note 13, &#x201c;Fair Value Measurements&#x201d; for more information.&lt;/div&gt;
</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6f887af8fb094e7bab646d5d39ff565b"
      unitRef="U001">38847462</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="2"
      id="Fact_0b3c21932a1649a3a70e11743b85c469"
      unitRef="U005">0.23</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-5"
      id="Fact_3ea8d968f9754879a7c6f485163e16f9"
      unitRef="U002">97100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-5"
      id="Fact_8850f50047674960b55be504d25ed619"
      unitRef="U002">117700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-5"
      id="Fact_0c3b7f0ae13c454185a8833eac8765b6"
      unitRef="U002">18300000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-5"
      id="Fact_d5acc1fa62b946a184075821189ef8e2"
      unitRef="U002">-20600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-5"
      id="Fact_28904081f4f2425c9f1484a7c1b6c338"
      unitRef="U002">16300000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-5"
      id="Fact_7c017ec4b9da4df5bbc0663fd8f15e39"
      unitRef="U002">-25300000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="2"
      id="Fact_49e1cc809d6a4c51bbb137c3de514e17"
      unitRef="U003">2.5</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="2"
      id="Fact_5945c0e7ef4a454d8e29135beb970de2"
      unitRef="U003">3.03</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"
      decimals="2"
      id="Fact_c0085d30f2d944adba22fae20325e33c"
      unitRef="U005">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"
      decimals="-5"
      id="Fact_bfd6c544333b42a88b735a776edc22fd"
      unitRef="U002">135900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"
      decimals="-5"
      id="Fact_f430154892b54b6d9bd215752808a740"
      unitRef="U002">178600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20231001to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"
      decimals="-5"
      id="Fact_181fab6916e2457caa5448f407730fc3"
      unitRef="U002">-28400000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"
      decimals="-5"
      id="Fact_f394aa643a9349e3a932fe23df798e0e"
      unitRef="U002">-42600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20221001to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"
      decimals="-5"
      id="Fact_4a3e4fb8c37b447089051e257e314c27"
      unitRef="U002">7500000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20220401to20221231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_CioxParentMember"
      decimals="-5"
      id="Fact_054dd873ae5a4d2895b0e03831b8592b"
      unitRef="U002">-21400000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="c20230401to20231231"
      id="Text_8140b11ee8f444c1844eeb61076e2a2e">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 4&#x2014;Intangible Assets&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;In July 2018, Dermavant acquired the worldwide rights (other than for China) with respect to certain intellectual property rights retained by
          Welichem Biotech Inc. (&#x201c;Welichem&#x201d;) to VTAMA and related compounds from Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Ltd. (collectively, &#x201c;GSK&#x201d;) pursuant to an asset purchase agreement. GSK previously acquired rights to
          a predecessor formulation from Welichem pursuant to an asset purchase agreement between GSK and Welichem entered into in May 2012. The Company evaluated the agreement and determined that the acquired assets did not meet the definition of a
          business and thus the transaction was accounted for as an asset acquisition.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Following the FDA approval of VTAMA in May 2022, the Company became obligated to pay a regulatory milestone to GSK of &#xa3;100.0 million (approximately $126
          million on the date of achievement) following the receipt of marketing approval of VTAMA in the United States. The milestone was paid in July 2022.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Additionally, the first sale of VTAMA in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$25.0 million (approximately $20
          million on the date of achievement). The milestone was paid in August 2022.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Both of the above milestones were capitalized as intangible assets upon achievement and are being amortized over their estimated useful lives. As
          of December 31, 2023, the remaining weighted average estimated useful lives of the intangible assets was 14.8 years.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The following table summarizes the Company&#x2019;s recognized intangible assets (in thousands):&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="text-align: center;"&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Gross amount&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;166,471&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;152,629&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Less: accumulated amortization&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(16,056&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(7,748&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Net book value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;150,415&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;144,881&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Amortization expense was $2.4
          million and $2.2 million for the three months ended December 31, 2023 and 2022, respectively, and $7.2 million and $5.2 million for the
          nine months ended December 31, 2023 and 2022, respectively. Amortization expense was recorded as part of &#x201c;Cost of revenues&#x201d; in the accompanying condensed consolidated statement of operations. Future amortization expense is approximately $2.5 million for the remainder of the year ended March 31, 2024, $10.1 million for each of the years ended from March 31, 2025 through March 31, 2028 and $107.5
          million thereafter. The Company&#x2019;s intangible assets are denominated in currencies other than U.S. dollar and therefore are subject to foreign currency movements.&lt;/div&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <roiv:MilestonePayable
      contextRef="c20220531_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember"
      decimals="-5"
      id="Fact_cb0b319280de4cb5b6cb14d4134c5104"
      unitRef="U006">100000000</roiv:MilestonePayable>
    <roiv:MilestonePayable
      contextRef="c20220531_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember"
      decimals="-6"
      id="Fact_c08db14b5ff24c11831c2359969a87d9"
      unitRef="U002">126000000</roiv:MilestonePayable>
    <roiv:MilestonePaid
      contextRef="c20220701to20220731_CounterpartyNameAxis_GlaxoSmithKlineIntellectualPropertyDevelopmentLtdMember"
      decimals="-6"
      id="Fact_67b347d83c69441f8e52c3c9f53870d9"
      unitRef="U002">126000000</roiv:MilestonePaid>
    <roiv:MilestonePayable
      contextRef="c20220531_CounterpartyNameAxis_WelichemBiotechIncMember"
      decimals="-5"
      id="Fact_b08bd6dcb1104600825881a39609848a"
      unitRef="U007">25000000</roiv:MilestonePayable>
    <roiv:MilestonePayable
      contextRef="c20220531_CounterpartyNameAxis_WelichemBiotechIncMember"
      decimals="-6"
      id="Fact_3f2f250f38624bf1a9d5d704a2d67c00"
      unitRef="U002">20000000</roiv:MilestonePayable>
    <roiv:MilestonePaid
      contextRef="c20220801to20220831_CounterpartyNameAxis_WelichemBiotechIncMember"
      decimals="-6"
      id="Fact_06bd60fbf8ba449bad7bbe102d9e79c8"
      unitRef="U002">20000000</roiv:MilestonePaid>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="c20231231"
      id="Fact_e1fc62c547d14cc6a1f93fe216b672c1">P14Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="c20230401to20231231"
      id="Text_95a21f7a95a144749221d9ed517cd8b7">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The following table summarizes the Company&#x2019;s recognized intangible assets (in thousands):&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="text-align: center;"&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Gross amount&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;166,471&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;152,629&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Less: accumulated amortization&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(16,056&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(7,748&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Net book value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;150,415&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;144,881&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ac5c4a3a6f8f4f31835ef853d4462773"
      unitRef="U002">166471000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20230331"
      decimals="-3"
      id="Fact_bc0caeaeb2ff44428e2b4865f3fe43a8"
      unitRef="U002">152629000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231"
      decimals="-3"
      id="Fact_2e0c2221307b40f78fcdcb432b0238ae"
      unitRef="U002">16056000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20230331"
      decimals="-3"
      id="Fact_4559d4250de9481f8bf2df6644570092"
      unitRef="U002">7748000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20231231"
      decimals="-3"
      id="Fact_bce1856282704dd4b3f2103c6812d777"
      unitRef="U002">150415000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20230331"
      decimals="-3"
      id="Fact_4bc2c2394e2c4ba5b62ba7be0b155c8b"
      unitRef="U002">144881000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20231001to20231231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-5"
      id="Fact_e386be5a6e304d4e9e1284face211d24"
      unitRef="U002">2400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20221001to20221231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-5"
      id="Fact_8217bb37e8d0471ca13b3ebfb00aeb8d"
      unitRef="U002">2200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230401to20231231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-5"
      id="Fact_63f74b7a56424620a5053a83e7c887a2"
      unitRef="U002">7200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20220401to20221231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-5"
      id="Fact_bd78a92c7546466c8574ff7a5d48b7a7"
      unitRef="U002">5200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="c20231231"
      decimals="-5"
      id="Fact_f95ce84fa66a417699f595f280545ad0"
      unitRef="U002">2500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="c20231231"
      decimals="-5"
      id="Fact_97027214bc804037ac6c0f9516915b48"
      unitRef="U002">10100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="c20231231"
      decimals="-5"
      id="Fact_7208f85590754516a18bbea114a58063"
      unitRef="U002">10100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="c20231231"
      decimals="-5"
      id="Fact_2e774aaad2ff4b1e8c0ee4dfaf0d5aa3"
      unitRef="U002">10100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="c20231231"
      decimals="-5"
      id="Fact_03a555debc7f413c9b874d2e32b7affc"
      unitRef="U002">10100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <roiv:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="c20231231"
      decimals="-5"
      id="Fact_e383e66dac6144c0ad6ffab3a8861176"
      unitRef="U002">107500000</roiv:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <roiv:RecentTransactionsTextBlock
      contextRef="c20230401to20231231"
      id="Text_3dbdcf9ffe6c43d384092a690a342e31">
&lt;div style="font-weight: bold; text-align: justify;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note
          5&#x2014;Recent Transactions&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(A) Telavant Disposition&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;On December 14, 2023 (the &#x201c;Transaction Date&#x201d;), the Company completed the sale of its entire equity interest in its majority-owned subsidiary, Telavant
      Holdings, Inc. (&#x201c;Telavant&#x201d;), to Roche Holdings, Inc. (&#x201c;Roche&#x201d;) (the &#x201c;Roche Transaction&#x201d;). The Roche Transaction was made pursuant to a Stock Purchase Agreement dated October 22, 2023 among the Company, Telavant, Pfizer Inc. (&#x201c;Pfizer&#x201d;), and Roche (the
      &#x201c;Stock Purchase Agreement&#x201d;). Telavant was jointly formed by the Company and Pfizer in November 2022 to develop and commercialize RVT-3101, an anti-TL1A antibody in development for ulcerative colitis (&#x201c;UC&#x201d;) and Crohn&#x2019;s disease, in the United States
      and Japan. Prior to the Roche Transaction, the Company held&#160;75% of the issued and outstanding shares of common stock and preferred stock of
      Telavant, and Pfizer owned the remaining&#160;25%, in each case on an as-converted basis.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;Pursuant to the Stock Purchase Agreement, Roche acquired all of the issued and outstanding shares of capital stock of Telavant in exchange for
      approximately $7.1 billion in cash at the closing of the Roche Transaction and a one-time milestone payment of $150 million in cash payable upon the initiation of a Phase 3 trial in UC. The $7.1 billion in closing consideration was paid to all of Telavant&#x2019;s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant
      prior to the closing of the Roche Transaction, and this same treatment will be applied to the one-time milestone payment. The Company received an upfront payment of approximately $5.2 billion in cash as its pro rata portion of the consideration upon closing of the Roche Transaction. Additionally, the Company is eligible to receive approximately $110 million for its pro rata portion of the one-time milestone payment if the milestone payment condition is satisfied.&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;At the closing of the Roche Transaction, Roche acquired the full rights to further develop and manufacture RVT-3101 and commercialize it in the United
      States and Japan pending clinical and regulatory success. Outside of the United States and Japan, Pfizer holds commercialization rights. In addition, following the closing of the Roche Transaction, Roche acquired Telavant&#x2019;s option to enter into a
      global collaboration with Pfizer on a next generation p40/TL1A directed bispecific antibody, currently in Phase 1.&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;The Telavant entity that was sold did not meet the definition of a
        business, and therefore the Company concluded that the Roche Transaction was a sale of non-financial assets, with control transferred at closing.&lt;/span&gt; The sale of Telavant did not meet the criteria for reporting discontinued operations as the
      sale does not represent a strategic shift in the Company&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;&#x2019;s&lt;/span&gt; business. &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;The
        Company recognized a gain on sale of Telavant net assets of approximately &lt;/span&gt;$5.3 billion&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; during the &lt;/span&gt;three&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; and &lt;/span&gt;nine&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; months ended December &lt;/span&gt;31,&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;&#160;&lt;/span&gt;2023&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; in the
        accompanying condensed consolidated statements of operations. The gain does not include the Company&#x2019;s portion of the &lt;/span&gt;one&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;-time milestone payment, which will
        be recognized in the period it is achieved. The gain on sale of Telavant net assets qualifies under the substantial shareholding exemption and consequently is not subject to the corporation income tax. &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;The table below summarizes
      the calculation of the gain.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);"&gt;(in&lt;/span&gt;&lt;span style="font-weight: bold;"&gt; thousand&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);"&gt;&lt;span style="font-weight: bold;"&gt;s&lt;/span&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Consideration:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Upfront cash payment&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;5,234,373&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Carrying amount of noncontrolling interest derecognized&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;87,500&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total consideration&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;5,321,873&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Assets sold&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,253&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Liabilities transferred&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;29,790&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Net liabilities sold&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(26,537&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;)&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Gain on sale of Telavant net assets&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"&gt;5,348,410&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;The pretax loss generated by Telavant was $27.3
      million for the period from October 1, 2023 to the Transaction Date and $71.1 million for the period from April 1, 2023 to the Transaction
      Date. The pretax loss generated by Telavant for the period from inception on November 14, 2022 to December 31, 2022 was $89.4 million. The
      entirety of the Telavant pretax losses was attributable to the Company.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(B) Asset Acquisition&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;In July 2023, a
        newly-formed subsidiary in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment. The
        transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The acquired rights represent in-process research and development assets, which were determined to have no alternative future
        use. Accordingly, the Company recorded $14.0 million as acquired in-process research and development expense in the accompanying
        condensed consolidated statements of operations for the nine months ended December 31, 2023.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Additionally,


          the newly-formed subsidiary agreed to pay up to $280 million of future development, regulatory, and commercial milestone payments and
          tiered high-single digit sales-based royalties.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
       &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&#160;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(C) Deconsolidation of Subsidiaries&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;In July 2023, VantAI
        Holdings, Inc. (&#x201c;VantAI&#x201d;), a wholly-owned subsidiary of the Company, completed a transaction pursuant to which SK, Inc. (&#x201c;SK&#x201d;) contributed $6.0
        million to VantAI in exchange for preferred shares in VantAI (the &#x201c;VantAI Preferred Financing&#x201d;). In August 2023, the Company and SK Biopharmaceuticals Co., Ltd. (&#x201c;SK Bio&#x201d;), a subsidiary of SK, completed a transaction pursuant to which SK Bio
        purchased all of the Company&#x2019;s shares in Proteovant Sciences, Inc. (&#x201c;Proteovant&#x201d;) in exchange for $47.5 million (the &#x201c;Proteovant Sale&#x201d;).&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;As a result of changes in
        governance and voting rights, the Company determined that it no longer held a controlling financial interest in VantAI. Accordingly, the Company deconsolidated VantAI as of July 2023. The Company recorded a $17.4 million gain on deconsolidation of Proteovant and VantAI in the accompanying condensed consolidated statements of operations for the nine months ended December 31, 2023.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;Upon deconsolidation, the
        Company recorded its $9.0 million retained investment in VantAI based upon the fair value of the preferred shares held by the Company.
        Due to the Company&#x2019;s significant influence over the operating and financial policies of VantAI, the Company will account for its retained interest under the equity method of accounting.&lt;/div&gt;
</roiv:RecentTransactionsTextBlock>
    <roiv:OwnershipPercentage
      contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember"
      decimals="2"
      id="Fact_c9296330fb5e472c802ee3f1d3cc5170"
      unitRef="U005">0.75</roiv:OwnershipPercentage>
    <roiv:OwnershipPercentage
      contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_PfizerMember"
      decimals="2"
      id="Fact_7a82589a7ea0454d814e11258a1ddd92"
      unitRef="U005">0.25</roiv:OwnershipPercentage>
    <roiv:UpfrontCashPaymentReceivedForSaleOfAssets
      contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember"
      decimals="-8"
      id="Fact_a813deec13a340bbad3c17c6aea86923"
      unitRef="U002">7100000000</roiv:UpfrontCashPaymentReceivedForSaleOfAssets>
    <roiv:FutureMilestoneToBeReceivedFromSaleOfAssets
      contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember"
      decimals="-6"
      id="Fact_a099a80e0b5d4b69a9c781fcacf0780b"
      unitRef="U002">150000000</roiv:FutureMilestoneToBeReceivedFromSaleOfAssets>
    <roiv:UpfrontCashPaymentReceivedForSaleOfAssets
      contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember"
      decimals="-8"
      id="Fact_1e77298042f14d429af9b9aee29305dc"
      unitRef="U002">7100000000</roiv:UpfrontCashPaymentReceivedForSaleOfAssets>
    <roiv:UpfrontCashPaymentReceivedForSaleOfAssets
      contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-8"
      id="Fact_09fe123a557c42aa809e4a7cf06e0be5"
      unitRef="U002">5200000000</roiv:UpfrontCashPaymentReceivedForSaleOfAssets>
    <roiv:FutureMilestoneToBeReceivedFromSaleOfAssets
      contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-6"
      id="Fact_6a701c647bdb4669bcfa2fe864faefd6"
      unitRef="U002">110000000</roiv:FutureMilestoneToBeReceivedFromSaleOfAssets>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20231001to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-8"
      id="Fact_47d4feb4a57b4d3c81c6ac61af4d302f"
      unitRef="U002">5300000000</roiv:GainLossOnSaleOfAssets>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20230401to20231231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-8"
      id="Fact_3be30fa4de31440d938082ef1d39bed6"
      unitRef="U002">5300000000</roiv:GainLossOnSaleOfAssets>
    <roiv:ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_1b920a8d1862484ab5e697548887f622">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;The table below summarizes
      the calculation of the gain.&lt;/span&gt;
&lt;div&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);"&gt;(in&lt;/span&gt;&lt;span style="font-weight: bold;"&gt; thousand&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);"&gt;&lt;span style="font-weight: bold;"&gt;s&lt;/span&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Consideration:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Upfront cash payment&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;5,234,373&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Carrying amount of noncontrolling interest derecognized&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;87,500&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total consideration&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;5,321,873&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Assets sold&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,253&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Liabilities transferred&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;29,790&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; margin-left: 6pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Net liabilities sold&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(26,537&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;)&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Gain on sale of Telavant net assets&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"&gt;5,348,410&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</roiv:ScheduleOfGainOnSaleOfAssetsCalculationTableTextBlock>
    <roiv:UpfrontCashPaymentReceivedForSaleOfAssets
      contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-3"
      id="Fact_9bd28393144f4aa08d88e93b4edbf293"
      unitRef="U002">5234373000</roiv:UpfrontCashPaymentReceivedForSaleOfAssets>
    <roiv:DisposalGroupNoncontrollingInterestDerecognizedValue
      contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-3"
      id="Fact_9b9f3d585b044731863d93167dabfbf3"
      unitRef="U002">87500000</roiv:DisposalGroupNoncontrollingInterestDerecognizedValue>
    <roiv:ConsiderationReceivedForSaleOfAssets
      contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-3"
      id="Fact_831e38fa92124ae9aadf8b2a86f8dd33"
      unitRef="U002">5321873000</roiv:ConsiderationReceivedForSaleOfAssets>
    <roiv:DisposalGroupAssets
      contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-3"
      id="Fact_b3ab04380a3f43b899d4399c1a2991e3"
      unitRef="U002">3253000</roiv:DisposalGroupAssets>
    <roiv:DisposalGroupLiabilities
      contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-3"
      id="Fact_e57bb7ace94b487f9f72c675bdbc6e72"
      unitRef="U002">29790000</roiv:DisposalGroupLiabilities>
    <roiv:DisposalGroupNetAssetsLiabilities
      contextRef="c20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-3"
      id="Fact_ee0fac31c6e344e0b0875b8327e12f68"
      unitRef="U002">-26537000</roiv:DisposalGroupNetAssetsLiabilities>
    <roiv:GainLossOnSaleOfAssets
      contextRef="c20231214to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_RocheTransactionMember_StatementEquityComponentsAxis_RSLMember"
      decimals="-3"
      id="Fact_c98aa651119542069dae91cf52c95f17"
      unitRef="U002">5348410000</roiv:GainLossOnSaleOfAssets>
    <roiv:IncomeLossFromDisposalGroupBeforeIncomeTax
      contextRef="c20231001to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember"
      decimals="-5"
      id="Fact_6b09f20346dc492fbae538c91ca26f34"
      unitRef="U002">-27300000</roiv:IncomeLossFromDisposalGroupBeforeIncomeTax>
    <roiv:IncomeLossFromDisposalGroupBeforeIncomeTax
      contextRef="c20230401to20231214_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember"
      decimals="-5"
      id="Fact_995c502baa4d458a97659ad3f78b7305"
      unitRef="U002">-71100000</roiv:IncomeLossFromDisposalGroupBeforeIncomeTax>
    <roiv:IncomeLossFromDisposalGroupBeforeIncomeTax
      contextRef="c20221114to20221231_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_TelavantHoldingsIncMember"
      decimals="-5"
      id="Fact_6447aed369b047429b112aa615a29b43"
      unitRef="U002">-89400000</roiv:IncomeLossFromDisposalGroupBeforeIncomeTax>
    <roiv:UpfrontCashPayment
      contextRef="c20230701to20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember"
      decimals="-5"
      id="Fact_38a5a0e14cb845a387feb35eeeccc6ca"
      unitRef="U002">14000000</roiv:UpfrontCashPayment>
    <roiv:AssetAcquisitionResearchAndDevelopmentExpenseInProcess
      contextRef="c20230401to20231231_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember"
      decimals="-5"
      id="Fact_a8cc612cc6794b289b37d5602949c7ba"
      unitRef="U002">14000000</roiv:AssetAcquisitionResearchAndDevelopmentExpenseInProcess>
    <roiv:MilestonePaymentPayable
      contextRef="c20230731_BusinessAcquisitionAxis_NewlyFormedSubsidiaryMember_RangeAxis_MaximumMember"
      decimals="-6"
      id="Fact_5eee853b78dd4fd1b7c1d5d08b6af3a4"
      unitRef="U002">280000000</roiv:MilestonePaymentPayable>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
      contextRef="c20230701to20230731_RelatedPartyTransactionsByRelatedPartyAxis_SKIncMember_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember"
      decimals="-5"
      id="Fact_7aeb64811c51414eb9c06404d16b541d"
      unitRef="U002">6000000</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c20230801to20230831_BusinessAcquisitionAxis_ProteovantSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_SKBiopharmaceuticalsCoLtdMember"
      decimals="-5"
      id="Fact_4ce48f2eadab4a9eb8be6741e89d8f6e"
      unitRef="U002">47500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="c20230401to20231231_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember"
      decimals="-5"
      id="Fact_7a6d59e056224384b5b2407bc124ff84"
      unitRef="U002">17400000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230731_SubsidiarySaleOfStockAxis_VantAIPreferredFinancingMember"
      decimals="-5"
      id="Fact_e70c74c4cccb4fbaa11a1c17fa83837b"
      unitRef="U002">9000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="c20230401to20231231"
      id="Text_39abf10154f04c1c8fd7f088a3540706">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 6&#x2014;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Certain Balance Sheet Components&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;(A) Other Current Assets&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;"&gt;Other current assets at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 24.5pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';"&gt;March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Prepaid expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;52,642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;60,827&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Trade receivables, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;41,078&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;30,379&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;Restricted cash&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;5,165&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;5,011&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; font-weight: normal;" valign="bottom"&gt;Inventory &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom"&gt;5,240&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom"&gt;2,761&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Income tax receivable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;3,209&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;2,356&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;Interest receivable&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;18,901&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,909&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;9,688&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;15,531&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; text-align: justify;"&gt;Total other current assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;135,923&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;121,774&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;(B) Accrued Expenses&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Accrued expenses at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Research and development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;43,627&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;76,278&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Compensation-related expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;41,406&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;55,186&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Sales allowances&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;16,808&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;17,569&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Other expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;20,307&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;18,096&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Total accrued expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;122,148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;167,129&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;(C) Other Current
          Liabilities&lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Other current liabilities at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Deferred revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;4,695&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;12,444&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Income tax payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;25,223&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;542&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;1,424&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;2,090&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: 0pt; margin-left: 9pt;"&gt;Total other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;31,342&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;15,076&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;
</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_e287129444c645e5ade6bed20cfc10db">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;"&gt;Other current assets at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 24.5pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman';"&gt;March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Prepaid expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;52,642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;60,827&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Trade receivables, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;41,078&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;30,379&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;Restricted cash&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;5,165&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" valign="bottom"&gt;5,011&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; font-weight: normal;" valign="bottom"&gt;Inventory &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom"&gt;5,240&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" valign="bottom"&gt;2,761&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Income tax receivable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;3,209&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;2,356&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;Interest receivable&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;18,901&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,909&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;9,688&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal;"&gt;15,531&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="margin-left: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: normal; text-align: justify;"&gt;Total other current assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;135,923&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-weight: normal;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;121,774&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-weight: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4f9a814638414ba493dceb084b956f78"
      unitRef="U002">52642000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_509b5d2ffa5e496b81598ef6c0f2aa5d"
      unitRef="U002">60827000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_68429926a55f4539bca9f9090f2ca269"
      unitRef="U002">41078000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_21c327a55f754fb19d816dd9a9632dcd"
      unitRef="U002">30379000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_e2a9d5b31a074b9d869416ffad474526"
      unitRef="U002">5165000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_4a3e57681b4748888cbf016ebbfbc4cb"
      unitRef="U002">5011000</us-gaap:RestrictedCashCurrent>
    <us-gaap:InventoryNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4d6f54b3547c482785d5c3550d537711"
      unitRef="U002">5240000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20230331"
      decimals="-3"
      id="Fact_c80286014d5442329c3ffdce619ff051"
      unitRef="U002">2761000</us-gaap:InventoryNet>
    <us-gaap:IncomeTaxesReceivable
      contextRef="c20231231"
      decimals="-3"
      id="Fact_2ab3a9b8b13648d9b88f41420020a885"
      unitRef="U002">3209000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="c20230331"
      decimals="-3"
      id="Fact_4cca12502ed946589e9dbba2fb51e9d9"
      unitRef="U002">2356000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:InterestReceivable
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3a67a14aebab48bca407e108f5e82b5b"
      unitRef="U002">18901000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="c20230331"
      decimals="-3"
      id="Fact_d5582e989ced4f0d967828a411c86f40"
      unitRef="U002">4909000</us-gaap:InterestReceivable>
    <roiv:OtherOfOtherAssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_669b00b7af7a42d0b41e18eb0da06944"
      unitRef="U002">9688000</roiv:OtherOfOtherAssetsCurrent>
    <roiv:OtherOfOtherAssetsCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_006d041a1ffd4a669ee7d7f5999be57c"
      unitRef="U002">15531000</roiv:OtherOfOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_7cf2cde8d97448198a1b186e8b43be60"
      unitRef="U002">135923000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_43406c3f863c4e3fa9d962b1cc1316f1"
      unitRef="U002">121774000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_e9959af064d4496bb773b88542f23b29">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Accrued expenses at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Research and development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;43,627&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;76,278&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Compensation-related expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;41,406&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;55,186&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Sales allowances&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;16,808&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;17,569&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Other expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;20,307&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;18,096&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt;"&gt;Total accrued expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;122,148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;167,129&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <roiv:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3c78d6ea7207422ab165a0bc5134b1c8"
      unitRef="U002">43627000</roiv:AccruedResearchAndDevelopmentExpensesCurrent>
    <roiv:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_fed1200bb4dc49779f53a0d3d282e5f6"
      unitRef="U002">76278000</roiv:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_58a418e6dc4a48ed93aa325edbc7920e"
      unitRef="U002">41406000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_7f8bed6bdf734aa58863d2c2c02952e1"
      unitRef="U002">55186000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <roiv:AccruedSalesAllowancesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f409af36e4e84392b884e7576fe3a21b"
      unitRef="U002">16808000</roiv:AccruedSalesAllowancesCurrent>
    <roiv:AccruedSalesAllowancesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_3b683fd06a3f49a188f01d431f853558"
      unitRef="U002">17569000</roiv:AccruedSalesAllowancesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_2f9d6dfc9c91462aad4cfe7173afdd0d"
      unitRef="U002">20307000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_83c12dc939964d11b25da0f045082646"
      unitRef="U002">18096000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_cdfa4c6726594cef8d163ea06b71ed6c"
      unitRef="U002">122148000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_18338a317a0349939bb32253fdd7d54b"
      unitRef="U002">167129000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_96e9b8dc67874415a14406b68482ee05">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Other current liabilities at December 31, 2023 and March 31, 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Deferred revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;4,695&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;12,444&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Income tax payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;25,223&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;542&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;1,424&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;2,090&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: 0pt; margin-left: 9pt;"&gt;Total other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;31,342&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;15,076&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;
</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_944a682cc23d44ceb6b0049876708959"
      unitRef="U002">4695000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_b5dd3bcd459a48cf86094466fe326abc"
      unitRef="U002">12444000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_77d00156dd1d4037a49361bd0da361f5"
      unitRef="U002">25223000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_3e639588823c4ce68e9bf91508f9daa7"
      unitRef="U002">542000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4deadd14aaaa4302bb438050de65e094"
      unitRef="U002">1424000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_e4d363633b0e4d07b44fdb1c9543afaa"
      unitRef="U002">2090000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_17c506f47db44ccbbca636691c0d9804"
      unitRef="U002">31342000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20230331"
      decimals="-3"
      id="Fact_101d134ac1d74b508df94e0fb25cf6d7"
      unitRef="U002">15076000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="c20230401to20231231"
      id="Text_efd1d9f6b7544733a3f9031e39538923">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 7&#x2014;Long-Term Debt&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Dermavant&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Funding Agreement with NovaQuest&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;In connection with Dermavant&#x2019;s acquisition of tapinarof from GSK pursuant to an asset purchase agreement (the &#x201c;GSK Agreement&#x201d;), Dermavant and
          NovaQuest Co-Investment Fund VIII, L.P. (&#x201c;NovaQuest&#x201d;) entered into a funding agreement (the &#x201c;NovaQuest Agreement&#x201d;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $100.0 million in August 2018 and $17.5 million in October 2018.
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;In exchange for the $117.5 million
          in total funding from NovaQuest, Dermavant agreed to make fixed payments to NovaQuest under the NovaQuest Agreement upon regulatory approval of tapinarof. For each of the atopic dermatitis and psoriasis indications, Dermavant is required to make
          quarterly payments to NovaQuest totaling $176.3
          million per indication over a six-year period following regulatory approval of tapinarof for the applicable indication in the United
          States. In the event that Dermavant receives regulatory approval for one indication, and Dermavant terminates the development of the other indication for any reason other than a Technical Failure (as defined below), then Dermavant will be
          required to make the above-referenced quarterly payments to NovaQuest up to $440.6 million over a 15-year period for the approved indication, which are referred to as 15-year Payments. A Technical Failure is deemed to occur for an indication if the development program for such indication is terminated due to (1) significant safety concerns, (2) material adverse developments or
          (3) the receipt by Dermavant of a complete response letter or a final non-approval letter from the FDA is expected to result in significant delay in or cost to reach commercialization for the applicable indication. In addition, Dermavant is
          required to make up to $141.0 million in payments to NovaQuest upon achievement of certain commercial milestones. In the event that
          Dermavant is required to start making 15-year Payments, then Dermavant has the right to offset such amounts by up to $88.1 million of the commercial milestone payments, with such offset being applied to the quarterly payments in reverse chronological order (such that
          the final quarterly payments owed will be used first to offset the commercial milestone payments). The NovaQuest Agreement does not contain any royalty payment requirements on commercialization of tapinarof. Upon receiving FDA approval for the
          psoriasis indication, Dermavant made its first quarterly payment of $7.3 million under the NovaQuest Agreement in May 2022 and has made
          cumulative quarterly payments totaling $51.4
          million as of December 31, 2023.&#160; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In
          lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the statements of operations at the end of each reporting period.
          Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of December 31, 2023 and March 31, 2023, the fair value of the debt was $221.5 million and $207.6 million, respectively. Refer to Note
          13, &#x201c;Fair Value Measurements&#x201d; for additional details regarding the fair value measurement.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The carrying balance of the debt issued to NovaQuest was as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Fair value of long-term debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;221,510&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;207,640&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Less: current portion&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(26,950&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(26,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total long-term debt, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;194,560&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;180,700&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Credit Facility with XYQ Luxco&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;In May 2021, Dermavant and certain of its subsidiaries entered into a $40.0 million senior secured credit facility (the &#x201c;Credit Facility&#x201d;) with XYQ Luxco S.A.R.L (&#x201c;XYQ Luxco&#x201d;), as lender, and U.S. Bank National Association, as collateral agent. The Credit
          Facility has a five-year maturity and bears an interest rate of 10.0% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the
          maturity date. Dermavant is also obligated to pay an exit fee of $5.0 million. The exit fee can be reduced to $4.0 million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of December 31, 2023. In connection
          with the funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase 1,199,072 common shares of Dermavant at
          an exercise price of $0.01 per common share.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Outstanding debt obligations to XYQ Luxco were as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Principal amount&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Exit fee&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Less: unamortized discount and debt issuance costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(8,221&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(10,170&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Total debt, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;36,779&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;34,830&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Less: current portion&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total long-term debt, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;36,779&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;34,830&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Revenue Interest Purchase and Sale Agreement&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;In
          May 2021, Dermavant, as seller, entered into a $160.0 million revenue interest purchase and sale agreement (the &#x201c;RIPSA&#x201d;) for its
          investigational product tapinarof with XYQ Luxco, NovaQuest Co-Investment Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P., together with U.S. Bank
          National Association, as collateral agent. Under the terms of the RIPSA, Dermavant is obligated to pay royalties based on a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States, up
          to a cap of $344.0 million, in exchange for the $160.0 million in committed funding, which was paid to Dermavant in June 2022 following the approval of tapinarof by the FDA.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;The













          transaction is accounted for as debt. Over the term of the arrangement, the effective interest rate will be updated prospectively each reporting period based on the carrying amount of the note, payments made to date, and the estimated remaining
          cash flows related to the note.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0px;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The RIPSA carrying balance was as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Carrying balance&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;195,297&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;178,571&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Less: unamortized issuance costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(4,543&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(4,806&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Total debt, net&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;190,754&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&lt;br/&gt;
                    &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;173,765&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&lt;br/&gt;
                    &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Less: current portion&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(18,756&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(13,780&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Total long-term debt, net&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;171,998&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;159,985&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20180831_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_228fb8e309284427bdbbc0e0bece6724"
      unitRef="U002">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_dd99840eccc040c0adb12c83a5cba070"
      unitRef="U002">17500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_ff8a2f792be04dc6bc7eef445da9da69"
      unitRef="U002">117500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      id="Fact_a17e22b0110d496f906580472908b569">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <roiv:TotalRequiredDebtInstrumentQuarterlyPaymentsMade
      contextRef="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_40b027499b3545d6a4ecfe528149c6c5"
      unitRef="U002">176300000</roiv:TotalRequiredDebtInstrumentQuarterlyPaymentsMade>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20220530to20280430_BusinessAcquisitionAxis_DermavantMember_StatementScenarioAxis_ScenarioForecastMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      id="Fact_2ab8d4c259ef4cd484361bd60b352b29">P6Y</us-gaap:DebtInstrumentTerm>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="c20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_2babb88cdd34484aa555e6d01becb33b"
      unitRef="U002">440600000</roiv:MaximumMilestonePaymentObligation>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      id="Fact_9cc950d7cb604278a421c52d6d5a96fc">P15Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      id="Fact_00eb707dc39d489b86a4789a29d03af4">P15Y</us-gaap:DebtInstrumentTerm>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="c20180831_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_34c7bce721f5410fbe494cb76fec6982"
      unitRef="U002">141000000</roiv:MaximumMilestonePaymentObligation>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20181031to20181031_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      id="Fact_16fc28babf8642cbac1792039e12b182">P15Y</us-gaap:DebtInstrumentTerm>
    <roiv:MaximumMilestonePaymentOffsetAmount
      contextRef="c20180831_BusinessAcquisitionAxis_DermavantMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_91f7b24a9cca4174b6ffb945d60db973"
      unitRef="U002">88100000</roiv:MaximumMilestonePaymentOffsetAmount>
    <roiv:DebtInstrumentQuarterlyPaymentsMade
      contextRef="c20220501to20220531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_cebd521ed64b4793ac927dab4b47ff0f"
      unitRef="U002">7300000</roiv:DebtInstrumentQuarterlyPaymentsMade>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      id="Fact_c26389a4e37a48cc85dd1d0ea9c07174">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <roiv:TotalRequiredDebtInstrumentQuarterlyPaymentsMade
      contextRef="c20220530to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_6ea09ddae92f42b3be5c141715993ea9"
      unitRef="U002">51400000</roiv:TotalRequiredDebtInstrumentQuarterlyPaymentsMade>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_8921e67f9af24c60a6f021960de9958d"
      unitRef="U002">221500000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-5"
      id="Fact_07208de8798c4672ba5534061d0a383c"
      unitRef="U002">207600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      id="Text_807bdf51ddbe4ec99802a5d557edece0">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The carrying balance of the debt issued to NovaQuest was as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Fair value of long-term debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;221,510&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;207,640&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Less: current portion&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(26,950&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(26,940&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total long-term debt, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;194,560&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;180,700&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-3"
      id="Fact_8e286b017e944299acd5374166999208"
      unitRef="U002">221510000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-3"
      id="Fact_e08bb2e6c18145e8bb40bf70888ee2e3"
      unitRef="U002">207640000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-3"
      id="Fact_64a986ff98164782acc8f8e9b5ca42db"
      unitRef="U002">26950000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-3"
      id="Fact_05cdda6a203d4ddfaf75beba97fe59da"
      unitRef="U002">26940000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-3"
      id="Fact_d77de7340ebc466d9cc17e163ed41135"
      unitRef="U002">194560000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_FundingAgreementWithNovaQuestMember"
      decimals="-3"
      id="Fact_49b663fa59954da1b77b7a309f5887d2"
      unitRef="U002">180700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-5"
      id="Fact_22ec21367178494fbb65e6aaf751905e"
      unitRef="U002">40000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      id="Fact_6756826a10874a899920d484910228ba">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="3"
      id="Fact_a36a13c29d184e308843f44415f38488"
      unitRef="U005">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <roiv:DebtInstrumentExitFeeAndEndOfTermCharge
      contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-5"
      id="Fact_99536e04b41143e390b29b902ad44381"
      unitRef="U002">5000000</roiv:DebtInstrumentExitFeeAndEndOfTermCharge>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-5"
      id="Fact_c94d65800e0b4144b5b21c0a22585fe8"
      unitRef="U002">4000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="0"
      id="Fact_9cdd609898c2493fad6853a714b6acd7"
      unitRef="U001">1199072</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="2"
      id="Fact_12ed9daf0f7d478db7347b1a5a33a2aa"
      unitRef="U003">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      id="Text_3517a87cfe534e17a41b8d61acac6125">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Outstanding debt obligations to XYQ Luxco were as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Principal amount&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Exit fee&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Less: unamortized discount and debt issuance costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(8,221&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(10,170&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Total debt, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;36,779&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;34,830&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Less: current portion&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total long-term debt, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;36,779&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;34,830&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_5e41185baeab4b3c9fd0e170736c9440"
      unitRef="U002">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_9f13b0db65db48afb00075e351e74358"
      unitRef="U002">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <roiv:DebtInstrumentExitFee
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_59d63c3ffee348d2a8bdfc22a0dcf83a"
      unitRef="U002">5000000</roiv:DebtInstrumentExitFee>
    <roiv:DebtInstrumentExitFee
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_19d5ba7969394bb4b7818d0227be0c4a"
      unitRef="U002">5000000</roiv:DebtInstrumentExitFee>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_0afabb3b4e39410c926809a72a8e2d87"
      unitRef="U002">8221000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_79519d6e74bf4fe18032430cb87cd2a8"
      unitRef="U002">10170000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_38291391b5034db9ae462d63ff0c5660"
      unitRef="U002">36779000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_d72b1bd7828947db98faf71b1b330ee9"
      unitRef="U002">34830000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_47319ae2c82245178df0528d7621fd00"
      unitRef="U002">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_5bfcb9611ad949dfa0b67c9325a5aaf7"
      unitRef="U002">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_9c67093600ef4e799b180e3b0b76773a"
      unitRef="U002">36779000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_CreditFacilityWithXYQLuxcoMember"
      decimals="-3"
      id="Fact_8c783dc704324933a9e4f101d0993395"
      unitRef="U002">34830000</us-gaap:LongTermDebtNoncurrent>
    <roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement
      contextRef="c20210501to20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-5"
      id="Fact_25a09944d63240c8a7ae520d2a5562cf"
      unitRef="U002">160000000</roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement>
    <roiv:CommittedFundingUnderRIPSA
      contextRef="c20210531_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-5"
      id="Fact_a40a2bdf332c44c7b48757e4cb470b17"
      unitRef="U002">344000000</roiv:CommittedFundingUnderRIPSA>
    <roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived
      contextRef="c20220601to20220630_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-5"
      id="Fact_7ef0d5afb4174a5b8b3deaa82cc25887"
      unitRef="U002">160000000</roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreementReceived>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="c20230401to20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      id="Text_b467bc448c164d02821574edb5c659e0">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The RIPSA carrying balance was as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;March 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Carrying balance&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;195,297&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;178,571&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;Less: unamortized issuance costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(4,543&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(4,806&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Total debt, net&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;190,754&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&lt;br/&gt;
                    &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;173,765&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;&lt;br/&gt;
                    &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Less: current portion&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(18,756&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;(13,780&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div&gt;Total long-term debt, net&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;171,998&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;159,985&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_57bf40fb04544b1baefcb24fd07c8eb8"
      unitRef="U002">195297000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_782262380cd3468db1e6a4f58150ae03"
      unitRef="U002">178571000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_fb8140cdb4494c8791468489cffc9d29"
      unitRef="U002">4543000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_4118daa2db36418388344490bed3a35c"
      unitRef="U002">4806000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_458547d7e82345da9ca272192a1d1e32"
      unitRef="U002">190754000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_864b861836aa4b9da856dbf73709fbe2"
      unitRef="U002">173765000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_e8e5c2ad655141aca9f015b83a7d18b3"
      unitRef="U002">18756000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_05830475145942d7b63ca5cbea8f3492"
      unitRef="U002">13780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="c20231231_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_34163b4ecc7d4379b340014df898ab96"
      unitRef="U002">171998000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="c20230331_BusinessAcquisitionAxis_DermavantMember_TypeOfArrangementAxis_RevenueInterestPurchaseAndSaleAgreementWithXYQLuxcoNovaQuestMember"
      decimals="-3"
      id="Fact_1a64e48f95d34454892823615c1c6af0"
      unitRef="U002">159985000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20230401to20231231"
      id="Text_f49d16b5daf44b9786b3e73378a630ba">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 8&#x2014;Shareholders&#x2019; Equity&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(A) At-the-Market Equity Offering Program&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;"&gt;On September 19, 2022, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC
            (&#x201c;Cowen&#x201d;) to sell its common shares having an aggregate offering price of up to $400.0 million from time to time through an
            &#x201c;at-the-market&#x201d; equity offering program under which Cowen acts as the Company&#x2019;s agent (the &#x201c;ATM Facility&#x201d;).&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;"&gt;As of December 31, 2023, the Company had $400.0 million of remaining capacity available under the ATM Facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"&gt;(B) Common Share
              Purchase and Share Agreements&lt;/div&gt;

&lt;div style="text-align: left; font-weight: normal; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;In September 2023, the Company entered into common share purchase and sale agreements with certain institutional investors, pursuant to which the Company sold an aggregate of 19,600,685 of its common shares at a purchase price of $10.21
              per share. Net proceeds to the Company were approximately $199.8 million after deducting offering expenses.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(C) Consolidated Vant Equity Transaction&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
                  &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Immunovant&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;In &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;October 2023, the Company&#x2019;s subsidiary, Immunovant, Inc. (&#x201c;Immunovant&#x201d;), completed an underwritten public offering of 8,475,500
                shares of its common stock (including 1,526,316 shares of common stock purchased by the Company on the same terms as other
                investors in the offering and the full exercise of the underwriters&#x2019; option to purchase 1,105,500 additional shares of common
                stock) at a price to the public of $38.00 per share. Concurrent with the public offering, the Company purchased 4,473,684 shares of Immunovant&#x2019;s common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as
                amended, at the same price per share as investors in the public offering of $38.00 per share. The net proceeds to Immunovant were
                approximately $466.7 million after deducting underwriting discounts and commissions, placement agent fees and offering expenses.
                The Company&#x2019;s equity ownership interest in Immunovant is approximately 55% as of&#160;&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, and the Company continues to consolidate
                Immunovant&lt;/span&gt;. &lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <roiv:CommonSharesOfferingPriceAuthorized
      contextRef="c20220919_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember"
      decimals="-5"
      id="Fact_c8f0aecc97ab40ba80cfb52f1d4d80c0"
      unitRef="U002">400000000</roiv:CommonSharesOfferingPriceAuthorized>
    <roiv:CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable
      contextRef="c20231231_RelatedPartyTransactionAxis_CowenAndCompanyLLCMember_SubsidiarySaleOfStockAxis_EquityOfferingsAtTheMarketMember"
      decimals="-5"
      id="Fact_af03b8506b99407996106acbfdb5afd2"
      unitRef="U002">400000000</roiv:CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230901to20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember"
      decimals="0"
      id="Fact_3f17fd2deeae4f8ebc29cacbedc7d47d"
      unitRef="U001">19600685</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember"
      decimals="2"
      id="Fact_1bc1797759554f94aa7b56b84bd73dd0"
      unitRef="U003">10.21</us-gaap:SaleOfStockPricePerShare>
    <roiv:NetProceedsFromIssuanceOfCommonStock
      contextRef="c20230901to20230930_StatementEquityComponentsAxis_CommonStockMember_TitleOfIndividualAxis_InvestorMember"
      decimals="-5"
      id="Fact_8c887ca5ae1f4867b9b63b5e8646e328"
      unitRef="U002">199800000</roiv:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember"
      decimals="0"
      id="Fact_907c5fd676e543ad8d1cd9c53a8fecce"
      unitRef="U001">8475500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <roiv:StockPurchasedDuringPeriodByEntityShares
      contextRef="c20231001to20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember"
      decimals="0"
      id="Fact_0e9f366846b941959378e29400fc5641"
      unitRef="U001">1526316</roiv:StockPurchasedDuringPeriodByEntityShares>
    <roiv:OptionToPurchaseAdditionalSharesOfCommonStock
      contextRef="c20231001to20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember"
      decimals="0"
      id="Fact_07173017e3d541a088fb9ef7d8f1e4d3"
      unitRef="U001">1105500</roiv:OptionToPurchaseAdditionalSharesOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c20231031_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RoivantParticipationOfImmunovantStockOfferingMember"
      decimals="2"
      id="Fact_92060141bfd54cd682a38df68edd6d65"
      unitRef="U003">38</us-gaap:SaleOfStockPricePerShare>
    <roiv:StockPurchasedDuringPeriodByEntityShares
      contextRef="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="0"
      id="Fact_f414ff1c2c554485800189802ae33791"
      unitRef="U001">4473684</roiv:StockPurchasedDuringPeriodByEntityShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="2"
      id="Fact_159f83456c544acb9b79fb39417fc41c"
      unitRef="U003">38</us-gaap:SaleOfStockPricePerShare>
    <roiv:EstimatedNetProceedsFromIssuanceOfCommonStock
      contextRef="c20231001to20231031_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="Fact_8b5b8cf605114374b8369137354b46fc"
      unitRef="U002">466700000</roiv:EstimatedNetProceedsFromIssuanceOfCommonStock>
    <roiv:OwnershipPercentage
      contextRef="c20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImmunovantIncMember"
      decimals="2"
      id="Fact_3a42b1dad4c94b94b6170b43bcf2b387"
      unitRef="U005">0.55</roiv:OwnershipPercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20230401to20231231"
      id="Text_a8fc0f7c950c462d8aa62c99675ec623">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 9&#x2014;Share-Based Compensation&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(A) RSL Equity Incentive Plans&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;RSL has three equity incentive
          plans: the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#x201c;RSL 2021 EIP&#x201d;), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan
          (collectively, the &#x201c;RSL Equity Plans&#x201d;). The RSL 2021 EIP was approved and adopted in connection with the Business Combination and became effective immediately prior to closing. At December 31, 2023, a total of 41,986,389 common shares were available for future grants under the RSL 2021 EIP.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Stock Options and Performance Stock Options&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Activity for stock options and performance stock options under the RSL Equity Plans for the nine months ended December 31, 2023 was as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of Options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Options outstanding at&#160;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;154,271,791&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,497,911&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 0pt; margin-left: 9pt; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;Exercised&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(10,796,348&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited/Canceled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(604,245&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Options outstanding at December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;147,369,109&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Options exercisable at&#160;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;91,671,364&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Restricted Stock Units and Performance Stock Units&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Activity for restricted stock units and performance stock units under the RSL Equity Plans for the nine months ended December 31, 2023 was as
          follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;20,700,788&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,199,120&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(5,498,323&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(1,175,450&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;18,226,135&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Capped Value Appreciation Rights&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline;"&gt;March 2020 CVAR Grants&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;As &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;of&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, 27,531,825 CVARs remain outstanding and subject to
              the applicable hurdle price and knock-in condition. All outstanding capped value appreciation rights&lt;/span&gt; (&#x201c;CVARs&#x201d;) &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;relating to the March 2020 grants had met the service vesting condition as of December 31, 2023. During the&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;nine months ended December 31, 2023&lt;/span&gt;,
            4,499,113 service-vested CVARs satisfied their applicable hurdle price and the knock-in condition, if relevant, on the applicable
            measurement date, and as a result, 1,445,420 common shares were issued upon their settlement&lt;/span&gt;.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline;"&gt;November 2021 CVAR Grants&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Activity for CVARs under the RSL 2021 EIP for the nine months ended December 31, 2023 was as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of CVARs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,222,645&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(955,782&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Forfeited&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(128,377&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,138,486&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;During the nine months ended December 31, 2023, 955,782 common shares were issued upon their settlement.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: bold;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(B) Subsidiary Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: bold;"&gt; &lt;span style="font-weight: normal;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Certain subsidiaries of
              RSL adopt their own equity incentive plan (&#x201c;EIP&#x201d;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#x2019; employees, directors, officers and consultants are eligible to receive non-qualified and incentive
              stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. The Company recorded share-based compensation expense of $23.3 million and $53.1 million for
              the three and nine months ended December 31, 2023, respectively, and $13.7 million and $37.8 million for the three and nine months ended December 31, 2022, respectively, related to subsidiary EIPs.&lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <roiv:NumberOfEquityIncentivePlans
      contextRef="c20230401to20231231"
      decimals="INF"
      id="Fact_dcbe0e60d37f47eaac04f3ce45ff08b1"
      unitRef="U008">3</roiv:NumberOfEquityIncentivePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20231231_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"
      decimals="0"
      id="Fact_60c323f540d742afb5a479213f030da3"
      unitRef="U001">41986389</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <roiv:ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_a7b8373926fa49849cba2681e5056d5e">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Activity for stock options and performance stock options under the RSL Equity Plans for the nine months ended December 31, 2023 was as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of Options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Options outstanding at&#160;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;154,271,791&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,497,911&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 0pt; margin-left: 9pt; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;Exercised&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(10,796,348&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited/Canceled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(604,245&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Options outstanding at December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;147,369,109&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Options exercisable at&#160;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;91,671,364&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</roiv:ScheduleOfShareBasedCompensationStockOptionsAndPerformanceOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20230331_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_c499337aabfb46c0b5235e76900ffc91"
      unitRef="U001">154271791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_d7715f3365274d41acc2219f97f82320"
      unitRef="U001">4497911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_780e17436fc54854b7c79aab5de98771"
      unitRef="U001">10796348</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20230401to20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_d7a83367d3a345d985c4a189553a9ec8"
      unitRef="U001">604245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_5d610324609444248d305205c228af49"
      unitRef="U001">147369109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20231231_AwardTypeAxis_StockOptionsAndPerformanceStockOptionsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_bc12984bf0fb4f2cbd953b287ec791da"
      unitRef="U001">91671364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <roiv:ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_f98932c4daf1400d829ed43c084cb8dd">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Activity for restricted stock units and performance stock units under the RSL Equity Plans for the nine months ended December 31, 2023 was as
          follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;20,700,788&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,199,120&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(5,498,323&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(1,175,450&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;18,226,135&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</roiv:ScheduleOfShareBasedCompensationRestrictedStockAndPerformanceStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20230331_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_08bfd43d05d747cab4f7820cd7bc7d9b"
      unitRef="U001">20700788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_bfe8b585c1ef4fb590f77fe78b572676"
      unitRef="U001">4199120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_be7b6ef5e7f3410788311ecb33d677fe"
      unitRef="U001">5498323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20230401to20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_333185303f354cd4a4fbe781e311a5cb"
      unitRef="U001">1175450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_AwardTypeAxis_RestrictedStockAndPerformanceStockUnitsMember_PlanNameAxis_RoivantSciencesLtdEquityPlansMember"
      decimals="0"
      id="Fact_2aeb4dda7f92432e855bab2e3f9a8bbc"
      unitRef="U001">18226135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares
      contextRef="c20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember"
      decimals="0"
      id="Fact_a353319b562f4a1ca61c060638d7aec6"
      unitRef="U001">27531825</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingShares>
    <roiv:EquityInstrumentsVestedAndSettledShares
      contextRef="c20230401to20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember"
      decimals="0"
      id="Fact_6f48c64fbbbd41449f09c8043d910156"
      unitRef="U001">4499113</roiv:EquityInstrumentsVestedAndSettledShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c20230401to20231231_AwardDateAxis_March2020CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember"
      decimals="0"
      id="Fact_c8b192d947ba43e0aa9fcff299b5e972"
      unitRef="U001">1445420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <roiv:ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_8034fc63aa64495daa3caa31e527c9ca">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;Activity for CVARs under the RSL 2021 EIP for the nine months ended December 31, 2023 was as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of CVARs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;March 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,222,645&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(955,782&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Forfeited&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(128,377&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Non-vested balance at&#160;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,138,486&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</roiv:ScheduleOfNovember2021CappedValueAppreciationRightsStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20230331_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"
      decimals="0"
      id="Fact_b431c5e31b454c81bc31134780167c93"
      unitRef="U001">3222645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"
      decimals="0"
      id="Fact_61b771720c324147b56672f3e3462d59"
      unitRef="U001">955782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"
      decimals="0"
      id="Fact_8d7345ff79ef44fea09d8405c7b48e68"
      unitRef="U001">128377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember_PlanNameAxis_RoivantSciencesLtd2021EquityIncentivePlanMember"
      decimals="0"
      id="Fact_193bc10ead90464f9b491b1d1dd1251d"
      unitRef="U001">2138486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c20230401to20231231_AwardDateAxis_November2021CappedValueAppreciationRightsGrantsMember_AwardTypeAxis_CappedValueAppreciationRightsMember"
      decimals="0"
      id="Fact_7a66c7268b2b4a6f86209f6c67daaf96"
      unitRef="U001">955782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20231001to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"
      decimals="-5"
      id="Fact_738d3832ea0e4818b0cb170b0db2afc7"
      unitRef="U002">23300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230401to20231231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"
      decimals="-5"
      id="Fact_dcd2971e3fa74a5cbd04bbd13bc8a0e4"
      unitRef="U002">53100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20221001to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"
      decimals="-5"
      id="Fact_7df950b8081b4716820b354cb6bdb636"
      unitRef="U002">13700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220401to20221231_PlanNameAxis_SubsidiaryEquityIncentivePlansMember"
      decimals="-5"
      id="Fact_731f6f2264bc4b8794268fdad98ab58a"
      unitRef="U002">37800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20230401to20231231"
      id="Text_d61be8a3a8804cc3b9ac36ad0f0557e2">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 10&#x2014;Income Taxes&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company&#x2019;s effective tax rate for the three and nine &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;months













            ended &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;December 31&lt;/span&gt;, 2023 was &lt;/span&gt;0.5%
          and 0.7%, respectively, and the effective tax rate for the three and nine months ended December 31, 2022&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; was (0.7)% and (0.9)%, &lt;/span&gt;respectively. The effective tax rates for three and nine months ended December 31, 2023 are driven by the Company&#x2019;s gain on sale of Telavant net assets,
          which qualifies for the substantial shareholding exemption and consequently is not subject to the corporation income tax, as well as the jurisdictional earnings by location and a valuation allowance that eliminates the Company&#x2019;s global net
          deferred tax assets. The effective tax rates for three and nine months ended December 31, 2022 are driven by the jurisdictional earnings by location and a valuation allowance that eliminates the Company&#x2019;s global net deferred tax assets.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt;The Company assesses the realizability of its deferred tax assets at each balance sheet date based on available positive and negative evidence in
          order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary.&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20231001to20231231"
      decimals="3"
      id="Fact_08435601b3fd4ea284b63fd926a3870d"
      unitRef="U005">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20230401to20231231"
      decimals="3"
      id="Fact_2880661df03e4759b520a1f3050105fa"
      unitRef="U005">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20221001to20221231"
      decimals="3"
      id="Fact_b443e01173584957af974187cc8fa8bb"
      unitRef="U005">-0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20220401to20221231"
      decimals="3"
      id="Fact_4c8f5973c56b41d9ab267ad50868dea4"
      unitRef="U005">-0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20230401to20231231"
      id="Text_9425667ffed7404dba9616741b06600e">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 11&#x2014;Commitments and Contingencies&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;(A) Commitments&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company has entered into commitments under various asset acquisition and license agreements. Additionally, the Company enters into agreements with contract service providers to assist in the performance of its
            research and development activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods
            and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and
            supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company also has commitments relating to its long-term debt and leases. Refer to Note 7, &#x201c;Long-Term Debt&#x201d; for further information. There have been no material changes to the commitments relating to the Company&#x2019;s
              leases during the nine months ended December 31, 2023 outside the ordinary course of business. For further information regarding the Company&#x2019;s lease commitments, refer to Note 15, &#x201c;Leases&#x201d; in the Company&#x2019;s Annual Report on Form 10-K for the
              year ended March 31, 2023. &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Purchase Commitments&lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 18pt; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-variant: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-transform: none;"&gt;In conjunction with Dermavant&#x2019;s entry into the GSK
            Agreement in 2018, Dermavant entered into a clinical supply agreement pursuant to which GSK would provide a supply of tapinarof and clinical product at an agreed upon price during the Company&#x2019;s clinical trials. In April 2019, Dermavant entered
            into a commercial supply agreement with GSK to continue to provide certain quantities of tapinarof and commercial product at agreed upon minimum quantities and price. The commercial supply agreement commenced in April 2022 upon completion of
            certain quality and regulatory conditions. In July 2022, Dermavant and GSK amended the terms of the clinical supply and commercial supply agreements which released GSK of certain commitments to supply tapinarof and released Dermavant of certain
            commitments to purchase tapinarof in exchange for a supplementary fee. Other supply and purchase commitments under the agreements remain in effect. In addition, Dermavant and Thermo Fisher Scientific (&#x201c;TFS&#x201d;) entered into a Commercial
            Manufacturing and Supply Agreement for which TFS agreed to provide a supply of tapinarof to Dermavant at an agreed upon price. The agreements discussed above require Dermavant to purchase certain quantities of inventory over a period&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; of five years. As of December 31, 2023, the remaining minimum purchase commitment related to these agreements was estimated to be approximately $43.1 million. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;In
        November 2021, the Company&#x2019;s subsidiary, Immunovant, entered into a Product Service Agreement (&#x201c;PSA&#x201d;) with Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) by which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial
        sale and perform other manufacturing-related services with respect to batoclimab. As of December 31, 2023, the remaining minimum purchase commitment related to this agreement was estimated to be approximately $18.3 million. Immunovant had the right to terminate the PSA with 30 days&#x2019; written notice to Samsung, exercisable no later than January 2024, in the event Immunovant decided to stop all development of, and all attempts to obtain regulatory approval for,
        batoclimab; subject to payment to Samsung of non-cancellable service fees and costs incurred by Samsung for all batches of batoclimab scheduled to be manufactured during the two-year period following such termination. Because efforts to develop and
        obtain regulatory approval for batoclimab remain ongoing, Immunovant did not exercise that early termination right and it has lapsed. As a result, Immunovant has an additional minimum obligation to Samsung of approximately $28.0 million to purchase additional batches of batoclimab in the four-year period of 2026 through 2029.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In May 2021, the Company entered into a master subscription agreement with Palantir Technologies Inc. (&#x201c;Palantir&#x201d;) for access to Palantir&#x2019;s proprietary software for a five-year period. As of December 31, 2023, the remaining minimum payments for this software subscription were $19.1 million.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt; &lt;span style="font-weight: bold; font-style: italic; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cash
          Bonus Program&lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In December 2023, the Company approved a special one-time cash retention bonus award to its employees in the aggregate amount of $76.9 million (the &#x201c;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash Bonus Program&#x201d;)&lt;/span&gt;. During the three and nine months ended December 31, 2023, the Company recognized selling, general and administrative expense and research and development expense of $27.2 million and $8.1
            million, respectively, representing the portion of the bonus award that was vested and payable immediately. The remaining portion will be recognized over the applicable service period of the award. In February 2024, the Company expanded this
            Cash Bonus Program to include an award to its Chief Financial Officer on similar terms as the other awards previously made to other employees. The Chief Financial Officer did not receive a payment from the Cash Bonus Program approved in
            December. This award to the Chief Financial Officer was in the aggregate amount of $2.8 million. Fifty percent of the bonus will be payable within 30 days of the grant date, with the balance subject to vesting tied to the employee&#x2019;s continued service to the Company, as described in more detail in Part II, Item 5 of this Quarterly Report.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;(B) Loss Contingencies&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable
            that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim,
            including an estimable range, if possible. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;Immunovant Securities
          Litigation&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In February 2021, a putative securities class action complaint was filed against Immunovant and certain of its current and former officers in the U.S. District Court for the Eastern District of New
              York on behalf of a class consisting of those who acquired Immunovant&#x2019;s securities from October 2, 2019 and February 1, 2021. The complaint alleged that Immunovant and certain of its officers violated Sections 10(b) and 20(a) of the
              Securities Exchange Act of 1934, as amended, by making false and misleading statements regarding the safety of batoclimab and sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including
              reasonable attorneys&#x2019; fees. In December 2021, the U.S. District Court appointed a lead plaintiff. In March 2022, the lead plaintiff filed an amended complaint adding both (i) the Company and (ii) Immunovant&#x2019;s directors and underwriters as
              defendants, and asserting additional claims under Section 11, 12(a)(2), and 15 of the Securities Act of 1933, as amended, on behalf of a putative class consisting of those who purchased or otherwise acquired Immunovant&#x2019;s securities pursuant
              and/or traceable to Immunovant&#x2019;s follow-on public offering on or about September 2, 2020. In February 2023, after further briefing on the amended complaint the U.S. District Court issued an order permitting the lead plaintiff to file a second
              amended complaint. That second amended complaint was filed in March 2023. The defendants&#x2019; served motions to dismiss the second amended complaint on April 28, 2023. The fully briefed motions to dismiss, including defendants&#x2019; opening briefs,
              lead plaintiff&#x2019;s opposition and defendants&#x2019; replies, were filed with the court on June 30, 2023. No hearing date has yet been set. The Company intends to continue to vigorously defend the case and has not recorded a liability related to this
              lawsuit because, at this time, the Company is unable to reasonably estimate possible losses or determine whether an unfavorable outcome is either probable or remote.&lt;/span&gt; &lt;/span&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;Acuitas Declaratory
          Judgment Action&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In March 2022,
              Acuitas Therapeutics Inc. (&#x201c;Acuitas&#x201d;) filed a lawsuit in the U.S. District Court for the Southern District of New York (&#x201c;SDNY&#x201d;) against two of the Company&#x2019;s affiliates, Genevant and Arbutus, seeking a declaratory judgment that certain patents
              held by Arbutus and licensed by Genevant are not infringed by the manufacture, use, offer for sale, sale or importation into the United States of COMIRNATY, Pfizer&#x2019;s and BioNTech&#x2019;s vaccine for COVID-19 and are otherwise invalid. On September
              6, 2022, Acuitas filed a First Amended Complaint. In response, on October 4, 2022, Genevant and Arbutus filed a motion to dismiss the first amended complaint for lack of a controversy and supporting brief. Briefing on this motion was
              completed in mid-November. On August 4, 2023, Acuitas voluntarily dismissed the action in the SDNY and re-filed a complaint in the U.S. District Court for the District of New Jersey. On October 13, 2023, Genevant and Arbutus filed a motion to
              dismiss the re-filed complaint. No hearing date has been set. Each of Genevant and Arbutus intends to continue to vigorously defend the case.&lt;/span&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;(C) Indemnification
          Agreements&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the
            occurrence of certain events. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company also indemnifies each of its directors and officers for certain events or occurrences,
            subject to certain limits. The maximum amount of potential future indemnification is unlimited; however, the Company currently maintains director and officer liability insurance, which may cover certain liabilities arising from the Company&#x2019;s
            obligation to indemnify its directors and officers. To date, the Company has not incurred any material costs related to these indemnification obligations and has not accrued any liabilities related to such obligations in the condensed
            consolidated financial statements as of December 31, 2023 and March 31, 2023. &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="c20230401to20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember"
      id="Fact_8c1f86a48a5f4c72a9baeb3e50c75600">P5Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <roiv:RemainingMinimumPurchaseCommitmentRelatedToAgreement
      contextRef="c20231231_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_GSKMember"
      decimals="-5"
      id="Fact_c86d1e4841304033b093b0697c9062d1"
      unitRef="U002">43100000</roiv:RemainingMinimumPurchaseCommitmentRelatedToAgreement>
    <roiv:RemainingMinimumPurchaseCommitmentRelatedToAgreement
      contextRef="c20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member"
      decimals="-5"
      id="Fact_55ff4e6dca274f98937128a1f1d9305f"
      unitRef="U002">18300000</roiv:RemainingMinimumPurchaseCommitmentRelatedToAgreement>
    <roiv:PeriodOfRightToTerminateTheProductServiceAgreement
      contextRef="c20230401to20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member"
      id="Fact_73035ad7c8db4ea7853fa736b78f327f">P30D</roiv:PeriodOfRightToTerminateTheProductServiceAgreement>
    <us-gaap:PurchaseObligation
      contextRef="c20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member"
      decimals="-5"
      id="Fact_953c70f562304d1e9e8dedacd2b4b592"
      unitRef="U002">28000000</us-gaap:PurchaseObligation>
    <roiv:PeriodToPurchaseAdditionalBatchesOfBatoclimab
      contextRef="c20230401to20231231_TypeOfArrangementAxis_SamsungBiologicsCo.Ltd.Member"
      id="Fact_5b775fe3b94143919b67668c13c424f0">P4Y</roiv:PeriodToPurchaseAdditionalBatchesOfBatoclimab>
    <roiv:ProprietarySoftwareSubscriptionPeriod
      contextRef="c20230401to20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember"
      id="Fact_39ad6db789924cc482fa498c1f27cdeb">P5Y</roiv:ProprietarySoftwareSubscriptionPeriod>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="c20231231_TypeOfArrangementAxis_PalantirTechnologiesIncMember"
      decimals="-5"
      id="Fact_34aea1cc127d4c75823e27a2ce0bca4c"
      unitRef="U002">19100000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20231231_TypeOfArrangementAxis_CashBonusProgramMember"
      decimals="-5"
      id="Fact_9fd2986ee45e4c4fa76c7844d9ec32fc"
      unitRef="U002">76900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20230401to20231231_TypeOfArrangementAxis_CashBonusProgramMember"
      decimals="-5"
      id="Fact_f2a2941f5ee6417fb62d2c4c8f7f67db"
      unitRef="U002">27200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20231001to20231231_TypeOfArrangementAxis_CashBonusProgramMember"
      decimals="-5"
      id="Fact_3ccc5cbdb575400082719783bed9968b"
      unitRef="U002">27200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20231001to20231231_TypeOfArrangementAxis_CashBonusProgramMember"
      decimals="-5"
      id="Fact_52eeef07e81347c6b500329d19034079"
      unitRef="U002">8100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230401to20231231_TypeOfArrangementAxis_CashBonusProgramMember"
      decimals="-5"
      id="Fact_167857d8e84c42e584943dd9c6adaf20"
      unitRef="U002">8100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember"
      decimals="-5"
      id="Fact_13c9f8e6565d4e35b411c419add91a93"
      unitRef="U002">2800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <roiv:PercentageOfBonusPayableInNext30DaysOfGrantDate
      contextRef="c20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember"
      decimals="2"
      id="Fact_6c4ea09009e64aa2a0d50d5cfb0d666f"
      unitRef="U005">0.50</roiv:PercentageOfBonusPayableInNext30DaysOfGrantDate>
    <roiv:FiftyPercentBonusPayablePeriodFromGrantDate
      contextRef="c20240209to20240209_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_CashBonusProgramMember"
      id="Fact_d1209397e349416281d7f4bd6c4557d7">P30D</roiv:FiftyPercentBonusPayablePeriodFromGrantDate>
    <roiv:EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock
      contextRef="c20230401to20231231"
      id="Text_77803b80dce94600a52d0df74389fef6">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 12&#x2014;Earn-Out Shares, Public Warrants and Private Placement Warrants&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Earn-Out Shares&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with the Business Combination, the Company issued the following: &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="c2d6ce1f9431483b81d4e2da22271795" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 27pt;"&gt;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(a)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                &lt;div style="text-align: justify;"&gt;2,033,591 common shares to Patient Square Capital LLC (the &#x201c;MAAC Sponsor&#x201d;) and 10,000 common shares issued to each of MAAC&#x2019;s independent directors (collectively, the &#x201c;20% Earn-Out Shares&#x201d;), which will vest if the closing price of the Company&#x2019;s common shares is greater than or equal to $15.00 over any &lt;span style="-sec-ix-hidden:Fact_2cef63e668c241b7bc426da933f7f568"&gt;twenty&lt;/span&gt; out of &lt;span style="-sec-ix-hidden:Fact_d2125a9df960461aa915b45e9db9e81b"&gt;thirty&lt;/span&gt; trading day period during the Vesting Period (defined below).&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="c759375f6a474886b6c60be6cd797d32" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 27pt;"&gt;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;(b)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto; text-align: justify;"&gt;1,016,796 common shares issued to the MAAC Sponsor and 5,000 common shares issued to each of MAAC&#x2019;s independent directors (collectively, the &#x201c;10% Earn-Out Shares&#x201d; and, together with the 20% Earn-Out Shares, the
                &#x201c;Earn-Out Shares&#x201d;), each in respect of its MAAC Class B Shares, will vest if the closing price of the Company&#x2019;s common shares is greater than or equal to $20.00 over any &lt;span style="-sec-ix-hidden:Fact_227cc2a973b342cdadc7924eb0824d99"&gt;twenty&lt;/span&gt; out of &lt;span style="-sec-ix-hidden:Fact_938065e85885426b93d64ce0a73dd639"&gt;thirty&lt;/span&gt; trading day period during the Vesting Period (as defined below).&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ad9db901fae345a298e6d370b7b21acf" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 27pt;"&gt;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;(c)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                &lt;div style="text-align: justify;"&gt;The remaining number of common shares issued to the MAAC Sponsor and each of MAAC&#x2019;s independent director are not subject to the vesting conditions described above (the &#x201c;Retained Shares&#x201d;).&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Vesting Period commenced on November 9, 2021 and ends no later than September 30, 2026 (the &#x201c;Vesting Period&#x201d;). The Vesting Period will, if a definitive purchase agreement with respect to a Sale (as defined in the
            Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs
            during such Vesting Period, then all of the Earn-Out Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any Earn-Out Shares have not vested on or prior to the end of such Vesting
            Period, then such Earn-Out Shares will be forfeited. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;
          The Earn-Out Shares require liability classification and are classified as &#x201c;Liability instruments measured at fair value&#x201d; on the condensed consolidated balance sheets. The Earn-Out Shares liability is subject to remeasurement at each balance
          sheet date with changes in fair value recognized in the Company&#x2019;s statements of operations. As of December 31, 2023, no Earn-Out
          Shares have vested. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Public Warrants and Private Placement Warrants&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Immediately following the Business Combination, the Company had 10,214,365 outstanding warrants for the
            purchase of one of the Company&#x2019;s common shares, which were held by the MAAC Sponsor at an exercise price of $11.50 (the &#x201c;Private
            Placement Warrants&#x201d;), and 20,535,896 outstanding warrants for the purchase of one of the Company&#x2019;s common shares, which were held by
            MAAC&#x2019;s shareholders at an exercise price of $11.50&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;(the &#x201c;Public Warrants&#x201d; and, together with the Private Placement
              Warrants, the &#x201c;Warrants&#x201d;). Pursuant to the Warrant Agreement, dated October 6, 2020, by and between the Montes Archimedes Acquisition Corp. (&#x201c;MAAC&#x201d;) and Continental Stock Transfer &amp;amp; Trust Company, as predecessor warrant agent, as modified
              by the Warrant Assumption Agreement, dated September 30, 2021, by and among MAAC, the Company and American Stock Transfer &amp;amp; Trust Company, LLC as successor warrant agent (as modified, the &#x201c;Warrant Agreement&#x201d;), the Warrants &lt;/span&gt;became
            exercisable 30 days following the completion of the Business Combination and would expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
         &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Prior to their settlement, the Warrants required liability classification and were classified as &#x201c;Liability instruments measured at fair value&#x201d; on the condensed consolidated balance sheets. The Private Placement
              Warrants liability and Public Warrants liability were subject to remeasurement with changes in fair value recognized in the Company&#x2019;s statements of operations. The Warrants were remeasured immediately prior to settlement. These remeasurements
              were recognized in &#x201c;Change in fair value of debt and liability instruments&#x201d; in the accompanying condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 18pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Under the terms of the Warrant Agreement, the Company was entitled to redeem the Public Warrants at a redemption price of $0.10
            per Public Warrant because the last reported sales price (the &#x201c;Reference Value&#x201d;) of the Company&#x2019;s common shares was at least $10.00
            per share for any twenty (20) trading days within the thirty (30) trading-day period ending on the third trading day prior to the date on which RSL gave a Notice of Redemption. In addition, because the Reference Value was less than $18.00 per share, the outstanding Private Placement Warrants were also required to be concurrently called for redemption on the same terms as the
            outstanding Public Warrants. This share price performance requirement was satisfied as of July 28, 2023. On August 2, 2023, the Company announced that it would redeem all Warrants that remain outstanding on September 1, 2023 (the &#x201c;Redemption
            Date&#x201d;).&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 18pt;"&gt;Prior
















          to the Redemption Date, Warrant holders were permitted to exercise the Warrants (i) for cash, at an exercise price of $11.50 per common
          share, or (ii) on a &#x201c;cashless basis&#x201d; whereby, in lieu of paying the Company the $11.50 exercise price per common share, the
          surrendering holder would receive approximately 0.2495 common shares per Warrant as determined in accordance with the terms of the
          Warrant Agreement.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Of the 20,475,875 Public Warrants that were outstanding as of June 30, 2023, 397 Public Warrants were exercised for cash at an exercise price of $11.50 per common share in exchange for an aggregate of 397 common shares and 20,061,507 were exercised on a cashless basis in exchange for an aggregate of 5,005,531 common shares. The remaining 413,971 unexercised Public Warrants
            were redeemed at the $0.10 redemption price. In addition, all of the Private Placement Warrants were exercised on a cashless basis in
            exchange for an aggregate of 2,548,621 common shares.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</roiv:EarnOutSharesPublicWarrantsAndPrivatePlacementWarrantsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember"
      decimals="INF"
      id="Fact_b4e47c70c53d439088ed657f3acc9cf9"
      unitRef="U001">2033591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      decimals="INF"
      id="Fact_4dc7700346be4d1eaa7b0c136c43c870"
      unitRef="U001">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <roiv:PercentageOfEarnOutShares
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember"
      decimals="2"
      id="Fact_b1d8fe6c67af4103a7311048952a75bd"
      unitRef="U005">0.20</roiv:PercentageOfEarnOutShares>
    <roiv:EarnOutSharePrice
      contextRef="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      decimals="2"
      id="Fact_55260793c3e64bcba7718f459ae02fd2"
      unitRef="U003">15</roiv:EarnOutSharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember"
      decimals="INF"
      id="Fact_25bfe8002f554f1182877ac92938b64d"
      unitRef="U001">1016796</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      decimals="INF"
      id="Fact_7ceba1aff1c74b53b9cf10dd9197f0ba"
      unitRef="U001">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <roiv:PercentageOfEarnOutShares
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember"
      decimals="2"
      id="Fact_fb58c7089d4846319f6413554d862216"
      unitRef="U005">0.10</roiv:PercentageOfEarnOutShares>
    <roiv:PercentageOfEarnOutShares
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TwentyPercentEarnOutSharesMember"
      decimals="2"
      id="Fact_aa7f3dbae3e84f7fa927e659196e92e0"
      unitRef="U005">0.20</roiv:PercentageOfEarnOutShares>
    <roiv:EarnOutSharePrice
      contextRef="c20231231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember_StatementEquityComponentsAxis_TenPercentEarnOutSharesMember_TitleOfIndividualAxis_DirectorMember"
      decimals="2"
      id="Fact_d85d00a5e2bd46cb91beb2359bf48576"
      unitRef="U003">20</roiv:EarnOutSharePrice>
    <roiv:NumberOfEarnOutSharesVested
      contextRef="c20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"
      decimals="INF"
      id="Fact_36109f42fa4b42f0a09c9919616ad43b"
      unitRef="U001">0</roiv:NumberOfEarnOutSharesVested>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"
      decimals="0"
      id="Fact_4a7f651986b74bdca2c712a7ca11e3c8"
      unitRef="U001">10214365</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"
      decimals="2"
      id="Fact_f17c4d512b7b4e2ab518aedf176b01f9"
      unitRef="U003">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"
      decimals="0"
      id="Fact_2e3a57be45cc439ab67a334957547ff7"
      unitRef="U001">20535896</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"
      decimals="2"
      id="Fact_711d2bf6d9f44fb6b5fc4ed22dc687d7"
      unitRef="U003">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <roiv:PeriodToExerciseWarrantsAfterBusinessCombination
      contextRef="c20230401to20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"
      id="Fact_2410d7f112464efa80b9093fe43c57f4">P30D</roiv:PeriodToExerciseWarrantsAfterBusinessCombination>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20231231_RelatedPartyTransactionsByRelatedPartyAxis_PatientSquareCapitalLimitedLiabilityCompanyMember"
      id="Fact_d117ec0937c749cfa3f71eea205f1e29">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <roiv:ClassOfWarrantOrRightRedemptionPrice
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember"
      decimals="2"
      id="Fact_67871a5fd45d43c2a2b55c03d17c1db2"
      unitRef="U003">0.1</roiv:ClassOfWarrantOrRightRedemptionPrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="2"
      id="Fact_635c4914319046deb43dccd9bc10a209"
      unitRef="U003">10</us-gaap:SaleOfStockPricePerShare>
    <roiv:NumberOfTradingDays
      contextRef="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MinimumMember"
      id="Fact_00644c9cb41a4255a34668345f61e4e4">P20D</roiv:NumberOfTradingDays>
    <roiv:NumberOfTradingDays
      contextRef="c20230401to20231231_ClassOfWarrantOrRightAxis_PublicWarrantsMember_RangeAxis_MaximumMember"
      id="Fact_7b6e7425895e434e8cb9b76a8103962f">P30D</roiv:NumberOfTradingDays>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_da41eed7c32941ffac71b167c1d38a71"
      unitRef="U003">18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <roiv:CashExercisePrice
      contextRef="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="2"
      id="Fact_d3e0df4a3e8844c5a2f1a00909e2750e"
      unitRef="U003">11.5</roiv:CashExercisePrice>
    <roiv:ExercisePrice
      contextRef="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="2"
      id="Fact_a667d5006b414e3e87267cca7ad98fe5"
      unitRef="U003">11.5</roiv:ExercisePrice>
    <roiv:StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant
      contextRef="c20230831to20230831_ClassOfWarrantOrRightAxis_PublicWarrantsAndPrivatePlacementWarrantsMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="4"
      id="Fact_18df1efe4a774195b1830380f76f4ce6"
      unitRef="U001">0.2495</roiv:StockIssuedDuringPeriodNumberOfSharesIssuedToSurrenderingHolderPerWarrant>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember"
      decimals="0"
      id="Fact_0a8c805f3043418187e732ea92da968a"
      unitRef="U001">20475875</us-gaap:ClassOfWarrantOrRightOutstanding>
    <roiv:PublicWarrantCashExercised
      contextRef="c20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember"
      decimals="0"
      id="Fact_8ae8188f9a58405dbf8fbe8fa6903d36"
      unitRef="U001">397</roiv:PublicWarrantCashExercised>
    <roiv:CashExercisePrice
      contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="2"
      id="Fact_bde6401d312f453a889b4ac8865c65cb"
      unitRef="U003">11.5</roiv:CashExercisePrice>
    <roiv:StockIssuedDuringPeriodSharesCashWarrantExercises
      contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember"
      decimals="0"
      id="Fact_4c410ed2ddcf49e8b037afb8ec4e86ee"
      unitRef="U001">397</roiv:StockIssuedDuringPeriodSharesCashWarrantExercises>
    <roiv:CashlessPublicWarrantExercised
      contextRef="c20230630"
      decimals="0"
      id="Fact_8ec28dd873864e49913938a6bdff8f5c"
      unitRef="U001">20061507</roiv:CashlessPublicWarrantExercised>
    <roiv:StockIssuedDuringPeriodSharesCashlessWarrantExercises
      contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PublicWarrantsMember"
      decimals="0"
      id="Fact_0ae8f5cfda1441ceba715717b152a013"
      unitRef="U001">5005531</roiv:StockIssuedDuringPeriodSharesCashlessWarrantExercises>
    <roiv:ClassOfWarrantOrRightUnexercisedPriceOfWarrants
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_c07f665660cd4ea4b5711343bfdf66e1"
      unitRef="U001">413971</roiv:ClassOfWarrantOrRightUnexercisedPriceOfWarrants>
    <roiv:ClassOfWarrantOrRightRedemptionPrice
      contextRef="c20230630"
      decimals="2"
      id="Fact_60fce00170e1483db8439851031fa82d"
      unitRef="U003">0.1</roiv:ClassOfWarrantOrRightRedemptionPrice>
    <roiv:StockIssuedDuringPeriodSharesCashlessWarrantExercises
      contextRef="c20230401to20230630_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"
      decimals="0"
      id="Fact_ba667f92d61046c18dd2e35474725642"
      unitRef="U001">2548621</roiv:StockIssuedDuringPeriodSharesCashlessWarrantExercises>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20230401to20231231"
      id="Text_a70d3ff60cd5420dbfa2f5b9e89b8d1f">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 13&#x2014;Fair Value Measurements&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Recurring Fair Value Measurements&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;The
      following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and March 31, 2023, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 9pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Balance as of&lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Balance as &lt;br/&gt;
            &lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;of March 31,&lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;2023 &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Assets:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Money market funds&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,513,936&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,513,936&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,496,726&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,496,726&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Investment in Datavant Class A units&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Investment in Arbutus common shares&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;97,119&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;97,119&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;117,708&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;117,708&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Other investments&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,874&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,874&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;8,030&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;8,030&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total assets at fair value&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,617,929&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,753,863&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,622,464&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,801,043&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Liabilities:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Debt issued by Dermavant to NovaQuest&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;221,510&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;221,510&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;207,640&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;207,640&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Liability instruments measured at fair value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;28,374&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;28,374&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;29,895&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;33,651&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;63,546&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total liabilities at fair value&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;249,884&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;249,884&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;29,895&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;241,291&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;271,186&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 4%; vertical-align: top;"&gt;
            &lt;div style="font-style: normal;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td style="width: 96%; vertical-align: top;"&gt;
            &lt;div style="text-align: justify;"&gt;At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $24.9 million and other liability instruments issued of $3.5 million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $29.9
              million, and Level 3 includes the fair value of the Earn-Out Shares of $15.2 million, Private Placement Warrants of $15.2 million, and other liability instruments issued of $3.3 million.&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy that occurred during the nine months ended December 31, 2023. &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Level 3 Disclosures&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company measures its Level 3 assets and liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. The
        valuation of the Level 3 assets and liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as
        additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt; The
      fair value of Level 3 assets and liabilities may change significantly as additional data are obtained, impacting the Company&#x2019;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information,
      considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value
      amounts, and such changes could materially impact the Company&#x2019;s results of operations in future periods. &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;br/&gt;
    &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;
  &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;The changes in fair value of the Level 3
      assets during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;193,963&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_5ffcc6c700034d4587790a5e791d733c"&gt;Changes in fair value of investment in Datavant, included in net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(21,452&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;172,511&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_1bcdc2e95f0b40ac8041dbfa7444510a"&gt;Changes in fair value of investment in Datavant, included in net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;(42,645&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;)&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;The
      changes in fair value of the Level 3 liabilities during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;/span&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;204,293&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Fair value of liability instrument issued &lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;248&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Payments related to long-term
                debt&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(22,031&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_93006666e195494db2e26107da08a25a"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;68,328&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;250,838&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;241,291&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Payments related to long-term
                debt&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(22,031&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Exercise of Private Placement Warrants&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(28,090&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_ca3f4592024941f287ede17a07ff606d"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;58,714&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;249,884&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Investment in Datavant&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method
        (&#x201c;OPM&#x201d;). The OPM allows for the allocation of a company&#x2019;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#x2019; liquidation preferences, participation rights, dividend
        policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value was calculated using significant unobservable inputs including the following: &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Point Estimate Used&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
            &lt;div style="font-weight: bold; font-style: normal;"&gt;Input&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;Volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;95.0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;100.0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
            &lt;div&gt;Risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;4.46%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;4.02%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Debt issued by Dermavant to NovaQuest&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; text-align: justify; text-indent: 18pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value of the debt instrument as of December 31, 2023 and March 31, 2023 represents the fair value of amounts payable to NovaQuest calculated using the Monte Carlo simulation method under the income approach
        determined by using probability assessments of the expected future payments through 2032. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The
        estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Earn-Out Shares&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value of the Earn-Out Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the lock-up periods to
        which the Earn-Out Shares are subject. Refer to Note 12, &#x201c;Earn-Out Shares, Public Warrants and Private Placement Warrants&#x201d; for additional details. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant unobservable inputs used to calculate the fair value of the Earn-Out Shares included the following: &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Point Estimate Used&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-weight: bold;"&gt;Input&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;Volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;61.9%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;79.9%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
            &lt;div&gt;Risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;4.07%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;3.76%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31, 2023 and March 31, 2023, the fair value of the Earn-Out Shares was $24.9 million and $15.2 million, respectively. Earn-Out Shares were included in &#x201c;&lt;span style="-sec-ix-hidden:Fact_896fc6f03cbf47ba9500416e14491b89"&gt;Liability instruments measured at fair value&lt;/span&gt;&#x201d; in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Private Placement Warrants&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt; &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Prior to their settlement, the fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured
        to incorporate the redemption features as discussed in Note 12, &#x201c;Earn-Out Shares, Public Warrants and Private Placement Warrants&#x201d; and the added restriction by which the Company could not redeem the Private Placement Warrants if the Reference Value
        was greater than $18.00. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant unobservable
        inputs used to calculate the fair value of the Private Placement Warrants included the following: &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Point Estimate Used&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-weight: bold;"&gt;Input&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div&gt;Volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;50.5%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.43%;" valign="bottom"&gt;
            &lt;div&gt;Risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;3.76%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div&gt;Term (in years)&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;3.50&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In August 2023, the Company announced that it would redeem all Warrants that remain outstanding on September 1, 2023. All of the Private Placement Warrants were exercised. As of March 31, 2023, the fair value of the Private Placement
        Warrants was $15.2 million, which was included in &#x201c;&lt;span style="-sec-ix-hidden:Fact_8076c0698f4040ad9216b28dd1dd2471"&gt;Liability instruments measured at fair value&lt;/span&gt;&#x201d; in the accompanying condensed consolidated balance sheets. &lt;/span&gt;  &lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_cc3aa55eefd14e91a020c9b1d4e02595">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;The
      following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and March 31, 2023, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 9pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Balance as of&lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Balance as &lt;br/&gt;
            &lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;of March 31,&lt;/div&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;2023 &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Assets:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Money market funds&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,513,936&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,513,936&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,496,726&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,496,726&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Investment in Datavant Class A units&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Investment in Arbutus common shares&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;97,119&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;97,119&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;117,708&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;117,708&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Other investments&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,874&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,874&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;8,030&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;8,030&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total assets at fair value&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,617,929&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;6,753,863&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,622,464&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;1,801,043&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Liabilities:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Debt issued by Dermavant to NovaQuest&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;221,510&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;221,510&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;207,640&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;207,640&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Liability instruments measured at fair value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;28,374&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;28,374&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;29,895&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;33,651&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;63,546&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 20%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total liabilities at fair value&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;249,884&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;249,884&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;29,895&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;241,291&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;271,186&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 4%; vertical-align: top;"&gt;
            &lt;div style="font-style: normal;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td style="width: 96%; vertical-align: top;"&gt;
            &lt;div style="text-align: justify;"&gt;At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $24.9 million and other liability instruments issued of $3.5 million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $29.9
              million, and Level 3 includes the fair value of the Earn-Out Shares of $15.2 million, Private Placement Warrants of $15.2 million, and other liability instruments issued of $3.3 million.&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_0c13619bab054cebb09033253ee50412"
      unitRef="U002">6513936000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_f61b2c5432fe4d04be1da85057d76cf9"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_fbaf16a57f2444f2a8b29177f806ac68"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_37b1738bd94f4af8af5c03e1a4f6da10"
      unitRef="U002">6513936000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_cd0771b0e00549898dc302274ae36af9"
      unitRef="U002">1496726000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_4d938c76aba64f49bbd6ceeb923036bd"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_e57dfcee0edb4fdcabea8eaadb6605d3"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_3d0fb8e33b714b84b571fc9acea21e3a"
      unitRef="U002">1496726000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_929c262008874a0282712825b0971146"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_98b053480d3648a387feea4714f5277c"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_81f8cced0ab64658be4271403eaa4573"
      unitRef="U002">135934000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_5702140e237d4b04b62f159ffd88316f"
      unitRef="U002">135934000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_4079b9dfb62443bcac5c97f066768557"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_db2ded18af3f4a35b5fad1bb43133ec4"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_c641f9a9b6934327b038b5d279847c30"
      unitRef="U002">178579000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="-3"
      id="Fact_d02e720e566c46fb813bcc188b1eb121"
      unitRef="U002">178579000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_ecb6305054734f009328e7b02477e6f4"
      unitRef="U002">97119000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_70365858095f455a92a6432699c1ba3a"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_1f39157fcd3c4e48aa8c8449a91deeb3"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_ab70119a614d4ea48fe7ef17f01cbfb2"
      unitRef="U002">97119000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_f975256cfcb94a2daa52c0e332238a7e"
      unitRef="U002">117708000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_f30b7b5514574a24bf7d81fbf29b3866"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_c6c2812738f94c99bec8188c5afc651c"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_CommonStockMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ArbutusBiopharmaCorporationMember"
      decimals="-3"
      id="Fact_f3e6d53a678b4ce7a749b07535a22604"
      unitRef="U002">117708000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_33b1612ad67046628e28557f2e95568e"
      unitRef="U002">6874000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_37ae4088ec844009b5ae1d7b848fd71a"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_20c751e2831d4cf3a5a4f97a2216adf1"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_7d9cbd56dd604f1db1a4bdab9e8ebdff"
      unitRef="U002">6874000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_419c9faf0d7a416cb3feaa085205d7e6"
      unitRef="U002">8030000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_c82c3622937547758706ee5915407ab7"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9c14ce8d99004ffbb1678c4549fa2616"
      unitRef="U002">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20230331_FairValueByAssetClassAxis_OtherInvestmentCompaniesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_143570076be145f694cb6526cf5aa286"
      unitRef="U002">8030000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_6f4e59226abf47708f951de49bcfbd98"
      unitRef="U002">6617929000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_bba5e9ad94334c1797476501927d28eb"
      unitRef="U002">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_86f52576cbae4fba891e4ce67cb50868"
      unitRef="U002">135934000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_8f331db804c7441aa6e3f962a8fcedee"
      unitRef="U002">6753863000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_5dd594fe01424e8b9502cc45003ee321"
      unitRef="U002">1622464000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_28d9948e5ed143f09b04d8fc6c921134"
      unitRef="U002">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_27c5a8f943884552b63795b62e55f731"
      unitRef="U002">178579000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_e053960a65fe4059854f67ce9f908fdc"
      unitRef="U002">1801043000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_62581ebf79ee4f7eb2210b14ccb3fee9"
      unitRef="U002">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_47be66c539db46049fade43f0923da91"
      unitRef="U002">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_b744e489af96491db325b1809ba0d1bc"
      unitRef="U002">221510000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_d6eb51a7e5984c8c8d219ba401c07b7b"
      unitRef="U002">221510000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_905801e5ee82488f9f4781246bcbdca0"
      unitRef="U002">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_4cde8c79bb6d4ae18864e3f9d44eddbf"
      unitRef="U002">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_e80f0a3b7cfe4516a706fc842e3c1ea1"
      unitRef="U002">207640000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_f770fed778514296ba1903c5cbd68d9f"
      unitRef="U002">207640000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_88d301b06f3b4647bd1a7bd6a42d22e1"
      unitRef="U002">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_4dfeb1fa823a44f986b1f8c8747e6e3b"
      unitRef="U002">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_7aa6e3e059604b539d74d42ac4d41f07"
      unitRef="U002">28374000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9d3967aaf8b84bd59f44e1c76670b3b8"
      unitRef="U002">28374000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_d60545cae465462f845da4052288e0b4"
      unitRef="U002">29895000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_f98ef47d156a48a3b5586b2e4b978334"
      unitRef="U002">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_428210c60e944730a20f7b55694bf111"
      unitRef="U002">33651000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1e7097176cf645f1845fbbe6eea85e94"
      unitRef="U002">63546000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeLiabilities
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_79ba7f9ae638489ab7fe02fbd5e62884"
      unitRef="U002">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_81e7e6ee12b244859d7d94a079b514bc"
      unitRef="U002">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_0ff59a98cd8c406aacee90f7851b3a39"
      unitRef="U002">249884000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20231231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_f0cd7542fd6b45b3a87b1cbc10bde76e"
      unitRef="U002">249884000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_eccfb9007b754fe8aabddc5c0362a2f1"
      unitRef="U002">29895000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_e6b9545d0f7348598e3b5b5d0bbe7bc9"
      unitRef="U002">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_ad9102e481a84d15a67379c57212298d"
      unitRef="U002">241291000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="c20230331_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9f6b7639ca524e44a4ed07fa2a539c15"
      unitRef="U002">271186000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="-5"
      id="Fact_e74ff6ff61574036a863f096d8a7bde3"
      unitRef="U002">24900000</us-gaap:LiabilitiesFairValueDisclosure>
    <roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember"
      decimals="-5"
      id="Fact_a5c0a52c0f9d46d3810cd832b3ed7af7"
      unitRef="U002">3500000</roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20230331_ClassOfWarrantOrRightAxis_PublicWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FinancialInstrumentAxis_WarrantMember"
      decimals="-5"
      id="Fact_183021528e7944e2a052039e0781e614"
      unitRef="U002">29900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="-5"
      id="Fact_bb6efee56a8a4984989a53845b736851"
      unitRef="U002">15200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_WarrantMember"
      decimals="-5"
      id="Fact_d66c42e9db1d4596bf30e9058ef4b34b"
      unitRef="U002">15200000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FinancialInstrumentAxis_OtherLiabilityInstrumentsMeasuredAtFairValueMeasurementMember"
      decimals="-5"
      id="Fact_9951d6dda98a413887f7f124e7f01458"
      unitRef="U002">3300000</roiv:OtherLiabilityInstrumentsMeasuredAtFairValueMeasurement>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20230401to20231231"
      id="Text_c7575c269a9142e6b8f4279ef7bd0f5b">
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;
  &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;The changes in fair value of the Level 3
      assets during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;193,963&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_5ffcc6c700034d4587790a5e791d733c"&gt;Changes in fair value of investment in Datavant, included in net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(21,452&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;172,511&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;178,579&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_1bcdc2e95f0b40ac8041dbfa7444510a"&gt;Changes in fair value of investment in Datavant, included in net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;(42,645&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;)&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;135,934&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="c20220331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_7f617ceaf53a4ca6a75aa9343239cb54"
      unitRef="U002">193963000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_e2ae86f1f1064e81843007057664ebca"
      unitRef="U002">-21452000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_1b68a8ad84d9470e970eadf8d4a59e99"
      unitRef="U002">172511000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_c156f2d70ed444db9f457857bba57741"
      unitRef="U002">178579000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_0d7f35e1f4ec42f9a729785ef8f72867"
      unitRef="U002">-42645000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_d5d56083200b4acf976187d714174988"
      unitRef="U002">135934000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20230401to20231231"
      id="Text_0a78f89e05f54726be734be8422fea1a">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 18pt;"&gt;The
      changes in fair value of the Level 3 liabilities during the nine months ended December 31, 2023 and 2022 were as follows (in thousands): &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;/span&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;204,293&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Fair value of liability instrument issued &lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;248&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Payments related to long-term
                debt&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(22,031&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_93006666e195494db2e26107da08a25a"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;68,328&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;250,838&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;March 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;241,291&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Payments related to long-term
                debt&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(22,031&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Exercise of Private Placement Warrants&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(28,090&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="text-indent: 0pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_ca3f4592024941f287ede17a07ff606d"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;58,714&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Balance at&#160;&lt;span style="text-indent: 0pt;"&gt;December 31&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;249,884&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20220331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_2a2ca2aa014344e89df8bbcbc8d8d839"
      unitRef="U002">204293000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_0eefc3b7db6047a9b7ba32bf751c6015"
      unitRef="U002">248000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_37758ae4f2be41259976356a209afb3f"
      unitRef="U002">22031000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="c20220401to20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_73ac526a841f446b8642c38614b8f520"
      unitRef="U002">68328000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_0ab33bd5d99049f59ca84f14515985c6"
      unitRef="U002">250838000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20230331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_d361d907b9b245bea7c2d26aa230c47e"
      unitRef="U002">241291000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_ef05d771eee040c0b08d822f7e425150"
      unitRef="U002">22031000</us-gaap:RepaymentsOfLongTermDebt>
    <roiv:ExerciseOfPrivatePlacementWarrantsValue
      contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_6cece2a67adb4867803cbf3abaf1a3c4"
      unitRef="U002">28090000</roiv:ExerciseOfPrivatePlacementWarrantsValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="c20230401to20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_32ce11d7b99a4fc480960f438231f0f4"
      unitRef="U002">58714000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_79ebedd4b10c4d0c87de6e70144d5871"
      unitRef="U002">249884000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20230401to20231231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      id="Text_9778c6fa0e6d4bc38c7055b20005db6d">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value was calculated using significant unobservable inputs including the following: &lt;/span&gt;&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Point Estimate Used&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
            &lt;div style="font-weight: bold; font-style: normal;"&gt;Input&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;Volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;95.0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;100.0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
            &lt;div&gt;Risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;4.46%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;4.02%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <roiv:FairValueAssetMeasurementInput
      contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="3"
      id="Fact_7fe28950f75b41a1a44bc7114b3dadf2"
      unitRef="U005">0.95</roiv:FairValueAssetMeasurementInput>
    <roiv:FairValueAssetMeasurementInput
      contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="3"
      id="Fact_51f43aabc8bc40329616b03f4fa96c77"
      unitRef="U005">1</roiv:FairValueAssetMeasurementInput>
    <roiv:FairValueAssetMeasurementInput
      contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="4"
      id="Fact_e7d859a751c5467082af8860e8d3de4a"
      unitRef="U005">0.0446</roiv:FairValueAssetMeasurementInput>
    <roiv:FairValueAssetMeasurementInput
      contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_DatavantHoldingsIncMember"
      decimals="4"
      id="Fact_0d1c406981254fe8a35dda576a162def"
      unitRef="U005">0.0402</roiv:FairValueAssetMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20230401to20231231_StatementEquityComponentsAxis_EarnoutSharesMember"
      id="Text_1d87f29774f242f094d0bdea5fa559ad">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant unobservable inputs used to calculate the fair value of the Earn-Out Shares included the following: &lt;/span&gt;&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Point Estimate Used&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-weight: bold;"&gt;Input&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div&gt;Volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;61.9%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;79.9%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
            &lt;div&gt;Risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;4.07%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;3.76%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <roiv:FairValueEarnoutSharesMeasurementInput
      contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="3"
      id="Fact_0212e2d774924f7e89101bb0dea01248"
      unitRef="U005">0.619</roiv:FairValueEarnoutSharesMeasurementInput>
    <roiv:FairValueEarnoutSharesMeasurementInput
      contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="3"
      id="Fact_176924d4f5174393a9ee15cf6d1e5115"
      unitRef="U005">0.799</roiv:FairValueEarnoutSharesMeasurementInput>
    <roiv:FairValueEarnoutSharesMeasurementInput
      contextRef="c20231231_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="4"
      id="Fact_e5c856279ff945bf9a1231d7497bce7b"
      unitRef="U005">0.0407</roiv:FairValueEarnoutSharesMeasurementInput>
    <roiv:FairValueEarnoutSharesMeasurementInput
      contextRef="c20230331_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="4"
      id="Fact_4a1f5aced78e4379b0d3ee19ebc53365"
      unitRef="U005">0.0376</roiv:FairValueEarnoutSharesMeasurementInput>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20231231_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="-5"
      id="Fact_4849e76e09ae4160859cffcd3dbc48b6"
      unitRef="U002">24900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20230331_StatementEquityComponentsAxis_EarnoutSharesMember"
      decimals="-5"
      id="Fact_a42461a63c8943828eb9052cd41a6a1b"
      unitRef="U002">15200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="c20230401to20231231_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"
      id="Text_92e07351b6f04b73aa3f712e05b6e69d">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant unobservable
        inputs used to calculate the fair value of the Private Placement Warrants included the following: &lt;/span&gt;&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;Point Estimate Used&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-weight: bold;"&gt;Input&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-weight: bold;"&gt;As of March 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div&gt;Volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;50.5%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.43%;" valign="bottom"&gt;
            &lt;div&gt;Risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%;" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;3.76%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.43%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div&gt;Term (in years)&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.36%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 10.54%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-align: center;"&gt;3.50&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.19%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="Fact_59fa66ffd0494e578387725375417f38"
      unitRef="U005">0.505</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_aa533eeefd914da998f50d9fd4fd175f"
      unitRef="U005">0.0376</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_09b357257e7d4d8bbd6884656f082400">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20230331_ClassOfWarrantOrRightAxis_PrivatePlacementWarrantsMember"
      decimals="-5"
      id="Fact_586ca63baa4048c4a98640d374fc19d5"
      unitRef="U002">15200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="c20230401to20231231"
      id="Text_d45c814617b643bf963a44208d1bc69e">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Note 14&#x2014;Net Income (Loss) per Common Share&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) attributable to Roivant Sciences Ltd. by the
          weighted-average number of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common
          stock outstanding during the period.&lt;/span&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The computations for basic and diluted net income (loss) per common share were as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended December 31,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2023&lt;/div&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2022&lt;/div&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Numerator:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Net income (loss) attributable to Roivant Sciences Ltd.&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;5,096,184&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(352,014&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;4,500,041&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(975,413&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 52%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Denominator:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Weighted average shares outstanding, basic&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;800,587,716&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;713,319,399&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;776,759,728&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;703,054,773&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Effect of dilutive common stock equivalents&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;43,873,969&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;47,550,285&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Weighted average shares outstanding, diluted&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;844,461,685&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;713,319,399&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;824,310,013&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;703,054,773&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Net income (loss) per common share, basic&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;6.37&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(0.49&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;5.79&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(1.39&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Net income (loss) per common share, diluted&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;6.03&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(0.49&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;5.46&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(1.39&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
    &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. For the three and nine months ended
          December 31, 2022, all outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss. &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;
    &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As
        of December 31, 2023 and 2022, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net income (loss) per common share because including them would have been anti-dilutive: &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Stock options and performance stock options&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;65,518,394&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;154,631,025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Restricted stock units and performance stock units (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;5,422,465&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;22,153,774&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;March 2020 CVARs&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;17,548,368&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;32,011,996&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;November 2021 CVARs (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;359,730&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;3,609,021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Restricted common stock (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;238,059&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;730,522&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Earn-Out Shares (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;3,080,387&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;3,080,387&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Private Placement Warrants&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;10,214,365&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Public Warrants&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;20,475,875&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Other stock based awards and instruments issued&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;4,147,404&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;6,178,990&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 4%; vertical-align: top;"&gt;
              &lt;div&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td style="width: 96%; vertical-align: top;"&gt;
              &lt;div style="text-align: justify;"&gt;Refer to Note 9, &#x201c;Share-Based Compensation&#x201d; for details regarding settlement of CVARs.&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="c20230401to20231231"
      id="Text_448a3ee29d52400aac4c0a55f155b478">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The computations for basic and diluted net income (loss) per common share were as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended December 31,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2023&lt;/div&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;2022&lt;/div&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Numerator:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Net income (loss) attributable to Roivant Sciences Ltd.&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;5,096,184&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(352,014&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;4,500,041&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(975,413&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 52%;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Denominator:&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Weighted average shares outstanding, basic&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;800,587,716&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;713,319,399&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;776,759,728&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;703,054,773&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Effect of dilutive common stock equivalents&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;43,873,969&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;47,550,285&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 18pt;"&gt;Weighted average shares outstanding, diluted&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;844,461,685&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;713,319,399&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;824,310,013&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;703,054,773&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Net income (loss) per common share, basic&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;6.37&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(0.49&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;5.79&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(1.39&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Net income (loss) per common share, diluted&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;6.03&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(0.49&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;5.46&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;$&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;(1.39&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;)&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="c20231001to20231231"
      decimals="-3"
      id="Fact_790ce43355fc49369e7889670dc73025"
      unitRef="U002">5096184000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20221001to20221231"
      decimals="-3"
      id="Fact_27ce233d64314e1d9e0ba1ac3b7074b1"
      unitRef="U002">-352014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20231231"
      decimals="-3"
      id="Fact_ea85a02895d54969943f775618137bfc"
      unitRef="U002">4500041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220401to20221231"
      decimals="-3"
      id="Fact_cb17ea3f52c947d69b7081aaa87344b1"
      unitRef="U002">-975413000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20231001to20231231"
      decimals="0"
      id="Fact_135ab34e86634d95b0953c848e6f81f0"
      unitRef="U001">800587716</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20221001to20221231"
      decimals="0"
      id="Fact_aca5323244634d12a277dd9ad311fb01"
      unitRef="U001">713319399</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230401to20231231"
      decimals="0"
      id="Fact_51d72cbcd7194b4089ec3fed5436f98d"
      unitRef="U001">776759728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220401to20221231"
      decimals="0"
      id="Fact_0cb5d389a2934b8b8357a1d7648f7b2f"
      unitRef="U001">703054773</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20231001to20231231"
      decimals="0"
      id="Fact_0209ccd9e7794fa1a8686f1a18a6ed56"
      unitRef="U001">43873969</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20221001to20221231"
      decimals="0"
      id="Fact_0a9efb5db85f443a80138830caf015c7"
      unitRef="U001">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20230401to20231231"
      decimals="0"
      id="Fact_4e394db7e1b649d7bfaee53ee38404e8"
      unitRef="U001">47550285</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20220401to20221231"
      decimals="0"
      id="Fact_37ce6492ddde4b44875f5a234af56ca6"
      unitRef="U001">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20231001to20231231"
      decimals="0"
      id="Fact_224f85bb916f4e2a9ce4f39436085168"
      unitRef="U001">844461685</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20221001to20221231"
      decimals="0"
      id="Fact_ffa449edb6904a6ba9be9a0ee3a7906c"
      unitRef="U001">713319399</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230401to20231231"
      decimals="0"
      id="Fact_8790d4b7328e41e29178875738d427fe"
      unitRef="U001">824310013</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220401to20221231"
      decimals="0"
      id="Fact_7aeee14d5b76432ba1c3dc0a99707ba4"
      unitRef="U001">703054773</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20231001to20231231"
      decimals="2"
      id="Fact_f6be068f89dd4fdd92d9337a3871e42f"
      unitRef="U003">6.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20221001to20221231"
      decimals="2"
      id="Fact_5d389ca30c6f4356a1466137a5be4872"
      unitRef="U003">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230401to20231231"
      decimals="2"
      id="Fact_7694bbfcc888444db3c38d7637e42bd1"
      unitRef="U003">5.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220401to20221231"
      decimals="2"
      id="Fact_beb10629910744a3abaa86bd18aedbf0"
      unitRef="U003">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20231001to20231231"
      decimals="2"
      id="Fact_a515f715ea3844849d590ba11801ce8c"
      unitRef="U003">6.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20221001to20221231"
      decimals="2"
      id="Fact_9d80d3a706934f958fc0c35f3ae22c6f"
      unitRef="U003">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230401to20231231"
      decimals="2"
      id="Fact_1db15951b05c4b1b9fde3d583b8d9a93"
      unitRef="U003">5.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220401to20221231"
      decimals="2"
      id="Fact_d1efbe20efc74564b4c139e311d0b287"
      unitRef="U003">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20230401to20231231"
      id="Text_19b3c06a3d8747de81cf9dd64123d536">
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;
    &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 18pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As
        of December 31, 2023 and 2022, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net income (loss) per common share because including them would have been anti-dilutive: &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Stock options and performance stock options&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;65,518,394&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;154,631,025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Restricted stock units and performance stock units (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;5,422,465&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;22,153,774&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;March 2020 CVARs&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;17,548,368&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;32,011,996&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;November 2021 CVARs (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;359,730&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;3,609,021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Restricted common stock (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;238,059&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;730,522&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Earn-Out Shares (non-vested)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;3,080,387&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;3,080,387&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Private Placement Warrants&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;10,214,365&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Public Warrants&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div&gt;20,475,875&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Other stock based awards and instruments issued&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;4,147,404&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;6,178,990&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 4%; vertical-align: top;"&gt;
              &lt;div&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td style="width: 96%; vertical-align: top;"&gt;
              &lt;div style="text-align: justify;"&gt;Refer to Note 9, &#x201c;Share-Based Compensation&#x201d; for details regarding settlement of CVARs.&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember"
      decimals="0"
      id="Fact_c25f3b23b89846619cb18562522270ee"
      unitRef="U001">65518394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsAndPerformanceStockOptionsMember"
      decimals="0"
      id="Fact_25aa8798ba534da5b2c66a21db205b5c"
      unitRef="U001">154631025</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember"
      decimals="0"
      id="Fact_8cabd30cb28c413ebd00564eccc6fa03"
      unitRef="U001">5422465</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockAndPerformanceStockUnitsMember"
      decimals="0"
      id="Fact_8d6e227ab54247bcbd4956f26442d2d8"
      unitRef="U001">22153774</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember"
      decimals="0"
      id="Fact_549a656b35d94b4d967ad2c826a11b60"
      unitRef="U001">17548368</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_March2020CappedValueAppreciationRightsGrantsMember"
      decimals="0"
      id="Fact_4752edd86aed4ee592ba9116cf19a4e5"
      unitRef="U001">32011996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember"
      decimals="0"
      id="Fact_5d1032caa3cf421db1845e0499d13cb5"
      unitRef="U001">359730</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_November2021CappedValueAppreciationRightsGrantsMember"
      decimals="0"
      id="Fact_b83a4a95ad354bc9a33e3a49d1b71ee3"
      unitRef="U001">3609021</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_4fbc4213675648c4a420716b208e4f85"
      unitRef="U001">238059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_b51f66a20cf245bc836e696d19001c4d"
      unitRef="U001">730522</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember"
      decimals="0"
      id="Fact_d64632882dac49ce9bb0e40cc87964be"
      unitRef="U001">3080387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EarnOutSharesNonvestedMember"
      decimals="0"
      id="Fact_ec6dc9eaffec45a5ab60183d0748f1f7"
      unitRef="U001">3080387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember"
      decimals="INF"
      id="Fact_8569cbd6baa242daa128e9ffdc6737e2"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PrivatePlacementWarrantsMember"
      decimals="0"
      id="Fact_6baae4fa580e438abecd8737eb7d236c"
      unitRef="U001">10214365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember"
      decimals="INF"
      id="Fact_2c88c79311de46fb8e689a21c56ec94f"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_PublicWarrantsMember"
      decimals="0"
      id="Fact_8f7f5b2fbef0422a854c4946c9315d24"
      unitRef="U001">20475875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230401to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember"
      decimals="0"
      id="Fact_de762d50491243d4aecfdc02459a480f"
      unitRef="U001">4147404</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220401to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OtherStockBasedAwardsAndInstrumentsIssuedMember"
      decimals="0"
      id="Fact_32b7f496b4984b7d84d20eb458da5e8a"
      unitRef="U001">6178990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_428210c60e944730a20f7b55694bf111"
          xlink:label="Fact_428210c60e944730a20f7b55694bf111"
          xlink:type="locator"/>
        <link:footnote id="Foot_284c7966a91e41ae90598fd7dee6f320" xlink:label="Foot_284c7966a91e41ae90598fd7dee6f320" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $24.9 million and other liability instruments issued of $3.5 million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $29.9
              million, and Level 3 includes the fair value of the Earn-Out Shares of $15.2 million, Private Placement Warrants of $15.2 million, and other liability instruments issued of $3.3 million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_428210c60e944730a20f7b55694bf111"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_88d301b06f3b4647bd1a7bd6a42d22e1"
          xlink:label="Fact_88d301b06f3b4647bd1a7bd6a42d22e1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_88d301b06f3b4647bd1a7bd6a42d22e1"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_4dfeb1fa823a44f986b1f8c8747e6e3b"
          xlink:label="Fact_4dfeb1fa823a44f986b1f8c8747e6e3b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_4dfeb1fa823a44f986b1f8c8747e6e3b"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_1e7097176cf645f1845fbbe6eea85e94"
          xlink:label="Fact_1e7097176cf645f1845fbbe6eea85e94"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_1e7097176cf645f1845fbbe6eea85e94"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_7aa6e3e059604b539d74d42ac4d41f07"
          xlink:label="Fact_7aa6e3e059604b539d74d42ac4d41f07"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_7aa6e3e059604b539d74d42ac4d41f07"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_d60545cae465462f845da4052288e0b4"
          xlink:label="Fact_d60545cae465462f845da4052288e0b4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_d60545cae465462f845da4052288e0b4"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_f98ef47d156a48a3b5586b2e4b978334"
          xlink:label="Fact_f98ef47d156a48a3b5586b2e4b978334"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f98ef47d156a48a3b5586b2e4b978334"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_9d3967aaf8b84bd59f44e1c76670b3b8"
          xlink:label="Fact_9d3967aaf8b84bd59f44e1c76670b3b8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_9d3967aaf8b84bd59f44e1c76670b3b8"
          xlink:to="Foot_284c7966a91e41ae90598fd7dee6f320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_549a656b35d94b4d967ad2c826a11b60"
          xlink:label="Fact_549a656b35d94b4d967ad2c826a11b60"
          xlink:type="locator"/>
        <link:footnote id="Foot_ce5839120cd543e7984048999d69cde8" xlink:label="Foot_ce5839120cd543e7984048999d69cde8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Refer to Note 9, &#x201c;Share-Based Compensation&#x201d; for details regarding settlement of CVARs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_549a656b35d94b4d967ad2c826a11b60"
          xlink:to="Foot_ce5839120cd543e7984048999d69cde8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_4752edd86aed4ee592ba9116cf19a4e5"
          xlink:label="Fact_4752edd86aed4ee592ba9116cf19a4e5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_4752edd86aed4ee592ba9116cf19a4e5"
          xlink:to="Foot_ce5839120cd543e7984048999d69cde8"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
